Exhibit 2.01
 
Strategic Alliance Agreement
 
This agreement is made and entered into this 30th day of November, 2017 by and between Bravatek Solutions, Inc., a corporation organized under
the laws of the State of Colorado, ("Bravatek"), with an address at 2028 E. Ben White Blvd., Unit #240-2835, Austin, Texas, 78741, and Sibannac,
Inc. ("COMPANY"), a corporation organized under the laws of Nevada, with an address at 2122 E Highland Avenue, Suite 425, Phoenix, Arizona
85016.
 
Whereas, Bravatek is a corporation, which has technical expertise in security-related software, tools and systems/services (including telecom
services) to support, deploy and test its current and potential customers' most critical initiatives.
 
Whereas, COMPANY a corporation engaged in the business of providing a novel, patented Air Cylinder Wheel, to replace the need for
conventional rubber tires on a large range of vehicles used in the mining, military, construction and industries, delivering cost savings and reducing
adverse environmental impact.
 
Whereas, the parties desire to enter into a business relationship which will designate Bravatek as the project based business partnership channel
for governmental and non-governmental departments / agencies / units for the purpose of promoting COMPANY's relevant capabilities, products
and/or service solutions. Now therefore, the parties mutually agree to enter into a strategic alliance under the following terms and conditions:
 
1) Duties of Bravatek
 
Bravatek agrees to serve as a non-exclusive project sales lead finder for COMPANY. In this capacity, Bravatek will use its best efforts to
provide the following services to COMPANY.
 
a. Promote, market and introduce the Products to prospective clients in the government space nationwide.
 
b. Provide a quarterly Pipeline or project information leads report to COMPANY on a monthly basis which contains a 3-month rolling
forecast of potential sales.
 
c. Follow-up on on-going project leads that COMPANY is actively engaged with or believes is appropriate.
 
d. Provide COMPANY with any promotional materials, technical papers, white papers, proposals, etc. prior to publication or delivery to
prospective clients.
 
 
 
 12) Duties of COMPANY
 
COMPANY agrees to use its best efforts to promote and support project lead finding and after-sales support of Bravatek by:
 
a. Listing Bravatek in all appropriate sales and marketing materials as a non-exclusive alliance partner (with focus of government
customers)
 
b. Provide timely responses to both technical and administrative questions posed by Bravatek.
 
c. Promote Bravatek's product and service offerings whenever possible.
 
d. Aid Bravatek in the writing of any technical/marketing/sales documents when requested and participate in mutually-agreed upon
sales calls.
 
e. Provide Bravatek with co-branded marketing material that can be emailed or handed to prospective clients.
 
3) Obligations of the Parties
 
Bravatek and COMPANY agree to jointly:
 
a. Develop and implement a joint Product Solution and Application Strategy whereby targeted markets/potential client-
types/applications are mutually agreed upon;
 
b. Support each other in all agreed-upon technical, marketing and promotional efforts;
 
c. Develop a joint strategy for developing new product/services/capabilities to mutually benefit both parties;
 
d. Utilize each other as Preferred Vendors for services whenever possible upon mutual agreement.
 
4) Compensation
 
When custom Products are designed, developed and to be delivered to Bravatek-identified perspective clients, the parties shall agree to a
proposed sales price for use during the project in writing prior to the commencement of each project.
 
 
 
 2For any Product or Solution sold to any perspective clients introduced by Bravatek registered with COMPANY via email to COMPANY's CEO
and delivered through Bravatek or a COMPANY-designated distribution affiliate(s) or sales channel(s), Bravatek will receive a lead-finder fee,
to be mutually discussed and finally decided by COMPANY at the range of minimum of 10% to maximum of 20% of project revenue, with an
exact fee to be depending upon the overall project sales margin and cost of development and delivery of each project, payable NET 30 days
after each client payment on delivered products received at COMPANY's bank account.
 
5) Confidentiality
 
"Confidential information" shall mean any and all technical and non-technical information, documents and materials related to client projects
of party and products, services and business of each of the parties. COMPANY and Bravatek agree to maintain in strict confidence and not to
disclose or disseminate, or to use for any purposes other than performance of the projects, the Confidential Information disclosed.
 
The obligation of non-disclosure shall not apply to the following:
 
a. Information at or after such time that is publicly available through no fault of either party
 
b. Information at or after such time that is disclosed to either party by a third party entitled to disclose such information
 
c. Information which is required by law to be disclosed to federal, state or local authorities.
 
6) Term of Confidentiality
 
For a period of five (5) years after termination of this Agreement, the parties shall treat as confidential all information and take every
reasonable precaution and use all reasonable efforts to prevent the unauthorized disclosure of the same. The parties agree to take all steps
reasonably necessary and appropriate to ensure that their employees, agents, and/or assistants treat all information as confidential and to
ensure that such employees, agents, and/or assistants are familiar with and abide by the terms of this Agreement.
 
7) Term
 
The term of this Agreement is twelve (12) months from the date hereof, and will be automatically renewed for one (1) additional twelve month
period unless either party shall notify the other in writing of its intention not to renew. Such notice must be given ninety (90) days prior to
expiration of the original term. This Agreement may also be terminated by either party upon ninety (90) days written notice.
 
 
 
 38) Notices
 
Any notices required under this Agreement shall be delivered to:
 
Bravatek Technologies, Inc.
2028 E. Ben White Blvd.,
Unit #240-2835
Austin, Texas 78741
 
Sibannac, Inc.
2122 E Highland Avenue, STE 425
Phoenix, AZ 85016
 
9) Governing Law
 
This Agreement is entered into in the State of Texas and shall be interpreted according to the laws of the State of Texas.
 
10) Indemnification
 
COMPANY shall indemnify Bravatek, its directors, officers and employees, for any and all damages, costs, expenses, and other liabilities,
including reasonable attorney's fees and court costs incurred in connection with any third-party claim, action or proceeding arising from the
negligence or intentional misconduct of COMPANY or breach of COMPANY of any of its obligations under this Agreement.
 
Bravatek shall indemnify COMPANY, its directors, officers and employees, for any and all damages, costs, expenses, and other liabilities,
including reasonable attorney's fees and court costs, incurred in connection with any third-party claim, action or proceeding arising from the
negligence or intentional misconduct of Bravatek or breach of Bravatek of any of its obligations under this Agreement.
 
11) Modifications
 
No changes or modifications of this Agreement or any of its terms shall be deemed effective unless in writing and executed by the parties
hereto.
 
12) Assignment
 
This Agreement shall not be assignable by either party without the prior written consent of the other party.
 
 
 
 413) Entire Agreement
 
This Agreement represents the complete and entire understanding between the parties regarding the subject matter hereof and supersedes all
prior negotiations, representations, or agreements, either written or oral, regarding this subject matter.
 
 
 
This Agreement shall not be considered accepted, approved or otherwise effective until signed by the appropriate parties.
 
 
Bravatek Technologies, Inc.  Sibannac, Inc.
   
By: /s/ Thomas A.Cellucci  By: /s/ David Mersky
   
Name: Thomas A. Cellucci  Name: David Mersky
   
Title: Chairman & CEO  Chief Executive Officer
   
Date: November 30, 2017  Date: November 30, 2017
   
 
 
 
 
 
 
 5STRATEGIC ALLIANCE AGREEMENT  This STRATEGIC ALLIANCE AGREEMENT (the “Agreement”) is entered into as of March 18, 2010 (the “Effective Date”), between AURA SYSTEMS INC., a Delaware Corporation (“Aura”) and ZANOTTI EAST INC., a Massachusetts Corporation (“Zanotti”).  WHEREAS, Aura has invented, manufactures and distributes a unique, integrated electromagnetic mobile power generation system capable of delivering on-demand both AC and DC power for numerous end-uses, including without limitation, all-electric transport refrigeration (the “AuraGen”);   WHEREAS, the AuraGen is the subject of substantial proprietary information, including but not limited to patents, trademarks, trade secrets, know-how, and confidential information owned by Aura;  WHEREAS, Zanotti is a world-wide leading manufacturer and distributor of transport refrigeration systems and is desirous of expanding its market share within the United States, and  WHEREAS, Zanotti and Aura are desirous of incorporating the AuraGen power system with various Zanotti transport refrigeration systems to be sold by Aura to end-users in the United States as an integrated all-electric transport refrigeration solution;  NOW, THEREFORE, in consideration of their mutual covenants and obligations contained herein, and the mutual benefits to be derived herefrom, Aura and Zanotti (collectively the “Parties”), intending to be legally bound, do hereby covenant and agree as follows:  Article 1: Definitions  1.1 The term “AETRU System” means an integrated all-electric vehicle refrigeration system comprising of Product as the refrigeration mechanism and the AuraGen as the power-supply.   1.2 The term “Confidential Information” means all know-how, formulations, recipes, specifications, catalogs, books, price books, maintenance, parts and service manuals, data sheets, sales, service and technical bulletins, customer lists, sales and marketing programs, price lists, cost data, sales aids, such as filmstrips and recordings, and all other publications and information, whether or not reduced to writing, relating to the formulation, manufacture, use, marketing and sale of the AuraGen and/or the Products, as well as any other information which may be divulged by one party under this Agreement to the other in the course of its performance of this Agreement, which is marked as Confidential or which is disclosed under circumstances that reasonably place the recipient on notice of the confidentiality of the information. Confidential Information does not, however, include any information which the recipient can establish (i) was publicly known and made generally available in the public domain prior to the time of disclosure by the discloser; (ii) becomes publicly known and made generally available after disclosure by the discloser to recipient through no fault or breach of recipient; (iii) is already in the possession of recipient without restriction on use or disclosure at the time of disclosure by discloser as shown by recipient’s files and records prior to the time of thedisclosure; (iv) is obtained by recipient lawfully and without restriction on use or disclosure from a third party without a breach of such third party’s obligations of confidentiality; or (v) is independently developed by recipient without use of or reference to discloser’s Confidential Information, as shown by recipient’s files and records.   1.3 The term “Field of Use” means exclusively transport refrigeration systems for vehicles and trailers.   1.4 The term “Products” means collectively those transport refrigeration systems listed in Exhibit A attached hereto, as well as any future modifications, enhancements or improvements thereto.   1.5 The term “Proprietary Rights” means all Technology, Trademarks, data, inventions, information (including, without limitation, Confidential Information), processes, know-how, trade secrets, sketches, prototypes, notebooks, papers, drawings, formulae (including copies or extracts thereof) and similar intellectual property rights which the respective parties have or may hereafter develop and which are necessary or useful for the development, manufacture, or sale of the AuraGen, the Products, or any components of the Products and/or AuraGen. Further, Proprietary Rights shall include all analyses, specifications, proposals, reports or other information, data or documents (whether in raw, preliminary or final form) and all inventions, discoveries, modifications and improvements, whether or not patentable, which: (a) are concerned in some manner with, but not directed to the AuraGen, the Products or any components thereof; or (b) pertain to processes, procedures, methods, and the like manufacturing, assembling or servicing of the AuraGen or Products.   1.6 The term “Technology” means all patent rights concerning each and every patent, whether U.S. or foreign, owned by or licensed to Company and any associated Aura Proprietary Rights appurtenant thereto which are necessary, used or useful to develop, manufacture, or sell the Products or any of the components of the Products. Aura Technology shall further mean any future modifications, enhancements or improvements to the technology embodied in the patents owned or licensed by Company, the Products, or the Aura Proprietary Rights.   1.7 The term “Territory” means exclusively the United States of America and Canada.   1.8 The term “Trademarks” means all those trademarks, service marks, designs, logos, slogans and trade names belonging or licensed to Aura and/or Zanotti, worldwide.   Article 2 Grant of Rights  2.1 Appointment. Pursuant to the terms and conditions set forth in this Agreement, Aura appoints Zanotti as its exclusive supplier of the Products within the Territory and Field of Use and Zanotti hereby accepts such appointment. In order to maintain the exclusivity granted hereunder, Zanotti shall provide Aura with orders for a minimum of (i) one thousand (1,000) AETRU Systems during the first twenty-four (24) months of this Agreement and (ii) seven hundred and fifty (750) AETRU Systems per year thereafter for so long as this Agreement remains in effect (the “Minimum Order”). In the event that Zanotti fails to secure purchasesamounting to the Minimum Order for any particular period, the exclusive supplier rights granted pursuant to this Article 2 shall become non-exclusive commencing immediately following such period in which the Minimum Order was not achieved and Aura shall have full discretion to purchase or otherwise obtain Product from sources other than Zanotti. Aura shall serve as seller for all orders for AETRU Systems (whether such orders are provided by Zanotti or otherwise) and shall directly invoice all buyers and collect the purchase price for all AETRU Systems sold.  Article 3 Terms and Conditions  3.1 Ordering of Products. Within thirty (30) days from the Effective Date hereof, Zanotti shall deliver to Aura a minimum total of twelve (12) Products to be delivered to Aura’s facilities McDonough, Georgia, of such type as mutually agreed by the Parties (the “Initial Order”). All purchases and delivery of Products shall be made pursuant to separate individual purchase orders issued by Aura to Zanotti consistent with the terms of this Agreement. If any term of a purchase order is inconsistent with this Agreement, then this Agreement shall govern to the extent of any such inconsistency. Except with respect to the Initial Order, Aura shall place all purchase orders for Products at least forty-five (45) days prior to the requested delivery date.  3.2 Warehousing. Zanotti hereby agrees that Aura may, at any given time, store up to two (2) AuraGen systems in such Zanotti facilities as Aura may designate from time to time. Zanotti shall not charge Aura any fee or cost in connection with such warehousing. Zanotti shall not acquire any interest in or right to any property warehoused pursuant to this Section 3.2 by virtue of such warehousing and such property shall remain the sole and exclusive property of Aura (or its respective owner) at all times. It is expressly understood and agreed by the Parties that Zanotti shall incur no liability for any property stored in its facilities pursuant to this Section 3.2 (including without limitation risk of loss, theft or damage) and that all risk of loss and/or damage with respect to any such warehoused property shall belong solely to Aura. Aura shall have full access to all AuraGen systems and/or other Aura equipment warehoused in any Zanotti facilities during normal business hours and at all other reasonable times.  3.3 Pricing. Throughout the first consecutive twelve (12) months of this Agreement, all Products shall be sold to Aura by Zanotti at those prices as listed in Exhibit B, attached hereto. Prior to each twelfth month anniversary of the Effective Date of this Agreement, the Parties shall jointly reevaluate the Product price list and shall mutually agree as to prices for the upcoming twelve-month period. In accordance with Section 3.6 below, at no time shall any Product price exceed the lowest price for which Zanotti sells such Product (or substantial equivalent thereof) in similar quantities to any third party. Notwithstanding anything to the contrary contained in any applicable provision herein, Zanotti shall be permitted to adjust the price of the Products prior to each twelfth month anniversary of the Effective Date to reflect any actual fluctuation in the Consumer Price Index (CPI) during the prior twelve-month period. In the event that the final price of any Product to be sold to Aura by Zanotti pursuant to this Agreement upto, equal or exceeds 150% of the final price of any substantially-similar third part produc, Aura shall notify Zanotti of this lower price and provide Zanotti with the opportunity to match such price with respect to such Product. If, within five (5) business days of receipt of such notice from Aura, Zanotti does not agree to match such price, the exclusive supplier rights granted pursuant toArticle 2 above shall, upon Aura’s sole election, immediately become non-exclusive with respect to such specific Product to which the lower price applies and Aura shall have full discretion to purchase or otherwise obtain such Product from sources other than Zanotti.  3.4 Payment. Aura shall remit payment to Zanotti for the invoiced price of any given Product within the earlier of: (i) fifteen (15) business days following Aura’s receipt and acceptance of payment from its customer for such AETRU System into which such Product is incorporated; or (ii) forty-five (45) calendar days from the date of Aura’s shipment to a customer of such AETRU System into which such Product is incorporated. Aura shall have no obligation to remit payment for any Product before fifteen (15) days following sale to a third-party of such Product nor shall Aura have any obligation to remit payment for any Product not sold by Aura.  3.5 Shipment, Delivery and Risk of Loss. Unless otherwise specifically agreed by the Parties, all Products delivered to Aura from Zanotti pursuant to this Agreement shall be F.C.A., Aura’s designated facility. From time to time, the parties may enter into other shipping arrangements. However, no shipping arrangements shall affect or alter in any way the provisions of this Section with respect to transfer of title, responsibility of safe carriage and risk of loss.  
 
 
 3.6 Most Favored Nation. During the term of this Agreement, Zanotti agrees that Aura shall be allowed the full benefit of any and all lower prices and/or any more favorable terms and/or conditions (“MFN” Terms) contained in any other agreement entered into by Zanotti for the sale of any product substantially similar to the Product in the same or lesser quantities described in this Agreement to third parties. Zanotti shall notify Aura in writing of any such MFN Terms within fifteen (15) calendar days after agreeing thereto, and shall make the MFN Terms available to Aura as of the effective date of such agreement and thereafter for the greater of (i) three (3) months or (ii) such time that the MFN Terms remain in effect.  3.7 End-User Warranty. At all times during the Term of this Agreement, Zanotti shall warrant the Products to purchasers of AETRU Systems in accordance with the terms of its standard warranty attached hereto as Exhibit “C” (“End User Warranty”), as such End User Warranty may be modified from time to time by Zanotti, provided however that at no time shall such End User Warranty provide for a warranty coverage period of less than thirty-six (36) months from the time of purchase by the initial end-user. A copy of the End User Warranty shall be included as part of the packaging included with all Product delivered to Aura and Aura shall distribute each Product with all warranty cards, a copy of the End User Warranty and all other    
 
  (a) Deliveries may be made in partial shipments. With respect to all deliveries (partial or otherwise) Zanotti shall invoice each Product separately. 
  (b) Title and risk of loss shall pass to Aura at the time the Products are tendered by Zanotti to the initial carrier and Aura alone shall be responsible for all freight, customs duties, insurance or other shipping costs. 
  (c) In the absence of specific instructions from Aura, Zanotti shall select a reasonable carrier but shall not thereby assume any liability in connection with shipment, nor shall the carrier be construed to be the agent of Zanotti.packaging materials intact. Additionally, Zanotti shall offer to end-users the option to purchase extended warranty coverage for an additional twenty-four (24) months - making the total warranty period sixty (60) months.   Article 4 Additional Obligations  4.1 Compliance with Law. Each party shall at all times comply with the provisions of all applicable laws and the rules and regulations thereunder, and refrain from engaging in any illegal, unfair or deceptive trade practices or unethical business practices whatsoever with respect to the promotion and sale or service of Products.   4.2 Recalls. Zanotti shall maintain records of all Products sold by Zanotti and shall immediately alert Aura in the event that Zanotti becomes aware of any defect in or hazard posed by any Product. If Aura, any governmental agency or other proper authority issues a product recall or product advisory of any of the Products, Zanotti agrees to cooperate with Aura (i) in contacting purchasers during the course of any such product advisories, recalls and complaints, (ii) in communicating to such purchasers such information or instructions as Aura may reasonably desire be transmitted to such purchasers, (iii) in obtaining the removal of all such recalled Products from customers and (iv) in disposing of such recalled Product as Aura so directs. Aura agrees to reimburse Zanotti for all costs and expenses incurred by Zanotti in connection with such Product advisories, recalls and complaints, unless such advisory, recall or complaint is due to the fault or negligence of Zanotti, its representatives or affiliates.   4.3 Press Releases. In the event any party desires to issue any press release or public announcement concerning any provisions of this Agreement or the transactions contemplated hereby, such party shall so advise the other party hereto, and the parties shall thereafter use commercially reasonable efforts to cause a mutually agreeable release or announcement to be issued. Neither party will publicly disclose or divulge any provisions of this Agreement or the transactions contemplated hereby without the other party’s written consent, except as way be required by applicable law, including applicable securities laws or stock exchange regulations, and except for communications to such party’s employees and professional advisors.   4.4 Joint Training. Zanotti and Aura shall jointly schedule periodic training sessions at mutually agreed reasonable intervals with respect to installation and maintenance of the AETRU Systems, which Aura and Zanotti shall make available to AETRU System dealers and service providers. Zanotti and Aura shall each bear all living and travel expenses associated with their respective personnel during such training sessions but shall split equally all other costs associated with such training sessions such as, without limitation, facility or equipment rentals - such costs to be mutually agreed to in advance by the Parties. Upon mutual agreement by the Parties, AETRU System dealers and service providers may be charged attendance or other fees in connection with training and/or certification, provided however, that in the event that any such fees are assessed, such fees shall be divided equally among the Parties.  4.5 Joint Sales and Marketing Plan. Within thirty (30) days following the Effective Date of this Agreement, Aura and Zanotti shall develop both a joint marketing plan and a joint sales plan for cooperative worldwide marketing and sales of AETRU Systems. Any such agreementreached between Zanotti and Aura regarding such worldwide sales and marketing shall prohibit competition among Zanotti and Aura with regard to AETRU Systems and shall be memorized in a separate agreement between the Parties.  4.6 Confidentiality. Each party shall hold all Confidential Information in strict confidence and will in no way disclose or provide such Confidential Information to any person or entity, except (i) with the prior written approval of the owner of such Confidential Information or (ii) as expressly permitted under this Agreement. Each party shall take all necessary measures to prevent such disclosure by its present and future employees, officers, agents, subsidiaries, dealers or consultants during the term of this Agreement and thereafter. Each party shall give prompt notice to the other party of any unauthorized disclosure or use of Confidential Information and must cooperate fully with such other party in remedying each unauthorized use or disclosure. Neither receipt of notice of disclosure under this Section 4.6 nor any action taken by the owner of the improperly disclosed Confidential Information to assist in rectifying an unauthorized disclosure or use of Confidential Information shall constitute a waiver by such party of any breach by the disclosing party of this Article 4. The Parties each expressly acknowledge that all Confidential Information shall remain the sole property of the respective owning party and that all documents and other tangible media that embody any such Confidential Information must be, at such owning party’s option, either promptly returned or destroyed, except as otherwise may be required from time to time by applicable law. Confidential Information in documentary or other tangible form, and all copies of it, must be returned promptly to the owning party upon termination of this Agreement or, as applicable, upon earlier expiration of a party’s rights thereto in accordance with this Agreement. Each party further acknowledges and agrees that because: (i) an award of money damages in inadequate to compensate a party for any breach of this Article 4; and (ii) any breach of this Article 4 will causes irreparable harm, if there is a breach or threatened breach of this Article 4 by either party, the non-breaching party shall be entitled to equitable relief, including injunctive relief and specific performance, without proof of actual damages. The covenants and agreements contained herein with respect to any Confidential Information deemed a trade secret under applicable law shall continue until the information ceases to be a trade secret under applicable law. The obligations with respect to all other Confidential Information shall continue for a period of five (5) years following termination of this Agreement.  Article 5 Representations and Warranties  5.1 Representations and Warranties by Aura:  Aura represents and warrants to Zanotti that, as of the date of this Agreement:  
 
 
  (a) Power and Authority: Aura has the corporate power and authority to enter into and to carry out the terms and provisions of this Agreement; and this Agreement is the legal, valid and binding obligation of Aura and is enforceable against Aura in accordance with its terms.(b) No Conflicting Agreement: Aura has not granted to any person other than Zanotti any right, title or interest or entered into any agreement which is in conflict with or inconsistent with any of the terms or conditions of this Agreement.  
 
 5.2 Representations and Warranties by Zanotti:   Zanotti represents and warrants to Aura that, as of the date of this Agreement:   
  
  
  
  Article 6 Intellectual Property  6.1 During the Term of this Agreement and subject to its provisions, Aura grants to Zanotti a limited, non-exclusive license to use Aura’s Trademarks to identify and promote the sale of the AETRU System within the Field of Use in the Territory and Zanotti grants to Aura a limited, non-exclusive license to use Zanotti’s Trademarks to identify and promote the Products used in conjunction with the AETRU System within the Field of Use in the Territory. Zanotti may not use Trademarks belonging or licenses to Aura in connection with the sale or promotion of any goods, services, products, equipment or process other than the Products within the Field of Use in the Territory. Aura may not use Trademarks belonging or licensed to Zanotti in connection with the sale or promotion of any goods, services, products, equipment or process other than the Products within the Field of Use in the Territory. Upon termination of this Agreement, Zanotti and Aura shall each promptly cease using any trademarks belonging to the other Party.  
 
  (c) Litigation: There are no actions or proceedings pending, or to Aura’s knowledge, threatened, which would prevent or make unlawful the consummation of the transactions contemplated by this Agreement. 
  (d) Infringement: Aura has no actual knowledge, that the AuraGen System or, as assembled the AETRU System conflicts with, violate or infringe any rights of any third party. 
  (a) Power and Authority: Zanotti has the corporate power an authority to enter into and to carry the terms and provisions of this Agreement; and this Agreement is the legal, valid and binding obligation of Zanotti and is enforceable against Zanotti in accordance with its terms. 
  (b) No Conflicting Agreements: The execution, delivery and performance of this Agreement by Zanotti will not conflict with or violate any agreements or understandings to which Zanotti is a party or by which it may be bound. 
  (c) Litigation: There are no actions or proceedings pending, or to Zanotti’s knowledge, threatened, which would prevent or make unlawful the consummation of the transactions contemplated by this Agreement. 
  (d) Infringement: Zanotti has no actual knowledge, that any Product conflicts with, violates or infringes any rights of any third party.6.2 Trademark Markings. The Parties agree that each AETRU System shall prominently bear appropriate Aura and Zanotti Trademarks and shall clearly indicate the respective Parties’ ownership of such Trademarks. The Parties further agree to take all reasonably required action in connection with trademark marking or the giving of such other notices as provided for under United States or applicable foreign trademark laws. Neither Party shall remove or deface any Trademark belonging to the other Party without such Party’s prior written authorization. 6.3 Trademark Ownership. Zanotti acknowledges and agrees that Aura is the sole and exclusive owner of the Aura Trademarks. Aura likewise acknowledges and agrees that Zanotti s.p.a is the sole and exclusive owner of the Zanotti Trademarks. As such, neither Party shall at any time acquire any rights in the other Party’s trademarks by virtue of its use thereof. Further, nothing contained in this Agreement shall be construed as an assignment or grant by either party of any right, title or interest in or to such party’s Trademarks, it being understood that all rights relating thereto (except for the licenses granted hereunder for the right to use and utilize the Parties’ Trademarks as expressly provided herein) are reserved by the respective Parties. Further, the Parties agree that at no time shall either of them use any Trademark, mark or name confusingly similar to a Trademark, mark or name owned by or licensed to the other party, in any manner without the prior written approval of the other party. Each party each agrees that it will not knowingly do anything inconsistent with the other party’s ownership of such party’s intellectual property, including without limitation, questioning the validity of that party’s Trademarks or registering or attempting to register the other party’s Trademarks in its own name or that of any other firm, person or corporation.   6.4 Patent Markings. Each party shall each do everything reasonably required of it by the other party in connection with patent marking or the giving of such other notices as provided for under United States or applicable foreign patent laws.   6.5 Protection of Intellectual Property. Each party agrees to take such actions as the other party may reasonably require for the protection of such other party’s proprietary interest in its Trademarks, Technology, and all other Proprietary Rights. Each Party shall cooperate fully and in good faith with the other party for the purpose of preserving such other party’s rights in and to the its Trademarks, Technology and all other Proprietary Rights. Each party agrees to promptly notify the other party in writing of any uses, which may be infringements of the trademarks, technology or other proprietary rights which come to its attention. In the event of infringement of a party’s Trademarks, Technology, and other Proprietary Right, such party alone shall have the sole right to determine whether or not any action shall be taken on account of any such infringement(s).   Article 7 Term and Termiantion  7.1 Term. This Agreement shall be for a period of five (5) years commencing upon the Effective Date hereof unless sooner terminated in accordance with this Agreement (the “Initial Term”). Unless terminated prior to the natural expiration of the Initial Term, upon the expiry of the Initial Term this Agreement shall automatically renew for successive terms of the same duration, unless either party gives written notice to the other of such party’s desire not to renew not less than ninety (90) days prior to the date of the expiration of the Initial Term or anysuccessive term thereafter. For purposes of this Agreement, “Term” shall mean collectively the Initial Term as well as any successive renewal or extension thereof.  7.2 Termination. Notwithstanding Section 7.1 above, this Agreement may be terminated upon the occurrence of any of the following events:  
 
 
 
 
 7.3 Rights and Obligations upon Termination. Upon termination of this Agreement for whatever reason whatsoever, the Parties shall have the following rights and obligations:  
 
 
 
 
  (a) At the election of either party, in writing, if: (i) all or substantially all of the assets of the non-terminating party are transferred, sold or liquidated; (ii) the non-terminating party is dissolved; (iii) the non-terminating party is adjudged a bankrupt or becomes insolvent; (iv) the non-terminating party enters into an assignment or other arrangement for the benefit of its creditors; or (v) the ownership or operations of the non-terminating party have materially changed; 
  (b) By Aura, in writing in the event that Zanotti fails to meet the minimum purchase requirements as described in Article 3 above, provided, however, that such default has not been remedied by Zanotti within sixty (60) days after receipt of written notice thereof from Aura; 
  (c) By either party, if an event of force majeure continues for more than three (3) months as provided in Article 8 below; 
  (d) By either party hereto upon sixty (60) days prior written notice to the other party hereto; or 
  (e) By the non-defaulting party, (i) upon any default by the other party in the performance of any of its material obligations under this Agreement, if such default has not been remedied within thirty (30) days after receipt of written notice thereof from the non-defaulting party; or (ii) if any representation or warranty of either party herein proves to be incorrect in any material respect. 
  (a) Neither party shall be discharged for any antecedent obligations or liabilities to the other party under this Agreement, unless otherwise agreed in writing; 
  (b) Aura shall have the right but not the obligation to purchase any or all Products then in Aura’s possession at the invoiced price(s). In the event that Aura does not elect to purchase said Products, Aura, at its cost, shall return all such non-purchased Products to Zanotti. 
  (c) For a period of not less than two (2) years after the date of termination, each party shall maintain, and make available to the other party upon its request, for inspection and copying all books and records that pertain to performance of and compliance with obligations, warranties and representations under this Agreement.7.4 Effect of Termination. On and after termination of this Agreement, whether pursuant to the provisions of Section 7.3 of otherwise:  
 
 
  Article 8 General Provisions  8.1 Entire Agreement. This Agreement, including any Exhibits hereto, represents the entire agreement between the Parties on the subject matter hereof and supersedes all prior discussions, agreements and understandings of every kind and nature between them. This Agreement may be modified, amended, rescinded, cancelled or waived, in whole or in part, only by written instrument signed by all of the Parties hereto.   8.2 Notice. All notices under this Agreement shall be in English and shall be in writing and given by airmail, certified or registered, postage prepaid, return receipt requested, cable, telex or facsimile, promptly confirmed by airmail, addressed to the parties at the addresses immediately below their respective signatures hereto, or to such other address of which either party may advise the other in writing. Any notice given by airmail shall be deemed received by the addressee three (3) business days from the date of mailing. All other forms of notice will be deemed given when sent.   8.3 Force Majeure. Neither party shall be in default hereunder by reason of any failure or delay in the performance (either in whole or in part) of any obligation under this Agreement (other than the payment of money) where such failure or delay arises out of any cause beyond the reasonable control and without the fault or negligence of such party (an “Event of Force Majeure”). Such causes shall include, without limitation, storms, floods, other acts of nature, fires, explosions, riots, war, terrorism or civil disturbance, strikes or other labor unrests, embargoes, shortage or failure in supply of raw materials from the then contemplated sources of supply and no other source or supply can be located or obtained with commercially reasonable    
 
  (a) The Parties shall immediately cease all advertising and sale of the AETRU System although Aura may fill any orders received before the date of termination, subject to the provisions hereto; 
  (b) NEITHER PARTY SHALL NOT BE LIABLE TO THE OTHER FOR ANY DAMAGES, LOSSES OR EXPENSES RESULTING FROM ANY TERMINATION OR EXPIRATION OF THIS AGREEMENT ARISING FROM ANY CLAIMS ASSERTED WHICH ARE BASED UPON LOSS OF GOODWILL, PROSPECTIVE PROFITS OR ANTICIPATED ORDERS, OR ON ACCOUNT OF ANY EXPENDITURES, INVESTMENTS, LEASES OR COMMITMENTS MADE BY SUCH PARTY; 
  (c) All rights granted to either party hereunder shall forthwith and without further act or instrument, be assigned and revert to the original party. In addition, each party will execute any instruments requested by the other which are necessary to accomplish or confirm the foregoing. Any such assignment, transfer or conveyance shall be without consideration other than the mutual agreements contained hereindiligence and effort, and other governmental actions or regulations which would prohibit either party from ordering or furnishing Products or from performing any other aspects of the obligations hereunder. Within ten (10) days from the date of commencement of an Event of Force Majeure, the party affected by such an event shall advise the other party (the “Other Party”) of the date when such delay in performance commenced, and the reasons therefore as enumerated in this Agreement; likewise, within ten (10) days after the delay ends, the party affected by such an Event of Force Majeure shall advise the Other Party of the date when such delay ended, and shall also specify the redetermined time by which the performance of the obligation hereunder is to be completed. In the event that the Event of Force Mejeure continues for a period of sixty (60) days then the Other Party shall have the right to elect to terminate this Agreement upon ten (10) days notice to the party affected by such an event.   8.4 Severability. In the event any one or more of the provisions contained in this Agreement are deemed illegal or unenforceable, in whole or in part, the remaining provisions, and any partially unenforceable provisions to the extent enforceable, shall nevertheless be binding and enforceable. In the event that any act, regulation, directive, or law of a government having jurisdiction and respect of this Agreement, including its departments, agencies or courts, should make it impossible or prohibit, restrain, modify or eliminate any act or obligation of either party under this Agreement, the non-affected party shall have the right, at its option, to suspend this Agreement or the parties may, at their mutual agreement, make such modifications therein as may be necessary.   8.5 Assignment. Except as expressly provided for herein, neither party may assign or otherwise transfer any of its rights or obligations under this Agreement without the other party’s prior written approval and any such assignment or transfer shall be void. This Agreement does not create, and shall not be construed as creating, any rights enforceable by any person not a party to this Agreement.   8.6 Applicable Law. This Agreement is deemed made and entered into in the State of California and shall be construed, enforced and performed in accordance with the laws of the State of California, without reference, to choice of law. THE RIGHTS AND OBLIGATIONS OF THE PARTIES IN CONNECTION WITH THIS AGREEMENT AND ANY PURCHASE OF THE PRODUCTS SHALL NOT BE GOVERNED BY THE PROVISIONS OF THE 1980 U.N. CONVENTION ON CONTRACTS FOR THE INTERNATIONAL SALE OF GOODS.   8.7 Dispute Resolution. Any and all disputes of whatever nature, arising between the Parties of this Agreement or the underlying business relationship, including termination thereof and statutory claims, and which are not resolved between the parties themselves, shall be submitted to binding and final arbitration to be conducted in English, in Los Angeles, California, before a panel of three arbitrators in accordance with the Commercial Arbitration Rules of the American Arbitration Association for Complex Commercial Cases in effect as of the date of this Agreement.Judgment upon the award of the arbitrators may be entered in any court having jurisdiction thereof. In the event of any proceeding in arbitration between the Parties arising in any manner out of this Agreement or the asserted breach thereof, the prevailing party shall recover court costs or costs of arbitration, as appropriate, and reasonable attorneys' fees.8.8 Waiver. The waiver or excuse by either party hereto as to any breach, default or deficiency and the performance by the other party of any duty or obligation by the other party to be performed hereunder shall not constitute or be deemed a continuing waiver or excuse of the same or any other duty or obligation owed by the other.   8.9 Interpretation. In the event any claim is made by any party relating to any conflict, omission or ambiguity in this Agreement, no presumption or burden of proof or persuasion shall be implied by virtue of the fact that this Agreement was prepared by or at the request of a particular party or that party’s counsel. Reference to “include,” “includes” and “including” shall be deemed to be followed by the phrase “without limitation.”   8.10 Captions. Captions of sections of this Agreement are included for reference only, shall not be construed as part of this Agreement and shall not be used to define, limit, extend or interpret the terms hereof.   8.11 Currency. Unless otherwise agreed by the parties in writing, all payments required to be made under this Agreement shall be made in United States Dollars via cash, check, wire transfer, or other immediately available funds. The remitting party shall pay at its own expense all charges and expenses associated with the other party’s receipt of such payment, including but not limited to credit card transaction fees.   8.12 Remedies Not Exclusive. No remedy conferred by any of the specific provisions of this Agreement is intended to be exclusive of any other remedy and each and every right and remedy hereunder is cumulative with each and every other right and remedy herein or in any other agreement between the parties or under applicable law.   8.13 Counterparts. This Agreement may be executed in any number of counterparts, each of which shall constitute an original and all of which together shall constitute one and the same instrument.   8.14 No Consequential Damages. IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER PARTY FOR ANY SPECIAL, CONSEQUENTIAL OR INDIRECT DAMAGES, HOWEVER CAUSED.   8.15 Successors. Except as otherwise provided herein, this Agreement shall be binding upon and inure to the benefit of the parties hereto and their permitted successors and assigns.   8.16 No Joint Venture. Nothing contained herein shall be construed to deem the Parties in the relationship of partners or joint venturers, and no party hereto shall have any power to obligate any other party hereto in any manner whatsoever, except as expressly provided for herein.   8.17 Indemnity. Zanotti agrees to indemnify, defend and hold Aura, including its employees, agents and affiliates, harmless from and against any and all payments, damages, demands, claims, losses, expenses, costs, obligations and liabilities (including reasonable attorney’s fees and costs), which arise out of, result from or are related to: (i) any breach by Zanotti of any provision contained in this Agreement, including without limitation any obligation, representation, warranty or covenant herein; (ii) any occupational injury or illness sustained by any employee or agent of Zanotti to the extent claims are made against, or held to be payable byAura; (iii) any applicable sales or other taxes due from or on behalf of Zanotti regardless of whether such taxes must be collected by Aura on behalf of the taxing authority and regardless of whether Zanotti shall challenge the assessment or amount of such taxes (iv) any negligent or willful act or omission or violation of any contractual arrangement of Zanotti or any of Zanotti’s affiliates, officers, directors, agents or employees of each, in connection with its or their performance relating to this Agreement; or (v) Zanotti’s agreements, if any, with any other third parties. Aura agrees to indemnify, defend and hold Zanotti, including its employees, agents and affiliates, harmless from and against any and all payments, damages, demands, claims, losses, expenses, costs, obligations and liabilities (including reasonable attorney’s fees and costs), which arise out of, result from or are related to the breach by Aura of any representation, warranty or covenant contained in this Agreement. Either party seeking indemnification under this Agreement (the “Indemnified Party”) shall give notice to the party required to provide indemnification hereunder (the “Indemnifying Party”) promptly after the Indemnified Party has actual knowledge of any claim as to which indemnity may be sought hereunder, and the Indemnified Party shall permit the Indemnifying Party (at the expense of the Indemnifying Party) to assume the defense of any claim or litigation resulting thereform; provided that: (i) counsel for the Indemnifying Party who shall conduct the defense of such claim or litigation shall be reasonably satisfactory to the Indemnified Party; (ii) the Indemnified Party may participate in such defense, but only at the Indemnified Party’s own cost and expense; and (iii) the omission by the Indemnified Party to give notice as provided herein shall not relieve the Indemnifying Party of its indemnification obligations hereunder except to the extent that such omissions results in a failure of actual notice to the Indemnifying Party and the Indemnifying Party is damaged as a result of such failure to give notice. The Indemnifying Party shall not, except with the consent of the Indemnified Party, consent to entry of any judgment or administration order or enter into any settlement that (i) could affect the intellectual property rights or other business interests of the Indemnified Party or (ii) does not include as an unconditional term thereof the giving by the claimant or plaintiff to the Indemnified Party of a release form all liability with respect to such claim or litigation. In the event that the Indemnified Party shall reasonably and in good faith determine that the conduct of the defense of any claim subject to indemnification hereunder or any proposed settlement of any such claim by these Indemnifying Party might be expected to affect adversely the Indemnified Party’s intellectual property rights or ability to conduct future business, the Indemnified Party shall have the right at all times to take over and assume control over the defense, settlement, negotiations or lawsuit relating to any such claim at the sole cost and expense of the Indemnifying Party. In the event that the Indemnifying Party does not accept the defense of any matter as provided herein, the Indemnified Party shall have the full right to defend against any such claim or demand, and shall be entitled to settle or agree to pay in full such claim or demand, in its sole discretion. The provisions of this Section 8.17 shall survive the expiration or sooner termination of this Agreement.  8.18 Insurance. Both Parties will each have and maintain in full force and effect during the Term of this Agreement (including any post-termination period for which indemnification obligations continue), all product liability and other insurance reasonably necessary to coversuch party’s anticipated indemnification obligation and other risk of loss for which it may be liable under this Agreement. All such insurance coverages shall be occurrence based and not claims made. Such policy or policies will (a) have aggregate limits of liability of not less than $1,000,000 with respect to any incident or occurrence and of not less than $2,000,000 in the aggregate; (b) name both Zanotti and Aura as insured parties; and (c) provide that such policy may not be canceled except upon not less than 30 days’ written notice to both Zanotti and Aura. Each party will provide such evidence of the effectiveness of such insurance to the other party as may be reasonably requested.            [signature page to follow]IN WITNESS WHEREOF, Aura and Zanotti have caused this instrument to be executed by their duly authorized employees, as of the day and year first above written.      AURA SYSTEMS, INC. ZANOTTI USA A Delaware Corporation A Massachusetts Corporation    By: By:   _____________________________ _____________________________ Melvin Gagerman Zoltan Lemperth CEO [title]   _____________________________ Greg Demetri [title]   _____________________________ Scott Demetri [title]   _____________________________ Michael Driscoll [title]Exhibit A “Products”   
 
 V3.03/17/10 AURA/ZANOTTI STRATEGIC ALLIANCE AGREEMENT Exhibit AExhibit B Product Prices   
 
 V3.03/17/10 AURA/ZANOTTI STRATEGIC ALLIANCE AGREEMENT Exhibit BExhibit C End-User Warranty  
 
 V3.03/17/10 AURA/ZANOTTI STRATEGIC ALLIANCE AGREEMENT Exhibit CStrategic Alliance Agreement
 
This agreement is made and entered into this 10th day of January, 2018 by and between Bravatek Solutions, Inc., a corporation organized under the
laws of the State of Colorado, (“Bravatek”), with an address at 2028 E. Ben White Blvd., Unit #240-2835, Austin, Texas 78741 and Fazync LLC, a
limited liability company organized under the laws of the State of Colorado with an address at 2376 Gold River Drive, Rancho Cordova, CA 95670
(“Fazync”). Fazync is a wholly owned subsidiary of publicly traded company Intelligent Highway Solutions, Inc., (“IHSI”), a Nevada corporation.
 
Whereas, Bravatek is a corporation, which has technical expertise in security-related software, tools and systems/services (including telecom
services) to support, deploy and test its current and potential customers’ most critical initiatives.
 
Whereas, Fazync is a company engaged in the business of providing energy-saving solutions and capabilities to the Critical Infrastructure/Key
Resources arena.
 
Whereas, the parties desire to enter into a business relationship which will designate Bravatek as the project based business partnership channel
for governmental and non-governmental departments / agencies / units for the purpose of promoting Fazync relevant capabilities, products and/or
service solutions. Now therefore, the parties mutually agree to enter into a strategic alliance under the following terms and conditions:
 
1) Duties of Bravatek
 
Bravatek agrees to serve as a non-exclusive project sales lead finder for Fazync. In this capacity, Bravatek will use its best efforts to provide
the following services to Fazync
 
 a. Promote, market and introduce the Products to prospective clients in the government space nationwide.
   
 b. Provide a quarterly Pipeline or project information leads report to Fazync a monthly basis which contains a 3-month rolling forecast of
potential sales.
   
 c. Follow-up on on-going project leads that Fazync actively engaged with or believes is appropriate.
   
 d. Provide Fazync with any promotional materials, technical papers, white papers, proposals, etc. prior to publication or delivery to
prospective clients.2) Duties of Fazync
 
Fazync agrees to use its best efforts to promote and support project lead finding and after-sales support of Bravatek by:
 
 a. Listing Bravatek in all appropriate sales and marketing materials as a non-exclusive alliance partner (with focus of government
customers)
   
 b. Provide timely responses to both technical and administrative questions posed by Bravatek.
   
 c. Promote Bravatek’s product and service offerings whenever possible.
   
 d. Aid Bravatek in the writing of any technical/marketing/sales documents when requested and participate in mutually-agreed upon
sales calls.
   
 e. Provide Bravatek with co-branded marketing material that can be emailed or handed to prospective clients.
 
3) Obligations of the Parties
 
Bravatek and Fazync agree to jointly:
 
 a. Develop and implement a joint Product Solution and Application Strategy whereby targeted markets/potential client-
types/applications are mutually agreed upon;
   
 b. Support each other in all agreed-upon technical, marketing and promotional efforts;
   
 c. Develop a joint strategy for developing new product/services/capabilities to mutually benefit both parties;
   
 d. Utilize each other as Preferred Vendors for services whenever possible upon mutual agreement.
 
4) Compensation
 
When custom Products are designed, developed and to be delivered to Bravatek-identified perspective clients, the parties shall agree to a
proposed sales price for use during the project in writing prior to the commencement of each project.For any Product or Solution sold to any perspective clients introduced by Bravatek registered with Fazync via email to IHSI’s CEO, Devon
Jones, and delivered through Bravatek or a Fazync -designated distribution affiliate(s) or sales channel(s), Bravatek will receive a lead-finder
fee, to be mutually discussed and finally decided by Fazync at the range of minimum of 10% to maximum of 20% of project revenue, with an
exact fee to be depending upon the overall project sales margin and cost of development and delivery of each project, payable NET 30 days
after each client payment on delivered products received at Fazync bank account.
 
5) Confidentiality
 
“Confidential information” shall mean any and all technical and non-technical information, documents and materials related to client projects of
party and products, services and business of each of the parties. Fazync and Bravatek agree to maintain in strict confidence and not to
disclose or disseminate, or to use for any purposes other than performance of the projects, the Confidential Information disclosed.
 
The obligation of non-disclosure shall not apply to the following:
 
 a. Information at or after such time that is publicly available through no fault of either party
   
 b. Information at or after such time that is disclosed to either party by a third party entitled to disclose such information
   
 c. Information which is required by law to be disclosed to federal, state or local authorities.
 
6) Term of Confidentiality
 
For a period of five (5) years after termination of this Agreement, the parties shall treat as confidential all information and take every reasonable
precaution and use all reasonable efforts to prevent the unauthorized disclosure of the same. The parties agree to take all steps reasonably
necessary and appropriate to ensure that their employees, agents, and/or assistants treat all information as confidential and to ensure that
such employees, agents, and/or assistants are familiar with and abide by the terms of this Agreement.
 
7) Term
 
The term of this Agreement is twelve (12) months from the date hereof, and will be automatically renewed for one (1) additional twelve month
period unless either party shall notify the other in writing of its intention not to renew. Such notice must be given ninety (90) days prior to
expiration of the original term. This Agreement may also be terminated by either party upon ninety (90) days written notice.8) Notices
 
Any notices required under this Agreement shall be delivered to:
 
Bravatek Technologies, Inc.
2028 E. Ben White Blvd.
Unit #240-2835
Austin, Texas 78741
 
Fazync, Inc.
2376 Gold River dr.
Ranch Cordova, CA 95670
 
9) Governing Law
 
This Agreement is entered into in the State of Texas and shall be interpreted according to the laws of the State of Texas.
 
10) Indemnification
 
Fazync shall indemnify Bravatek, its directors, officers and employees, for any and all damages, costs, expenses, and other liabilities, including
reasonable attorney’s fees and court costs incurred in connection with any third-party claim, action or proceeding arising from the negligence
or intentional misconduct of Fazync or breach of Fazync of any of its obligations under this Agreement.
 
Bravatek shall indemnify Fazync, its directors, officers and employees, for any and all damages, costs, expenses, and other liabilities, including
reasonable attorney’s fees and court costs, incurred in connection with any third-party claim, action or proceeding arising from the negligence
or intentional misconduct of Bravatek or breach of Bravatek of any of its obligations under this Agreement.
 
11) Modifications
 
No changes or modifications of this Agreement or any of its terms shall be deemed effective unless in writing and executed by the parties
hereto.
 
12) Assignment
 
This Agreement shall not be assignable by either party without the prior written consent of the other party.
 
13) Entire Agreement
 
This Agreement represents the complete and entire understanding between the parties regarding the subject matter hereof and supersedes all
prior negotiations, representations, or agreements, either written or oral, regarding this subject matter.This Agreement shall not be considered accepted, approved or otherwise effective until signed by the appropriate parties.
 
Bravatek Technologies, Inc. Fazync LLC
     
By:   By:  
     
Name: Thomas A. Cellucci  Name: Devon Jones
     
Title: CEO  Title: Manager
     
Date: January 10, 2018  Date: January 10, 2018Exhibit 10.1
 
Text Marked By [* * *] Has Been Omitted Pursuant To A Request For Confidential Treatment And Was Filed Separately With The Securities
And Exchange Commission.
 
STRATEGIC ALLIANCE AGREEMENT
Effective Date: April 17, 2017
 
THIS STRATEGIC ALLIANCE AGREEMENT (this “Agreement”), is entered into by and between Lion Biotechnologies, Inc., with a place of
business located at 999 Skyway Road, Suite 150, San Carlos, CA 94070 (“LBIO”), and The University of Texas M. D. Anderson Cancer Center, with
a place of business located at 1515 Holcombe Blvd., Houston, TX 77030 (“MD Anderson ”), a member institution of The University of Texas System
(“System”), as of the date set forth above (the “ Effective Date”). MD Anderson and LBIO are hereinafter individually referred to as a “ Party” and
are collectively known as the “ Parties”.
 
WHEREAS, as a comprehensive cancer research, treatment, and educational center, MD Anderson undertakes research and experimental activities
in a variety of disciplines; and
 
WHEREAS, the Parties hereby wish to establish a collaboration (“ Collaboration”) with respect to the performance of one or more research studies
to be conducted pursuant to this Agreement (each such study, a “ Study ”, and collectively the “ Studies ”, and the activities to be performed with
respect to the Studies collectively, the “ Research”).
 
NOW, THEREFORE, in consideration of the mutual covenants contained herein, the receipt and sufficiency of which are hereby acknowledged,
LBIO and MD Anderson hereby agree to be legally bound as follows:
 
1. Governance.
 
1.1 Joint Steering Committee. The Parties will establish a joint steering committee (“JSC”) of equal representation, comprised of three
members from each Party, with the members of each Party collectively having one vote on all matters to be decided upon by the JSC. Each Party can
appoint and replace its members in the JSC at its own discretion through timely written notice to the other Party. The Principal Investigators for
each Study (as defined hereinafter) shall attend each JSC meeting, except in the event of exigent circumstances that do not permit such attendance.
 
1.2 JSC Meetings. The JSC will have meetings (either in person, by teleconference or via electronic means) at least quarterly. At least one
meeting per year will be conducted in person or by videoconference (including the kick-off meeting), with the location alternating between a site a
selected by LBIO and a site selected by MD Anderson. LBIO will choose the location of the first such in-person meeting. Subject to Section 1.4
below, the JSC will decide on matters by unanimous vote; provided, however, that no action may lawfully be taken at any meeting unless at least
two members from each Party (including for this purpose any proxy member appointed as provided below) are present at the meeting. If a member of
the JSC is unable to attend a meeting, he or she may appoint, in writing, a proxy to participate and vote in his or her stead.
 
 11.3 JSC Responsibilities. The main task of the JSC will be to oversee the Collaboration. In order to achieve the objectives of the
Collaboration, the JSC will oversee each Study under the Collaboration. The JSC will provide technical, scientific, clinical, and regulatory guidance
regarding the Studies and will be responsible for monitoring progress of the Studies. In addition, the JSC will be responsible for coordinating
resolution of problems arising in the Studies or in the Collaboration as a whole. Additional members can be invited by the JSC on a case by case
basis should discussion of certain topics require so; provided, that such members will be subject to obligations of confidentiality and non-use at
least as strict as those set forth in Section 5 below.
 
1.4 Dispute Resolution . Decisions regarding Study design, changes and/or additions to the initially-agreed Protocols must be unanimous,
with each Party exercising one vote each, and in the absence of such unanimity the status quo shall be maintained. For all other matters before the
JSC, a unanimous decision, with each Party exercising one vote, is required; provided, that, if unanimity cannot be achieved regarding such other
matters, then LBIO’s chief executive officer may make the decision on behalf of the JSC, provided that LBIO’s chief executive officer will first make a
good faith effort to consult with a designated executive at MD Anderson to resolve such matter.
 
2. Performance of Studies.
 
2.1 Studies .
 
(a) During the Term (as defined below), LBIO and MD Anderson may periodically agree to collaborate with respect to the
performance of one or more Studies. In connection with each Study, the Parties shall execute, as applicable, a Study-specific clinical trial agreement
or a pre-clinical work order where a clinical trial is not being conducted (each, a “Study Order”). Study Orders shall be numbered sequentially and,
when executed, appended to this Agreement and made a part hereof. The first three Study Orders, when completed, will be incorporated into this
Agreement as Exhibit I, Exhibit II, and Exhibit III, and the Studies that are the subject of such Study Orders are also referred to herein as the “ Initial
Studies ”. Each Study Order shall detail the specifics of the Study to be performed under such Study Order including (i) a detailed Study-specific
protocol (“Protocol”) that will be developed jointly by the Parties working together in good faith and (ii) any Study-specific resources or support to
be provided by LBIO, including any financial consideration (“ Collaboration Funding ”, but excluding financial support associated with the Initial
Studies to the extent addressed in Section 4 of this Agreement). Any revisions or amendments to a Study Order or Protocol shall be implemented, if
at all, solely in accordance with the terms of the relevant Study Order and shall be subject to the approval of the JSC. The Parties acknowledge and
agree that MD Anderson will be the “sponsor” of the Initial Studies that are clinical studies, as defined at 21 C.F.R. §§ 50.3(f) and 312.3(b), and will
be the holder of the investigational new drug applications (INDs) submitted to the FDA (as defined hereinafter) for such Initial Studies.
 
(b) In the event of any conflict of any terms of this Agreement and the terms of a Study Order, the terms of this Agreement shall
govern, unless the Study Order specifically and expressly supersedes this Agreement with respect to a specific term, and then only with respect to
the particular Study Order and specific term. If there is any discrepancy or conflict between the terms contained in a Protocol and this Agreement
and/or the relevant Study Order, the terms of the Protocol shall govern and control with respect to clinical matters and the terms of this Agreement
and/or the relevant Study Order shall govern and control with respect to all other matters (e.g., legal and financial matters).
 
 22.2 Investigators.
 
(a) Principal Investigator . Each Study Order will identify the individual that will serve as the “Principal Investigator ” for the
relevant Study at MD Anderson and shall be responsible for MD Anderson’s administration and supervision of its portion of such Study. If the
originally named Principal Investigator becomes unable or unwilling to continue a Study for any reason, MD Anderson shall propose a substitute
Principal Investigator with comparable qualifications within two business days of MD Anderson becoming aware of such event. If the proposed
candidate is not available or is not acceptable to LBIO, LBIO may terminate the applicable Study in accordance with Section 8.3(ii).
 
(b) MD Anderson and Principal Investigator may appoint one or more collaborating physicians (“ Sub-Investigators ”) to
participate in a Study. Such Sub-Investigators shall work under the supervision of, shall report to and be the sole responsibility of Principal
Investigator, and Principal Investigator and MD Anderson shall each ensure that all Sub-Investigators undertake all activity related to the Study in
accordance with the terms of this Agreement, the applicable Study Order, and the Protocol.
 
(c) On a Study Order-by-Study Order basis, in the event that a Principal Investigator leaves or is removed from MD Anderson (or
is otherwise unwilling or unavailable to direct the applicable Study in accordance with this Agreement and the applicable Study Order), then MD
Anderson shall, as soon as practicable but in any event within two (2) business days of such event, provide written notice of such event to LBIO.
Any subsequently appointed principal investigator must be approved, in writing in advance, by LBIO and such new principal investigator shall be
required to agree to all the terms and conditions of the applicable Study Order and this Agreement and to sign each such document as evidence of
such agreement (although failure to so sign will not relieve such new principal investigator from abiding with all the terms and conditions of the
applicable Study Order and this Agreement). If LBIO does not approve of the new principal investigator, or the new principal investigator does not
sign this Agreement, then LBIO may terminate the applicable Study Order in accordance with Section 8.3(ii).
 
2.3 Performance; Compliance with Law.
 
(a) MD Anderson shall, and shall cause each of its employees, agents, contractors, and subcontractors performing Research
activities or other obligations under this Agreement, including the Principal Investigator (collectively, “ Representatives ”) to, conduct such
activities, and  use, store and handle all materials used in the performance of activities under this Agreement and each Study Order, or cause the
same to be done, in accordance with (i) all applicable laws, regulations, and guidelines, including, to the extent applicable, the Federal Food, Drug,
and Cosmetic Act (“FFCDA”); the anti-kickback and related provisions of the Social Security Act; the Public Health Services Act; the regulations
promulgated by the Food and Drug Administration (“ FDA”), including 21 C.F.R. Parts 50, 56, and 58, and, with respect to clinical Studies, the
requirements of the Statement of Investigator, FDA Form 1572 (as described in 21 312.53), the terms of which are incorporated by reference into any
Study Order pertaining to a clinical Study (and the Principal Investigator for any such clinical Study shall complete, sign, and deliver a Form 1572 to
LBIO prior to the commencement of such Study); the United States Health Insurance Portability and Accountability Act of 1996, as amended by the
HITECH Act, including the Standards for Privacy of Individually Identifiable Health Information; the EU Data Protection Directive; and all other
applicable privacy, security and data protection laws (collectively, this sub-clause (i), “ Laws”), and, as applicable, the quality standards of “ Good
Clinical Practice” (which term shall mean generally accepted good clinical practices including those set out in the current version of the Declaration
of Helsinki and the International Conference on Harmonization Guidelines for Good Clinical Practice in force from time to time and FDA’s most
recent guidance and regulations concerning current Good Clinical Practice), (ii) the provisions of this Agreement (including each applicable Study
Order and Protocol), and (iii) all written instruction from LBIO, as well as MD Anderson’s internal policies and procedures to the extent they do not
conflict with the foregoing subsections (i) and (ii).
 
 3(b) LBIO is a United States corporation subject to the provisions of the Foreign Corrupt Practices Act (the “ FCPA”). Under the
FCPA it is unlawful to pay or to offer to pay anything of value, directly or indirectly, to foreign government officials, government employees,
political candidates, or political parties, or to persons or entities who will offer or give such payments to any of the foregoing, in order to obtain or
retain business or to secure an improper commercial advantage for LBIO. MD Anderson shall not, and MD Anderson shall ensure that its
Representatives do not, take or permit any action, including paying or transferring anything of value, directly or indirectly, to any official or other
person to influence any decision to obtain or retain business or gain an advantage in the conduct of business, or to induce such official or other
person to perform a function in violation of any Laws, that will either constitute a violation under, or cause LBIO to be in violation of, the
provisions of the FCPA or applicable local bribery and corruption Laws.
 
(c) MD Anderson shall register each Study that is a clinical study with the relevant governmental authorities and government
websites (including http://www.clinicaltrials.gov) and make all updates as required under the Laws, and shall identify LBIO as a financial
collaborator (e.g., a “Collaborator” for the purposes of www.clinicaltrials.gov) in such registrations.
 
(d) To the extent required by Law, MD Anderson and Principal Investigator shall be responsible for ensuring that the Research
and all applicable documents, including any Protocol and informed consent and authorization forms are properly approved by applicable regulatory
authorities and an Institutional Review Board (“ IRB”). As may be required by Law, and with respect to any given applicable Study hereunder, MD
Anderson and Principal Investigator shall further be responsible for making all reports and obtaining the continuing approval from the applicable
IRB. Prior to making any submission to an IRB with respect to any given applicable Study hereunder (including a Protocol, and information to be
provided to potential Study subjects including the informed consent and HIPAA authorization, and as applicable, the Case Report Forms (“ CRFs”)
or supporting source documentation), MD Anderson shall provide the proposed submission to LBIO for LBIO’s review and approval. MD
Anderson shall promptly further provide LBIO with documentation of the IRB’s initial and continuing review and approval with respect to any
given applicable Study hereunder, as well as any other communications and/or interactions with the IRB (summaries in the case of oral interactions
and/or communications) that is related to or which may impact the Research, prior to the commencement of the Research and promptly thereafter. In
the event MD Anderson’s IRB requires changes in any Protocol, informed consent or related forms for a Study after the Effective Date of the
applicable Study Order, LBIO shall be advised in advance and all such modifications must be approved in advance and in writing by the JSC under
this Agreement. MD Anderson and Principal Investigator shall not modify a Study described in a Protocol without the prior written approval of the
JSC.
 
 4(e) MD Anderson and/or Principal Investigator shall be responsible for reporting and tracking of all adverse events with respect
to a Study (“ AEs”) in compliance with all Laws and each applicable Protocol and Principal Investigator shall be responsible for updating all AEs,
including any expedited safety reports. MD Anderson and LBIO will share information with each other of any findings that may impact the safety
of a Study Drug including as Study Drug safety may adversely affect the health and safety of any Study subject, influence the conduct of a Study,
alter an IRB’s approval to continue a Study, or affect the willingness of a Study subject to continue participation in the Study. Principal Investigator
and MD Anderson shall notify LBIO within twenty-four (24) hours after learning of any serious AE and any special situation report (both as
defined in the applicable Protocol) incurred during or as the result of the Study, and provide a written confirmation report of such individual serious
adverse event and special situation report promptly thereafter, as well as a monthly listing of all such serious adverse events and special situation
reports, by electronic mail to: lionbiosafety@lionbio.com . LBIO shall have the ability to request additional information related to any such safety
finding, serious AE or special situation report, if applicable, thereafter. Additionally, MD Anderson and/or Principal Investigator will promptly
provide LBIO with all information in their possession or control as may be needed to assist LBIO in the identification and resolution of problems or
unexpected occurrences involving the Study Drug or its use in the Study.
 
2.4 Facilities. MD Anderson shall cause its Representatives to perform the Research only at the facility(ies) identified in the applicable
Study Order (the “ Facility(ies)”). MD Anderson may not utilize any facility, other than the Facility(ies), for performing any portion of the Research
without obtaining LBIO’s prior written consent to do so. MD Anderson shall maintain, or cause to be maintained, the Facility(ies), all personal
property, equipment, machinery, excipients, materials, systems, intangibles, intellectual property and contract rights in use at the Facility(ies) free of
defects, except for defects attributable to wear and tear consistent with the age and usage of such assets, and except for such defects as do not and
will not, in the aggregate, materially impair the ability to use such assets in connection with the Research.
 
2.5 No Inducement. MD Anderson agrees that LBIO’s support of the Research is not conditioned on the value or volume of business
generated between the Parties and is not being provided or received as a reward or in exchange for recommending, prescribing, dispensing,
purchasing, supplying, selling, administering, referring, arranging for, or ordering any product that is manufactured, sold, or distributed by LBIO, or
to induce recommending, prescribing, dispensing, purchasing, supplying, selling, administering, referring, arranging for, or ordering any product
that is manufactured, sold, or distributed by LBIO in the future.
 
 
 53. Materials.
 
3.1 Study Materials and Equipment . Unless otherwise provided by this Agreement (including as expressly set forth in a Study Order),
Principal Investigator shall conduct the Research with MD Anderson’s materials and equipment. MD Anderson shall be responsible for the
acquisition, purchasing, replacement, repair, maintenance, and calibration, to the extent applicable, of all materials and equipment, unless otherwise
provided by this Agreement (including as expressly set forth in a Study Order), necessary for MD Anderson to conduct the Research. LBIO shall
have no role, responsibilities, and or liability with regard to any materials and equipment necessary for MD Anderson and Principal Investigator to
conduct the Research, except as provided in this Agreement (including as expressly set forth in a Study Order).
 
3.2 Informed Consent . MD Anderson shall ensure that all patients from whom Patient Materials (as defined below) were obtained,
provided their informed consent and authorization for MD Anderson’s and Principal Investigator’s transfer of the applicable Patient Materials,
data, and information to LBIO as called for in any applicable Study Order, LBIO’s use of Patient Materials, data, and information, and LBIO’s further
transfer of the Patient Materials, data, and information to governmental or regulatory authorities and other third parties, as applicable. Upon LBIO’s
request, MD Anderson shall provide LBIO with copies of the patient informed consent and authorization forms for LBIO to confirm the provisions
of this Section 3.2.
 
3.3 LBIO Materials.
 
(a) “Material” shall mean the tangible materials, Patient Materials (as defined below) and equipment described in an exhibit to a
given Study Order (such exhibit, if provided, the “ Materials Exhibit”). The Parties will amend a given Materials Exhibit from time to time as
additional Materials are provided by or to LBIO in connection with a given Study Order. The Parties shall provide, or cause to be provided,
Materials, and rights with respect to associated intellectual property, to each other in the quantities described in the applicable Study Order (or if no
such quantities are described, in reasonable quantities) and at the times set forth in the applicable Study Order (or if no such times are set forth, as
soon as reasonably practicable and necessary after the effective date of the applicable Study Order). All Materials supplied to MD Anderson by or
on behalf of LBIO shall, as between LBIO and MD Anderson, remain the exclusive property of LBIO.
 
(b) THE MATERIALS PROVIDED TO INSTITUTION BY LBIO ARE PROVIDED BY LBIO ON AN “AS IS” BASIS. LBIO HEREBY
DISCLAIMS ANY WARRANTIES, EXPRESS OR IMPLIED, CONCERNING THE MATERIALS, INCLUDING ANY WARRANTIES OF TITLE,
INFRINGEMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. NO OFFICER, EMPLOYEE, AGENT OR REPRESENTATIVE
OF LBIO HAS ANY AUTHORITY TO BIND LBIO TO ANY AFFIRMATION, REPRESENTATION OR WARRANTY CONCERNING THE
MATERIALS, EXCEPT AS SET EXPRESSLY FORTH HEREIN. THE MATERIALS PROVIDED TO LBIO BY INSTITUTION ARE PROVIDED BY
INSTITUTION ON AN “AS IS” BASIS. INSTITUTION HEREBY DISCLAIMS ANY WARRANTIES, EXPRESS OR IMPLIED, CONCERNING THE
MATERIALS, INCLUDING ANY WARRANTIES OF TITLE, INFRINGEMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR
PURPOSE. NO OFFICER, EMPLOYEE, AGENT OR REPRESENTATIVE OF INSTITUTION HAS ANY AUTHORITY TO BIND INSTITUTION TO
ANY AFFIRMATION, REPRESENTATION OR WARRANTY CONCERNING THE MATERIALS, EXCEPT AS SET EXPRESSLY FORTH HEREIN.
 
 6(c) The Materials provided by or on behalf of LBIO shall only be used as necessary to conduct the Research, in accordance with
the Research Plan, this Agreement, all written instructions from LBIO and all Laws and not for any other uses or activities whatsoever, including in
connection with research for any third person or entity. MD Anderson shall maintain control over Materials received by it from or on behalf of
LBIO hereunder and shall not transfer any portion of such Materials to any third party for any purpose other than the purposes of performing its
obligations under, and in accordance with, this Agreement, the Research Plan, all written instructions from LBIO and all Laws. MD Anderson shall
maintain complete and accurate records relating to the disposition of all Materials provided by or on behalf of LBIO. MD Anderson shall return to
LBIO all unused supplies of Materials provided by or on behalf of LBIO in accordance with Section 8.4 or at LBIO’s earlier request. MD Anderson
shall have no right to provide samples of the Materials provided by or on behalf of LBIO (or products created thereby) to any person or entity.
 
3.4 Patient Materials . “Patient Materials ” shall mean those certain biological materials, and derivatives thereof and related patient data and
information, received from individual patients and described in an applicable Materials Exhibit. Without limiting Section 3.3, MD Anderson shall
further handle, transport, use and store Patient Materials exclusively at the Facility(ies) or otherwise in accordance with this Agreement, unless
otherwise requested by LBIO in writing, and at all times strictly in accordance with (a) MD Anderson’s standards of security and confidentiality
and (b) all applicable privacy, security and data protection Laws (including the United States Health Insurance Portability and Accountability Act
of 1996, as amended by the HITECH Act, including the Standards for Privacy of Individually Identifiable Health Information, and the EU Data
Protection Directive).
 
 74. Certain Financial Matters.
 
4.1 Initial Funding. LBIO agrees to commit funding in an amount not to exceed $14,211,864.00 for the performance of the Studies during the
Term (collectively, “Initial Funding”), with the Initial Funding specifically allocated as follows: (a) $[* * *] for an upfront payment, and a minimum of
$[* * *] for enrollment and treatment of a minimum of 40 patients in the Study described in Exhibit I (i.e., the Minimum Enrollment Target as defined
in Exhibit 1) or up to $[* * *] (an “Individual Study Budget ”) for enrollment and treatment of up to 60 patients in the Study described in Exhibit I
(i.e., the Maximum Enrollment Target as defined in Exhibit 1); (b) $[* * *] (which shall also be considered an Individual Study Budget ) for
enrollment, manufacturing of product, and treatment of 30 patients in the Study described in Exhibit II; and (c) $[* * *] for the Study described in
Exhibit III. LBIO shall pay the Initial Funding in accordance with Section 4.3. For clarity, the Initial Funding is Collaboration Funding. MD Anderson
agrees that all costs of this Collaboration, with the sole exceptions of any costs to supply clinical-grade aldesleukin and 4-1BB agonist for use in
the expansion of tumor infiltrating lymphocytes (“ TILs”), and in the case of aldesleukin, for use in the treatment of patients, are included in the
Initial Funding. Subject to the foregoing exceptions, MD Anderson shall be solely responsible for any costs it incurs in performing the Studies that
are in excess of the Initial Funding.
 
4.2 Collaboration Funding Generally. MD Anderson shall use the Collaboration Funding solely to conduct the applicable Study and MD
Anderson shall be responsible for managing cash flow between payments. It is understood and agreed that the Collaboration Funding shall cover
all administrative, IRB review, patient recruitment, and all other fees, costs and expenses of MD Anderson and any of its Representatives for the
conduct of the Studies or the provision of equipment or services to facilitate the Studies, and that no other form of compensation shall be paid to
MD Anderson in connection with the Studies except as otherwise may be specifically and mutually agreed upon by the Parties in writing.
 
4.3 Payments. LBIO shall pay the Initial Funding to MD Anderson as follows. An upfront payment of $[* * *] (the “ Upfront Payment”)
shall be invoiced by MDACC on the Effective Date. The remainder of the Initial Funding shall be paid as follows:
 
(a) In the event that the Study Order covers the performance of a clinical trial, funding shall be invoiced based on Study patient
enrollment as follows, based on the Maximum Enrollment Target as defined in each Study Order:
 
Milestone (on Study Order-by-Study Order
basis)
 Payment (% of the Individual Study 
Budget) to be provided in 
connection with such Study Order*
Enrollment of [* * *]% of the target patient enrollment as set forth in the
applicable Protocol
 [* * *]%
Enrollment of [* * *]% of the target patient enrollment as set forth in the
applicable Protocol
 [* * *]%
Enrollment of [* * *]% of the target patient enrollment as set forth in the
applicable Protocol
 [* * *]%
Enrollment of final patient as set forth in the applicable Protocol  [* * *]%
Receipt by LBIO of both (a) the final clinical study report and (b) all raw
clinical data (anonymized and without including any identifying
information)
 [* * *]%
 
*With respect to Exhibit 1, the Individual Study Budget shall be the one associated with the Minimum Enrollment Target (as defined in Exhibit 1),
and in the event that the Parties move to the Maximum Enrollment Target (as defined in Exhibit 1) then this table shall be applied to the incremental
additional patients as if the incremental additional patients constitute their own protocol/budget. For example, if LBIO decides to add ten (10)
additional patients to the clinical study in Exhibit 1, each patient will be accrued at $[* * *] per patient, and LBIO will be invoiced for percentage
enrollment of these ten (10) patients based on the table above.
 
 8(b) In the event that the Study Order covers activities other than the performance of a clinical trial, a payment schedule will be set
forth in the relevant Study Order.
 
(c) Notwithstanding the foregoing, LBIO may suspend payment if, in LBIO’s reasonable opinion after review of the Reports (as
defined below), MD Anderson has not been performing the Research diligently and in the manner agreed upon herein.
 
(d) Upon the occurrence of one of the milestones identified in the table in Section 4.3(a), or described in an applicable Study
Order for a non-clinical Study according to Section 4.3(b), MD Anderson shall invoice LBIO for the related payment amount. In each case, invoices
shall be itemized, including by reference to Study Order title, and otherwise shall include such supporting documentation as LBIO may reasonably
request. LBIO shall pay all undisputed invoices within thirty (30) days of receipt of such invoice.
 
(e) If the Study described in Exhibit II is not commenced, the portion of the Upfront Payment that would have been applied to that
Study ($[* * *]) will be credited by MD Anderson towards the Studies described in Exhibit I and Exhibit III.
 
(f) All terms and payments of compensation, benefits, and any other conditions of engagement, including payment of taxes, for
any person working with Principal Investigator and any other support staff who may be used in the performance of a Study (including any Sub-
Investigator) shall be solely a matter between MD Anderson and such individuals. Principal Investigator and any MD Anderson personnel shall
not be deemed to be employees of LBIO or entitled to any benefits offered by LBIO to LBIO’s employees.
 
5. Records and Reports.
 
5.1 Records. MD Anderson shall, and shall cause its Representatives to, keep appropriate records of the Research, including laboratory
notebooks, in accordance with MD Anderson policies and all Laws, sufficient to properly document the results of the Research and otherwise
sufficient to determine identity and dates of inventorship of Inventions (as defined in Section 7.1(a)). MD Anderson shall make such records
available to LBIO upon reasonable notice during MD Anderson’s normal business hours. LBIO may use the records and Reports (as defined
below) for any purpose, including interactions and communications with, and/or submissions and filings to the applicable governmental or
regulatory authorities.
 
 95.2 Reports. MD Anderson, through the Principal Investigator, shall provide to LBIO (a) interim written reports regarding the Research, no
less than once per calendar quarter, and (b) on Study-by-Study basis, (i) a draft final written Study report within thirty (30) days after completion (or
earlier termination) of each such Study and (ii) a final written Study report within thirty (30) days after receipt of LBIO’s comments to the draft final
written Study report with respect to each such Study, which shall be given by LBIO not later than thirty (30) days after LBIO’s receipt of the draft
final Study report (collectively, the “Reports”); provided, that, if this schedule of reports differs from the reporting obligations provided in a Study
Order, the schedule listed in the Study Order shall be followed. LBIO shall own all Reports and data compilations resulting from the Research,
excluding the physical original lab notebooks themselves (but not excluding the data and data compilations contained therein, which shall be
deemed to be owned by LBIO) and any patient medical records.
 
5.3 Electronic Transfer. In addition to MD Anderson’s reporting obligations under Section 5.2, no less than once per calendar quarter, MD
Anderson shall provide to LBIO an electronic transfer of all data and results (including all raw data and process data) generated through the
performance of the Research.
 
5.4 Other Notifications. During the performance of the Research, MD Anderson shall notify LBIO promptly if the Research reveals any
unexpected result or any accident or harm occurs, and shall also comply with any safety notifications required under each Study Order.
 
 106. Confidentiality and Publications.
 
6.1 Confidential Information.
 
(a) “Confidential Information” means any proprietary or confidential information, technical data, trade secrets or know-how,
including research, product plans, products, services, customer lists and customers, markets, software, developments, inventions, processes,
formulas, technology, designs, drawings, engineering, marketing, distribution and sales methods and systems, sales and profit figures, finances and
other business information disclosed by a Party or its Representatives (“ Disclosing Party ”) to the other Party or its Representatives (“ Receiving
Party”), whether in writing, orally or by drawings or inspection of documents or other tangible property; provided that: (i) Confidential Information
shall not include any of the foregoing items to the extent that (1) they are or have become publicly known and made generally available through no
wrongful act of Receiving Party, (2) they were known to Receiving Party prior to disclosure by Disclosing Party, as evidenced by pre-existing
written records promptly provided to Disclosing Party by Receiving Party, (3) they were disclosed to Receiving Party without an obligation of
confidentiality by a third party having a lawful right to make such disclosure, or (4) they were developed by Receiving Party without use or aid of
Disclosing Party’s Confidential Information, and (ii) the results of the Research (including the contents of each Report and any Inventions) shall be
deemed to be LBIO’s Confidential Information, subject to MD Anderson’s right to publish any Research data and information as set forth in and in
accordance with Section 6.4, MD Anderson’s right to use any Inventions (and any Work) as set forth in and in accordance with Section 7.2, and
MD Anderson’s right to use any Research data and information for internal research, academic, and non-commercial patient care purposes prior to
publication or public disclosure and for any purpose thereafter. LBIO shall be deemed the Disclosing Party with respect to such results of the
Research, regardless of the Party initially disclosing the same.  
 
(b) Receiving Party shall take reasonable steps to ensure that Disclosing Party’s Confidential Information (as defined in Section
6.1(a)) is maintained in confidence, used only for the purpose of exercising rights and performing obligations under this Agreement, and disclosed
only to persons and/or entities authorized under this Agreement. As used herein, “reasonable steps” means the steps that Receiving Party takes to
protect its own, similar confidential and proprietary information, which shall not be less than a reasonable standard of care. Receiving Party further
agrees not to reveal, publish or otherwise disclose Disclosing Party’s Confidential Information to any third party without the prior written consent
of Disclosing Party as described in Section 6.4 below, however, Receiving Party is permitted to disclose Confidential Information obtained under the
terms of this Agreement to its Representatives on a need-to-know basis related to the exercise of rights and performance of its obligations under
this Agreement and only if such Representatives are informed by Receiving Party of the confidential nature of such information and are bound by
confidentiality obligations consistent with those set forth in this Section 6.1. Receiving Party shall ensure that its Representatives having a need-
to-know Disclosing Party’s Confidential Information observe these obligations of confidentiality. These obligations of confidentiality and
nondisclosure shall remain in effect after the termination or expiration of this Agreement for a period of five (5) years.
 
 11(c) Neither Party shall improperly use or disclose to the other Party or any of its directors, officers, employees or agents, any
confidential information of any current or former client or other person or entity with whom such Party has an agreement or duty to keep such
information confidential, and such Party shall not bring onto the premises of the other Party any such information in any medium unless consented
to in writing by such client, person or entity. In the event of a Party’s breach of this Section 6.1(c), the breaching Party shall ensure that the other
Party may freely and fully utilize the information so disclosed for any and all purposes.
 
6.2 Required Disclosure of Confidential Information.
 
(a) If Receiving Party is required by Law or court order to disclose Disclosing Party’s Confidential Information, Receiving Party
shall give Disclosing Party prompt written notice of such requirement such that Disclosing Party shall have the opportunity to apply for a
protective order, injunction or for confidential treatment of such Confidential Information. Receiving Party shall cooperate with Disclosing Party in
seeking any Disclosing Party requested protective order, injunction or confidential treatment of such Confidential Information and shall only
disclose the minimal amount of such Confidential Information required under Law or court order. Notwithstanding the forgoing, any information
disclosed by Receiving Party pursuant to Law or a court order shall remain Confidential Information hereunder, and may not be disclosed under any
other circumstances unless and until the Confidential Information so disclosed falls into one of the exceptions set forth in subclauses (1) through
(4), inclusive, in Section 6.1(a).
 
(b) If Principal Investigator is a member of or affiliated with any committee that sets formularies or develops clinical practice
guidelines that could influence the prescribing of medicines or is otherwise affiliated with any other healthcare institution, medical committee, or
other medical or scientific organization, Principal Investigator will inform the committee of the existence and nature of Principal Investigator’s
relationship with LBIO under this Agreement. Principal Investigator also agrees to disclose Principal Investigator’s relationship with LBIO as
needed to comply with any disclosure requirements of any healthcare institution, medical or formulary committee, or other medical or scientific
organization with which Principal Investigator is affiliated and agrees to comply with any such entities’ recusal or other requirements relating to the
relationship with LBIO. This duty to disclose will continue during the term of this Agreement and for two years after its termination
 
6.3 LBIO Mandatory Disclosures . MD Anderson and Principal Investigator recognize that LBIO may be required under Law, including the
Physician Payment Sunshine Act, to report to the relevant governmental or regulatory authorities or publicly disclose information related to this
Agreement and/or the Research, including any payments, reimbursements, or other transfers of value made to MD Anderson or Principal
Investigator. Nothing herein shall prevent LBIO from making any reports or disclosures required under Law or by a relevant governmental or
regulatory authority. Moreover, nothing herein shall prevent LBIO from disclosing any information relating to this Agreement and/or the Research
for the purpose of making any regulatory or other submissions, patent applications and pursuing patent prosecution.
 
 126.4 Publications . MD Anderson agrees to provide LBIO with a copy of any manuscript, abstract or other proposed publication or
presentation relating to the Research or the Materials (a “ Publication”), prior to submission thereof to a publisher or to any third party, and in any
case, not less than 45 days prior to any public disclosure, for the purpose of protecting proprietary or intellectual property of LBIO that might be
contained in such Publication. Following receipt of such proposed Publication, LBIO shall have the right to cause MD Anderson to (i) withhold
publication or other public disclosure thereof for a period of up to 90 days in order to provide LBIO time to obtain appropriate intellectual property
protection thereof, and (ii) remove any proprietary, or otherwise confidential, information of LBIO contained in such Publication (excluding
Research results). In any event, MD Anderson will not disclose proprietary, or otherwise confidential, information in an “unblinded” manner when
it can be done so in a “blinded” manner. In the event of any Publication (including any public presentation relating to the Research or the
Materials), MD Anderson agrees to acknowledge LBIO and/or give credit to LBIO scientists, as scientifically appropriate, based on any
contribution they may have made to the work which shall be in accordance with any relevant policies and guidelines of the publication,
presentation forum, as well as policies and guidelines of general applicability, such as the International Committee of Medical Journal Editors
recommendations. In addition, to the extent that it is legally able to do so, MD Anderson hereby grants LBIO a royalty-free right and license to use
and reproduce any Publication. LBIO shall be acknowledged as a financial collaborator of the Study reported in a Publication.
 
6.5 Unauthorized Disclosure . Receiving Party shall be responsible for any breach of this Section 6 by any of its Representatives. Receiving
Party shall take reasonable steps to ensure that unauthorized persons do not gain access to Disclosing Party’s Confidential Information. Receiving
Party shall promptly notify Disclosing Party of any unauthorized release of or access to Disclosing Party’s Confidential Information. For clarity,
such notice shall not remedy any breach of this Agreement resulting from such unauthorized release or access.
 
6.6 Prior CDA. This Agreement supersedes that certain Confidentiality Agreement between LBIO and MD Anderson, dated July 22, 2016
(“Prior CDA”), which is hereby terminated; provided, however, that all information disclosed or received by the Parties under the Prior CDA will be
deemed Confidential Information hereunder (to the extent applicable) and will be subject to the terms and conditions of this Agreement. The Parties
agree that this Agreement provides the written notice required for termination of the Prior CDA pursuant to Section 6.8 of the Prior CDA.
 
6.7 Publicity. LBIO shall be permitted to publicly disclose the existence of this Agreement, and the title and purpose of each clinical Study,
in LBIO’s electronic materials, printed materials, oral presentations, and press releases, and LBIO shall be permitted to include each clinical Study as
a component of LBIO’s clinical product pipeline.
 
6.8 Health Information. Notwithstanding anything to the contrary in this Agreement or any Study Order, all individually identifiable health
information shall be treated as confidential by the Parties in accordance with all Laws governing the confidentiality and privacy of individually
identifiable health information, including HIPAA, and any regulations and official guidelines promulgated thereunder, and the Parties agree to take
such additional steps and/or to negotiate such amendments to this Agreement as may be required to ensure that the Parties are and remain in
compliance with the HIPAA regulations and official guidance.
 
 137. Inventions.
 
7.1 Background Intellectual Property and Definitions .
 
(a) Neither Party will, as a result of this Agreement, acquire any right, title or interest in, to, or under any Intellectual Property (as
defined below) owned or controlled by the other Party or the other Party’s affiliates prior to the Effective Date or developed independently of this
Agreement (“Background Intellectual Property ”), except for the licenses expressly granted under this Agreement.
 
(b) “Invention ” means any idea, invention or discovery, whether or not patented or patentable, that is first conceived,
discovered, developed or reduced to practice by a Party in connection with this Agreement, including through MD Anderson’s performance of the
Research (solely or jointly with others) or that result, to any extent, from use of Confidential Information or the Study article that is the subject of a
given Study, including any developments, discoveries, improvements, compositions, know-how, trade secrets, procedures, technical information,
data, reports, processes, methods, devices, formulae, protocols, techniques, designs, drawings, methodologies, and biological or chemical material.
 
(c) “Intellectual Property Rights ” means any and all moral rights and intellectual property rights, including all patent rights,
copyrights, trademarks, know-how and trade secrets and the rights to apply for the same.
 
(d) “Fields” means the treatment of platinum resistant ovarian cancer, chondrosarcoma, and pancreatic ductal adenocarcinoma,
and, solely for the purposes of Section 7.3(b), double refractory melanoma, such treatment being performed using TILs manufactured by MD
Anderson using a 4-1BB agonist; provided that Fields shall also include the treatment of other diseases in the event that the JSC decides to amend
or replace the initially-agreed clinical Protocol for the Study Order provided in Exhibit II to include the treatment of such other diseases.
 
7.2 Assignment of Inventions; Further Assurances .
 
(a) MD Anderson shall promptly make full written disclosure to LBIO, shall hold in trust for the sole right and benefit of LBIO,
and hereby assigns, transfers and conveys to LBIO, or its designee, all of MD Anderson’s worldwide right, title and interest in and to any and all
Inventions and all Intellectual Property Rights therein and relating thereto[, provided that MD Anderson shall retain the right to use any such
Invention for internal research, academic, and patient care purposes]. MD Anderson further acknowledges and agrees that all original works of
authorship that are made by MD Anderson (solely or jointly with others) in the performance of the Research, excluding any publication made in
accordance with Section 6.4 (a “Work”) and that are protectable by copyright are “works made for hire,” as that term is defined in the United States
Copyright Act. However, to the extent that any Work may not, by operation of any Laws, be a work made for hire, MD Anderson hereby assigns,
transfers and conveys to LBIO all of MD Anderson’s worldwide right, title and interest in and to such Work, including all Intellectual Property
Rights therein and relating thereto, subject to MD Anderson’s right to use such Work for internal research, academic, and non-commercial patient
care purposes prior to publication or public disclosure.  
 
 14(b) Upon the request and at the reasonable expense of LBIO, MD Anderson shall execute and deliver any and all instruments and
documents and take such other acts as may be reasonably necessary to document or perfect the assignment and transfer described in Section
7.2(a) or to enable LBIO to secure its rights in the Inventions, Works and Intellectual Property Rights therein and relating thereto in any and all
jurisdictions, or to apply for, prosecute and enforce Intellectual Property Rights in any and all jurisdictions with respect to any Inventions or
Works, or to obtain any extension, validation, re-issue, continuance or renewal of any such Intellectual Property Right.
 
(c) As between the Parties, and without limiting MD Anderson’s assistance obligations under Section 7.2(b), LBIO shall have the
sole and exclusive right to file patents covering or claiming Inventions and shall bear all costs with respect to the prosecution and maintenance
thereof. In furtherance of the foregoing, the Parties shall work together in good faith to, as expeditiously as possible following the Effective Date,
put in place a power of attorney granted by the System to LBIO for purposes of enabling LBIO to apply for or to pursue any application for any
United States or foreign patent, trademark, copyright or other registration covering Inventions or Works assigned to LBIO hereunder in the event
that LBIO is unable to secure MD Anderson’s assistance in connection with the same.
 
7.3 Background Licenses .
 
(a) MD Anderson hereby grants LBIO a non-exclusive, royalty free, perpetual license (with rights to sub-license) under, in and to
all Background Intellectual Property that is: (a) owned by MD Anderson; (b) consists of and/or comprises the manufacturing protocol utilized by
MD Anderson in the conduct of a Study; and (c) reasonably necessary to exploit (including developing, obtaining and maintaining regulatory
approval for, manufacturing, or commercializing) any Invention, Study result, or Study article, or any improvement or derivative thereof, strictly
limited to the Fields (collectively, the “Non-Exclusively Licensed MD Anderson Background Intellectual Property ”), to the extent that such Non-
Exclusively Licensed MD Anderson Background Intellectual Property does not include Third Party IP (as defined hereinafter).
 
(b) MD Anderson also grants LBIO a non-exclusive, royalty free, perpetual license (with rights to sub-license) under, in and to
any and all data generated by MD Anderson in conducting studies of TILs in double refractory melanoma outside of the Collaboration and as of
the Effective Date, and LBIO shall have unrestricted rights to use such double refractory melanoma data in governmental and regulatory
submissions, including submissions that may become public.
 
7.4 Third Party Intellectual Property . To the extent that MD Anderson controls any Background Intellectual Property that it will use in
conducting a Study or manufacturing any Study article through a license agreement with a third party (“ Third Party IP”), MD Anderson shall notify
LBIO thereof as soon as any such Third Party IP is identified. MD Anderson shall not use any Third Party IP in performing activities under this
Agreement or otherwise in connection with a Study unless and until the JSC approves the use thereof. In addition, MD Anderson shall provide
such assistance as is reasonably requested by LBIO in connection with LBIO obtaining a license in and to any such Third Party IP.
 
 157.5 No Implied Licenses; Retained Rights . Except as explicitly set forth in this Agreement, neither Party grants any license, express or
implied, under its intellectual property rights to the other Party, whether by implication, estoppel or otherwise, and each Party hereby agrees that it
does not have rights under any intellectual property of the other Party that are broader than the licenses expressly granted herein.
 
7.6 Effectiveness . The provisions of Section 7 shall become effective upon payment by LBIO of the Upfront Payment and the approval by
LBIO of the Study Orders in Exhibit I and Exhibit III. For clarity, the commencement of work, or the lack thereof, under the Study Order in Exhibit II
shall have no effect upon the effectiveness of the provisions of Section 7.
 
8. Term and Termination.
 
8.1 Term. The term of this Agreement commences on the Effective Date and shall continue in effect until the later of (a) the fourth (4th)
anniversary of the Effective Date, or (b) the completion or termination of the Research and receipt by LBIO of all deliverables due from MD
Anderson hereunder, unless sooner terminated in accordance with the provisions of Section 2.2 or Section 9.14.
 
8.2 Termination. Either Party may terminate this Agreement for the material breach or default of any of the terms or conditions of this
Agreement by the other Party upon thirty (30) days’ written notice and the opportunity to cure during such notice period; and such termination
shall be in addition to any other remedies that it may have at law or in equity. Additionally, LBIO may terminate this Agreement if MD Anderson is
declared insolvent or enters into liquidation or has a receiver or an administrator appointed over all or any part of its assets or ceases or threatens
to cease to carry on business, or a resolution is passed or a petition presented to any court for the winding up of the Party or for the granting of an
administration order in respect of MD Anderson, or any proceedings are commenced relating to the insolvency or possible insolvency of MD
Anderson.
 
8.3 Termination of a Study Order. LBIO may terminate a Study Order immediately upon written notice to MD Anderson if:
 
(i) the applicable approvals, authorizations, and/or continuing reviews for a Study are not obtained or maintained;
 
(ii) Principal Investigator is no longer available for the Study and a replacement deemed acceptable by LBIO is not
provided;
 
(iii) the Study is canceled, terminated, suspended, delayed or placed on hold for any reason;
 
(iv) an Institutional Review Board or other review authority, including governmental or regulatory authorities, does not
approve a Study or recommends the cancelation, termination, suspension, or hold of a Study for any reason;
 
(v) immediate termination of the Study is necessary due to LBIO’s evaluation of risks to Study subjects, such risks
including the futility of treatment; or
 
 16(vi) MD Anderson or Principal Investigator materially breaches any obligations with respect to the Study, including
failure to comply with this Agreement, the Protocol or the Study Order or any Law relevant to the Study.
 
8.4 Obligations upon Termination . Upon expiration or termination of this Agreement, in addition to its other obligations hereunder,
including Section 5.2, MD Anderson shall return to LBIO all of its Confidential Information and all Materials or, at LBIO’s option, destroy or
completely delete such Confidential Information and Materials, at LBIO’s option. With respect to each item of Confidential Information and
Materials destroyed or completely deleted, such destruction or complete deletion shall be certified in writing to LBIO. In the event that this
Agreement is terminated prior to MD Anderson’s receipt of all internal approvals to commence work on the Study Orders in Exhibit I, Exhibit II
and/or Exhibit III, MD Anderson shall refund the Upfront Payment to LBIO.
 
8.5 Effects of Termination. Termination of this Agreement by either Party shall not affect the rights and obligations of the Parties accrued
prior to the effective date of termination. No termination of this Agreement, however effectuated, shall release the Parties, the Principal Investigator,
or any other Representative of MD Anderson having access to Confidential Information from their respective rights and obligations under Sections
6, 7, and 9.
 
9. Miscellaneous.
 
9.1 Mutual Representations . Each Party hereto hereby represents, warrants and covenants to the other that: (a) it is duly incorporated or
otherwise formed, validly existing and in good standing; (b) it has taken all necessary actions on its part to authorize the execution, delivery and
performance of the obligations undertaken in this Agreement, and no other corporate or regulatory actions (e.g., obtaining permits, licenses or
authorizations) are necessary with respect thereto; (c) it is not a party to, and will not become a party to, any agreement or understanding and
knows of no law or regulation that would prohibit it from entering into and performing this Agreement, or that would conflict with this Agreement;
and (d) when executed and delivered by it, this Agreement will constitute a legal, valid and binding obligation of it, enforceable against it in
accordance with this Agreement’s terms.
 
9.2 MD Anderson Representations . MD Anderson represents, warrants, and, to the extent applicable, covenants, that:
 
(a) MD Anderson and all of its Representatives maintain as current the applicable licenses and permits, including medical
practitioner licenses as required by the applicable national, state, and/or local licensing body and that no license or permit has been revoked,
limited, suspended, or otherwise modified.
 
(b) Neither MD Anderson nor any of its Representatives have (i) violated or caused a violation of any federal or state health care
fraud and abuse or false claims statute or regulation, including the anti-kickback provisions of the Social Security Act, 42 U.S.C. § 1320a-7b(b), (ii)
violated or caused a violation of any federal or state privacy or security law or regulation, including HIPAA, (iii) not been excluded or threatened
with exclusion under state or federal statutes or regulations, including under 42 U.S.C. § 1320a-7 or relevant regulations in 42 C.F.R. Part 1001, or (iv)
not been assessed or threatened with assessment of civil money penalties pursuant to 42 C.F.R. Part 1003, or any foreign equivalent.
 
 17(c) Neither MD Anderson nor any of its Representatives have been charged, named in an action, found liable, or convicted for
conduct relating to the development or approval of, or otherwise related to the regulation of any healthcare product or the practice of medicine.
 
(d) Neither MD Anderson nor any of its Representatives (i) have been found by the FDA or any other relevant governmental or
regulatory authority to have violated any Laws, regulations or guidelines concerning the conduct of clinical investigations or related services; (ii)
have been debarred, denied, or suspended by the FDA under 21 U.S.C. § 335a, disqualified or restricted by the FDA, named on any FDA list related
to investigator disqualifications, restrictions, restrictions removed, or adequate assurances, or are otherwise ineligible to participate in federal
procurement or non-procurement programs or any foreign equivalents of the above; and (iii) have any unresolved FDA warning letter, Form 483, or
other regulatory enforcement action threatened against or issued to them;
 
(e) MD Anderson and its Representatives will not make and have not made any untrue statement of material fact to or filed a false
claim or report with any governmental or regulatory authority, or failed to disclose a material fact required to be disclosed to any governmental or
regulatory authority, or have ever been investigated by the FDA, National Institutes of Health (“ NIH”), Office of the Inspector General for the
Department of Health and Human Services (“ OIG”), Department of Justice or other comparable governmental or regulatory authority for data or
healthcare program fraud.
 
(f) There is no investigation, threat, pending, or proposed proceeding, notice, or action by a governmental or regulatory entity
which could result in 9.2(a)-9.2(e) above.
 
(g) MD Anderson has no knowledge of any facts or circumstances that may affect the accuracy or completeness of any the
foregoing representations and warranties. MD Anderson is responsible for (i) requiring all of its Representatives to disclose the occurrence of
9.2(a)-9.2(f) above and (ii) reviewing on reasonable intervals all available public filings and lists to confirm that it and its Representatives are not
subject to 9.2(a)-9.2(f) above. If MD Anderson becomes aware of any such facts or circumstances during the Term or otherwise determines that any
representation or warranty made by it under this Agreement is no longer true, correct, or complete, MD Anderson will notify LBIO immediately, but
in no case later than twenty-four (24) hours after MD Anderson becomes aware of such facts, circumstances, or determination. MD Anderson shall
immediately remove any of its Representatives from performing activities relating to the Research to which the facts, circumstances, or
determination relate. Any such facts, circumstances, or determinations shall be grounds for termination of this Agreement.
 
(h) Each of MD Anderson’s Representatives is under a written obligation to assign to MD Anderson all Inventions and any
Intellectual Property Rights therein or relating thereto made by such Representative in the course of his or her employment.
 
(i) Neither the United States government nor any agency thereof nor any other third party has funded or will fund any part of the
Research.
 
 18(j) MD Anderson’s applicable database applications and electronic records systems and facilities which are used in the
performance of the Research, including the database to be used by MD Anderson and Principal Investigator for the tracking, handling, recording,
reporting and transmitting of data generated during a Study, have been fully validated and are compliant with all Laws.
 
(k) MD Anderson is not entering into this Agreement (i) as a result of any pre-existing or future business relationships between
MD Anderson and/or Principal Investigator and LBIO, (ii) as a result of any business or other decisions MD Anderson and/or Principal
Investigator have made or may make in the future relating to LBIO or LBIO products, or (iii) as a reward or in exchange for MD Anderson or
Principal Investigator prescribing or purchasing LBIO products or to induce the prescription or purchase of LBIO products by MD Anderson or
Principal Investigator.
 
9.3 Warranty of cGMP. LBIO represents and warrants that any Study Drug (as defined in an applicable Study Order) manufactured by and
provided by it for any Study hereunder has been and will be manufactured in accordance with current Good Manufacturing Practice regulations.
 
9.4 Independent Status . MD Anderson shall not be considered a partner, co-venturer, agent, employee, or representative of LBIO by
reason of this Agreement, but shall remain in all respects an independent contractor, and neither Party shall have any right or authority to make or
undertake any promise, warranty or representation, to execute any contract or otherwise to assume any obligation in the name of or on behalf of the
other Party. MD Anderson’s employees, including the Principal Investigator and the other Representatives of MD Anderson, are not and shall not
be deemed to be employees of LBIO, and MD Anderson shall indemnify and hold harmless LBIO from all liabilities arising from any allegation or
determination to the contrary.
 
9.5 Notices. All notices and other communications required or permitted hereunder shall be in writing and deemed to have been given
when hand delivered, or mailed by registered or certified mail or overnight courier with tracking capabilities, as follows or as a Party may otherwise
notify to the other in accordance with this Section 9.5 (provided that such notice of change of address or recipient shall be deemed given only
when received), with an electronic copy to an email address if specified below:
 
If to LBIO, to:  If to MD Anderson:
Lion Biotechnologies, Inc.  The University of Texas
  M.D. Anderson Cancer Center
999 Skyway Road, Suite 150  1515 Holcombe Blvd.
San Carlos, CA 94070  Houston, TX 77030
Attention: Legal Department  Attention: Chief Legal Officer
With a copy to: legal@lionbio.com   
 
 199.6 Assignment; No Third Party Beneficiaries . LBIO may assign or transfer this Agreement without the prior written consent of but with
written notice to MD Anderson promptly following consummation of the relevant transaction. MD Anderson hereby acknowledges and agrees that
the rights and obligations hereunder are of a personal nature and, therefore, neither this Agreement nor any right or obligation contained within
shall be assignable, transferable or delegable in whole or in part by MD Anderson and MD Anderson shall not, without the prior written consent of
LBIO, sub-contract or otherwise engage any consultant or other third party to perform any of MD Anderson’s activities or obligations under this
Agreement or any Study Order. All of the terms and provisions of this Agreement shall be binding upon, and inure to the benefit of and be
enforceable by, the respective successors and permitted assigns of the Parties. Nothing in this Agreement, express or implied, is intended to confer
on any person or entity, other than the Parties or their respective successors and permitted assigns, any benefits, rights or remedies.
 
9.7 Governing Law, Jurisdiction. This Agreement shall be governed by and interpreted in accordance with the laws of the State of Texas,
United States of America, without giving effect to any conflict of laws provisions. The Parties agree that any dispute or controversy arising out of
or relating to any interpretation, construction, performance or breach of this Agreement may be brought in a United States District Court in Texas,
or if such court does not accept jurisdiction or will not accept jurisdiction, in any court of general jurisdiction in the State of Texas.
 
9.8 Equitable Relief. MD Anderson agrees that it may be impossible or inadequate to measure and calculate LBIO’s damages from any
breach of MD Anderson’s obligations under Section 6 and/or Section 7 of this Agreement, and that a breach of such obligations could cause
serious and irreparable injury to LBIO. Accordingly, LBIO shall have available, in addition to any other right or remedy available to it, the right to
seek an injunction from a court of competent jurisdiction restraining such a breach (or threatened breach) and to specific performance of any such
Section. MD Anderson further agrees that no bond or other security shall be required in obtaining such equitable relief.
 
9.9 Entire Agreement, Amendment and Waiver. This Agreement contains the entire understandings of the Parties and supersedes all
previous agreements (oral and written), negotiations and discussions with respect to the subject matter herein. The Parties may modify any of the
provisions hereof only by an instrument in writing duly executed by the Parties. No waiver of any rights under this Agreement shall be effective
unless in writing signed by the Party to be charged.
 
9.10 Severability. In the event of the invalidity of any provisions of this Agreement containing any gaps, the Parties agree that such
invalidity or gap shall not affect the validity of the remaining provisions of this Agreement. The Parties will replace an invalid provision or fill any
gaps with valid provisions, which most closely approximate the purpose and economic effect of the invalid provision or, in the case of a gap, the
Parties’ presumable intentions.
 
9.11 Further Assurances . Each Party shall, as and when reasonably requested by the other Party, do all acts and execute all documents as
may be reasonably necessary to give effect to the provisions of this Agreement.
 
9.12 Interpretation . The headings in this Agreement are intended solely for convenience or reference and shall be given no effect in the
construction or interpretation of this Agreement. This Agreement shall be construed as if both Parties drafted it jointly, and shall not be construed
against either Party as principal drafter. The words “include”, “includes” and “including” (and words of similar meaning) shall be deemed to be
followed by the phrase “without limitation”.
 
 209.13 Counterparts . This Agreement may be executed in two (2) or more counterparts, including by “PDF” exchange, each of which shall be
deemed to be an original as against any Party whose signature appears thereon, but all of which together shall constitute but one and the same
instrument.
 
9.14 Texas State Agency . MD Anderson is an agency of the State of Texas and under the constitution and laws of the State of Texas
possesses certain rights and privileges and only such authority as is granted to it under the constitution and laws of the State of Texas.
Notwithstanding any provision hereof, nothing herein is intended to be, nor will it be construed to be, a waiver of the sovereign immunity of the
State of Texas or a prospective waiver or restriction of any of the rights, remedies, claims, and privileges of the State of Texas. Moreover,
notwithstanding the generality or specificity of any provision hereof, the provisions of this agreement as they pertain to MD Anderson are
enforceable only to the extent authorized by the constitution and laws of the State of Texas.
 
9.15 DISCLAIMER OF SPECIAL DAMAGES. NEITHER LBIO NOR MD ANDERSON, NOR ANY OF THEIR AFFILIATES, NOR ANY OF
THEIR RESPECTIVE DIRECTORS, OFFICERS, MEMBERS OR EMPLOYEES, SHALL HAVE ANY LIABILITY OF ANY TYPE, FOR ANY SPECIAL,
PUNITIVE, INCIDENTAL, INDIRECT OR CONSEQUENTIAL DAMAGES, INCLUDING THE LOSS OF OPPORTUNITY, LOSS OF USE, OR LOSS OF
REVENUE OR PROFIT, IN CONNECTION WITH OR ARISING OUT OF THIS AGREEMENT OR ANY STUDY ORDER; PROVIDED, THAT, THE
FOREGOING DISCLAIMER SHALL NOT APPLY WITH RESPECT TO (1) A PARTY’S INDEMNIFICATION OBLIGATIONS, (2) A PARTY’S
BREACH OF ITS OBLIGATIONS UNDER THIS AGREEMENT WITH RESPECT TO CONFIDENTIALITY AND NON-USE OR INTELLECTUAL
PROPERTY-RELATED MATTERS OR (3) A PARTY’S GROSS NEGLIGENCE OR WILLFUL MISCONDUCT.
 
[Signature Page Follows]
 
 21IN WITNESS WHEREOF, the undersigned, intending to be legally bound, have duly executed this Agreement as of the Effective Date.
 
LION BIOTECHNOLOGIES, INC.  THE UNIVERSITY OF TEXAS
M. D. ANDERSON CANCER CENTER
   
/s/ Maria Fardis  /s/ Chris McKee
Authorized Signature  Authorized Signature
   
Name: Maria Fardis  Name: Chris McKee, M.H.A.
Title: CEO & President  Title: VP, Business Operations
Date: April 17, 2017  Date: April 12, 2017
 
This Agreement is to be executed in duplicate.
Please return one fully executed copy to LBIO at the address for notices set forth above.Exhibit 10.26
STRATEGIC ALLIANCE AGREEMENT
This STRATEGIC' ALLIANCE AGREEMENT (including the exhibits and schedules hereto, this  "Agreement") is made and entered into this
16 day of August. 2012 (the  "Effective Date") by and between Lightbridge Corporation, a Nevada Corporation  ("Lightbridge"), and Lloyds
Register FNMA, acting through its office in  Abu Dhabi ("Lloyds" and. together with Lightbridge. the  "Parties").
BACKGROUND
Lightbridge and Lloyds believe  that, by cooperatively combining their considerable experience, expertise and  financial and market
resources, they can increase the volume of business they  can conduct in in the area of nuclear consulting and strategic advisory services  in the
United Arab Emirates. Accordingly, in consideration of the foregoing and  of the mutual representations, warranties, covenants and agreements
contained in  this Agreement and of other good and valuable consideration, the receipt and  sufficiency of which are hereby acknowledged, the
Parties, intending to be legally bound by this Agreement, agree as follows:
ARTICLE I 
DEFINITIONS
As used in this Agreement:
"Affiliate" shall mean,  with respect to any referenced Person, any other Person that directly or  indirectly, through one or more
intermediaries, controls, is controlled by or is under common control with such referenced Person.
"Business Day" shall mean  any day other than a Saturday, a Sunday or a day on which commercial banks in  New York or London are
generally authorized or required to close.
"Confidential Information" shall mean, as to any Party as a Recipient, (a) all non-public written,  graphic, oral, electromagnetic or other
information (including technical, financial and business information regarding models, market studies, business  plans. clients' names, reports, plans.
projections, data or any other  information) relating to the business, strategy, prospects or plans of the other  Party or any of the other Party's
Affiliates and (b) any reproductions, copies,  notes, analyses, work papers. compilations, studies, interpretations or any  other document or
information derived from any of the foregoing. 
"Project" shall mean any  undertaking involving the provision of nuclear consulting or strategic advisory  services to any entity in the
United Arab Emirates. 
"Government Authority" shall mean any national, federal, provincial, state, prefectural or  municipal governmental tribunal or organization,
or any political subdivision.  instrumentality. Ministry, department, legislative body, agency, court,  tribunal, authority, corporation, commission or
other body or entity of, or  under the direct or indirect control of, any of the foregoing, including any  central bank or other fiscal, monetary or other
authority. 
- 1 -“Law” shall mean any law,  statute, ordinance, act, legislation, bill, enactment, policy, treaty,  international agreement, ordinance, judgment,
injunction, award, decree, rule, regulation, interpretation, determination, requirement, writ or order of, or any  term of any license or permit issued by,
any Government Authority.
“Person” shall mean any  individual, corporation, partnership, limited liability company, joint venture,  association, trust, unincorporated
organization or other entity.
"Recipient" shall mean each Party. whenever it has received or is receiving Confidential Information  directly or indirectly from the other
Party or any of its Affiliates.
ARTICLE II 
GENERAL SCOPE; RELATIONSHIP OF THE PARTIES
Section 2.1  General Scope. During the term of this Agreement, the Parties shall actively seek attractive  Projects and, in pursuit of any
potential Project, shall promote the  Lightbridge-Lloyds strategic alliance whenever given the opportunity to do so.  Each Party shall present to the
other Party every potential Project which such  Party desires to pursue . 
Section 2.2 Relationship of Parties. With respect to any Project, regardless of which Party  identified such Project, the Parties agree that
Lloyds shall act as prime  contractor on any Project and that Lightbridge shall have a right of first  refusal to participate in such Project as a sub-
contractor to Lloyds, and shall  be entitled to perform such work which would generate up to twenty-five percent  (25%) of the total fees payable to
Lloyds as general contractor under the  Project.
Section 2.3 Identification of Projects. Upon identification of a Project, the Parties shall jointly  prepare a proposed plan for the acquisition
and execution of the Project, which  shall include a detailed forecasted budget therefore. Upon the award of a prime  contract regarding a Project to
Lloyds, the Parties shall attempt in good faith  to negotiate and enter into a subcontract agreement whereby the scope of  Lightbridge's services on
the Project, and compensation to Lightbridge  therefore, shall be specified.
Section 2.4 No Commitment. Notwithstanding anything to the contrary, the Parties understand and agree  that each Party shall have the
right, at all times and in their sole and  absolute discretion, to pursue or not pursue or continue with or not continue  with a Project and that neither
Party shall have any obligation or liability to  the other Party arising out of or relating to a decision not to pursue a Project  for any reason. Each
Party agrees that it shall not pursue any damages against  the other Party or any of its Affiliates arising out of or relating to a  decision by such Party
or any of its Affiliates not to pursue or continue with a  Project, regardless of' the reason for such decision.  
ARTICLE III 
COMPLIANCE WITH LAWS
Each Party shall, and shall  cause its Affiliates to. at all times, comply in all respects with all  applicable Laws in connection with the
transactions contemplated by this  Agreement. Without limiting the generality of the foregoing, each Party (the  "Relevant Party") shall not, and
shall cause its Affiliates not to, do or cause to be done  any of the following in connection with the transactions contemplated by this  Agreement:
(a) directly or indirectly through any other Person. pay, offer to  pay, promise to pay, or authorize the payment of any monies or anything of value  to
any official or employee of any Government Authority or any political party  or candidate for political office for the purpose of illegally or improperly
inducing or rewarding any action by such official, employee or candidate  favorable to the Relevant Party or any of its Affiliate or (b) take any other
action that, if taken by a Person subject to United States law, would violate  the United States Foreign Corrupt Practices Act. Each Party
acknowledges and agrees that is familiar with the United States Foreign Corrupt Practices Act.
- 2 -ARTICLE IV 
CONFIDENTIALITY
Section 4.1  Obligation to  Maintain and Protect Confidentiality. The Recipient agrees that it shall  receive, protect and maintain the
Confidential Information in the strictest  confidence. The Recipient agrees to keep all of the Confidential Information  confidential, not to use that
Confidential Information other than for the  purpose of this Agreement and not to disclose the same to any Person other than  in accordance with
this Agreement without the prior written consent of the Party  from whom such Confidential Information was received, unless:
(a) the Recipient is required to make the disclosure by Law or under any  administrative guideline or directive (whether or not having
the force of Law) the observance of which, if not having the force of Law, is in accordance with  the practice of responsible persons similarly
situated;
(b) the disclosure is necessary for the purpose of obtaining any consent,  authorization, approval or license from any Government
Authority with respect to  the transactions effected pursuant to this Agreement;
(c) it is necessary that the disclosure be made to any taxation or fiscal authority;
(d) the disclosure is made in accordance with Section 4.3 to the officers,  employees, or agents of the Recipient, or to the professional
advisors of the  Recipient for the purpose of obtaining professional advice in  relation to this Agreement or any matter the subject thereof or
otherwise for the purpose of consulting those professional advisors;
(e) the disclosure is necessary or desirable in relation to any procedure for discovery of documents  and any proceedings before any
court, tribunal (including any arbitral tribunal) or regulatory body; or
In respect of any Confidential Information to be disclosed by  the Recipient pursuant to the exceptions referred to in this Section 4.1, the  Recipient
must, prior to such disclosure, notify the Party from whom the  Confidential Information was received of the need or intention to disclose.
Section 4.2 Exceptions to Confidentiality. The confidentiality provisions contained in this  Agreement do not apply to information or details
of the Confidential Information which:
- 3 -(a) are part of the public domain at the time acquired by the Recipient;
(b) are not acquired by the Recipient. either directly or indirectly, from the disclosing Party or its Affiliates;
(c) are made known to the Recipient by a Person who did not acquire knowledge of the  information or of the details, either directly or
indirectly, under an obligation of confidentiality or has an independent right to disclose same;
(d) after being made known to the Recipient, becomes part of the public domain  through no fault of the Recipient or of any Person to
which the Recipient has disclosed details of the Confidential Information; or
(e) the Recipient can establish were in its possession prior to the date of  disclosure of such details by the disclosing Party.
Section 4.3 Disclosure to Affiliates; Safekeeping. The Recipient agrees that prior to disclosure of  Confidential Information to any Affiliate,
it will inform the Affiliate of the confidential nature of the Confidential Information and require such Affiliate  to treat the Confidential Information as
confidential according to this  Agreement as if such Affiliate were a Recipient. The Recipient shall, and shall  cause each of its Affiliate to, use its
best endeavors to procure and ensure at  all times the safe and confidential storage of Confidential Information in their  possession or control.
Without limiting the foregoing, the Recipient shall, and  shall cause its Affiliate to, safeguard the Confidential Information to the same  extent as if it
were information of or pertaining to the Recipient. and the  Recipient acknowledges that the release, publication or dissemination of the  Confidential
Information could be harmful to a Project or a Party.
Section 4.4 Return of Confidential Information. The Recipient agrees that upon the written request  of the disclosing Party it will promptly
(a) return all Confidential Information and any and all copies thereof to the disclosing Party and shall require each of  its Affiliate to do likewise or
(b) destroy the same and deliver a certificate  of destruction to the disclosing Party.  
Section 4.5 Survival of Confidentiality Obligations. This Article IV shall survive termination of this Agreement.
ARTICLE V 
EVENTS OF DEFAULT; TERM AND TERMINATION
Section 5.1  Events of Default. Each of the following events constitutes an event of default (an  "Event of Default") by a Party (the
"Defaulting Party") under this Agreement:
5.1.1 the Defaulting Party fails to perform in any material  respect any obligation under this Agreement. or any representation or
warranty made by the Defaulting Party in this Agreement is untrue in any material  respect, and such failure is not cured within 30 days after
the non-Defaulting Party notifies the Defaulting Party of such failure; or
- 4 -5.1.2  the Defaulting Party:
(a) files a petition or otherwise commences, or authorizes or acquiesces in the  commencement of. a proceeding or cause under any
bankruptcy, winding up,  liquidation. insolvency, receivership or similar law for the protection of  creditors or has such a petition filed or
proceeding commenced against it.  which, in the case of an involuntary petition or proceeding, remains undismissed  and unstayed for 90
days; or
(b) is otherwise adjudicated insolvent or unable to pay its debts as they become due,  otherwise makes an assignment for the benefit
of its creditors or is dissolved  or otherwise terminated.
Section 5.2 Remedies. Upon the occurrence and during the continuation of any Event of Default, the  non-Defaulting Party may immediately
terminate this Agreement by giving notice  to the Defaulting Party. The non-Defaulting Party's remedy set forth in the  immediately preceding
sentence is not intended to be exclusive and is in  addition to, and may be exercised concurrently with, any other right or remedy  that may otherwise
be available to the Non-Defaulting Party at law or in equity.  Without limiting the foregoing and for the avoidance of doubt, the  Non-Defaulting
Party may recover damages against the Defaulting Party even if  this Agreement is terminated (including damages arising out of such  termination).
Section 5.3 Term and Termination. This Agreement is effective on the Effective Date and shah  continue in effect until the earlier of (a) the
fifth (5th) anniversary of the Effective Date, and (b) termination by either Party for any  reason upon thirty (30) days' written notice to the other
Party; provided, however, that no Party shall be able to terminate this Agreement so long as  such Party is a Defaulting Party under this Agreement.
The occurrence of the  Termination Date shall not relieve either Party of any unfulfilled obligation or  undischarged liability of such Party relating to
the period prior to the Termination Date.
ARTICLE VI 
NOTICE
Section 6.1  Notices. All  notices, consents, demands or other communications (collectively, the  "Notices") made pursuant to this
Agreement shall be in writing, in the  English language and signed and correctly dated by the Party sending same. All  Notices shall he delivered
personally (by courier or otherwise) or by facsimile to the receiving Party at the address given below:
If to Lightbridge  With copy to: 
Addressed to:  
   
Lightbridge Corporation Pillsbury Winthrop Shaw Pittman LLP
1600 Tysons Boulevard 2300 N Street, NW
Tysons Corner, VA 22102 Washington, DC 20037
Attn: James D. Guerra Attn: Louis A. Bevilacqua
Tel.: 571-730-1200 Tel.: 202-663-8158
- 5 -If to Lloyds  With copy to:
Addressed to:   
   
Energy Area Business Manager Global Nuclear Director
Lloyd's Register, EMEA Lloyd's Register
Festival Office Tower, Suite 2001 71 Fenchurch Street
Dubai Festival City London
Al Rebat Street EC3M 4BS
Ras Al Khor, Deira United Kingdom
Dubai Tel: +44 20 7423 1677
United Arab Emirates  
Tel.: +971 4 701 4236  
Section 6.2 Effective Date of Notices. Any Notice delivered personally shall be deemed to have been  given on the date it is so delivered, or
upon attempted delivery if acceptance  of delivery is refused, and any notice delivered by facsimile transmission shall  be deemed to have been
given on the first Business Day it is received (or on the  first Business Day after it is received, if received on other than a Business  Day). Notice
given in any other manner shall be deemed to have been given on the  first Business Day it is received (or on the first Business Day after it is
received, if received on other than a Business Day).  
Section 6.3 Change of Address for Notices. A Party may change the address to which Notices hereunder are  to be sent to it by giving
Notice of such change of address in the manner  provided in Section 11.1. 
ARTICLE VII 
MISCELLANEOUS
Section 7.1  No Partnership; No Agency. Nothing contained in this Agreement shall be construed so as to  create a partnership, joint
venture or common enterprise between the Parties.  Neither Party shall be liable for the debts or obligations of the other Party.  Each Party shall limit
its activities pursuant to the terms of this Agreement to  that of the functions and related services expressly set forth herein. Without  limiting the
foregoing, neither Party is authorized to assume or create any  obligation, liability, or responsibility, expressed or implied, on behalf of or in the name
of the other Party or any of its Affiliates or to bind the other  Party or any of its Affiliates in any manner whatsoever, and neither Party shall  hold
itself out as an agent or legal representative of the other Party or any of  its Affiliates.
Section 7.2 Governing Law. The terms of this Agreement shall be governed by and construed in accordance  with the laws of England.
- 6 -Amendment and Modifications. This Agreement may be  amended, modified or supplemented at any time by the Parties but only pursuant  to an
instrument in writing signed by both of them.
Section 7.4 Binding Effect. This Agreement shall be binding upon and inure to the benefit of the Parties  and their respective successors
and permitted assigns.
Section 7.5 Assignment. No Party may assign this Agreement without the prior written consent of the other  Party. 
Section 7.6  Entire Agreement. This Agreement, together with that certain Non-Circumvention and  Confidentiality Agreement, dated
December 16, 2011, between Lightbridge and Lloyd's Register Group Services Limited, contains the entire Agreement of the  Parties with respect to
the transactions contemplated hereby and supersedes all  prior understandings and agreements of the Parties with respect to the subject  matter
hereof. 
Section 7.7 Severability. If any provision of this Agreement is held invalid or unenforceable. all  other provisions will not be affected. With
respect to the provision held  invalid or unenforceable, the Parties will amend this Agreement as necessary to  effect the original intent of the parties
to this Agreement as closely as  possible.
Section 7.8 No Third-Party Beneficiaries. Nothing in this Agreement, expressed or implied, is intended  to confer any rights or remedies
under or by reason of this Agreement on any  Person other than the Parties and their respective successors and permitted  assigns, nor is anything
in this Agreement intended to relieve or discharge any  obligation of any third person to any Party or give any third person any right  of subrogation
or action against any Party.
Section 7.9 Execution in Counterparts. This Agreement may be executed in any number of counterparts  and by different Parties in separate
counterparts, each of which when so  executed and delivered shall be deemed to be an original and all of which taken  together shall constitute but
one and the same instrument. Delivery of an  executed counterpart of the signature page of this Agreement by facsimile  transmission shall he
equally as effective as delivery of a manually executed counterpart of this Agreement.  
Section 7.10 Expenses. Each of the Parties shall pay its own costs  incurred in connection with the negotiation, preparation and execution of
this Agreement. 
[THE REST OF THIS PAGE IS LEFT INTENTIONALLY BLANK]
- 7 -IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be duly executed as of the day and year  first above written.
Lightbridge Corporation 
   
By:/s/ James D. Guerra
  Name: James D. Guerra
  Title: COO
Lloyds Register EMEZ 
   
By:/s/ N.D.A.M. Nooren
  Name: N.D.A.M. Nooren
  Title: AREA Business Manager – Energy MEAA
- 8 -Exhibit 10.2  SHBV (HONG KONG) LTD.   and   WASTE2ENERGY GROUP HOLDINGS PLC     
  STRATEGIC ALLIANCE AGREEMENT   
  1THIS AGREEMENT IS MADE ON THE 19 DAY OF MAY , 2010   PARTIES   (1) SHBV (HONG KONG) LTD, a company incorporated in Hong Kong whose registered office is at Unit 3208, 32/F Office Tower (“SHBV”); and Convention Plaza, 1 Harbour Rd, Hong Kong   (2) WASTE2ENERGY GROUP HOLDINGS PLC a company incorporated in Isle of Man whose registered office is at Stanley House, Lord Street, Douglas, Isle of Man 1M1 2BF (“W2E”),   each a “Party” and together the “Parties”.   BACKGROUND   (A) SHBV is engaged in the business of design, marketing, manufacture, commissioning and post sales servicing of steam and hot water plant and possesses certain proprietary products, technologies, formulations, know-how and/or rights within the fields of steam and hot water plant and equipment, engineering, and process designs (hereinafter, “SHBV Technologies”).   (B) W2E is a provider of engineered solutions for waste to energy plants (each being an “Engineered Solution”) utilising W2E proprietary technology for the destruction of waste through gasification and the conversion of latent energy into thermal energy.   (C) The Parties wish to collaborate together to provide for a world class manufacturing facility for W2E Equipment, for the integration of SHBV Technologies into the Engineered Solution and to exploit joint sales channels and post sales support, for the mutual benefit of both Parties.   (D) The Parties wish to cooperate and work together to promote, market and sell their respective products and services in accordance with the terms of this Agreement.   AGREED PROVISIONS   1. DEFINITIONS AND INTERPRETATION   1.1 In this Agreement, the terms and expressions below shall have the following meanings:   2 
THAffiliates means subsidiaries or other entities that will be mutually agreed in writing.   Agreement means the body of this agreement and its schedules, as each may be amended from time to time in accordance with its provisions;   Alliance means the strategic alliance between the Parties facilitated under this Agreement;   SHBV Boiler means a boiler that is manufactured and supplied by SHBV from time to time;   SHBV Technologies has the meaning given in Recital A above;   Commencement Date means the date of this Agreement;   Dispute means any dispute, issue or claim arising out of or relating to this Agreement;   Engineered Solution has the meaning given in Recital B above;   Good Industry Practice means the exercise of that degree of skill, diligence, prudence, foresight and practice which would reasonably and ordinarily be expected from a skilled and experienced person engaged in performing obligations the same as or similar to the obligations under this Agreement or any part of them (as appropriate to the context in which this expression is used);   Group means, in relation to any company, that company and the following for the time being: (i) its Holding Company, (ii) its Subsidiaries and (iii) the Subsidiaries of its Holding Company;   Holding Company has the meaning given in $1159 Companies Act 2006;   Intellectual Property Rights means (i) patents, designs, trade marks and trade names (whether registered or unregistered), copyright and related rights, database rights, know-how and confidential information; (ii) all other intellectual property rights and similar or equivalent rights anywhere in the world which currently exist or are recognised in the future; and (iii) applications, extensions and renewals in relation to any such rights;   Manufacturing Agreement has the meaning given in clause 5.1;   Subsidiary has the meaning given to it in $1159 Companies Act 2006;   Supply Agreement means an agreement under which an Engineered Solution is to be delivered to a customer of W2E by W2E or such other entity established or nominated for that purpose;   Term has the meaning set out in Clause 3.1;   3Territory shall mean the world with the exception of the following countries which are expressly reserved by W2E: Spain, Italy and Canada.   Working Day means any day that is not a Saturday, a Sunday or a bank or public holiday in England;   W2E Equipment means products, plant and equipment to be manufactured pursuant to the Manufacturing Agreement and which may incorporate W2E Technology, including as specified in Schedule 1 of this Agreement; and   W2E Technology means ‘W2E’s proprietary technology for the destruction of waste through gasification and the conversion of latent energy into thermal energy.   1.2 The Clause and Schedule headings are for convenience only and shall not affect the interpretation of this Agreement.   1.3 References to Clauses are to Clauses in the main body of this Agreement, and references to Paragraphs are to paragraphs of the Schedules.   1.4 References to the singular include the plural and vice versa, and references to one gender include the other gender.   1.5 Any reference to persons includes natural persons, firms, partnerships, limited liability partnerships, companies, corporations, unincorporated associations, local authorities, governments, states, foundations and trusts (in each case whether or not having separate legal personality) and any agency of any of the above.   1.6 Any phrase introduced by the expressions “including,” “include,” “in particular” or any similar expression shall be construed as illustrative and shall not limit the sense of the words preceding those terms.   1.7 Any reference to a statute, statutory provision or subordinate legislation (legislation) (except where the context otherwise requires) (i) shall be deemed to include any bye-laws, licences, statutory instruments, rules, regulations, orders, notices, directions, consents or permissions made under that legislation and (ii) shall be construed as referring to any legislation which replaces, re-enacts, amends or consolidates such legislation (with or without modification) at any time.   2. OBJECTIVES   2.1 The Parties enter into this Agreement with the intention that they meet the following key objectives (“Objectives”):   2.1.1 the achievement of mutual business goals by the servicing of W2E customers;   2.1.2 the establishment of a Manufacturing Agreement, as that term is hereinafter defined, for the ongoing manufacture and fulfilment of W2E Equipment in accordance with the terms of W2E’s agreements with its customers.;   42.1.3 the establishment of a waste heat recovery solution for W2E proprietary equipment and a technical process for handling new enquiries;   2.1.4 the establishment of a pricing methodology and business process for answering new business enquiries; and   2.1.5 the establishment of a cooperative relationship between the Parties, with agreement on the roles, responsibilities, and specific terms and conditions which will govern it.   2.2 The Parties acknowledge and agree that the Objectives are not contractually binding upon the Parties and shall only be referenced to the extent that there is any inconsistency or ambiguity in this Agreement, in which case the Parties shall attempt to resolve that inconsistency or ambiguity by having regard to the Objectives.   3. TERM   3.1 This Agreement shall commence on the Commencement Date and shall continue for a term of ten (10) years, unless previously terminated in accordance with Clause 15 (Termination).   4. COOPERATION OBLIGATIONS   4.1 Without prejudice to the other provisions of this Agreement, each Party shall perform its obligations under this Agreement in accordance with Good Industry Practice.   4.2 Each Party shall, during the course of its normal business, use reasonable endeavours subject to the terms of this Agreement to:   4.2.1 promote and market the experience and capabilities of the Parties in order to identify opportunities for W2E, such promotion and marketing activities to be as agreed by the Parties from time to time;   4.2.2 identify, assess and communicate opportunities for W2E; and   4.2.3 undertake joint marketing initiatives and other marketing activities which are mutually beneficial for the business interests of both Parties and as shall be agreed by the Parties from time to time.   4.3 Each Party will provide cooperation, support, assistance and information to the other Party in order to:   4.3.1 coordinate efforts to seek to obtain work from the new or prospective customer;   4.3.2 promote and market the services of both Parties, including by the development of standardised pricing, joint sales proposals and joint marketing materials;   54.3.3 where appropriate, form a consortium for the purposes of undertaking joint pitches or presentations;   4.3.4 develop and agree to the pricing structure to be offered to Customers from time to time, having regard to the cost of delivery and related products and services, including the cost of raw materials, quality assurance, volume, manufacturing overhead, G&A overhead and health and safety costs; and   4.3.5 develop and agree to the pricing strategies (including a hedging strategy where appropriate) to guard against significant variance in product and service costs over the term of this Agreement as a result of fluctuations in raw material prices, currency fluctuations, wage inflation and other factors.   4.4 The Parties shall jointly collaborate on all aspects of the Alliance (including in relation to technology for process and manufacture) and shall convene regular meetings from time to time in order to discuss joint activities and to give effect to the terms of this Agreement.   5. SHBV OBLIGATIONS   5.1 SHBV agrees that it shall manufacture and supply to W2E (or as it shall direct), W2E Equipment, in each case in accordance with the terms of the manufacturing agreement (“Manufacturing Agreement”) to be entered into by the Parties on or following the entry into this Agreement.   5.2 SHBV agrees that it shall at the request of W2E, supply (and if requested, install) SHBV Boilers, as well as primary chambers, secondary chambers and economises (which SHBV agrees to manufacture and supply) to such persons as W2E shall nominate, on the terms specified in or otherwise agreed to by the Parties.   5.3 SHBV shall continually during the Term and from time to time at W2E’s request, provide W2E with verbal and written technical and business advisory assistance concerning SHBV Technologies where these would integrate into an Engineered Solution as part of servicing W2E Customers. This assistance shall include the development and provision of research, technical papers, background information, product and process information, process and equipment schematics, marketing presentations, capital cost information, industry reports, pricing models, scientific data, project proposals, technology evaluation, and preliminary project development services for any proposed projects. This advisory assistance will be in outline only and therefore to be considered not comprehensive detail.   5.4 SHBV shall from time to time at W2E’s request, perform and provide to W2E project specific technical calculations and assessments needed to support the delivery of an Engineered Solution for servicing W2E Customers..   66. W2E OBLIGATIONS   6.1 W2E agrees that it will use reasonable endeavours to procure that a SHBV Boiler, and where applicable, a primary chamber, a secondary chamber and an economiser (in each case as supplied by SHBV as contemplated by Clause 5.2), forms part of the Engineered Solution implemented for a W2E Customer within the Territory. W2E shall have no obligations under this Clause where a W2E Customer elects for whatever reason not to include a SHBV Boiler, a primary chamber, a secondary chamber or an economiser supplied by SHBV as part of the Engineered Solution or directs W2E to utilise an alternative product.   6.2 Without prejudice to the obligations of the Parties under Clause 4, W2E shall be responsible, as it deems appropriate in relation to individual projects and unless otherwise agreed in writing, for the following:   6.2.1 conceptual and front end engineering design (FEED) in order to establish unknowns for customers and to establish a basis for plant design;   6.2.2 entering into construction and installation contracts for the Engineered Solution as it sees fit;   6.2.3 the commissioning of waste2energy plants; and   6.2.4 the negotiation and entry into operations and maintenance contracts in respect of waste to energy plants as customer demand requires.   6.3 W2E agrees that it shall use reasonable endeavours to procure the right for SHBV to commission SHBV Boilers (and where applicable, primary chambers, secondary chambers and economisers that are supplied by SHBV as contemplated by Clause 5.2) that form part of the Engineered Solution.   7. MANUFACTURING AGREEMENT   7.1 The Parties agree that they shall on or following the date of this Agreement, enter into the Manufacturing Agreement which shall govern the manner and terms upon which they will co-operate and fulfil their respective obligations to each other relating to the W2E Equipment and the SHBV Technologies (including the quantity of SHBV Boilers, primary chambers, secondary chambers and economisers that SHBV shall supply, their price and timetable for delivery).   7.2 Each Party agrees to negotiate in good faith the terms of the Manufacturing Agreement and to use its reasonable endeavours to enter into said agreement within 1 DAY DN 20/5/2010 of the Commencement Date.   7.3 The Manufacturing Agreement shall take precedence over the terms of this Agreement to the extent of any inconsistency.   77.4 It is the intention of the Parties that W2E (or such other entity that it shall nominate) shall be the prime contractor entering into agreements with its customers, with SHBV acting as a subcontractor under the Manufacturing Agreement for the responsibilities that fall to SHBV. The Parties agree that it is the intention that they shall have the following responsibilities to fulfil under their agreements with W2E Customer:   7.4.1 SHBV will be responsible for all engineering and design work for the SHBV Technologies and related equipment that it supplies for any applicable project;   7.4.2 W2E shall be responsible for all engineering and design work for the W2E Technologies and related equipment that it supplies for any applicable project; and   7.4.3 the Parties shall share responsibility for the preparation of all reports, statements, proposals, applications, or disclosures, in relation to their own technology supply which are required by applicable governmental laws and/or regulations in order to implement any of the projects.   8. NON-SOLICITATION   Each Party agrees that during the Term of this Agreement and for a period of six (6) months thereafter it shall not, without the prior written consent of the other Party, either on its own account or through its employees or agents or otherwise or on behalf of any other person, firm, company or other organisation and other than by general advertising, solicit, interfere with, procure or entice away (or, in each case, attempt so to do), either directly or indirectly, any employee or contractor of the other Party.   9. NON-CIRCUMVENTION   9.1 W2E agrees not to engage in business dealings, discussions, or otherwise work directly with any third parties introduced to W2E through SHBV, or to exploit any pre-existing relationship of SHBV with any third party that has been represented to W2E by SHBV, without the prior consent and/or direct participation of SHBV.   9.2 SHBV agrees not to engage in business dealings, discussions, or otherwise work directly with any third parties introduced to SHBV through W2E, or to exploit any pre-existing relationship of W2E with any third party that has been represented to SHBV by W2E, without the prior consent and/or direct participation of W2E.   810. INTELLECTUAL PROPERTY RIGHTS   10.1 Except as expressly agreed otherwise in writing, all Intellectual Property Rights vested in a Party prior to the date of this Agreement shall remain vested in that Party. Further, any improvements, enhancements, modifications or developments to a Party’s intellectual property shall automatically vest in that Party irrespective of who generates the relevant improvement, enhancement, modification or development.   10.2 Each Party grants to the other Party a non-exclusive, non-transferable, royalty-free licence to use the other Party’s Intellectual Property Rights as far is strictly necessary to comply with its marketing and promotional obligations under this Agreement. For the sake of certainty, the licence created by this Agreement does not extend to the use of the other Party’s Intellectual Property Rights for any other commercial purpose.   10.3 The licence granted in Clause 10.2 above will automatically expire at the end of the Term of this Agreement.   10.4 Each Party shall indemnify and keep indemnified the other Party against all costs, claims, losses, expenses and damages incurred by the other Party as a result of any breach of the provisions set out in this Clause 10 or arising directly or indirectly out of any infringement by that Party of the other Party’s Intellectual Property Rights.   11. CONFIDENTIALITY   11.1 For purposes of this Clause:   Authorised Persons means the directors, employees, officers, professional advisers, agents and contractors of each Party;   Confidential Information means all information in any medium or format (written, oral, visual or electronic, and whether or not marked or described as “confidential”), together with Copies, which relates to a Party (the “Disclosing Party”), to its Group, or to its (or its Group members’) employees, officers, customers or suppliers, and which is directly or indirectly disclosed by the Disclosing Party to the other Party (the “Recipient Party”) in the course of its dealings relating to this Agreement, before or after the date of this Agreement. However, the following information is not “Confidential Information” for the purposes of this Agreement:   (i) information which is in the public domain other than as a result of breach of this Agreement or any separate confidentiality undertaking between the Parties;   (ii) information which the Recipient Party received, free of any obligation of confidence, from a third party which itself was not under any obligation of confidence in relation to that information; and   9(iii) information which was developed or created independently by or on behalf of the Recipient Party or any member of the Recipient Party’s Group; and   Copies means all reproductions (hard copy or electronic), extracts, summaries or analyses of Confidential Information in any medium or format made by or on behalf of any Party.   11.2 In return for the disclosure by each Party of Confidential Information and for other consideration given under this Agreement, each Party shall (except as expressly permitted by this Agreement or with the written consent of the Disclosing Party);   11.2.1 keep all Confidential Information secret;   11.2.2 only use or make Copies of Confidential Information in connection with and to the extent necessary for the purposes of this Agreement;   11.2.3 take all reasonable action to ensure that, within its organisation, the Confidential Information is not made available to any person who is not an Authorised Person;   11.2.4 use all reasonable endeavours to ensure that Confidential Information within its control is kept securely protected against theft or unauthorised access, and in any event shall maintain its security, integrity and confidentiality to at least the same standard as it applies to its own confidential information; and   11.2.5 not reverse engineer, or attempt to reverse engineer, any software comprised within the Confidential Information, except to the extent permitted by law.   11.3 A Party may disclose Confidential Information to any Authorised Persons on a “need-to-know” basis solely in relation to the Agreement, provided that that Party:   11.3.1 informs all Authorised Persons that the Confidential Information is confidential; and   11.3.2 ensures that all Authorised Persons (other than those already under a professional duty of confidence to that Party or an obligation of confidence as part of employment arrangements) enter into written confidentiality undertakings with it on equivalent terms to this Clause, and provides copies of such undertakings to the other Party to this Agreement upon that other Party’s reasonable request; and   11.3.3 shall be responsible for all acts and omissions of Authorised Persons as though they were its own acts or omissions under this Agreement.   11.4 Either Party may disclose Confidential Information to a third party, provided that before any such disclosure the express written consent of the other Party has been received in writing and signed by a duly authorised signatory. Such consent lies in the entire discretion of the Party owning the Confidential Information and   10without prejudice to that, the Party’s consent may be conditional upon the third party entering into a confidentiality or non-disclosure agreement with the owner of the Confidential Information prior to any disclosure being made.   11.5 Each Party shall promptly notify the other Party if it becomes aware of any unauthorised use or disclosure by any Authorised Person or any other person of any Confidential Information.   11.6 A Party may disclose any Confidential Information to any regulator, law enforcement agency or other third party if it is required to do so by law, regulation, or similar authority. In those circumstances:   11.6.1 that Party shall (provided that it is practical and lawful to do so) notify the other Party in writing as soon as practicable before the disclosure;   11.6.2 the Parties shall use all reasonable endeavours to consult with each other with a view to agreeing the timing, manner and extent of the disclosure; and   11.6.3 the Party required to disclose shall in any event use all reasonable endeavours to obtain written confidentiality undertakings in its favour from the third party.   11.7 If the Party required to disclose is unable to inform the Disclosing Party before Confidential Information is disclosed, it shall (provided that it is lawful to do so) fully inform the Disclosing Party immediately afterwards in writing of the circumstances of the disclosure and the Confidential Information which has been disclosed.   11.8 Nothing in this Agreement or the disclosures envisaged by this Clause shall (except as expressly agreed otherwise) operate to transfer any Intellectual Property Rights in the Confidential Information.   11.9 The undertakings and other provisions of this Clause shall continue in force without limit in time and shall survive termination of this Agreement, but shall cease to apply to information which may enter the public domain otherwise than through the unauthorised disclosure by or fault of the recipient of the Confidential Information or by a person with whom such recipient is connected in any way.   11.10 Each Party acknowledges that damages alone would not be an adequate remedy in the event of breach by the other Party of the provisions of this Clause. Accordingly, it is agreed that either Party shall be entitled, without proof of special damages, to seek an injunction or other interim remedy for any threatened or actual breach of this Clause, without prejudice to any other rights and remedies which that Party mayhave.   12. PUBLICITY   12.1 The Parties shall cooperate in any public relations or publicity exercises pertaining to the Alliance, and agree to share with each other and coordinate the content and   11timing of press releases, prior to submission of such information for public release. Unless specifically agreed in writing by the Parties (including as to form and content) or required by law, by relevant regulations, or by a relevant Stock Exchange, neither Party may make any public announcement (including any press release) in respect of the subject matter of this Agreement, its terms or its operation.   12.2 Neither Party, nor any of their respective customers, end-users, or licensees may use the name or marks of the other Party in any way including in any advertising of products or processes without the prior specific written authorization of that other Party.   12.3 Notwithstanding Clauses 11 (Confidentiality) and this Clause 12:   12.3.1 W2E may advise others of the source of the SHBV Technology and the nature of the Alliance formed under this Agreement; and   12.3.2 each Party may disclose the existence, but not the details, of this Agreement in a release to the general public within thirty (30) days of the Commencement Date hereof.   2.4 Each Party shall take all reasonable steps to ensure the observance of the provisions of this Clause 12 by all employees, agents, subcontractors and consultants (including professional advisers) of that Party.   13. WARRANTIES   13.1 Each Party hereby represents and warrants to the other Party that:   13.1.1 all acts, conditions, authorisations, consents (including shareholder or parent company consents) and other things (including all licences and permits) required in order to enable it lawfully to enter into, exercise its rights under or perform its obligations under this Agreement and any other documents to be executed in connection with it or to authorise the same, have been duly done, fulfilled, obtained and performed and are in full force and effect; and   13.1.2 neither the execution nor the delivery nor the performance of this Agreement will:   13.1.2.1 result in a breach of, or constitute a default under, or require the consent of a person under, any agreement or arrangement by which it is bound;   13.1.2.2 conflict with its constitutional documents/result in a breach of any provision of its memorandum or articles of association; or   13.1.2.3 result in a breach of any law, regulation, order, judgement or decree of any court or government.   1213.2 The express provisions of this Agreement are in place of corresponding warranties, conditions, terms, undertakings and obligations implied by statute, common law, custom, trade usage, course of dealing or otherwise (including implied undertakings of satisfactory quality, conformity with description and reasonable fitness for purpose), all of which are hereby excluded to the maximum extent permitted by law.   14. INDEMNITIES   14.1  Each Party agrees to indemnify, hold and save harmless the other Party, and defend at its own expense, from and against all suits, claims, demands and liability of any nature and kind, including their cost and expenses, arising from:   14.1.1 the negligence; or   14.1.2 any intentionally wrongful acts or omissions, of the Party’s own employees, agents, affiliates or subcontractors in connection with this Agreement.   15. TERMINATION   15.1 Either Party may (without prejudice to its other rights) terminate this Agreement at any time by giving written notice to the other Party if:   15.1.1 the other Party becomes unable to pay its debts (within the meaning of section 123 (l)(e) or (2) of the Insolvency Act 1986), admits its inability to pay its debts or becomes insolvent, or (ii) a petition is presented, an order made or a resolution passed for the liquidation (otherwise than for the purposes of a solvent amalgamation or reconstruction), administration, bankruptcy or dissolution of the other Party, or (iii) an administrative or other receiver, manager, trustee, liquidator, administrator or similar person or officer is appointed to the other Party and/or over all or any part of the assets of the other Party, or (iv) the other Party enters into or proposes any composition or arrangement concerning its debts with its creditors (or any class of its creditors) generally, or (v) anything equivalent to any of the events or circumstances stated in (i) to (iv) inclusive occurs in any applicable jurisdiction; or   15.1.2 the other Party commits a material or persistent breach of the provisions of this Agreement (a “Breach”), provided that if the Breach is remediable, the other Party shall be given thirty (30) days to remedy the Breach from receipt of the first Party’s written notice specifying the nature of the Breach and requesting that the same be remedied.   15.2 Any termination of the Agreement under Clause 15.1 above shall take effect either immediately on receipt of written notice or at such other date as may be specified in the written notice.   1315.3 On termination of this Agreement:   15.3.1 each Party shall ensure that all documentation and all information (including all copies of such information stored in any written or electronic form) which constitutes Confidential Information shall be returned to the other Party forthwith; and   15.3.2 each Party shall immediately cease to use the other Party’s Intellectual Property Rights and shall destroy or on request return to the other all materials in its possession bearing the other Party’s trade marks, logos, brand name and other intellectual property.   15.4 The termination of this Agreement for any reason whatsoever, or its expiry:   15.4.1 shall not affect any provision of this Agreement which by its very nature should survive or operate in the event of the termination of this Agreement; and   15.4.2 shall not prejudice or affect the rights of either Party against the other in respect of any breach of this Agreement or in respect of any monies payable by one Party to another in respect of any period prior to termination.   15.5 The parties may terminate this Agreement at any time by mutual consent.   15.6 Each party may terminate this Agreement if in the 12 months period immediately prior to such termination they fail to achieve the target annual business levels set out in Schedule 2 of the Manufacturing Agreement between the Parties.   15.7 Each party may terminate this Agreement without liability if, despite their best efforts, the parties fail to conclude the Manufacturing Agreement pursuant to Clauses 10 – 13 of this Agreement within one month from the date of this Agreement.   16. FURTHER ASSURANCE   16.1 Each Party shall at its own cost and expense carry out, or use all reasonable endeavours to ensure the carrying out of, whatever further actions (including the execution of further documents) the other Party reasonably requires from time to time for the purpose of giving that other Party the full benefit of the provisions of this Agreement.   17. ASSIGNMENT   17.1 SHBV acknowledges and agrees that W2E may from time to time establish or nominate a separate entity for the purpose of entering into agreements with   14SHBV, in which case W2E shall have the right to require that SHBV’s obligations under the Manufacturing Agreement (including warranties and indemnities) and any project schedules to be given in favour of both W2E and such entity.   18. ENTIRE AGREEMENT   18.1 This Agreement (together with the Manufacturing Agreement and any project schedule entered into by the Parties as contemplated herein) constitutes the entire agreement between the Parties in relation to its subject matter, and replaces and extinguishes all prior agreements, draft agreements, arrangements, undertakings, or collateral contracts of any nature made by the Parties, whether oral or written, in relation to such subject matter.   18.2 Each Party acknowledges that in entering into this Agreement it is not relying on, and shall have no rights or remedies (whether in tort, under statute or otherwise) in respect of any statements, collateral or other warranties, assurances, undertakings or representations (whether innocently or negligently made) by any person or entity in relation to the subject-matter of this Agreement, except for those rights and remedies available under this Agreement.   18.3 Nothing in this Clause shall exclude or restrict the liability of either Party arising out of fraud, fraudulent misrepresentation or fraudulent concealment.   19. DISPUTE RESOLUTION   19.1 The Parties agree to co-operate with each other in an amicable manner with a view to achieving the successful implementation of this Agreement.   19.2 If a Dispute arises it shall first be referred to the Managing Director (or equivalent) of SHBV and the Managing Director (or equivalent) of W2E for resolution.   19.3 If the Parties are unable to resolve a Dispute within ten (10) Working Days of its referral to the Managing Director (or equivalent) of SHBV and the Managing Director (or equivalent) of W2E referred to in Clause 19.2 above, then the Parties will attempt to settle it by mediation in accordance with the Centre for Effective Dispute Resolution (“CEDR”)’s Model Mediation Procedure and the following shall prevail in the event of a conflict with that procedure:   19.3.1 the mediation shall be conducted by a single mediator who shall be appointed by agreement in writing between the Parties or, if the Parties are unable to agree on the identity of the mediator within ten (10) Working Days of the date of the request that the Dispute be determined by a mediator, or if the mediator appointed is unable or unwilling to act, shall be appointed by the CEDR;   1519.3.2 the mediation shall be conducted in London and in the English language;   19.3.3 the mediation shall be conducted in private and without prejudice to the rights of the Parties in any future proceedings; and   19.3.4 the mediation shall be held within thirty (30) Working Days of the appointment of the mediator pursuant to Clause 19.3.1 above.   19.4 Nothing in this Clause shall prejudice the right of either Party to:   19.4.1 apply to Court for interim relief to prevent the violation by a Party of any proprietary interest, or any breach of either Party’s obligations which could cause irreparable harm to the other Party; or   19.4.2 to bring proceedings intended to result in the enforcement of a settlement agreement or of a binding determination of a dispute between the Parties.   20 NOTICES   20.1 Except as otherwise expressly provided, any notice or other communication from either Party (“Sender”) to the other Party (“Recipient”) which is required to be given under this Agreement (“Notice”) must be in writing (which for these purposes excludes e-mail), signed by or on behalf of the Sender, and be addressed to the officer of the Recipient whose details are set out in Clause 20.3 below.   20.2 The Sender may either:   20.2.1 deliver the Notice, or arrange for its delivery, by hand and retain satisfactory proof of delivery; or   20.2.2 send the Notice by fax and retain a successful fax transmission report recording the correct number of pages; or   20.2.3 send the Notice by recorded delivery or registered post and retain a receipt of delivery or sending; or   20.2.4 send the Notice by registered airmail if it is to be served by post outside the country from which it is sent and retain a receipt of sending.   20.3 The details of the Parties for the purpose of Notices are as follows:   16Each Party may alter the above details that relate to it and shall promptly notify the other of any such change by a Notice in accordance with this Clause.   20.4 Any Notice shall be deemed to have been served:   20.4.1 if delivered by hand, at the time and date of delivery;   20.4.2 if sent by fax, at the time and date of the successful fax transmission report;   20.4.3 if sent by recorded delivery or registered post, 48 hours from the date of posting (such date as evidenced by postal receipt etc); or   20.4.4 if sent by registered airmail, five days from the date of posting.    21 GENERAL   21.1 Variations only in writing   21.2 No variation of or amendment to this Agreement (including its Schedules) shall be effective unless made in writing and signed by or on behalf of both Parties or by their duly authorised representatives.   21.3 Remedies cumulative   21.4 The rights, powers and remedies provided in this Agreement are (except as expressly provided) cumulative and not exclusive of any rights, powers and remedies provided by law, or otherwise.   17 
SHBV 
   
    For the attention of: Managing Director     Address: 
   
    With copy to: Managing Director,     Telephone number: 
   
Fax number: 
   
    W2E 
   
    For the attention of:  Mr John Murphy     Address: Dargavel Stores, Lockerbie Road, Dumfries, 
   DG1 3PG     Telephone number:  [Insert details]     Fax number: [Insert details]21.5 No partnership or agency   21.5.1 Nothing in this Agreement shall (except as expressly provided) be deemed to constitute a partnership, or create a relationship of principal and agent for any purpose between the Parties.   21.5.2 Any statement or representation made by either Party shall not be binding on the other unless agreed otherwise agreed in writing and neither Party shall be liable to any third party for any loss or damages arising out of such statements or representations.   21.6 No waiver   21.7 The failure to exercise, or delay in exercising, a right, power or remedy provided by this Agreement or by law shall not constitute a waiver of that right, power or remedy. If a Party waives a breach of any provision of this Agreement this shall not operate as a waiver of a subsequent breach of that provision, or as a waiver of a breach of any other provision.   21.8 Costs of each of the Parties   21.9 Each Party shall bear its own costs and expenses in connection with the preparation, negotiation, and execution of the Agreement.   21.10 Third Party Rights   A person who is not a party to this Agreement may not enforce any of its provisions under the Contracts (Rights of Third Parties) Act 1999.   21.11 Counterparts / Execution of Agreement   21.12 This Agreement may be entered into by the Parties in any number of counterparts. Each counterpart shall, when executed and delivered, be regarded as an original, and all the counterparts shall together constitute one and the same instrument. This Agreement shall not take effect until it has been executed by both the Parties. This Agreement may be validly exchanged and delivered by fax.   21.13 Severability   21.13.1 If any Clause, or part of a Clause, of this Agreement, is found by any court or administrative body of competent jurisdiction to be illegal, invalid or unenforceable, and the provision in question is not of a fundamental nature to the Agreement as a whole, the legality, validity or enforceability of the remainder of this Agreement (including the remainder of the Clause or sub Clause which contains the relevant provision) shall not be affected.   21.13.2 If the foregoing applies, the Parties shall use all reasonable endeavours to agree within a reasonable time upon any lawful and reasonable variations to the   18Agreement which may be necessary in order to achieve, to the greatest extent possible, the same effect as would have been achieved by the Clause, or the part of the Clause, in question.   22 GOVERNING LAW   22.1 This Agreement is governed by English law.   22.2 The Parties submit to the non-exclusive jurisdiction of the courts of England and Wales.   This Agreement shall come into force on the date given at the beginning of this Agreement.     
  19 
SIGNED by   
   ) 
    ) 
(name), 
      
          
  )  
a duly authorised signatory of 
   ) (signature) SHBV (HONG KONG) LTD 
      
      )             
SIGNED by   
     )       ) (name), 
      
      
  
      ) 
a duly authorised signatory of 
   ) (signature) WASTE2ENERGY GROUP HOLDINGS PLC  
   )Exhibit 10.2
STRATEGIC ALLIANCE AGREEMENT
dated as of August 26, 2015
among
Sucampo Pharmaceuticals, Inc.,
Sucampo Pharma, LLC.
and
R-Tech Ueno, Ltd.TABLE OF CONTENTS
ARTICLE I DEFINITIONS AND INTERPRETATION
Section 1.01 Definitions 2
Section 1.02 Interpretation 8
ARTICLE II TRANSACTION
Section 2.01 Strategic Alliance 8
Section 2.02 Obligations of Acquiror 9
Section 2.03 Obligations of the Company 11
ARTICLE III REPRESENTATIONS AND WARRANTIES
Section 3.01 Representations and Warranties of the Company 11
Section 3.02 Representations and Warranties of Acquiror 12
ARTICLE IV COVENANTS OF THE PARTIES
Section 4.01 The Company’s Obligation 12
Section 4.02 Consummation of the Squeeze-out 15
Section 4.03 Applications and Consents; Governmental Communications and Filings 15
Section 4.04 Further Assurance 15
Section 4.05 Access 15
Section 4.06 Notifications 16
Section 4.07 Confidentiality 16
Section 4.08 Public Announcement 17
Section 4.09 No Lender Liability 17
Section 4.10 Employees of Company 17
Section 4.11 Development Programs and Clinical Trials 18
ARTICLE V INDEMNIFICATION
Section 5.01 Indemnification by the Company 18
Section 5.02 Indemnification by Acquiror 18
Section 5.03 Indemnification Procedure 18
Section 5.04 Limitations 18
iARTICLE VI TERMINATION
Section 6.01 Termination 19
Section 6.02 Notice of Termination 19
Section 6.03 Effect of Termination 19
ARTICLE VII GUARANTEE
Section 7.01 Guarantee 19
ARTICLE VIII MISCELLANEOUS
Section 8.01 Governing Law 19
Section 8.02 Jurisdiction 19
Section 8.03 Cost and Expenses 20
Section 8.04 Assignment 20
Section 8.05 Amendments and Waivers 20
Section 8.06 Severability 20
Section 8.07 Counterparts 21
Section 8.08 Entire Agreement 21
Section 8.09 Notices 21
Section 8.10 Language 22
Section 8.11 Disclosure Schedules 22
Section 8.12 Fraud 22
Section 8.13 Third-party Beneficiaries 23
iiSTRATEGIC ALLIANCE AGREEMENT
This STRATEGIC ALLIANCE AGREEMENT is made and entered into as of August 26, 2015 (this “Agreement”), by and among R-Tech
Ueno, Ltd., a corporation organized under Japanese law (the “ Company”), Sucampo Pharma, LLC., a corporation organized under Japanese law
(“Acquiror”), and Sucampo Pharmaceuticals, Inc., a corporation organized under Delaware law (“ SPI,” and, together with the Company and
Acquiror, collectively, the “Parties”).
RECITALS
WHEREAS, the Acquiror is a wholly-owned subsidiary of SPI, which operates a biopharmaceutical business focused on the research
and development of proprietary drugs;
WHEREAS, the Company operates a drug discovery and manufacturing business;
WHEREAS, Acquiror and the Company share the objective of creating a combined biopharmaceutical company that can drive
considerable growth in global markets, including Japan;
WHEREAS, the Company has currently in issuance and outstanding 19,312,300 shares of common stock (the “ Common Stock”) and
stock options representing an additional 328,600 shares of Common Stock (the “ Stock Options”, and together with the issued and outstanding
Common Stock, the “Target Securities”);
WHEREAS, pursuant to the terms and subject to the conditions set forth herein, Acquiror has agreed to commence a tender offer bid
(such tender offer bid, including any amendments or extensions thereto made in accordance with the terms of this Agreement and applicable Law,
including Articles 27-2 through 27-22 of the FIEL, the “Offer”) to acquire for cash (i) all of the issued and outstanding shares of Common Stock at a
price per share of JPY1,900 (the “Share Offer Price”) and (ii) all of the outstanding Stock Options at the price prescribed in this Agreement;
WHEREAS, the Company has agreed, on the terms and subject to the conditions set forth herein, to support the Offer and recommend
the holders of Target Securities to tender their shares of Common Stock and Stock Options to the Offer and publicly announce such statement;
WHEREAS, Jefferies Finance LLC (“Jefferies ”) has entered into a financing commitment letter, dated as of August 26, 2015, between SPI
and Jefferies (the “Financing Commitment”), pursuant to which Jefferies has committed to provide debt financing for the Offer in the aggregate
amount and on the terms and conditions set forth therein (the “ Financing”);
1NOW, THEREFORE, in consideration of the foregoing and the mutual covenants and agreements herein contained, and intending to be
legally bound hereby, the Parties hereby agree as follows:
ARTICLE I
DEFINITIONS AND INTERPRETATION
Section 1.01 Definitions. As used in this Agreement, the following terms have the respective meanings set forth below:
“Acquiror” shall have the meaning set forth in the preamble hereto.
“Action” shall mean any claim, action, suit, arbitration, mediation, proceeding or investigation, whether civil, criminal or administrative,
by or before any Governmental Authority or arbitral body.
“Affiliate” shall mean, (i) with respect to a particular individual, (A) the individual’s spouse and any parent, child, sibling, grandparent,
grandchild, aunt, uncle, niece, nephew of the individual or the individual’s spouse, (B) any Person that is directly or indirectly controlled by the
particular individual or any such family member of the particular individual or his/her spouse, (C) any Person in which the particular individual or
any such family member of the particular individual or his/her spouse has a material financial interest, and (D) any Person with respect to which the
particular individual or such family member of the particular individual or his/her spouse serves as a director, officer or partner (or in a similar
capacity); and (ii) with respect to any specified Person other than an individual, (A) any Person that directly, or indirectly through one or more
intermediaries, Controls, or is Controlled by, or is under common Control with, the Person specified, (B) any Person in which the specified Person
has a material financial interest, and (C) any Person which has a material financial interest in the specified Person. “Control” and its derivative
words mean the possession, direct or indirect, of the power to direct or cause the direction of the decisions, management and policies of a Person,
whether through the ownership of voting securities, by contract or otherwise, including the ability to elect the majority of the directors or the
members of a similar governing body of a Person.
“Agreement” shall have the meaning set forth in the preamble hereto.
“Annual Financial Statements” shall have the meaning set forth in Section (j) of Schedule 3.01.
“Business Day ” shall mean any day other than a Saturday or Sunday, or any other day on which commercial banks in Tokyo, Japan or
New York in the U.S.A. are authorized or required by applicable Law to close.
“Closing” shall mean the Settlement in accordance with the terms of this Agreement.
2“Closing Date” shall mean the date on which the Closing occurs.
“Common Stock” shall have the meaning set forth in the recitals hereto.
“Company” shall have the meaning set forth in the recitals hereto.
“Company Disclosure Letter” shall mean the letter dated the same date as this Agreement from the Company to the Acquiror disclosing
information constituting exceptions to the representations and warranties given by the Company pursuant to Section 3.01.
“Company’s Position Statement” shall have the meaning set forth in Section 2.03(b).
“Contract” shall mean any contract, agreement, instrument, undertaking, indenture, commitment, loan, license or other legally binding
obligation, whether written or oral.
“Environmental Claim” shall mean any claim, action, cause of action, suit, investigation or proceeding by any Person alleging liability
(including liability for investigatory costs, cleanup costs, governmental response costs, natural resource damages, fines or penalties) for any
Losses arising from (a) presence or Release of any Hazardous Substance at any location, whether or not owned or operated by the Company or any
Subsidiaries, or (b) circumstances forming the basis of noncompliance with or liability under any Environmental Laws.
“Environmental Laws” shall mean any Law or Order of any Governmental Authority relating to the protection of the environment
(including protection of air, water, soil, and natural resources), human health, natural resources or the use, storage, handling, release, exposure to or
disposal of any Hazardous Substance, as in effect on the date hereof.
“FIEL” shall mean the Financial Instruments and Exchange Law of Japan ( kinyuu-shohin-torihiki-ho ) (Law No. 25 of 1948, as amended).
“Financing” shall have the meaning set forth in the recitals hereto.
“Financing Commitment” shall have the meaning set forth in the recitals hereto.
“Financing Party” shall have the meaning set forth in Section 4.09.
“Financial Statements Date” shall have the meaning set forth in Section (j) of Schedule 3.01.
“GAAP” shall mean Japanese generally accepted accounting principles in effect from time to time.
3“Governmental Authority” shall mean any domestic, foreign or supranational government, governmental authority, court, tribunal,
agency or other regulatory, administrative or judicial agency, commission or organization (including self-regulatory organizations), tribunal or
arbitral body, stock exchange, and any subdivision, branch or department of any of the foregoing.
“Hazardous Substance” shall mean any substance that is regulated as hazardous, toxic, radioactive, or as a pollutant, contaminant or
harmful biological agent, including petroleum and any derivative or by-products thereof, that may give rise to liability under any Environmental
Laws.
“Indebtedness” shall mean, for any Person, all obligations, contingent or otherwise, of that Person (i) for borrowed money, (ii) evidenced
by notes, debentures or similar instruments, (iii) under capitalized lease obligations, (iv) in respect of the deferred purchase price of securities or
other assets, and (v) in respect of reimbursement obligations to reimburse any other Person for or in respect of any letter of credit, bankers’
acceptance, surety bonds or other financial guaranties.
“Indemnified Party” shall have the meaning set forth in Section 5.03.
“Indemnifying Party” shall have the meaning set forth in Section 5.03.
“Intellectual Property Rights” shall mean all patents, patent rights, licenses, inventions, copyrights, trademarks, service marks, logos,
trade dress, design rights, trade or business names, domain names, trade secrets, know-how, in each case of a proprietary nature and any
proprietary confidential information systems processes or procedures of the intellectual property (whether, in each case, registered, unregistered or
unregistrable, and including pending applications for registration and rights to apply for registration) and all rights of a similar nature or having
similar effect which may subsist in any part of the world.
“Japan Business Day” shall mean any day other than a Saturday or Sunday, or any other day on which commercial banks in Tokyo,
Japan are authorized or required by Japanese Law to close.
“Jefferies ” shall have the meaning set forth in the recitals hereto.
“Launch Date” shall have the meaning set forth in Section 2.02(a).
“Law” shall mean, with respect to any Person, any law, statute or ordinance, or any rule, regulation, standard, judgment, order, writ,
injunction, ruling, decree, arbitration award, agency requirement, license or permit of any Governmental Authority that is legally binding on such
Person.
“Lenders” shall mean Jefferies and a syndicate of banks, financial institutions and other lenders providing the Financing pursuant to the
terms of the Financing Commitment.
4“Lien” shall mean a lien, charge, option, mortgage, pledge, security interest, claim, deed of trust, hypothecation or encumbrance of any
kind.
“Losses ” shall mean damages, losses or liabilities (including judgments, awards, interest and penalties), together with costs and
expenses reasonably incurred, including the reasonable fees and disbursements of legal counsel.
“Material Adverse Effect” shall mean any fact, event, circumstance, occurrence, change or effect that individually or in the aggregate
has or is reasonably likely to have a material adverse effect on the business, financial condition, assets, operations, or results or prospects of
operations of the Company, taken as a whole.
“Material Contract” shall mean any Contract or other agreement to which the Company is a party, and is material to the business,
operations, or material properties or assets of the Company. The Material Contracts shall include, without limitation, any Contract or other
agreement:
(i) which is described under “Part 1. Company’s Information – II. Description of the Company – 5. Material Contracts Relating to
Business” in the securities report ( yuka-shoken-hokokusho ) of the Company filed with the Kanto Local Finance Bureau on June 24, 2015
in accordance with Article 24, Paragraph 1 of the FIEL, except for the License Agreement with Astellas Pharma Inc., which is no longer
effective;
(ii) under which the Company has incurred outstanding Indebtedness, guarantees or Liens, or has assumed other similar
obligations;
(iii) which will materially limit ability of the Company to compete in any line of business or geographic area or make use of any
material Intellectual Property Rights owned by the Company;
(iv) relating to the acquisition or disposition of companies or businesses by the Company (whether by purchase or sale of shares
or assets, by merger, or otherwise);
(v) under which the Company has made a loan or capital contribution to or any investment in any Person other than the
Company;
(vi) which establishes or relates to the termination, creation or operation of a joint venture, partnership, or other similar profit (or
loss) sharing arrangement;
(vii) which requires or restricts the payment of dividends or distributions in respect of the capital stock of the Company;
(viii) which was entered into outside the ordinary course of business and which involves obligations or liabilities in excess of […
***…];
5(ix) which requires the Company or any successor or acquiror of the Company to make any payment to another Person as a result
of a change of control of the Company;
(x) with any Affiliate, director, executive officer, any holder of 5% or more of the outstanding shares of Common Stock or
immediate family members (other than Contracts for stock options); or which, either as a single Contract or series of related or affiliated
Contracts or work orders, constituted one of the 20 largest Contracts of the Company on the basis of revenues generated in the most
recent fiscal year.
“Offer” shall have the meaning set forth in the recitals hereto.
“Offer Documents” shall have the meaning set forth in Section 2.02(d).
“Offer Period” shall have the meaning set forth in Section 2.02(a).
“Order” shall mean any order, injunction, judgment, decree, ruling, assessment, judicial or administrative order, award or determination of
any Governmental Authority or arbitrator.
“Organizational Documents” shall mean the articles of incorporation, the rules of the board of directors, the share handling regulations,
the partnership agreement, the limited liability company agreement, the operating agreement or other similar governing instruments, in each case as
amended as of the date specified, of any Person.
“Owned Real Property” shall mean the land listed on Schedule III.
“PAL” shall mean the Pharmaceutical Affairs Law of Japan (iyakuhin-iryoukikito-no-hinshitu-yukousei-anzensei-no-kakuhoto-ni-
kansuru-horitu ) (Law No. 145 of 1955, as amended).
“Parties” shall have the meaning set forth in the preamble hereto, and “ Party” shall mean either of the Parties.
“Permits” shall have the meaning set forth in Section (g) of Schedule 3.01.
“Person” shall mean any natural person, general or limited partnership, limited liability company, limited liability partnership, corporation,
joint stock company, trust, unincorporated association, joint venture, Governmental Authority, or other entity, whether acting in an individual,
fiduciary or other capacity.
“Products” shall have the meaning set forth in Section (u) of Schedule 3.01.
“Registered IP” shall have the meaning set forth in Section (v) of Schedule 3.01.
6“Release” shall mean any release, spill, emission, leaking, pumping, pouring, dumping, emptying, injection, deposit, disposal, discharge,
dispersal, leaching or migration on or into the Environment or into or out of any property.
“Settlement” shall have the meaning set forth in Section 2.02(e).
“Settlement Date” shall mean the 5th  Japan Business Day following the last day of the Offer Period, except as such date may be adjusted
pursuant to Section 2.02(f).
“Share Offer Price” shall have the meaning set forth in the recitals hereto.
“SPI” shall have the meaning set forth in the recitals hereto.
“Squeeze-out” shall mean any squeeze out transaction that Acquiror determines necessary and appropriate to make the Company wholly
owned subsidiary of the Acquiror after the Settlement.
“Stock Options” shall have the meaning set forth in the recitals hereto.
“Stock Purchase Agreement” shall mean the stock purchase agreement among, dated August 26, 2015 entered into by Acquiror, and
Ryuji Ueno, MD, Sachiko Kuno, S&R Technology Holdings, LLC and S&R Foundation.
“Strategic Business Alliance ” shall have the meaning set forth in Section 2.01.
“Subsidiaries” shall mean, with respect to any Person, any juridical Person of which more than 50% of the voting power of the
outstanding voting securities or more than 50% of the outstanding economic equity interest is held, directly or indirectly, by such Person, and in
any event will include any Person that is fully included in the consolidated financial statements of such Person prepared in accordance with GAAP.
“Sucampo Group” shall have the meaning set forth in Section 2.01.
“Superior Offer” shall have the meaning set forth in Section 2.03(a).
“Target Securities” shall have the meaning set forth in the recitals hereto.
“Taxes” shall mean all taxes, charges, fees, levies or other assessments, including income, capital, gross receipts, excise, property, stamp,
registrations, sales, license, payroll, consumption, withholding and franchise taxes, escheat obligation, and any secondary tax liability, imposed by
Japan or any other country or any local government or taxing authority or political subdivision or agency thereof or therein, and such term shall
include any interest, penalties or additions attributable to such taxes, charges, fees, levies or other assessments.
“Tax Returns” shall mean any return, declaration, report, claim for refund, or information return or statement filed or required to be filed
with any Governmental Authority with respect to Taxes, including any schedule or attachment thereto, and including any amendment thereof.
7“Tender Offer Agent” shall mean Nomura Securities Co., Ltd.
“Tender Offer Explanatory Statement” shall have the meaning set forth in Section 2.02(d).
“Tender Offer Registration Statement” shall have the meaning set forth in Section 2.02(d).
Section 1.02 Interpretation . Unless otherwise indicated to the contrary in this Agreement by the context or use thereof: (a) the words,
“herein,” “hereto,” “hereof” and words of similar import refer to this Agreement as a whole and not to any particular section or paragraph of this
Agreement; (b) references in this Agreement to articles, sections or paragraphs refer to articles, sections or paragraphs of this Agreement; (c)
headings of sections are provided for convenience only and should not affect the construction or interpretation of this Agreement; (d) words
importing the masculine gender shall also include the feminine and neutral genders, and vice versa; (e) words importing the singular shall also
include the plural, and vice versa; (f) the words “include”, “includes” and “including” shall be deemed to be followed by the phrase “without
limitation”; (g) any reference to a statute refers to such statute as it may have been or may be amended from time to time, or to such statute’s
successor, and shall be deemed also to refer to all rules and regulations promulgated thereunder; (h) any reference to a Contract or other document
as of a given date means the Contract or other document as amended, supplemented and modified from time to time through such date; (i) “or” shall
include the meanings “either” or “both”; and (j) the symbols “JPY” or “¥” shall refer to the lawful currency of Japan.
ARTICLE II
TRANSACTION
Section 2.01 Strategic Alliance. For the purpose of creating a combined company that can drive considerable growth in global markets,
including Japan, the Parties agree to form a strategic business alliance (the “ Strategic Business Alliance ”) among Acquiror and SPI and its
Affiliates (collectively, the “Sucampo Group”) and the Company, subject to the successful Closing. The Parties intend to achieve the purpose of
such Strategic Business Alliance by mutual cooperation in, among others, the following areas:
(a) ensuring that the transaction contemplated in this Agreement would provide Sucampo Group with increased revenues—primarily
from combining Sucampo Group’s existing sales with those from the Company—enhanced profitability, strong cash flow generation and a robust
balance sheet and the improved financial strength of SPI as the parent company would also accrue to the benefit of its subsidiaries, which will
include the Company after the Closing;
(b) ensuring that Sucampo Group and the Company together would have a deeper and broader development pipeline of potential drug
candidates in development across four major therapeutic areas—gastroenterology, ophthalmology, autoimmune, and inflammation—and greater
resources, both financially and operationally, to maximize these opportunities, and consistent with the Target Company’s business strategy, such
development pipelines (some of these drug candidates) could be out-licensed to external firms to create even greater value; and
8(c) ensuring that both Sucampo Group and the Company would have greater opportunity to conduct business development
transactions, and through the relationships of the Company and increased presence in the Japanese market, Sucampo Group would gain greater
access to the Japanese biotech community and Japan’s well-regarded scientific institutions and researchers, and the Company would receive
access to Sucampo Group’s expertise in identifying, negotiating and managing key alliances.
Section 2.02 Obligations of Acquiror .
(a) Commencement of the Offer. Subject to the terms and conditions herein, Acquiror agrees to commence the Offer on August 27, 2015
(the “Launch Date”) to acquire for cash (i) all of the issued and outstanding shares of Common Stock at the Share Offer Price and (ii) all of the
outstanding Stock Options at the price as set out in Schedule I. The Offer shall be open for acceptance from the time of commencement until a time
that is not earlier than 3:30 p.m. (Tokyo time) on the 30th  Japan Business Day from and including the Launch Date (as adjusted pursuant to Section
2.02(f) below, the “Offer Period”).
(b) Conditions to the Commencement of the Offer. Acquiror’s obligation to commence the Offer will be subject to satisfaction (or waiver
in writing by Acquiror in its sole discretion) of each of the following conditions on the Launch Date:
(i) The representations and warranties of the Company set forth in Section 3.01 shall be true and correct in all material respects;
(ii) The Company shall have duly performed its obligations required to be performed by it prior to the Launch Date under this
Agreement;
(iii) The board of directors of the Company unanimously (a) shall have made a resolution approving a statement of opinion in
support of the Offer and recommending the holders of shares of Common Stock and Stock Options to tender their shares and Stock
Options to the Offer, with recommendation by the independent committee of the Company, and have publicly announced such statement,
and (b) have not revoked such statement;
(iv) The board of directors of the Company unanimously shall have made a resolution revealing its intention to support the
Squeeze-out (including the price to be offered therein) and have publicly announced such intention, and have not revoked such
intention;
(v) For the purpose of approving the transfer of Stock Options that will be tendered to the Offer and releasing any transfer
restriction for such Stock Options provided in relevant contracts between the Company and the holders of such Stock Options, the
board of directors of the Company shall have made a resolution to authorize and instruct appropriate board members to approve the said
transfer and release the said transfer restriction in a timely manner if requested in writing by any holders of such Stock Options;
9(vi) The Financing Commitment shall have been duly made and entered into by Jefferies;
(vii) No temporary restraining order, preliminary or permanent injunction or other Order preventing the commencement of the
Offer or the consummation of the Squeeze-out shall be in effect, and no Law shall have been enacted or shall be deemed applicable to the
Offer or the Squeeze-out which makes the consummation of the Offer or the Squeeze-out illegal;
(viii) All necessary consents, approvals (including, but not limited to, approval of the Financial Services Agency, Kanto Local
Financial Bureau and Tokyo Stock Exchange) for the Offer shall have been obtained by Acquiror and the Company;
(ix) The Company shall not have suffered a Material Adverse Effect since the Financial Statements Date; and
(x) Acquiror shall have concurrently entered into a Stock Purchase Agreement with Ryuji Ueno, MD, Sachiko Kuno, S&R
Technology Holdings, LLC and S&R Foundation.
(c) Withdrawal of the Offer. Acquiror may withdraw the Offer upon the occurrence of any event listed in the FIEL Enforcement Ordinance
and the Tender Offer Registration Statement.
(d) Publication and Filing. Upon the commencement of the Offer, Acquiror shall publish a tender offer public notice and shall file a tender
offer registration statement (the “ Tender Offer Registration Statement”) with the Kanto Local Finance Bureau, each in accordance with the terms
and conditions set forth in this Section 2.02 and Article 27-3 of the FIEL. Acquiror shall file with the relevant Governmental Authorities, publish
and/or mail to holders of the Target Securities as required by Law (i) a copy of the Tender Offer Registration Statement, (ii) a tender offer
explanatory statement (the “ Tender Offer Explanatory Statement”) and (iii) each other document required under applicable Law to be so filed,
published or mailed by it in connection with the Offer (collectively, the “ Offer Documents”).
(e) Settlement of the Offer. Unless the Offer has been withdrawn by Acquiror in accordance with terms of this Agreement, Acquiror shall
cause payment in full for all Target Securities validly tendered (and not withdrawn) under the Offer (the “ Settlement”) to be made by the Tender
Offer Agent in immediately available funds as promptly as practicable following the end of the Offer Period and in no event later than the Settlement
Date.
10(f) Extensions of the Offer Period and Amendments . Acquiror may, in its sole discretion, extend the Offer Period for such period as
designated by Acquiror in accordance with Article 27-6 of the FIEL.
Section 2.03 Obligations of the Company .
(a) Support of the Offer. Upon the commencement of the Offer, the Company (i) shall, by a unanimous resolution of its board of directors,
and with recommendation by the independent committee of the Company, approve a statement of opinion in support of the Offer and
recommending the holders of shares of Common Stock and Stock Options to tender their shares and Stock Options to the Offer and have publicly
announced such statement, and (ii) shall not revoke such statement. The Company (1) shall also, by a unanimous resolution of its board of
directors, and with recommendation by the independent committee of the Company, reveal its intention to support the Squeeze-out and (2) publicly
announce such intention, and (3) shall not revoke such intention. Notwithstanding the forgoing, the Company may, upon prior consultation with
the Acquiror, revoke or change such statement or intention, only if (A) there is any counter tender offer bid or any bona fide offer to acquire the
Target Securities that is a Superior Offer and (B) the failure to take such action, on the basis of legal opinion issued in writing by legal counsel of
the Company, would be reasonably expected to cause the board of directors of the Company to be in breach of its duty of care ( zenkan-tyui-gimu )
under Japanese law. For purposes of this Agreement, “ Superior Offer” shall mean an unsolicited bona fide  written offer by a third party to
purchase all of the outstanding Target Securities that the Board of Directors of the Company determines, in its good faith judgment, after
consultation with its outside legal counsel and its financial advisors, is reasonably likely to be consummated in accordance with its terms, taking
into account all legal, regulatory and financing aspects (including certainty of closing) of the offer and the ability of the Person making the offer to
consummate the transaction and that would result in a transaction more favorable to the Company’s stockholders (solely in their capacity as such)
from a financial point of view than the transaction contemplated by this Agreement.
(b) Publication and Filing. Upon the commencement of the Offer, the Company shall make public disclosure and file a company’s position
statement ( iken-hyoumei-houkokusho ) (the “Company’s Position Statement”) with the Kanto Local Finance Bureau, each in accordance with in
accordance with Section 2.03(a) and applicable Laws and in a manner and content as agreed with Acquiror.
ARTICLE III
REPRESENTATIONS AND WARRANTIES
Section 3.01 Representations and Warranties of the Company . The Company hereby represents and warrants to Acquiror that, except as
disclosed in the Company Disclosure Letter, the statements set forth in Schedule 3.01 are true and correct as of the date of this Agreement and will
be true and correct as of the Launch Date and the Closing Date (or, if made as of a specified date, as of such specified date only).
11Section 3.02 Representations and Warranties of Acquiror . Each of Acquiror and SPI hereby represents and warrants to the Company that
the statements set forth in Schedule 3.02 are true and correct as of the date of this Agreement and will be true and correct as of the Launch Date
and the Closing Date (or, if made as of a specified date, as of such specified date only).
ARTICLE IV
COVENANTS OF THE PARTIES
Section 4.01 The Company’s Obligation.
(a) Ordinary Course of Business of the Company’s Operation.  During the period from the date of this Agreement and the completion of
the Squeeze-out (the “ Restricted Period”), except as contemplated by this Agreement, required by applicable Law or otherwise agreed to in writing
by Acquiror, the Company shall operate in the ordinary course of business consistent with the past practice and use its reasonable efforts to
preserve intact the material components  of its current business organization, including keeping available the services of current officers and key
employees, and use its reasonable efforts to maintain its relations and good will with all material suppliers, material customers, governmental bodies
and other material business relations intact its business relationships.
(b) Restrictive Covenants . Without limiting Section 4.01(a), during the Restricted Period, except as contemplated by this Agreement, set
forth in Schedule 4.01(b), required by applicable Law or otherwise agreed to in writing by Acquiror, the Company shall not:
(i) sell, issue, grant, pledge or transfer or authorize the sale, issuance, grant, pledge or transfer of any capital stock or equity interest
or other security of the Company or any instrument convertible into or exchangeable for any security of the Company, except for
approval of the transfer of Stock Options that will be tendered to the Offer and release from any transfer restriction for such Stock
Options provided in relevant contracts between the Company and the holders of such Stock Options;
(ii) establish or adopt new employee benefits plans or provide increases in employee salaries, or benefits outside the ordinary course
of business;
(iii) hire new employees, other than at positions with annual salary and benefits costs of not more than […***…] or positions listed
on Schedule 4.01(b) hereto;
(iv) enter into change-in-control, severance, bonus or retention agreements with any directors, officers, employees or consultants of
the Company;
(v) enter into any collective bargaining agreement or other agreement with any labor organization or work council;
12(vi) make any material capital expenditure;
(vii) license, acquire, dispose or cause or permit any Lien on any material right or material asset or property other than the sale of
inventory in the ordinary course of business or dispositions of obsolete, surplus or worn out assets;
(viii) amend or relinquish any material rights under any Material Contract or enter into any new Material Contracts;
(ix) enter into any new line of business or discontinue any existing business, including commencement of any new development
programs, pre-clinical studies or clinical trials except for those activities and costs that cannot be postponed and the Company is
contractually obligated to perform or pay during the Restricted Period, and not to exceed the costs set forth in Schedule 4.01(b)(ix)
of this Agreement, which Schedule shall include the budgeted costs of the development activities listed therein;
(x) make any material change to any accounting methods or make any material tax election;
(xi) commence or settle any legal proceeding;
(xii) enter into any action or decision that could fall under any category of information subject to insider trading regulation under
Article 166, Paragraph 1 or Article 167, Paragraph 1 of the FIEL;
(xiii) declare or make payment of any dividends or other distribution to its shareholders;
(xiv) revoke the resolution by the board of directors as set out in Section 2.02(b)(v);
(xv) incur any Indebtedness or grant any Liens on any of its property or assets outside the ordinary course of business;
(xvi) adopt, implement or take any actions or measures except for those permitted under this Agreement that could require Acquiror to
amend or change, in part or whole, any of the Offer Documents or extend the Offer Period; or
(xvii) authorize any of, or agree or commit to take, any of the actions described in clauses (i) through (xv) of this Section 4.01(b).
(c) Notice and Consent . Prior to Closing, the Company shall provide a written notice to, or use its commercially reasonable efforts to
obtain a written consent from each counterparty to a Material Contract to which the Company is party, if such contract so requires the Company in
connection with the consummation of the transactions contemplated hereby.
13(d) Cooperation with the Offer. The Company agrees to take all reasonable actions available to them to cooperate with Acquiror in
making the Offer and gathering tenders from existing shareholders of the Company, and shall provide such information and assistance as Acquiror
or its agents may reasonably request in connection with communicating the Offer and any amendments and supplements thereto to the holders of
the Target Securities and to such other Persons as are entitled to receive the Offer Documents under applicable Law, including, to the extent
permissible, under the Personal Information Protection Law of Japan and other applicable Law. The Company acknowledges and agrees that
Acquiror may state in any Offer Document or press release the Company’s support of the Offer and the Squeeze-out as set out in Section 2.03(a).
(e) Financing. Acquiror shall use its reasonable efforts to take all actions and to do all things necessary, proper or advisable to arrange,
consummate and obtain the proceeds of the Financing. The Company shall use its reasonable efforts to provide to Acquiror such customary
cooperation as may be reasonably requested by Acquiror to assist Acquiror in causing the conditions in the Financing Commitment to be satisfied
and such customary cooperation as is otherwise reasonably necessary and reasonably requested by Acquiror solely in connection with obtaining
the Financing, which cooperation shall include (without limitation):
(i) causing its management team, external auditors and other non-legal advisors to assist in preparation for and to participate in a
reasonable number of meetings with the Lenders, and conference calls (including customary one-on-one meetings with the parties acting
as lead arrangers, bookrunners or agents for, and prospective lenders of, the Financing and senior management (with appropriate
seniority and expertise) of the Company), presentations and sessions with prospective lenders, investors and ratings agencies in
connection with any of such Financing;
(ii) using its reasonable efforts to cause the syndication and marketing efforts in connection with the Financing to benefit from
the Company’s relationships with potential financing sources;
(iii) providing customary authorization letters to the Lenders under the Financing Commitment authorizing the distribution of
information to other prospective lenders and containing customary representations to the Lenders under the Financing Commitment;
(iv) furnishing Acquiror and the Lenders promptly, and in any event at least five (5) business days prior to Closing, with all
documentation and other information that any Lender has reasonably requested and that such Lender has determined is required by
regulatory authorities in connection with the Financing under applicable “know your customer” and anti-money laundering rules and
regulations, including without limitation the PATRIOT Act;
14(v) assisting in preparing of and, subject to the successful Squeeze-out, executing and delivering of any customary pledge and
security documents, credit agreements, indentures, guarantees, ancillary documents and instruments and customary closing certificates
and documents and assisting in preparing schedules (and providing necessary information relating thereto) as may be reasonably
requested by Acquiror;
(vi) obtaining customary payoff letters, Lien terminations and instruments of discharge to be delivered at Closing to allow for the
payoff, discharge and termination in full on the Closing Date of all Indebtedness;
(vii) permitting the use of the Company’s logos, trademarks and trade names in connection with the Financing contemplated by
the Financing Commitment; provided, that such logos, trademarks and trade names are used solely in a manner that is not intended to,
nor reasonably likely to, harm or disparage the Company;
(viii) timely preparing a customary confidential information memorandum and other customary marketing materials with respect to
the Financing; and
(ix) promptly furnishing any other information as reasonably requested by Acquiror or the Lender in connection with the
Financing.
Section 4.02 Consummation of the Squeeze-out . Subject to the successful Closing, the Company agrees to take all reasonable actions
available to it to consummate the Squeeze-out and appointment of new directors of the Company as designated by Acquiror as soon as possible
after the Closing, as reasonably requested by Acquiror, and shall provide such information and assistance as Acquiror or its agents may
reasonably request in connection with communicating the Squeeze-out.
Section 4.03 Applications and Consents; Governmental Communications and Filings . Each Party shall cooperate and use its reasonable
efforts in making all notifications to, and seeking all consents of, Governmental Authorities necessary or advisable to consummate the transactions
contemplated hereby as promptly as practicable. No Party shall take any action that would reasonably be expected to prevent or materially delay or
impede the filing or receipt of such necessary or advisable notifications or consents.
Section 4.04 Further Assurance . Subject to the terms and conditions hereof, each Party covenants and agrees to use its reasonable
efforts to take, or cause to be taken, all actions, and to do, or cause to be done, in good faith, all things applicable to it that are necessary, proper or
desirable, or advisable under applicable Law to carry out the provisions contained in this Agreement and the transactions contemplated hereunder.
Section 4.05 Access . During the Restricted Period, upon reasonable advance notice to the Company, the Company shall: (a) provide
Acquiror with reasonable access during normal business hours of the Company to the Company’s employees, consultants and other personnel and
assets and to all existing books, records, Tax Returns, work papers and other documents and information relating to the Company; and (b) promptly
provide Acquiror copies of the existing books, records, Tax Returns, work papers and other documents and information relating to the Company,
and with such additional financial, operating and other data and information regarding the Company, as Acquiror may reasonably request;
provided, however, that any such access shall be conducted at Acquiror’s expense, at a reasonable time, under the supervision of appropriate
personnel of the Company and in such a manner as not to unreasonably interfere with the normal operation of the business of the Company.
15Section 4.06 Notifications. Each Party shall give prompt notice to the other Parties (and subsequently keep the other Parties informed on
a current basis) upon its becoming aware of (a) any Actions commenced or, to such Party’s knowledge, threatened against, relating to or involving
or otherwise affecting such Party or any of its Affiliates which relate to the Offer or the transactions contemplated by this Agreement, or (b) the
occurrence or existence of any fact, event or circumstance that would or would be reasonably likely to (i) cause or constitute a material breach of
any of its covenants or agreements contained herein, or (ii) impair or delay the completion of the Offer or the Closing; provided , however, the
delivery of any notice pursuant to this Section 4.06 shall not (x) cure any breach of, or non-compliance with, any other provision of this Agreement
or (y) limit the remedies available to any Party receiving such notice.
Section 4.07 Confidentiality.
(a) For […***…] ([…***…]) years from and after the date of this Agreement, the Company will hold and treat in confidence, and will not
use, and will cause their Affiliates to hold and treat in confidence, all non-public documents and information (including any information with regard
to terms and conditions of this Agreement) concerning Acquiror and each of its respective Affiliates, except to the extent that such documents and
information (1) are required or requested (with prompt notice of such request to be made to Acquiror) to be disclosed by applicable Law or any
Governmental Authority, (2) generally become available to the public through no fault of the Company, (3) become available to the Company on a
non-confidential basis, or (4) are independently developed by the Company or its Affiliates without reference to the furnished information.
(b) Until earlier of (i) the consummation of the Squeeze-out and (ii) the expiration of […***…] ([…***…]) year period from and after the
date of this Agreement, Acquiror will hold and treat in confidence, and will not use, and will cause its Affiliates to hold and treat in confidence, all
non-public documents and information concerning the Company, except to the extent that such documents and information (1) are required or
requested (with prompt notice of such request to be made to Acquiror) to be disclosed by applicable Law or any Governmental Authority, (2)
generally become available to the public through no fault of Acquiror or its Affiliates, (3) become available to Acquiror or its Affiliates on a non-
confidential basis, or (4) are independently developed by Acquiror or its Affiliates without reference to the furnished information. Notwithstanding
the foregoing, Acquiror may disclose such documents and information to its directors, officers, agents, consultants and other representatives
(including attorneys, financial advisors, accountants, potential financing sources and the Lenders) of Acquiror or its Affiliates to the extent
reasonably necessary for execution or performance of this Agreement.
16Section 4.08 Public Announcement . Notwithstanding Section 4.07(b), Acquiror may make public announcement regarding the
transactions contemplated by this Agreement, including the tender offer public notice, the Tender Offer Registration Statement, the Tender Offer
Explanatory Statement, any amendments to any of the foregoing, and public announcements to be made in connection with the execution of this
Agreement and after the Closing, in each case taking into account the requirements of all applicable Law. The Company shall not otherwise
communicate with any news media in respect of this Agreement or the transactions contemplated by this Agreement without the prior written
consent of Acquiror.
Section 4.09 No Lender Liability. Notwithstanding anything herein to the contrary, the Company hereby waives any rights or claims
against Jefferies, each lead arranger and each other agent or co-agent (if any) with respect to the Financing, the Lenders, or any affiliate thereof and
all of their respective affiliates and each director, officer, employee, representative and agent thereof (each, a “ Financing Party”) in connection with
this Agreement, the Financing or the Financing Commitment, whether at law or equity, in contract, in tort or otherwise, and the Company agrees not
to commence (and if commenced agrees to dismiss or otherwise terminate) any Action against any Financing Party in connection with this
Agreement or the transactions contemplated hereby (including any action relating to the Financing or the Financing Commitment). In furtherance
and not in limitation of the foregoing waiver, it is agreed that no Lender shall have any liability for any claims, losses, settlements, damages, costs,
expenses, fines or penalties to the Company in connection with this Agreement or the transactions contemplated hereby (including the Financing
or the Financing Commitment).
Section 4.10 Employees of Company. Following the Closing Date, SPI shall develop an integration plan in consultation with the
management of the Company as required for combining the business operations of the two companies. Subject to the goals, parameters and
integration activities outlined in the integration plan, SPI shall (i) provide the employees of the Company with employee incentives under such
terms and conditions as not less favorable (taking into account, among other things, tax implications) to the incentives made available by the
Company to such its employees as of the date of this Agreement […***…], and thereafter under such terms and conditions as not less favorable
(taking into account, among other things, tax implications, local laws, and SPI’s practices with respect to the employees of Acquiror) to those of the
incentives made available by SPI to its employees, and (ii) […***…] the […***…] of the […***… ] of the […***…] as of the […***…] of this […
***…] at […***…] the […***…] of the […***…] of the […***…] on […***…]. For the sake of achieving the purpose of the strategic alliance as
set forth in Section 2.01, both Parties acknowledge their mutual intention to, in principle, maintain the Company’s employment at levels consistent
with the requirements of the Company from time to time.
17Section 4.11 Development Programs and Clinical Trials. Following the Closing Date, SPI hereby agrees to engage in a program review in
consultation with the management of the Company with respect to the development programs and clinical trials listed in Schedule 4.11, with the
goal of […***…] an […***…] of […***…] and […***…]. Such review shall be conducted consistent with SPI’s process and practices applied to
the assessment of its own product candidates, including the […***…] of a […***…] of […***…] on […***…] of the […***…] of […***…] and
[…***…] and the […***…] for […***…], and the […***…] at the […***…] be […***…]; provided , however, that […***…] the […***…] to
[…***…] or […***…] and […***…] its […***…] or […***…] of […***…].
ARTICLE V
INDEMNIFICATION
Section 5.01 Indemnification by the Company . The Company shall indemnify Acquiror from and against all Losses incurred by Acquiror
to the extent arising out of or resulting from (i) any inaccuracy or breach of a representation or warranty made by the Company under Section 3.01
or (ii) any breach or failure by the Company to perform any of their covenants or obligations contained in this Agreement.
Section 5.02 Indemnification by Acquiror . Acquiror shall indemnify the Company from and against all Losses incurred by the Company
to the extent arising out of or resulting from (i) any inaccuracy or breach of a representation or warranty made by Acquiror under Section 3.02 or (ii)
any breach or failure by Acquiror to perform any of its covenants or obligations contained in this Agreement.
Section 5.03 Indemnification Procedure. Whenever any claim shall arise for indemnification under this Article V, the indemnified Person
making such claim (the “Indemnified Party”) shall notify the Party from whom indemnification is sought (the “ Indemnifying Party”) in writing of
the claim and, when known, the facts constituting the basis for such claim; provided , however, that the failure timely to provide such notice shall
not release the Indemnifying Person from its obligations under this Article V.
Section 5.04 Limitations. The Indemnifying Party’s liability for all claims made under this Agreement shall be subject to the following
limitations: (i) the Indemnifying Party shall […***…] for such claims until the […***…] of the […***…] shall […***…] of the […***…] by the
[…***…] of all of the […***…] and […***…] of […***…], in which case the Indemnifying Party shall be liable only for the […***…] of the […
***…] of the […***…] by the […***…] of all of the […***…] and […***…] of […***…], and (ii) the Indemnifying Party’s […***…] for […
***…] shall not […***…] of the […***…] by the […***…] of all of the […***…] and […***…] of […***…]. Notwithstanding the above
provisions of this Section 5.04, the limitations provided in this Section 5.04 shall not apply to (i) any claim for fraud or intentional misrepresentation
or (ii) any claim for breach of any agreement or covenant contained herein.
18ARTICLE VI
TERMINATION
Section 6.01 Termination. This Agreement may be terminated prior to the end of the Offer Period by Acquiror if a condition for withdrawal
of the Offer has occurred.
This Agreement shall be automatically terminated if the Offer has been withdrawn or the Offer is not successful due to the failure of
obtaining the minimum threshold. This Agreement may not be terminated after the end of the Offer Period if the Offer is successful.
Section 6.02 Notice of Termination. Any Party desiring to terminate this Agreement pursuant to Section 6.01 shall give written notice of
such termination to the other Party to this Agreement.
Section 6.03 Effect of Termination. In the event of the termination of this Agreement as provided in Section 6.01, this Agreement shall
forthwith become void and there shall be no liability on the part of any Party to this Agreement or any Financing Party except as set forth in Article
V. This sentence and Section 4.07, Section 4.09, Article V and Article VIII shall survive any termination of this Agreement.
ARTICLE VII
GUARANTEE
Section 7.01 Guarantee. SPI hereby absolutely, unconditionally and irrevocably guarantees to and in favor of the Company that the
Acquiror shall perform and discharge any and all of its obligations under this Agreement as set forth in this Agreement.
ARTICLE VIII
MISCELLANEOUS
Section 8.01 Governing Law. The construction, validity and performance of this Agreement shall be governed in all respects by the laws
of Japan.
Section 8.02 Jurisdiction.
(a) Any dispute, action or proceeding arising out of or in connection with this Agreement, including any question regarding its
existence, validity, binding effect, breach, amendment or termination shall be subject to the exclusive jurisdiction of the Tokyo District Court.
19(b) Notwithstanding anything herein to the contrary, the Parties hereto acknowledge and irrevocably agree (i) that any dispute, action, or
proceeding, whether in law or in equity, whether in contract or in tort or otherwise, involving the Lenders arising out of, or relating to, the
transactions contemplated hereby, the Financing or the performance of services thereunder or related thereto shall be subject to the exclusive
jurisdiction of any state or federal court sitting in the County of New York, Borough of Manhattan, New York, New York and any appellate court
thereof and each Party hereto submits for itself and its property with respect to any such dispute, action or proceeding to the exclusive jurisdiction
of such court, (ii) not to bring or permit any of their Affiliates to bring or support anyone else in bringing any such dispute, action or proceeding in
any other court, (iii) to waive and hereby waive, to the fullest extent permitted by law, any objection which any of them may now or hereafter have
to the laying of venue of, and the defense of an inconvenient forum to the maintenance of, any such dispute, action or proceeding in any such
court, (iv) to waive and hereby waive any right to trial by jury in respect of any such dispute, action or proceeding, (v) that a final judgment in any
such action shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by law and (vi)
that any such dispute, action or proceeding shall be governed by, and construed in accordance with, the laws of the State of New York, without
regard to the conflicts of law rules of such State that would result in the application of the laws of any other jurisdiction.
Section 8.03 Cost and Expenses . Except as otherwise provided in this Agreement, each Party shall bear the costs, expenses and fees
(including fees and expenses of the attorneys, certified public accountants, tax advisors and other advisors) incurred by such Party in relation to
the preparation, execution and performance of this Agreement.
Section 8.04 Assignment . No Party shall assign or transfer or purport to assign or transfer (whether by operation of Law or otherwise)
any of its rights, interests or obligations hereunder without the prior written consent of the other Party; provided, that Acquiror may assign this
Agreement and its rights and interests herein without any such consent as collateral to the Lenders in connection with the Financing. Subject to
the preceding sentence, this Agreement shall be binding upon and shall inure to the benefit of the Parties and their respective successors and
assigns.
Section 8.05 Amendments and Waivers . No amendment, modification or discharge of this Agreement, and no waiver hereunder, shall be
valid or binding unless set forth in writing and duly executed by the Party against whom enforcement of the amendment, modification, discharge or
waiver is sought (except that Section 4.09, Section 6.03, Section 8.02(b), Section 8.04, this Section 8.05 and Section 8.13 shall not be amended,
modified, discharged or waived in a manner that is adverse to the Lenders without the prior written consent of the Lenders). No failure or delay by
Acquiror or the Company in exercising any right hereunder shall operate as a waiver thereof nor shall any single or partial exercise thereof preclude
any other or further exercise of any other right hereunder.
Section 8.06 Severability. If any term or other provision of this Agreement is invalid, illegal or incapable of being enforced under any Law
or as a matter of public policy, all other conditions and provisions of this Agreement shall nevertheless remain in full force and effect so long as the
economic or legal substance of the transactions contemplated by this Agreement is not affected in any manner materially adverse to either Party.
The Parties shall negotiate in good faith in order to seek to agree on the terms of a mutually satisfactory provision to be substituted for any
provision found to be invalid, illegal or unenforceable.
20Section 8.07 Counterparts . This Agreement may be executed in two or more counterparts (including by facsimile or email pdf format),
each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.
Section 8.08 Entire Agreement. This Agreement (including the Schedules and Disclosure Letters hereto) constitutes the entire agreement
of the Parties hereto with respect to the subject matter hereof, and supersede any and all previous oral or written agreements or understandings
between the Parties in relation to the matters dealt with herein. The Schedules referred to in this Agreement are intended to be and hereby are
specifically made a part of this Agreement. Any and all previous agreements and understandings between the Parties regarding the subject matter
hereof, whether written or oral, are superseded by this Agreement.
Section 8.09 Notices. Any notice or communication under this Agreement shall be sent to the Parties in English at their respective
addresses set forth below or such other addresses as may from time to time be notified. Notices may be sent by hand, or by registered mail
(internationally recognized courier service if overseas) or by fax or email, and shall be deemed to be received, if sent by hand, fax or email, one
normal working hour (at the place of delivery) after delivery or transmission, and if by registered mail the second Business Day after posting (or, in
the case of international courier service, on the fifth Business Day following the date of deposit with such courier service, or such earlier delivery
date as may be confirmed in writing to the sender by such courier service).
If to Acquiror:
Sucampo Pharma, LLC.
2-2-16, Sonezakishinchi, Kita-ku, Osaka
Attention: […***…]
Phone: […***…]
Fax: […***…]
Email address: […***…]
If to SPI:
Sucampo Pharmaceuticals, Inc.
4520 East West Highway
Bethesda, MD 20814
USA
Attention: General Counsel
Phone: […***…]
21Fax: […***…]
Email address: […***…]
If to the Company:
R-Tech Ueno, Ltd.
NBF Hibiya Bldg. 10F
Uchisaiwaicho 1-1-7
Chiyoda-ku, Tokyo 100-0011
JAPAN
Attention: Office of the President
Phone: […***…]
Fax: […***…]
Email address: […***…]
Section 8.10 Language . This Agreement has been prepared and executed in, and shall be construed in accordance with, the English
language. Any Japanese translation prepared by any Party shall be for convenience purposes only,  and in the event of a dispute as to
interpretation of this Agreement, shall have no bearing on such interpretation.
Section 8.11 Disclosure Schedules . Each Party acknowledges and agrees that disclosure of any item in any section or subsection of a
Disclosure Letter shall be deemed disclosure by such Party with respect to any other section or subsection to which the item relates, to the extent
the relevance of such item is readily apparent. Matters reflected in the Company Disclosure Letter are not necessarily limited to matters required by
this Agreement to be so reflected. Such additional matters are set forth for informational purposes and do not necessarily include other matters of a
similar nature. No reference to or disclosure of any item or other matter in any Section, Disclosure Letter or Schedule of this Agreement shall be
construed as an admission or indication that such item or other matter is material or that such item or other matter is required to be referred to or
disclosed in this Agreement. Without limiting the foregoing, no such reference to or disclosure of a possible breach or violation of any contract,
Law or Governmental Order shall be construed as an admission or indication that such a breach or violation exists or has actually occurred.
Section 8.12 Fraud. Each Party acknowledges and agrees that nothing herein shall relieve or release a Person of any liability in
connection with any fraudulent or criminal acts committed by such Person, its Affiliates or their respective representatives, and nothing herein shall
provide any indemnification to or release of any Person committing such fraudulent or criminal acts.
22Section 8.13 Third-party Beneficiaries. It is expressly agreed by the Parties that the Lenders shall be third party beneficiaries of Section
4.09, Section 6.03, Section 8.02(b), Section 8.04, Section 8.05 and this Section 8.13. Nothing in this Agreement shall be construed to create a right in
any employee to employment with Acquiror or the Company or any of their respective Affiliates or successors. No current or former employee or
any other individual associated with the Company shall be regarded as a third party beneficiary of this Agreement or have a right to enforce any
provisions hereof.
[remainder of page intentionally left blank ]
23IN WITNESS WHEREOF, the Parties have executed this Agreement as of the date first above written.
Sucampo Pharmaceuticals, Inc.
By: /s/ Peter Greenleaf
Name: Peter Greenleaf
Title: Chief Executive Officer
Sucampo Pharma, LLC.
By: /s/ Misako Nakata
Name: Misako Nakata
Title: Representative Executor
R-Tech Ueno, Ltd.
By: /s/ Y. Mashima
Name: Yukihiko Mashima
Title: PresidentExhibit 10.11   Execution Copy   STRATEGIC ALLIANCE AGREEMENT   This STRATEGIC ALLIANCE AGREEMENT (this “Agreement”) is made as of December 21, 2006 by and among OXBOW CARBON& MINERALS LLC, a Delaware limited liability company having a principal office address at 1601 Forum Place, Suite 1400, West Palm Beach, Florida33401 (“Oxbow”) and GLOBAL ENERGY, INC., an Ohio corporation having a principal office address at 312 Walnut Street, Suite 2650, Cincinnati,Ohio 45202 (“Global Energy”). Oxbow and Global each may be referred to from time to time herein as a “Party” and collectively as the “Parties”.   RECITALS   WHEREAS, Oxbow is a world leader in petroleum coke trading, marketing, sales, and shipping; and   WHEREAS, Global Energy is a world leader in petroleum coke gasification, having optimized operations of the leading petroleum cokegasification technology, EGAS™ technology, at its Wabash gasification facility in Indiana; and   WHEREAS, Oxbow leases a marine terminal site in Texas City, Texas which it believes to be well-suited for installation of petroleum cokegasification technology, in that gasification would optimize Oxbow’s flexibility in the sale and use of petroleum coke currently stored on the site, whichcould be converted into pipeline SNG or hydrogen, as well as being shipped onward to Oxbow’s traditional petroleum coke customers; and   WHEREAS, Global Energy is a leader in the development and permitting of gasification facilities, and currently is the only gasification facilityowner/operator with permits to construct new gasification facilities (specifically, its Lima and Westfield Projects); and   WHEREAS, the Parties believe that an alliance as described in this Agreement will prove mutually beneficial;   NOW, THEREFORE, in consideration of the premises and for other good and valuable consideration, the receipt and sufficiency of which ishereby acknowledged, the Parties agree as follows:   AGREEMENT   1. Purchase of Shares. Global Energy shall issue and sell to Oxbow, and Oxbow shall purchase from Global Energy, on the Closing Date,Twenty-Five Thousand (25,000) common shares of Global Energy (the “Shares”), on the following terms and conditions, and subject to satisfaction ofthe conditions set forth in Section 6 hereof:   (a) Purchase Price. The purchase price for the Shares shall be Five Million and No/100 Dollars ($5,000,000.00), or $200.00 per Share.  
 
1(b) Payment. Payment of the Purchase Price shall be made on the Closing Date by wire transfer of immediately available funds to Global Energy,as applicable, at the applicable account designated by Global Energy, as follows:                                    Bank:    PNC Bank, N.A.                          Cincinnati, OH                     ABA No.:    042000398                     Account No.:    40-7690-5189                     Account Name:    Global Energy, Inc.                       (c) Closing. Unless this Agreement shall have been terminated and subject to the satisfaction or waiver of the conditions set forth in Section 6,the closing of the purchase of the Shares (the “Closing”) shall take place at 11:00 a.m., on December 22, 2006 (such date of closing referred to herein asthe “Closing Date”) at the offices of Oxbow, 1601 Forum Place, Suite 1400, West Palm Beach, Florida 33401, unless another date, time or place is agreedto in writing by the parties hereto. At the Closing, Oxbow shall pay to Global Energy the Purchase Price and Global Energy shall deliver to Oxbow astock certificate evidencing the issuance to Oxbow of the Shares. The Closing shall be deemed effective as of 12:01 a.m. U.S. Eastern Standard Time,on the Closing Date.   2. Strategic Alliance. The Parties hereby form a strategic alliance having the following key elements:   (a) Preferred Suppliers. Oxbow and Global Energy hereby designate one another as their preferred suppliers of certain goods and services, asfollows:   (i) Oxbow shall be the preferred petroleum coke supplier to petroleum coke gasification projects owned or controlled by GlobalEnergy.   (ii) Oxbow shall be a preferred supplier of coal, coal fines, gob or waste coal products (collectively, “Coal”) to gasification projectsowned or controlled by Global Energy.   (iii) Global Energy shall be the preferred gasification technology supplier to petroleum coke gasification projects majority ownedor controlled by Oxbow.   (iv) Global Energy shall be the preferred gasification project operator for petroleum coke gasification projects at sites majorityowned or controlled by Oxbow.  
 
2(b) Further Cooperation. The Parties also agree to cooperate in good faith as follows in furtherance of their strategic alliance:   (i) Oxbow will identify Oxbow petroleum coke related sites for collaboration with Global Energy.   (ii) Global Energy will identify Global Energy petroleum coke related sites for collaboration with Oxbow.   The obligations of the Parties pursuant to this Section 2 are subject to continued demonstrated performance and their mutual agreement on theschedule, pricing, financing, economics and other terms and conditions applicable to any such project.   3. Lima Project. In addition to the strategic alliance described in Section 2 of this Agreement, the parties specifically agree to the following withrespect to Global Energy’s proposed Lima, Ohio gasification project (the “Lima Project”):   (a) Investment by Oxbow. Oxbow will make a investment (the “Lima Investment”) in the company which owns the Lima Project (the “LimaProject Company”) in the amount of [*], as consideration for obtaining the fuel supply management agreement for the Lima Project and the otherrevenues and benefits described in this Section 3. Oxbow’s obligation to make this investment would be subject to:   (i) Oxbow obtaining the consent of its existing lenders; and   (ii) Global Energy securing one or more firm written commitments in form and substance reasonably acceptable to Oxbow for atleast Two Hundred Seventeen Million and No/100 Dollars ($217,000,000.00) of equity funding for the Lima Project, or in the alternative, evidencedemonstrating that Global has available cash of Two Hundred Seventeen Million and No/100 Dollars ($217,000,000.00) in its account.   (iii) Global Energy providing evidence satisfactory to Oxbow in its reasonable discretion that it has secured the right to purchasethe site for the Lima Project from the City of Lima, Ohio for a purchase price of One Million Five Hundred Thousand and No/100 Dollars($1,500,000.00).   (b) Revenues and Benefits to Oxbow. If Oxbow makes the Lima Investment:   (i) Oxbow will receive four percent (4%) of the Lima Project’s pre-tax project cash flow after debt service and operation andmaintenance (“O&M”) expenses. The Lima Project Company’s obligation to make such payment would be subject to satisfaction of the samelender covenants which will apply to distributions to equity investors in the Lima Project; and  
 
3(ii) Oxbow will receive two percent (2%) of those non-O&M revenues of Global Energy’s affiliate, Gasification EngineeringCorporation, Inc. (“GEC”) related to the Lima Project (e.g., any of the $200 million EPC reserves/construction contingency which is not spent).   (iii) Oxbow will have a seat on the Board of Directors of GEC or any subsidiary or affiliate of GEC which is responsible for theengineering, procurement and construction (“EPC”) contract for the Lima Project.   (c) Fuel Management and Supply Agreement. In addition, if Oxbow makes the Lima Investment, Oxbow and Global Energy will enter into a fuelmanagement and supply agreement (the “Fuel Management and Supply Agreement”) for all fuel to be utilized by the Lima Project, which wouldinclude the following material provisions:   (i) Oxbow will manage all fuel coke and Coal supply and logistics for the Lima Project.   (ii) Oxbow will be paid a management fee of One Million and No/100 Dollars ($1,000,000.00) per year, such fee to be paidirrespective of actual Coal or petroleum coke use by the Lima Project.   (iii) As fuel supply manager, Oxbow will receive a base commission of $0.12 per MMBTU consumed by the Lima Project,independent of fuel type (the “Base Commission”). As an incentive to obtain the lowest cost of fuel throughout the life of the Lima Project, theLima Project Company would receive two-thirds (2/3) of any cost savings below $1.07 per MMBTU delivered to the project (such price, the“Price Basis”), escalated each year beginning in 2009 in accordance with increases in the Consumer Price Index, and Oxbow would receive one-third (1/3) of any such cost savings. Should the price of fuel delivered to the Lima Project be above the Price Basis, the commission will bereduced on a sliding scale according to the following formula:   C= BC+(PB-PI)*0.1094   Where:   C = commission BC = Base Commission PI = price invoiced per MMBTU PB = Price Basis per MMBTU   However, the commission will never be less than $0.05 per MMBTU regardless of fuel price. For purposes of calculating this commission, theprice of all fuel supply transactions would be based on the direct cost of supply and transportation expenses as invoiced.  
 
4(iv) Global Energy may provide up to ten percent (10%) of the annual fuel requirements of the Lima Project from renewable sources.Oxbow would receive the same commission on a per-BTU basis on any such fuel supplied by Global Energy.   (d) Project Management. In the event Oxbow funds its investment in the Lima Project Company as set forth in Section 3(a), and either or both ofthe following occur:     (i)  Closing and funding of the Lima Project financing does not occur on or before December 15, 2007; or     (ii)  There is a delay of twelve months or more in meeting any project milestones as set forth in Schedule 3(d) (“Project Milestones”);  then Oxbow shall have the right to take over the development and management of the Lima Project; provided, however, that the Lima Project fuelsupply arrangements shall continue to be managed as set forth in the Fuel Management and Supply Agreement and Oxbow shall not be entitled todirect the disposition of ownership interests in the Lima Project Company, unless additional equity is required to finance the project. Further, if Oxbowelects to take over the development and management of the Lima Project and Oxbow subsequently determines that it does not desire to continue toparticipate in the Lima Project, it may withdraw from further participation, relinquish its economic interests in the Lima Project Company and GEC andterminate the Fuel Management and Supply Agreement, without further liability or obligation to Global Energy and/or the other Lima Projectparticipants.   4. Representations and Warranties of Global Energy. Global Energy represents and warrants that the statements contained in this Section 4 aretrue and correct as of the date of this Agreement and will be true and correct as of the Closing Date.   (a) Organization. Global Energy is a corporation duly formed, validly existing and in good standing under the laws of the State of Ohio, and hasfull corporate power and authority to own, or hold under lease, and operate its properties, and to conduct its business as such business is now beingconducted.   (b) Capitalization of Global Energy. The total authorized share capital of Global Energy as of the date of this Agreement is 10,000,000 commonshares and 500,000 preferred shares. As of this date, 5,549,847 common shares and 105,086 preferred shares have been issued. The preferred shares areconvertible into common shares at the conversion rate of 1.0 preferred shares to 1.71 common shares. As of the Closing Date, after giving effect to theShare purchase and the conversion of the preferred shares, 5,729,544 common shares of Global Energy will be issued and outstanding.   (c) The Shares.   (i) The Shares are duly authorized, validly issued and fully paid and non-assessable and were issued in accordance with allapplicable securities laws or pursuant to exemptions therefrom. As of the Closing Date, after giving effect to the Share purchase and theconversion of Global Energy’s preferred shares, the Shares will constitute a forty-four hundredths of one percent (0.44%) interest in thecommon shares of Global Energy.  
 
5(ii) As of Closing Date, Global Energy shall own, beneficially and of record, all of the Shares free and clear of all Liens.   (iii) No Person has a right to acquire any of the Shares. None of the Shares are subject to any preemptive or subscription right,right of first refusal or offer, option, warrant, put or call right, consent right, restrictive covenant, or any other agreement with any Person otherthan Oxbow.   (d) No Violation; Consents.   (i) The execution and delivery of, and performance under, this Agreement by Global Energy and the consummation of thetransactions contemplated hereby by Global Energy and GEC, will not:   (A) violate any provision of Applicable Law or require any approval from or filing with any Governmental Authority;   (B) violate the provisions of any Governmental Approval, or the organizational or governing documents of Global Energyor GEC, or any agreement or other restriction to which Global Energy or GEC is a party or by which the property of Global Energy or GEC isbound or subject;   (C) result in a breach of or constitute (with due notice or lapse of time or both) a default under (or require notice or give riseto any right of termination, consent, cancellation, or acceleration under) any contract or agreement to which Global Energy or GEC is a party orby or to which the property of Global Energy or GEC is subject or bound; or   (D) result in or give to any Person any right of termination, cancellation, acceleration or modification in or with respect to orresult in any loss of benefit under or with respect to, or give any Person any additional rights or entitlement to increased, additional, acceleratedor guaranteed payments under, or result in the creation or imposition of any Lien upon Global Energy, GEC or any of their assets, in each caseunder any contract or license to which Global Energy or GEC is a party or by which any of its respective assets is bound or any ApplicableLaw.   (ii) The execution and delivery of, and performance under, this Agreement by Global Energy and the consummation of thetransactions contemplated hereby will not require any Consent as to Global Energy.   (e) Authority; Enforceabilitv. Global Energy has full legal capacity, power and authority to execute, deliver and perform this Agreement, and theother agreements and instruments to be executed and delivered by him pursuant hereto and to consummate the transactions  
 
6contemplated hereby and thereby. This Agreement has been duly and validly executed and delivered by Global Energy and, assuming dueauthorization, execution and delivery hereof by Oxbow, is a legal, valid and binding obligation of Global Energy, enforceable against it in accordancewith its terms.   (f) Disclosure. No representation or warranty of Global Energy made in this Agreement or any certificate, statement, schedule, list or otherinformation furnished or to be furnished to Oxbow (or any Affiliate or representative thereof) pursuant to this Agreement or in connection with thetransactions contemplated hereby (“Transaction Information”) contains any untrue statement or omits to state a material fact necessary to make thestatements herein, in light of the circumstances in which they are made (including any materiality or knowledge qualifiers), not misleading.   (g) Qualification; Organization. Global Energy is qualified to conduct its business as such business is now being conducted and is in goodstanding in all jurisdictions listed on Schedule 4(g), which are all the jurisdictions in which the nature of its business makes such qualificationnecessary or advisable. True and complete copies of the Articles or Certificates of Incorporation and Bylaws of Global Energy and GEC (the“Governing Documents”) have been furnished to Oxbow. Each such Governing Document is in full force and effect and has not been amended ormodified.   (h) Bankruptcy. Neither Global Energy nor GEC has filed any voluntary petition in bankruptcy or been adjudicated bankrupt or insolvent, orfiled any petition or answer seeking any reorganization, liquidation, dissolution or similar relief under any federal or state bankruptcy, insolvency orother debtor relief or similar law, or sought or consented to or acquiesced in the appointment of any trustee, receiver, conservator or liquidator of all orany substantial part of its properties. No court of competent jurisdiction has entered an order, judgment or decree approving a petition filed againstGlobal Energy or GEC seeking any reorganization, arrangement, composition, readjustment, liquidation, dissolution or similar relief under any federal orstate bankruptcy act, or other debtor relief or similar law, and no other liquidator has been appointed for any of them, or of all or any substantial part ofany of their properties. No proceeding has been commenced or, to Global Energy’s knowledge, has been threatened, seeking to adjudicate GlobalEnergy or GEC as bankrupt or seeking any reorganization, arrangement, composition, readjustment, liquidation, dissolution or other similar relief.   (i) Shareholder List. Global Energy has provided to Oxbow prior to the execution of this Agreement a true and correct list of the shareholders ofGlobal Energy and their respective shareholdings as of the date of such list.   (j) Officers and Directors. The officers and directors of Global Energy and GEC are listed on Schedule 4(j) hereto.   (k) Litigation and Claims. There are no Proceedings pending or threatened against Global Energy which question the validity of this Agreementor any of the transactions contemplated hereby, and Global Energy does not have knowledge of any substantive basis for any such Proceeding.Global Energy is not subject to any Decree and does not have any knowledge of any substantive basis for any Decree.  
 
7(1) Environmental Matters. Except as set forth on Schedule 4(1) hereto:   (i) Each of Global Energy and GEC has complied in all respects with all Environmental Laws or has resolved any non-compliance tothe satisfaction of the Governmental Authority having jurisdiction thereof and has provided Oxbow with evidence of such satisfaction. Each ofGlobal Energy and GEC is in compliance with all Environmental Laws.   (ii) Neither Global Energy nor GEC has any liability, known or unknown, contingent or absolute, under any Environmental Law,nor is either Global Energy or GEC responsible for any such liability of any other Person under any Environmental Law, whether by contract, byoperation of law or otherwise. There are no pending or, to the knowledge of Global Energy threatened, Environmental Claims and there are nofact(s) which might reasonably form the basis for any Environmental Claim and Neither Global Energy nor any of its Affiliates, including GEC,has received any notice of any Environmental Claim or threatened Environmental Claim.   (m) Permits, Approvals and Site for Lima Project. Global Energy and/or its Affiliates:   (i) have obtained all licenses, permits or franchises required to be issued by or obtained from any Governmental Authority for theconstruction, commissioning and operation of the Lima Project; and   (ii) have obtained a legally binding right to purchase the site for the Lima Project from the City of Lima, Ohio for a purchase priceof One Million Five Hundred Thousand and No/100 Dollars ($1,500,000.00).   The representations and warranties set forth in this Section 4 shall survive the Closing.   5. Representations and Warranties of Oxbow. Oxbow represents and warrants that the statements contained in this Section 5 are true andcorrect as of the date of this Agreement and will be true and correct as of the Closing Date.   (a) Organization. Oxbow is a limited liability company duly organized, validly existing and in good standing under the laws of the State ofDelaware, and has full power and authority to conduct its business as such business is now being conducted. Oxbow is properly registered to dobusiness in all jurisdictions in which the nature of the business conducted by it makes such registration necessary in order to avoid any materialdisadvantage or liability to it.   (b) Authority; Enforceability. Oxbow has full power and authority to execute, deliver and perform this Agreement, and the other agreements andinstruments to be executed and delivered by it pursuant hereto, and to consummate the transactions contemplated hereby and thereby. ThisAgreement has been duly and validly authorized, executed and delivered by Oxbow and, assuming  
 
8due authorization, execution and delivery hereof by Global Energy, is a legal, valid and binding obligation of Oxbow, enforceable against Oxbow inaccordance with its terms, except as enforcement thereof may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or othersimilar laws affecting the rights of creditors generally or by general principles of equity (regardless of whether such enforceability is considered in aproceeding at law or equity). No other or further authorization is required for Oxbow’s performance hereunder other than those authorizations to beobtained by Oxbow on or prior to the consummation of the transactions contemplated by this Agreement.   (c) No Violation: Consents. The execution and delivery of, and performance under, this Agreement by Oxbow and the consummation by Oxbowof the transactions contemplated hereby and thereby, will not: (a) violate any provision of Applicable Law; (b) violate the provisions of anyGovernmental Approval, or the organizational or governing documents of Oxbow, or any agreement or other restriction to which any Oxbow is a partyor by or pursuant to which Oxbow or the property of Oxbow is bound or subject; or (c) result in a breach of or constitute (with due notice or lapse oftime or both) a default under (or give rise to any right of termination, consent, cancellation, or acceleration under) any material contract or agreement towhich Oxbow is a party or by or pursuant to which Oxbow’s property is subject or bound. The execution and delivery of, and performance under, thisAgreement by Oxbow will not require any Consent, other than (i) such Consents which, if not obtained or made, will not prevent Oxbow fromperforming its obligations hereunder, (ii) such Consents which become applicable to Oxbow solely as a result of the specific regulatory status ofGlobal Energy or GEC, and (iii) the Consents set forth on Schedule 5(c).   (d) Litigation and Claims. There are no Proceedings pending or threatened against Oxbow which question the validity of this Agreement or anyof the transactions contemplated hereby, and Oxbow does not have knowledge of any substantive basis for any such Proceeding. Oxbow is notsubject to any Decree and does not have any knowledge of any substantive basis for any Decree.   (e) Investment Representations. Oxbow is acquiring the Shares for its own account for investment, and not with a view to resale or otherdistribution within the meaning of the Act, and Oxbow will not distribute the Shares or any part thereof in violation of the Act or any other applicablesecurities law. Oxbow understands that the Shares have not been, and prior to appropriate registration statements becoming effective will not be,registered under the Act, by reason of a specific exemption from the registration provisions of the Act which depends upon, among other things, thebona fide nature of the investment intent and the accuracy of Oxbow’s representations as expressed herein. Oxbow acknowledges that it is able tofend for itself, can bear the economic risk of its investment and has such knowledge and experience in financial and business matters that it is capableof evaluating the merits and risks of the investment in the Shares.   (f) Bankruptcy. There are no bankruptcy, reorganization, or arrangement proceedings pending against, being contemplated by or, to theknowledge of Oxbow, threatened against, Oxbow.   The representations and warranties set forth in this Section 5 shall survive the Closing.  
 
96. Conditions to Closing of the Share Purchase.   (a) Oxbow Conditions. The obligation of Oxbow to proceed with the Closing of the Share purchase contemplated under Section 1 is subject tothe satisfaction of all of the conditions set forth in this Section 6(a):   (i) Representations and Warranties. The representations and warranties made by Global Energy in this Agreement shall be trueand correct in all material respects on and as of the Closing Date with the same force and effect as though all such representations andwarranties were made on and as of that date (without giving effect to any materiality qualifications contained therein), and Global Energy shallhave delivered to Oxbow a certificate, dated as of the Closing Date and signed by Global Energy, to such effect.   (ii) Covenants and Agreements. All of the covenants and agreements in this Agreement to be complied with and performed byGlobal Energy on or before the Closing Date shall have been complied with and performed in all material respects, and Global Energy shall havedelivered to the Oxbow a certificate, dated as of the Closing Date and signed by Global Energy, to such effect.   (iii) Consents. Each Consent necessary in order to authorize the acquisition by Oxbow of the Shares and to execute and deliverthis Agreement, including all those applicable Consents set forth on Schedule 5(c), shall have been obtained and delivered to Oxbow and shallbe in full force and effect.   (iv) No Injunction. No preliminary or permanent injunction or other order or Decree by any Governmental Authority which,prevents the consummation of the purchase of the Shares shall have been issued and remain in effect (and Global Energy and Oxbow agree touse commercially reasonable efforts to have any such injunction, order, or Decree lifted).   (v) Constitutive Documents. Global Energy shall have delivered to Oxbow copies of the Governing Documents of Global Energyand GEC, including all amendments thereto, each certified as true, correct, complete and in effect as of the Closing by the secretary of each suchcompany.   (b) Global Energy Conditions. The obligations of Global Energy to proceed with the Closing of the Share purchase contemplated under Section1 is subject to the satisfaction of all of the conditions set forth in this Section 6(b):   (i) Representations and Warranties. The representations and warranties made by Oxbow in this Agreement shall be true andcorrect in all material respects on and as of the Closing Date with the same force and effect as though all such representations and warrantieswere made on and as of that date (without giving effect to any materiality or qualifications contained therein), and Oxbow shall have deliveredto the Global Energy a certificate, dated as of the Closing Date and signed by an officer of Oxbow, to such effect.  
 
10(ii) Covenants and Agreements. All of the covenants and agreements in this Agreement to be complied with and performed byOxbow on or before the Closing Date shall have been complied with and performed in all material respects, and Oxbow shall have delivered tothe Global Energy a certificate, dated as of the Closing Date and signed by an executive officer of such Oxbow, to such effect.   (iii) Consents. All Consents necessary in order to authorize the acquisition by Oxbow of the Shares and to execute and deliver thisAgreement shall have been obtained and delivered to Global Energy and shall be in full force and effect.   (iv) No Injunction. No preliminary or permanent injunction or other order or Decree by any Governmental Authority whichprevents the consummation of the purchase of the Shares shall have been issued and remain in effect (and Global Energy and Oxbow agree touse commercially reasonable efforts to have any such injunction, order, or Decree lifted.)   7. Covenants of the Parties.   (a) Access to Information. Global Energy and Oxbow shall, in good faith, and subject to the terms and conditions hereof, disclose to oneanother such information relative to the strategic alliance contemplated by this Agreement as may be necessary or appropriate to effectuate thepurposes thereof.   (b) Further Assurances.   (i) Subject to the terms and conditions of this Agreement, each of the Parties hereto shall use commercially reasonable efforts totake, or cause to be taken, all actions, and to do, or cause to be done, all things reasonably necessary, proper or advisable to consummate andmake effective the purchase and sale of the Shares pursuant to this Agreement and the other transactions contemplated herein.   (ii) Each Party also further agrees that it will not take any action in breach of this Agreement or that will cause any representationor warranty contained herein to become untrue in any material respect, including any action which would result in any assignment or transfer of(or encumbrance not permitted hereunder upon) any of the Shares or which would restrict such Party’s ability to consummate the transactionsherein contemplated.   (c) Confidential Information. Confidential Information shall not be used for any purpose other than to evaluate and consummate thetransactions contemplated by this Agreement, and shall not be disclosed without prior written consent of the other Party, except to:   (i) those employees with a need to know the Confidential Information for the purpose of performing work related to thetransactions contemplated by this Agreement; provided, however that the Parties shall require all such employees receiving the ConfidentialInformation abide by the terms of this confidentiality covenant. Each Party shall be responsible for any breach of this Agreement by itsemployees or Affiliates; or  
 
11(ii) those advisors, agents, contractors or lenders with a need to know the Confidential Information for the purpose of performingwork related to the transactions contemplated by this Agreement; provided, however that the Parties shall require all such advisors, agents,contractors or lenders to agree to abide by the terms of this Agreement and to undertake the same obligations as the Parties have undertakenhereunder. Each Party shall be responsible for any breach of this Agreement by its advisors, agents, contractors or lenders.   (iii) If a Party is requested or required by legal or regulatory authority to disclose any Confidential Information, such disclosingParty shall promptly notify the other Party of such request or requirement prior to disclosure so that the other Party may seek an appropriateprotective order and/or waive compliance with the terms of this Agreement. If a protective order or other remedy is not obtained, or the otherParty waives compliance with the provisions hereof, the disclosing Party agrees to furnish only that portion of the Confidential Information thatit reasonably determines, in consultation with its counsel, is consistent with the scope of the subpoena or demand, and to exercise reasonableefforts to obtain assurance that confidential treatment will be accorded such Confidential Information.   (iv) Each Party agrees that money damages would not be a sufficient remedy for any breach of this Section 7(c) and that theParties shall be entitled to injunctive or other equitable relief to remedy or prevent any breach or threatened breach of this Section 7(c). Suchremedy shall not be the exclusive remedy for any breach of this Section 7(c), but shall be in addition to all other rights and remedies available atlaw or in equity.   (v) Any Confidential Information, including all copies of same (including that portion of the Confidential Information that consistsof analyses, forecasts, studies or other documents prepared by a Party or its advisors, agents, contractors or lenders), shall be returned to theother Party, or at such Party’s option destroyed, within five (5) days of (A) a request by a Party at anytime; or (B) the termination of thisAgreement in accordance with the terms hereof. Upon the written request of a Party, the other Party shall certify the destruction of suchmaterial by written notice to the requesting Party.   (vi) This covenant shall survive the termination or expiration of this Agreement and shall continue in full force and effect for aperiod of three (3) years thereafter.   (d) Regulatory Approvals.   (i) Each Party shall use all commercially reasonable efforts to obtain all authorizations, consents, orders, and approvals of, and togive all notices to and make all filings with, all Governmental Authorities (including those pertaining to the Governmental Approvals) and thirdparties that may be or become necessary for its execution and delivery of, and the performance of its obligations under, this Agreement and willcooperate fully with the other Party in promptly seeking to obtain all such authorizations, consents, orders, and approvals, giving such notices,and making such filings.  
 
12(ii) Each Party agrees to use its commercially reasonable efforts to assist the other Party in obtaining any consents of third partiesand Governmental Authorities which may be necessary or advisable for such Party to obtain in connection with the transactions contemplatedby this Agreement, including providing to such third parties and Governmental Authorities such financial statements and other financialinformation with respect to such Party and their Affiliates as such third parties or Governmental Authorities may reasonably request.   (e) Exclusive Dealing. Each Party agrees that it will not circumvent or attempt to circumvent the other by contacting or participating with anythird party with respect to, or otherwise attempting to consummate, the transactions contemplated by this Agreement, except in participation with eachother.   (f) Price Protection. If at any time on or prior to the earlier of (i) December 31, 2007, or (ii) the date on which Global Energy completes an initialpublic offering (“IPO”) of its common stock, Global Energy sells additional common shares or other financial instruments convertible into its commonshares, or enters into any similar transaction for the sale of an ownership interest in Global Energy which is the same or substantially the same as thatsold to Oxbow under Section 1 of this Agreement, and the price of which is less than $200.00 per share, Global Energy shall issue additional commonshares to Oxbow such that Oxbow’s adjusted per-share price for its stockholdings shall be no greater than the lowest price paid by any suchsubsequent purchaser of its shares. It is understood that the price protection afforded by this covenant extends to and includes the offering pricepursuant to the IPO.   (g) Board of Directors. During the term of this Agreement, and so long as Oxbow continues to own at least 15,000 common shares of GlobalEnergy (as such amount may be adjusted to reflect any subsequent stock splits), Global Energy agrees that Oxbow shall have a seat on GlobalEnergy’s Board of Directors.   8. Term; Termination and Remedies.   (a) Term. This Agreement shall be for an initial term of five (5) years, and unless earlier terminated in accordance with this Agreement,shall automatically renew for an additional term of five (5) years thereafter.   (b) Termination for Default or Bankruptcy. Either Party may terminate this Agreement by written notice to the other Party in the event ofthe following:   (i) Default. Material nonperformance by the other Party of any provisions set forth in this Agreement which is not cured withinthirty (30) days after receipt of notice thereof from the Party not in default; or  
 
13(ii) Bankruptcy. The filing by or against the other Party of a petition or application in any proceeding relating to such other Partyas debtor under any bankruptcy or insolvency law of any jurisdiction; provided that in the event of an involuntary bankruptcy or insolvencyproceeding, such other Party shall have a sixty (60) day period in which to obtain dismissal or withdrawal of such petition or application.   (c) Remedies. In the event of termination of this Agreement, the Party not in default shall be entitled to obtain all appropriate reliefavailable to it under this Agreement and at law or equity.   (d) Survival. The expiration or earlier termination of this Agreement shall not terminate or otherwise affect Oxbow’s ownership of theShares or the validity of any other definitive agreements executed prior to such expiration or termination in connection with the Lima Project, the TexasCity Project or any other business arrangement arising out of the strategic alliance contemplated by this Agreement.   9. Defined Terms.   (a) As used in this Agreement, the following terms have the following meanings:   “Act” means the Securities Act of 1933, as amended, and the rules and regulations thereunder.   “Affiliate” of any Person means any other Person directly or indirectly controlling, controlled by or under common control with such Person.For purposes of this definition, “control” when used with respect to any specified Person means the power to direct the management and policies ofsuch Person, directly or indirectly, whether through the ownership of voting securities, by contract or otherwise, and the terms “controlling” and“controlled” have meanings correlative to the foregoing.   “Agreement” has the meaning specified in the preamble to this Agreement, and includes all exhibits and schedules hereto.   “Applicable Law” means, with reference to any Person, all Laws applicable to such Person or its property or in respect of its operations.   “Base Commission” has the meaning specified in Section 3(c).   “BTU” means British Thermal Units.   “Closing” has the meaning specified in Section 1(c).   “Closing Date” has the meaning specified in Section 1(c).   “Coal” has the meaning specified in Section 2(a).  
 
14“Confidential Information” means any information not in the public domain, in any form, whether acquired prior to or after the Closing Date,received by a Party from the other Party or any of its Affiliates or advisors, relating to the business and operations of such Party and its respectiveAffiliates, including, without limitation, information regarding vendors, suppliers, trade secrets, training programs, technical information, contracts,systems, procedures, know-how, trade names, improvements, price lists, financial or other data, business plans, computer programs, software systems,internal reports, personnel files or any other compilation of information, written or unwritten, which is or was used in the business of such Party or itsAffiliates, except for information (i) that was or becomes generally available to the public, other than as a result of disclosure by a Party receiving suchinformation; or (ii) that is received by a Party on a non-confidential basis from a third party that is not prohibited from disclosing such information byobligation to the disclosing Party.   “Consent” means any authorization, approval, consent, waiver, license, filing, registration, ruling, permit or certification by or with any Person.   “Consumer Price Index” shall mean the Consumer Price Index for all Urban Consumers (CPI-U), base years 1982-1984=100, for the Cleveland-Akron OH metropolitan area, as published by the United States Department of Labor, Bureau of Labor Statistics.   “Decree” means any claim, consent decree, conciliation agreement, settlement agreement, outstanding judgment, rule, order, writ, injunction orother decree of a Governmental Authority.   “Environmental Claim” means any and all administrative or judicial actions, suits, orders, claims, liens, notices, notices of violations,investigations, complaints, proceedings, or other written communication, whether criminal or civil, pursuant to or relating to any applicableEnvironmental Law by any Person, including any Governmental Authority, based upon, alleging, asserting, or claiming any actual or potential (i)violation of, or liability under any Environmental Law, (ii) violation of any Environmental Permit, or (iii) liability for investigatory costs, cleanup costs,removal costs, remedial costs, response costs, natural resource damages, property damage, personal injury, fines, or penalties arising out of, based on,resulting from, or related to the presence, Release, or threatened Release into the environment of any Hazardous Materials at, from, or related to anyReal Property or any other property owned, leased, licensed, or operated by any of the Companies, including any off-site location to which HazardousMaterials, or materials containing Hazardous Materials, were sent for handling, storage, treatment or disposal.   “Environmental Law” means all Applicable Laws relating to pollution or protection of the environment, natural resources and health and safety,including laws relating to Releases or threatened Releases of Hazardous Materials (including Releases to ambient air, surface water, groundwater, land,surface and subsurface strata) or otherwise relating to the generation, manufacture, processing, distribution, use, treatment, storage, Release,transport, disposal or handling of Hazardous Materials. “Environmental Laws” include the Comprehensive Environmental Response Conservation andLiability Act (“CERCLA”) (42 U.S.C. §§ 960 et seq.), the Hazardous Materials Transportation Act (49 U.S.C. §§1801 et seq.), the ResourceConservation and Recovery Act (42 U-S.C. §§ 6901 et seq.), the Federal Water Pollution Control Act (also known as the Clean  
 
15Water Act) (33 U.S.C. §§ 1251 et seq.), the Clean Air Act (42 U.S.C. §§ 7401 et seq.), the Toxic Substances Control Act (15 U.S.C. §§ 2601 et seq.), theOil Pollution Act (33 U.S.C. §§ 2701 et seq.), the Emergency Planning and Community Right-to-Know Act (42 U.S.C. §§ 11001 et seq.), theOccupational Safety and Health Act (29 U.S.C. §§ 651 et seq.) and their implementing regulations, state implementation plans, and analogous state orlocal laws or regulations, and all other applicable federal state or local laws that address the release or discharge of Hazardous Materials into theenvironment or the impact of Hazardous Materials on human health or the environment.   “Fuel Management and Supply Agreement” has the meaning specified in Section 3(c).   “GEC” has the meaning specified in Section 3(b).   “Governing Documents” has the meaning specified in Section 4(g).   “Governmental Approval” means any authorization, approval, consent, waiver, license, filing, registration, ruling, permit or certification by orwith any Governmental Authority, including all environmental permits.   “Governmental Authority” means any applicable federal, state, county, municipal or local governmental, judicial or regulatory authority,agency, arbitration board, body, commission, instrumentality or court.   “Hazardous Material” means (i) any substance or material regulated under applicable Environmental Laws or any other product, substance,pollutant, chemical, material or waste whose presence, nature, quantity and/or intensity of existence, use, manufacture, disposal, transportation, spill,Release or effect, either by itself or in combination with other materials used by the Business, is either potentially injurious to the public health, safetyor welfare, or the environment, or (ii) could reasonably be expected to provide a basis for liability of any of the Companies or to any GovernmentalAuthority or other Person under any Applicable Environmental Law. Hazardous Material shall include, without limitation, infectious or toxicsubstances, pollutants, radioactive materials, toxic hydrocarbons, petroleum or petro chemical products, gasoline, oil, diesel fuel or polychlorinatedbiphenyls or any products, by-products or fractions thereof, and asbestos.   “IPO” has the meaning specified in Section 6(f).   “Laws” means all laws, statutes, rules, regulations, ordinances and other pronouncements having the effect of law in the United States or anyother country, or any domestic or foreign state, county, city or other political subdivision or of any Governmental Authority.   “Lima Investment” has the meaning specified in Section 3(a).   “Lima Project” has the meaning specified in Section 3.   “Lima Project Company” has the meaning specified in Section 3 (a).   “MMBTU” mean one million British Thermal Units.  
 
16“Party” and “Parties” means either or both of Global Energy or Oxbow.   “Person” means and includes (i) an individual, (ii) a legal entity, including a partnership, a joint venture, a corporation, a trust, a limited liabilitycompany, a limited duration company, or a limited liability partnership, (iii) companies or associations or bodies of persons, whether or notincorporated, and (iv) a Governmental Authority.   “Price Basis” has the meaning specified in Section 3(c).   “Proceedings” means judicial or administrative actions, labor disputes, suits, proceedings, arbitrations, citations, complaints, or investigations.   “Project Milestones” has the meaning specified in Section 3(d).   “Purchase Price” has the meaning specified in Section 1.   “Release” means any spilling, leaking, pumping, pouring, discharging, injecting, dumping or disposing of any (i) Hazardous Material or (ii) othersubstance which is not a Hazardous Material, in each case not in compliance with all applicable Laws, whether intentional or unintentional.   “Shares” has the meaning specified in Section 1.   “Transaction Information” has the meaning specified in Section 4(f).   (b) In this Agreement, unless otherwise indicated or otherwise required by the context:   (i) Reference to and the definition of any document (including this Agreement) shall be deemed a reference to such documentincluding the exhibits and schedules thereto and as such document may be amended, supplemented, revised, assigned or modified from time totime prior to the applicable Closing Date; provided, however, that this rule of interpretation shall not apply to references to documents in theSchedules;   (ii) All references to an “Article”, “Section”, “Schedule” or “Exhibit” are to an Article or Section hereof or to a Schedule or anExhibit attached hereto, unless otherwise noted;   1. The table of contents, article and Section headings, and other captions in this Agreement are for the purpose of reference onlyand do not limit or affect its meaning;   2. Defined terms in the singular include the plural and vice versa, and the masculine, feminine, or neuter gender include allgenders;   3. Accounting terms used herein but not defined in this Agreement shall have the respective meanings given to them underGAAP;  
 
174. The words “hereof”, “herein” and “hereunder” and words of similar import when used in this Agreement refer to thisAgreement as a whole and not to any particular provision of this Agreement;   5. Any reference herein to a time of day means Eastern Standard Time or Eastern Daylight Time, as appropriate;   6. References to any Person or Persons shall be construed as a reference to any successors or permitted assigns of such Personor Persons; and   7. The words “including”, “include” and “includes”, when used in this Agreement shall mean, as required by the context,including, include, and includes “without limitation” and “without limitation by specification.”   10. Miscellaneous.   (a) Contracts. All contracts contemplated to be entered into by the Parties pursuant to this Agreement shall be negotiated in good faith andshall contain terms and conditions, and be performed for prices, which are commercially reasonable.   (b) Publicity. No public statements or press releases shall be issued by either Party relating to the terms of this Agreement or the businessaffairs of the Parties hereunder without the prior consent of the other Parties, However, nothing herein shall prevent a Party from supplying suchinformation or making such statements relating to this Agreement as such Party may consider necessary in order to satisfy its legal obligations(including, but not limited to, its obligations of disclosure under applicable securities laws).   (c) Notices. All notices and other communications required or permitted hereunder shall be in writing and shall be deemed to have been dulygiven upon delivery, if delivered personally or by recognized overnight courier service; if sent by first-class mail, five (5) days after being mailed,return receipt requested and postage prepaid; or if sent by facsimile or e-mail, upon receipt. Such notices shall be sent to the following addresses, or atsuch other address as either Party shall hereafter specify in writing.   If to Global:   Global Energy, Inc. 312 Walnut Street, Suite 2650 Cincinnati, Ohio 45202 Facsimile No.: (513) 621-5947 Attention: H.H. Graves, President and CEO HHG@globalenergyinc.com  
 
18If to Oxbow:   Oxbow Carbon & Minerals LLC 1601 Forum Place, Suite 1400 West Palm Beach, FL 33401 Facsimile No.: (561) 697-1876 Attention: John P. Stauffer, Vice President john.stauffer@oxbow.com   (d) Consequential Damages. Neither Party shalI be liable to the other Party in connection with this Agreement or the subject matter hereof forany indirect, incidental, special or consequential damages, including but not limited to loss of revenue, cost of capital or loss of profit or businessopportunity, whether such liability arises out of contract, tort (including negligence), strict liability or otherwise.   (e) Successor and Assigns: No Partnership. This Agreement shall be binding upon and shall inure to the benefit of the Parties and theirrespective Affiliates, and to their respective successors and permitted assigns. Nothing contained in this Agreement shall be construed as creating apartnership among the Parties.   (f) Exclusive Understanding. This Agreement and the exhibits hereto sets forth the sole and complete understanding between the Parties withrespect to the subject matter hereof, and supersedes all other prior oral or written agreements, arrangements and understandings between the Partieswith respect thereto. This Agreement shall not confer any legal rights or benefits on any third party (other than Affiliates of the Parties hereto, to theextent set forth herein).   (g) Attorneys’ Fees. In the event either Party files an action to enforce or otherwise arising out of this Agreement, the prevailing Party in suchaction shall be entitled to reasonable attorneys’ fees and court costs in addition to such other relief to which it may be entitled.   (h) Governing Law. This Agreement, and the rights and obligations of the Parties hereunder, shall be subject to, and construed in accordancewith, the laws of the State of New York.   (j) Counterparts. This Agreement may be executed in counterparts, each of which shall constitute an original for all purposes, but all of whichshall constitute one and the same instrument.   [BALANCE OF PAGE LEFT BLANK. SIGNATURES ON NEXT PAGE]  
 
19IN WITNESS WHEREOF, the Parties have entered into this Agreement as of the date first set forth above.             OXBOW CARBON & MINERALS LLC            By /s/ Brian L. Acton 
      Brian L. Acton       President         GLOBAL ENERGY, INC.            By /s/ H.H. Graves 
      H.H. Graves       President and Chief Executive Officer       20Exhibit 99.4
 
STRATEGIC ALLIANCE AGREEMENT
 
“EDGE-FTE”
 
THIS STRATEGIC ALLIANCE AGREEMENT (the “Agreement”), made effective this 17 th day of February 2016, through February 16,
2019 (the “Initial Term”) is entered into by and between EDGE Communications Solutions, LLC, with its principal place of business at 6505
Windcrest Drive, Suite 200, Plano, TX 75024 (hereinafter referred to as “EDGE”), and FTE Networks, Inc. with its principal place of business at 999
Vanderbilt Beach Road, Suite 601, Naples, FL 34108 (hereinafter referred to as “FTE” or “Subcontractor”) sets forth the terms and conditions by
which FTE will supply labor, materials, equipment, supervision and/or services for FTE’s scope of work. FTE’s work shall be identified in a purchase
order, which if issued, will be issued subject to the terms of this Agreement (“Purchase Order”). Each Purchase Order, taken together with the terms
and conditions of this Agreement, shall constitute a separate agreement between the parties and shall be considered independent of any other
agreements between the parties that incorporate the terms and conditions of the Agreement.
 
FTE agrees to perform its scope of work, in accordance with the terms and conditions of this in accordance with the terms and conditions
of the respective issued Purchase Order(s).
 
The Work, as defined below, is a portion of the services to be provided by for a communications service provider Mediacom, LLC (the
“Customer”).
 
1. TERMS
 
A. This Agreement shall remain in effect for the duration of the Initial Term, unless earlier terminated pursuant to the provision entitled
“Termination of Agreement”. After the Initial Term, this Agreement shall continue on a month to month basis until terminated by either party upon
thirty (30) days prior written notice to the other setting forth the effective date of such termination. The termination of any Purchase Order shall not
affect the obligations of either party to the other party pursuant to any other Purchase Order or to this Agreement. The termination of this
Agreement shall terminate the obligations of either party to the other party pursuant to any Purchase Order and those obligations pursuant to this
Agreement, except as to obligations that are identified herein or in a terminated Purchase Order as surviving termination.
 
B. Should the Agreement expire during the period of performance, all remaining Work of each Purchase Order will be completed under the
terms of the Agreement then in effect on the date of award for each respective Purchase Order, unless modified in writing by mutual consent of the
parties.
 
C. Prior to performing or providing the labor, materials, equipment and services required to complete the work described in a Purchase
Order, if any, (the “Work”), Subcontractor must have a properly executed Agreement with EDGE, complied with all terms and conditions therein,
including have submitted the required proofs of insurance. EDGE shall receive authorization from the Customer to approve Subcontractor as an
approved vendor and to approve the Work terms and conditions of this Agreement if required to do so under Edge’s contract with the Customer.
 
 
STRATEGIC ALLIANCE AGREEMENT “EDGE-FTE”  Page 12. SCOPE OF WORK
 
A. Subcontractor shall perform work for EDGE referred to as “Route Feasibility & Site Acquisition,” “Materials Management,” “OSP
Construction,” and “Other Work” as outlined in the attached Exhibits A, B, C and D and as described and set forth in Purchase Orders.
 
B. Descriptions of the Work to be performed by Subcontractor for EDGE shall be listed in a Purchase Order. EDGE engages Subcontractor
to furnish the Work described in the Purchase Order. All Work under any Purchase Order shall be performed in a professional manner and in
accordance with the applicable specifications and drawings. Purchase Orders, shall be issued and administered as set forth in Section 3 below.
 
C. Unless otherwise provided in the Purchase Order, the Contractor shall provide and pay for materials, and other facilities and services
necessary for proper execution and completion of the Work, whether temporary or permanent and whether or not incorporated or to be incorporated
in the Work.
 
3. DISBURSEMENT OF PURCHASE ORDER
 
A. Issuance of Work under this Agreement may be made from time to time by the issuance of Purchase Orders to Subcontractor. Purchase
Orders, if any, shall reference and incorporate the terms and conditions of the Agreement which shall apply to all Work performed under the
Purchase Order.
 
B. Nonexclusive Rights. This Agreement is an as-ordered agreement between EDGE  and Subcontractor, anticipating the potential but not
promised issuance of Purchase Orders for specific work in amounts in excess of $20MM.
 
4. COMPENSATION & PAYMENTS
 
A. All Work shall be performed on the basis of certain agreed upon prices specified in the related Exhibit or individual Purchase Order
once accepted by Subcontractor.
 
B. Payment. EDGE shall pay Subcontractor for Work completed in accordance with the related Exhibit or individual Purchase Order once
accepted by Subcontractor.
 
C. This Agreement shall not be construed as a “Pay When Paid” contract. EDGE’s obligation to pay Subcontractor under this Agreement
shall not be predicated upon the Customer approving or paying EDGE for the Work.
 
D. Release and Waiver of Liens. Subcontractor will pay for all services, equipment, material and labor used under this Agreement and will
keep EDGE’ and Customer’s property and work sites free of all claims or liens.
 
 
STRATEGIC ALLIANCE AGREEMENT “EDGE-FTE”  Page 2(1) If Subcontractor fails to make payments to subcontractors, materialmen, or suppliers, of any tier, including but not limited to suppliers
of labor, material, equipment or services or to union benefits funds (hereinafter “Lower-tier Subcontractors”), its employees or laborers in the
performance of the Work, EDGE shall have the right to deduct or temporarily withhold out of payments due or to become due to Subcontractor,
reasonable amounts to satisfy any claims, bonds, or liens against the Work site, to issue joint checks to (i) Subcontractor and (ii) its Lower-tier
Subcontractors, employees or laborers, and any potential bond or lien claimant, as applicable, or to pay such claimant(s) to protect EDGE from any
and all loss, damage and expense (including attorneys’ fees) arising out of or related to a claim or lien by such claimant
 
(2) Subcontractor agrees to indemnify and defend EDGE from and against any lien claims and to discharge any lien or furnish an indemnity
bond equal to the lien amount (or any greater amount required by law) within ten (10) days notice from EDGE of the presence of any lien.
 
E. Acceptance of any payment by Subcontractor shall not constitute a waiver of claims by Subcontractor except those previously made in
writing and identified by Subcontractor as settled at the time of final invoice.
 
5. INDEPENDENT SUBCONTRACTOR RELATIONSHIP
 
Nothing in this Agreement shall cause Subcontractor in any way to be construed as a partner or joint venture with, or an employee of,
EDGE in connection with or arising from Subcontractor’s rendering of Work to  EDGE pursuant to this Agreement.  EDGE retains Subcontractor only
for the purposes and to the extent as set forth in this Agreement, and Subcontractor’s relation to  EDGE during the term of this Agreement shall be
that of an independent contractor and nothing herein shall create or imply any other or different relationship.
 
Subcontractor acknowledges that: (a) nothing herein constitutes the exercise by  EDGE of control or direction over the manner or method
by which Subcontractor will perform the Work, (b) Subcontractor is solely responsible for the withholding and payment of all federal, state and
local income, social security and unemployment taxes, salaries, and other payments required to be made by it from funds received from  EDGE
hereunder, and (c) that EDGE is not required to and will not provide any worker’s compensation or other insurance coverage of any nature, or any
other unemployment, medical, dental, welfare or pension benefits to Subcontractor or any of its employees, associates or subcontractors. In
addition, Subcontractor shall exercise full control of and supervision over its employees. Subcontractor acknowledges that its personnel (if any)
performing Work are agents, employees or subcontractors of Subcontractor and are not employees or agents of  EDGE.
 
6. SUBCONTRACTING
 
A. Subcontractor shall be permitted to subcontract any part of the Work without the prior written notification and consent of EDGE.
However, Subcontractor will follow subcontracting requirements and processes of EDGE and provide joint access to subcontractor database and
information concerning quality control. All Work performed by a Lower-tier Subcontractor shall be deemed Work performed by Subcontractor.
Subcontractor agrees not to hire any Lower-tier Subcontractor to whose employment EDGE reasonably objects.
 
 
STRATEGIC ALLIANCE AGREEMENT “EDGE-FTE”  Page 3B. If the Work of any Lower-tier Subcontractor is unsatisfactory or unnecessarily delayed, or the Lower-tier Subcontractor violates any of
the provisions of this Agreement, EDGE may request Subcontractor to terminate such Lower-tier Subcontractor and Subcontractor shall
immediately terminate the agreement with its Lower-tier Subcontractors without any liability to EDGE whatsoever. Additionally, Subcontractor shall,
at its cost, properly complete the Work within the required time or arrange for a capable subcontractor, approved by EDGE, to do so.
 
7. MODIFICATIONS AND CHANGES TO THE SCOPE OF WORK
 
A. EDGE and Subcontractor, without invalidating this Agreement, may agree to changes in the Work consisting of additions, deletions, or
modifications (“Change Order”), pursuant to a completed written change order documented by the parties. Such Change Order shall set forth any
changes to the applicable Purchase Order and the price and time adjusted accordingly if any. In connection with the Change Order, EDGE will issue
to Subcontractor a subsequent Purchase Order identifying any agreed upon change in the Work price and/or time.
 
B. All modifications to the terms of this Agreement shall be by written Amendment signed by both parties or otherwise documented by
the parties.
 
8. INSPECTION OF WORK
 
As set forth in the Exhibit, EDGE shall have the opportunity to review and inspect all elements of the Work in a reasonable manner.  EDGE
shall have the right to require repair or replacement of any Work which is defective or not performed in accordance with the Purchase Order or
deviates from other requirements of this Agreement, provided Subcontractor shall have until acceptance to complete such repair or replacement.
Subcontractor shall be solely responsible for all construction means, methods, techniques, procedures and safety and security programs in
connection with the performance of the Work.
 
9. INSURANCE
 
A. Subcontractor shall obtain at its own cost and expense and maintain the insurance in full force and effect during the term of the
Agreement as required herein. A copy of the (i) certificate(s) of insurance and (ii) endorsements, acceptable to EDGE , shall be submitted to  EDGE
prior to commencement of any Work and renewals or replacements of such certificates shall be so delivered at least 30 days prior to the expiration
or termination of each such policy. A copy of the insurance policies shall promptly be made available to  EDGE upon EDGE’ request. Subcontractor
expressly acknowledges while  EDGE retains the right to review the insurance provided by Subcontractor and’ Lower-tier Subcontractors,  EDGE is
not obligated to perform such review. In addition, EDGE exercise of such right is for EDGE’ benefit alone and shall confer no rights to Subcontractor
or to any third party.  EDGE’s acceptance of or failure to object to the submitted documents does not constitute approval of coverage that is not in
compliance with this Agreement or as acceptance or affirmation of the adequacy or applicability of such insurance.
 
 
STRATEGIC ALLIANCE AGREEMENT “EDGE-FTE”  Page 4(1) Commercial General Liability Insurance providing the limits of coverage written on an occurrence basis, in no event less than $1,000,000
combined single limit and $2,000,000 in the aggregate for personal and bodily injury and death arising therefrom and Broad Form property damage
arising out of any one occurrence in connection with the Work or any part thereof, which insurance shall include coverage with the same minimum
limits for contractual liability and completed operations liability. General Liability and Umbrella/Excess Liability policies must have “per location or
per project” aggregates.
 
(2) Motor Vehicle Insurance covering bodily injury, death of a person or property damage arising out of the ownership, maintenance or use
of any motor vehicles in an amount not less than $1,000,000 combined single limit for personal and bodily injury and death.
 
(3) Workers’ Compensation Insurance as required by state law where the Work is performed. Employer Liability insurance with limits of at
least $1,000,000 for each occurrence.
 
(4) Umbrella/Excess Liability with limits of not less than $5,000,000 in excess of all the above-referenced Commercial General Liability,
Employer’s Liability and Business Auto Liability, except the following Subcontractor classifications will have limits of not less than the following:
HVAC $2,000,000, Landscaping and Fencing $1,000,000. Such Umbrella/Excess Liability policies shall follow form to the terms and conditions of the
underlying coverages and shall include a drop down feature in the event any underlying limits are exhausted.
 
(5) EDGE and Mediacom, LLC shall be named as an additional insured.
 
(6) All insurance must be written on an “occurrence” basis.
  
10. TIME AND PROGRESS OF WORK
 
A. Subcontractor shall commence Work on the date(s) stipulated on each Purchase Order for each project. Subcontractor shall carry the
Work forward expeditiously according to the work schedule and with adequate forces to achieve final completion of the Work identified on the
Purchase Order.
 
B. No extension of performance time for any Work will be accepted without the consent of EDGE, which consent shall not be unreasonably
withheld.
 
11. TERMINATION OF AGREEMENT
 
A. RIGHT TO CURE/TERMINATION FOR SUBCONTRACTOR’S DEFAULT
 
After fifteen (15) days prior written notice to Subcontractor to cure, or additional time as may be reasonably required by EDGE to cure the
event of default, EDGE may terminate this Agreement, or any one or more awarded Purchase Orders and take control of the Work for such
terminated Purchase Orders, including any or all materials for the Work, and may proceed with the completion of the Work as contemplated by this
Agreement by whatever method deemed expedient by EDGE upon the occurrence of any of the following events, which shall be deemed events of a
default by Subcontractor hereunder:
 
 
STRATEGIC ALLIANCE AGREEMENT “EDGE-FTE”  Page 51) Subcontractor fails to supply a sufficient number of skilled workers or suitable materials or equipment for performance of the Work;
 
2) Subcontractor fails to make payments to its Lower-tier Subcontractors or employees or laborers for labor, material or equipment;
 
3) Subcontractor disregards laws, ordinances, rules, regulations or orders of any public authority;
 
4) Any Lower-tier Subcontractor files a (i) notice of intention to file a construction or mechanic’s lien, (ii) mechanic’s lien, or (iii)
construction lien, and such filing is not removed by Subcontractor within three (3) days after the period required by this Agreement;
 
5) Subcontractor makes a general assignment for the benefit of its creditors, a receiver or liquidator shall be appointed for Subcontractor or
for any of its property, or Subcontractor or its creditors initiate bankruptcy proceedings (11 U.S.C.A.) with respect to Subcontractor; or
 
6) Subcontractor otherwise violates any provision of this Agreement.
 
B. REMEDIES FOR SUBCONTRACTOR’S DEFAULT
 
The cost of completion by EDGE in the event of a termination based on the occurrence of any of the conditions specified in Section 11(A)
above shall be deducted from the unpaid balance, if any, then due Subcontractor under the Agreement.
 
12. SUSPENSION OF WORK
 
EDGE shall have the right to suspend the Work in progress for a reasonable time at the direction of Customer. Subcontractor shall resume
performance of the Work at  EDGE’ direction. Subcontractor may be entitled to additional compensation or damages as a consequence of this
suspension.
 
13. INDEMNIFICATION
 
A. Subcontractor shall indemnify, defend and hold harmless  EDGE and Customer and both of their subsidiaries, directors, shareholders,
partners, principals (disclosed or undisclosed), employees, agents and representatives (hereinafter the “Indemnitees”) from and against any and all
claims, demands, damages, actions, causes of action, suits, losses, judgments, obligations, and any liabilities, costs and expenses, including but
not limited to, investigative and repair costs, attorney fees and costs, and consultant’s fees and costs (collective, “Claims”) arising out of or in
connection with the Work performed, materials furnished, or services provided or omitted under this Agreement by Subcontractor or its agents
 
 
STRATEGIC ALLIANCE AGREEMENT “EDGE-FTE”  Page 6B. These obligations to defend and indemnify shall not limit, or be limited by, the defense and/or additional insured obligations of the
Subcontractor’s insurance carrier(s).
 
C. The obligations of this Section 13 shall survive termination of this Agreement.
 
14. DUE ORGANIZATION
 
Subcontractor certifies that it is duly organized, existing and in good standing under the laws of its state of formation, and is duly qualified
as necessary and is in good standing with respect to all jurisdictions in which it is required to be so qualified to do business.
 
15. TAXES
 
Fees are inclusive of all taxes and similar assessments, levies and government-imposed obligations with respect to income derived from
Subcontractor’s performance of the Work (“Taxes”). All Taxes shall be the obligation of and be paid by Subcontractor.
 
16. PERMITS, COMPLIANCE WITH LAWS AND OTHER AGREEMENTS
 
Subcontractor shall obtain and maintain all licenses, permits or certificates (collectively “Licenses”) required by any applicable law in
connection with Subcontractor’s performance of Work hereunder. Subcontractor represents and warrants to EDGE that Subcontractor’s
performance of this Agreement will not violate any other employment, services, confidentiality, consulting or other agreement to which
Subcontractor is a party or by which it may be bound.
 
17. WARRANTY
 
A. Subcontractor warrants to EDGE that the Work will be performed with promptness and diligence and shall be executed in a quality
manner consistent with workmanship standards in the particular trades involved.
 
B. EDGE may accept any nonconforming Work instead of requiring its removal and correction upon the condition that Subcontractor shall
pay EDGE an appropriate amount for damages and compensation as is mutually agreed upon by EDGE and Subcontractor. Warranty is not waived
under such conditions.
 
C. If within one (1) year from the date of completion of Work acceptance, or within one (1) year from the completion of all other work or
services and acceptance by EDGE (or within any longer materials warranty period as set forth above), any defects exists or arise, then in each case
upon receipt of notice of such defect, Subcontractor shall (unless EDGE chooses another remedy) promptly cause such defect(s) to be repaired or
remedied at Subcontractor’s sole cost and expense, including but not limited to the costs of transportation, uncovering, removal, disposal,
replacement, correction, installation and covering. Subcontractor shall commence or cause the commencement of repairs immediately upon receipt
of notice from EDGE and thereafter diligently pursue same to completion or cause the same to be diligently pursued to completion. EDGE shall have
the right without prejudice to any other rights or remedies available to it, (i) to make such repairs and offset the cost thereof against any amounts
owed to be paid by EDGE to Subcontractor or invoice Subcontractor therefore which invoice shall be paid net 30 days or (ii) require Subcontractor
to refund the price of the Work not meeting the warranties. Subcontractor will extend the warranty period if Subcontractor has been grossly
negligent in the performance of any Work under this Agreement. Notwithstanding anything to the contrary contained in this Agreement,
Subcontractor shall not be liable or responsible for any defect in any materials used by Subcontractor if such defect was not due to
Subcontractor’s acts or omissions.
 
 
STRATEGIC ALLIANCE AGREEMENT “EDGE-FTE”  Page 7D. These warranties extend to the future performance of the materials and shall continue for the longer of (a) the warranty period
applicable to EDGE’ sales to Customer of the material or of products which incorporate the material, (b) one year after the material is accepted by
EDGE or (c) such greater period as may be specified elsewhere in this Agreement. Repaired and replacement material shall be warranted as set forth
above in this clause.
 
18. PROTECTION OF PERSONS AND PROPERTY
 
A. Subcontractor represents and warrants (i) that Subcontractor has experience in the type of Work to be performed and in the
occupational safety and health practices that are required for that type of work; (ii) that Subcontractor’s employees are properly trained and
equipped to perform the Work; (iii) that Subcontractor is aware of the risks inherent in performing such Work and Subcontractor expressly assumes
the risk of loss or injury that may result from the Work.
 
B. Subcontractor shall comply with all applicable laws (including, without limitation the Federal Occupational Safety and Health Act,
Hazardous Communication Requirements, and all applicable environmental protection laws, rules, regulations and ordinances), ordinances, rules,
regulations and lawful orders of any public authority having jurisdiction for the safety of persons or property or to protect them from damage,
injury or loss. Subcontractor shall comply with all occupational safety and health requirements, including such related publications (not included;
but incorporated herein by reference):
 
· National Electrical Code Handbook, most recent edition.
 
· Occupational Safety and Health Administration Handbook.
 
· National Electrical Safety Code, most recent edition.
 
· All System pole attachment agreements.
 
· Applicable utility practices of states named, General Order #95 and General Order #128.
 
C. Without limitation of the Subcontractor’s obligations regarding safety and protection, Subcontractor shall:
 
 
STRATEGIC ALLIANCE AGREEMENT “EDGE-FTE”  Page 81) Confine operations at the site to areas permitted by law, ordinances, permits, this Agreement and the Purchase Orders;
 
2) erect and maintain, as required by existing conditions and performance of the Work, safeguards for safety and protection, including
posting danger signs and other warnings against hazards, promulgating safety regulations and notifying owners and users of adjacent sites and
utilities;
 
3) not unreasonably encumber the site with materials or equipment or load or permit any part of the construction or site to be loaded so as
to endanger its safety;
 
4) not bring hazardous materials onto the site without prior written authorization by  EDGE;
 
5) exercise utmost care and carry on its activities under supervision of properly qualified personnel, when use or storage of explosives or
other hazardous materials or equipment or unusual methods are necessary for execution of the Work; and
 
6) dispose of any hazardous materials in accordance with applicable law.
 
D. Without limitation of Subcontractor’s obligation under this Agreement, the Subcontractor shall indemnify EDGE as identified in Section
13 for any Claims caused by hazardous materials.
 
19. CLEAN UP
 
Subcontractor shall at all times keep the Work premises free from accumulations of waste material, rubbish, and any other debris resulting
from the Work. On an ongoing basis as the Work progresses, and at the completion of the Work, Subcontractor shall restore to essentially its
former condition, and to the satisfaction of EDGE, all aspects of the Work site and shall remove all waste and excess materials, tools, and equipment
resulting from or used in the Work and legally dispose thereof. All costs and expenses of any type for cleanup, restoration, and removal noted
above will be borne by Subcontractor at no cost to EDGE. If Subcontractor fails in its duties under this clause, EDGE may upon notice to
Subcontractor perform the necessary clean up and deduct the costs thereof from any amounts due or to become due to Subcontractor or invoice
Subcontractor therefore, which invoice shall be paid net 30 days. Manholes, cable vaults, and central office Work areas will be cleared of all litter by
Subcontractor on a daily basis where Work is being performed.
 
20. NOTICE OF MATERIAL DEFECTS
 
Subcontractor agrees to promptly notify EDGE upon learning of any material defect, misstatement or omission in rendering any Work.
 
 
STRATEGIC ALLIANCE AGREEMENT “EDGE-FTE”  Page 921. WAIVER
 
The waiver by either party of any breach of this Agreement by the other party in a particular instance shall not operate as a waiver of
subsequent breaches of the same or different kind. The failure of either party to exercise any rights under this Agreement in a particular instance
shall not operate as a waiver of the party’s right to exercise the same or different rights in subsequent instances.
 
22. NOTICES
 
A. Any written notice or demand which under the terms of this Agreement or under any statute must or may be given or made by EDGE or
Subcontractor shall be in writing and addressed to the respective parties as stated in this Agreement. Notice shall be sent by certified, registered or
express mail, other overnight delivery service, or shall be hand delivered. Written notice by facsimile shall satisfy the notice requirements of this
Agreement where the individual to whom the facsimile is addressed acknowledges receipt of such notice by return facsimile or other means as
provided in this Section. The addresses below may be changed at any time by giving prior written notice as above provided.
 
TO: TO:
   
EDGE Communications Solutions, LLC FTE Networks, Inc.
Attn: Mark Miller, EVP – Operations Attn: General Counsel
6505 Windcrest Drive 999 Vanderbilt Beach Blvd
Suite 200 Suite 601
Plano, TX 75024 Naples, FL 34108
 
Such notice shall be deemed to have been given or made when actually received or seventy-two (72) hours after being sent as specified above,
whichever occurs first.
 
23. ASSIGNMENT
 
Subcontractor shall not assign any right or interest under this Agreement (excepting monies due, or to become due) or delegate or
subcontract any Work or other obligation to be performed or owed under this Agreement without prior consent of EDGE. Notwithstanding,
Subcontractor may delegate or assign Work under this Agreement to a subsidiary operating entity. All Work performed by Subcontractor’s Lower-
tier Subcontractors shall be deemed Work performed by Subcontractor.
 
24. BINDING EFFECT
 
This Agreement shall bind and inure to the benefit of the parties hereto and their respective heirs, legal representatives, successors and
permitted assigns.
 
 
STRATEGIC ALLIANCE AGREEMENT “EDGE-FTE”  Page 1025. CHOICE OF LAW/FORUM
 
The construction, interpretation, and performance of this Agreement and all transactions under it shall be governed by the laws of the
State of Texas, irrespective of its conflict of law principles. Subcontractor and EDGE shall not be obligated to resolve by arbitration any claim or
dispute related to the Agreement. It is mandatory that any controversy or claim arising out of or relating to the Agreement or the breach thereof
shall be subject to the jurisdiction of the State of Texas and the venue shall be exclusively in Collin County, Texas for resolution.
 
26. TEXAS ALTERNATIVE DISPUTE RESOLUTION
 
All claims, disputes and other matters in question arising out of or relating to this subcontract with a breach thereof, except for claims
which have been waived by the making or acceptance of final payment, shall be decided by mediation or non-binding arbitration pursuant to the
Texas Arbitration Dispute Resolution Act, (Texas Practice and Remedies Code, Chapter 154), and in accordance with the construction industry rules
then in effect unless the parties mutually agree otherwise. Each party shall pay its own legal and other costs relating to the mediation or the non-
binding arbitration regardless of the outcome of the mediation or the non-binding arbitration.
 
27. LEGAL JURISDICTION/ VENUE
 
The Parties:
 
(a) consent to the exclusive venue the State of Texas, Collin County, in any action arising out of or relating to this Agreement
including the jurisdiction and venue in connection with Paragraph 26 : TEXAS ALTERNATIVE DISPUTE RESOLUTION ACT;
 
(b) waive any objection they might have to jurisdiction or venue of such forums or that the forum is inconvenient; and
 
(c) agree not to bring any such action in any other jurisdiction or venue to which either party might be entitled by domicile or
otherwise.
 
28. ATTORNEY’S FEES
 
In the event that a dispute arises with respect to this Agreement, the party prevailing in such dispute shall be entitled to recover all
expenses, including, without limitation, reasonable attorneys’ fees and expenses, incurred in ascertaining such party’s rights under this Agreement,
whether or not it was necessary for such party to institute suit.
 
29. NUMBER AND GENDER
 
Whenever the singular number is used in this Agreement and when required by the context, the same shall include the plural. The
masculine gender shall include the feminine and neuter genders, and the word “person” shall include a corporation, firm, partnership, or other form
of association.
 
 
STRATEGIC ALLIANCE AGREEMENT “EDGE-FTE”  Page 1130. ENTIRE AGREEMENT; INCONSISTENCIES
 
A. This Agreement shall incorporate the typed or written provisions of EDGE’ Purchase Orders issued pursuant to this Agreement and
shall constitute the entire agreement between the parties with respect to the subject matter of this Agreement and shall not be modified or
rescinded except by a writing signed by Subcontractor and EDGE. All references in these terms and conditions to this Agreement or to Work,
services, material, equipment, products, software, or information furnished under, in performance of, pursuant to, or in contemplation of this
Agreement shall also apply to any Purchase Orders or Amendments issued pursuant to this Agreement. All provisions on Subcontractor’s forms
shall be deemed deleted. Additional or different terms inserted in this Agreement by Subcontractor, or deletions thereto, whether by alterations,
addenda, or otherwise, shall be of no force and effect, unless expressly consented to by EDGE in writing. The provisions of this Agreement
supersede all contemporaneous oral agreements and all prior oral and written quotations, communications, agreements, and understandings of the
parties with respect to the subject matter of this Agreement.
 
B. The documents referenced in this Agreement are complementary, and what is called for by any one shall be as binding as if called for by
all. The intention of the Agreements, Exhibits, and Purchase Order (collectively “Contract Documents”) is to include all labor, materials,
supervision, equipment, transportation and expense necessary for the proper execution of the Work; performance by Subcontractor shall be
required to the extent consistent with the Contract Documents to produce the intended results. If a conflict or inconsistency exists between the
provisions of this Agreement, the pre-printed terms and conditions on either side of the Purchase Order, any other document, the order of
precedence to resolve the conflict or inconsistency is as follows: (a) the Agreement; (b) Exhibits to the Agreement; (c) Purchase Orders; and (d)
drawings and specifications. In the event of an irreconcilable conflict, discrepancy, error, or omission, the provision imposing the greater duty on
Subcontractor shall apply. Materials or work described in words that have a well-known technical or trade meaning shall be held to refer to such
recognized standards.
 
31. SEVERABILITY
 
If any provision of this Agreement is illegal or unenforceable, its invalidity shall not affect the other provision of this Agreement that can
be given effect without the invalid provision. If any provision of this Agreement does not comply with any law, ordinance or regulation, such
provision to the extent possible shall be interpreted in such a manner to comply with such law, ordinance or regulation, or if such interpretation is
not possible, it shall be deemed to satisfy the minimum requirements thereof. All provisions required by law shall be deemed incorporated herein by
reference.
 
 
STRATEGIC ALLIANCE AGREEMENT “EDGE-FTE”  Page 1232. AMENDMENT
 
This Agreement may be amended or modified only by a written instrument executed by both EDGE and Subcontractor.
 
33. RIGHT OF REPLACEMENT
 
EDGE may, upon reasonable request, require Subcontractor to replace any personnel, including a project manager, deployed by
Subcontractor under the terms of this Agreement. Subcontractor will replace any personnel promptly after request from EDGE with an employee of
Subcontractor reasonably acceptable to EDGE.
 
34. NON-SOLICITATION
 
Subcontractor, during the term of this Agreement and for a period of one year thereafter, shall not, directly or indirectly, for itself or on
behalf of or in conjunction with any other person, partnership, corporation, business or organization, solicit, hire, contract with or engage the
employment of an employee of EDGE with whom Subcontractor or its personnel have contact as a result of Subcontractor’s performance of this
Agreement, unless Subcontractor (i) obtains the written consent of EDGE, as applicable, and (ii) pays EDGE as applicable a fee to be mutually
agreed upon. In the event Subcontractor directly employs or contracts with an employee of EDGE without the consent of EDGE, Subcontractor
shall pay as liquidated damages two times the then monthly salary of the employee for a three-month period of time.
 
 
STRATEGIC ALLIANCE AGREEMENT “EDGE-FTE”  Page 1335. DOCUMENT OWNERSHIP AND CONFIDENTIALITY AND USE OF INFORMATION
 
Each party may make available (“Disclosing Party”) to the other (“Receiving Party”) access to certain information whether of a technical,
business or other nature, including without limitation trade secrets, know-how and information relating to the technology, Customers, business
plans, promotional and marketing activities, finances and other business affairs of such Party (collectively, “Confidential Information”). So long as
and to the extent that Confidential Information is clearly and identifiably marked “Confidential” or “Proprietary” (if in tangible form) or is not
generally available to the public from other sources, each Party shall safeguard such Confidential Information in the manner in which it safeguards
its own confidential information, and shall not disclose Confidential Information to its employees, Lower-tier Subcontractors and agents, except to
the extent necessary to enable it to fulfill its obligations under this Agreement. The Parties obligations set forth in this Section shall not apply with
respect to any portion of the Confidential Information that the Receiving Party can document by competent proof that such portion: (a) was in
public domain at the time it was communicated to the Receiving Party by the Disclosing Party; (b) entered the public domain through no fault of the
Receiving Party, subsequent to the time it was communicated to the Receiving Party by the Disclosing Party; (c) was in Receiving Party’s
possession free of any obligation of confidence at the time it was communicated to Receiving Party by Disclosing Party; (d) was developed by
employees or agents of Receiving Party independently of and without reference to any information communicated to Receiving Party by Disclosing
Party; or (e) was communicated by Disclosing Party to an unaffiliated third party free of any obligation of confidentiality. In addition, Receiving
Party may disclose the Disclosing Party’s Confidential Information in response to a valid court order by a court or other governmental body, as
otherwise required by law. All Confidential Information furnished to the Receiving Party by the Disclosing Party is the sole and exclusive property
of the Disclosing Party or its suppliers or Customers. This Paragraph shall survive termination of this Agreement.
 
END OF DOCUMENT
 
[SIGNATURES ON FOLLOWING PAGE]
 
 
STRATEGIC ALLIANCE AGREEMENT “EDGE-FTE”  Page 14IN WITNESS WHEREOF, EDGE AND FTE HAVE EXECUTED THIS AGREEMENT AS OF THE DATE FIRST ABOVE WRITTEN.
 
EDGE Communications Solutions, LLC   FTE Networks, Inc.  
           
           
BY: /s/ Mark Miller   BY: /s/ Carlie Ancor  
NAME: Mark Miller   NAME: Carlie Ancor  
TITLE: Executive Vice-President - Operations   TITLE: Chief Technology Officer  
 
 
STRATEGIC ALLIANCE AGREEMENT “EDGE-FTE”  Page 15Exhibit 10.24 
 
[***] Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the
Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
 
EXECUTION VERSION
 
STRATEGIC ALLIANCE AGREEMENT
 
THIS STRATEGIC ALLIANCE AGREEMENT (“Agreement”) is made and entered into as of November 6, 2016 (the “ Effective Date”) by
and between Dialog Semiconductor (UK) Ltd., a corporation organized under the laws of England and Wales, having its principal office at 100
Longwater Avenue, Green Park, Reading, RG2 6GP, United Kingdom (“DIALOG”) and Energous Corporation, a Delaware corporation, having its
principal office at 3590 North First Street, Suite 210, San Jose, CA 95134 (“ENERGOUS”).
 
WHEREAS DIALOG is a supplier of mixed-signal semiconductor products;
 
WHEREAS ENERGOUS is a supplier of uncoupled wirefree charging systems, including antennas, semiconductors, firmware, software,
algorithms, and sensors;
 
WHEREAS concurrently with their execution of this Agreement, DIALOG and ENERGOUS are entering into a separate Securities Purchase
Agreement, pursuant to which DIALOG will make an investment in ENERGOUS, and ENERGOUS will issue to DIALOG shares of its common stock
and a warrant to purchase its common stock on the terms set forth therein.
 
WHEREAS DIALOG and ENERGOUS desire to enter into a strategic relationship to distribute to the marketplace certain ENERGOUS
products and technology and to potentially collaborate on further initiatives pursuant to the terms and conditions of this Agreement.
 
NOW, THEREFORE, in consideration for the premises and mutual covenants contained herein, DIALOG and ENERGOUS hereby agree as
follows:
 
1. DEFINITIONS.
 
All capitalized terms used in this Agreement will have the meaning set out below, or if not defined below, the meaning as defined elsewhere
in the Agreement.
 
1.1 “Affiliate” means any person or entity that controls, is controlled by or is under common control with the specified person or entity,
but only so long as such control exists. The term “control” means the possession, directly or indirectly, of the power to direct or cause the direction
of the management and policies of an entity, whether through ownership of voting securities, by contract or otherwise.
 
1.2  “Approved Production Specifications” means those materials, processes and workmanship specifications of Manufacturing
Subcontractors as approved by ENERGOUS for the manufacture and production of the Products.
 
1.3 “Change of Control” means any transaction or series of transactions that results in (i) the consolidation or merger of the specified
party (“Target”) into or with any other corporation or corporations, (ii) the sale, conveyance or disposition of all or substantially all of the assets of
the Target, (iii) the transfer of more than fifty percent (50%) of the voting power of the Target to any entity or entities not controlled by the Target,
or (iv) any similar form of acquisition or any liquidation, dissolution or winding up of the Target or other transaction that results in the
discontinuance of the Target’s business; provided, however, that Change of Control will not include any transaction or series of transactions
entered into primarily for equity financing purposes (including, without limitation, any private equity investment or any public offering of
securities).1.4 “Deposit Materials” means all chip level design databases, circuit schematics, test and characterization programs and associated
documentation reasonably required to have Products manufactured, or to allow design bugs or Epidemic Defects to be fixed in the Product.
 
1.5 “Design-In Phase” means the phase in the sales cycle with a prospective customer for a Product that follows the customer’s decision
to move forward with the potential Product, during which chip samples are delivered to customer and the parties work together to design the
evaluation board for in-system evaluation.
 
1.6 “Documentation” means all information that is necessary or useful to support DIALOG’s authorized manufacture, testing, sale and
support of the Products, including but not limited to Product Specifications, data sheets, application notes, application board gerber files/BOM,
sales and marketing collateral, Product errata, test reports, characterization reports, software (e.g., firmware, GUI), test plans and yield data in
connection with the manufacture and sale of Products, Approved Production Specifications, test and characterization programs and associated
documentation reasonably required to have Products manufactured, assembled and tested, designs of all Tooling and all other items reasonably
required for the manufacture of the Products.
 
1.7 “Epidemic Defects” means material defects of any Product resulting from a common root cause solely attributable to the Product
Specifications or Approved Production Specifications and which results in returns (in accordance with the returns procedure mutually agreed
between the parties in the Commercialization Plan) of more than [***] percent ([***]%) of the quantity of such Product manufactured in any [***]
day period. Any number of material defects affecting any number of Products which result from a single common root cause or combination of
causes and result in returns of more than [***] ([***]%) of such Products manufactured in any [***] day period will be treated as the occurrence
of a single Epidemic Defect for purposes of this Agreement.
 
1.8 “Insolvency Event” means (a) without a successor, the specified party fails to function as a going concern or to operate in the ordinary
course, or (b) other than in the case when the specified party is a debtor-in-possession and continuing to fulfill all its obligations under this
Agreement, a receiver or trustee in bankruptcy is appointed for such party or its property, or such party makes a general assignment for the benefit
of its creditors, or such party commences, or has commenced against it, proceedings under any bankruptcy, insolvency or debtor’s relief law, in
each case which proceedings are not dismissed within ninety (90) days.
 
1.9 “Intellectual Property Rights” means any and all Patent Rights, copyright rights, Marks rights (including all associated goodwill),
mask work rights, trade secret rights and all other intellectual and industrial property rights of any sort throughout the world (including any
application therefor).
 
 
* Confidential Treatment Requested
 
  Page 21.10 “Invention” means any idea, concept, discovery, invention, development, technology, work of authorship, trade secret, software,
firmware, library, component, tool, mask work, process, method, technique, know-how, show-how, data, plan, formula, device, apparatus,
specification, design, documentation or other material or information, tangible or intangible, whether or not it may be patented, copyrighted or
otherwise protected (including all versions, modifications, enhancements and derivative works thereof).
 
1.11 “Manufacturing Subcontractors” means (a) [***] and/or its Affiliate that is the wafer foundry for the Products (“[***]”), (b) [***]
and/or its Affiliate that is responsible for the assembly, packaging and testing of the Products, and (c) and other third party contractors DIALOG or
ENERGOUS use, or may from time to time use, for the manufacturing, assembly, testing, or packaging of the Licensed Products or Licensed Product
components.
 
1.12 “Marks” means trademarks, service marks, trade dress and trade names.
 
1.13 “Mask Set” means the mask set for fabrication of wafers at a foundry supplier.
 
1.14 “Mass Production Qualified Product” means a fully qualified Product which has completed 500 hour high temperature over lifetime
(HTOL) testing and has been shipped in excess of  [***] units for purposes of incorporation in customer products.
 
1.15 MCM means a multichip module, being a single package that includes multiple integrated circuit dies, including a Product die.
 
1.16 “Net Sales” means the invoiced amounts for the Sale of Products less: (a) amounts credited for return of any such Products; (b)
amounts separately stated with respect to shipment of such Products for insurance, handling, duty, freight, and taxes; and (c) any discounts,
credits or rebates in the relevant royalty or service fee period.
 
1.17 “New Product” means a product developed by or on behalf of ENERGOUS after the Effective Date that is not a Product Update;
provided, however, that “New Products” exclude any product developed by a successor or acquirer of ENERGOUS.
 
1.18 “Patent” means any United States or foreign patent or patent application, including any provisional application, continuation,
continuation-in-part, divisional, registration, confirmation, revalidation, reissue, PCT application, patent term extension, supplementary protection
certificate, and utility model, as well as all foreign counterparts of any of the foregoing, and related extensions or restorations of terms thereof.
 
1.19 “Patent Rights” means rights under any Patent.
 
1.20 “Person” a human being or group of human beings, a company, corporation, a partnership or other legal entity (artificial or juristic
person) recognized by law as having rights and duties.
 
 
* Confidential Treatment Requested
  Page 31.21 “Products” means the ENERGOUS products set forth in  Exhibit A, as such Exhibit may be amended from time to time by mutual
agreement between the parties, that have been released by ENERGOUS to production, including all Product Updates, which will be deemed to have
been added to  Exhibit A automatically, without any further action required by the parties, immediately following the release to production date.
 
1.22 “Product Die” means the silicon die incorporated within Products.
 
1.23 “Product IP” means (a) all Intellectual Property Rights in and to the Products, including all Product Updates, (b) any other Inventions
and work products created or developed in connection with research and development or manufacturing efforts relating to the Products, including
all Intellectual Property Rights therein and (c) all Intellectual Property Rights in and to the Mask Sets and Tooling, in each of the foregoing cases,
that are owned or controlled by ENERGOUS, its Affiliates or any successor or assign.
 
1.24 “Product Specifications” means ENERGOUS’ written technical specifications for the Products as referenced in datasheets and related
documentation such as errata sheets. All Product Specifications are subject to change with at least one (1) months prior written notice to DIALOG,
provided that with respect to any warranty for Products covered by this Agreement, the Product Specification in effect at the time of shipment of
the relevant Product will apply for warranty purposes notwithstanding any subsequent change to the Product Specifications as provided herein.
 
1.25 “Product Updates” means any updates, improvements and other modifications to the Products made by or for ENERGOUS, including,
without limitation: (a) any updates or modifications to the software (DSP code, firmware, GUI (graphical user interface) code); (b) modifications of
silicon, including, without limitation; such modifications made solely for cost reduction purposes, and including only metal layer as well as all layer
mask changes; (c) modifications which increase the distance over which wireless power is transmitted or received, subject to the limitations set out
in Exhibit A; (d) modifications which increase the amount of power which is transmitted or received; (e) modifications to improve functionality or
efficiency or add or improve features; and (f) modifications required to attain regulatory approvals, including, but not limited to, FCC approval;
provided, however, that “Product Updates” will only include any of the foregoing developed by an acquirer or successor of ENERGOUS for a
period of [***] after a Change of Control of ENERGOUS, and provided further that any Products incorporating Product Updates will be subject to
separate terms and conditions to be agreed in good faith by the Parties, which terms and conditions will be no less favourable to DIALOG than
those with respect to the Product to which the Product Update corresponds.
 
1.26 “Sale,” “Sell” or “Sold” mean the sale, transfer, exchange or other disposition of Products, by DIALOG or any of its Affiliates to any
customer or other third party, directly or indirectly through one or more tiers of distribution, for consideration that is recognized as revenue by
DIALOG or its Affiliates according to applicable generally accepted accounting principles.
 
1.27 “Semiconductor Supplier” means any Person, other than DIALOG or its Affiliates, which primarily, or in its ordinary course of
business, sells or distributes integrated circuits in packaged, die, multichip module or similar form.
 
* Confidential Treatment Requested
  Page 41.28 “Term” means the Initial Term and any and all Renewal Term(s) as set forth in Section 15.1 hereof.
 
1.29 “Third Party IP” means Intellectual Property Rights licensed from a third party relating to the Products.
 
1.30 “Tooling” means the physical Mask Sets, packaging fixtures, test fixtures, test programs, processes, software source code and any
other physical tooling or program source code required for the manufacture, packaging, assembly and testing of the Products.
 
1.31 “Uncoupled Power Transfer Technology” means  a family of wire-free technology  defined by the AirFuel Alliance  that provides
power to devices at a distance,  and that currently includes (i)  RF, (ii) ultrasonic transduction, and (iii) Laser power beaming.  Notwithstanding the
foregoing, the meaning of Uncoupled Power Transfer Technology excludes technology which functions primarily for data transmission or direct-
current-to-direct-current (DC-to-DC) power conversion.
 
2. LICENSE.
 
2.1 License Grant. Subject to the restrictions set out in Section 2.2, ENERGOUS hereby grants to DIALOG a non-exclusive (subject to
Section 2.5), irrevocable, worldwide, sub-licensable (solely in accordance with Section 2.4), royalty-bearing license during the Term under all
Product IP to:
 
(a) repackage or have repackaged the Product Die into various package formats or layouts, and to integrate the Product Die into
MCMs, which may incorporate DIALOG or third party intellectual property (such repackaged Product Die, MCMs and Products, are individually
and/or collectively referred to as the “ Licensed Products”);
 
(b) have the Licensed Products manufactured, tested and packaged by Manufacturing Subcontractors;
 
(c) Sell, offer for Sale, import, export and support the Licensed Products, including without limitation, providing system design,
troubleshooting and failure analysis support for DIALOG’s customers and their customers;
 
(d) use and modify the Tooling and Documentation for the purposes of paragraphs (a) to (d) of this Section 2.1.
 
2.2 Excluded Applications. Until the earlier of (i) termination of ENERGOUS’ exclusivity obligations to the Key Customer set forth in Exhibit
F (the “ Key Customer”) existing as of the Effective Date with respect to the following applications, or (ii) [***] that incorporates ENERGOUS
wireless charging technology, or (iii) [***] and subject to the exceptions set out in Section 2.3, DIALOG will not be permitted to Sell Licensed
Products for use in the following applications (the “ Excluded Applications”):
 
(a) [***];
 
* Confidential Treatment Requested
  Page 5(b) [***];
 
(c) [***];
 
(d) [***]; and
 
(e) [***] designed for use with any of the applications in paragraphs (a) to (d) of this Section 2.2.
 
For the avoidance of doubt, DIALOG will be permitted to Sell Licensed Products for use in any or all of the Excluded Applications (A) at any time
on or after [***] or, if earlier, (B) [***] that incorporates ENERGOUS wireless charging technology, or (C) upon the termination of ENERGOUS’
exclusivity obligations to the  Key Customer existing as of the Effective Date with respect to the above applications.
 
2.3 Exceptions to Excluded Applications . The following applications are exceptions to and excluded from the Excluded Applications (the
“Permitted Applications”):
 
(a) [***];
 
(b) [***];
 
(c) [***];
 
(d) [***];
 
(e) [***];
 
(f) [***];
 
(g) [***];
 
(h) [***];
 
(i) [***]; and
 
(j) [***].
 
The fact that a [***] has [***] does not automatically preclude such device from falling under paragraphs (b), (c) and (d) of this Section 2.3
 
2.4 Sublicenses. DIALOG may sublicense the foregoing license rights to any of its Affiliates. DIALOG will be responsible for the
observance and performance by all such Affiliates of all of DIALOG’s obligations pursuant to this Agreement. DIALOG may sublicense the
foregoing license rights to Manufacturing Subcontractors solely to the extent necessary and appropriate for them to manufacture, assemble, test
and provide support for the Products. DIALOG may not sublicense the foregoing license rights to any other third party without ENERGOUS’ prior
written consent.
 
* Confidential Treatment Requested
  Page 62.5 Exclusivity.
 
(a) Subject to paragraph (b) of this Section 2.5, ENERGOUS will not, and will not enable any Semiconductor Supplier, to
manufacture, have manufactured, offer for sale, sell, import or export the Products or Product Die in commercial volumes, except a Semiconductor
Supplier to the Key Customer for use in the Excluded Applications.
 
(b) ENERGOUS will use its diligent, good faith efforts to promote DIALOG as the preferred supplier of Products and Product Die.
However, ENERGOUS is allowed to engage with a Semiconductor Supplier to supply comparable products or product die to a customer if either (i)
the customer which has not been engaged with DIALOG with respect to such product or product die notifies ENERGOUS or DIALOG in writing by
an authorized officer of the customer that it does not want to use DIALOG or a DIALOG Affiliate as a supplier of such product or product die; or (ii)
if DIALOG has been engaged with the customer, the customer notifies ENERGOUS or DIALOG in writing prior to commencement of the Design-In
Phase that it does not want to use DIALOG or a DIALOG Affiliate as a supplier of such product or product die. For clarity, ENERGOUS shall not
intentionally supply Products, Product Die or comparable products or product die to customers directly or through distribution channels.
 
2.6 Branding.
 
(a) Products Sold by DIALOG or its Affiliates may be branded as DIALOG products. All sales and marketing collateral, software
tools and material for promotional activities relating to the Products will utilize ENERGOUS branding in a prominent basis as an equivalent partner
with respect to such Products.
 
(b) To the extent the parties engage in any co-branding activities, then, subject to the terms and conditions of this Agreement and
during the Term, each party (in such capacity, “ Licensor”) hereby grants to the other party (in such capacity, “ Licensee”) a non-exclusive, non-
transferable, worldwide right and license (without the right to sublicense), under Licensor’s Intellectual Property Rights in Licensor’s Marks, to use
those Marks of Licensor set forth in  Exhibit D solely in connection with the marketing, sale and distribution of such co-branded Products in
accordance with this Agreement.
 
(c) Use of Licensor’s Marks will be subject to the following terms and conditions: (i) all goodwill generated by use of Licensor’s
Marks by Licensee will inure to the benefit of Licensor; (ii) Licensee will use Licensor’s Marks only in such forms and with such graphics as
authorized by Licensor; and (iii) Licensee will identify Licensor’s Marks as being owned by Licensor and will (A) cause the symbol “®” to appear
adjacent to and slightly above any registered Licensor Mark, or (B) alternatively, for any Licensor Marks that are not registered, the symbol “TM”
or “SM”, as applicable.
 
2.7 No Other Rights . Except for the rights and licenses expressly granted in this Agreement, no other right is granted, no other use is
permitted and all other rights are expressly reserved.
 
  Page 73. SOURCING.
 
3.1 Product Manufacture . Concurrent with or before execution of this Agreement, and substantially in the form attached as Exhibit C,
ENERGOUS will provide written authorization to its Manufacturing Subcontractors to confirm DIALOG’s and, if applicable, DIALOG’s Affiliates’
rights to procure the Licensed Products and related services directly from such Manufacturing Subcontractors utilizing ENERGOUS’ Tooling and
any associated manufacturing resources. DIALOG and its sublicensed Affiliates may directly contract with the Manufacturing Subcontractors for
the manufacture and supply of Licensed Products under terms and conditions that DIALOG or such Affiliates may directly negotiate with such
third parties.
 
3.2 Additional Manufacturing Subcontractors . DIALOG at its sole discretion may qualify and establish an alternative source to some or all
of ENERGOUS’ Manufacturing Subcontractors for the manufacturing of the Licensed Products and ENERGOUS will provide its written
authorization thereof if requested by DIALOG.
 
3.3  Tooling. Subject to ENERGOUS’ rights in the Product IP and any Third Party IP (including, without limitation, that of any
Manufacturing Subcontractors), each party will own all right, title and interest in the physical Tooling procured or generated by that party for the
manufacturing, testing and packaging of the Licensed Products. For the avoidance of doubt, as between the parties, ENERGOUS will also continue
to own all right, title and interest in and to the firmware, DSP code and GUI software embedded in the Products, including all Intellectual Property
Rights embodied therein. Upon the termination of DIALOG’s right to manufacture the Licensed Products following any expiration or termination of
the Agreement or any Wind Down Period or Continuing Obligation period, as applicable, then all right, title and interest in the Tooling will
automatically transfer to ENERGOUS subject to any Third Party IP, and DIALOG will, at ENERGOUS’ option, either sell any Tooling in its
possession to ENERGOUS at cost or destroy the Tooling and certify in writing as to same.
 
4. PRODUCT COMMERCIALIZATION.
 
4.1 Commercialization Plan.
 
(a) Exhibit E hereto sets out the plan for the commercialization of the Licensed Products (the “ Commercialization Plan”). The
Commercialization Plan sets forth the parties’ respective rights and obligations with respect to commercial and technical activities to be performed
to maximize potential Sales of Licensed Products. The Commercialization Plan will be reviewed and (if necessary) updated by the parties on a
quarterly basis during the Term.
 
(b) Each party will appoint (and notify the other party of the name of) a member of their management team who will serve as that
party’s primary contact for all matters related to this Agreement (each, a “ Liaison”), including resolution of issues that may arise under this
Agreement. Each party may replace its Liaison at any time by notice in writing to the other party.
 
(c) The Commercialization Plan includes a go-to-market plan. ENERGOUS will provide commercially reasonable sales training,
material and support to DIALOG’s global application, sales and marketing teams and customers, including the support set out in Section 4.3.
 
  Page 8(d) ENERGOUS will also support DIALOG with an operations and quality plan, which will set forth information relating to quality
matters, including, but not limited to, testing, yield management, RMA process, failure analysis/corrective action procedure, ECN/PCN process and
detailed agreement on mutual rights and responsibilities with respect to any quality issues or warranty claims (hereinafter “ Quality Plan”). Both
parties will work in good faith to finalize and implement the Quality Plan within 90 days after the Effective Date of this Agreement. DIALOG will be
responsible for its own frontline quality function and corrective actions, with technical input from ENERGOUS as required.
 
(e) The parties may promote the relationship with marketing initiatives and also agree to engage in joint marketing communication
activities related to the relationship described in this Agreement or to the promotion of the Licensed Products, as set forth in the Commercialization
Plan or otherwise mutually agreed between the parties from time to time.
 
4.2 Commercialization Meetings. The parties will meet regularly, but at least once each month during the Term, either in person or by
telephone, video or internet conference call, to share technical and commercial information as reasonably required to facilitate the parties’ exercise
of their respective rights and performance of their respective obligations under this Agreement. The information shared by the parties will include,
but is not limited to (a) market and competitive dynamic updates, (b) activities and progress updates at DIALOG’s customers, (c) technical review
and feedback from customers, (d) non-binding 12 month rolling Sales and Royalty and Service Fee forecasts for the Licensed Products, (e)
initiatives to boost sales potential for the Licensed Products. Customer information shared will be within the limits allowed by any non-disclosure
agreements DIALOG may have entered into with such customers.
 
4.3 Technical Support. ENERGOUS will support DIALOG’s or its Affiliates’ engineers and, in some cases and at DIALOG’s request, the
customer directly in providing standard design-in support (including antenna design support) for customers’ products. If the customer requires
unique or custom engineering services (i.e., support and services not limited to those with general application to Product customers), then
ENERGOUS will contract directly with such customer for the provision of such services. ENERGOUS will provide DIALOG with any and all
information that is necessary or useful to support its authorized manufacture, testing, marketing, Sale, troubleshooting, compatibility analysis,
performance tuning, failure analysis, and other support of the Licensed Products, including the Documentation and any updates thereto or
revisions thereof which are reasonably necessary or appropriate to provide technical support for the Products to DIALOG customers. ENERGOUS
receives the Service Fee for providing the support described in this Section 4.3 to DIALOG and its customers during the Term. In the event the
Technical Support provided by ENERGOUS falls below a mutually-agreed upon service level that is common to the semiconductor industry or
reasonably requested by DIALOG’s customers, and after failure by ENERGOUS to address such deficiency within a twenty (20) day notice period,
DIALOG may suspend the payment of Service Fees until such service level is provided. Furthermore, in the event ENERGOUS fails to meet its
obligations as set forth in the Quality Plan, and after failure by ENERGOUS to address such deficiency within a thirty (30) day notice period,
DIALOG may suspend the payment of Service Fees until such obligations are met.
 
  Page 95. PRODUCT DEVELOPMENT AND PRODUCT UPDATES.
 
ENERGOUS will have control and authority over the design and development of the Products, including without limitation, developing
and implementing all Product Updates. ENERGOUS reserves the right to implement Product Updates at any time in its sole discretion. The parties
will consult each other on the perceived product needs of the market and DIALOG’s customers and how best to respond to such needs. DIALOG
may suggest Product Updates to ENERGOUS provided, but all the development of Product Updates will be at ENERGOUS’ sole discretion.
ENERGOUS will share its relevant product roadmaps from time to time to maximize collaboration opportunities.
 
6. INTELLECTUAL PROPERTY OWNERSHIP.
 
6.1 Product IP. ENERGOUS retains right, title and interest in and to the Product IP, ENERGOUS’ Marks and ENERGOUS’ Confidential
Information, including all Intellectual Property Rights embodied therein. No transfer or grant is made hereunder by ENERGOUS of any of these
rights or any of its other rights, whether by implication, estoppel or otherwise, other than the limited rights and licenses expressly granted by
ENERGOUS in this Agreement, and all such other rights are hereby reserved.
 
6.2 DIALOG Intellectual Property . DIALOG retains rights, title and interest in and to DIALOG’s Marks and DIALOG’s Confidential
Information, including all Intellectual Property Rights embodied therein. No transfer or grant is made hereunder by DIALOG of any of these rights
or any of its other rights, whether by implication, estoppel or otherwise, other than the limited rights and licenses expressly granted by DIALOG in
this Agreement and all such other rights are hereby reserved.
 
7. PRODUCT SALES.
 
7.1 Sales. Subject to the terms and conditions of this Agreement, and except as set forth in the Commercialization Plan or otherwise agreed
in writing between the parties, DIALOG will market and Sell the Licensed Products as authorized under this Agreement. DIALOG will independently
manage and process its own forecasting, operations and order management.
 
7.2 Discontinuation of Sale of Products . If DIALOG decides to discontinue Sales of any Product, it will notify ENERGOUS at least  [***]
prior to such discontinuance, and following such notification, the exclusivity rights, if any, associated with that Product will cease; provided,
however, this provision will not apply in the event that DIALOG continues Sales of Product Updates, repackaged Product Dies or MCMs.
 
7.3 Supply of Products to ENERGOUS. DIALOG will provide 1000 samples of each Product free of charge to ENERGOUS for the purposes of
evaluation and demonstration. For additional volumes required by ENERGOUS, DIALOG will sell to ENERGOUS on a reasonable cost plus basis for
the purposes of evaluation and demonstration. These samples are provided as is, are not intended for resale by ENERGOUS, and no
indemnification or other warranties from DIALOG will apply.
 
* Confidential Treatment Requested
  Page 108. OTHER PRODUCTS.
 
8.1 New Products. In the event that ENERGOUS develops New Product, ENERGOUS will provide DIALOG with written notice describing
the New Product before marketing, selling or distributing the New Product with or to any third party. Upon receipt of such notice, DIALOG will
have [***] to notify ENERGOUS in writing that it desires to add such New Product as Product under this Agreement. If DIALOG provides such a
notice, for a period of [***] following ENERGOUS’ receipt of such notice, ENERGOUS and DIALOG will negotiate in good faith the terms pursuant
to which such New Product will be added as a Product to this Agreement. ENERGOUS may not negotiate with any third party the rights to market,
sell or distribute any New Product until the earliest to occur of the following (a) DIALOG does not provide ENERGOUS with notice that it desires to
add such New Product to this Agreement within the above-described [***] period, (b) ENERGOUS and DIALOG do not reach mutually agreeable
terms for adding such New Product to this Agreement during the [***] negotiation period or (c) DIALOG provides ENERGOUS with written notice
that it does not wish to negotiate with respect to such New Product. For clarity, after any of the events described in the foregoing subsections (a),
(b) or (c) occurs, the New Product will not be covered under this Agreement, and ENERGOUS will be free to manufacture, market, sell, distribute and
otherwise exploit such New Product as it deems fit in its sole discretion, including in collaboration with or through one or more third parties.
 
8.2 No Competing Products.
 
(a) Until expiration or earlier termination of the Agreement, DIALOG agrees that it and its Affiliates will not, without ENERGOUS’
written approval, intentionally sell, distribute or work with any third party to develop products incorporating any Uncoupled Power Transfer
Technology other than Licensed Products; provided, however, that DIALOG shall not be under any such restrictions in relation to services or
products it provides to the Key Customer in the event the Key Customer terminates its agreement with ENERGOUS.
 
(b) In the event that ENERGOUS does not receive Federal Communications Commission approval of any Licensed Product for
power transmission [***] by the [***], (i) ENERGOUS may provide written notice to DIALOG which references this Section 8.2(b) and indicates
ENERGOUS’ intention to enable one or more Semiconductor Suppliers to supply Products for [***]; and (ii) DIALOG may provide written notice to
ENERGOUS which references this Section 8.2(b) and indicates DIALOG’s intention to sell, distribute or work with one or more third parties to
develop products incorporating Uncoupled Power Transfer Technology for [***]. [***] following the date such notice is given pursuant to Section
20.1, the restrictions in Section 8.2(a) shall no longer apply to DIALOG for Uncoupled Power Transfer Technology in [***] and the restrictions
relating to enabling a Semiconductor Supplier in Section 2.5(a) shall no longer apply to ENERGOUS for Products or Product Die in [***].
 
(c) In the event that ENERGOUS does not receive Federal Communications Commission approval of any Licensed Product for
power transmission in [***] by the [***], (i) ENERGOUS may provide written notice to DIALOG which references this Section 8.2(c) and indicates
ENERGOUS’ intention to enable one or more Semiconductor Suppliers to supply Products for [***]; and (ii) DIALOG may provide written notice to
ENERGOUS which references this Section 8.2(c) and indicates DIALOG’s intention to sell, distribute or work with one or more third parties to
develop products incorporating Uncoupled Power Transfer Technology for [***]. [***] following the date such notice is given pursuant to Section
20.1, the restrictions in Section 8.2(a) shall no longer apply to DIALOG for Uncoupled Power Transfer Technology in  [***] and the restrictions
relating to enabling a Semiconductor Supplier in Section 2.5(a) shall no longer apply to ENERGOUS for Products or Product Die in [***].
 
* Confidential Treatment Requested
  Page 119. ROYALTIES AND SERVICE FEES.
 
9.1 Royalties. DIALOG will pay ENERGOUS the Royalties set forth in  Exhibit B. For clarity, DIALOG will be responsible for paying to
ENERGOUS any Royalties payable hereunder as a result of its Affiliates’ Licensed Product Sales.
 
9.2 Service Fee. Subject to Section 4.3, DIALOG will pay ENERGOUS the Service Fees set forth in Exhibit B. For clarity, subject to Section
4.3, DIALOG will be responsible for paying to ENERGOUS any Service Fees payable hereunder for services provided by ENERGOUS hereunder to
DIALOG’s Affiliates or any of DIALOG’s or its Affiliates’ customers.
 
9.3 Payment. Payments of Royalties and Service Fees will be due on a calendar quarterly basis, within [***] days after the end of the
calendar quarter in which the applicable Licensed Products were Sold or services were rendered. From the date a payment is due, unless otherwise
agreed, any late payment will accrue a late payment fee of [***] per month, or the highest interest rate permitted by law, whichever is less.
 
9.4 Reports. Each payment made hereunder will be accompanied by a report detailing (a) the total number of units, on a product-by-
product basis, of the Licensed Products Sold during the previous calendar quarter, (b) DIALOG’s and its Affiliates’ Net Sales attributable to such
Licensed Product units during such calendar quarter, and (c) reasonable details regarding the calculation of the quarterly Royalty payment and
Service Fee. Such information will be maintained in strict confidence by ENERGOUS under Section 10 of this Agreement.
 
9.5 Books. With respect to its exercise of the rights and licenses granted in, and payment obligations under, this Agreement, DIALOG and
its Affiliates will keep accurate books and other records, including but not limited to supporting documentation for the Royalties and Service Fees
paid hereunder (the “ Records”). These Records will be maintained for a period of at least three (3) years from the date of the related payment
(“Record Retention Period”), notwithstanding any termination of expiration of this Agreement.
 
9.6 Audit Rights. During the Record Retention Period, ENERGOUS may appoint a mutually agreed independent, internationally recognized
third-party certified auditor who will have the right to inspect and copy the Records upon reasonable prior notice, and DIALOG will (and will cause
its Affiliates to) allow necessary access including, as applicable, to its premises where such Records are located. ENERGOUS may exercise such
right to this independent-third party audit no more than one time per calendar year and each such audit will be conducted during normal business
hours. Such audit may also not interfere with DIALOG’s or its Affliates’ quarterly closing of its books. In the event that such audit reveals an
underpayment of Royalties or Service Fees owed by DIALOG, DIALOG will promptly pay ENERGOUS the amount of the underpayment. If such
underpayment is in excess of [***] of the Royalties or Service Fee due for the period audited, DIALOG will also reimburse ENERGOUS for its
reasonable, out-of-pocket cost of such audit. In the event that such audit reveals an overpayment of Royalties or Service Fees owed by DIALOG,
ENERGOUS will promptly pay DIALOG the amount of the overpayment.
 
* Confidential Treatment Requested
  Page 129.7 Taxes. Each party will be responsible to collect, bear and pay any and all taxes levied or based upon the party’s sale of the Products,
Product Die or Licensed Products, including, all sales, use, value added, withholding or similar taxes. In the event that the government of a country
imposes any income taxes on payments made by a party to the other hereunder and requires a party to withhold such tax from such payments, such
party may deduct such tax from such payments. Each party will be responsible for its own banking costs relating to the receipt of payments of
Royalties and Service Fees and any other monies payable to it in connection with this Agreement.
 
9.8 Payment Currency. All payments due under this Agreement will be payable in U.S. Dollars. With respect to Net Sales invoiced in a
currency other than U.S. Dollars, the Net Sales will be expressed in the domestic currency of the entity making the Sale, together with the U.S.
Dollar equivalent, calculated using the conversion rate existing in the United States (as reported in the Wall Street Journal) on the last working day
of each month of the calendar quarter in which the Net Sales were made. Such payments will be without deduction of exchange, collection or other
charges.
 
10. CONFIDENTIALITY.
 
10.1 Scope. The term “Confidential Information” means all financial, business and technical information disclosed by or on behalf of a
party in relation to this Agreement (whether tangible or intangible, and including all copies, analyses and derivatives thereof), that is marked or
otherwise identified as proprietary or confidential at the time of disclosure, or which by its nature would be understood by a reasonable person to
be proprietary or confidential, including all copies, abstracts, summaries, analyses and derivatives thereof. Confidential Information does not
include information the receiving party can demonstrate (a) was rightfully furnished to it without restriction by a third party without breach of any
obligation to the disclosing party, (b) is generally available to the public without breach of this Agreement, (c) was available to or already in the
possession or control of the receiving party on a non-confidential basis before receipt from the disclosing party or (d) is independently developed
by it or its employees without reliance on such information. Information associated with DIALOG’s quarterly Royalty or Service Fee disclosures is
Confidential Information of DIALOG.
 
10.2 Non-Disclosure. The receiving party agrees (a) not to copy or use the disclosing party’s Confidential Information except and only for
the purposes contemplated by this Agreement, (b) to maintain it as confidential, and exercise reasonable precautions to prevent unauthorized
access, use and disclosure, (c) not to disclose it to any third party other than the receiving party’s employees and contractors who have a need to
know for the permitted purpose and who are bound by obligations that are at least as protective as the restrictions in this Agreement and (d) not to
export or re-export in violation of U.S. or other export control laws or regulations any such Confidential Information or product thereof. Each party
will bear the responsibility for any breach of this Section 10 by its and its Affiliates’ employees and contractors. Upon any termination of this
Agreement or, in the event of any Wind Down Period or Continuing Obligation period, upon the expiration of such period, and within fifteen (15)
days after request by the disclosing party, each receiving party will return the Confidential Information of the other or destroy such Confidential
Information and all copies of it and all information, records and materials developed therefrom, except that the recipient may retain one copy for
archival purposes to ensure compliance with the provisions of this Agreement, and nothing contained herein will require the erasure, deletion,
alteration or destruction of any Confidential Information required to be retained for legal or regulatory purposes or stored on back-up tapes or other
back-up media or archiving systems made in the ordinary course of business, subject in each case to the confidentiality obligations set forth herein.
Each party may only disclose the general nature, but not the specific terms, of this Agreement without the prior consent of the other party;
provided, however, either party may provide a copy of this Agreement or otherwise disclose its terms on a confidential basis in connection with
any legal or regulatory requirement, financing transaction or due diligence inquiry. For clarity, in the event that use, disclosure or retention of any
Confidential Information is required in order for DIALOG to exercise the license granted in Section 2, this Section 10 will not be deemed to prevent
such use, disclosure or retention.
 
  Page 1310.3 Required Disclosure. Nothing herein will prevent a receiving party from disclosing all or part of the other’s Confidential Information as
necessary pursuant to court order, the lawful requirement of a governmental agency or when disclosure is required by operation of law (including
disclosures pursuant to applicable securities laws or regulations thereunder); provided, that prior to any such disclosure, the receiving party will
use reasonable efforts to (a) promptly notify the disclosing party in writing of such requirement to disclose, and (b) cooperate fully with the
disclosing party in protecting against or minimizing any such disclosure or obtaining a protective order.
 
11. REPRESENTATIONS AND WARRANTIES; DISCLAIMERS.
 
11.1 Mutual Representations and Warranties . ENERGOUS and DIALOG hereby each represent and warrant to the other that as of the
Effective Date:
 
(a) it is a duly and validly organized and existing corporation in good standing under the laws of the state or country of its
incorporation, as applicable, and that it is legally qualified to do business in each jurisdiction in which this Agreement may be performed and the
performance of its activities hereunder requires such qualification;
 
(b) the performance of this Agreement and the consummation of the transactions contemplated herein will not result in any
breach or violation of any terms or provisions of, or constitute a default under, its certificate of incorporation or by-laws or other organizational
documents, or any material agreement or instrument to which it is a party, by which it is bound, or to which any of its property is subject;
 
(c) all requisite corporate action has been taken for the due authorization, execution, delivery and performance of this Agreement
by it, and this Agreement constitutes a legally binding obligation, enforceable against such party in accordance with its terms, except insofar as
enforceability may be limited by bankruptcy, insolvency, reorganization or similar laws affecting the rights of creditors generally; and
 
  Page 14(d) it is not a party to any litigation relating to, or that could reasonably be expected to affect, its ability to perform its obligations
under this Agreement.
 
11.2 Product Warranty.
 
(a) ENERGOUS warrants that (i) when manufactured in accordance with the Approved Production Specifications, and as
implemented in a suitable circuit application in accordance with the Product Specifications, the Products and Product Die will conform to the
Product Specifications and will be free from defects that could have been avoided in their design; (ii) the Products, any constituent parts or
functionality thereof, the Documentation and the Deposit Materials do not infringe any third party’s Intellectual Property Rights; (iii) it did not
misappropriate any third party’s trade secrets in the development of the Products, any constituent parts or functionality thereof, the
Documentation or the Deposit Materials; and (iv) when delivered (including any software updates if any), no Product will contain any viruses,
“Trojan horses” or other harmful code. The above warranties are valid for a period of  [***] from the date of shipment of any Licensed Product to
any customer.
 
(b) The warranty contained in Section 11.2(a) does not apply to the extent any Product is operated in a manner other than that
specified by the Product Specifications, is treated with abuse, negligence or other improper treatment (including, without limitation, use outside the
device maximum ratings, package MSL (moisture sensitivity level) guidelines or environmental limits as may be set forth in the Product
Specifications), or is defective as a result of any materials or workmanship of the Manufacturing Subcontractors or failure of the Manufacturing
Subcontractors to manufacture the Product according to Approved Production Specifications. As such, any warranty claims due to defects in
build, materials or workmanship will be directed to the Manufacturing Subcontractors as part of that contract between DIALOG or, if applicable, its
Affiliate and such parties.
 
(c) With the exception of the warranties in Section 11.2(a)(ii) (third party IP infringement) and Section 11.2(a)(iii) (misappropriation
of third party trade secrets) related to any Product Die, the warranties in this Section 11.2 do not apply to MCMs or repackaged Product Die
developed by or for DIALOG or its Affiliates.
 
(d) In the event any warranty claim is due to or arises from an Epidemic Defect, ENERGOUS will be responsible for all costs and
expenses directly incurred by DIALOG or its Affiliates or their respective customers as a result of reasonable inspection, servicing, repairs,
replacements, recall notices, recalls and responses with respect thereto, provided that ENERGOUS’ aggregate liability to DIALOG and its Affiliates
and their respective customers under this paragraph (d) will not exceed [***] per occurrence of an Epidemic Defect. Each party will immediately
notify the other upon becoming aware of the circumstance that could reasonably be construed to be an indication of an Epidemic Defect, and, in
any event, will notify the other party immediately upon becoming aware of the existence of an Epidemic Defect. ENERGOUS and DIALOG will
expeditiously work together in good faith to determine a technical resolution of the Epidemic Failure. ENERGOUS agrees to make all commercially
reasonable efforts to promptly diagnose the Epidemic Failure’s root cause, provide DIALOG a report detailing the results of ENERGOUS’
investigation and plan an effective workaround and a permanent solution. ENERGOUS will consult with DIALOG on any proposed workarounds
and other solutions.
 
* Confidential Treatment Requested
  Page 1511.3 Infringement of Intellectual Property Rights . If any of the Products, Product Die, Documentation or Deposit Materials is, or in
ENERGOUS’ or DIALOG’s opinion is likely to become, the subject of an Intellectual Property Rights infringement claim, and as a result DIALOG or
any of its Affiliates or their respective customers are enjoined, or in ENERGOUS’ or DIALOG’s opinion are likely to be enjoined, from using the
Products, Product Die, Documentation or Deposit Materials, ENERGOUS will use its best efforts to:
 
(a) procure for DIALOG and its Affiliates and their respective customers the right to continue to use the Products, Product Die,
Documentation or Deposit Materials, as applicable; or, but only in the event that, despite ENERGOUS’ best efforts to do so, ENERGOUS is unable
to so procure such right,
 
(b) replace or modify the Products, Product Die, Documentation or Deposit Materials, as applicable, to make them non-infringing,
provided that the replaced or modified Products, Product Die, Documentation and Deposit Materials remain substantially similar in performance to
the infringing Products, Product Die, Documentation and Deposit Materials.
 
If none of the foregoing alternatives is available within a commercially reasonable time period, DIALOG may terminate this Agreement with
immediate effect, provided that it will give ENERGOUS prompt prior written notice thereof. Nothing in this Section 11.3 is intended to limit
DIALOG’s rights to indemnification under Section 12 in connection with any such infringement claim.
 
11.4  Disclaimer. EXCEPT AS EXPRESSLY SET FORTH IN THIS SECTION 11, THE PRODUCTS, THE PRODUCT IP, TOOLING,
DOCUMENTATION, DEPOSIT MATERIALS, CONFIDENTIAL INFORMATION AND ALL LICENSES, SERVICES AND OTHER ITEMS PROVIDED
BY A PARTY TO THE OTHER PARTY HEREUNDER ARE PROVIDED “AS IS”, WITHOUT WARRANTY OF ANY KIND. EXCEPT FOR THOSE
WARRANTIES EXPRESSLY PROVIDED HEREIN, EACH PARTY SPECIFICALLY DISCLAIMS ALL WARRANTIES, WHETHER ORAL OR
WRITTEN, EXPRESS, IMPLIED, STATUTORY OR OTHERWISE, WITH RESPECT TO ANY SUBJECT MATTER OF THIS AGREEMENT,
INCLUDING, WITHOUT LIMITATION, ALL WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE AND ALL
WARRANTIES ARISING FROM COURSE OF PERFORMANCE, COURSE OF DEALING OR USAGE IN TRADE.
 
12. INDEMNIFICATION.
 
12.1 Indemnification by Energous . Subject to Section 12.2, ENERGOUS agrees to indemnify, hold harmless and, in the case of any third
party claims, defend DIALOG and its Affiliates and each of their respective directors, officers, employees, contractors, agents, distributors and
customers (collectively, “DIALOG Indemnitees”) from and against and in respect of any and all alleged or actual demands, claims, actions, causes
of action, suits or proceedings, assessments, awarded damages (including punitive damages), liabilities, interest and penalties, costs and expenses
(including, without limitation, court costs and reasonable legal fees and disbursements in connection therewith) (each, a “ Claim”) to the extent
resulting from, arising out of, relating to, or imposed upon or incurred by any DIALOG Indemnitees by reason of (a) death or bodily injury caused
by or resulting from use of the Products, (b) any breach of any representation or warranty made by ENERGOUS hereunder or to any third party in
relation to the Products or Product Die, (c) the infringement or misappropriation of any third party Intellectual Property Rights in relation to the
Products or Product Die, (d) the infringement or misappropriation of any third party Intellectual Property Rights as a result of DIALOG’s or its
Affiliates’ exercise of rights in accordance with the terms of this Agreement, including, but not limited to, the Manufacturing Subcontractors’
manufacture of the Products on their behalf, provided that the Products are manufactured in strict compliance with the Product Specifications and
Approved Production Specifications and only to the extent such Claims arise due to compliance with the Product Specifications and/or the
Approved Production Specifications or use of the Tooling provided by ENERGOUS hereunder, (e) the infringement by DIALOG of any third party
Marks rights as a result of its authorized use of the ENERGOUS Marks, (f) any failure by ENERGOUS to comply with applicable laws, regulations
and standards, or (g) ENERGOUS’ negligence, intentional misconduct or fraud.
 
  Page 1612.2 Exclusion. Notwithstanding the provisions of Section 12.1, ENERGOUS will not be liable to the extent any Claim results from (a)
modification of the Products by DIALOG, its Affiliates and/or any third party (including the Manufacturing Subcontractors), or combination of the
Products with other products, offered by DIALOG, its Affiliates and/or any third party, (b) acts or omissions of any Manufacturing Subcontractor
(except to the extent such Claims are due to the infringement or misappropriation of third party Intellectual Property Rights arising from such
Manufacturing Subcontractor’s manufacturing of the Products on behalf of DIALOG in strict compliance with the Product Specifications,
Approved Production Specifications and Tooling provided by ENERGOUS), (c) failure of any DIALOG Indemnitee to comply with applicable laws,
regulations and standards, or (d) negligence, intentional misconduct or fraud of any DIALOG Indemnitee. For clarification, if any of the foregoing is
not the cause, in whole or in part of the Claim, ENERGOUS is not relieved of its obligations under Section 12.1.
 
12.3 Conditions. DIALOG must notify ENERGOUS within thirty (30) business days after receipt of actual notice of any Claim by a third
party for which it seeks indemnification; provided, however, any failure or delay in notice will not relieve ENERGOUS of its obligations hereunder
except to the extent that ENERGOUS is actually prejudiced by such failure to notify. ENERGOUS will have control and authority with respect to the
defense, litigation, compromise or settlement of such third party Claim (except to the extent that any settlement involves any commitments,
responsibilities or obligations on the part of DIALOG, in which case such settlement will require the prior written consent of DIALOG, which
consent will not be unreasonably delayed, conditioned or withheld). DIALOG will cooperate and provide assistance and information as may
reasonably be required by ENERGOUS (but at ENERGOUS’ expense) in connection therewith. DIALOG reserves the right to participate at its own
cost in any third party proceedings with counsel of its own choosing. In the event that ENERGOUS does not respond to any third party Claim or
does not sufficiently defend such third party Claim, DIALOG, acting reasonably, may step in and take over the defense of such Claim. Costs
incurred in the settlement of any Claim, including, but not limited to, reasonable legal expenses, may be off set against future Royalties and Service
Fees payable.
 
  Page 1712.4 Insurance. Each party will maintain, during the Term and for three (3) years thereafter, such comprehensive general liability insurance
(including without limitation, products liability) as will adequately protect it against its potential liabilities under this Agreement, in amounts
customary in the semiconductor industry for similar services and products. Each party will, at the other party’s request, provide to the other party a
certificate of insurance evidencing the foregoing insurance coverage.
 
13. LIMITATION OF LIABILITY.
 
13.1 EXCEPT IN THE CASE OF (a) ANY BREACH OF SECTION 10 (CONFIDENTIALITY), (b) THE PARTIES’ OBLIGATIONS UNDER
SECTION 12 (INDEMNIFICATION), (c) A PARTY’S GROSS NEGLIGENCE OR WILLFUL MISCONDUCT, OR (d) LIABILITY ARISING FROM
EPIDEMIC DEFECTS (WHICH WILL BE SUBJECT TO THE LIMITATION SET FORTH IN SECTION 11.2(d)), IN NO EVENT WILL EITHER PARTY
BE LIABLE UNDER THIS AGREEMENT, REGARDLESS OF THE FORM OF ANY CLAIM OR ACTION (WHETHER IN CONTRACT, NEGLIGENCE,
STRICT LIABILITY OR OTHERWISE), FOR ANY (i) INDIRECT, PUNITIVE, INCIDENTAL, RELIANCE, SPECIAL, EXEMPLARY OR
CONSEQUENTIAL DAMAGES, INCLUDING, BUT NOT LIMITED TO, LOSS OF BUSINESS, REVENUES, PROFITS OR GOODWILL, OR (ii)
AGGREGATE DAMAGES IN EXCESS OF [***]. IN ADDITION, ENERGOUS’ LIABILITY WITH RESPECT TO ITS OBLIGATIONS UNDER
SECTION 12.1(b) SHALL IN NO EVENT EXCEED [***]. THESE LIMITATIONS ARE INDEPENDENT FROM ALL OTHER PROVISIONS OF THIS
AGREEMENT AND WILL APPLY NOTWITHSTANDING THE FAILURE OF ANY REMEDY PROVIDED HEREIN.
 
14. COMPLIANCE WITH LAWS.
 
Each party will comply with all law and regulations applicable such party’s performance under this Agreement, including but not limited to
U.S. Export Administration laws and regulations and any other export, import and re-export control laws applicable to such party. The parties will
refrain from exporting or re-exporting the Products or Product IP or any technical data or other materials received from each other, or the direct
product of any of these, to any country, individual or organization proscribed by the United States government, unless properly authorized by the
appropriate agencies of the United States government. Each party will provide all information under its control which is necessary or useful for the
other party to ship or receive the Products, including, but not limited to, U.S. Export Control Classification Numbers (ECCNs), U.S. Customs
Certificates of Delivery, Certificates of Origin and U.S. Federal Communications Commission identifier, if applicable. Each party agrees that it will not
act in any fashion or take any action in violation of any applicable anti-bribery or anti-corruption legislation in any jurisdiction in which it does
business, which prohibits the offering, giving or promising to offer or give, directly or indirectly, money or anything of value to any official of a
government, political party or instrumentality to assist it in obtaining or retaining business, including the U.S. Foreign Corrupt Practices Act or any
comparable legislation in another country.
 
* Confidential Treatment Requested
  Page 1815. TERM AND TERMINATION.
 
15.1 Term. This Agreement is effective on the Effective Date. Unless earlier terminated as provided herein, this Agreement continues in
effect for an initial term of seven (7) years (“Initial Term”) and will automatically renew for one or more annual periods after the Initial Term (each a
“Renewal Term”) unless either party gives notice of non-renewal at least one hundred eighty (180) days prior to the beginning of any Renewal
Term.
 
15.2 Termination.
 
(a) Mutual Termination Rights. Either party may, in addition to any other remedies available to it under this Agreement or at law or
in equity, terminate this Agreement (or, in the event this Agreement has been previously terminated, the Wind Down Period, if any) immediately
upon the issuance of written notice to the other party in the event that (i) the other party materially breaches a material provision of this Agreement,
and fails to cure such breach within thirty (30) days, or (ii) the other party undergoes an Insolvency Event.
 
(b) Termination By ENERGOUS.
 
(i) If ENERGOUS is acquired by a third party, ENERGOUS’ acquirer will have the right, for a period of [***] following
closing of such acquisition, to terminate this Agreement upon written notice to DIALOG.
 
(ii) ENERGOUS will have the right to terminate this Agreement immediately upon the issuance of written notice to
DIALOG (A) if DIALOG undergoes a Change of Control involving a competitor of ENERGOUS (as reasonably determined by ENERGOUS), or (B) if
DIALOG or any of its Affiliates acquires, whether directly or indirectly through a sale of assets or a Change of Control transaction or otherwise,
any competitor of ENERGOUS. DIALOG will provide ENERGOUS with notice of any such Change of Control or acquisition within [***] after the
closing thereof and ENERGOUS’ right to terminate the Agreement will expire [***] after receipt of such notice.
 
(iii) ENERGOUS may, at any time after the third anniversary of the Effective Date, terminate this Agreement with or
without cause upon not less than one hundred and eighty (180) days prior written notice to DIALOG.
 
(iv) ENERGOUS will have the right to terminate this Agreement, upon not less than [***] prior written notice to
DIALOG, in the event that, following termination by the [***] of its agreement with ENERGOUS, DIALOG participates in or indicates its intention
to participate in the development, design or manufacture of products incorporating Uncoupled Power Transfer Technology not provided by
ENERGOUS to [***].
 
(c) Termination by DIALOG.
 
(i) If DIALOG is acquired by a third party, DIALOG’s acquirer will have the right, for a period of [***] following closing
of such acquisition, to terminate this Agreement upon written notice to ENERGOUS.
 
* Confidential Treatment Requested
  Page 19(ii) DIALOG may terminate this Agreement, immediately upon issuance of written notice to ENERGOUS in the event that:
(A) DIALOG or its Affiliates fail to achieve a design-win pipeline with an annual projected sales value to DIALOG of at least [***] in the [***] after
the availability of a Mass Production Qualified Product; or (B) the aggregate annual Net Sales of Products are below [***] by the [***] of the
availability of a Mass Production Qualified Product, or below [***] by the [***] of the availability of a Mass Production Qualified Product, or
below [***] by each [***] of the availability of a Mass Production Qualified Product during the remainder of the Term.
 
(iii) DIALOG will have the right to terminate this Agreement immediately upon the issuance of written notice to
ENERGOUS (A) if ENERGOUS undergoes a Change of Control involving a competitor of DIALOG, or (B) if ENERGOUS acquires, whether directly
through a sale of assets or through a Change of Control transaction, any competitor of DIALOG (as reasonably determined by DIALOG).
ENERGOUS will provide DIALOG with notice of any such Change of Control or acquisition within [***] after the closing thereof and DIALOG’s
right to terminate the Agreement will expire [***] after receipt of such notice.
 
15.3 Effect of Termination. Upon any termination or expiration of this Agreement, all rights, licenses (including any sublicenses granted by
DIALOG) and obligations hereunder will cease, except that the provisions of Sections 6 (Intellectual Property Ownership), 9 (Royalties and Service
Fees), 10 (Confidentiality), 11 (Representations and Warranties; Disclaimers), 12 (Indemnification), 13 (Limitation of Liability), 15.3 (Effect of
Termination), 15.4 (Wind Down Period), 16 (Escrow), 18 (Non-Solicitation), 19 (Choice of Law and Dispute Resolution) and any provisions to give
effect thereto, will survive such termination or expiration and remain in full force and effect in accordance with their terms.
 
15.4 Wind Down Period.
 
(a) Notwithstanding any statement in Section 15.3 to the contrary, upon any termination or expiration of this Agreement and until
the later to occur of (i) [***] from the Effective Date or (ii) [***] following the effective date of termination or expiration of this Agreement (the
“Wind Down Period”), the parties’ respective rights and obligations under Sections 2 (License), 3 (Sourcing), 7 (Product Sales), 9 (Royalties and
Service Fees), 11 (Representations and Warranties; Disclaimers), 12 (Indemnification), 13 (Limitation of Liability), 14 (Compliance with Laws), 15.2
(Termination), 16 (Escrow) and all Exhibits hereto which are associated with any of the foregoing listed sections will remain in full force and effect as
to (A) any Products or repackaged Product Die with respect to which DIALOG or any of its Affiliates has secured a design win at a customer prior
to or within one (1) month after the start of the Wind Down Period, or (B) the sale of any MCMs which have been released for production at a
foundry, provided, however, that DIALOG’s license rights under Section 2.1 (including any sublicenses granted by DIALOG pursuant to Section
2.4) will be non-exclusive during the Wind Down Period.
 
(b) If, at the time of notice of any termination of this Agreement, DIALOG or any of its Affiliates has a written supply contract
with a customer that extends beyond the end of the Wind Down Period (a “ Continuing Obligation”), DIALOG and/or its Affiliates may continue to
Sell Licensed Products to such customer through the term of the Wind Down Period and for the remainder of the term of such Continuing
Obligation, provided that in no event may DIALOG or its Affiliates Sell Licensed Products to such customer pursuant to this Section 15.4(b) for a
period longer than [***] after the effective date of termination of this Agreement. In such event, the provisions of this Agreement that survive
during the Wind Down Period will continue to survive for the remainder of the period of time that DIALOG is authorized to Sell Licensed Products
to any customer in accordance with the foregoing sentence. The rights granted under this Section 15.4(b) will be conditioned upon DIALOG
providing ENERGOUS a complete or redacted copy of the applicable supply contract demonstrating the existence of the Continuing Obligation as
of the date of notice of termination or, if DIALOG or its Affiliate is prohibited from providing a copy of the contract by the confidentiality
obligations set forth therein, a written certification from an officer of DIALOG attesting to the existence of the Continuing Obligation.
 
* Confidential Treatment Requested
  Page 2016. ESCROW.
 
16.1 Escrow. ENERGOUS will at its expense, at DIALOG’s written request during the Term and any Wind Down Period, enter into a three-
party escrow deposit arrangement, in accordance with this Section 16, with a recognized escrow agent (the “ Escrow Agent”) of mutual agreement.
ENERGOUS will keep the Deposit Materials in escrow and ensure on a quarterly basis that all the information relating to the Deposit Materials in
escrow is current, including deposit of any Product Updates.
 
16.2 Release of Deposit Materials. In the event of any Insolvency Event and where the design files need to be accessed by DIALOG to fix
an Epidemic Defect or other Product design or production issue impacting yield or quality (“ Release Condition”), the Escrow Agent will, in
accordance with the terms of the escrow agreement between the parties and the Escrow Agent (the “ Escrow Agreement”), release the Deposit
Materials to DIALOG.
 
16.3 License. ENERGOUS hereby grants DIALOG a non-exclusive, non-transferable (except as set forth in Section 2) license under the
Product IP to use any of the Deposit Materials released from escrow for the purpose of fixing an Epidemic Defect or other Product design or
production issue impacting yield or quality during the Term and, if applicable, any Wind Down Period or Continuing Obligation period, including,
but not limited to, authorizing any third party subcontractor to manufacture and supply Products, provided, however, that DIALOG continues to
make all Royalty payment owed to ENERGOUS (or the then-current owner of the Product IP) as provided in this Agreement. No Service Fees will be
payable under this license. DIALOG agrees not to exercise such license until occurrence of a Release Condition, subject to the other restrictions set
forth in this Section 16. Such license may be exercised by DIALOG only during the Term and any Wind Down Period or Continuing Obligation
period and is subject to DIALOG’s continued compliance with all of the other applicable terms and conditions of this Agreement during any such
applicable period. All Deposit Materials will be deemed ENERGOUS’ Confidential Information hereunder. DIALOG’s license to possess and use the
Deposit Materials does not include any right to disclose, market, sublicense or distribute the Deposit Materials to any third party other than its
Affiliates and Manufacturing Subcontractors.
 
16.4 Rights in Bankruptcy. The licenses granted pursuant to this Agreement are license to rights in “intellectual property” (as that term is
defined in Section 101 of the United States Bankruptcy Code) and governed by 11 USC Section 365(n). Accordingly, if a trustee in bankruptcy
rejects the Escrow Agreement and/or this Agreement as executory contracts, then Company may elect to retain its rights under this Agreement in
accordance with and subject to the provisions of 11 USC Section 365(n).
 
  Page 2117. PUBLICITY.
 
17.1 Publicity. Within 30 days of the Effective Date each party will issue a mutually agreed joint press release regarding the strategic
cooperation for the supply of Products and the strategic cooperation between the parties.
 
18. NON-SOLICITATION.
 
18.1 Non-Solicitation. During the Term and for a [***], neither party will without the written consent of the other party (which may be
granted or denied in its sole discretion) (a) directly or indirectly recruit or solicit for employment or for the provision of services any employee of
the other party, (b) otherwise solicit, induce or influence any employee to leave their employment with the other party, or (c) attempt to do any of
the foregoing; provided, however, that the foregoing will not apply to (y) any employee of the other party that responds to a public advertisement
of employment opportunities or (z) any employee that was terminated without cause by the other party. ENERGOUS and DIALOG acknowledge and
agree that the covenants in this Section 18 are reasonable and necessary to protect each of their trade secrets, Confidential Information and stable
workforces.
 
19. CHOICE OF LAW AND DISPUTE RESOLUTION.
 
19.1 Applicable Law. This Agreement will be governed by and construed in accordance with the laws of the State of California, exclusive
of conflict of laws principles.
 
19.2 Dispute Resolution; Jurisdiction . Any dispute or claim arising out of or relating to this Agreement (including any matters regarding its
existence, scope, validity, breach or termination, or any non-contractual obligations arising out of or related to it) that is not able to be resolved
through negotiations will be submitted to arbitration in San Francisco, California, administered by the International Chamber of Commerce under its
Rules of Arbitration. There will be one arbitrator. The language of the arbitration will be English. The award will be in writing, state the reasons for
the award and be final and binding. Judgment on the award may be enforced in any court of competent jurisdiction. Except as may be required by
law, the parties will preserve the confidentiality of all aspects of the arbitration. The arbitration will be the sole and exclusive forum for final
resolution of any such dispute or claim, provided, however, that, because each party will have access to and become acquainted with Confidential
Information of the other party, the unauthorized use or disclosure of which may cause irreparable harm and significant injury which may be difficult
to ascertain and which may not be compensable by damages alone, the parties agree that the damaged party will have the right to seek an
injunction, specific performance or other equitable relief without prejudice to any other rights and remedies that it may have for such unauthorized
use or disclosure. Each party irrevocably waives all rights to a jury trial in any judicial proceeding permitted hereunder. For the avoidance of doubt,
the validity, construction, and enforceability of this Agreement and the resolution of disputes arising out of and relating to this Agreement, will be
governed solely by this Section 19.
 
* Confidential Treatment Requested
  Page 2220. MISCELLANEOUS PROVISIONS.
 
20.1 Notices. All notices required or permitted under this Agreement will be in writing, reference this Agreement and be deemed given: (a)
when delivered personally; or (b) when sent by electronic mail with electronic confirmation of receipt, provided that such notice is immediately
confirmed as provided in (c) or (d) below; or (c) seven (7) days after having been sent by registered or certified mail,; or (d) two (2) days after
deposit with a commercial courier service, with written verification of receipt. All communications will be sent to the addresses set forth below.
Either party may change its address by giving notice pursuant to, and specifically referring to, this Section 20.
 
If to ENERGOUS:
 
Energous Corporation
3590 North First Street
Suite 210
San Jose, California 95134
U.S.A.
Attn: Brian Sereda, CFO
If to DIALOG:
 
Dialog Semiconductor (UK) Ltd
100 Longwater Avenue
Green Park
Reading, RG2 6GP
United Kingdom
Attn: Legal Department
 
20.2 Relationship of Parties . ENERGOUS and DIALOG are independent business entities. Neither party nor its employees, consultants,
contractors or agents are agents, employees, partners or joint venturers of the other party, nor do they have any authority to bind the other party
by contract or otherwise to any obligation. The parties will not represent to the contrary, either expressly, implicitly, by appearance or otherwise.
 
20.3 Force Majeure. Except for obligations to pay amounts due under this Agreement, neither party will be liable for any failure or delay in
its performance under this Agreement due to causes which are beyond its reasonable control, including, but not limited to, acts of God, acts of civil
or military authority, fires, epidemics, floods, earthquakes, riots, wars, sabotage, labor shortages or disputes, and governmental actions; provided,
however, that the affected party: (a) gives the other party written notice of such cause promptly, and in any event within fifteen (15) days of
discovery thereof; and (b) uses its reasonable efforts to correct such failure or delay in its performance as soon as possible. The affected party’s
time for performance or cure under this Section 20.3 will be extended for a period equal to the duration of the cause.
 
20.4 Severability. If any provision of this Agreement is held to be invalid or unenforceable in any jurisdiction in which this Agreement is
being performed, then: (a) such provision will be deleted from this Agreement in that jurisdiction to the extent of such invalidity or unenforceability
without invalidating the remaining provisions of this Agreement, and any such unenforceability in that jurisdiction will not make that provision
unenforceable in any other jurisdiction; and (b) the parties will agree on an alternative provision that best accomplishes the objectives of such
provision, to the extent legally permissible in such jurisdiction.
 
  Page 2320.5 No Waiver. No waiver or consent in connection with or relating to this Agreement will bind either party unless in writing and signed
by the party against which enforcement is sought. Waiver by either party of any default will not be deemed a waiver by such party of the same or
any other default that may thereafter occur.
 
20.6 Counterparts. This Agreement may be executed in one or more counterparts, each of which will be an original, but taken together
constituting one and the same instrument. Execution of a facsimile copy (including PDF) will have the same force and effect as execution of an
original, and a facsimile/electronic signature will be deemed an original and valid signature.
 
20.7 Headings and References . The headings and captions used in this Agreement are used for convenience only and are not to be
considered in construing or interpreting this Agreement.
 
20.8 Construction. The parties and their respective counsel have negotiated this Agreement. This Agreement will be fairly interpreted in
accordance with its terms and without any strict construction in favor of or against either party.
 
20.9 Complete Agreement. This Agreement constitutes the entire agreement between the parties with respect to the subject matter hereof
and supersedes and replaces all prior or contemporaneous understandings or agreements, written or oral, regarding such subject matter. No
amendment to or modification of this Agreement will be binding unless in writing and signed by a duly authorized representative of both parties.
 
20.10 Assignment. This Agreement may not be assigned by either party without the express written consent of the other party, which
approval will not be unreasonably withheld or delayed, except that either party may (without consent but with notice to the other party) assign this
Agreement in its entirety to any successor in the event of a Change of Control of such party.
 
20.11 Notice of Merger or Acquisition . Until the date that this Agreement terminates or is terminated in accordance with Section 15 hereof,
ENERGOUS agrees that, [***].
 
* Confidential Treatment Requested
  Page 24IN WITNESS WHEREOF, the parties have caused this Agreement to be executed by their duly authorized representatives as of the Effective Date.
 
ENERGOUS CORPORATION   DIALOG SEMICONDUCTOR (UK) LTD
         
By: /s/ Stephen R. Rizzore   By: /s Mark Tyndall
         
Name: Stephen R. Rizzore   Name: Mark Tyndall
         
Title: President and Chief Executive Officer   Title: SVP Corporate Development and Strategy
 
  Page 25EXHIBIT A
 
PRODUCTS
 
Any ENERGOUS integrated circuit (IC) designed to receive power wirelessly and any ENERGOUS IC used in a wireless transmitter, including, but
not limited to, the following Products (and any related Product Updates):
 
[***]
 
 
* Confidential Treatment Requested
  Page 26EXHIBIT B
 
ROYALTIES AND SERVICE FEES
 
Royalties and Service Fees payable by DIALOG and/or its Affiliates to ENERGOUS hereunder will be calculated on a Product by Product basis as
defined herein.
 
Margin Split:
 
Combined Royalties and Service Fees shall equal [***].
 
Dialog will retain the remaining [***].
 
[***].
 
[***].
 
Notwithstanding any provision of the Agreement, no Royalties or Service Fees will be payable to ENERGOUS hereunder in connection with any
Sale to any customer of prototype or sample Licensed Products [***].
 
* Confidential Treatment Requested
  Page 27EXHIBIT C
 
Example of Letter of Authorization: Mask Set(s) Authorization for Third Party’s Product(s)
 
To whom it may concern
 
Pursuant to a STRATEGIC ALLIANCE Agreement between Dialog Semiconductor (UK) Ltd and Energous Corporation dated November 6, 2016 (to
which [Manufacturing Subcontractor] is not a party), we, Energous Corporation (Energous), hereby agree and authorize [Manufacturing
Subcontractor], under the terms of this Letter of Authorization, to use the Mask Set(s) specified below for manufacturing products for the supply to
the Third Party specified in paragraph 2 below only:
 
1. Mask Set(s) details:
Mask Set(s) Product Type:
Foundry Code:
 
2. Third Party details:
Third Party’s Name: Dialog Semiconductor [purchasing entity to be determined]
Third Party’s Address:
Contact name of Third Party:
 
3. Volume of products
The number of products to be manufactured with the Mask Set(s) will be unlimited, unless otherwise instructed by us below:
 
Authorized Amount: [UNLIMITED]
 
4. Duration of Authorization
The duration of this Letter of Authorization will be unlimited, unless otherwise instructed by us below:
 
Duration of Authorization: [UNLIMITED]
 
5. Confidential Information
Other than wafers for products specified under paragraph 1 above (which contain Energous designs), [Manufacturing Subcontractor] will not
disclose to the Third Party any information which is proprietary or confidential to Energous.
 
  Page 286. Reporting
Upon Energous’ request (but not more frequently than once per calendar year), [Manufacturing Subcontractor] will provide Energous with the
accumulated wafer volumes ordered (and shipped) to the Third Party under this Letter of Authorization. By signing this Letter of Authorization, the
Third Party authorizes [Manufacturing Subcontractor] to report to Energous accordingly.
 
8. Governing Law
This Letter of Authorization will be governed by and construed in accordance with the laws of California, excluding its conflict of laws provisions,
and be subject to the non-exclusive jurisdiction of the California courts.
 
Very truly yours,  
   
Energous Incorporated  
   
   
Name:  
   
Title:  
   
Date:  
   
   
   
   
Agreed by Dialog Semiconductor (UK) Ltd  
   
   
Name:  
   
Title:  
   
Date:  
 
This Letter of Authorization is subject to the approval of the Manufacturing Subcontractors.
 
  Page 29EXHIBIT D
 
LICENSED MARKS
 
DIALOG LICENSED MARKS:
 
Dialog
Dialog Semiconductor
 
ENERGOUS LICENSED MARKS:
 
Energous
WattUp
Unleash your power
 
Pending:
 
[***]
 
* Confidential Treatment Requested
  Page 30EXHIBIT E
 
Commercialization plan
 
Objective
 
The Commercialization Plan sets forth the parties’ respective rights and obligations with respect to commercial and technical activities to be
performed to maximize potential Sales of Licensed Products.
 
[***]
 
Review
 
O The Commercialization Plan will be reviewed and (if necessary) updated by the parties on a quarterly basis throughout the Term
of the agreement.
 
 
* Confidential Treatment Requested
  Page 31EXHIBIT F
 
CUSTOMER: [***]
 
 
* Confidential Treatment Requested
  Page 32Exhibit 10.2
STRATEGIC ALLIANCE AGREEMENT
This Strategic Alliance Agreement is entered into as of September 24, 2013 (the “Effective Date”) by and between Yaskawa Electric Corporation, alimited company duly organized and existing under the law of Japan, having its address at 2-1 Kurosakishiroishi, Yahatanishi-ku, Kitakyushu,Fukuoka, 806-0004, Japan. (Business Identity Code 2908-01-010767, hereinafter referred to as “YEC”) and Argo Medical Technologies Ltd., a privatecompany duly organized and existing under the law of Israel, having its address at Kokhav Yokneam Building, P.O. Box 161, Yokneam Ilit 20692,Israel (Business Identity Code 51-312137-6, hereinafter referred to as “ARGO”).
RECITALS:
 
(A) Argo is a venture company engaged in the business of healthcare robotics, and possesses valuable know-how regarding development,marketing and distribution of bipedal exoskeleton equipment for individuals with spinal cord injuries, multiple sclerosis or cerebral palsy inNorth America and the European Union.
 
(B) YEC is a leading company engaged in the business of electrical engineering and robotics, and possesses valuable know-how regardingdevelopment, manufacturing, marketing and distribution of various innovative solutions globally.
 
(C) The parties hereto recognize that the sales volume and demand of customers for healthcare equipment utilizing robotics technologies hasincreased and may increase further in the future.
 
(D) The agreements have so far been reached between the parties hereto in regard to the formation and operation of a strategic alliance with thegoal of evaluation, development and commercialization of such healthcare products.
NOW, THEREFORE, YEC AND ARGO AGREE AS FOLLOWS:
AGREEMENTS:
 
1. SCOPE OF STRATEGIC ALLIANCE 
The parties acknowledge that the purpose of this agreement shall be to seek and develop possibilities for collaboration in the followingareas:
 
  (a) Marketing, distribution, and commercialization of ARGO’s products by YEC, subject to the terms and conditions contained in thisAgreement and a separate Distribution Agreement being entered into concurrently with this Agreement (hereafter “DA”).
 
  (b) Marketing and distribution of future YEC products in the area of healthcare equipment by ARGO within the scope of its salesnetwork.(c) Improvement of ARGO’s products by applying YEC’s know-how and expertise in the field of motion control and robotics, especiallyimprovements necessary for YEC to successfully market ARGO’s products within the scope agreed to in the DA.
 
  (d) Quality improvements of ARGO’s Products by applying YEC’s know-how and expertise in the field of motion control and robotics.
 
  (e) Definition of the responsibilities and areas of coverage of YEC and ARGO in the future research and development of ARGO’sproducts, as to be defined in detail on a case-by-case basis with separate joint development agreements in the future.
 
2. INVESTMENT BY YEC 
As part of the implementation and execution of this Agreement, both parties agree to enter into a separate Share Purchase Agreement(hereafter “SPA”), at the same time and subject to the execution of the DA. Upon the terms and subject to the conditions contained in theSPA, YEC has agreed to purchase Series D-1 Convertible Preferred Shares of ARGO, par value NIS 0.01 each. The obligations of ARGOunder this Agreement will not become invalid in case that YEC sells part or all of its shares of ARGO to another party.
 
3. DISTRIBUTION OF ARGO’S PRODUCTS BY YEC 
As part of the implementation and performance of this Agreement, both parties are entering into the DA concurrently with this Agreement.Pursuant to the DA, and subject to its terms, ARGO agreed to appoint YEC as the exclusive distributor of its products in the Territoryspecified therein, and YEC agreed to market and distribute Argo’s products in a professional manner. In case the DA is terminated inaccordance with the terms and conditions of the DA, this provision shall be considered void.
 
4. JOINT STEERING COMMITTEE 
YEC and ARGO agree to pursue further opportunities for collaboration in the areas of research and development, manufacturing, marketingand sales, for the purposes stated in this Agreement. As a platform to discuss such opportunities, YEC and ARGO agree to form a JointSteering Committee (hereafter “JSC”), which will meet at least four (4) times per year, once in every quarter, for the following purposes:
 
  (a) Subject to the DA being in effect, to review and share the progress of marketing and sales of ARGO Products by YEC and ARGOworldwide, as defined in the DA.
 
  (b) Subject to the DA being in effect, to establish sales targets and minimum purchase requirements for ARGO’s Products under thedistribution relationship that is defined in the DA.(c) To discuss the possibilities of sales of YEC’s products in the healthcare field using ARGO’s sales network.
 
  (d) To discuss possibilities for improvements of ARGO’s Products, especially improvements necessary for YEC to successfully marketARGO’s products as defined in the DA, by granting YEC access to cost information and applying YEC’s know-how and expertise inthe field of motion control and robotics.
 
  (e) To discuss the responsibilities and areas of coverage of YEC and ARGO in the future research and development of ARGO Products,and to establish rules for proper compensation of the developing party for usage and/or licensing of any invention, know-how andimprovement created by such party in the course of joint development.
 
  (f) To discuss the potential for licensed manufacturing of ARGO’s Products by YEC.
 
  (g) To discuss the potential for quality improvements of ARGO’s Products by applying YEC’s know-how and expertise in the field ofmotion control and robotics.
 
5. TERM 
This Agreement will be effective as of the Effective Date. Unless sooner terminated in accordance with the provisions hereof, the initial termof this Agreement (“Initial Term”) will be ten (10) years from the Effective Date, provided that at any time following the 7th anniversary ofsuch date, either party may terminate such strategic alliance upon not less than 60 days’ prior written notice to the other party. After theInitial Term, this Agreement may only be renewed if authorized officers of ARGO and YEC agree in writing at least thirty (30) days before theexpiration of the Initial Term or any renewal term to a renewal, including the period of the renewal term. “Term” means the Initial Term andany such renewal term. The parties may terminate this Agreement during the Term as follows:
 
 
(a) Termination by either party. Either party may terminate this Agreement by giving written notice of termination to the other party,which termination will be effective immediately upon such notice, if the other party defaults in the performance of any of its materialobligations provided for in this Agreement and fails to cure such default within sixty (60) days after receipt of notice from the otherparty of such default, unless a plan for remedying such default has been proposed by the defaulting party and accepted by the non-defaulting party within such period.
 
  (b) Termination by both parties. ARGO and YEC may terminate this Agreement at any point provided that both parties agree in writingto such a termination.6. COORDINATION 
A contact person for each party will coordinate the efforts of that party under this agreement. The initial contact person for each party is asfollows:
 
Yaskawa Electric Corporation Argo Medical Technologies Ltd. 
Kei Shimizu  Larry Jasinski  
806-0004  33 Locke Drive, 2nd Floor  
2-1 Kurosakishiroishi, Yahatanishi-ku c/o Argo Medical Technologies, Inc 
Kitakyushu, Fukuoka, 806-0004 Marlborough, MA 01752  
Tel: +81 93 645 8949  USA  
Fax: +81 93 645 8948  Tel: +1 (508)251-1154  
E-mail: shimizu@yaskawa.co.jp Fax: +1 (508)251-2970  
 E-mail: larry.jasinski@rewalk.com 
A party’s contact person may be changed at any time by giving notice of the change to the other party. The notice must include the nameand contact information for the new contact person. The contact person for each party must be available at reasonable times and onreasonable notice to meet with, converse with, or otherwise communicate with the contact person for the other party regarding issuesarising under this agreement.
 
7. RELATIONSHIP OF PARTIES 
Nothing herein contained shall be construed to imply a joint venture, partnership or principal-agent relationship between YEC and ARGO,and neither party shall have the right, power or authority to obligate or bind the other in any manner whatsoever, except as otherwise agreedin writing. During the performance of any of the collaborative efforts set forth in this Agreement, ARGO’s employees will not be consideredemployees of YEC, and vice versa.
 
8. INTELLECTUAL PROPERTY; CO-DEVELOPMENT, IMPROVEMENT, MODIFICATION 
This agreement does not give either party any rights, title or interest in the other party’s trade name, trademarks, copyrights, patents, tradesecrets, know-how, proprietary data, confidential information, or other intellectual property (hereinafter collectively “Intellectual Property”).Except as expressly stipulated in this Agreement, each party shall not without any prior written consent, use, copy, modify or license theother party’s Intellectual Properties supplied pursuant to this Agreement. Unless otherwise agreed between the parties or stipulated in aseparate related agreement such as the SPA or DA, each party confirms and agrees that any Intellectual Properties are hereby supplied tothe other party on an “as is” basis. There are no warranties by either party with respect to such Intellectual Properties, express or impliedincluding the implied warranties of merchantability, fitness for a particular purpose and non-infringement. In the event that the partiesmutually agree to explore jointly in any manner, design and/or develop new products or improve or modify ARGO’s current products, theparties will negotiate, in good faith, in an attempt to conclude one or more appropriate license agreements prior to either party’s use of theIntellectual Property of the other.9. CONFIDENTIAL INFORMATION 
On or prior to the execution of this Agreement, both parties shall sign a new Confidentiality and Non-Disclosure Agreement (hereinafter the“New NDA”) and both parties shall comply with any terms and conditions stipulated in the New NDA with respect to handling of anyconfidential information disclosed by the other party hereunder.
 
10. NON-SOLICITATION OF PERSONNEL 
During the performance of the any of the collaborative efforts set forth in this Agreement, each of ARGO and YEC agrees not to engage inany attempt whatsoever to hire, or to engage as independent contractors, the other’s employees or independent contractors during the termof the collaboration and for a period of twelve (12) months following expiration or termination of the collaboration, except as may bemutually agreed in writing.
 
11. REMEDIES 
Each of the parties agrees that money damages will not be a sufficient remedy for any breach of the above agreement relating to non-solicitation of personnel. Accordingly, a party will be entitled to specific performance and injunctive or other equitable relief as a remedy forany such breach, and the parties each further agree to waive any requirement for the securing or posting of any bond in connection withsuch remedy.
 
12. MISCELLANEOUS PROVISIONS 
 
  12.1.Assignment
Neither this Agreement nor any part of this Agreement may be assigned or transferred by either party without the prior writtenconsent of the other party. Any assignment or transfer without such consent shall be null and void.
 
  12.2.Notice
All notices or other communications required or desired to be sent to either of the parties will be invalid, unless made in writing andsent by registered or certified mail, postage prepaid, return receipt requested, or sent by recognized international courier service(e.g., Federal Express, DHL, etc.) with charges prepaid, or by facsimile or electronic mail which is subject to confirmation by letter.The address for all notices or other communications required to be sent to ARGO or YEC will be the mailing address stated on thesignature page to this Agreement, or such other address as may be provided from one party to the other on at least ten (10) daysprior written notice. Any such notice will be effective upon the date of receipt.12.3.Litigation Expense
If there is a default under this agreement, the defaulting party must reimburse the non-defaulting party for all costs and expensesreasonably incurred by the non-defaulting party in connection with the default, including attorney’s fees. Additionally, if a suit oraction is filed to enforce this agreement or with respect to this Agreement, the prevailing party is entitled to reimbursement from theother party for all costs and expenses incurred in connection with the suit or action, including reasonable attorney’s fees at the triallevel and on appeal.
 
  12.4.Waiver
No waiver of any provision of this Agreement may be deemed, or will constitute, a waiver or any other provision, whether or notsimilar, not will any waiver constitute a continuing waiver. No waiver will be binding unless executed in writing by the party makingthe waiver.
 
  12.5.Applicable Law
This agreement will be governed by and must be construed in accordance with the laws of the State of Israel. All disputes arisingpursuant to this Agreement shall be exclusively brought in the courts of competent jurisdiction residing in Tel Aviv, Israel.
 
  12.6.Entire Agreement
This Agreement constitutes the entire agreement between the parties with regard to the matters contained herein, and may not beamended except in a writing signed by both parties.
 
  12.7.Severability
Immediately upon the execution by the parties of this Agreement, the Confidentiality and Non-Disclosure Agreement of August25TH, 2011 by and between the parties and the Letter as of July 5th, 2013 shall be terminated by mutual consent of the parties hereto,and become null and void. Notwithstanding the foregoing, should this Agreement be terminated or proven to be invalid, suchtermination or invalidation will in no way affect, impair or invalidate any other related agreement including the SPA, DA and/or theNew NDA, which will be in full force and effect. In addition, any amendment, invalidity or termination of the SPA, DA and/or theNew NDA respectively or divestiture of Series D-1 Convertible Preferred Shares of ARGO by YEC will not in any way affect, impair orinvalidate this Agreement.
 
  12.8.Counterparts of the Agreement
This Agreement has been executed in two (2) identical copies, one (1) for each party.ARGO MEDICAL TECHNOLOGIES LTD.   YASKAWA ELECTRIC CORPORATIONExhibit 7.3
 
STRATEGIC ALLIANCE AGREEMENT
This Strategic Alliance Agreement is made and entered into this 9th day of September 2005, by and between UTEK Corporation (“UTK”), 202
South Wheeler Street, Plant City, Florida 33566 a Delaware corporation, and World Energy Solutions, (“AVDU”), 3900A 31st Street North, St.
Petersburg, Florida, a Florida corporation.
WITNESSETH:
WHEREAS, AVDU desires to engage UTK to provide the services as set forth in this Agreement, and
WHEREAS, UTK is agreeable to provide these services.
NOW THEREFORE, in consideration of the mutual promise made in this Agreement, and for other good and valuable consideration, the
receipt and sufficiency of which is hereby acknowledged, the parties hereto agree as follows:
I. ENGAGEMENT  
AVDU hereby retains UTK to provide those services as defined herein and UTK hereby agrees to the appointment on the terms and conditions
hereinafter set forth and agrees to use commercially reasonable efforts in providing said services.
II. INDEPENDENT CONTRACTOR 
UTK shall be, and in all respects be deemed to be, an independent contractor in the performance of its duties hereunder.
 
  A. AVDU shall be solely responsible for making all payments to and on behalf of its employees and UTK shall in no event be liable
for any debts or other liabilities of AVDU.
 
 
B. UTK shall not have or be deemed to have, fiduciary obligations or duties to AVDU, and shall be able to pursue, conduct and
carry on for its own account (or for the account of others) such activities, ventures, businesses and other pursuits as UTK in its
sole, absolute and unfettered discretion, may elect.
 
  C. Notwithstanding the above, no activity, venture, business or other pursuit of UTK, during the term of this Agreement shall
conflict with UTK’s obligations under this Agreement.III. SERVICES 
UTK agrees to provide the following services, hereinafter collectively referred to as “Services”:
SEE “CONFIDENTIAL TERM SHEET” (EXHIBIT A) ATTACHED AND MADE A PART HEREOF.
 
  A. UTK shall devote such time and efforts, as it deems commercially reasonable, under the circumstances to the affairs of the
AVDU, as is reasonable and adequate to render the Services contemplated by this Agreement.
 
 
B. UTK cannot guarantee results on behalf of AVDU, but shall pursue all reasonable avenues available through its network of
contacts. The acceptance and consumption of any transaction is subject to acceptance of the terms and conditions by its sole
discretion.
 
  C. In conjunction with the Services, UTK agrees to:
 
  1. Make itself available at the offices of AVDU or at another mutually agreed upon place, during normal business hours, for
reasonable periods of time, subject to reasonable advance notice and mutually convenient scheduling.
 
  2. Make itself available for telephone conferences with the principal officer(s) of AVDU during normal business hours.
IV. EXPENSES 
It is expressly agreed and understood that each party shall be responsible for its own normal and reasonable out-of-pocket expenses.
V. COMPENSATION 
 
  A. In consideration for the services to be provided, AVDU agrees that it will remit the agreed upon stock certificate within five (5)
days of both parties executing this Agreement.
 
  B. AVDU agrees that UTK shall be entitled to compensation as follows:
SEE STRATEGIC ALLIANCE CONFIDENTIAL TERM SHEET (EXHIBIT A) ATTACHED AND MADE A PART HEREOF.
VI. TERM AND TERMINATION 
The term of the Agreement will be for 12 months unless terminated sooner. This agreement may be renewed upon mutual, written agreement of the
parties. Either party may terminate this Agreement at any time with 30 days written notice.
 
- 2 -VII. LEGAL COMPLIANCE 
AVDU agrees that it will put in place, if it has not already done so, policies and procedures relating to and addressing, with the commercially
reasonable intent to ensure compliance with, applicable securities laws, rules and regulations, including, but not limited to:
 
  A. The use, release or other publication of forward-looking statements.
 
 
B. Disclosure requirements regarding the required disclosure of the nature and terms of UTK’s relationship with, including, but not
limited to press releases, publications on its web site, letters to investors and telephone or other personal communication with
potential or current investors.
 
  C. No press releases or any other forms of communication to third parties which mention both UTK CORPORATION and AVDU,
shall be released without the prior written consent and approval of both UTK and AVDU. 
 
 
D. EXECUTION. The execution, delivery and performance of this Agreement, in the time and manner herein specified will not
conflict with, result in a breach of, or constitute a default under any existing agreement, indenture, or other instrument to which
either AVDU OR UTK is a party or by which either entity may be bound or affected.
 
  E. TIMELY APPRISALS. AVDU shall use its commercially reasonable efforts to keep UTK up to date and apprised of all business,
market and legal developments related to and its relationship to UTK.
 
  F. CORPORATE AUTHORITY. Both AVDU and UTK have full legal authority to enter into this Agreement and perform the same in
the time and manner contemplated.
 
  G. The individuals whose signatures appear below are authorized to sign this Agreement on behalf of their respective corporations.
 
  H. AVDU will cooperate with UTK and will promptly provide UTK with all pertinent materials and requested information in order for
UTK to perform its Services pursuant to this Agreement.
 
  I. When delivered, the shares of AVDU Common Stock shall be duly and validly issued, fully paid and non-assessable.
 
 
J. UTK represents to AVDU that a) it has the experience as may be necessary to perform all the required, b) all Services will be
performed in a professional manner, and c) all individuals it provides to perform the Services will be appropriately qualified and
subject to appropriate agreements concerning the protection of trade secrets and confidential information of which such
persons may have access to over the term of this Agreement.
 
  K. Until termination of the engagement, AVDU will notify UTK promptly of the occurrence of any event, which might materially
affect the condition (financial or otherwise), or prospects of AVDU.
 
- 3 -VIII. CONFIDENTIAL DATA 
 
 
A. UTK shall not divulge to others, any trade secret or confidential information, knowledge, or data concerning or pertaining to the
business and affairs of AVDU, obtained by UTK as a result of its engagement hereunder, unless authorized, in writing by AVDU.
UTK represents and warrants that it has established appropriate internal procedures for protecting the trade secrets and
confidential information of AVDU, including, without limitation, restrictions on disclosure of such information to employees and
other persons who may be engaged in such information to employees and other persons who may be engaged in rendering
services to any person, firm or entity which may be a competitor of AVDU.
 
 
B. AVDU shall not divulge to others, any trade secret or confidential information, knowledge, or data concerning or pertaining to
the business and affairs of UTK or confidential information revealed by UTK obtained as a result of its engagement hereunder,
unless authorized, in writing, by UTK.
 
 
C. UTK shall not be required in the performance of its duties to divulge to AVDU, or any officer, director, agent or employee of
AVDU, any secret or confidential information, knowledge, or data concerning any other person, firm or entity (including, but not
limited to, any such person, firm or entity which may be a competitor or potential competitor of) which UTK may have or be able
to obtain other than as a result of the relationship established by this Agreement.
IX. OTHER MATERIAL TERMS AND CONDITIONS 
 
  A. INDEMNITY.
 
 
1. UTK shall indemnify, defend and hold harmless AVDU from and against any and all losses incurred by AVDU which arise
out of or result from misrepresentation, breach of warranty or breach or non- fulfillment of any covenant contained herein
or Schedules annexed hereto or in any other documents or instruments furnished by UTK pursuant hereto or in
connection with this Agreement.
 
 
2. AVDU shall indemnify, defend and hold harmless UTK from and against any and all losses incurred by UTK which arise
out of or result from misrepresentation, breach of warranty or breach or non-fulfillment of any covenant contained herein
or Schedules annexed hereto or in any other documents or instruments furnished by AVDU pursuant hereto or in
connection with this Agreement.
 
  B. PROVISIONS. Neither termination nor completion of the assignment shall affect the provisions of this Agreement, and the
Indemnification Provisions that are incorporated herein, which shall remain operative and in full force and effect.
 
 
C. AVDU agrees that for a twenty four months (24) following the execution of this Agreement, AVDU shall not, without UTEK’s
prior written consent, directly or indirectly solicit for employment any present employee of UTEK, or request induce or advise
any employee of UTEK to leave the employ of UTEK. In turn, UTEK agrees that it will not directly or indirectly solicit any
present employee of AVDU.
 
- 4 -D. ADDITIONAL INSTRUMENTS. Each of the parties shall from time to time, at the request of others, execute, acknowledge and
deliver to the other party any and all further instruments that may be reasonably required to give full effect and force to the
provisions of this Agreement.
 
 
E. ENTIRE AGREEMENT. Each of the parties hereby covenants that this Agreement, is intended to and does contain and embody
herein all of the understandings and agreements, both written or oral, of the parties hereby with respect to the subject matter of
this Agreement, and that there exists no oral agreement or understanding expressed or implied liability, whereby the absolute,
final and unconditional character and nature of this Agreement shall be in any way invalidated, empowered or affected. There
are no representations, warranties or covenants other than those set forth herein.
 
 
F. ASSIGNMENTS. The benefits of the Agreement shall inure to the respective successors and assignees of the parties and
assigns and representatives, and the obligations and liabilities assumed in this Agreement by the parties hereto shall be binding
upon their respective successors and assigns; provided that the rights and obligations of UTK under this Agreement may not
be assigned or delegated without the prior written consent of AVDU and any such purported assignment shall be null and void.
Notwithstanding the foregoing, UTK may assign this Agreement or any portion of its Compensation as outlined herein to its
subsidiaries in its sole discretion.
 
  G. ORIGINALS. This Agreement may be executed in any number of counterparts, each of which so executed shall be deemed an
original and constitute one and the same agreement.
 
 
H. ADDRESSES OF PARTIES. Each party shall at all times keep the other informed of its principal place of business if different from
that stated herein, and shall promptly notify the other of any change, giving the address of the new place of business or
residence.
 
 
I. NOTICES. All notices that are required to be or may be sent pursuant to the provision of this Agreement shall be sent by
certified mail, return receipt requested, or by overnight package delivery service to each of the parties at the addresses
appearing herein, and shall count from the date of mailing or the validated air bill.
 
 
J. MODIFICATION AND WAVIER. A modification or waiver of any of the provisions of this Agreement shall be effective only if
made in writing and executed with the same formality as this Agreement. The failure of any party to insist upon strict
performance of any of the provisions of this Agreement shall not be construed as a waiver of any subsequent default of the
same or similar nature or of any other nature.
 
 
K. INJUNCTIVE RELIEF. Solely by virtue of their respective execution of this Agreement and in consideration for the mutual
covenants of each other, AVDU and UTK hereby agree, consent and acknowledge that, in the event of a breach of any material
term of this Agreement, the non-breaching party will be without adequate remedy-at-law and shall therefore, be entitled to
immediately redress any material breach of this Agreement by temporary or permanent injunctive or mandatory relief obtained in
an action or proceeding instituted in any court of competent jurisdiction without the necessity of proving damages and without
prejudice to any other remedies which the non-breaching party may have at law or in equity.
 
- 5 -L. ATTORNEY’S FEES. If any arbitration, litigation, action, suit, or other proceeding is instituted to remedy, prevent or obtain relief
from a breach of this Agreement, in relation to a breach of this Agreement or pertaining to a declaration of rights under this
Agreement, the prevailing party will recover all such party’s attorneys’ fees incurred in each and every such action, suit or other
proceeding, including any and all appeals or petitions there from. As used in this Agreement, attorneys’ fees will be deemed to
be the full and actual cost of any legal services actually performed in connection with the matters involved, including those
related to any appeal to the enforcement of any judgment calculated on the basis of the usual fee charged by attorneys
performing such services.
APPROVED AND AGREED:
 
UTEK CORPORATION   WORLD ENERGY SOLUTIONS
By:  /s/ Clifford M. Gross   By:  /s/ Benjamin C. Croxton
  Clifford M. Gross, Ph.D.     Benjamin C. Croxton
  Chief Executive Officer     Chief Executive Officer
 
- 6 -Exhibit A
 
CONFIDENTIAL TERM SHEET
PROPOSED STRATEGIC ALLIANCE BETWEEN
UTEK CORPORATION (UTK) & WORLD ENERGY SOLUTIONS (AVDU)
Statement of Work: To identify technology acquisition opportunities for AVDU from research universities and government laboratories. A first
step in this process is the development of a Technology Acquisition Profile. Once completed, we will identify and present technologies that meet
this profile. While conducting our search we will maintain the confidentiality of AVDU.
Term: The term of the Agreement will be for 12 months unless terminated sooner. This Agreement may be renewed upon mutual, written agreement
of the parties. Either party may terminate this agreement at any time with 30 days written notice.
Services: UTK agrees to provide the following distinct services to AVDU:
 
  i. Identify synergistic new technologies from universities and government laboratories to help provide AVDU with an
enhanced new product pipeline.
 
  ii. Review technology acquisition opportunities for AVDU while maintaining AVDU’s confidentiality.
 
  iii. Present technology acquisition opportunities for AVDU. AVDU will have 30-days to determine if they want to go forward
with the technology license.
 
  a. UTK after 30 days shall have the right to present the technology to other clients.
 
  iv. AVDU acknowledges that the sources of technologies represented by UTEK are 3 rd party research institutions for which
UTEK does not control whether the technology will be shown to other parties by the licensor.
 
  v. At AVDU’s request, UTK will prepare, and compile additional information regarding the technology acquisition
opportunities for AVDU.
 
  vi. At AVDU’s request and upon mutual agreement between AVDU and UTK, UTK will negotiate and seek to acquire a license
to the requested technology for subsequent sale to and acquisition by AVDU.
 
  vii. On a case-by-case basis, at AVDU’s request and UTK’s sole discretion, UTK will propose an equity-financing plan for
AVDU’s consideration, to finance select technology acquisition opportunities for AVDU.
 
  viii. AVDU will not seek to acquire any technologies presented to AVDU by UTK directly from the technology developer for a
period of 24 months following the termination of this Strategic Alliance agreement.ix. The compensation quotation is valid for projects authorized and initiated within 30 days of the date of this term sheet.
a. In arms length negotiation with the technology developer, UTK will seek to acquire the license to the technology
through one of its subsidiaries. UTEK will then negotiate with AVDU to acquire this subsidiary in a stock for stock
exchange under an “Agreement and Plan of Acquisition”. The consideration to be paid by AVDU to UTK will be based
upon a markup to the value of the license and other assets in the subsidiary as determined by UTK and agreed to by
both parties.
b. Should AVDU decide not to proceed in the acquisition of the technology/company as described above, then AVDU
shall be prohibited from acquiring the technology/company either directly or indirectly, from the technology/company
developer for a period of 24 months following the termination of this Strategic Alliance Agreement.
Technology Transfer: When a technology is shown to AVDU that AVDU wants to acquire, UTK will seek to acquire the license to a technology
through one of its subsidiaries. UTK will then seek to provide a term sheet to AVDU outlining the consideration to be paid by AVDU for the
acquisition of this technology. UTK shall transfer this subsidiary to AVDU in a stock for stock exchange under an “Agreement and Plan of
Acquisition.” The consideration to be paid by AVDU to UTK will be based upon a markup to the value of the license and other assets in the
subsidiary as determined by UTK and agreed to by both parties.   
Compensation:
In consideration for providing these Services, AVDU shall pay UTK $120,000 worth of unregistered shares of common stock (31,413 shares) upon
the execution of this Strategic Alliance Agreement. 1/12th of the shares (2,617) shall vest each month during the term of this Agreement. If this
Agreement is terminated any unvested shares will be returned to AVDU. Both AVDU and UTK will cover their own out-of-pocket expenses incurred
during the performance of this Strategic Alliance Agreement.
Approved by:
 
/s/ Clifford M. Gross   /s/ Benjamin C. Croxton
UTEK Corporation   World Energy Solutions
Clifford M. Gross, Ph.D.   Benjamin C. Croxton
Chief Executive Officer   Chief Executive Officer
Date: September 9, 2005   Date: September 9, 2005Exhibit 10.1
STRATEGIC ALLIANCE AGREEMENT
THIS AGREEMENT dated for reference the 5th day of December 2008.
BETWEEN:
  GOLD RESOURCE CORPORATION, a company organized under the laws of the State of Colorado, with registered office locatedat 222 Milwaukee Street, Suite 301, Denver, CO 80206 (“GRC” or “the Company”)
AND: 
  HOCHSCHILD MINING HOLDINGS LIMITED, a private limited company organized under the laws of England and Wales, with
registered office located at 46 Albemarle Street, London, England W1S 4JL (“HOC”)  
WHEREAS:
A. The Company is a mineral exploration and development company engaged in the acquisition and exploration, as well as development of mineralproperties (the “Properties”) in Mexico through its Mexican subsidiaries with prospects for hosting gold, silver and base metal deposits, andthrough such subsidiaries holds interests in several mineral resource properties, including but not limited to (i) El Aguila, (ii) Las Margaritas, (iii)Solaga, and (iv) El Rey located in Oaxaca, Mexico (the “Existing Properties”);
B. HOC is an Affiliate of Hochschild Mining plc., a leading underground precious metals producer operating in the Americas with a primary focuson silver and gold;
C. The Company and HOC believe that their respective corporate strategies are compatible and, as such, wish to establish a strategic alliance on theterms and conditions set forth herein;
D. The Company and HOC are entering into this Agreement as a condition to and in furtherance of the investment in Shares (as defined below)contemplated in the Subscription Agreement dated December 5, 2008 (the “Subscription Agreement”) between the Company and HOC without theCompany having executed and delivered this Agreement; and
E. The Board of Directors has authorized the Company to enter into this Agreement.
NOW THEREFORE THIS AGREEMENT WITNESSES that in consideration of the mutual premises, covenants and agreements contained herein,and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged by both parties, the parties herebycovenant and agree as follows:
ARTICLE 1
INTERPRETATION
1.1 Definitions. In this Agreement, unless the context otherwise requires:(a) “Acceptance Notice” has the meaning ascribed to it in Section 4.1(e);
  (b) “Additional Securities” has the meaning ascribed to it in Section 4.1(a);
  (c) “Additional Shares” has the meaning ascribed to it in Section 2.1;
  (d) “Affiliate” shall have the meaning ascribed thereto in the Securities Act;
  (e) “Agreement” means this strategic alliance agreement and any instrument amending this Agreement and “hereof”, “hereto”,“hereunder” and similar expressions mean and refer to this Agreement and not to a particular Article, Section, Subsection orParagraph;
  (f) “Alternative Proposal” has the meaning ascribed to it in Section 9.1;
  (g) “Authority” and “Authorities” means any (i) multinational, federal, provincial, state, regional, municipal, local or other government,governmental or public department, securities commission (including the Securities Commissions), central bank, court, tribunal,arbitral body, commission, board, bureau or agency, domestic or foreign, (ii) any subdivision, agent, commission, board, or authorityof any of the foregoing, or (iii) any quasi-governmental or private body exercising any regulatory, expropriation or taxing authorityunder or for the account of any of the foregoing, and includes a stock exchange and any other self-regulatory authority;
  (h) “Board of Directors” means the board of directors of the Company;
  (i) “Business Day” means any day which is not a Saturday, a Sunday or a day on which banks are generally closed for business inDenver, Colorado or London, England;
  (j) “Claims” means all losses, damages, expenses, Liabilities, claims and demands of whatever nature or kind, including all reasonablelegal fees and disbursements;
  (k) “Closing Date” has the meaning given to it in the Subscription Agreement;
  (l) “Commencement of Production” has the meaning given to it in Section 2.3;
  (m) “Common Stock” has the meaning given to it in Section 4.1(a);
  (n) “Company” has the meaning given to it in the preamble hereto;
  (o) “Company Indemnitees” has the meaning given to it in Section 11.2;
  (p) “Convertible Securities” means all warrants, rights, agreements, options, or Debt Instruments present or future, contingent orabsolute, or any right or privilege capable of becoming a right, agreement or option, for the purchase, subscription or issuance ofany Shares in the Company or any other security or Debt Instruments convertible or exchangeable for Shares, including optionsgranted to officers, directors or employees, and whether issued pursuant to the Stock Option Plan;
2(q) “Debt Instrument” means any loan, bond, debenture, promissory note or other instrument evidencing material indebtedness of theCompany for borrowed money or other material liability;
  (r) “Equity Securities” means Shares, Convertible Securities and any other equity or voting securities of the Company;
  (s) “Existing Properties” has the meaning given to it in the preamble hereto;
  (t) “Financing Election” has the meaning ascribed to it in Section 2.3;
  (u) “HOC Director” has the meaning ascribed to it in Section 5.1;
  (v) “HOC Entities” means HOC and its Affiliates, and any person acting jointly or in concert with any of them, excluding, for greatercertainty, the Company and any of its Subsidiaries to the extent they may be or become Affiliates at any relevant point in time;
  (w) “HOC Indemnitees” has the meaning ascribed to it in Section 11.1;
  (x) “HOC JV Acceptance Notice” has the meaning ascribed to it in Section 6.2(b);
  (y) “HOC Option” has the meaning ascribed to it in Section 2.1;
  (z) “Joint Venture Proposal Notice” has the meaning ascribed to it in Section 6.2(a);
  (aa) “JV Negotiation Period” has the meaning ascribed to it in Section 6.2(b);
  (bb)“Laws” means any and all applicable (i) laws, constitutions, treaties, statutes, codes, ordinances, orders, decrees, rules, regulationsand municipal by-laws, (ii) judicial, arbitral, administrative, ministerial, departmental or regulatory judgments or orders of anyAuthorities, and (iii) policies, guidelines and protocols;
  (cc) “Liabilities” means, with respect to any Person, any liability or obligation of such Person of any kind, character or description,whether known or unknown, absolute or contingent, accrued or unaccrued, disputed or undisputed, liquidated or unliquidated,secured or unsecured, joint or several, due or to become due;
  (dd)“Lien” means any mortgage, easement, encroachment, adverse claim, and assignment by way of security, security interest,servitude, pledge, charge, lien, assignment, hypothecation, conditional sale agreement, title retention, preferential right, trustarrangement, right of set-off, counterclaim or banker’s lien, financing statement, privilege or priority, or other encumbrance of anykind having the effect of security, any designation of loss payees or beneficiaries or any similar arrangement under or with respect toany insurance policy or any preference of one creditor over another arising by operation of law;
  (ee) “Market Purchases” has the meaning ascribed to it in Section 3.1;
3(ff) “Option Exercise Notice” has the meaning ascribed to it in Section 2.1;
  (gg)“Option Expiration Date” has the meaning ascribed to it in Section 2.1;
  (hh)“Options” means outstanding options to acquire Shares under the Stock Option Plan;
  (ii) “Other Purchasers” has the meaning ascribed to it in Section 4.1(a);
  (jj) “Parties” means the Company and HOC and their successors and permitted assigns; and “Party” means any one of them;
  (kk)“Person” means an individual, partnership, unincorporated association, organization, syndicate, corporation or trust or a trustee,executor, administrator or other legal or personal representative;
  (ll) “Private Agreement Purchases” means purchases of Equity Securities other than on any stock exchange on which the Shares arethen listed or quoted provided such purchases are made in accordance with applicable Laws, including applicable Securities Laws;
  (mm)“Pro Rata Interest” has the meaning ascribed to it in Section 4.1(a);
  (nn)“Proposed Joint Venture” has the meaning ascribed to it in Section 6.1(a);
  (oo)“Properties” has the meaning ascribed to it in the Preamble hereto;
  (pp)“Purchased Shares” shall mean the shares of Common Stock to be acquired by HOC pursuant to the terms of the SubscriptionAgreement.
  (qq)“Rights Notice” has the meaning ascribed to it in Section 4.1(c);
  (rr) “Securities Exchange Act” means the Securities Exchange Act of 1934;
  (ss) “Securities Commissions” means the securities regulator in each jurisdiction whose Securities Laws are applicable to the Company;
  (tt) “Securities Laws” means the Laws relating to securities of the Company, and the regulations and rules made and forms prescribedthereunder together with all applicable published policy statements, blanket orders, rulings and notices adopted by the SecuritiesCommissions of each such jurisdiction or applicable in such jurisdictions;
  (uu)“Shareholders” means the holders of Shares;
  (vv)“Shares” means common shares or any other securities into which the common shares in the capital of the Company arereorganized, exchanged or converted;
  (ww)“Stock Option Plan” means any stock option plan, agreement or arrangement adopted by the Company from time to time whichprovides for the issuance of options to acquire Shares;
4(xx) “Subscription Agreement” has the meaning ascribed to it in the Preamble hereto;
(yy) “Subsequent Closing Date” has the meaning ascribed to it in Section 2.1;
(zz) “Transactions” means the transactions contemplated in this Agreement.
1.2 Gender and Certain References. Whenever the context requires, the gender of all words used shall include the masculine, feminine and neuter,and the number of all words shall include the singular and plural. The terms “hereof”, “herein” or “hereunder”shall refer to this Agreement as awhole and not to any particular Article or Section hereof. All titles and headings to Articles and Sections in this Agreement are included forconvenience and ease of reference. Titles and headings shall not affect in any way the meaning or interpretation of Articles or Sections of thisAgreement. Any references to specific Articles or Sections shall mean the Articles and Sections in this Agreement.
ARTICLE 2 ADDITIONAL INVESTMENTS BY HOC
2.1 HOC Option to Purchase Additional Shares. From and after the Closing Date and until 5:00 pm Denver time on the date which is eighty (80)days from the Closing Date (the “Option Expiration Date”), HOC shall have the option (the “Option”), at its sole discretion, to subscribe for all, butnot less than all, of an additional 4,330,000 Shares from the Company (the “Additional Shares”) at a price of US$3.00 per share, or a total ofUS$12,990,000. If HOC wishes to exercise the Option, it shall give written notice to the Company (the “Option Exercise Notice”) prior to the OptionExpiration Date in the manner set forth in Section 12.1 of this Agreement. If HOC fails to deliver the Option Exercise Notice on or before the OptionExpiration Date, HOC shall be deemed to have waived its rights under this Section 2.1. In the event HOC exercises the Option, one or more of theHOC Entities shall subscribe and pay for and the Company shall issue to the relevant HOC Entities, free and clear of any liens or encumbrances, theAdditional Shares and the Parties shall exchange representations and warranties substantially similar to those contained in the SubscriptionAgreement and execute such documents as may be necessary to complete the subscription and sale of the Additional Shares. Closing of thepurchase and sale of the Additional Shares shall take place within ten (10) business days of the delivery of the Option Exercise Notice, such datebeing referred to as the “Subsequent Closing Date”. 
2.2 Use of Proceeds. In the event HOC exercises the Option, the Company agrees to use not less than five million U.S. Dollars (US$5,000,000) of theproceeds from the subscription of the Purchased Shares and the Additional Shares to fund exploration activities (including but not limited todrilling, assaying and staking new claims) on the El Aguila project. The Company further agrees that the balance of the proceeds from thesubscription of the Purchased Shares and the Additional Shares shall be used as follows: (i) ten million U.S. Dollars (US$10,000,000) to fund thedevelopment and construction of the mine and plant for the El Aguila project; and (ii) three million U.S. Dollars (US$3,000,000) for working capitalof the Company and other investments in the El Aguila project.
52.3. Additional Financing. Subject to the provisions of Section 8.2, if the Company determines to solicit additional equity financing subsequent toexercise of the Option but prior to Commencement of Production (hereinafter defined) at the El Aguila project, it shall provide written notice to thateffect to HOC and HOC shall be entitled to exclusively provide such financing upon the terms and conditions hereinafter set forth. For purposes ofthe preceding sentence, “Commencement of Production” shall be defined as the production and delivery to the point of sale (refiner) by theCompany (either directly or through a subsidiary) of not less than 4,000 ounces of gold within a 45 day period. HOC shall have ten (10) BusinessDays from delivery of such notice in which to notify the Company that it desires to provide all of such financing (the “Financing Election”). IfHOC delivers the Financing Election, the purchase price for each share shall be equal to eighty percent (80%) of the average closing price of theShares during the thirty (30) calendar days preceding the date HOC delivers the Financing Election. Closing of the subscription, purchase and saleshall be at such place and time as the Parties agree but not more than ten (10) days from delivery of the Financing Election. If HOC delivers theFinancing Election, one or more of the HOC Entities shall pay the purchase price for, and the Company shall issue, additional Shares, free and clearof all liens and encumbrances. The Parties shall exchange representations and warranties, in form and in substance substantially similar to thoseprovided in the Subscription Agreement and execute such documents as may be necessary to complete the subscription and sale of the Shares. Inthe event HOC fails to provide the Financing Election as set forth above, the Company shall be free to obtain such financing from one or moreadditional parties, free of any obligation to HOC.
ARTICLE 3 MARKET PURCHASES AND PRIVATE PURCHASES
3.1 Market Purchases.Subject to compliance with applicable laws, the HOC Entities shall at any time and from time to time, in their sole discretion,be entitled to make purchases of the Company’s common stock in the over-the-counter market or on any stock exchange on which its commonstock is then quoted or listed (the “Market Purchases”); provided, however, that for a period of two (2) years following the Closing Date, unlessthe Parties otherwise agree, the HOC Entities do not beneficially own, directly or indirectly, more than forty percent (40%) of the Company’soutstanding common stock on an undiluted basis, following any Market Purchase and any Private Agreement Purchase. For purposes of thisAgreement, beneficial ownership shall be determined in accordance with the provisions of Rule 13d-3 of the Securities Exchange Act.
3.2 Private Purchase.In addition to Market Purchases, as described in Section 3.1 above, HOC shall be entitled to make Private AgreementPurchases, provided that such purchases are made in accordance with all applicable laws; and provided further, that for a period of two (2) yearsfollowing the Closing Date, unless the Parties otherwise agree, the HOC Entities will not beneficially own more than forty percent (40%) of theCompany’s outstanding common stock on an undiluted basis following any Market Purchase and/or Private Agreement Purchase. At the requestof HOC, the Company shall introduce HOC to persons whom the Company believes may be interested in selling its common stock.
6ARTICLE 4 PRE-EMPTIVE RIGHT
4.1 HOC’s Pre-emptive Right.  
(a) Subject to the provisions of subsection (g) of this Section 4.1 and Section 8.2 hereof, if at any time after the Closing Date, the Companyproposes to issue or sell Equity Securities (“Additional Securities”) other than (i) under any Stock Option Plan, (ii) pursuant to the exerciseof options under any Stock Option Plan, (iii) upon the exercise, exchange or conversion of any Convertible Securities, or (iv) for propertyother than money, the HOC Entities shall have the right to subscribe for and purchase Additional Securities, at the price at which suchAdditional Securities are offered for sale to other purchasers (the “Other Purchasers”), up to its Pro Rata Interest (as defined below) priorto giving effect to the issuance or sale of such Additional Securities. “Pro Rata Interest” means, at any relevant time, the ownershipinterest of HOC, expressed as a percentage, equal to: (i) the number of outstanding shares of common stock of the Company (“CommonStock”) beneficially owned by the HOC Entities, including all shares of Common Stock issuable upon the conversion, exercise or exchangeof all Convertible Securities beneficially owned by the HOC Entities divided by (ii) the aggregate number of outstanding shares of CommonStock, plus the number of shares of Common Stock issuable upon the conversion, exercise or exchange of all outstanding ConvertibleSecurities;
(b) If the Company issues Equity Securities in circumstances that would not give rise to the rights of the HOC Entities pursuant to Section4.1(a) (the “Non-Participating Transaction”), then in any concurrent or subsequent transaction which does give rise to the rights of theHOC Entities pursuant to Section 4.1(a) (the “Participating Transaction”), the Company shall allow the HOC Entities to subscribe for andpurchase Additional Securities in an amount greater than HOC’s Pro Rata Interest; provided that in the Participating Transaction, HOC shallnot be entitled to purchase any more than its Pro Rata Interest of the securities sold collectively in the Non-Participating Transaction andthe Participating Transaction.
(c) If the Company intends to authorize and/or issue equity securities that give rise to the rights of HOC pursuant to Section 4.1(a), theCompany shall provide notice to HOC (the “Rights Notice”) no less than ten (10) business days before the date on which the Companyintends to issue equity securities giving rise to the rights of HOC in Section 4.1(a).
(d) The Rights Notice shall specify sufficient information regarding the particulars of the issuance or sale of the Additional Securities toallow HOC to make a reasoned decision in respect of making the investment, including to the extent any such terms are determinable at suchtime: (i) the total number of equity securities outstanding as of the date thereof; (ii) the total number of Additional Securities which arebeing offered; (iii) the rights, privileges, restrictions, terms and conditions of such Additional Securities; (iv) the amount payable by HOCfor the Additional Securities to which it is entitled pursuant to Section 4.1(a); and (v) the proposed closing date, and thereafter, to the extentit is not included in the Rights Notice, the Company shall immediately provide notice to HOC of such information as it is determined.
(e) HOC shall give notice (an “Acceptance Notice”) to the Company not later than 5:00 p.m. (Denver time) on the tenth business dayfollowing the deemed receipt of any Rights Notice given under paragraph 4.1(c) setting out the number of Additional Securities, if any,which any of HOC Entities intends to subscribe for and purchase and, if applicable, the name and address of HOC Entity whose name inwhich such securities should be registered, provided that if HOC, acting reasonably, determines that it has insufficient information to makesuch investment decision, HOC shall notify the Company of the information required to make such investment decision and thereafter shallhave the longer of (i) the remainder of the ten (10) Business Days set out in the first sentence of this paragraph; or (ii) two (2) BusinessDays from the receipt of such additional information to make the investment decision and deliver or refrain from delivering the AcceptanceNotice. Notwithstanding the preceding sentence, the Rights Notice shall be deemed to include sufficient information to make suchinvestment decision if it includes the information specified in items (i) to (iv) of Section 4.1(d). If no Acceptance Notice has been providedto the Company within the required time, HOC will be deemed to have elected not to subscribe for or purchase any such AdditionalSecurities.
7(f) Following delivery of the Acceptance Notice, if any, the HOC Entities shall pay for, and the Company shall issue to the relevant HOCEntities, free and clear of any liens, the number of Additional Securities specified in the Acceptance Notice and, except as otherwise agreed,the Company shall provide HOC with substantially the same closing documents, including opinions, if applicable, as are delivered to theother persons subscribing for Additional Securities on the closing date for such issuance.
(g) The rights granted to HOC under this Article 4 shall terminate and be of no further force or effect if HOC does not exercise Option andcomplete the purchase of the Additional Shares.
ARTICLE 5BOARD REPRESENTATION
5.1 Appointment of HOC Nominee. If, but only if HOC exercises the Option and completes the acquisition of the Additional Shares, HOC shall beentitled to nominate one (1) individual to the Board of Directors (the “HOC Director”). Upon receipt of such nomination and its satisfaction thatthe individual nominated by HOC meets the qualification requirements for directors under applicable laws, the Board of Directors further agrees toexpand its membership to four (4) positions and appoint the individual nominated by HOC to the newly-created vacancy. The Board of Directorsfurther agrees that if HOC maintains a Pro Rata Interest of at least 14.5%, it shall nominate such individual to the slate of directors at eachsubsequent annual meeting so long as the provisions of Section 8.2 are not invoked.
5.2 Increase in Membership of the Board of Directors. If HOC acquires the Additional Shares and subsequently acquires additional Shares suchthat it holds a Pro Rata Interest of 40% or more, HOC shall be entitled to appoint one (1) additional individual to the Board of Directors. For greaterclarity, if HOC exercises the Option and holds a Pro Rata Interest of at least 40%, HOC shall be entitled to appoint a total of two (2) individuals tothe Board of Directors. Upon receipt of a nomination from HOC for the second director and its satisfaction that the individual meets thequalification requirements for directors under applicable law, the Board of Directors agrees to expand its membership to five positions and appointthe individual nominated by HOC to the newly created vacancy. The Board of Directors further agrees that so long as HOC maintains a Pro RataInterest of at least 35%, it shall nominate such individual to the slate of directors at each subsequent annual meeting so long as the provisions ofSection 8.2 are not invoked. The Company further agrees that if HOC exercises the Option and so long as the provisions of Section 8.2 are notinvoked, it will not take any action to authorize and will cause the Board of Directors not to authorize any proposal to expand the Board beyond five(5) members without the advance written approval of HOC.
85.3 Board Meetings. At all times when the provisions of Section 5.1 are satisfied, the Company shall provide HOC Director(s) not less than 7(seven) Business Days advance written notice of the date on which any meeting of the Board of Directors shall be held. In providing such notice,the Company shall take into consideration the matters to be discussed at the meeting, the proximity to the place of the meeting and the time zone inwhich the HOC Director is resident.
5.4 Resignation of HOC Director(s). If (x) one or both HOC Directors do not meet the individual qualifications for a director prescribed byapplicable laws, (y) the Pro Rata Interest of HOC falls below 14.5%, or (z) the provisions of Section 8.2 hereof become applicable and the Companydelivers notice to HOC to that effect, all of the HOC Directors shall forthwith resign; provided, however, that in the event of (x), HOC shall then beentitled to appoint an individual to replace the resigning director(s) and such resigning director(s) shall be afforded the benefits of any indemnityand insurance as may exist for all matters occurring prior to such resignation.
5.5 Indemnification and Director’s and Officer’s Insurance. So long as HOC is entitled to nominate and maintain a director pursuant to this Article5, the Company shall indemnify each current and former HOC Director and shall maintain director’s and officer’s liability insurance for the benefit ofeach such director, with the same rights and benefits as are accorded the directors of the Company generally.
ARTICLE 6 RIGHT OF FIRST OFFER
The provisions of this Article 6 shall apply if, but only if, HOC exercises the Option and acquires the Additional Shares and so long as theprovisions of Section 8.2 do not apply:
6.1 Joint Venture  
  (a) If the Company or any of its Subsidiaries decides to seek a joint venture partner to develop, acquire or otherwise earn an interest in anyProperties including the Existing Properties, in circumstances where the Company’s participation in such joint venture is not dependent onthe participation of a particular third party as joint venture partner (such as in the case of an earn-in) (each a “Proposed Joint Venture”),the Company shall immediately provide notice to HOC (the “Joint Venture Proposal Notice”) specifying sufficient information regardingthe particulars of the Proposed Joint Venture to allow HOC to make a reasoned decision in respect of participating in the Proposed JointVenture, including to the extent any such terms are determinable at such time: (A) a description of the Property in respect of which theProposed Joint Venture relates, and (B) the terms, including the purchase price, for the Proposed Joint Venture, and if applicable, a truecopy of any related term sheet setting forth such terms.
Notwithstanding the foregoing, nothing in this Section 6.1 shall prevent the Company from concurrently negotiating with third parties with respectto those matters set out in this Section 6.1.
  (b) If HOC, acting reasonably, determines that the Joint Venture Proposal Notice contains insufficient information to make a reasoneddecision in respect of participating in the Proposed Joint Venture, it shall notify the Company of the information required to make suchdecision and thereafter shall have the greater of (i) five (5) Business Days from the receipt of such information from the Company, and (ii)the days remaining in the period specified in Section 6.2 to make such decision and deliver or refrain from delivering the HOC JVAcceptance Notice in accordance with such Section 6.2. Notwithstanding the foregoing, a copy of the term sheet for the Proposed JointVenture shall be deemed to be sufficient information to make such reasoned decision, if it includes the information specified in Section6.1(a).
96.2 Joint Venture Proposal  
  (a) Receipt of the Joint Venture Proposal Notice by HOC shall be deemed to constitute an invitation to HOC Entities to participate in theProposed Joint Venture.
  (b) If any of HOC Entities provides the Company an acceptance (the “HOC JV Acceptance Notice”) in writing in respect of the JointVenture Proposal Notice, within fifteen (15) Business Days of receipt thereof or such shorter period as may be specified in the Joint VentureProposal Notice of a determination in respect of the Proposed Joint Venture, the Company shall negotiate exclusively in good faith withHOC to finalize terms of the Proposed Joint Venture acceptable to each of the Parties, acting reasonably, within a period of sixty days orsuch additional period as the Parties may from time to time agree in writing (the “JV Negotiation Period”), failing which the Company shallbe entitled to pursue other partners for the Proposed Joint Venture. If HOC does not provide HOC JV Acceptance Notice to the Companywithin fifteen (15) Business Days or such shorter period as may be specified in the Joint Venture Proposal Notice, of receiving of the JointVenture Proposal Notice, the Company may enter into negotiations with any other person regarding the Proposed Joint Venture. If theCompany truncates the period during which the HOC JV Acceptance Notice is required to be returned by HOC, it shall include in the JointVenture Proposal Notice a statement certified by an officer of the Company that the Company has determined that it is necessary to truncatesuch period to avoid losing the opportunity to make such acquisition or other related transaction and that it has used commerciallyreasonable efforts to avoid truncating such period.
ARTICLE 7 STANDSTILL
The provisions of this Article 7 shall apply if HOC acquires the Additional Shares and for a period of two (2) years after the Subsequent ClosingDate:
7.1 Standstill  
  (a) HOC covenants and agrees that, except as otherwise contemplated in this Agreement, HOC will not, and will not allow any HOCEntities to, in either case, without the prior written consent of the Company, directly or indirectly:
  (i) acquire or enter into any agreement to acquire or make any proposal or offer to acquire in any manner any equity securities ofthe Company (whether issued or unissued) that would result in a Pro Rata Interest greater than 40% other than (A) as a resultof a stock dividend or distribution made by or a recapitalization of the Company, (B) in accordance with the terms of anydividend reinvestment or share purchase plan made available from time to time by the Company to holders of equitysecurities; (C) pursuant to the exercise of rights issued pursuant to a rights offering made by the Company to the holders ofits equity securities; or (D) pursuant to the exercise of rights issued pursuant to any shareholder rights plan of the Companyand attached to equity securities;
10(ii) assist, encourage or advise any other person to acquire or agree to acquire in any manner any equity securities;
  (iii) propose or support or engage in any discussions or negotiations with respect to, or enter into any agreement, commitment orunderstanding with any third party to effect, any tender offer, merger, business combination, asset or share transaction,financing transaction or corporate restructuring involving the Company;
  (iv) make or participate directly or indirectly in any solicitation of proxies from shareholders of the Company;
  (v) form, join or in any way participate in any group acting jointly or in concert with any of the foregoing; or
  (vi) make any public disclosure of any intention in connection with the foregoing;
  (each an "Acquisition Proposal").
(b)Notwithstanding Section 6.1, none of the HOC Entities shall be prohibited from making an Acquisition Proposal:
  (i) in the event the Company materially breaches its obligations under Section 2.3 (Additional Financing), Article 4 (Pre-EmptiveRight), Article 5 (Board Representation) or Article 6 (Right of First Offer), provided that HOC has notified the Company ofany alleged breach and the Company has failed to cure such alleged breach, if curable, within thirty days of such notice;
  (ii) from the date any public announcement of or public disclosure of an intention to commence or enter into any agreement withrespect to any of the following is made by any person (other than any HOC Entity) to the date of the withdrawal orcancellation of the Tender Offer Transaction or Business Combination Transaction (each as defined below):
  A) a tender offer or an intention to undertake a tender offer for equity securities of the Company by any person or groupof persons (other than any HOC Entities) which if completed would result in such tender offer person or group ofpersons holding 20% or more on a non-diluted basis of any class of then outstanding equity securities of theCompany (a “Tender Offer Transaction”); or
11
  B) any acquisition (excluding a Tender Offer Transaction), merger, asset purchase and sale, business combinationB) any acquisition (excluding a Tender Offer Transaction), merger, asset purchase and sale, business combinationtransaction or other extraordinary transaction involving or relating to the Company or any of its subsidiaries, or anintention to make an offer to the Company and/or its subsidiaries to undertake such a transaction, by any person orgroup of persons (other than any HOC Entities) which would, if completed, result in (I) any class of outstandingequity securities being converted into cash or securities of another person resulting in shareholders holding less than50% of the equity and/or voting securities of the resulting entity; or (II) all or substantially all of the Company’sassets being sold to any person or group of persons (other than any HOC Entities) (a “Business CombinationTransaction”), provided that in the case of this Section 6.1(b)(ii)(B) HOC must make such Acquisition Proposalconfidentially to the Board of Directors and not by way of public offer to the shareholders.
  For greater certainty, if HOC has commenced an Acquisition Proposal in reliance on this Section 6.1(b)(ii) or in respect ofSection 6.1(b)(ii)(B), has agreed with the Company to an Acquisition Proposal, prior to the withdrawal or cancellation of suchTender Offer Transaction or Business Combination Transaction, HOC shall not be precluded from continuing with suchAcquisition Proposal by reason only of the withdrawal or cancellation of any relevant Tender Offer Transaction or BusinessCombination Transaction; or
  (iii) if a person or group of persons other than any of the HOC Entities, the Company or its subsidiaries obtains proxies carrying amajority of the votes attached to all outstanding voting securities of the Company and exercises such votes to replace theBoard of Directors.
7.2 Most Favored Nation. The Company shall immediately inform HOC and provide HOC with a copy of any other standstill provisions in anyagreement pertaining to the matters set forth in this Article 6, entered into by the Company with another person subsequent to the date hereof, andnotwithstanding delivery of such notice and a copy of any such provisions, HOC shall have the full benefit of any materially more favourableterms, in the opinion of HOC, contained in such standstill and Section 6.1 shall be deemed to be amended accordingly.
ARTICLE 8 COVENANTS
8.1 Designation of Consulting Geologists. During the time up to the Option Expiration Date, and thereafter if HOC exercises the Option andacquires the Additional Shares and the provisions of Section 8.2 do not apply, HOC shall have the right to designate one full or part time geologistto act as a consultant to the Company at any of its Existing Properties for the purpose of advising the Company with regard to ongoing explorationand development. The Company shall provide such geologist with room and board while such geologist is on-site at any of the Existing Properties.HOC, however, shall be responsible for payment of any compensation for such geologist. Other consulting services which may be required by theCompany, including metallurgical, underground mining engineering or concentrate contract negotiations, may be requested from HOC, andprovided that HOC agrees to deliver those services, any charges for such services shall be billed by HOC to the Company at no more than HOC’sactual cost plus 1%.
128.2 Termination of Certain HOC Rights. Notwithstanding anything in this Agreement to the contrary, in the event (i) HOC shall hold a Pro RataInterest less than 14.5% or (ii) HOC shall have achieved a Pro Rata Interest greater than 14.5% but subsequently sells or otherwise disposes of 20%or more of its Pro Rata Interest in any one or more transactions, the benefits provided to HOC pursuant to the provisions of Section 2.3 (AdditionalFinancing), Article 4 (Pre-Emptive Rights), Article 5 (Board Representation), Article 6 (First Offer) and Section 8.1 (Designation of Geologist) aboveshall immediately terminate and be of no further force or effect. Furthermore, any HOC Director nominated and appointed pursuant to theprovisions of Section 5.1 or 5.2 shall immediately resign in the event that the provisions of subsection (i) or (ii) above shall be applicable.
ARTICLE 9 ADDITIONAL COVENANTS
9.1 Covenants of the Company.  
  (a) Prior to the Option Expiration Date, the Company shall not and shall not permit its Affiliates, agents or other representatives(including any director, officer, investment banker, legal advisor or accountant retained by the Company or any of its Susidiaries) to:
  (i) initiate, solicit, promote or encourage, directly or indirectly, inquiries or the submission of proposals or offers from anyPerson with respect to any proposal or offer or action that would reasonably be expected to delay, prevent or frustrate theTransactions or any part thereof (an “Alternative Proposal”);
  (ii) encourage, or participate or engage in negotiations concerning, or furnish to any Person other than to HOC Entities, anynon-public information with respect to, or otherwise co-operate in any way with, or participate in, or facilitate or encourageany Person to make an Alternative Proposal; or
  (iii) endorse, accept, approve or recommend a proposal of, or enter into any Contract or understanding with , any Person relatingto an Alternative Proposal, or otherwise facilitate any effort or attempt to make or implement an Alternative Proposal.
  (b) Notwithstanding anything else in this Section 9.1, if the Company or any of its subsidiaries receives an unsolicited AlternativeProposal prior to the Option Exercise Date, the Board of Directors may participate in discussions with, furnish information to, orenter into an agreement with the Person that initiated the Alternative Proposal only if: (x) the Board of Directors determines in goodfaith, after consultation with outside counsel, that such action is necessary in order for them to act in a manner consistent with theirfiduciary duty under applicable Laws; (y) the Company shall have provided to HOC notice at least five (5) Business Days prior tothe date on which the agreement to effect such Alternative Proposal is to be entered into specifying the terms of the AlternativeProposal; and (z) after taking into account modifications to this Agreement proposed by HOC during such five Business Day period,such proposal would constitute a superior proposal (“Superior Proposal”). If HOC makes a proposal to amend this Agreement toincrease the purchase price payable for the Additional Shares, such that the proposal of such other Person shall no longer be aSuperior Proposal, and shall complete the purchase of the Additional Shares upon such terms, then neither the Company nor itssubsidiaries shall enter into such Alternative Proposal.
13(c) The Company shall comply with all securities regulatory filing requirements on a timely basis in connection with the issuance of anyEquity Securities of the Company to any HOC Entity, including filing within the periods stipulated under Securities Laws, at theCompany’s expense, all private placement forms required to be filed by the Company and paying all filing fees required to be paid inconnection therewith so that such issuance may lawfully occur without the necessity of filing a prospectus, registration statement orany similar document under the Securities Laws.
  (d) The Company shall, to the extent and for so long as HOC Entities hold at least 14.5% of the Shares on a non-diluted basis, uponHOC’s request, permit representatives of the HOC Entities to have access to the site and any of the premises where the businessand operations of the Company and its Subsidiaries are conducted and access and duplicating rights (and use commerciallyreasonable efforts to cause persons or firms possessing such documentation or information to give similar access and duplicatingrights) to the Company and its Subsidiaries’ books of account and records and such other documents, communications, items andmatters, within the knowledge, possession or control of the Company, which HOC may reasonably request, at HOC’s own cost(other than those it is permitted to examine and make copies of free of charge pursuant to applicable Laws) provided that, except tothe extent the information can be provided in the necessary course of business of the Company, acting reasonably including toprovide HOC Entities with information to assist the HOC Entities and their advisors with the preparation of the financial statementsfor such HOC Entities, nothing herein shall require the Company to provide HOC Entities with any information which wouldconstitute a material fact with respect to the Company which has not been generally disclosed.
  (e) In the event the Company shall breach any representation or warranty, covenant or any other right of HOC under this Agreement inany material respect, including but not limited to, the rights afforded to HOC under Articles 2, 4, 5, 6 and 8 hereof, then at the requestof HOC, the Company shall promptly prepare and file with the SEC a registration statement on Form S-l or S-3 (or, if Form S-l or S-3 isnot then available, on such form of registration statement as is then available to effect a registration for resale of the Purchase Sharesand the Additional Shares (“Registration Statement”)), covering the resale of all of the Shares owned by HOC; provided, however,that if prior to the filing of the Registration Statement, the provisions of Rule 144 of the Securities Act of 1933, as amended (the “1933Act”) allow the sale of all of the Shares in compliance with that Rule, the Company shall not be obligated to file such RegistrationStatement so long as the Company at its own expense, does the following: (i) complies with any necessary filing or reportingrequirements (under the 1933 Act or otherwise) to permit such sale, (ii) cooperates with HOC in removing any legend on thecertificates representing the Shares, including but not limited to instructing its transfer agent to remove such restrictive legend and(iii) provides HOC with an opinion of counsel confirming that such sale is permitted under Rule 144. Such Registration Statementalso shall cover, to the extent allowable under the 1933 Act and the rules promulgated thereunder (including Rule 416), suchindeterminate number of additional shares of Common Stock resulting from stock splits, stock dividends or similar transactions withrespect to the Shares. The Company shall pay all expenses associated with the registration, including filing and printing fees,counsel and accounting fees and expenses, and State “Blue Sky” fees and expenses. The Company shall use its commerciallyreasonable efforts to have the Registration Statement declared effective by the SEC as soon as practicable. The Company shallnotify HOC by facsimile or e-mail as promptly as practicable, and in any event, within three (3) business days, after the RegistrationStatement is declared effective and shall simultaneously provide HOC with copies of any related prospectus to be used inconnection with the sale or other disposition of the securities covered thereby.
14(f) In connection with the foregoing, the Company shall indemnify and hold harmless HOC against any losses, claims, damages orliabilities to which it may become subject under the 1933 Act or otherwise, insofar as such losses, claims, damages or liabilities (oractions in respect thereof) arise out of or are based upon (i) any untrue statement or alleged untrue statement of any material factcontained in the Registration Statement or any other public filing by the Company, so long as such statement has not been providedto the Company by HOC for inclusion in such registration statement; (ii) the omission or alleged omission to state therein a materialfact required to be stated therein or necessary to make the statements therein not misleading, so long as such omission or allegedomission does not relate to HOC or the manner of sale for the Shares as provided to the Company by HOC; or (iii) any violation ofthe 1933 Act, any rule or regulation thereunder or any other securities law, rule or regulation applicable to the Company and relatingto the action or inaction required of the Company in connection therewith. The foregoing indemnification obligation shall extend tothe fees and expenses of any counsel retained by HOC in connection with any such loss, claim, damage or liability.
ARTICLE 10 REPRESENTATIONS & WARRANTIES
10.1 Representations and Warranties of the Company. The Company represents, warrants and agrees with HOC as of the date of this Agreement,
that:  
  (a) The Company is a corporation duly incorporated under the laws of the State of Colorado, and is validly existing and in good standingunder the laws of the State of Colorado and no proceedings have been instituted or are pending for the dissolution or liquidation of theCompany;
  (b) The Company has all requisite legal and corporate power and authority to execute, deliver and perform its obligations under thisAgreement;
  (c) This Agreement has been duly authorized by all necessary corporate action on the part of the Company and has been duly executed anddelivered by the Company and constitutes a valid and legally binding obligation of the Company enforceable against the Company inaccordance with its terms; and
15(d) The execution and delivery of this Agreement and the performance by the Company of its obligations hereunder and the consummationof the Transactions, do not and will not conflict with, or result in a breach or violation of, any of the terms or provisions of, or constitute adefault under (whether after notice or lapse of time or both): (i) the constating documents of the Company; (ii) the resolutions of theshareholders or directors (or any committee thereof) of the Company which are in effect at the date hereof; (iii) any mortgage, note,indenture, contract, agreement, instrument, lease or other document to which the Company is a party or by which it is bound; or (iv) anyjudgement, writ, injunction, decree or order, of any court or of any Authority that is binding the Company or the property or assets of theCompany.
10.2 Representations and Warranties of HOC. HOC represents, warrants and agrees with the Company as of the date of this Agreement, that:  
  (a) HOC is a limited company incorporated under the Companies Act 1985 (England) as a limited company, registered in England andWales, and is validly existing and in good standing under the laws of England and no proceedings have been instituted or arepending for the dissolution or liquidation of HOC;
  (b) HOC has all requisite legal and corporate power and authority to execute, deliver and perform its obligations under this Agreement;
  (c) this Agreement has been duly authorized by all necessary corporate action on the part of HOC and has been duly executed anddelivered by HOC and constitutes a valid and legally binding obligation of HOC enforceable against HOC in accordance with itsterms; and
  (d) the execution and delivery of this Agreement and the performance by HOC of its obligations hereunder and the consummation of theTransactions, do not and will not conflict with, or result in a breach or violation of, any of the terms or provisions of, or constitute adefault under (whether after notice or lapse of time or both): (i) the constating documents of HOC; (ii) the resolutions of theshareholders or directors (or any committee thereof) of HOC which are in effect at the date hereof; (iii) any mortgage, note, indenture,contract, agreement, instrument, lease or other document to which HOC is a party or by which it is bound; or (iv) any judgement,writ, injunction, decree or order, of any court or of any Authority that is binding on HOC or the property or assets of HOC.
ARTICLE 11 INDEMNIFICATION
11.1 Indemnification by the Company.  
  The Company will indemnify and save harmless the HOC Entities and the directors, officers, employees and agents of the HOC Entities(collectively, the “HOC Indemnitees”) from and against all Claims incurred by any one or more of the HOC Indemnitees directly or indirectlyresulting from any breach of any covenant, representation or warranty of the Company contained in this Agreement.
1611.2 Indemnification by HOC.  
  HOC will indemnify and save harmless the Company and the directors, officers, employees and agents of the Company (collectively, the“Company Indemnitees”) from and against all Claims incurred by any one or more of the Company Indemnitees directly or indirectlyresulting from any breach of any covenant, representation or warranty of HOC contained in this Agreement.
11.3 Injunctive Relief.  
  Notwithstanding any other provision of this Agreement, nothing herein is intended to or shall restrict a Party from seeking and receivinginjunctive relief (whether as a temporary restraining order, preliminary injunction or otherwise) or specific performance.
ARTICLE 12 MISCELLANEOUS PROVISIONS
12.1 Notices. All notices or other communications required or permitted to be given by one party to another by the terms hereof shall be given inwriting by personal delivery or facsimile delivered to such other party as follows:
  To the Company:
  Gold Resource Corporation 222 Milwaukee St., Suite 301Denver, CO 80206 Attention: William Reid, President Facsimile No.: (303) 320-7835
  To HOC:
  Hochschild Mining Holdings Limited Calle La Colonia 180Surco, Lima 33, Peru Attention: VP & General Counsel Facsimile No.: +511-437-5009
or at such other address or facsimile number as may be given by either of them to the other in writing from time to time and such other notices orcommunications shall be deemed to have been received when delivered or, if by facsimile, on the next business day after such notice or othercommunication has been transmitted by facsimile (with receipt confirmed).
1712.2 Further Assurances. Each of the parties hereto upon the request of each of the other parties hereto, whether before or after the date of thisAgreement, shall do, execute, acknowledge and deliver or cause to be done, executed, acknowledged and delivered all such further acts, deeds,documents, assignments, transfers, conveyances, powers of attorney and assurances as may reasonably be necessary or desirable to complete thetransactions contemplated herein.
12.3 Costs and Expenses. All costs and expenses (including, without limitation, the fees and disbursements of legal counsel) incurred in connectionwith this Agreement and the transactions herein contemplated shall be paid and borne by the party incurring such costs and expenses.
12.4 Applicable Law. This Agreement shall be construed and enforced in accordance with, and the rights of the parties shall be governed by, thelaws of the State of New York and the laws of the United States applicable therein. Any and all disputes arising under this Agreement, whether asto interpretation, performance or otherwise, shall be subject to the non-exclusive jurisdiction of the courts of Colorado and each of the partieshereto hereby irrevocably attorns to the jurisdiction of the courts of such province.
12.5 Entire Agreement. This Agreement constitutes the entire agreement between the parties with respect to the transactions contemplated hereinand cancels and supersedes any prior understandings, agreements, negotiations and discussions between the parties. There are norepresentations, warranties, terms, conditions, undertakings or collateral agreements or understandings, express or implied, between the partieshereto other than those expressly set forth in this Agreement or in any such agreement, certificate, affidavit, statutory declaration or otherdocument as aforesaid.
12.6 Amendment and Waivers. No amendment of this Agreement will be effective unless made in writing and signed by the Parties. A waiver ofany default, breach or non-compliance under this Agreement is not effective unless in writing and signed by the Party to be bound by the waiver.No waiver shall be inferred from or implied by any failure to act or delay in acting by a Party in respect of any default, breach or non-observance orby anything done or omitted to be done by the other Party in respect of any default, beach or non-observance or by anything done or omitted to bedone by the other Party. The waiver by any Party of any default, breach or non-compliance under this Agreement shall not operate as a waiver ofthat Party’s rights under this Agreement in respect of any continuing or subsequent default, breach or non-observance (whether of the same orany other nature).
12.7 Severability. If any one or more provisions in this Agreement, for any reason, shall be determined to be invalid, illegal or unenforceable in anyrespect, the validity, legality and enforceability of any such provision in any other respect and the remaining provisions of this Agreement shall notbe in anyway impaired.
12.8 Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed to be an original and all of whichtogether shall constitute one and the same Agreement. Counterparts may be delivered either in original or faxed form and the parties adopt anysignature received by a receiving fax machine as original signatures of the parties.
12.9 Assignment. This Agreement may not be assigned by either party except with the prior written consent of the other parties hereto.
1812.10 Enurement. This Agreement shall enure to the benefit of and be binding upon the parties hereto and their respective heirs, executors,successors (including any successor by reason of the amalgamation or merger of any party), administrators and permitted assigns.
IN WITNESS WHEREOF the parties hereto have executed this Agreement as of the day and year first above written.
GOLD RESOURCE CORPORATIOn  
By: ___________________________________________ Authorized Signing Officer
HOCHSCHILD MINING HOLDINGS LIMITED  
By: ___________________________________________ Authorized Signing Officer
19Exhibit 4.72
Confidential
(Translation, for reference only)
Strategic Alliance Agreement
This Strategic Alliance Agreement (“Agreement”) is executed on this 11th day of December, 2015 (“Execution Date”) by and between
ChipMOS TECHNOLOGIES INC., a company incorporated under the laws of Taiwan (“ChipMOS”), and Tsinghua Unigroup Ltd. (“Tsinghua
Unigroup”), a company incorporated under the laws of the People’s Republic of China (“PRC”). ChipMOS and Tsinghua Unigroup shall collectively
be referred to as the “Parties.”
WHEREAS, Tsinghua Unigroup actively searches for investment targets which are leading companies in upstream, midstream, or downstream
semiconductor industries, provides abundant funds to build strategic cooperation, and jointly shares the growing business opportunities of the
semiconductor market in Mainland China; ChipMOS is a leading company engaged in the assembly and testing services of LCD drivers and wafer
bumping process technologies.
WHEREAS, ChipMOS and Tsinghua Unigroup will also, on the Execution Date, enter into the Share Subscription Agreement (“Share
Subscription Agreement”). ChipMOS agrees, according to the terms and conditions of the Share Subscription Agreement, to increase its capital
and issue 299,252,000 common shares through private placement (“Private Placement Shares”) and the Private Placement Shares will be subscribed
to by a company over which Tsinghua Unigroup has de facto control (“Subscriber”); Tsinghua Unigroup also agrees that such Private Placement
Shares be subscribed to by the Subscriber from ChipMOS (“Transaction”).
WHEREAS, ChipMOS and Tsinghua Unigroup, in order to strengthen their relationship, are going to form a strategic alliance, establish a
long-term cooperative relationship, share resources and networks, support each other in the semiconductor industry, and strive for expansion and
growth. NOW, THEREFORE, the Parties hereby agree as follows:
 
Article 1 Strategic Alliance
1.1 Content of Strategic Alliance and Expected Benefits After the Closing Date (as defined in the Share Subscription Agreement), Tsinghua
Unigroup and ChipMOS shall cooperate, expand, strengthen and stabilize the relationship with the related upstream, midstream, and downstream
industries engaged in the assembly and testing services of LCD drivers, microelectromechanical systems (MEMS), the Internet of Things (IoT) and
Radio Frequency Integrated Circuits (RFIC) and/or wafer bumping services in Mainland China. Tsinghua Unigroup shall also introduce other
potential suppliers, customers and business partners in Mainland China to ChipMOS.
 
- 1 -Confidential
(Translation, for reference only)
 
1.2 Covenants of Parties 
(1) Tsinghua Unigroup covenants to follow the Share Subscription Agreement to subscribe for, via the Subscriber, in compliance with the
requirements of Taiwan’s laws and regulations relating to securities transactions and PRC investment in Taiwan, at the Subscription Price per Share
(as defined in the Share Subscription Agreement), 299,252,000 common shares through private placement from ChipMOS, and Tsinghua Unigroup
shall comply with, and shall cause the Subscriber to comply with the content of the Share Subscription Agreement, Taiwan’s laws and regulations
concerning securities transactions and PRC investments in Taiwan so that ChipMOS may make use of the Total Subscription Price (as defined in
the Share Subscription Agreement) to replenish operating capital, recruit talents, and upgrade its technologies related to the semiconductor
assembly and testing services, to create profits for each of the Parties and its shareholders.
(2) ChipMOS covenants that part or all of the Total Subscription Price shall be used:
 
  (a) To strengthen research and development, and technologies, and expand production capacity in Taiwan in order to strengthen its
roots in Taiwan, and increase job opportunities.
 
 
(b) To increase the capital of ChipMOS TECHNOLOGIES (Shanghai) LTD. (“ChipMOS Shanghai”), and replenish the operating
capital of ChipMOS Shanghai, in order to expand ChipMOS and its affiliates’ business scale in LCD driver and Specialty
Memory IC assembly and testing services and/or wafer bumping services markets, and thus increase ChipMOS’ global market
share.
 
  (c) As funds for the merger with ChipMOS TECHNOLOGIES (Bermuda) LTD.
 
  (d) As funds for the merger and acquisition by ChipMOS of other appropriate targets in the semiconductor industry in Taiwan
which have similar ideals, share a common goal, and are industrially complimentary.
 
- 2 -Confidential
(Translation, for reference only)
 
1.3 Implementation of Strategic Alliance Each of the Parties covenants to, after the Closing Date, designate related staff to hold regular
meetings to propose a specific plan and schedule in connection with Sections 1.1 and 1.2 herein, perform the specific plan together and review the
implementation status. Each Party shall use its reasonable best efforts to provide immediate assistance to, and actively cooperate with, the other
Party, to implement this Agreement.
 
Article 2 Term of Agreement
2.1 Term of Agreement Except as otherwise provided herein, the term of this Agreement is three (3) years from the Execution Date
(“Cooperation Period”). The Parties may negotiate for an extension of this Agreement six (6) months before the expiration of the Cooperation
Period.
2.2 Early Termination This Agreement may be terminated as follows:
(1) Tsinghua Unigroup and ChipMOS Taiwan terminate this Agreement by mutual agreement in writing;
(2) In the event that Tsinghua Unigroup or ChipMOS materially breaches this Agreement and such breach is incurable, the other Party may
immediately terminate this Agreement by giving written notice to the breaching Party; if such breach is curable, this Agreement will be terminated
automatically after ten (10) days from the date on which the breaching Party received the written notice given by the other Party, if the breaching
Party fails to cure such breach; or
(3) This Agreement shall be simultaneously terminated, rescinded or become invalid upon the termination, rescission, or invalidation of the
Share Subscription Agreement.
2.3 Effects of Termination This Agreement shall immediately become void and of no further force and effect after expiration, pursuant to
Section 2.1, or termination, pursuant to Section 2.2; provided, however, that Sections 2.2, 2.3, 3.1 and 3.9 shall survive after the termination of this
Agreement.
 
- 3 -Confidential
(Translation, for reference only)
 
Article 3 Miscellaneous
3.1 Governing Law and Jurisdiction This Agreement shall be governed by, and construed in accordance with the laws of Taiwan. The Parties
shall first seek to solve any dispute arising out of or related to this Agreement through negotiation. If the Parties fail to solve such dispute through
negotiation, each Party shall have the right to issue notice (“Dispute Notice”) to the other Party, and such Dispute Notice shall include the content
of the dispute. If the Parties fail to resolve such dispute amicably through negotiation within sixty (60) days from the date on which a Party issues
its Dispute Notice to the other Party, each Party shall have the right to submit such dispute to the Hong Kong International Arbitration Center, and
proceed with the arbitration procedures in accordance with the Rules of the International Chamber of Commerce with three (3) arbitrators. Each
Party shall each select one (1) arbitrator, and the third arbitrator shall be appointed by the two (2) arbitrators so selected. All language used in such
proceedings shall be Mandarin Chinese. The Parties agree to keep the content of the dispute and the proceeding of the arbitration confidential. The
arbitration award shall be final and binding on the Parties. The losing Party in such arbitration shall bear all of the costs and expenses related to the
arbitration as determined by the arbitrators in such dispute (including attorney’s fees).
3.2 Assignment of Rights and Obligations Neither Party shall assign any rights or obligations provided herein without the prior written
consent of the other Party.
3.3 Entire Agreement; Amendment This Agreement constitutes the entire agreement between the Parties, and supersedes all prior
documents and agreements in connection with the Transaction. Such documents or agreements shall be null and void immediately and cease to be
applied. Except as otherwise provided herein, both Parties’ consent in writing is necessary to amend, waive, rescind or terminate the Agreement or
any terms and conditions.
3.4 Notice All notices and other expression of intent hereunder shall be issued in writing and shall be deemed duly given by registered mail or
express delivery or personal delivery to the following address:
 
  (1) if to ChipMOS:
ChipMOS TECHNOLOGIES INC.
Representative: Shih-Jye Cheng
Address: No. 1, Yanfa 1st Rd., Hsinchu Science Park, Hsinchu, Taiwan
 
- 4 -Confidential
(Translation, for reference only)
 
  (2) if to Tsinghua Unigroup:
Tsinghua Unigroup Ltd.
Representative: Weiguo Zhao
Address: F10 Unis Plaza, Tsinghua Science Park, Haidian District, Beijing, PRC
The delivery may also be made to another address provided by a Party to the other Party in writing. The notices and other expressions of
intent for the purpose of this Agreement shall be deemed received: when delivered by express delivery or personal delivery, at the actual time of
receipt; when delivered by mail, at the actual time of receipt or 72 hours after mailing (whichever is earlier).
3.5 No Waiver No omission or delay of either Party to exercise any right, power or remedy herein shall prevent such Party from exercising
such right, power or remedy in the future. Any right, power and remedy that either Party enjoys pursuant to this Agreement shall survive, unless
the Party expressly waives such right, power or remedy in writing. All rights, powers or remedies which each Party of this Agreement may claim,
pursuant to the laws and this Agreement, shall not preclude other rights, powers or remedies that such Party may claim pursuant to the laws or this
Agreement.
3.6 Expenses Regarding the expenses arising from this Agreement and the Transaction, each Party shall bear the expenses occurred by it
pursuant to the nature of such expenses and the relevant provisions.
3.7 Severability If any provision of this Agreement is held to be illegal, unenforceable or invalid by the judgment or ruling of the court, other
provisions herein shall remain in full force and effect.
3.8 Headings and Subheadings The headings and subheadings herein are solely for ease of reference by the Parties, and shall not be used to
interpret this Agreement.
 
- 5 -Confidential
(Translation, for reference only)
 
3.9 Confidentiality The Parties agree that the Parties will not disclose information in connection with the execution, existence, content, and
performance of this Agreement to any third party before the Parties have made an announcement to the public pursuant to Section 3.11 of this
Agreement. However, the foregoing restriction shall not apply to disclosure made to the board of the directors, management team, and relevant
employees who need to know such information, attorneys, accountants, financial counsel, and competent authorities for the purposes of
performing this Agreement.
3.10 Actual Performance The Parties acknowledge and agree that if any of the provisions provided herein are not performed in accordance
with the specific terms and conditions or are otherwise violated, this will cause irreparable damages for which monetary compensation would not be
an adequate remedy. Therefore, the Parties agrees that, in addition to any other remedies available in common law or equity, each Party shall be
entitled to seek injunction and other equitable remedies, including the actual performance of the terms and conditions provided herein, and it is not
necessary to post any bond or other security.
3.11 Announcement The Parties shall not make an announcement to the public without the consent of the Parties regarding the execution and
content of this Agreement and information in connection with the performance of this Agreement, which includes, but is not limited to the
disclosure of material information, pursuant to the laws and the content thereof. The Parties shall negotiate and determine whether to make the
announcement by press release, press conference or any other method and the content of the announcement. However, in the event that a Party
discloses the above-mentioned information pursuant to the laws or requests made in judicial proceedings, and the disclosing Party could not
obtain the consent of the other Party in time or the other Party refused to provide its consent without proper reasons after the disclosing Party
notified the other Party of such situation, then the disclosing Party may disclose the above-mentioned information.
3.12 Counterparts This Agreement shall be executed in four (4) originals. ChipMOS and Tsinghua Unigroup shall hold two (2) originals each.
[Signature page follows]
 
- 6 -Confidential
(Translation, for reference only)
 
This is the signature page for the “STRATEGIC ALLIANCE AGREEMENT.”
 
ChipMOS TECHNOLOGIES INC.     Tsinghua Unigroup Ltd.
By:   /s/ Shih-Jye Cheng     By:   /s/ Weiguo Zhao
Name:  Shih-Jye Cheng     Name:  Weiguo Zhao
Title:   Chairman     Title:   Chairman
 
- 7 -Exhibit 10.11
 
***Certain portions of this exhibit have been omitted based on a request for confidential treatment pursuant to Rule 24b-2 under the Securities
Exchange Act of 1934, as amended. The omitted portions have been filed separately with the Securities and Exchange Commission.
 
STRATEGIC ALLIANCE AGREEMENT
 
 
This Strategic Collaboration Agreement (“Agreement”), effective as of the 23rd day of  September, 2016 (“Effective Date”), is
entered into by and between The University of Texas M. D. Anderson Cancer Center, with a place of business located at 1515
Holcombe Blvd., Houston, TX 77030, USA (“MD Anderson”), a member institution of The University of Texas System (“System”)
and Adaptimmune LLC, with a place of business located at 2001 Market Street, Philadelphia, PA 1903, USA (“Adaptimmune”); and
Adaptimmune Limited, with a place of business at 101 Milton Park, Abingdon, Oxfordshire, OX14 4RY (“Adaptimmune Limited”)
(MD Anderson and Adaptimmune each a “Party” and collectively the “Parties”).
 
WITNESSETH
 
Whereas Adaptimmune and Adaptimmune Limited are biotechnology companies involved in the field of research, development and
marketing of pharmaceutical products and therapies, including the sponsorship of clinical trials.
 
Whereas MD Anderson is a comprehensive cancer research, treatment, and prevention center, with scientists and technicians in
substantive fields relating to cancer research.
 
Whereas the Parties hereby wish to establish a strategic alliance, as further described herein, (“ Alliance”) whereby Adaptimmune
will provide funding and in-kind support for: (a) one or more preclinical studies (“Pre-clinical Studies”); and (b) one or more clinical
and related correlative studies (“Clinical Studies”) to be conducted by MD Anderson pursuant to this Agreement (each such Clinical
Study or Pre-clinical Study, a “Study,” and all such Clinical Studies and Pre-clinical Studies, the “Studies.”).
 
Now therefore, in consideration of the premises and the mutual covenants and conditions hereinafter recited, the Parties do hereby
agree as follows:
 
1. Subject and Scope of Agreement
 
1.1  The initial scope of the Alliance will consist of the Studies described in Exhibit I, the details of which are to be mutually agreed
upon by the JSC from time to time in accordance with Sections 1.5 – 1.8 below). The Studies and/or the scope of the Alliance may be
replaced and/or changed as agreed upon by the JSC. Adaptimmune shall have responsibility for IND filing and monitoring unless
otherwise agreed by JSC. The Alliance Funding (defined in Section 1.3 below) will cover enrollment of a minimum of *** Clinical
Study subjects into Clinical Studies (with Clinical Studies in this context excluding any screening Study or long term follow-up Study)
(“Minimum Patient Numbers”). MD Anderson represents and undertakes that (a) *** and (b) that the ***
 
(together (a) and (b) being the ***):
 
1.2  Adaptimmune shall be the sponsor of any Clinical Study. MDACC shall be responsible for the conduct of each Study in
accordance with the relevant protocol and/or workscope. The Agreement shall govern the performance of Studies by MD Anderson
and one or more Principal Investigator(s) on basis of
 
***  Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the
Commission.
 
1Study specific documents (“Study Orders”) as agreed upon by the Parties. This Agreement shall apply to all Studies set out in the
Study Orders performed by MD Anderson and the MD Anderson principal investigator(s) responsible for the performance of such
Studies (“Principal Investigator(s)”) upon execution of Study Orders during the term of this Agreement. Each Study Order shall be
substantially in the form attached as Exhibit III to this Agreement and shall detail the specifics of the Study to be performed under
such Study Order including, without limitation, (i) the detailed Protocol or workscope, (ii) the Principal Investigator and (iii) identify
any project-specific resources or support provided by Adaptimmune. In the event of any conflict of terms of this Agreement and the
terms of a Study Order, the terms of this Agreement shall govern, unless the Study Order specifically and expressly supersedes this
Agreement with respect to a specific term, and then only with respect to the particular Study Order and specific term. If there is any
discrepancy or conflict between the terms contained in a Protocol or workscope and this Agreement and/or the relevant Study Order,
the terms of the Protocol or workscope shall govern and control with respect to clinical/scientific matters and the terms of the
Agreement and/or the relevant Study Order in that order shall govern and control with respect to all other matters, e.g., legal and
financial matters.
 
1.3 Adaptimmune agrees to commit funding in an amount of at least nineteen million six hundred and forty four thousand Dollars US
($19,644,000) for the performance of the Studies as set out in Exhibit I during the term (“Alliance Funding”). The JSC may allocate
and/or re-allocate funds to Studies as necessary and agreed by JSC. The basic per patient estimate for Clinical Studies is as follows:
for screening Clinical Studies: $***, for long term follow-up Clinical Studies: $*** and for other Clinical Studies: $***. If the Parties
extend the term by mutual agreement as set forth herein, the Parties shall negotiate in good faith the amount of future Study funding
commitments by Adaptimmune applicable to such extended term. In the event a Study is terminated early, then in relation to any funds
allocated to such Study, the Parties shall promptly discuss and agree upon a replacement of that Study with a new study of similar
scope that is of mutual scientific interest to the Parties and that is approved by the JSC, and that will be funded by the Alliance
Funding. If there is any Alliance Funding at the expiration or termination of this Agreement, it will be allocated to studies, research or
tests agreed by the JSC, and such Alliance Funding will be payable in accordance with agreed milestones relevant to such agreed
studies, research or tests.
 
The Parties understand that the compensation being paid to MD Anderson under this Agreement constitutes the fair market value of
the services to be provided hereunder. Neither MD Anderson nor Principal Investigator shall seek or accept reimbursement from any
third-party payor for any Study items or procedures supplied by or paid for by Adaptimmune under this Agreement. MD Anderson
acknowledges that Adaptimmune may be obligated to disclose all payments made hereunder, including the provision of non-monetary
items of value, as may be required under Applicable Law, including the Physician Payments Sunshine Act, passed as Section 6002 of
the 2010 Patient Protection and Affordable Care Act and, to the extent required by Applicable Laws, agrees to keep and maintain
relevant records of such and, upon Adaptimmune’s reasonable request, provide such records to Adaptimmune to the extent such
information is not already in Adaptimmune’s possession, but only to the extent required for Adaptimmune to comply with its legally
required reporting obligations. MD Anderson consents to such disclosure, to the extent such disclosure is required for Adaptimmune
to comply with Applicable Laws. MD Anderson shall ensure that the Principal Investigator provides in a timely manner all such
reasonable information to Adaptimmune necessary for Adaptimmune to comply with any disclosure requirements to the extent
required by and in accordance with 21 C.F.R. Part 54, including but not limited to, any information required to be disclosed in
connection with any financial relationship between Adaptimmune and the Principal Investigators and sub-investigators involved in the
Study, as well as any immediate family members thereof. MD Anderson will ensure that Principal Investigator promptly updates any
provided information if any relevant changes occur during the performance of any Study and for one year following completion of any
Study.
 
***  Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the
Commission.
 
2No amounts paid under this Agreement are intended to be for, nor shall they be construed as, an offer or payment made in exchange
for any explicit or implicit agreement to purchase, prescribe, recommend, or provide a favorable formulary status, for any
Adaptimmune product or service. Any such compensation will be consistent with fair market value in arms-length transactions and
will not be determined in a manner that takes into account the volume or value of any referrals or business otherwise generated
between the Parties for which payment may be made in whole or in part under Medicare, Medicaid or other Federal health care
programs. MD Anderson and Adaptimmune each confirm that in entering into this Agreement they have not accepted any bribes or
illegal inducements to enter into this Agreement or to perform any Study and will not accept any bribe or illegal inducement or offer
any bribe or illegal inducement in the performance of or for the performance of any Study whether during or after the termination or
expiry of this Agreement.
 
 
1.4 The nineteen million six hundred and forty four thousand Dollars US ($19,644,000) for the Studies shall be due and payable to MD
Anderson according to the schedule outlined in Table 2 in Exhibit II. The JSC retains the right to prioritize and replace Studies as
necessary subject to Section 1.6.
 
1.5  The Parties will establish a Joint Steering Committee (“ JSC”) of equal representation, comprised of three (3) representatives
(employees, directors or consultants who are subject to appropriate confidentiality obligations) from each Party, with the
representatives of each Party collectively having one vote on all matters to be decided upon by the JSC. Each Party can appoint and
replace its representatives in the JSC at its own discretion through timely written notice to the other Party.
 
1.6 The JSC will have meetings (either in person, by teleconference or via electronic means) at least quarterly. At least one meeting
per year will be conducted in person or by videoconference (including the kick-off meeting). The JSC will decide on matters by
unanimous vote with each of MD Anderson and Adaptimmune exercising one vote each provided, however, that no action may
lawfully be taken at any meeting unless at least two representatives of each Party (including for this purpose any proxy representative
appointed as provided below) are present at the meeting.  If a member of the JSC is unable to attend a meeting, he or she may
appoint, in writing, a proxy to participate and vote in his or her stead. Decisions may also be made by electronic mail, provided such
electronic mail is provided by at least two representatives from Adaptimmune and MD Anderson and such electronic mail is
acknowledged to be received by the recipient. Although decision will be made by mutual agreement of the JSC, in the event of any
disagreement, ***
 
 
 
 
 
.
 
1.7 The main task of the JSC will be to oversee the Alliance. In order to achieve the objectives of the Alliance, the JSC will oversee
each Study under the Alliance. The JSC will provide technical, scientific, clinical, and regulatory guidance to the Studies and will be
responsible for monitoring progress of these Studies. Additional representatives can be invited by the JSC on a case by case basis
should discussion of certain topics require so, provided that such guests will be subject to an obligation of confidentiality and non-use
at least as strict as Section 5 below. In the event a Study is terminated early or does not initiate, the Parties shall promptly replace that
Study with a new study similar in scope that is of mutual scientific interest to the Parties. Once agreed by the JSC, such replacement
study will be funded by the Alliance Funding and payable in accordance with agreed milestones for such replacement study.
 
***  Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the
Commission.
 
31.8 In addition, the JSC will be responsible for coordinating resolution of problems arising in the Studies or in the Alliance as a whole.
In the event of any matter to which the JSC cannot reach resolution, or in the event of any dispute arising as to any matter subject to
JSC responsibility and save where Adaptimmune has the deciding vote in accordance with Section 1.6 above, such matter or dispute
will be escalated to executive management of MD Anderson and Adaptimmune for good faith resolution. Both Parties shall use all
reasonable efforts to resolve any matter or dispute on a timely basis.
 
1.9 MD Anderson represents and certifies that neither MD Anderson nor Principal Investigator will, directly or indirectly, offer or pay,
or authorize an offer or payment of, any money or anything of value to any Public Official (defined below) or public entity, with the
knowledge or intent that the payment, promise or gift, in whole or in part, will be made in order to improperly influence an official act
or decision that will assist Adaptimmune in securing an improper advantage or in obtaining or retaining business or in directing
business to any person or entity in relation to the Study.  In addition to other rights or remedies under this Agreement or at law,
Adaptimmune may terminate the affected Study Order if MD Anderson breaches any of the representations or certifications
contained in this Section or if Adaptimmune learns that improper payments are being or have been made to any Public Official by MD
Anderson or Investigator. For the purposes of this Agreement, “Public Official” means any officer or employee of a government, a
public international organization or any department or agency thereof, or any person acting in an official capacity, including, for a
public agency or enterprise; and any political party or party official, or any candidate for public office. Adaptimmune acknowledges
and agrees that MD Anderson is an agency of the State of Texas, and its investigator, employees, and officers do constitute a Public
Official, as used in this paragraph, for purposes of this Section. Notwithstanding anything in this Section 1.9, nothing in this Section
shall constitute a limitation on MD Anderson’s ability to operate within its legal capacity as an agency of the State of Texas, nor shall
anything in this Agreement require MD Anderson to violate any law or to refrain from complying with any law applicable to MD
Anderson.
 
 
2. Responsibilities and Compliance
 
2.1  Each Clinical Study shall be subject to review and approval of the Study protocol (“ Protocol”) as required by MD Anderson’s
Institutional Review Board (“Institutional Review Board” or “IRB”) and/or any relevant authorities prior to commencement of the
Study as may be required in order to comply with Applicable Laws.
 
2.2 The scope of the Study to be performed shall be set forth in the Protocol(s) or workscope referenced in the Study Order, which
shall be incorporated by reference into such Study Order. These Protocol(s)/workscope shall be considered final after being agreed to
by MD Anderson and Adaptimmune and, for Clinical Studies, including approval by MD Anderson’s IRB. The Principal Investigator
for a Clinical Study shall submit the Protocol and reports of the ongoing conduct of the Clinical Study to the IRB as required by the
IRB, obtain written approval from the IRB, and inform the IRB of Study closure.
 
2.3  MD Anderson shall and will ensure that each Principal Investigator shall conduct a Study in accordance with (a) the terms and
conditions of this Agreement and the relevant Study Order, (b) the provisions of the Protocol or workscope, as applicable, (c)
applicable Good Clinical Practice requirements as incorporated by FDA regulations (“ GCP”), (d) the ethical principles of the
Declaration of Helsinki, as applicable, and (e) any and all applicable orders and mandates of relevant authorities (including the FDA)
and IRB, and applicable MD Anderson policies. MD Anderson shall ensure that all persons participating in any Study are either
employees of MD Anderson or are under legally binding obligations to MD Anderson requiring performance in accordance with the
terms of this Agreement and that all persons
 
4conducting any Study are properly trained with respect to their tasks performed for the Study. The Study shall be conducted at MD
Anderson. Only Adaptimmune shall be entitled to amend or modify the Protocol, which amendments and modification must be
approved by the IRB prior to implementation. Neither MD Anderson or Principal Investigator shall be entitled to amend any Protocol
for any Study except as necessary to eliminate any immediate hazard to the safety, rights or welfare of the Study patient or unless
required by the IRB. Any deviation from the Protocol must be agreed by Adaptimmune in advance unless necessary to eliminate an
apparent immediate hazard to the safety, rights or welfare of any Study patient or unless required by the IRB. MD Anderson will
promptly report any known deviation to Adaptimmune.
 
2.4  MD Anderson and Adaptimmune shall comply with all federal, state, and local laws and regulations as well as ethical codes
applicable to the conduct of each such Study (“Applicable Laws”) to the extent, in each case, applicable to the relevant performance
of a Party’s obligations under this Agreement and any Study Order.
 
2.5  Prior to the enrollment of any patient into any Clinical Study, MD Anderson and/or Principal Investigator shall forward to
Adaptimmune evidence of approval of each Clinical Study by MD Anderson’s IRB, and with respect to Studies for which MD
Anderson serves as “sponsor” within the meaning of such term under Applicable Laws and regulations, evidence of approval of the
Study by relevant regulatory authorities (or exemption from such regulatory authority/ies review and approval). MD Anderson shall,
as required by Applicable Law, obtain from the IRB written evidence of continuing review and approval of the Study and shall provide
evidence of such approval to Adaptimmune.
 
2.6 If, in the course of any Clinical Study at MD Anderson, a Study subject is injured by such Study subject’s participation in the Study,
MD Anderson and/or Principal Investigator shall inform Adaptimmune of any such injury by fax or email in case of serious and
unexpected adverse reactions and/or serious and unexpected adverse events arising from the use of Study Drug as soon as
reasonably possible and in any event in accordance with the timescales set out in the Protocol,  and/or, if applicable, pregnancies,
within the timelines stipulated in the Protocol, or if such is not stipulated in the Protocol, within *** (***) business days following MD
Anderson or Principal Investigator becoming aware of such event.
 
2.7 MD Anderson represents that: (a) it has not been debarred by the FDA pursuant to its authority under Sections 306(a) and (b) of
the U.S. Food, Drug, and Cosmetic Act (21 U.S.C.. § 335(a) and (b)) and is not the subject of any investigation or proceeding which
may result in debarment by the FDA, and to the extent applicable, it shall not use any Principal Investigator or Study team member in
the performance of a Study that has been so debarred or subject to any such investigation or proceeding, and; (b) it is not included in
the List of Excluded Individuals/Entities (maintained by the U.S. Department of Health and Human Services Office of Inspector
General) or the List of Parties Excluded from Federal Procurement and Non-procurement maintained by the U.S. General Services
Administration, and is not the subject of any investigation or proceeding which may result in inclusion in any such list, and to the extent
applicable, it shall not use any Principal Investigator or Study team member in the performance of a Study that is so included or the
subject of any such investigation or proceeding. MD Anderson agrees to promptly notify Adaptimmune in writing if it becomes aware
of any such debarment, exclusion, investigation or proceeding of MD Anderson or, to the extent applicable, any Principal Investigator.
 
2.8 MD Anderson and Adaptimmune shall comply with all applicable federal, state and local laws pertaining to confidentiality, consent
and disclosure of all information or records obtained and reviewed in the course of the Study, and shall permit access to such
information or records only as authorized by a relevant Study subject, the IRB, and as authorized by law. Each Party agrees to comply
with all provisions of the Health Insurance Portability and Accountability Act (“HIPAA”) regulations (45 C.F.R.
 
***  Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the
Commission.
 
5Parts 160 and 164) as to the protection and security of Protected Health Information (“PHI”) to the extent applicable to a Party. Prior
to participation of each subject in a Clinical Study, MD Anderson will ensure that (a) it has obtained a signed written informed consent
document from the subject (“Consent”) and (b) it has obtained a signed, written, HIPAA authorization that adequately discloses the
circumstances under which the subject’s personal data might be disclosed, as applicable, and documents the subject’s express written
authorization for use and disclosure of the subject’s PHI for Study purposes, as applicable, pursuant to the HIPAA regulations
(“Authorization”). MD Anderson will agree to the contents of any Consent or Authorization provided to any Study patient or
prospective Study patient with Adaptimmune prior to use in any Clinical Study. Adaptimmune, Adaptimmune Limited and its Joint
Research Partners will only obtain, access, use and disclose the individually identifiable health information of each Study Subject in
accordance with and to the extent permitted by the IRB, Consent and the Authorization document and in accordance with this
Agreement and Applicable Laws. “Joint Research Partners,” for the purposes of this Agreement, means Adaptimmune Limited’s
strategic collaboration partner, GlaxoSmithKline (including all companies within the GlaxoSmithKline group of companies) but only to
the extent and for the duration that GlaxoSmithKline remains a collaboration partner of Adaptimmune or otherwise takes over control
of any Study Drug which is the subject of any Study. Adaptimmune shall have in place with its Joint Research Partners a written
agreement with terms at least as stringent as those set out in this Agreement in relation to the obtaining, access, use and disclosure of
individually identifiable health information under this Section 2.8 or the receipt, access, use and disclosure of MD Anderson
Confidential Information under Section 5.
 
2.9 MD Anderson and Adaptimmune will promptly notify each other upon identifying any aspect of a Protocol, including information
discovered during site monitoring visits, or Study results that may adversely affect the safety, well-being, or medical care of the Study
subjects, or that may affect the willingness of Study subjects to continue participation in a Study, influence the conduct of the Study, or
that may alter the IRB’s approval to continue the Study. MD Anderson will promptly notify the IRB of any such events. If the IRB at
any time suspends, qualifies or withdraws approval of the Study, MD Anderson shall promptly notify Adaptimmune, provide a
reasonable written explanation of the circumstances leading to such suspension, qualification or withdrawal, and cease the treatment
of all Study patients as medically appropriate and if required by the IRB. When Study subject safety or medical care could be directly
affected by Study results, then notwithstanding any other provision of this Agreement, MD Anderson will send Study subjects a
written communication about such results. ***
 
 
 
 
.
 
2.10  MD Anderson shall not subcontract any of its or the Principal Investigator’s responsibilities under this Agreement without the
prior written consent of Adaptimmune. Any consent provided under this Section 2.10 shall not enable the relevant sub-contractor to
further subcontract its responsibilities to any other third party. MD Anderson shall ensure that any subcontracting is governed by a
binding agreement which imposes on the subcontractor obligations and responsibilities substantially equivalent to those set out in this
Agreement, to the extent such apply to the subcontracted activity (including obligations of confidentiality and ownership of
Inventions). Regardless of any delegation of duties to any subcontractor, MD Anderson remains obligated to fulfill all MD Anderson
obligations to Adaptimmune and Adaptimmune Limited hereunder.
 
3. Personnel, Materials and Equipment
 
***  Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the
Commission.
 
63.1 Except as otherwise set forth in this Agreement, MD Anderson shall provide all necessary personnel, facilities, and resources to
accomplish their responsibilities under this Agreement and the relevant Study Order.
 
3.2 Adaptimmune agrees to promptly provide MD Anderson with the required quantities of the drug or therapy under a Study Order
that will be utilized in accordance with the provisions of the Protocol or workscope applicable to the Study (“Study Drug”), Alliance
Funding applicable to the Study, and/or support services to the extent required for the conduct of a Study as specified in the Protocol
or workscope. Any Study Drug provided by Adaptimmune will be used solely for the applicable Study and solely in accordance with
the Protocol or workscope for the relevant Study. MD Anderson will not use such Study Drug outside of the scope of the Study. MD
Anderson will not transfer or provide unsupervised access to the Study Drug to any third party for any purpose, without the prior
written consent of Adaptimmune. MD Anderson acknowledges that the Study Drug is experimental in nature, and shall exercise
prudence and reasonable care in its handling, storage, transportation, disposition and containment of the Study Drug and, if applicable,
any other Proprietary Materials provided by Adaptimmune.
 
3.3.  Use of Proprietary Materials. From time to time during the Term, either Party (the “Transferring Party”) may supply the other
Party (the “Receiving Party”) with proprietary materials of the Transferring Party (other than Study Drug) (“Proprietary Materials”)
for use in the Study as may be further listed in the Study Order. In connection therewith, each Receiving Party hereby agrees that: (a)
the Receiving Party will not use the Proprietary Materials for any purpose other than exercising its rights or performing its obligations
hereunder; (b) it will use such Proprietary Materials only in compliance with all Applicable Laws; (c) it will not transfer any such
Proprietary Materials to any third party without the prior written consent of the Transferring Party; (d) it will not acquire any rights of
ownership, or title in or to such Proprietary Materials as a result of such supply by the Transferring Party; and (e) upon the expiration
or termination of this Agreement or a Study Order, if requested by the Transferring Party, it will destroy or return any such
Proprietary Materials
 
3.4 Nothing in this Agreement shall be construed to limit the freedom of MD Anderson or of any Principal Investigator or Study team
member or Adaptimmune to engage in similar clinical trials or research performed independently under other grants, contracts, or
agreements with parties other than Adaptimmune.
 
3.5 MD Anderson will obtain, prepare, store and ship all Study patient samples required to be collected and shipped under Protocol for
any Clinical Study in accordance with and to the extent permitted by Applicable Laws, the Consent, Authorization, the IRB and any
applicable Study reference manuals and any reasonable written instructions provided by Adaptimmune. Both Parties shall retain all
such samples in accordance with and to the extent permitted by the Consent, Authorization, the IRB and Protocol and only
disseminate such samples to third parties to the extent permitted by the Consent and HIPAA Authorization the IRB, Applicable Laws,
and the Protocol. Adamptimmune, and service providers for the Study may only use the samples only to the extent permitted by the
Consent and HIPAA Authorization documents, the IRB, as necessary to conduct the Study and as permitted by Applicable Laws.
 
4. Payments
 
4.1 Payments of Alliance Funding applicable to a Study will be made according to the terms specified in Sections 1.3 and 1.4 above.
 
5. Confidential Information
 
75.1  In conjunction with each Study, the Parties may wish to disclose confidential information to each other.  For purposes of this
Agreement, “Confidential Information” means confidential, non-public information, know-how and data (technical or non-technical)
that is disclosed in writing, orally, graphically, in machine readable form, or in any other manner by or on behalf of a disclosing Party to
a receiving Party or its Affiliates for purposes of this Agreement or any Study Order (“Purpose”).  Data or Inventions arising in the
performance of the Study and which are owned by Adaptimmune will also constitute Confidential Information of Adaptimmune, even
where first disclosed by MD Anderson and in each case subject to the publication rights of MD Anderson in Section 12 and subject to
Section 7 below. Confidential Information may be disclosed in any form (e.g. oral, written, graphic, electronic or sample) by or on
behalf of disclosing Party or its Affiliates, or may be otherwise accessible to receiving Party or its Affiliates. Exchanges of
Confidential Information directly between the Affiliates and Joint Research Partners are also covered by this Agreement. “Affiliates”
means any individual, company, partnership or other entity which directly or indirectly, at present or in the future, controls, is controlled
by or is under common control of a Party, and “control” will mean direct or indirect beneficial ownership of at least fifty per cent
(50%) of the voting share capital in such company or other business entity, or to hold the effective power to appoint or dismiss
members of the management.
 
5.2  Without disclosing Party’s prior written consent, receiving Party will: (a) not use any part of or the whole of the Confidential
Information for any purpose other than the Purpose; (b) restrict the dissemination of Confidential Information to individuals within its
own organization and disclose the Confidential Information only to those of its officers, employees and Affiliates and Joint Research
Partners who have a legitimate need to have access to the Confidential Information, who will be bound by confidentiality and non-use
commitments no less restrictive than those of this Agreement, and who will have been made aware of the confidential nature of the
Confidential Information; (c) protect the Confidential Information by using the same degree of care, but not less than a reasonable
degree of care, to prevent the unauthorized use, dissemination, or publication of the Confidential Information as receiving Party uses
to protect its own confidential information of a like nature; (d) preserve the confidentiality of the Confidential Information, not disclose
it to any third party, and take all necessary and reasonable precautions to prevent such information from being accessible to any third
party; and (f) promptly notify the disclosing Party upon becoming aware of evidence or suspicion of any unauthorized use or
disclosure of the Confidential Information. The foregoing obligations will exist for a period of *** (***) years from the date of
completion of the last Study in relation to which the Confidential Information is disclosed or used.
 
5.3 The obligations of confidentiality and non-use listed in this Section 5 will not apply to information: (a) which is in the public domain
or public knowledge at the time of disclosure, or which subsequently enters the public domain through no fault of receiving Party; (b)
which was rightfully in the possession of receiving Party at the time of disclosure by disclosing Party; (c) which is independently
developed by receiving Party without use of disclosing Party’s Confidential Information; (d) which the receiving Party receives legally
from any third party and which is not subject to an obligation of confidentiality; (e) is communicated to the receiving party’s IRB or
other scientific committee; (f) is required to be disclosed in order to obtain informed consent from patients or subjects who may wish
to enroll in the Study, provided, however, that the information will be disclosed only to the extent necessary and will not be provided in
answer to unsolicited inquiries by telephone or to individuals who are not eligible to be Study subjects; or (g) is disclosed to a Study
subject for the safety or well-being of the Study subject. The receiving Party may also disclose Confidential Information of any other
Party where it is required to disclose such pursuant to Applicable Law; provided, however, that receiving Party will make reasonable
efforts, if legally permissible, to (i) notify disclosing Party prior to the disclosure of any part of or the whole of the Confidential
Information and (ii) allow disclosing Party the opportunity to
 
***  Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the
Commission.
 
8contest and avoid such disclosure, and provided, further, that receiving Party will disclose only that portion of such Confidential
Information that it is legally required to disclose.
 
5.4 For the purposes of this Section 5, any combination of features disclosed to the receiving Party will not be deemed to be within the
foregoing exceptions merely because individual features are. Moreover, specific disclosures made to the receiving Party will not be
deemed to be within the foregoing exceptions merely because they are embraced by general disclosures.
 
5.5  All Confidential Information disclosed to receiving Party pursuant to this Agreement will be and remain the disclosing Party’s
property. Nothing contained herein will be construed as granting to receiving Party any proprietary right on or in relation to any part of
or the whole of the Confidential Information, or any right to use any of the Confidential Information except for the Purpose. Receiving
Party will return to disclosing Party all documents and other materials which constitute Confidential Information, as well as all copies
thereof, promptly upon request or upon termination of this Agreement (whichever is earlier); provided, however, that receiving Party
may keep one copy of the Confidential Information received under this Agreement in its secure files in accordance with the terms of
this Agreement for the sole purpose of maintaining a record of the Confidential Information received hereunder and for compliance
with this Agreement and/or Applicable Laws.
 
5.6  Adaptimmune will not require MD Anderson to disclose any Protected Health Information. Notwithstanding the foregoing, if
Adaptimmune comes into knowledge or possession of any “Protected Health Information” (as such term is defined under HIPAA) by
or through MD Anderson or any information that could be used to identify any Study subject or other MD Anderson patients or
research subjects, Adaptimmune will maintain any such Protected Health Information or other information confidential in accordance
with laws and regulations as applicable to MD Anderson, including without limitation HIPAA, will use any such Protected Health
Information solely to the extent permitted by Applicable Laws, the IRB and the Consent/Authorization of the patient/research subject,
and will not use or disclose any such Protected Health Information or other information in any manner that would constitute a violation
of any Applicable Laws or regulation if such use or disclosure was made by MD Anderson. It is intended that MD Anderson will not
disclose any Protected Health Information to Adaptimmune under this Agreement.
 
5.7 Improper use or disclosure of the Confidential Information by receiving Party is likely to cause substantial harm to disclosing Party.
Therefore, in the event of a breach, threatened breach, or intended breach of this Agreement by receiving Party, in addition to any
other rights and remedies available to it at law or in equity, disclosing Party will be entitled to seek preliminary and final injunctions
enjoining and restraining such breach, threatened breach, or intended breach.
 
6. Clinical Data / Monitoring
 
6.1 MD Anderson shall maintain complete, accurate and current records with respect to the conduct of any Study as set forth in any
Protocol or Study Order, to the extent required by Applicable Laws and regulations (“Study Records”). All Study Records shall be
retained by MD Anderson in accordance with and for the time period as is required by Applicable Law. Prior to any disposal of such
Study Records, MD Anderson shall give Adaptimmune thirty (30) days’ prior written notice thereof to allow Adaptimmune the
opportunity to request in writing, within such time frame, that MD Anderson continue to store such Study Records at Adaptimmune’s
expense. In relation to Clinical Studies, MD Anderson will keep Adaptimmune reasonably informed of the progress of the Study and
respond to any reasonable queries of Adaptimmune in relation to such Study promptly. In relation to Pre-Clinical Studies, oral reports
or interim written status reports of the progress of the Studies will be provided by the Principal Investigator to Adaptimmune on a
regular basis and at least once every *** (***) months during the
 
***  Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the
Commission.
 
9course of a Study. Significant developments arising out of Studies will be communicated promptly to Adaptimmune. In the context of
any Clinical Study, MD Anderson shall timely prepare and submit to Adaptimmune (a) case report forms, as soon as reasonably
possible but in any event within *** (***) business days following completion of any Study patient visit; and (b) responses to data
resolution queries as soon as reasonably possible and in any event within *** (***) business days following receipt of such query.
 
6.2  As applicable to and appropriate for a Clinical Study, Adaptimmune may monitor the conduct of a Clinical Study in accordance
with Good Clinical Practice requirements of FDA Regulations, and may visit MD Anderson for the purpose of such monitoring. Such
monitoring visits shall also enable Adaptimmune to (a) inspect and review any or all Study Records and Study source documents for
comparison with case report forms; and (b) audit financial records relating solely to the performance of the Study under this
Agreement. During any visit, MD Anderson and Principal Investigator shall reasonably cooperate with Adaptimmune and will use
reasonably efforts to promptly provide any reasonably Study Records or Study information requested by Adaptimmune in accordance
with this Section. Any such visits shall be scheduled in coordination with MD Anderson and/or Principal Investigator during normal
administrative business hours, and shall be subject Adaptimmune’s and Adaptimmune Limited’s compliance with MD Anderson’s
reasonable measures for confidentiality, safety and security, and shall also be subject to compliance with generally applicable premises
rules at MD Anderson.
 
6.3  MD Anderson and Principal Investigator shall, during a Study, permit inspections by responsible legal and regulatory authorities
with respect to such Clinical Study. To the extent permitted by law and to the extent practicable, MD Anderson shall notify
Adaptimmune of such inspection and provide Adaptimmune with an opportunity to be present at such inspection (to the extent
reasonably possible). MD Anderson shall, to the extent permitted by Applicable Law, inform Adaptimmune of any findings resulting
from any such inspection and MD Anderson shall promptly correct any non-conformances or requests for correction identified as a
result of such inspection. MD Anderson shall promptly notify Adaptimmune of, and to the extent permitted by law, provide
Adaptimmune with copies of, any inquiries, correspondence or communications with any legal or regulatory authority with authority
over any Study, to the extent in each case applicable to any Study or the performance of such Study by MD Anderson. Where MD
Anderson intends to respond to any such communication, MD Anderson shall provide, to the extent permitted by law, Adaptimmune
with a copy of such response and an opportunity to comment on such response (to the extent reasonably practicable) in advance of
the due date for the response. MD Anderson will review any comments provided by Adaptimmune in good faith.
 
6.4  Notwithstanding any provision of this Section 6, to the extent that MD Anderson is the holder of an Investigational New Drug
Application (“IND”) or other applicable regulatory application or approval for a Study, the provisions of Section 6.2 and 6.3 shall not
apply, and MD Anderson shall have the sole responsibility for monitoring, auditing, and reporting for such Study, provided that MD
Anderson agrees to reasonably negotiate access to Study documentation and records relevant to the applicable Study Drug and
documentation and facilities applicable to the Study upon the request of Adaptimmune and provided that Adaptimmune shall be
subject to compliance with MD Anderson’s reasonable measures for confidentiality, safety and security, and shall also be subject to
compliance with generally applicable premises rules at MD Anderson.
 
7. Data & Inventions.
 
7.1  Each Party will retain all right, title and interest in and to its own Background IP and no license to use such Background IP is
granted to the other party except for MD Anderson’s use of Study Drug in a Study as set forth in Section 3.2 above and in the
Protocol and each Party’s use of the other Party’s
 
***  Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the
Commission.
 
10Proprietary Material as set forth in Section 3.3 above. “Background IP” means all intellectual property (including rights in Confidential
Information) of a Party that: (a) was generated by such Party before the Effective Date; (b) is generated by such Party outside the
scope or after expiration of this Agreement or any Study under this Agreement; and in each such case; (c) is owned by such Party,
either partially or wholly, or is licensed to, or otherwise controlled by such Party, and which is not an Invention under this Agreement.
 
7.2  Patient records, research notebooks, all original source documents, Protected Health Information (as such term is defined by
HIPAA), MD Anderson’s business records, regulatory and compliance documents, original medical records or any information
required to be maintained by MD Anderson in accordance with Applicable Laws, that is generated in the conduct of the Studies
(collectively, “MD Anderson Records”) will be owned by MD Anderson. All results, data and work product (excluding MD Anderson
Records) generated in the conduct of the Studies (“Data”) shall be owned by Adaptimmune Limited. MD Anderson shall maintain all
such Data as confidential, subject to the publication rights granted in Section 12 below. Data will be promptly disclosed by MD
Anderson to Adaptimmune in the form of a Study report or as otherwise reasonably requested by Adaptimmune. Notwithstanding any
other provision of this Agreement, MD Anderson shall have the right to use results and Data of the Study for its internal research,
academic, and patient care purposes and for publication in accordance with Section 12 below, save that no right or license is granted
to MD Anderson under any of Adaptimmune’s Background IP. Adaptimmune shall promptly disclose any Data it generates to MD
Anderson.
 
7.3  MD Anderson will provide to Adaptimmune a detailed written disclosure of each patentable invention and/or discovery (and all
intellectual property rights therein) conceived and reduced to practice in the conduct of a Study and arising from the performance of a
Study (“Invention”) promptly after a written invention disclosure report for such Invention is received by MD Anderson’s Office of
Technology Commercialization.
 
7.4 Inventions shall be owned by the Parties in accordance with the following:
(a) ***
 
 
 
 
 
 
 
“Adaptimmune Inventions” shall be the sole property of Adaptimmune Limited.
 
(b) With respect to any Inventions that are not Adaptimmune Inventions (“Other Inventions”), where made solely by MD
Anderson or its employees and agents, such Inventions will be solely owned by MD Anderson; where made jointly by MD Anderson
and Adaptimmune and/or Adaptimmune Limited and their employees and agents will be jointly owned by MD Anderson and
Adaptimmune Limited. Inventions that are made solely by Adaptimmune, Adaptimmune Limited or its employees and agents will be
solely owned by Adaptimmune Limited. Inventorship will be determined in accordance with United States patent law.
 
7.5  MD Anderson hereby grants Adaptimmune and Adaptimmune Limited a non-exclusive, worldwide, irrevocable royalty-free
license to any Invention in which MD Anderson has an ownership interest, for any purpose. Such license shall include an unrestricted
right to sublicense through multiple tiers. MD Anderson also hereby grants to Adaptimmune Limited an exclusive option to negotiate
an
 
*** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the
Commission.
 
11exclusive (subject to MD Anderson’s perpetual, irrevocable, no-cost right to use such Invention for non-commercial internal research,
academic and patient care purposes), royalty-bearing license to any Invention in which MD Anderson has an ownership interest,
provided that Adaptimmune Limited pays all reasonably incurred patent expenses for such Invention in the event Adaptimmune
Limited exercises its option. Adaptimmune Limited must exercise its option to negotiate a license to any Invention by notifying MD
Anderson in writing within six months’ of MD Anderson disclosing such Invention to Adaptimmune (the “Option Period”).  If
Adaptimmune Limited fails to timely exercise its option within the Option Period with respect to any Invention, Adaptimmune
Limited’s right to negotiate a license agreement with respect to such Invention will automatically terminate, and MD Anderson will be
free to negotiate and enter into a license with any other party.  If Adaptimmune Limited timely exercises its option, the terms of the
license shall be negotiated in good faith within six months of the date such option is exercised, or within such time the parties may
mutually agree in writing (the “Negotiation Period”). If, however, Adaptimmune Limited timely exercises its option, but MD Anderson
and Adaptimmune Limited are unable to agree upon the terms of the license during the Negotiation Period, Adaptimmune Limited’s
right to exclusively license such Invention will terminate, and MD Anderson will be free to enter into a license with any other party
(subject to the grant of the non-exclusive license above).
 
7.6.  Adaptimmune Limited hereby grants MD Anderson a perpetual, irrevocable, no-cost, non-exclusive, royalty-free license to any
Adaptimmune Invention or Other Invention in which Adaptimmune Limited has an ownership interest for MD Anderson’s internal
non-commercial research, academic and patient care purposes. For clarity the grant of any license under any Invention or assignment
of any Invention by either Party does not include any license under any of such Party’s Background IP, even where such Background
IP dominates or encompasses any Invention.
 
7.7 As between the Parties, the sole owner of any Invention will have the sole right to prepare, file, prosecute, maintain, enforce and
defend all U.S. and foreign patents, registrations and other forms of intellectual property in such Invention but nothing herein will
obligate the owner to take any such actions. As between the Parties, Adaptimmune will have the first right to prepare, file, prosecute,
maintain, enforce and defend all U.S. and foreign patents, registrations and other forms of intellectual property in any jointly-owned
Invention using patent counsel of its choice that is subject to the written approval of MD Anderson not to be unreasonably withheld
and at the sole cost and expense of Adaptimmune, with accounting to MD Anderson.  Adaptimmune will keep MD Anderson
reasonably informed of all such material preparations, filings, material prosecution, material maintenance, material enforcement and
defense and will consider MD Anderson’s recommendations in good faith (provided such recommendations are provided on a timely
basis) If Adaptimmune elects not to file in the United States or not to maintain an application or patent arising from any jointly-owned
Invention, Adaptimmune will promptly notify MD Anderson within reasonable time for MD Anderson to file, prosecute or maintain
such application or patent, and MD Anderson will have the right to file, prosecute or maintain such application or patent, at MD
Anderson’s expense. MD Anderson will keep Adaptimmune reasonably informed of all such material preparations, material filings,
material prosecution, material maintenance, material enforcement and defense it makes in relation to any jointly-owned Invention. The
Parties will reasonably cooperate with each other with respect to matters concerning jointly-owned Inventions to the extent
reasonably necessary for filing, prosecuting, maintaining, defending or enforcing any such patents, registrations and other forms of
intellectual property protection. MD Anderson will keep Adaptimmune reasonably informed of any material filings, material
prosecution, enforcement and defense patents, new patent applications, material registrations or other forms of intellectual property
covering Other Inventions.
 
7.8 ***
 
*** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the
Commission.
 
12.
 
8. Term and Termination
 
8.1 The term of this Agreement shall be five (5) years following the Effective Date or until the Studies are completed, whichever is
later, unless extended or unless terminated earlier in accordance with the provisions hereof.  In the event of expiration or early
termination of this Agreement, the terms and conditions of this Agreement shall remain binding with respect to any ongoing Studies
(including any new studies to which any remaining Alliance Funding is allocated under Section 1.3) until completion of the Studies or
termination of the respective Study Order/s.
 
8.2 A Party will have the right to terminate this Agreement if the other Party commits a material breach of the Agreement and fails to
cure such breach within thirty (30) days of receiving notice from the non-breaching Party of such breach.  Any expiration or
termination of this Agreement will not affect any then existing Study Orders, and any then outstanding Study Orders will continue
after the expiration or earlier termination of this Agreement in accordance with their respective provisions. Upon any expiration or
termination of this Agreement, provisions of this Agreement that are incorporated by reference into any then outstanding Study
Orders will survive termination of this Agreement and will continue to apply to such Study Orders until termination or expiration of
each such Study Orders in effect at the time this Agreement expires or is terminated.
 
8.3 A Party may terminate a Study Order: (a) if the other Party commits a material breach of this Agreement or the Study Order and
fails to cure such breach within thirty (30) days of receiving notice from the non-breaching Party of such breach; or (b) in the case of
any Clinical Studies, due to health and safety concerns related to the Study Drug or procedures in the Study (including regulatory
holds due to the health and safety of the Study Subjects); or (c) in the case of MD Anderson and in relation to any Clinical Studies,
where IRB requests termination of any Study; or (d) in the case of Adaptimmune, *** set out in Section 1.2 above. The Parties agree
that any termination of a Study Order shall allow for: (i) the wind down of the Study to ensure the safety of Study subjects; and (ii)
Adaptimmune’s final reconciliation of Data related to the Study in addition to Adaptimmune’s final monitoring visit. All reasonable
fees associated with the wind-down activities and final monitoring visit shall be paid by Adaptimmune, to the extent not covered by
Alliance Funding. Termination of one or more Study Orders will not automatically result in the termination of this Agreement or
termination of any other Study Orders. Upon termination of a Study Order, MD Anderson will immediately return (at Adaptimmune’s
cost) any Study Drugs provided by Adaptimmune for such Study as directed by Adaptimmune.
 
8.4  In case any regulatory or legal authorization necessary for the conduct of the Study is (i) finally rejected or (ii) withdrawn, the
relevant Study Order shall terminate automatically at the date of receipt of such final rejection. Termination or cancellation of this
Agreement or a Study Order will not affect the rights and obligations of the Parties that have accrued prior to termination, and any
provisions of this Agreement or a particular Study Order that by their nature extend beyond expiration or termination will survive the
expiration or termination of this Agreement and/or that particular Study Order. In particular, the provisions of Sections 2-13 as
applicable will survive any expiration or termination of this Agreement.
 
*** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the
Commission.
 
138.5 In the event the Parties cannot reach agreement on a new Principal Investigator pursuant to Section 14.1 or such new Principal
Investigator does not agree to the terms of this Agreement and the relevant Study Order, either Party may terminate such Study
Order upon notice to the other Party.
 
8.6 In addition, in order to accommodate the review and approval of this Agreement by the Office of General Counsel of UT System
(the “OGC”), for a period of *** (***) days following the Effective Date (the “Limited Unilateral Termination Period”), MD
Anderson will have the right to terminate this Agreement without cause upon ten (10) days’ notice to Adaptimmune; provided,
however, that (i) a termination by MD Anderson will be effective if notice of termination is sent by MD Anderson any time within the
Limited Unilateral Termination Period even if the ten day notice period extends beyond the Limited Unilateral Termination Period and
(ii) the Limited Unilateral Termination Period will expire on the earlier to occur of (x) the end of the sixty days, or (y) written notice to
Adaptimmune from MD Anderson that the Agreement has been approved by the OGC. Should MD Anderson terminate this
Agreement in accordance with this Section 8.6 then the Parties will use reasonable efforts to ensure that any Clinical Study in relation
to which any patient has been screened or enrolled shall continue under a separate clinical trial agreement to be entered into between
the Parties as soon as possible after receipt of notice of termination by Adaptimmune. The terms of such clinical trial agreement shall
be in substantially similar form to terms agreed for other clinical trial agreements between the Parties and a separate budget shall be
agreed pursuant to such clinical trial agreement.
 
8.7 For each Study, Adaptimmune shall make all payments due for Study performance reasonably incurred or obligated in good faith
hereunder which have accrued up to the date of termination of a Study Order or this Agreement, or, in case of a termination of this
Agreement or the relevant Study Order pursuant to Section 8.4, up to the date of receipt of such final rejection.
 
9. Indemnification
 
9.1  Adaptimmune and Adaptimmune Limited agree to defend, indemnify, and hold harmless MD Anderson, System, each Principal
Investigator and its/their Regents, trustees, directors, officers, staff, employees, students, faculty members, and its/their affiliates and
contracted clients and other parties as may be listed on a Study Order (“ Indemnified Party/ies”): (a) from and against any and all
liability, claims, lawsuits, losses, demands, damages, costs, and expenses as a result of third party claims or judgments (“Indemnified
Losses”) resulting from (i) personal injury (including death) to any person or damage to property to the extent arising from the design
or manufacture of the Study Drug, and (ii) the use of the Data or results of the Study by or on behalf of Adaptimmune, Adaptimmune
Limited or any Joint Research Partner and (iii) Adaptimmune’s or Adaptimmune Limited’s negligence in connection with a Study or
this Agreement; (b) from and against any Indemnified Losses arising from an injury to a Study subject caused by the Study Drug or
any procedure required by the Protocol.  The completion or termination of a Study shall not affect Adaptimmune’s obligation to
indemnify with respect to any claim or suit based upon the aforementioned Indemnified Losses.  Notwithstanding the foregoing,
Adaptimmune and Adaptimmune Limited will not be responsible for any Indemnified Losses to the extent that they arise from the
negligence, intentional misconduct, or malpractice of the Indemnified Parties or of any breach of the terms of this Agreement by any
Indemnified Party, it being understood that the proper administration of the Study Drug in accordance with the Protocol (including
permitted deviations) shall not constitute negligence, intentional misconduct, or malpractice for the purposes of this Agreement. For
clarity, a request for indemnity by any Indemnified Party under this Section 9.1 may only be made against one of Adaptimmune or
Adaptimmune Limited.
 
9.2  To the extent authorized by the constitution and laws of the State of Texas, MD Anderson, agrees indemnify, and hold harmless
Adaptimmune and Adaptimmune Limited: (a) from and against any and all
 
*** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the
Commission.
 
14Indemnified Losses resulting from any negligent or intentional act or omission of MD Anderson in conducting a Study hereunder; (b)
failure of MD Anderson or Principal Investigator to comply with Applicable Laws or to adhere to Protocol; or (c) any use by MD
Anderson of the results and Data of the Study outside of the performance of any Study.  The completion or termination of a Study
shall not affect MD Anderson’s obligation to indemnify with respect to any claim or suit based upon the aforementioned Indemnified
Losses. Notwithstanding the foregoing, MD Anderson will not be responsible for any Indemnified Losses to the extent that they arise
from the negligence, intentional misconduct, or malpractice of Adaptimmune or Adaptimmune Limited or from a breach of Agreement
by Adaptimmune or Adaptimmune Limited.
 
9.3 Subject to the statutory duties of the Texas State Attorney General, any indemnified Party shall: (a) notify the indemnifying Party
in writing as soon as is reasonably possible after receipt of notice of any and all claims, lawsuits, and demands, or any action, suit, or
proceeding giving rise to the right of indemnification; (b) permit the indemnifying Party to retain counsel to represent the named
indemnified Party; and (c) permit the indemnifying Party to retain control of any such claims, lawsuits, and demands, including the
right to make any settlement, except that the indemnifying Party shall not make any settlement or take any other action which would
be deemed to confess wrongdoing by any of the indemnified Parties without the prior written consent of the applicable indemnified
Party.
 
 
 
 
10. Subject Injury Medical Costs
 
10.1  Adaptimmune shall assume responsibility for reasonable medical expenses incurred by a Study subject for reasonable and
necessary treatment if the Study subject experiences an illness, adverse event or injury that is a result of the Study Drug or any
procedure required by the Protocol that the subject would not have undergone were it not for such Study subject’s participation in the
Study. Adaptimmune shall not be responsible for expenses to the extent that they are due to pre-existing medical conditions,
underlying disease, or the negligence or intentional misconduct or due to breach of this Agreement by MD Anderson or Principal
Investigator. Adaptimmune shall have no obligation to make any payments for any Study patient that is not eligible for inclusion in any
Protocol. Any payments for such medical expenses shall be subject to Adaptimmune receiving relevant documentation supporting the
claim for such medical expenses.
 
11. Insurance
 
11.1 During the term of any Study Order under this Agreement, Adaptimmune Limited shall maintain in full force and effect insurance
for its and Adaptimmune’s liabilities arising from the Study with limits of not less than $*** per loss and $*** annual aggregate.
Adaptimmune shall provide MD Anderson with evidence of such insurance upon request.
 
11.2 MD Anderson is self-insured pursuant to The University of Texas Professional Medical Liability Benefit Plan under the authority
of Chapter 59, Texas Education Code.  MD Anderson has and will maintain in force during the term of this Agreement adequate
insurance or financial resources to cover its obligations pursuant to this Agreement.
 
12. Publications
 
*** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the
Commission.
 
1512.1 Adaptimmune recognizes the value of disseminating research results and accepts that MD Anderson will have the right to publish
or otherwise publicly disclose the results and Data of any Study, subject in each case to this Article 12.
 
12.2 Clinical Studies: In relation to any Clinical Study, Adaptimmune shall have the *** right to publish or publicly disclose any Data or
results arising from such Clinical Study including where such publication arises from the submission of data and/or results to the
regulatory authorities. Such right to publish shall not include any MD Anderson Records or any public health information protected by
HIPAA or where any publication would be in breach of the Consent and/or Authorization. MD Anderson and/or Principal Investigator
shall have the right to independently publish or publicly disclose, either in writing or orally, the Data and results of the Clinical Study/ies
after the earlier of the (i) first publication (including any multi-site publication) of such Data and/or results; (ii) twelve (12) months
after completion of any multi-site study encompassing any Study or if none, six (6) months after completion of Study. MD Anderson
shall, at least thirty (30) days ahead of any proposed date for submission, furnish Adaptimmune with a written copy of the proposed
publication or public disclosure. Within such thirty (30) day period, Adaptimmune shall review such proposed publication for any
Confidential Information of Adaptimmune provided hereunder or patentable Data. Adaptimmune may also comment on such proposed
publication and MD Anderson shall consider such comments in good faith during the aforementioned thirty (30) day period. MD
Anderson and/or Principal Investigator shall remove Confidential Information of Adaptimmune provided hereunder that has been so
identified (other than Data or Study results), provided that Adaptimmune agrees to act in good faith when requiring the deletion of
Adaptimmune Confidential Information. In addition Adaptimmune may request delay of publication for a period not to exceed ***
(***) days from the date of receipt of request by MD Anderson, to permit Adaptimmune or Adaptimmune Limited or any Joint
Research Partner to file patent applications or to otherwise seek to protect any intellectual property rights contained in such
publication or disclosure. Upon such request, MD Anderson shall delay such publication until the relevant protection is filed up to a
maximum of *** (***) days from date of receipt of request for delay by MD Anderson.
 
12.3 Pre-Clinical Studies: MD Anderson and/or Principal Investigator shall have the *** right to publish or publicly disclose, either in
writing or orally, the Data and results of the Pre-Clinical Study/ies and shall have the sole determination of the authorship and
contents, provided that MD Anderson or Principal Investigator, as applicable, shall provide Adaptimmune with a copy of any such
proposed publication at least thirty (30) days prior to submission for publication. Within such thirty (30) day period, Adaptimmune shall
review such proposed publication for any Confidential Information of Adaptimmune provided hereunder or patentable Data.
Adaptimmune may also comment on such proposed publication and MD Anderson shall consider such comments in good faith during
the aforementioned thirty (30) day period. MD Anderson and/or Principal Investigator shall remove Confidential Information of
Adaptimmune provided hereunder that has been so identified (other than Data or Study results), provided that Adaptimmune agrees to
act in good faith when requiring the deletion of Adaptimmune Confidential Information. In addition Adaptimmune may request delay
of publication for a period not to exceed *** (***) days from the date of receipt of request by MD Anderson, which delay may be for
any reason including but not limited to permit Adaptimmune or Adaptimmune Limited or any Joint Research Partner to file patent
applications or to otherwise seek to protect any intellectual property rights contained in such publication or disclosure. Upon such
request, MD Anderson shall delay such publication up to a maximum of *** (***) days from date of receipt of request for delay by
MD Anderson or, if earlier, where the reason is for the filing of a patent application or other intellectual property right..
 
12.4  MD Anderson and/or Principal Investigator shall give Adaptimmune acknowledgment for its sponsorship of a Study in all
applicable Study publications. Authorship and acknowledgements for
 
*** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the
Commission.
 
16scientific publications shall be consistent with the principles embodied in the International Committee of Medical Journal Editors
(“ICMJE”) Uniform Requirements for Manuscripts.
 
12.5 The “sponsor” of a Study, within the regulatory meaning of such term, shall register the Study if required by, and in accordance
with, Section 801 of the Food and Drug Administration Amendments Act of 2007 on www.clinicaltrials.gov and on any other database
required by laws or regulations in accordance with applicable standards regarding scope, form and content and in accordance with
ICMJE guidelines such that the Study will be eligible for publication in those publications.
 
12.6 Nothing in this Agreement shall prevent Adaptimmune or any of its Affiliates from complying with any obligations it has to make
disclosure under Applicable Laws or under the rules of any security exchange or listing authority applicable to it.
 
13. Use of Name/Public Statements/ Press Release/ Disclosure
 
13.1 Except as expressly set forth in this Agreement, each Party agrees that it will not at any time during the term of this Agreement
or following termination of this Agreement use any name of the other Party or any other names, insignia, mark(s), symbol(s), or
logotypes associated with the other Party or any variant or variants thereof in any advertising, or promotional materials without the
prior written consent of the other Party.
 
13.2 Except as expressly set forth in this Agreement, to the extent required by law or regulation, or to the extent necessary for MD
Anderson or Adaptimmune for the recruitment of subjects to any Study hereunder, the Parties agree to make no public presentations
about any Study conducted under this Agreement, and to issue no news releases about any Study, without the prior written consent of
the other Party (provided that this statement shall not apply to any information already in the public domain).  Any advertisements
directed at recruitment of study subjects for a Study must comply with all Applicable Laws, rules and regulations (including the need
for IRB review), the confidentiality obligations herein, and shall not include the trademarked insignia, symbol(s), or logotypes, or any
variant or variants thereof, of the other Party. Except as required by law or for regulatory purposes, neither Party will use the name
(including trademark or other identifier) of the other Party or such other Party’s employee or staff member (except in an
acknowledgment of sponsorship) in publications, advertising, press releases (except as permitted below in Section 13.3) or for any
other commercial purpose without the written approval of the other Party.  Adaptimmune will not state or imply in any publication,
advertisement, or other medium that any product or service bearing any of Adaptimmune’s names or trademarks and/or
manufactured, sold or distributed by Adaptimmune has been tested, approved, or endorsed by MD Anderson. Notwithstanding any
other provision of this Agreement, each Party and its researchers and employees will have the right, to acknowledge the other Party
and its involvement with a Study in scientific or academic publications describing the Study or reporting the results of the Study.
 
13.3. The Parties agree to have a joint press release after the Effective Date, to be issued at a time mutually agreed by the Parties but
in any event within 30 days of Effective Date. The text of such press release is set out at Exhibit IV to this Agreement. Any press
release by either Party relating to this Agreement, the Alliance, or any Study shall require the prior review and written approval of the
other Party, which approval shall not be unreasonably withheld, delayed or conditioned unless such press release is required to be
issued by a Party to the extent required by it to comply with its legally required obligation to any securities exchange on which it is
listed.
 
13.4  Either Party may use the name of the other Party in any document filed with any governmental authority or regulatory agency
applicable to a Study, and to comply with any applicable legal or regulatory requirements. Further, each Party is permitted to disclose
the other Party’s name, the title of
 
17the Study, the name of the Principal Investigator, and an overall Study budget amount projected to be paid/actual total amount paid for
conducting the Study, provided that this information is presented together as part of mandatory disclosure in accordance with and to
the extent required Applicable Law.
 
14. Principal Investigator
 
14.1  If a designated Principal Investigator is terminated from a Study, or in the event of the death or other non-availability of the
Principal Investigator, MD Anderson shall use reasonable efforts to designate a duly qualified person to act as new Principal
Investigator, subject to the reasonable agreement of Adaptimmune. If the Parties are unable to agree on a new Principal Investigator
or if the new Principal Investigator is unwilling to agree to the terms and conditions of this Agreement and the relevant Study Order,
either Party shall be entitled to terminate the respective Study Order in accordance with Section 8.5.
 
15. General Provisions
 
15.1 Warranties. EXCEPT AS EXPRESSLY PROVIDED HEREIN, NEITHER PARTY MAKES ANY WARRANTIES, EXPRESS
OR IMPLIED, CONCERNING THE RESULTS OF ANY STUDY OR THE STUDY DRUG, OR OF THE
MERCHANTABILITY, OR FITNESS FOR A PARTICULAR PURPOSE OF SUCH DATA, RESULTS OR STUDY DRUG.
NEITHER PARTY SHALL BE LIABLE FOR ANY INDIRECT OR CONSEQUENTIAL DAMAGES SUFFERED BY THE
OTHER PARTY AS A RESULT OF PERFORMANCE OF ANY STUDY UNDER THIS AGREEMENT.  ADAPTIMMUNE
REPRESENTS AND WARRANTS THAT EACH STUDY DRUG HEREUNDER SHALL HAVE BEEN MANUFACTURED IN
ACCORDANCE WITH CURRENT GOOD MANUFACTURING PRACTICES IN THE UNITED STATES AND THAT AS AT
THE EFFECTIVE DATE OF THIS AGREEMENT IT HAS NOT RECEIVED ANY CLAIM THAT USE OF ANY STUDY
DRUG IN THE PERFORMANCE OF A STUDY WOULD INFRINGE THE RIGHTS OF ANY THIRD PARTY.
ADAPTIMMUNE REPRESENTS THAT AS AT THE EFFECTIVE DATE TO ITS KNOWLEDGE THERE ARE NO KNOWN
DEFECTS IN ANY STUDY DRUG;  ADAPTIMMUNE UNDERSTANDS AND ACKNOWLEDGES THAT THE
DEVELOPMENT AND DISSEMINATION OF SCIENTIFIC KNOWLEDGE IS A FUNDAMENTAL COMPONENT OF MD
ANDERSON’S MISSION, AND THAT MD ANDERSON MAKES NO REPRESENTATIONS, WARRANTIES, OR
GUARANTEES WITH RESPECT TO ANY SPECIFIC RESULTS OF THE STUDIES.
 
15.2  Assignment.  This Agreement and/or any Study Order may not be assigned by either Party except as agreed upon in writing by
the other Party. Any assignment or attempt to assign, or any delegation or attempt to delegate, not in accordance with this Section
shall be void and without effect. For any permitted assignment, the rights and obligations of the Parties hereunder will inure to the
benefit of and be binding upon their permitted successors and assigns.
 
15.3 Independent Contractors. MD Anderson and Adaptimmune shall be independent parties and nothing contained in this Agreement
shall be construed or implied to create an agency or partnership. No Party shall have the authority to agree to or incur expenses on
behalf of another except as may be expressly authorized by this Agreement or a Study Order.
 
15.4  Notices. Any notice or communication required or permitted to be given or made under this Agreement by one of the Parties
hereto to the other shall be in writing and shall be deemed to have been sufficiently given or made for all purposes on the date of
mailing by certified mail, postage prepaid, overnight courier service, and/or fax to be followed by mailed original addressed to such
other Party at its respective address as referenced in the Study Order.
 
1815.5 Severability. If any one or more of the provisions of this Agreement shall be held to be invalid, illegal or unenforceable, the validity,
legality or enforceability of the remaining provisions of this Agreement shall not in any way be affected or impaired thereby.
 
15.6 Entirety. This Agreement (including its Exhibits and Appendices) represents the entire agreement of the Parties with respect to
the subject matter hereof and it expressly supersedes all previous written and oral communications between the Parties.  No
amendment, alteration, or modification of this Agreement or any Study Orders attached hereto shall be valid unless executed in
writing by authorized signatories of all Parties.
 
15.7 Waiver. The failure of any Party hereto to insist upon strict performance of any provision of this Agreement or to exercise any
right hereunder will not constitute a waiver of that provision or right.
 
15.8  Force Majeure. In the event that performance of the obligations of a Party hereunder are prevented by events beyond their
reasonable control, including, but not limited to, acts of God, regulations or acts of any governmental authority, war, civil commotion,
strikes, or other labor disturbances, epidemics, fire, earthquakes, storms or other catastrophes of a similar nature (“Force Majeure”),
the affected Party  will promptly notify the other Party of such event using the procedure defined herein, and the Parties shall be
relieved of their respective obligations hereunder to the extent that the performance of such obligations is actually prevented thereby.
During the existence of any such condition, the affected Party shall, nevertheless, use its best efforts to remove the cause thereof and
resume performance of its obligations hereunder. The period of performance shall be extended for the Party who is unable to perform
due to Force Majeure reasons by a period of time equal to the length of the period during which the Force Majeure reason exists or
for a longer period if required to meet the requirements of the Study Protocol.
 
15.9  Counterparts. It is understood that this Agreement may be executed in one or more counterpart copies, each of equal dignity,
which when joined, shall together constitute one Agreement. In the event of execution by exchange of facsimile or electronic signed
copies, the Parties agree that, upon being signed by both Parties, this Agreement shall become effective and binding and that facsimile
or .pdf signed copies will constitute evidence of this Agreement.
 
15.10 Export Control. Notwithstanding any other provision of this Agreement, it is understood that the Parties are subject to, and shall
comply with, applicable United States laws, regulations, and governmental requirements and restrictions controlling the export of
technology, technical data, computer software, laboratory prototypes, and other commodities, information and items (individually and
collectively, “Technology and Items”), including without limitation, the Arms Export Control Act, the Export Administration Act of
1979, relevant executive orders, and United States Treasury Department embargo and sanctions regulations, all as amended from time
to time (“Restrictions”) and that the Parties’ obligations hereunder are contingent on compliance with applicable Restrictions.
 
15.11 Choice of Law. Any disputes or claims arising under this Agreement shall be governed by the laws of the State of Texas. MD
Anderson is an agency of the State of Texas and under the constitution and the laws of the State of Texas possesses certain rights
and privileges, is subject to certain limitations and restrictions, and only has such authority as is granted to it under the constitution and
laws of the State of Texas. Notwithstanding any provision hereof, nothing in this Agreement is intended to be, nor will it be construed
to be, a waiver of the sovereign immunity of the State of Texas or a prospective waiver or restriction of any of the rights, remedies,
claims, and privileges of the State of Texas.  Moreover, notwithstanding the generality or specificity of any provision hereof, the
provisions of this Agreement as they pertain to MD Anderson are enforceable only to the extent authorized by the constitution and
laws of the State of Texas; accordingly, to the extent any provision hereof conflicts with the constitution or laws
 
19of the State of Texas or exceeds the right, power or authority of MD Anderson to agree to such provision, then that provision will not
be enforceable against MD Anderson or the State of Texas.
 
 
[Signatures of Following Page]
 
20In witness whereof, the Parties hereto have caused this Agreement to be executed by their duly authorized representatives to be
effective as of the Effective Date.
 
             
The University of Texas M. D. Anderson Cancer Center
 
 
  Adaptimmune LLC
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Date:
 
9/23/16
 
 
 
 
 
  Date:
 
23  September 2016
 
 
 
 
 
 
 
 
 
 
 
 
 
 
/s/ Chris McKee
 
 
 
 
 
  /s/ Helen Tayton-Martin
 
Name Chris McKee, M.H.A
 
 
  Name Helen Tayton-Martin
 
Title: VP. Business Operations
 
 
  Title: Authorized Signatory
 
 
 
 
           
Adaptimmune Limited
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Date:
 
23  September 2016
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
/s/ James Noble
 
 
 
 
 
 
 
 
Name James Noble
 
 
 
 
 
Title: CEO
 
 
 
 
 
 
21
 
rd
rdExhibit I
 
  
***
 
***
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
***
***
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
***
 
 
***
 
*** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the
Commission.22***
 
***
                    
***
 
***
 
 
 
 
 
***
 
***
 
 
 
 
 
***
 
***
 
 
 
 
 
***
 
***
 
 
 
 
 
***
 
***
 
 
 
 
 
***
 
***
 
 
 
 
 
***
 
***
 
 
 
 
 
***
 
***
 
 
 
 
 
***
 
***
 
 
 
 
 
***
 
******
*** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the
Commission.
 
23***
***
 
***
 
 
.
 
 
***
 
.
 
***
 
 
 
 
 
 
 
 
 
.
 
 
***
 
.
 
***
 
 
 
.
 
***
 
 
 
 
 
.
 
 
*** .
 
***
 
***
 
 
 
 
.
 
 
***
*** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the
Commission.
 
24***
 
 
 
***:
 
            
***
 
***
***
***
 
***
***
 
***
***
***
 
***
***
***
 
***
 
 
 
 
 
 
 
 
 
 
  ***
 
***
 
***
 
***
 
***
 
 
 
 
 
 
  ***
 
 
 
 
 
 
 
 
 
***
***
***
 
***
 
***
 
***
 
***
 
***
 
***
 
***
 
 
 
***
***
 
***
 
***
 
***
 
***
 
***
 
***
 
 
 
 
 
***
 
***
 
***
 
***
 
***
 
***
 
***
 
 
 
 
 
***
***
 
***
 
***
 
***
 
***
 
***
 
***
 
 
 
 
 
***
***
 
***
 
***
 
***
 
***
 
 
  ***
 
***
 
 
 
***
***
 
 
 
 
  ***
 
***
 
 
 
 
 
 
 
 
 
***
***
 
 
 
 
 
 
  ***
 
 
 
 
 
 
 
 
 
***
***:
 
***
 
 
 
***:
 
       
***
 
***
***
 
***
 
***
 
***
 
***
 
***
***
***
 
***
 
***
 
***
***
 
***
 
 
***
 
***
 
***
 
***
 
***:
 
 
  ***
 
 
 
*** .
 
***.
 
***
 
***
 
***
 
 
 
.
 
 
***
*** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the
Commission.
 
25***
 
 
 
.
 
 
***
 
 
 
 
 
 
 
 
.
 
***
 
 
 
 
 
:
· ***
· ***
· ***
· ***
 
· ***
 
***
 
 
.
 
 
***
***
 
 
 
 
 
 
 
.
 
***
 
:
 
***
 
*** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the
Commission.
 
26***
 
· ***
· ***
· ***
 
.
 
***
 
.
 
***
 
 
.
 
 
***
***
 
.
 
***
 
.
 
***
 
 
.
 
***
 
.
 
***
***
 
 
.
 
***
 
 
 
.
 
***
 
.
 
***
 
*** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the
Commission.
 
27***
 
***
 
 
:
 
· ***
 
.
 
o ***
 
.
 
o ***
 
.
 
· ***
 
.
 
o ***
 
.
 
o ***
 
.
 
o ***
 
 
.
 
· ***
 
 
 
.
 
· ***
 
.
 
***
 
***
 
*** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the
Commission.
 
28***
 
 
.
 
***
***
 
 
:
 
· ***
· ***
· ***
· ***
 
 
***
 
 
.
 
***
 
***
***
 
.
 
***
 
1. ***
2. ***
 
.
 
3. ***
4. ***
5. ***
.
 
6. ***
 
7. ***
 
***
 
.
 
***
***
 
***
 
*** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the
Commission.
 
29***
 
 
 
.
 
***
 
 
.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
***
 
*** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the
Commission.30***
 
***
 
 
 
 
 
***
 
***:
 
 
 
***
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the
Commission.
 
31***
 
***
 
 
 
***:
 
***: ***
 
*** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the
Commission.
 
32***
 
***
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
***
 
*** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the
Commission.
 
33***
 
***:
 
***: ***
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
***
 
*** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the
Commission.
 
34***
 
***
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
***
 
*** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the
Commission.
 
35***
 
***:
 
***:***
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
***
 
*** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the
Commission.
 
36***
 
***
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
***
 
*** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the
Commission.
 
37***
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
***
 
*** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the
Commission.
 
38Exhibit II
Table 1
        
Clinical Study
(excluding screening
and long term follow-
up studies)
 
Study
Start
Date
 
***
 
***
 
 
 
 
 
 
 
 
 
 
  ***
 
***
 
***
 
***
 
***
 
***
 
***
 
***
 
***
 
***
 
***
 
***
 
***
 
***
 
 
 
***
 
***
 
***
 
***
 
***
 
 
 
***
 
***
 
***
 
***
 
***
 
 
 
***
 
***
 
***
 
 
  ***
 
***
 
 
 
Table 2-Payment Schedule
 
Clinical Studies (total funding US$13,374,000):
 
         
Milestone
 
Payment amount (US$)
 
Date on which Payment can be invoiced.
 
Effective Date
 
***
 
On expiry of Limited Unilateral Termination Period
 
Enrollment of *** Patients in a
Clinical Study (excluding
screening and long term follow-
up studies)
 
***
 
On notification to Adaptimmune that ***  patient is eligible and
has been enrolled.
 
Enrollment of *** Patients in a
Clinical Study (excluding
screening and long term follow-
up studies)
 
***
 
On notification to Adaptimmune that ***  patient is eligible and
has been enrolled.
 
Enrollment of *** Patients in a
Clinical Study (excluding
screening and long term follow-
up studies)
 
***
 
On notification to Adaptimmune that ***  patient is eligible and
has been enrolled.
 
Enrollment of *** Patients in a
Clinical Study (excluding
screening and long term follow-
up studies)
 
***
 
On notification to Adaptimmune that ***  patient is eligible and
has been enrolled.
 
Enrollment of *** Patients in a
Clinical Study (excluding
screening and long term follow-
up studies)
 
***
 
On notification to Adaptimmune that ***  patient is eligible and
has been enrolled.
 
Total  Alliance Funding
payable:
 
13,374,000
 
 
 
 
Pre-clinical Studies (total funding $6,270,000, including indirect costs of US$***):
 
*** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the
th
th
th
th
thCommission.
 
39Milestone
 
Payment amount (US$)
 
Date on which Payment can be invoiced.
 
Effective Date
 
***
 
 
.
 
On expiry of Limited Unilateral Termination Period
 
Completion of each analysis of
*** patient samples for ***
(Pre-clinical Study 1)
 
***
 
Completion of analysis of  samples for *** patients, up to a
maximum payment of US$*** and provision of results of such
analysis to Adaptimmune. (Max. *** patients)
 
Completion of each analysis of
*** patient samples arising from
*** (Pre-clinical Study 2)
 
***
 
Completion of analysis of  samples for 50 patients, up to a
maximum payment of US$*** and provision of results of such
analysis to Adaptimmune. (Max. *** patients)
 
Completion of each analysis of
*** patient samples arising from
the *** and additional *** Study
(Pre-clinical Study 3)
 
***
 
Completion of analysis of  samples for *** patients, up to a
maximum payment of US$*** and provision of results of such
analysis to Adaptimmune. (max. *** patients)
 
TOTAL Alliance Funding
payable:
 
6,270,000
 
 
 
 
 
For clarity: milestones and payments of Alliance Funding shall only be payable once the milestones set out above have been met by
MD Anderson. There shall be no obligation on Adaptimmune to make such payments where any such milestones have not been met;
and no payments of Alliance Funding will be due until expiry of Limited Unilateral Termination Period.
 
All payments will be paid by Adaptimmune within 45 days of receipt of an invoice from MD Anderson. Such invoice shall be
addressed to Adaptimmune and sent by electronic mail to accounts@adaptimmune.com with copies to lini.pandite@adaptimmune.com
and susan cousounis@adaptimmune.com for Clinical Study payments and with copies to Samik.basu@adaptimmune.com in relation to
Pre-clinical Study payments.
 
Payments will be made by Adaptimmune to The University of Texas M. D. Anderson Cancer Center:
The University of Texas
M. D. Anderson Cancer Center
P.O. Box 4390
Houston, Texas 77210-4390
 
Or if payment is made by wire transfer, wired to the following:
 
***
***
***
***
***
***
***
 
*** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the
Commission.
 
40***
***
 
*** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the
Commission.
 
41Exhibit III
 
STRATEGIC COLLABORATION AGREEMENT - STUDY ORDER
 
 
 
This Study Order (“Study Order”), effective as of the ___ day of  ______(“Effective Date” of Study Order), is entered into by and
between The University of Texas M. D. Anderson Cancer Center, with a place of business located at 1515 Holcombe Blvd.,
Houston, TX 77030, USA (“MD Anderson”), a member institution of The University of Texas System (“ System”); Adaptimmune
Limited with a place of business at 101 Milton Park, Abingdon, Oxfordshire, OX14 4RY; and Adaptimmune LLC, with a place of
business located at 2001 Market Street, Philadelphia, PA 1903, USA (“Adaptimmune”) (MD Anderson and Adaptimmune each a
“Party” and collectively the “Parties”). This Study Order is a part of, and is subject to, the terms and conditions of the Strategic
Collaboration Agreement entered into between MD Anderson and Adaptimmune dated August ___ 2015 (“Agreement”).
 
1. The Parties enter into this Study Order in connection with:
 
the [Pre-Clinical or Clinical]] Study entitled __________________, to be conducted pursuant
 
for Clinical: to Protocol No. [Insert Protocol number] as attached hereto and incorporated herein.
 
for Preclinical: to the workscope attached as Appendix A
 
2. _______ is the Principal Investigator (as defined in the Agreement) for the Study which will be conducted at MD Anderson.
 
3. Study Drug for the above referenced Study is ________________.
 
4. The parties may further exchange the following Proprietary Materials (other than Study Drug) with each other in connection with
the Study:
_________ being provided by [Insert name of providing party]
_________ being provided by [Insert name of providing party]
 
5. Term: This Study Order will continue until the Study is completed, which is expected to be ________ (__) months after the
Effective Date, or until terminated early as provided in the Agreement.
 
 
 
7. Notices.
 
Any notice or other formal communication related to this Agreement must be in writing and will be deemed given only if: (a) delivered
in person; or (b) sent by internationally recognized overnight delivery service or air courier guaranteeing next day delivery. Until a
change of address is communicated, as provided below, all notices and other communications must be sent to the Parties at the
following addresses or facsimile numbers:
 
If to MD Anderson:
 
The University of Texas
 
42M. D. Anderson Cancer Center
Attn: Vice President, Strategic Industry Ventures
1515 Holcombe Boulevard, Box 1643
Houston, TX 77030
 
With a copy to:
 
The University of Texas
M. D. Anderson Cancer Center
Legal Services—Unit 1674
PO Box 301407
Houston, Texas 77230-1407
Attn: Chief Legal Officer
 
And to:
 
 
[insert investigator information]
 
If to Adaptimmune:
 
[To Be Added]
 
With a copy to:
 
[To Be Added]
 
12.2 All notices will be effective and will be deemed delivered: (a) if by personal delivery, delivery service or courier, on the date of
delivery; and (b) if by electronic facsimile communication, on the date of transmission of the communication. Either Party may change
its notice address by sending notice of the change to the other Party in the manner set forth above.
 
 
8. Specific superseding terms: N/A.
 
In witness whereof , the Parties hereto have caused this Study Order to be executed by their duly authorized representatives to be
effective as of the Effective Date.
 
        
The University of Texas M. D. Anderson Cancer
Center
 
 
  Adaptimmune LLC
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Date:
 
 
 
 
 
 
  Date:
 
 
 
 
43Name
 
 
  Name
 
Function:
 
 
  Function:
 
 
 
 
           
Adaptimmune Limited
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Date:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Name
 
 
 
 
 
Title:
 
 
 
 
 
 
 
 
 
 
 
READ AND UNDERSTOOD:
 
I confirm that I have received a copy of the Agreement under which this Study Order is issued, and that I have read and understand the
Agreement and this Study Order.
 
              
Principal Investigator
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Date:Name
 
   
 
44EXHIBIT IV
 
45DRAFT RELEASE
 
MD Anderson Cancer Center and Adaptimmune Form Strategic Alliance to Advance Development of
Immunotherapies Targeting Multiple Cancers
 
PHILADELPHIA, and HOUSTON, U.S.A. and OXFORD, UK, September XX, 2016 — Adaptimmune Therapeutics plc
(Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, and The University of Texas MD Anderson Cancer Center
announced today that they have entered into a multi-year strategic alliance designed to expedite the development of novel
adoptive T-cell therapies for multiple types of cancer.
 
The alliance pairs MD Anderson’s preclinical and clinical teams with Adaptimmune’s scientists and proprietary SPEAR®
(Specific Peptide Enhanced Affinity Receptor) T-cell technology platform, which enables Adaptimmune to identify targets
expressed on solid and hematologic cancers and to develop affinity enhanced T-cell receptors (TCRs) with optimal
potency and specificity against them.
 
The teams will collaborate in a number of areas including preclinical and clinical development of Adaptimmune’s SPEAR
T-cell therapies targeting MAGE-A10 and future clinical stage first and second generation SPEAR T-cell therapies such as
MAGE-A4 across a number of cancers, including bladder, lung, ovarian, head and neck, melanoma, esophageal and
gastric cancers. The alliance will also drive research and development of other new SPEAR TCR therapies to targets in
other tumor types such as breast cancers and facilitate clinical study participation by MD Anderson in other Adaptimmune
trials. Access to MD Anderson’s tumor repository will guide further target selection and clinical trial design, while its
cancer immunology cores and expertise in performing translational medicine studies may help optimize the efficacy and
safety of SPEAR T-cell therapies.
 
“At MD Anderson, we are focused on providing the best possible care for cancer patients, including implementing
important new technologies and treatment modalities,” said Elizabeth Mittendorf, M.D., Ph.D., associate professor of
Breast Surgical Oncology.
 
David Hong, M.D., associate professor of Investigational Cancer Therapeutics at MD Anderson added, “It is our hope this
alliance will allow us to address numerous solid tumors and augment the patient’s immune system, directing it against
tumors based on their specific molecular makeup.”
 
“We believe that this strategic alliance will provide a strong partnership for the development of multiple new first and
subsequent generation SPEAR T-cell therapies against many intractable solid tumors in our near-term clinical programs,”
commented Rafael Amado, Adaptimmune’s chief medical officer. “It will also generate invaluable data from patient
samples that will help us understand these therapies and design the next generation of studies. We are very proud to
form this alliance with the outstanding team of cancer immunologists at MD Anderson, and are confident that together we
can move these novel immunotherapeutic candidates forward for patients who are fighting a variety of cancers.”
 
About MD Anderson
 
The University of Texas MD Anderson Cancer Center in Houston ranks as one of the world’s most respected centers
focused on cancer patient care, research, education and prevention. The institution’s sole mission is to end cancer for
patients and their families around the world. MD Anderson is one of only 45 comprehensive cancer centers designated by
the National Cancer Institute (NCI). MD Anderson is ranked No.1 for cancer care in U.S. News & World Report’s “Best
Hospitals” survey. It has ranked as one of the nation’s top two hospitals since the survey began in 1990, and has ranked
first for nine of the
 
46past 10 years. MD Anderson receives a cancer center support grant from the NCI of the National Institutes of Health (P30
CA016672).
 
About Adaptimmune
 
Adaptimmune is a clinical stage biopharmaceutical company focused on novel cancer immunotherapy products based on its SPEAR®
(Specific Peptide Enhanced Affinity Receptor) T-cell platform. Established in 2008, the company aims to utilize the body’s own
machinery - the T-cell - to target and destroy cancer cells by using engineered, increased affinity TCRs as a means of strengthening
natural patient T-cell responses. Adaptimmune’s lead program is a SPEAR T-cell therapy targeting the NY-ESO cancer antigen. Its
NY-ESO SPEAR T-cell therapy has demonstrated signs of efficacy and tolerability in Phase 1/2 trials in solid tumors and in
hematologic cancer types, including synovial sarcoma and multiple myeloma. Adaptimmune has a strategic collaboration and licensing
agreement with GlaxoSmithKline for the development and commercialization of the NY-ESO TCR program. In addition,
Adaptimmune has a number of proprietary programs. These include SPEAR T-cell therapies targeting the MAGE-A10 and AFP
cancer antigens, which both have open INDs, and a further SPEAR T-cell therapy targeting the MAGE-A4 cancer antigen that is in
pre-clinical phase with IND acceptance targeted for 2017. The company has identified over 30 intracellular target peptides
preferentially expressed in cancer cells and is currently progressing 12 through unpartnered research programs. Adaptimmune has
over 250 employees and is located in Oxfordshire, U.K. and Philadelphia, USA. For more information: http://www.adaptimmune.com
 
Forward-Looking Statements
 
This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995
(PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our
actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success,
cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic
candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could
cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our
business in general, we refer you to our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on
August 8, 2016, and our other SEC filings. The forward-looking statements contained in this press release speak only as of the date
the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent
events or circumstances.
 
Adaptimmune Contacts
 
Will Roberts
Vice President, Investor Relations
T: (215) 825-9306
E: will.roberts@adaptimmune.com
 
Margaret Henry
Head of PR
T: +44 (0)1235 430036
Mobile: +44 (0)7710 304249
 
47E: margaret.henry@adaptimmune.com
 
MD Anderson Contact:
 
Ron Gilmore
Rlgilmore1@mdanderson.org
Phone: 713-745-1898
 
48Exhibit 10.22
STRATEGIC ALLIANCE AGREEMENT
(Hyatt Ziva Cancun)
THIS STRATEGIC ALLIANCE AGREEMENT (the “Agreement”) is made and entered into as of December 14, 2016 (the “Effective Date”), by
and between Hyatt Franchising Latin America, L.L.C., a limited liability company organized and existing under the laws of the State of Delaware
(U.S.A.) with its principal place of business located at 71 South Wacker Drive, Chicago, Illinois 60606, U.S.A. (“Hyatt”), and Playa Hotels &
Resorts, B.V., a private limited liability company organized and existing under the laws of the Netherlands with its registered address at Prins
Bernhardplein 200, 1097 JB Amsterdam, the Netherlands (“Playa”). Hyatt and Playa are each referred to as a  “Party” and collectively as the
“Parties.” 
R E C I T A L S: 
WHEREAS, Hyatt and Playa are parties to that certain Master Development Agreement dated as of August 9, 2013 (as amended, the  “Master
Development Agreement”) under which Hyatt granted Playa the exclusive (to the extent set forth therein) right, provided that Playa met certain
conditions, to develop  all-inclusive resorts under either or both of the Hyatt Ziva ® or Hyatt Zilara® brands and other aspects of the proprietary
system owned by Hyatt or its affiliates (“ Hyatt All-Inclusive Resorts”) in the countries of Mexico, Costa Rica, the Dominican Republic, Jamaica and
Panama, as their boundaries exist as of the Effective Date (the  “Market Area”); and
WHEREAS, simultaneously with signing this Agreement, Hyatt and Playa or its affiliates are terminating the Master Development Agreement
and signing amendments to the following franchise agreements (collectively, the  “Existing Franchise Agreements”) covering the following Hyatt
All-Inclusive Resorts:
 
  •   Franchise Agreement dated as of August 9, 2013, amended and restated on January 31, 2014 between Hyatt and Playa Hall Jamaican
Resort Limited for the operation of the Hyatt Ziva/Zilara® resort at 1 Ritz-Carlton Drive, Rose Hall, Montego Bay, Jamaica
 
  •   Franchise Agreement dated as of August 9, 2013, amended and restated on January 31, 2014 between Hyatt and Playa Cabos Baja, S. De
R.L. De C.V. for the operation of the Hyatt Ziva® resort at Paseo de Malecón  I-5 D, San José del Cabo, 23405, Mexico
 
 
•   Franchise Agreement dated as of August 9, 2013, amended and restated on January 31, 2014 between Hyatt and Cameron Del Pacifico S.
De R.L. De C.V. for the operation of the Hyatt Ziva® resort at Carretera Barra de Navidad Km. 3.5, Zona Hotelera, 48300, Puerto Vallarta,
Jalisco, Mexico
 
 
•   Franchise Agreement dated as of August 9, 2013, amended and restated on January 31, 2014 between Hyatt and Cameron Del Caribe S.
De R.L. De C.V. for the operation of the Hyatt Ziva® resort at Blvd. Kukulkan Km 9.5, Zona Hotelera, Punta Cancún, 77500, Cancún,
Quintana Roo, Mexico•   Franchise Agreement dated as of August 9, 2013, amended and restated on January 31, 2014 between Hyatt and The Royal Cancun S.
De R.L. De C.V. for the operation of the Hyatt Zilara® resort at Blvd. Kukulkan Km 11.5, Zona Hotelera, 77500 Cancún, Quintana Roo,
Mexico; and
WHEREAS, Hyatt and Playa have agreed to terminate the Master Development Agreement and to enter into this Agreement.
NOW, THEREFORE, in consideration of the mutual covenants and agreements contained in this Amendment and for other good and
valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:
1. First Offer for Development Opportunities. During the period beginning on the Effective Date and ending on December 31, 2018 (the
“Development Term”), each Party (the “Offering Party”) agrees to provide to the other Party (the “ Receiving Party”) a right of first offer with
respect to any proposed offer or arrangement, which the Offering Party (or its affiliate) desires to accept, under which the Offering Party or one of
its affiliates would acquire the ownership of real property in the Market Area (the “ Development Property”) on which a Hyatt All-Inclusive Resort
would operate (a “Development Opportunity”).
If the Offering Party is required to offer the Receiving Party a Development Opportunity pursuant to this Section 1, the Offering Party must
deliver written notice to the Receiving Party, together with reasonable due diligence information in the Offering Party’s possession to enable the
Receiving Party to evaluate the Development Opportunity (collectively, the “ Offer Notice”). The Receiving Party will have ten (10) business days
after receiving the Offer Notice to notify the Offering Party whether the Receiving Party exercises its right of first offer for that Development
Opportunity. If the Receiving Party and exercises its right of first offer hereunder, and:
(a) if the Receiving Party is Playa, then Playa (or its affiliate) and Hyatt’s affiliate shall negotiate in good faith the terms of a management
agreement and related documents under which Playa (or its affiliate) would manage a Hyatt All-Inclusive Resort on the Development Property
(subject to a franchise agreement between Hyatt and the affiliate of Hyatt that would own the Development Property), provided that Hyatt’s
affiliate acquires the Development Property on terms acceptable to it within sixty (60) days after delivery of the Offer Notice, and
(b) if the Receiving Party is Hyatt, then Playa or its affiliate shall negotiate in good faith the terms of a franchise agreement and related
documents for the operation (and, if applicable, development) of the Hyatt All-Inclusive Resort on the Development Property, provided that
Playa’s affiliate acquires the Development Property on terms acceptable to it within sixty (60) days after delivery of the Offer Notice.
 
2If the Receiving Party declines its right of first offer with respect to any Development Opportunity, or fails to notify the Offering Party of its
decision within the ten (10) business-day period described above, or if Hyatt’s affiliate or Playa’s affiliate (as applicable) fails to acquire the
Development Property within the sixty (60)-day period described above, then the right of first offer with respect to that Development Opportunity
shall expire, and the Offering Party thereafter may acquire, develop and/or operate (and/or grant any other person or entity the right to acquire,
develop and/or operate) an all-inclusive resort or other business on the Development Property without any restriction under this Agreement,
subject to any restrictions under any Existing Franchise Agreement or other agreement between Hyatt (or its affiliate) and Playa (or its affiliate).
2. Introduction to Other Opportunities . If a third party (who is not an affiliate of Hyatt) approaches Hyatt during the Development Term with a
proposed offer or arrangement, which Hyatt desires to accept, under which the third party would operate a Hyatt All-Inclusive Resort in the Market
Area, and if that third party has not then already designated a management company to operate that Hyatt All-Inclusive Resort, then Hyatt agrees
to provide notice to Playa and introduce Playa to that third party for purposes of enabling Playa (at its option) to negotiate for the opportunity to
manage that Hyatt All-Inclusive Resort for that third party. Similarly, if a third party (who is not an affiliate of Playa) approaches Playa during the
Development Term with a proposed offer or arrangement, which Playa desires to accept, under which Playa or its affiliate would manage an all-
inclusive resort in the Market Area for that third party, and if that third party has not then already designated a brand under which that all-inclusive
resort would operate, then Playa agrees to provide notice to Hyatt and introduce Hyatt to that third party for purposes of enabling Hyatt (at its
option) to negotiate for the opportunity to provide that third party franchise rights to brand that resort as a Hyatt All-Inclusive Resort.
3. Notices. Any notice required under this Agreement to be given by either Party to the other Party shall be in writing in the English
language. Any required notice shall be effective two business days after it is sent by a recognized international courier service to the address of the
other Party stated in this Agreement, or such other address as shall be notified to the other Party in writing, and any receipt issued by the courier
service shall be conclusive evidence of the fact and date of sending of any such notice.
Contact details of the Parties are as follows:
For Hyatt:
Hyatt Franchising Latin America
Hyatt Hotels Corporation
Hyatt Center – 12th Floor
71 South Wacker Drive
Chicago, Illinois 60606 U.S.A.
Attention: SVP Latin America Development
 
3with a copy to:  
Hyatt Hotels Corporation
Hyatt Center – 12th Floor
71 South Wacker Drive
Chicago, Illinois 60606 U.S.A.
Attention: Executive Vice President, General Counsel
For Playa: 
Playa Hotels & Resorts, B.V.
c/o Playa Management USA LLC
Playa Hotels & Resorts
1560 Sawgrass Corporate Parkway, Suite 310
Fort Lauderdale, Florida 33323
Attention: General Counsel
or to such other address and to the attention of such persons as the Parties may designate by like notice hereunder.
4. Choice of Law. All matters relating to arbitration will be governed by the Federal Arbitration Act (9 U.S.C. Sections 1 et seq.). Except to the
extent governed by the Federal Arbitration Act or other federal law, this Agreement and all claims arising from the relationship between Hyatt
(and/or any of its Affiliates) and Playa (and/or any of its Affiliates) under this Agreement will be governed by the laws of the State of Illinois
(U.S.A.), without regard to its conflict of laws rules, except that any Illinois law or any other law regulating the offer or sale of franchises, business
opportunities, or similar interests, or governing the relationship between a franchisor and a franchisee or any similar relationship, will not apply
unless its jurisdictional requirements are met independently without reference to this Section 4.
5. Dispute Resolution.
(a) All disputes arising out of or in connection with this Agreement shall to the extent possible be settled amicably by negotiation
between the Parties within fifteen (15) days from the date of written notice by either Party of the existence of such dispute, and, failing such
amicable settlement, shall be finally settled by arbitration under the Rules of Arbitration of the International Chamber of Commerce (“ Rules”).
To the extent there is any conflict between the Rules and the Federal Arbitration Act as it pertains to such arbitration, the Rules shall prevail.
(b) The arbitration panel shall consist of:
(i) one arbitrator in the event the aggregate damages sought by the claimant are stated to be less than Five Hundred Thousand
US Dollars (US$500,000), and the aggregate damages sought by the counter-claimant are stated to be less than Five Hundred Thousand
US Dollars (US$500,000); or
 
4(ii) three arbitrators in the event the aggregate damages sought by the claimant are stated to be equal to or exceed Five Hundred
Thousand US Dollars (US$500,000), or the aggregate damages sought by the counterclaimant are stated to be equal to or exceed Five
Hundred Thousand US Dollars (US$500,000).
Each arbitrator (1) shall have no fewer than ten (10) years’ experience in the international hotel business, (2) shall be licensed to practice law
in the United States, and (3) shall not be a person, or an affiliate of a person, who has any past, present or currently contemplated future
business or personal relationship with either Playa, Hyatt or any of their respective affiliates.
(c) The place of arbitration shall be New York, New York (USA).
(d) The language to be used in the arbitration shall be English.
(e) The arbitrator(s) shall have the power to grant any remedy or relief that they deem just and equitable, including injunctive relief,
whether interim and/or final, and any provisional measures ordered by the arbitrator(s) may be specifically enforced by any court of
competent jurisdiction. Each Party hereto retains the right to seek interim measures from a judicial or other governmental authority, and any
such request shall not be deemed incompatible with the agreement to arbitrate or a waiver of the right to arbitrate.
(f) An arbitral tribunal constituted under this Agreement may, unless consolidation would prejudice the rights of any Party, consolidate
an arbitration hereunder with an arbitration under any Franchise Agreement between Hyatt (or its affiliate) and Playa (or its affiliate), if the
arbitration proceedings raise common questions of law or fact.  If two or more arbitral tribunals under these agreements issue consolidation
orders, the order issued first shall prevail.
(g) The Parties agree that the award(s) shall be binding upon Hyatt and Playa and each Party’s parent company or companies (and all
other Affiliates), principals, successors, and assigns, and that judgment on the award(s) may be entered in any court of competent
jurisdiction, and the Parties waive any personal jurisdiction objections for the purpose of any enforcement proceedings under the 1958
United Nations Convention on the Recognition of Enforcement of Foreign Arbitral Awards. The arbitrator(s) may not award damages in
excess of compensatory damages or otherwise in violation of the waiver in this Agreement.
(h) Any award(s) shall be payable in U.S. Dollars. In the event that monetary damages are awarded, the award(s) shall include interest
from the date of default to the date of payment of the award in full. The arbitrator(s) shall fix an appropriate rate of interest, compounded
annually, which in no event shall be lower than the prime commercial lending rate charged by Hyatt’s primary bank (as Hyatt may designate
from time to time), to its most creditworthy commercial borrowers, averaged over the period from the date of the default to the date of the
award.
 
5(i) Any award(s) rendered by the arbitrator(s) shall be final and binding on the parties, and each party hereby waives to the fullest
extent permitted by law any right it may otherwise have under the laws of any jurisdiction to any form of appeal or collateral attack or to seek
determination of a preliminary point of law by any courts (including any court within the Market Area or elsewhere).
(j) The prevailing Party in any arbitration arising out of or related to this Agreement shall be entitled to recover from the losing Party all
reasonable fees, costs and expenses incurred by the prevailing Party in connection with such arbitration (including any actions to enforce
any award(s) or any of the provisions of this Section 5). If a Party prevails on some, but not all, of its claims, such Party shall be entitled to
recover an equitable amount of such fees, costs and expenses as determined by the arbitrator(s). All amounts recovered by the prevailing
Party under this Subsection shall be separate from, and in addition to, any other amount included in any award(s) rendered in favor of such
Party pursuant to this Section 5.
(k) Except as may be required by law, neither a Party nor its representatives nor a witness nor an arbitrator may disclose the existence,
content, or results of any arbitration or amicable settlement under this Section 5 (collectively, “ Dispute Information”) without the prior written
consent of both Parties. Each Party shall ensure that the Dispute Information is not disclosed to the press or to any other third person or
entity without the prior consent of the other Party. The Parties shall coordinate with one another on all public statements, whether written or
oral and no matter how disseminated, regarding the Dispute Information.
6. Entire Agreement. This Agreement constitutes the entire agreement between the Parties with respect to the subject matter of this
Agreement and supersedes all prior understandings and writings between the Parties. No Party may rely on any alleged oral or written
understandings, agreements, or representations not contained in this Agreement. Any policies that either Party adopts and implements from time to
time to guide them in their decision-making are subject to change, are not a part of this Agreement, and are not binding on them.
7. Representations and Warranties . Each Party represents and warrants that neither the execution of this Agreement nor the completion of the
transactions contemplated hereby and thereby will (a) violate any provision of applicable law or any judgment, writ, injunction, order or decree of
any court or governmental authority having jurisdiction over it; (b) cause a breach or default under any indenture, contract, other commitment or
restriction to which it is a party or by which it is bound; or (c) require any filing, consent, vote or approval which has not been taken, or at the time
when the transaction involved shall not have been given or taken. Each Party represents and warrants that as of the date hereof it has the full
company power and authority to enter into this Agreement and to perform its respective obligations under this Agreement, and that such Party’s
execution, delivery and performance of this Agreement have been duly authorized by all necessary action on the part of such Party.
8. Amendment. The provisions of this Agreement shall not be supplemented or amended except by an instrument in writing executed and
delivered by both Parties.
 
69. Waiver. Failure of either Party at any time to require the performance by the other Party of any provision hereof shall in no way affect the
full right to require such performance at any time thereafter. Hyatt and Playa will not waive or impair any right, power, or option this Agreement
reserves because of any custom or practice that varies from this Agreement’s terms; Hyatt’s or Playa’s failure, refusal, or neglect to exercise any
right under this Agreement or to insist upon the other’s compliance with this Agreement; Hyatt’s or Playa’s waiver of or failure to exercise any
right, power, or option, whether of the same, similar, or different nature, with other Hyatt All-Inclusive Resorts or any other agreements between the
parties and/or their affiliates; or Hyatt’s or Playa’s acceptance of any payments due from the other Party after any breach of this Agreement (unless
such payments are made within any applicable cure periods).
10. Binding Effect. This Agreement shall inure to the benefit of and bind the permitted assignees, successors and representatives of the
Parties, except that no assignment, transfer, pledge, mortgage or lease by or through either Party in violation of the provisions of this Agreement
shall vest any rights in the assignee, transferee, mortgagee, pledgee, or lessee, as the case may be.
11. Severability. If any provision of this Agreement shall be determined to be void, illegal, or unenforceable under the law, all other provisions
of this Agreement shall continue in full force and effect. The Parties are, in this event, obligated to replace the void, illegal or unenforceable
provision with a valid, legal and enforceable provision which corresponds as far as possible to the spirit and purpose of the void, illegal, or
unenforceable provision.
12. Language and Counterparts . This Agreement may be executed in any number of counterparts, all of which, taken together, shall constitute
one and the same agreement and a Party may enter into this Agreement by executing a counterpart. This Agreement is executed in the English
language, which shall prevail over any translation.
13. No Representation Regarding Forecasts . In entering into this Agreement, Hyatt and Playa acknowledge that neither Playa nor Hyatt has
made any representation to the other regarding forecasted earnings, the probability of future success or any other similar matter respecting the
business contemplated under this Agreement and that Hyatt and Playa understand that no guarantee is made to the other as to any amount of
income to be received by Hyatt or Playa or as to the future financial success of the business contemplated under this Agreement.
14. Waiver of Non-compensatory Damages . In any action or proceeding between the Parties (including any arbitration proceeding) arising
under or with respect to this Agreement or in any manner pertaining to the Hyatt All-Inclusive Resorts or to the relationship of the Parties under
this Agreement, each Party hereby unconditionally and irrevocably waives and releases any right, power or privilege either may have to claim or
receive from the other Party any punitive or exemplary damages, each Party acknowledging and agreeing that the remedies herein provided and
other remedies at law or in equity will in all circumstances be adequate. Both Parties acknowledge that they are experienced in negotiating
agreements of this sort, and have had the advice of counsel in connection with, and fully understand the nature of, the waiver contained in this
Section 14.
 
715. Corrupt Practices. Neither Party, nor any person acting for or on behalf of such Party, shall make, and each Party acknowledges that the
other Party will not make, any expenditure for any unlawful purposes (i.e. unlawful under the laws or regulations of the United States, the European
Union or the Market Area) in the performance of its obligations under this Agreement or in connection with its activities in relation thereto. Neither
Party, nor any person acting for or on behalf of such Party, shall, and each Party acknowledges that the other Party will not, bribe or offer to bribe
any government official, any political party or official thereof, or any candidate for political office, for the purpose of influencing any action or
decision of such person in their official capacity or any governmental authority of any jurisdiction.
IN WITNESS WHEREOF, the parties hereto have duly executed and delivered this Amendment on the day and year first above written.
 
HYATT FRANCHISING LATIN
AMERICA, L.L.C.    
PLAYA HOTELS & RESORTS B.V.
By:  /s/ Peter Sears    By:  /s/ Bruce D. Wardinski
  Name:  Peter Sears       Name:  Bruce D. Wardinski
  Title:   President       Title:   Executive Director
 
8Exhibit 7.1
 
Strategic Alliance Agreement
THIS AGREEMENT is made this 15th day of July, 2010 (“Effective Date”) by and between IMedicor, Inc, a Nevada Corporation whoseaddress is 523 Avalon Gardens Drive, Nanuet, New York 10954, USA ("IMedicor") and USA Managed Care Organization (USA MCO) A TexasCorporation whose address is 916 South Capital of Texas highway, Austin Texas.
WITNESSETH: WHEREAS, iMedicor is a secure, HIPAA compliant online portal that creates a virtual healthcare community amongst physicians and other medicalprofessionals for the purpose of real-time Health Information Exchange. Physicians are provided with a secure HIPPA compliant transport account(s),similar to e-mail with attachments, that enable them to share patient specific personal health information with other participating physicians. iMedicoralso provides the ability to create social communities for the purpose of peer collaboration and the extension of referral networks. iMedicor’s portalalso provides physicians with an extensive catalogue of Continuing Medical Education (CME), skill development and product specific educationalresources;
WHEREAS, USA MCO represents a network of physicians through which USA MCO provides products and services for the medical industry that:generate additional revenue Streams; provide cost savings, streamline workflow; help patients save time, money and doctors achieve better outcomes;and assist physicians and medical practices to find ways to enhance patient satisfaction;
WHEREAS, both parties are interested in forming a strategic and marketing alliance beneficial to both organizations.
NOW, THEREFORE, for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree asfollows:
1. OBLIGATIONS OF THE PARTIES  ●Initiate a multi tiered marketing approach, by mutual consent of both parties, to integrate the iMedicor HIPAA Compliant transportnetwork as a communications network throughout the USA MCO user base,●The overall project would also include the ClearLobby pharmaceutical and medical device marketing platform and other value addedservices as mutually agreed into the future, as a Phase II activity.●A phased in approach for each of the components listed above with the first being the introduction of the core iMedicor, HIPAAcompliant communication / transport system into the USA MCO network.●The integrated service will generate revenue sharing opportunities for both companies.●USA MCO will allow access to their network to distribute promotional and educational material highlighting the value proposition ofthe iMedicor / USA MCO alliance.●Access will only be through, and controlled by USA MCO●Communication will be, but not limited to e-mail promotion, direct mail, bill stuffers, web site, newsletter or any other normalcommunication between USA MCO and their network of physicians and other healthcare providers upon mutual consent of bothparties●All material must be approved by USA MCO prior to any distribution to the USA MCO network.●Once a physician or other healthcare provider enrolls in iMedicor they will become part of the regular internal iMedicorcommunications system.●Every physician that enrolls in iMedicor, including those physicians or other qualified registrants into the iMedicor network that areinvited into USA MCO physician communities, through the efforts of USA MCO will be tagged as originating from that source (theUSA MCO network).●Monthly reports detailing revenue generated through subscriptions, ClearLobby or other methods will be detailed in the monthlyreports.●All revenue sharing will be reconciled monthly and funds distributed by the 20th of each month by wire transfer for all net collectedrevenues for the previous month (net of returns and refunds, if any).●IMedicor will make its records available for audit purposes at any time by USA MCO during regular business hours at theheadquarters of iMedicor.●USA MCO will not be responsible for any direct sales of the iMedicor communications system; USA MCO will not handle anycustomer service issues. All such activity will be referred to iMedicor.●Initially iMedicor will provide the three main attributes of the iMedicor network to the USA MCO provider base, physicians and otherhealthcare providers.●Those attributes are:  oA HIPAA compliant transport system for digital / electronic records and images,  oBuild and create community, patient-specific peer collaboration and expansion of referral networks,  oAccess to educational resources, certified, skill level and product / device specific.●  
2. COMPENSATION  ●IMedicor will charge a subscription fee to participating USA MCO providers. The suggested monthly subscription would be $19.95per month per subscriber. USA MCO would receive one third of the monthly subscription price, per month, per subscriber(approximately $6.65). All revenue sharing opportunities will be calculated for all parties after any credit card or other third partyprocessing fees are deducted from the gross sale.●USA MCO will be responsible for the marketing and initial / ongoing communication to their network highlighting the features ofiMedicor, the value proposition, and their support of the project. This will not be a direct sales requirement for USA MCO, but only anagreement to provide access to the USA MCO user base●Within 30 days of the execution of this agreement both companies agree to finalize a marketing plan that would detail theypromotional activity to the USA MCO network, promotional deliverables, frequency of communication with the USA MCO networkand other activities normally found in a strategic marketing plan●Both companies agree to publish a press release, upon mutual agreement of content, in regard to the execution of this agreement andperiodic updates of the success of this Strategic Alliance●It is understood that iMedicor is a public company and is obligated to make certain SEC required filings that from time to time willinclude mention of the Strategic Alliance between iMedicor and USA MCO●IMedicor shall provide access to the iMedicor system, training and customer support as required.●USA MCO will have the option to take all or part of its revenue share in equity up to a maximum of 4.9% ownership in iMedicor on afully diluted basis. For the purposes of this proposal, fully diluted means all issued and outstanding stock warrants priced at 15 timesthe average 5 day closing price at the day previous to reconciliation of revenues, which will be the 20th of the month for the priorcalendar month.●The iMedicor bookkeeping system will detail the payment option prior to releasing any funds or commitment of stock in order forUSA MCO to determine how payment is to be reconciled. It is anticipated that said report will be available by the 15th of the monthfor previous activity, returned to iMedicor by the 19th in order to effect a timely disbursement of funds and or stock●It is understood that the issuance of stock certificates can take up to four weeks but the issue date will be the 20th of the month ofreconcile.●Equity payout will be priced at the average 10 day trading day closing from the day previous to the monthly reconciliation.●IMedicor will provide a warrant to purchase 2 million shares of common stock to USA MCO to offset any up-front marketing expenseincurred by USA MCO in this project. The value of the Warrants will be determined by the average 10 day closing price of iMedicorstock eliminating the two lowest days and the two highest days for the period as of the day before the actual execution of the finalagreement.●The Warrants will be issued as a non-cash-transaction upon exercise of the Warrant, and, USA MCO will have up to five years fromthe date of issuance to exe4cute. USA MCO will also have the option to purchase the Warrant for the face value if it deemed thepurchase option to be more favorable to the cashless transaction.●In addition to the subscription fees, iMedicor would offer a 17% revenue share (cash payout only) through revenues generated withits ClearLobby program. Clearlobby represents the Pharma / Medical Device marketing division inside iMedicor that will exposephysicians and other providers within the USA MCO provider network to new products and services in a non-invasive, opt-inmanner. ClearLobby will be the Phase II part of the relationship.●iMedicor will inform USA MCO of all ClearLobby activity as new products and services are introduced into the system●IMedicor will, from time to time make available upgrade services to its members. In this event, USA MCO will receive a revenue shareto be determined on a case by case basis. 3. TERM This Agreement shall commence on the Effective Date of this Agreement and shall remain in effect for a period of 5 years (“Initial Term”). Thereafter,this Agreement shall be renewed automatically on a five (5) year basis, unless one party notifies the other of its desire to terminate this Agreement atleast sixty 90 days prior to the expiration of the Initial Term or then current renewal term, as applicable, or unless a new Agreement is signed betweenthe USA MCO and IMedicor which will then invalidate this Agreement.
In such an instance, all compensation will continue for a extended period of five years from the date of termination for all subscriptions tagged as USAMCO.4. INTELLECTUAL PROPERTY Each party shall exclusively own its respective trademarks and service marks, copyrights, trade secrets, and patents (collectively, the "IntellectualProperty") and will not have any claim or right to the other party’s Intellectual Property by virtue of this Agreement or the performance of serviceshereunder. Neither party will take any action or make any claim to any Intellectual Property belonging to the other party, whether during the Term ofthis Agreement or thereafter.
5. TERMINATION
A. Termination Without Cause. Both parties may terminate this Agreement upon ninety (“90”) days written notice to the other party at the addressstated in this Agreement as per section 3 above.
B. Both parties shall have the right to include this Agreement as an asset of their Company.
C. Upon termination of this Agreement for any reason whatsoever, both parties shall have the right to remove any references to the other party fromany of its materials and/or websites as well as be authorized to notify their customers of said termination without penalty and/or recourse by the otherparty if only if said notification contains no disparaging or disrespectful comments concerning the other party.
6. REPRESENTATIONS AND WARRANTIES
A. Each party represents and warrants that it has the right, title, interest and authority to enter into this Agreement and to fully perform its obligationshereunder, and that the rights granted hereunder shall not violate the rights of any third party. Each party represents and warrants that its conducthereunder shall conform to all applicable federal, state and local law and regulation.
B. Both parties will not have liability for any damages other than direct damages. Both parties DO NOT MAKE ANY WARRANTY REGARDING THEQUALITY OF ITS SERVICES. Both parties DO NOT MAKE ANY WARRANTY THAT ALL ERRORS OR FAILURES IN ITS WEBSITES WILL BECORRECTED. Both parties EXPRESSLY DISCLAIM ALL WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE.BEYOND THE WARRANTIES CONTAINED IN THIS PARAGRAPH, Both parties DO NOT WARRANT THAT their SITES ARE ERROR-FREE ORTHAT OPERATION OF their SITES WILL BE SECURE OR UNINTERRUPTED. THESE LIMITATIONS SHALL SURVIVE AND APPLYNOTWITHSTANDING THE VALIDITY OF THE LIMITED REMEDIES PROVIDED FOR IN THIS AGREEMENT.7. INDEMNITY Notwithstanding anything to the contrary herein, USA MCO shall indemnify, defend and hold harmless IMedicor, its officers, directors, shareholders,employees, parent and affiliate entities, agents and representatives, against all damages, claims, liabilities, losses and other expenses, includingwithout limitation, reasonable attorney fees and costs, whether or not a lawsuit or other proceedings is filed, that in any way arise out of or related to:(a) any claim against IMedicor arising out of any breach of any covenants, warranties, representations and agreements made by USA MCO to anythird party and/or (b) USA MCO's material breach of any provision of this Agreement; (c) the grossly negligent or willful acts or omissions of USAMCO; and/or (d) any claim by any party based on USA MCO’s Products failing to operate and/or function in any manner so advertised by USA MCOand/or its agents. In the event that USA MCO fails to promptly indemnify and defend such claims and/or pay expenses as provided above, IMedicorshall have the right to defend itself and USA MCO shall reimburse IMedicor for all of its reasonable attorneys' fees, costs and damages incurred insettling or defending such claims within sixty (60) days of IMedicor’ request for same.
Notwithstanding anything to the contrary herein, IMedicor shall indemnify, defend and hold harmless USA MCO, its officers, directors, shareholders,employees, parent and affiliate entities, agents and representatives, against all damages, claims, liabilities, losses and other expenses, includingwithout limitation, reasonable attorney fees and costs, whether or not a lawsuit or other proceedings is filed, that in any way arise out of or related to:(a) any claim against USA MCO arising out of any breach of any covenants, warranties, representations and agreements made by IMedicor to anythird party and/or (b) IMedicor material breach of any provision of this Agreement; (c) the grossly negligent or willful acts or omissions of IMedicor;and/or (d) any claim by any party based on IMedicor Products failing to operate and/or function in any manner so advertised by IMedicor and/or itsagents. In the event that IMedicor fails to promptly indemnify and defend such claims and/or pay expenses as provided above, USA MCO shall havethe right to defend itself and IMedicor shall reimburse USA MCO for all of its reasonable attorneys' fees, costs and damages incurred in settling ordefending such claims within sixty (60) days of USA MCO’ request for same.
8. NO JOINT VENTURE Nothing in the Agreement shall be deemed to constitute, create, give effect to or otherwise recognize a partnership, joint venture or formal businessentity of any kind; and the rights and obligations of the Parties shall be limited to those expressly set forth herein. No Party is granted any right orauthority to assume or create any obligation or responsibility, express or implied, on behalf of, or in the name of, another Party or to bind another inany matter or thing whatsoever.
9. CONFIDENTIALITY
A. "Confidential Information" as used in this Agreement shall mean any and all technical and non-technical information including but not limited topatent, copyright, trade secret, and proprietary information, techniques, sketches, drawings, models, inventions, know-how, processes, apparatus,equipment, algorithms, software programs, software source documents, and formulae related to the current, future, and proposed products andservices of IMedicor and its affiliates, and includes, without limitation, IMedicor and its affiliates information concerning research, experimental work,development, design details and specifications, engineering, financial information, procurement requirements, purchasing, manufacturing, USA MCOlists, business forecasts, sales and merchandising, and marketing plans and information. "Confidential Information" also includes proprietary and/orconfidential information of any third party that may disclose such information to USA MCO in the course of IMedicor’ business. All ConfidentialInformation disclosed both orally and in writing by the disclosing party ("Discloser") will be considered Confidential Information by the receivingparty ("Recipient") and subject to terms of this Agreement, even if such information is not conspicuously designated as "Confidential" or even whenprovided orally and not identified as confidential at the time of disclosure.B. All Confidential Information disclosed both orally and in writing by either party will be considered Confidential Information by USA MCO andsubject to terms of this Agreement, even if such information is not conspicuously designated as "Confidential" or even when provided orally and notidentified as confidential at the time of disclosure.
C. USA MCO acknowledges that Discloser has over many years devoted substantial time, effort and resources to developing Discloser’s trade secretsand its other confidential and proprietary information, as well as Discloser’s relationships with USA MCOs, suppliers, employees and others doingbusiness with Discloser; that such relationships, trade secrets and other information are vital to the successful conduct of Discloser’ business in thefuture; that Discloser, in the furtherance of its business, is providing Recipient with the opportunity and support necessary to them to establishpersonal and professional relationships with USA MCOs, suppliers, employees and others having business relationships with Discloser and isaffording Recipient access to Discloser’ trade secrets and other confidential and proprietary information; that because of the opportunities andsupport so provided to Recipient and because of Recipient's access to Discloser’ confidential information and trade secrets, Recipient would be in aunique position to divert business from Discloser and to commit irreparable damage to Discloser were Recipient to be allowed to compete withDiscloser or to commit any of the other acts prohibited by this Section 9 of the Agreement; that the enforcement of the restrictive covenants againstRecipient would not impose any undue burden upon Recipient; that none of the restrictive covenants is unreasonable as to period or geographic area;and that the ability to enforce the restrictive covenants against Recipient is a material inducement to the decision of Discloser to consummate thisAgreement
D. Recipient hereby agrees that it will not make use of, disseminate, or in any way disclose any Confidential Information of Discloser to any person,firm, or business, except to the extent necessary for negotiations, discussions, and consultations with personnel and/or authorized representatives ofDiscloser, any purpose of Discloser authorized by this Agreement and any purpose Discloser may hereafter authorize in writing. Recipient hereby alsoagrees that it will use the Confidential Information disclosed by Recipient for informational purposes only. Recipient hereby further agrees that it shallnot use the Confidential Information of Recipient in the production and/or the providing of any products and/or services now or in anytime in thefuture.
E. Recipient agrees that it shall treat all Confidential Information of Recipient with the same degree of care as it accords to its own ConfidentialInformation, and Recipient represents that it exercises reasonable care to protect its own Confidential Information.
F. Recipient hereby agrees that it shall disclose Confidential Information of Discloser only to those of its officer(s), manager(s), and/or employee(s)who need to know such information and certifies that such officer(s), manager(s), and/or employee(s) have previously agreed, either as a condition ofemployment or in order to obtain the Confidential Information, to be bound by terms and conditions substantially similar to those of this Agreement.
G. Recipient will immediately give notice to Recipient of any unauthorized use or disclosure of the Confidential Information. Recipient agrees to assistRecipient in remedying any such unauthorized use or disclosure of the Confidential Information.
H. Upon the request of Discloser and/or termination of this Agreement, the Recipient will promptly return all confidential information furnishedhereunder and all copies thereof.
I. Remedies. In the event of a breach or a threatened breach of any of the Provisions and/or Covenants set forth in this Section 9 of the Agreementabove (the ''Covenants''), Discloser will, in addition to the remedies provided by law, have: (a) the right and remedy to have the Covenants specifically enforced by any court having equity jurisdiction, it being acknowledged and agreed thatany material breach of any of the Covenants will cause irreparable injury to Discloser and that money damages will not provide an adequate remedy toDiscloser; and
(b) the right and remedy to require a person to account for and pay over to Discloser all compensation, profits, moneys, accruals, increments or otherbenefits (collectively the ''Benefits'') derived or received by Recipient as a result of any transactions constituting a breach of any of the Covenants,and Recipient hereby agrees to account for and pay over the Benefits to Discloser.
J. The obligations of the parties set forth in this paragraph 9 of this Agreement shall survive the termination of this Agreement.10. PUBLICITY The Parties agree that all publicity and public announcements concerning the formation and existence of this Agreement shall be jointly planned andcoordinated by and among the Parties. Neither party shall disclose any of the specific terms of this Agreement to any third party without the priorwritten consent of the other party, which consent shall not be withheld unreasonably. Notwithstanding the foregoing, any party may discloseinformation concerning this Agreement as required by the rules, orders, regulations, subpoenas or directives of a court, government or governmentalagency, after giving prior notice to the other party.
11. EFFECT OF TERMINATION Upon termination or expiration of this Agreement, all rights granted to the USA MCO and IMedicor shall forthwith revert to the granting party.
12. FORCE MAJEURE Neither party will be liable for, or will be considered to be in breach of or default under this Agreement on account of, any delay or failure to perform asrequired by this Agreement as a result of any causes or conditions that are beyond such Party's reasonable control and that such Party is unable toovercome through the exercise of commercially reasonable diligence. If any force majeure event occurs, the affected Party will give prompt writtennotice to the other Party and will use commercially reasonable efforts to minimize the impact of the event.
13. NOTICES
A. Any notice required to be given pursuant to this Agreement shall be in writing and mailed by certified or registered mail, return receipt requested ordelivered by a national overnight express service.
For IMedicor:   Fred Zolla, CEO  IMedicor, Inc.  523 Avalon Gardens Drive  Nanuet, New York 10954 For the USA MCO:   George Bogle, CEO / President  USA MCO Solutions Corp,  916 South Capital of Texas Highway  Austin, TX 78746
Either party may change the address or entity to which notice or payment is to be sent by written notice to the other party pursuant to the provisionsof this paragraph.14. JURISDICTION DISPUTES
A. This Agreement shall be governed by the internal laws State of New York.
B. All disputes hereunder shall be resolved in the applicable state or federal courts in County of Rockland in the State of New York. The partiesconsent to the jurisdiction of such courts, agree to accept service of process by mail, and waive any jurisdictional or venue defenses otherwiseavailable.
15. AGREEMENT BINDING ON SUCCESSORS This Agreement shall be binding upon and shall inure to the benefit of the parties hereto, their heirs, administrators, successors and assigns.
16. WAIVER No waiver by either party of any default shall be deemed as a waiver of any prior or subsequent default of the same or other provisions of thisAgreement.
17. SEVERABILITY If any provision hereof is held invalid or unenforceable by a court of competent jurisdiction, such invalidity shall not affect the validity or operation ofany other provision and such invalid provision shall be deemed to be severed from the Agreement.
18. ASSIGNABILITY The license granted hereunder is specific to the USA MCO and may not be assigned by any act of the USA MCO or by operation of law unless withthe written consent of IMedicor.
19. INTEGRATION This Agreement constitutes the entire understanding of the parties, and revokes and supersedes all prior Agreements between the parties and isintended as a final expression of their Agreement. It shall not be modified or amended except in a writing signed by the parties hereto and specificallyreferring to this Agreement. This Agreement shall take precedence over any other documents which may be in conflict therewith.IN WITNESS WHEREOF, the parties hereto, intending to be legally bound hereby, have each executed this agreement on the day indicated. USA MCO IMedicor, Inc.   By: /s/George Bogle By: /s/Fred ZollaGeorge Bogle, CEO /President Fred Zolla, CEOExhibit 10.19 STRATEGIC ALLIANCE AGREEMENT
Among SUMITOMO MITSUI BANKING CORPORATION,SMBC NIKKO SECURITIES INC. And MOELIS & COMPANY HOLDINGS LP,MOELIS & COMPANY HOLDINGS GP LLC Dated December 27, 2011TABLE OF CONTENTS 
                                           
ARTICLE I.
 
 
 
CERTAIN DEFINITIONS; INTERPRETATION.
 
 
 
1.1
 
Certain Definitions
 
2
 
1.2
 
Interpretations
 
5
 
 
 
 
 
 
 
ARTICLE II.
 
 
 
STRATEGIC ALLIANCE.
 
 
 
2.1
 
Strategic Alliance
 
6
 
2.2
 
Obligations of the Parties
 
6
 
 
 
 
 
 
 
ARTICLE III.
 
 
 
SCOPE.
 
 
 
3.1
 
Scope
 
6
 
3.2
 
Covered Businesses
 
6
 
3.3
 
Covered Regions
 
6
 
3.4
 
Japanese Companies
 
7
 
3.5
 
Client
 
7
 
3.6
 
Corporate Lending Business
 
7
 
 
 
 
 
 
 
ARTICLE IV.
 
 
 
FEE ALLOCATION.
 
 
 
4.1
 
General Allocation
 
7
 
4.2
 
Certain Moelis Holdings Sell-side Assignments
 
74.3
 
Target Transactions
 
8
 
4.4
 
Discretionary Fee Sharing
 
8
 
4.5
 
Primary Fee Allocation Criteria
 
8
 
 
 
 
 
 
 
ARTICLE V.
 
 
 
NON-CIRCUMVENTION/NON-SOLICITATION.
 
 
 
5.1
 
Non-Circumvention
 
8
 
5.2
 
Non-Solicitation
 
8
 
5.3
 
Japan Office
 
9
 
 iARTICLE VI.
 
 
 
SENIOR SPONSORSHIP; ALLIANCE REVIEW COMMITTEE.
 
 
 
6.1
 
Alliance Review Committee
 
9
 
 
 
 
 
 
 
ARTICLE VII.
 
 
 
TRAINING AND DEVELOPMENT.
 
 
 
7.1
 
Training and Development
 
9
 
7.2
 
Secondment Program
 
10
 
 
 
 
 
 
 
ARTICLE VIII.
 
 
 
ENGAGEMENTS.
 
 
 
8.1
 
Engagement Letters and other Agreements
 
10
 
8.2
 
Expenses
 
11
 
8.3
 
Conflict Clearance
 
11
 
8.4
 
Compliance with Laws
 
11
 
 
 
 
 
 
 
ARTICLE IX.
 
 
 
JOINT MARKETING.
 
 
 
9.1
 
Joint Marketing
 
11
 
 
 
 
 
 
 
ARTICLE X.
 
 
 
CONFIDENTIALITY.10.1
 
Confidentiality
 
11
 
 
 
 
 
 
 
ARTICLE XI.
 
 
 
TERM
 
 
 
11.1
 
Term
 
12
 
11.2
 
Termination
 
13
 
11.3
 
Effect of Termination
 
13
 
 
 
 
 
 
 
ARTICLE XII.
 
 
 
CERTAIN RIGHTS OF SMBC/NIKKO.
 
 
 
12.1
 
Advisory Board
 
14
 
12.2
 
Right of First Refusal
 
14
 
 ii12.3
 
Moelis General Partner’s Consent to Certain Transfers
 
15
 
12.4
 
Certain Transfer Matters
 
15
 
12.5
 
Amendments to the Moelis Holdings Agreement
 
17
 
12.6
 
Percentage Interest Limit
 
18
 
 
 
 
 
 
 
ARTICLE XIII.
 
 
 
REGISTRATION RIGHTS.
 
 
 
13.1
 
Registration
 
18
 
13.2
 
Piggyback Registration
 
19
 
13.3
 
Reduction of Size of Underwritten Offering
 
20
 
13.4
 
Registration Procedures
 
21
 
13.5
 
Conditions to Offerings
 
23
 
13.6
 
Suspension Period
 
24
 
13.7
 
Market Stand-Off Agreement
 
25
 
13.8
 
Registration Expenses
 
26
 
13.9
 
Indemnification; Contribution
 
26
 
13.10
 
Rule 144
 
29
 
13.11
 
Transfer of Registration Rights
 
29
 
13.12
 
Termination of Registration Rights
 
29
 
 
 
 
 
 
 
ARTICLE XIV.
 
 
 
REPRESENTATIONS AND WARRANTIES; CONDUCT OF BUSINESS
 
 
 
14.1
 
Representations and Warranties of Moelis
 
29
 
14.2
 
Representations and Warranties of SMBC/Nikko
 
30
 
14.3
 
Survival of Covenants, Representations and Warranties
 
30
 
 
 
 
 
 
 
ARTICLE XV.MISCELLANEOUS
 
 
 
15.1
 
Expenses; No Partnership or Joint Venture
 
31
 
15.2
 
Notice
 
31
 
15.3
 
Entire Agreement; Amendment; Waivers; Counterparts
 
31
 
15.4
 
No Assignment
 
32
 
15.5
 
Obligation and Responsibilities of SMBC/Nikko
 
32
 
15.6
 
Separability
 
32
 
15.7
 
Compliance with Laws
 
32
 
15.8
 
Governing Laws; Jurisdiction
 
32
 
15.9
 
Effect on Prior Agreement
 
33
 
15.10
 
Good Faith Discussion; Further Assurances
 
33
 
 iiiSTRATEGIC ALLIANCE AGREEMENT This Strategic Alliance Agreement is entered into as of December 27, 2011 by and among Sumitomo Mitsui Banking Corporation(“SMBC”), a Japanese corporation with its head office at 1-2, Marunouchi 1-chome, Chiyoda-ku, Tokyo 100-0006, Japan and its subsidiary SMBCNikko Securities Inc. (“Nikko” and together with SMBC, “SMBC/Nikko”), a Japanese corporation with its head office at 3-1, Marunouchi 3-chome,Chiyoda-ku, Tokyo 100-8325, Japan, on the one hand, and Moelis & Company Holdings LP (“Moelis Holdings”), a Delaware limited partnershipwith offices at 399 Park Avenue, New York, NY 10022, United States, and Moelis & Company Holdings GP LLC, a Delaware limited liability companywith offices at 399 Park Avenue, New York, NY 10022, United States (“Moelis General Partner”, and together with Moelis Holdings, the “MoelisEntities”), on the other hand. SMBC, Nikko, Moelis Holdings and Moelis General Partner are each referred to herein as a “party” and collectivelyreferred to as the “parties”.  W I T N E S S E T H: WHEREAS, on March 1, 2011, SMBC/Nikko and Moelis Holdings entered into that certain Strategic Alliance Agreement (Phase I) withrespect to certain investment banking businesses in certain regions involving Japanese companies (the “Prior Agreement”); WHEREAS, on the date hereof, SMBC entered into an Investment and Subscription Agreement (as modified or amended, the“Subscription Agreement”) with Moelis Holdings and Moelis General Partner, pursuant to which SMBC has agreed to acquire 57,364 newly issuedPartnership Interests; WHEREAS, the parties wish to amend and restate the Prior Agreement to further set forth the understanding of the parties with respect tocertain investment banking businesses in certain regions involving Japanese companies and to set forth certain agreements with respect to certaintransfer and registration rights relating to the Partnership Interests as of the Effective Date; and WHEREAS, the execution and delivery of this Agreement is a condition to the closing of the transactions contemplated by theSubscription Agreement. NOW, THEREFORE, in consideration of the foregoing and the respective promises contained herein and for other good and valuableconsideration, the receipt and sufficiency of which are hereby acknowledged:ARTICLE I. CERTAIN DEFINITIONS; INTERPRETATION. 1.1 Certain Definitions. “Agreement” means this Strategic Alliance Agreement, as amended or modified from time to time in accordance with Section 15.3,including all schedules and exhibits hereto. “Alliance Review Committee” has the meaning given in Section 6.1. “Client” has the meaning given in Section 3.5. “Closing” means the Closing as defined in the Side Letter. “Confidential Information” has the meaning given in Section 10.1. “control” shall mean possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of anentity whether through ownership of voting securities, by contract or otherwise, including the ability to elect the majority of the directors or themembers of a similar governing body of such entity. “Covered Businesses” has the meaning given in Section 3.2. “Covered Regions” has the meaning given in Section 3.3. “Demand Notice” has the meaning set forth in Section 13.1(a)(i). “Demand Registration” has the meaning set forth in Section 13.1(a)(i). “Effective Date” has the meaning set forth Section 11.1. “Indemnified Party” has the meaning set forth in Section 13.9(c). “Indemnified Persons” has the meaning set forth in Section 13.9(a). “Indemnifying Party” has the meaning set forth in Section 13.9(c). “Introduces” and “Introduced” means that a party arranges or arranged an initial substantive meeting (in person or by phone) between asenior decision maker at the Client and the other party. “IPO” means an initial underwritten public offering and sale of Partnership Interests (or any securities of Moelis Holdings or anysuccessor entity into which Partnership Interests are converted, exchanged or redesignated) for cash pursuant to an effective registrationstatement (other than on Form S-4 or S-8 or a comparable form). 2“Issuer FWP” has the meaning assigned to “issuer free writing prospectus” in Rule 433 under the Securities Act. “Japanese Companies” has the meaning given in Section 3.4. “Japanese Competitors” means any Japanese financial institution that engages in an investment banking business or any other CoveredBusiness in Japan or outside Japan. “KM” means Mr. Ken Moelis and any entity or person controlled by or affiliated with Mr. Moelis, including Moelis Manager, any familytrust or otherwise, through which Mr. Ken Moelis holds his Partnership Interests. “Losses” has the meaning set forth in Section 13.9(a). “Main-Advisor Party” has the meaning set forth in Section 8.4. “Major Japanese Competitors” means the following entities together with any ultimate parents controlling such entities: Mitsubishi UFJFinancial Group, Inc., Mizuho Financial Group, Inc., Nomura Holdings, Inc., Daiwa Securities Group Inc., Sumitomo Mitsui Trust Holdings, Inc.,Resona Holdings, Inc., Shinsei Bank, Limited., Orix Corporation, any of their respective subsidiaries as of the date of this Agreement thatsubstantially engages in an investment banking business or any other Covered Business in Japan, and any respective successors of any of theentities set forth herein. “Minimum Aggregate Fees” has the meaning given in Section 4.3. “Moelis Competitor” means any business enterprise that is engaged in, or owns or controls a significant interest in any entity that, ineither case, is engaged, primarily or in any substantial manner in, investment banking activities or any other business activities that MoelisHoldings and/or its affiliates are engaged in primarily or in any substantial manner; provided, however, that no private equity fund, sovereignwealth fund or merchant bank shall be deemed a “Moelis Competitor”. “Moelis Entities” has the meaning set forth in the preamble to this Agreement. “Moelis General Partner” has the meaning set forth in the preamble to this Agreement. “Moelis Holdings” has the meaning set forth in the preamble to this Agreement. “Moelis Holdings Agreement” means that certain Limited Partnership Agreement of Moelis Holdings, dated as of July 1, 2011 (asamended). “Moelis Manager” means Moelis & Company Manager LLC, a Delaware limited liability company. “Nikko” has the meaning set forth in the preamble to this Agreement. “Nikko Affiliate” has the meaning set forth in Section 10.1.  3“Non-Japanese Competitors” means the following entities together with any ultimate parents controlling such entities: Evercore PartnersInc., Hawkpoint Partners Limited, Perella Weinberg Partners LP, Sagent Advisors Inc., DC Advisory Partners Limited and Stifel Financial Corp.(which, for the avoidance of doubt, includes Stifel Nicolaus Weisel (f/k/a Thomas Weisel)). “Partnership Interests” means limited partnership interests and any securities of Moelis Holdings or any successor entity into whichPartnership Interests are converted, exchanged or redesignated, including in connection with any recapitalization of Moelis Holdings for thepurpose of conducting the IPO.  “party” or “parties” has the meaning set forth in the preamble to this Agreement. “Piggyback Registration” has the meaning set forth in Section 13.2.  “Prior Agreement” has the meaning set forth in the recitals to this Agreement. “Prospectus” means the prospectus (including any preliminary prospectus and any final prospectus) included in any RegistrationStatement, as amended or supplemented by any free writing prospectus, whether or not required to be filed with the SEC, prospectus supplementwith respect to the terms of the offering of any portion of the Registrable Securities covered by the Registration Statement and by all otheramendments and supplements to the prospectus, and all material incorporated by reference in such prospectus. “Registrable Securities” means all SMBC Units beneficially owned by the SMBC Unit-Holders at any time, and any securities of MoelisHoldings or any successor entity into which the SMBC Units are converted, exchanged or redesignated, including in connection with anyrecapitalization of Moelis Holdings for the purpose of conducting the IPO; provided, however, that an SMBC Unit shall cease to be a RegistrableSecurity when (i) it has been effectively registered under the Securities Act and disposed of in accordance with the Registration Statement coveringit, or (ii) it is distributed to the public pursuant to Rule 144. “Registration Statement” means any registration statement of Moelis Holdings that covers Registrable Securities pursuant to theprovisions of this Agreement, including the prospectus, amendments and supplements to such registration statement, including pre- and post-effective amendments, and all exhibits and all material incorporated by reference in such registration statement. “Representative” means, with respect to any person, such person’s, or such person’s subsidiaries’, directors, officers, employees,accountants, investment bankers, commercial bank lenders, attorneys and other advisors or representatives (including the employees or attorneysof such accountants, investment bankers or attorneys). “Rule 144” means Rule 144 promulgated under the Securities Act or any similar rule or regulation hereafter adopted by the Securities andExchange Commission having substantially the same effect as such rule. 4“Side Letter” means the letter from Moelis General Partner and Moelis Holdings to SMBC, re Investment in Moelis & Company HoldingsLP, dated the date hereof. “SMBC” has the meaning set forth in the preamble to this Agreement. “SMBC Affiliate” has the meaning set forth in Section 10.1. “SMBC Competitor” means (i) any of the Japanese Competitors, (ii) each of the Non-Japanese Competitors, (iii) any entity that iscontrolled by any Japanese Competitor or any Non-Japanese Competitor and that engages in an investment banking business or any otherCovered Business and (iv) any entity that is under common control with or controls any Major Japanese Competitor and that engages in aninvestment banking business or any other Covered Business. “SMBC Units” means all Partnership Interests, including Common Units, held by an SMBC Unit-Holder, which shall include all PartnershipInterests acquired pursuant to the Subscription Agreement or thereafter. “SMBC Unit-Holders” has the meaning set forth in Section 13.1(a)(i). “Securities Act” means the Securities Act of 1933, as amended. “SMB C/Nikko” has the meaning set forth in the preamble to this Agreement. “Strategic Alliance” means the rights and obligations of the parties set forth in ARTICLE II to XII of this Agreement. “Sub-Advisor Party” has the meaning set forth in Section 8.4. “Subscription Agreement” has the meaning set forth in the recitals to this Agreement. “Suspension Period” has the meaning set forth in Section 13.6. “Underwritten Offering” means a public offering of securities registered under the Securities Act in which an underwriter, placement agentor other intermediary participates in the distribution of such securities. 1.2 Interpretations.  (a) Capitalized terms used without definition herein shall have the respective meanings given to such terms in the MoelisHoldings Agreement.  5ARTICLE II. STRATEGIC ALLIANCE. 2.1 Strategic Alliance. SMBC/Nikko and Moelis Holdings wish to continue their Strategic Alliance with respect to certain investmentbanking business in certain regions involving Japanese Companies as set forth herein, and will continue to offer the other the same quality or levelof services that were offered under the Prior Agreement. SMBC/Nikko and Moelis Holdings will help the other continue the growth of the otherparty’s investment banking business.  2.2 Obligations of the Parties. Each of the parties acknowledge and agree that each other party may, and at the reasonable request fromanother party, shall, cause one or more of such party’s affiliates to act on behalf of such party in the performance of its duties or exercise of itsrights under this Agreement.  ARTICLE III. SCOPE. 3.1 Scope. Subject to the terms and conditions set forth in this Agreement and to the extent permitted by pre-existing arrangements ofeither party, SMBC/Nikko, on the one hand, and Moelis Holdings, on the other hand, shall use their commercially reasonable best efforts to worktogether on Covered Businesses involving Japanese Companies where all principal parties involved are located within Covered Regions. TheStrategic Alliance shall continue to be non-exclusive.  3.2 Covered Businesses. “Covered Businesses” shall mean M&A advisory, restructuring advisory (such as advising on recapitalizationand restructuring transactions), capital markets advisory (including agency private placements), risk advisory (such as advising on investing,structuring, managing, restructuring and divesting risk exposures and complex assets classes) and merchant banking businesses (such as principalinvestment) to the extent the applicable target transaction requirement set forth in Section 4.3 of this Agreement is satisfied, but specificallyexcludes (unless the parties mutually agree to include a specific transaction) (i) underwritten offerings and bank or similar committed financings, (ii)purely domestic Japanese transactions such as transactions solely between/among companies organized or headquartered in Japan (including anytransactions of or by subsidiaries or affiliates of such companies located throughout the world conducted as part of any such transaction), (iii) anytransactions introduced to a party by a person or entity (other than a principal party to the transaction) not affiliated with such party and (iv)transactions where a party, its subsidiary or controlled affiliate is a principal party.  3.3 Covered Regions. “Covered Regions” shall mean Japan, North America, Europe, the Middle East and North Africa, Australia, HongKong and China. For the avoidance of doubt, the definition of Covered Regions does not prohibit the parties from 6
 discussing or working together on Covered Businesses in regions outside the Covered Regions, such as non-Japan/Hong Kong/China Asia. 3.4 Japanese Companies. “Japanese Companies” shall mean (i) companies organized or headquartered in Japan and their subsidiaries andcontrolled affiliates outside Japan, (ii) subsidiaries and controlled affiliates organized or headquartered in Japan of parent companies in the CoveredRegions other than Japan and (iii) Japanese governmental and quasi-governmental entities and affiliates. 3.5 Client. A “Client” is (i) with respect to SMBC/Nikko, a Japanese Company or any other person or entity within Covered Regions thatSMBC/Nikko Introduces to Moelis Holdings pursuant to this Agreement and (ii) with respect to Moelis Holdings, a Japanese Company or anyother person or entity within Covered Regions that Moelis Holdings Introduces to SMBC/Nikko pursuant to this Agreement. 3.6 Corporate Lending Business. SMBC/Nikko and Moelis Holdings will continue to work together in good faith to seek ways to expandthe Strategic Alliance to cover corporate lending opportunities where Moelis Holdings sources corporate lending opportunities for SMBC/Nikko toMoelis Holdings’ clients and works with SMBC/Nikko to provide SMBC/Nikko clients and relationships access to Moelis Holdings capabilities inCovered Businesses. The parties may enter into additional agreements and/or addenda to this Agreement designed to elaborate upon and clarifythe arrangements contemplated by this Section 3.6.  ARTICLE IV. FEE ALLOCATION. 4.1 General Allocation. The parties agree to share fees 50%/50% on assignments within the scope of this Agreement set forth in Section 3.1where SMBC or Nikko, on the one hand, and Moelis Holdings, on the other hand, are jointly retained as co-advisors by a Client for suchassignments, except as otherwise mutually agreed with respect to a specific matter by the parties. The parties agree that the parties will generallyseek to be jointly retained as co-advisors by a Client on assignments within the scope of this Agreement. 4.2 Certain Moelis Holdings Sell-side Assignments. In the case of M&A sell-side assignments originated by Moelis Holdings within thescope of this Agreement set forth in Section 3.1 for which SMBC or Nikko does not serve (together with Moelis Holdings) as a co-advisor to theseller, if SMBC or Nikko introduces the actual buyer, and neither SMBC nor Nikko obtains a mandate to serve as an advisor to such buyer inconnection with such acquisition, Moelis Holdings will pay SMBC/Nikko an introduction fee equal to 15% of the sale transaction fee paid toMoelis Holdings. There will be no other sharing of fees received from the seller between Moelis Holdings and SMB C/Nikko on any suchassignments.  74.3 Target Transactions. The Strategic Alliance will target transactions on which both parties work together as co-advisors to a Client onthe terms and conditions set forth in Section 3.1 with minimum aggregate fees (the “Minimum Aggregate Fees”) of: (1) M&A advisory, $3 million,(2) restructuring advisory, $2 million and (3) capital markets advisory and risk advisory, $1 million. 4.4 Discretionary Fee Sharing. One or more senior representatives of Moelis Holdings or SMBC/Nikko, as the case may be, will consider ona case by case basis if requested by a senior representative of the other party, discretionary fee sharing when Moelis Holdings or SMBC/Nikko, asthe case may be, provides demonstrable value.  4.5 Primary Fee Allocation Criteria. The parties may mutually agree on a fee allocation different from the foregoing allocations in good faithbased on, among other things, the following criteria: (a) Whether one or both parties have an important relationship that is crucial to securing an assignment (b) Resource contribution  (c) Product expertise  (d) Industry expertise  (e) Transaction size  (f) Resource constraints  ARTICLE V. NON-CIRCUMVENTION/NON-SOLICITATION. 5.1 Non-Circumvention. Subject to pre-existing arrangements of either party, each party agrees not to circumvent this Agreement and toact in good faith in the spirit of the Strategic Alliance. Each party shall ensure that its controlled affiliates comply with the terms and conditions ofthis Agreement.  5.2 Non-Solicitation. Each of SMBC/Nikko and Moelis Holdings agrees not to solicit or hire any employee of the other party during theterm of this Agreement and for a period of 12 months thereafter; provided, however, that the foregoing restriction shall not apply to generalsolicitations to the public that are not specifically directed to employees of other party (or employment of applicants to such solicitations). Each ofSMBC/Nikko and Moelis Holdings agrees, during the term of this Agreement (except pursuant to this Agreement) and for a period of 12 monthsthereafter, not to solicit any Client Introduced by the other party in connection with an assignment on Covered 8Businesses involving Japanese Companies where all principal parties involved are located within Covered Regions. Notwithstanding the foregoing, this provision shall not prevent any party from soliciting or otherwise contacting any Client (i)for any purpose other than working on or obtaining an assignment on Covered Businesses involving Japanese Companies in Covered Regionswhere all principal parties involved are located within Covered Regions or (ii) with whom such party (or its employees or consultants) has had apre-existing relationship, including, but not limited to, a pre-existing contractual or business relationship, prior to the Introduction of such Client inconnection with an assignment covered by this Agreement. 5.3 Japan Office. Moelis Holdings agrees not to open an office in Japan conducting Covered Businesses during the term of thisAgreement.  ARTICLE VI. SENIOR SPONSORSHIP; ALLIANCE REVIEW COMMITTEE. 6.1 Alliance Review Committee. As soon as reasonably practicable following the Effective Date, SMBC/Nikko and Moelis Holdings shallform a six person committee comprised of two senior executives from each of SMBC, Nikko and Moelis Holdings to review and discuss theprogress of the Strategic Alliance (the “Alliance Review Committee”). Each party shall notify the other parties if it replaces either of its designees tothe Alliance Review Committee. The Alliance Review Committee will meet annually and will have the authority to recommend changes to theStrategic Alliance or this Agreement if deemed appropriate. For the avoidance of doubt, the recommendations of the Alliance Review Committeewill not be binding upon any party unless and until this Agreement is amended or modified pursuant to Section 15.3.  ARTICLE VII. TRAINING AND DEVELOPMENT. 7.1 Training and Development. During the term of this Agreement, Moelis Holdings shall offer certain full-time analysts and associates ofSMBC/Nikko, or employees with similar responsibilities, the opportunity to participate annually in Moelis Holdings’ training program for newlyhired full-time analysts and associates, to the extent that Moelis Holdings’ holds such a program. SMBC/Nikko shall reimburse Moelis Holdings forall out-of-pocket and allocated expenses incurred by Moelis Holdings in connection with SMBC/Nikko employees’ attending the Moelis Holdingstraining program.  97.2 Secondment Program.  (a) During the term of this Agreement, SMBC/Nikko shall second 3 or 4 bankers to Moelis Holdings’ New York office and second2 or 3 bankers to Moelis Holdings’ London office as local staff of Moelis Holdings. Moelis Holdings shall use its commercially reasonable bestefforts to second a banker to SMBC/Nikko’s Tokyo office as local staff of SMBC/Nikko. All secondees shall be investment bankers that serve in aposition with responsibilities typically associated with an Associate or a Vice President at a major international investment bank, except asotherwise agreed between SMB C/Nikko and Moelis Holdings. (b) Each party shall be responsible for all out-of-pocket and allocated expenses incurred by its employees who are seconded. Aparty’s secondee(s) must be reasonably acceptable to the other parties and shall agree to be subject to any policies and procedures, includingwithout limitation, relating to confidential and proprietary information and securities and other trading activity limitations, that the party acceptingsuch secondee may determine are necessary and/or appropriate. (c) SMBC/Nikko and Moelis Holdings will from time to time during the term of this Agreement, review and discuss thesecondment program and such additions and changes the parties consider appropriate to further the Strategic Alliance. ARTICLE VIII. ENGAGEMENTS.  8.1 Engagement Letters and other Agreements.  (a) Parties. Where the parties are executing an assignment together pursuant to this Agreement, it is anticipated that generallyboth parties (or one of their respective affiliates) will sign the engagement letter (and, where necessary, other relevant agreements) with the relevantClient in connection with the assignment. In certain limited circumstances mutually agreed upon by the parties, one party may sign the engagementletter with the Client and then such party would also sign an agreement with the other party or parties for such party or parties to provide servicesto the Client and receive compensation, indemnification and other protections after receiving the written consent of such Client. (b) Rights and Obligations. The engagement letters will (unless otherwise agreed) include a provision to the effect that: “Therights and obligations of SMBC, Nikko and Moelis Holdings are the several rights and obligations of SMBC, Nikko and Moelis Holdings and thateach of SMBC, Nikko or Moelis Holdings shall not be liable or responsible for the actions or omissions of the others.” (c) Payment. The engagement letters will (unless otherwise agreed) provide that payments would be made to either SMBC/Nikkoor Moelis Holdings and SMBC/Nikko and Moelis Holdings will split the fees pursuant to this Agreement. 108.2 Expenses. If only one party is engaged for an assignment, such party will submit expenses of the other parties for reimbursement by theClient. If there is an expense cap or any other expense reimbursement reduction, the parties will (unless otherwise agreed) bear the cost of suchunreimbursed expenses in the same proportion as the parties agreed to split the fees from such assignment. 8.3 Conflict Clearance. Each party shall have its own separate conflict identification, business selection and client vetting procedures. Theparties will cooperate to identify and resolve potential conflict issues. 8.4 Compliance with Laws. In the case where one party executes an engagement letter with a Client (the “Main-Advisor Party”) and theMain-Advisor Party appoints and retains the other party or parties as a sub-advisor (the “Sub-Advisor Party”), each of the Main-Advisor Partyand the Sub-Advisor Party shall comply in all material respects with all applicable laws or regulations, including the UK Bribery Act 2010, the USForeign Corrupt Practices Act of 1977 and any other similar anti-bribery act in its execution and performance of its services for the CoveredBusinesses for such Client. If either of the Main-Advisor Party or Sub-Advisor Party breaches its obligations set forth in this Section 8.4, the non-breaching party shall have the right to immediately terminate its sub-advisor agreement or any other similar agreement entered into with respect tothe Covered Businesses for such Client by providing a written notice to the breaching party that specifically identifies how the breaching party hasbreached this Section 8.4.  ARTICLE IX. JOINT MARKETING. 9.1 Joint Marketing. The parties shall establish a joint marketing effort for the Strategic Alliance. Among other things, the parties shallagree upon a joint press release and communication strategy for announcing the Strategic Alliance and certain joint marketing materials whicheither party may use in marketing to Clients.  ARTICLE X. CONFIDENTIALITY. 10.1 Confidentiality. The parties each agree to keep confidential all non-public information disclosed by another party or a Client orprospective Client or a representative thereof in connection with the Strategic Alliance (including this Agreement) (“Confidential Information”), (i)except to subsidiaries, affiliates or their professional advisors (and provided that the Party shall cause the recipient to assume and perform theconfidentiality obligations equivalent to those imposed on such party under this Agreement and shall be responsible for breach of suchobligations by such recipient) and (ii) except as required by judicial process or such party’s regulatory authorities, and 11to use such information only for purposes of the Strategic Alliance (including this Agreement); provided, however, that Confidential Informationshall not include (i) information that is already in the receiving party’s possession when it is received and not subject to a confidentiality agreementor other obligation of confidentiality to the disclosing party, (ii) information separately obtained by the receiving party from a third party that is notknown or should not reasonably be known to the person receiving such information to be bound by a confidentiality agreement or other obligationof confidentiality to the disclosing party and (iii) information independently developed by the receiving party without any use of ConfidentialInformation. In the event that any disclosure of Confidential Information is required by judicial process or such party’s regulatory authorities, theparty required to make such disclosure shall, to the extent commercially practicable and legally permissible, consult with the party that providedsuch Confidential Information prior to making any such disclosure. Nothing in this section shall restrict the receiving party’s ability to make anylegally required disclosures of Confidential Information to bank examiners or other supervisory authorities having jurisdiction over the receivingparty. Each of Moelis Holdings and SMBC/Nikko shall also ask the other if it has internally cleared the receipt of non-public information regarding aClient or prospective Client before the party providing such information delivers any such information to the receiving party. Due to Japanesefirewall restrictions, (i) SMBC will not disclose Confidential Information relating to its Clients to Nikko (ii) Nikko will not disclose ConfidentialInformation relating to its Clients to SMBC and (iii) Moelis Holdings shall not disclose Confidential Information relating to a Client received fromSMBC or any of its affiliates (excluding Nikko and any person that would be an affiliate of Nikko if Nikko were not an affiliate of SMBC) (an “SMBCAffiliate”) to Nikko or its affiliates (excluding SMBC and any person that would be an affiliate of SMBC if Nikko were not an affiliate of SMBC) (a“Nikko Affiliate”) or Confidential Information relating to a Client received from Nikko or any Nikko Affiliate to SMBC or any SMBC Affiliate,without first obtaining such Client’s consent to such disclosure. This Section 10.1 shall terminate with respect to Confidential Information relatingto a (prospective) Client, two years following receipt of such information, and with respect to any other Confidential Information, two yearsfollowing the termination of this Agreement.  ARTICLE XI. TERM 11.1 Term. This Agreement shall be effective as of January 1, 2012 (the “Effective Date”), provided, however, that, ARTICLE XII andARTICLE XIII shall not be effective until after the Closing. The initial term of this Agreement shall begin on the Effective Date and continue forthree (3) years, subject to the prior termination rights provided below. At the end of such initial term, and any renewed term, as applicable, thisAgreement shall automatically renew for an additional one (1) year term, unless a party provides written notice to the other parties at least six (6)months prior to the end of the  12initial term. At any time during a renewed term, this Agreement may be terminated by any party on six (6) months prior notice that it wishes toterminate the Agreement.  11.2 Termination. This Agreement may be terminated as follows: (a) effective immediately upon mutual agreement of each of the parties; (b) immediately by a non-breaching party, if either SMBC or Nikko, on the one hand, or Moelis Holdings, on the other hand, shallmaterially breach the terms and conditions of this Agreement, and such breach is continuing after written notice has been given by the non-breaching party to the breaching party that specifically identifies how the breaching party has breached this Agreement, and a reasonable period oftime has elapsed in which to cure such breach, which period shall not be less than ninety (90) calendar days from the date that such breachingparties receive such notice; (c) immediately upon the bankruptcy, insolvency, or making of the assignment for the benefit of creditors by a party; unless suchtermination is waived by the parties in writing not subject to any of the foregoing proceedings; (d) by any party if the SMBC Unit-Holders cease to hold any Partnership Interests as a result of sale or transfer pursuant toSection 12.4 of this Agreement or Section 8.4 of the Moelis Holdings Agreement, such termination to be effective six (6) months following the dateon which the other parties receive written notice of such party’s election to terminate this Agreement; and (e) immediately by Moelis Holdings if the Closing has not occurred by March 1, 2012 or such later date if the Closing is delayedpursuant to the terms of the Subscription Agreement.  11.3 Effect of Termination. In the event of the termination of this Agreement, no party shall have any liability to any other party in respectof this Agreement except for any liabilities relating to any breach or any payment obligation hereunder and arising prior to such termination;provided, that, Sections 5.2 (Non-Solicitation) and 8.2 (Expenses) and ARTICLE X (Confidentiality), XII (Certain Transfer Rights of SMBC/Nikko)(other than Section 12.6, after the SMBC Unit-Holders no longer hold any Partnership Interests), XIII (Registration Rights) and XV (Miscellaneous)shall survive any expiration or termination of this Agreement; provided, however, if Moelis Holdings terminates this agreement pursuant to Section11.2(b) due to a material breach by either SMBC or Nikko, or if this Agreement is terminated pursuant to Section 11.2(c) due to the bankruptcy,insolvency or making of the assignment for the benefit of creditors by either SMBC or Nikko, ARTICLE XII (Certain Transfer Rights ofSMBC/Nikko) and XIII (Registration Rights) shall not survive such termination; provided, further, that, if this Agreement is terminated prior to theClosing, XII (Certain Transfer Rights of SMB C/Nikko), XIII (Registration Rights) shall not survive such termination. 13ARTICLE XII. CERTAIN RIGHTS OF SMBC/NIKKO. 12.1 Advisory Board. During the term of the Strategic Alliance, SMBC/Nikko shall have the right to appoint one person to serve as amember of the Advisory Board of Moelis Holdings. 12.2 Right of First Refusal.  (a) Prior to the IPO and during the term of the Strategic Alliance, SMBC shall have the right of first refusal to purchase all (but notless than all) Additional Units that Moelis Holdings proposes to issue to an SMBC Competitor, including (x) in a proposed issuance that isexcepted from Section 3.4.2 of the Moelis Holdings Agreement as an issuance to a Strategic Investor, and (y) in a proposed issuance that is subjectto Section 3.4.2 of the Moelis Holdings Agreement, to the extent that the Partners do not exercise in full their right of first refusal thereunder. Theabove rights are in addition to the pro rata right of first refusal granted to all Partners with respect to issuances of Additional Units in Section 3.4.2of the Moelis Holdings Agreement. (b) In the event Moelis Holdings proposes to undertake an issuance of Additional Units to which clause (x) of Section 12.2(a)applies, it shall give SMBC written notice of its intention describing the price and terms upon which Moelis Holdings proposes to issue the same.SMBC shall have ten (10) days from the date of delivery of any such notice to agree to purchase all, but not less than all, of such Additional Units,for the price and upon the terms specified in the notice, by delivering written notice to Moelis Holdings. Following the expiration of such 10-dayperiod, Moelis Holdings shall have one hundred and eighty- (180-) days to sell or enter into an agreement to sell the Additional Units with respectto which SMBC’s right of first refusal was not exercised, at a price and upon terms no more favorable to the purchasers of such securities thanspecified in Moelis Holdings’ notice. In the event Moelis Holdings has not sold the Additional Units or entered into an agreement to sell theAdditional Units within such one hundred and eighty- (180-) day period, Moelis Holdings shall not thereafter issue or sell any Additional Unitswithout first complying again with this Section 12.2. (c) In the event Moelis Holdings proposes to undertake any issuance of Additional Units to which clause (y) of Section 12.2(a)applies, SMBC shall specify in its notice delivered to Moelis Holdings pursuant to Section 3.4.2(b) of the Moelis Holdings Agreement, in additionto whether or not it elects to purchase its pro rata portion of such Additional Units, whether or not it shall exercise its right of first refusal topurchase all (but not less than all) of the Additional Units that other Partners do not purchase pursuant to their right of first refusal under Section3.4.2 of the Moelis Holdings Agreement. (d) The right of first refusal granted hereunder may not be assigned or transferred, except that such right is assignable by SMBCto any of its respective Wholly-Owned Subsidiaries. 1412.3 Moelis General Partner’s Consent to Certain Transfers.  (a) Prior to the IPO and during the term of the Strategic Alliance, Moelis General Partner shall not consent to a sale or transfer by aPartner of its Partnership Interests to an SMBC Competitor unless the Moelis General Partner caused the Partner proposing to sell or transfer itsPartnership Interests to provide SMBC with a right to purchase, on the same terms and conditions, including price, all (but not less than all) of thePartnership Interests that such Partner proposes to sell or transfer to an SMBC Competitor. (b) In the event a Partner proposes to undertake a sale or transfer of Partnership Interests to which the foregoing right applies,and Moelis General Partner must consent to the sale or transfer, Moelis General Partner shall require that Partner to give SMBC written notice of itsintention to sell or transfer Partnership Interests to an SMBC Competitor describing the price and terms upon which such Partner proposes to sellor transfer its Partnership Interests. SMBC shall have ten (10) days from the date of delivery of any such notice to agree to purchase all, but notless than all, of such Partnership Interests, for the price and upon the terms specified in the notice, by delivering written notice to such Partner andMoelis Holdings. (c) Following the expiration of such 10-day period, the Partner proposing to sell or transfer Partnership Interests shall have onehundred and eighty- (180-) days to sell or transfer, or enter into an agreement to sell or transfer the Partnership Interests with respect to whichSMBC ‘s right under Section 12.3(a) was not exercised, at a price and upon terms no more favorable to the purchasers of such securities thanspecified in the Partner’s notice. In the event the Partner has not sold or transferred the Partnership Interests, or entered into an agreement to sell ortransfer the Partnership Interests, within such one hundred and eighty- (180-) day period, Moelis General Partner shall not consent to the Partner’sselling or transferring its Partnership Interests to an SMBC Competitor thereafter without first requiring the Partner to comply again with thisSection 12.3.  (d) The rights granted under this Section 12.3 may not be assigned or transferred, except that such right is assignable by SMBCto any of its respective Wholly-Owned Subsidiaries. (e) Nothing in this Section 12.3 shall affect the power of Moelis General Partner to withhold consent to any transfer of PartnershipInterests in its sole discretion to the extent authorized under Section 8.1 of the Moelis Holdings Agreement. 12.4 Certain Transfer Matters.  (a) During the term of the Strategic Alliance, if KM sells all or a portion of KM’s Partnership Interests, the SMBC Unit-Holdersmay sell a pro rata portion of the SMBC Units without regard to any timing or transfer restrictions imposed by this Agreement or the MoelisHoldings Agreement, except that such sale or transfer may not be to a Moelis Competitor. In the event KM proposes to undertake a sale or 15transfer of KM’s Partnership Interests to which the foregoing right applies, KM shall give written notice to SMBC and Moelis General Partner atleast ten (10) days in advance of such sale or transfer, describing the percent of KM’s Partnership Interest being sold or transferred. KM shall givewritten notice to SMBC and Moelis General Partner within five (5) days of any cancellation or postponement of such sale. When an SMBC Unit-Holder elects to sell or transfer the SMBC Units pursuant to its rights granted under this Section 12.4(a), the SMBC Unit-Holder shall provideMoelis General Partner with a notice stating its intent to sell or transfer the SMBC Units pursuant to this Section 12.4(a). Within ten (10) days ofreceiving such notice from an SMBC Unit-Holder, Moelis General Partner shall deliver to such SMBC Unit-Holder its consent for the proposed saleor transfer, unless the proposed sale or transfer is to a Moelis Competitor. For the avoidance of doubt, if the transaction is subject to (i) a Drag-Along Right or a Tag-Along Right, and such right was exercised, the SMBC Unit-Holders shall be deemed to have sold its pro rata portion of itsPartnership Interests with respect to such transaction and shall not have any additional rights under this Section 12.4(a) or (ii) Section 13.2 of thisAgreement, and an SMBC Unit-Holder exercised its right thereunder, such SMBC Unit-Holder shall be deemed to have sold its pro rata portion ofits Partnership Interests with respect to such transaction and shall not have any additional rights under this Section 12.4(a). The above right shallbe in addition to the Drag-Along Right and the Tag-Along Right with respect to transfers by Moelis General Partner set forth in Sections 8.4.1 and8.4.2, respectively, of the Moelis Holdings Agreement.  (b) During the term of the Strategic Alliance, and after the first anniversary of Moelis Holdings’ commencing a public registeredshare sale program for managing directors and other employees of Moelis Holdings or its affiliates, the SMBC Unit-Holders may sell or transferPartnership Interests pursuant to such public registered share sale program for any given period in an amount equal to (i) the number of PartnershipInterests that can be sold pursuant to the program in such period multiplied by (ii) a fraction whose numerator is the number of PartnershipInterests the SMBC Unit-Holders have elected to sell in such program during such period and whose denominator is the total number ofPartnership Interests the SMBC Unit-Holders have elected to sell plus the number of Partnership Interests all other persons have elected to sell insuch program during such period (whether such Partnership Interests are held as outstanding common stock of a successor or parent company ofMoelis Holdings or as interests in an affiliate of such public company) (for example, if 50 Partnership Interests can be sold during the period, theSMBC Unit-Holders has elected to sell 400 Partnership Interests and all persons other than the SMBC Unit-Holders have elected to sell 1,600Partnership Interests, then the SMBC Unit-Holders may sell 10 Partnership Interests and the other persons may sell 40 Partnership Interests);provided, that, (1) the SMBC Unit-Holders shall be subject to the same conditions and terms as the other participants in the program; (2) such rightunder this Section 12.4(b) shall not apply to sales Moelis Holdings may permit certain of its managing directors and other employees to make underRule 144 or otherwise; and (3) if both Section 12.4(a) and Section 12.4(b) apply to a sale or transfer of Partnership Interests, an SMBC Unit-Holdermay sell the higher of the amount under Section 12.4(a) or Section 12.4(b). If such public registered share sale program as set forth in this Section12.4(b) is established, Moelis Holding will provide the SMBC Unit-Holders with a monthly report which provides the number of PartnershipInterests being  16
 sold in such share sale program during the relevant month and the outstanding number of Partnership Interests that are left in the public saleregistered sale program as of the end of the relevant month. (c) After the termination of the Strategic Alliance: (i) prior to the IPO, Moelis General Partner shall not unreasonably withhold its consent to an SMBC Unit-Holder’stransferring all or a portion of the SMBC Units to any other person who is not a Moelis Competitor; and (ii) following the IPO, the SMBC Unit-Holders may freely transfer the SMBC Units, subject to applicable securitieslaws.  (d) Following the third anniversary of the Closing, whether or not during the term of the Strategic Alliance, the SMBC Unit-Holders may sell up to 9,231 SMBC Units (i) prior to the IPO, with the consent of Moelis General Partner (which consent may not be unreasonablywithheld), provided such sale is not to a Moelis Competitor, or (ii) following the IPO, without restriction, subject only to applicable securities laws. (e) During the term of the Strategic Alliance and prior to the IPO, Moelis Holdings shall notify SMBC in advance of publiclyannouncing the sale or issuance of any interests in Moelis Holdings (other than Management Units) to a Strategic Investor, provided, that MoelisHoldings shall notify SMBC in advance only to the extent and in such manner as it is permissible under any confidentiality agreement entered intoin connection with such sale or issuance.  12.5 Amendments to the Moelis Holdings Agreement. Without the prior written consent of SMBC (which consent shall not beunreasonably withheld, delayed or conditioned), Moelis General Partner shall not enter into any side letter or agreement (other than the VestingAgreement of any Management Partner) with any Limited Partner in respect of the issuance or holding of any class or type of interests in thePartnership that (i) modifies the limited liability of the SMBC Unit-Holders, (ii) materially and adversely affects in a disproportionate manner theinterest of the SMBC Unit-Holders in Net Income, Net Loss or Available Assets, (iii) increases the Capital Contributions required to be made by theSMBC Unit-Holders, (iv) modifies the SMBC Unit-Holders’ Drag-Along Rights or Tag-Along Rights under the Moelis Holdings Agreement, or (v)materially and adversely affects in a disproportionate manner the interest of the SMBC Unit-Holders in the distributions, regardless of whethersuch side letter or agreement is entered into by such Limited Partner in its capacity as such, and regardless of whether SMBC is entitled toparticipate or does participate in such issuance of or otherwise holds any such interests; provided, however, the foregoing consent of SMBC shallnot be required if the side letter or agreement affects Management Units in a substantially similar manner. 1712.6 Percentage Interest Limit. Notwithstanding anything to the contrary in this Agreement or the Moelis Holdings Agreement, none ofSMBC, Moelis Holdings or any of their controlled affiliates shall take any action, including with respect to the acquisition of any PartnershipInterests pursuant to the exercise of any right under this Agreement or the Moelis Holdings Agreement, that would reasonably be expected to (i)cause SMBC, or any of its affiliates, to require approval of the Board of Governors of the Federal Reserve System under Section 4 of the U.S. BankHolding Company Act of 1956, as amended (including Regulation Y promulgated thereunder), or otherwise, to acquire or retain any interest inMoelis Holdings or (ii) cause Moelis Holdings to be deemed to be or presumed to be “controlled” by SMBC, or any of its affiliates, for purposes ofthe U.S. Bank Holding Company Act of 1956, as amended (including Regulation Y promulgated thereunder). SMBC and Moelis Holdings shallcooperate with each other and use their reasonable best efforts to avoid any of the events in the preceding sentence by taking any and all actionsnecessary, including, without limitation, in connection with any restructuring to facilitate the IPO, which shall include, among other things, issuinga new class or series of Partnership Interests or alternative economic interests to SMBC, or its affiliates, as applicable. Notwithstanding anything tothe contrary in this Section 12.6, nothing shall prevent SMBC, or its affiliates, from seeking a noncontrol determination from the staff of the Boardof Governors of the Federal Reserve System with respect to any action that would otherwise be prohibited by this Section 12.6, and, after receivinga noncontrol determination, taking such action, including acquiring additional Partnership Interests. ARTICLE XIII. REGISTRATION RIGHTS.  13.1 Registration.  (a)  (i) Following the IPO and the termination of the Strategic Alliance, SMBC shall have the right to demand that MoelisHoldings register the sale of all, but not less than all, of the Registrable Securities held by SMBC and its affiliates (together the“SMBC Unit-Holders”) under the Securities Act (the “Demand Notice”), provided, however, SMBC shall not be permitted todeliver the Demand Notice within (i) 180 days of the IPO or (ii) 60 days of any public offering and sale of Partnership Interests(and/or any securities of Moelis Holdings or any successor entity into which Partnership Interests are converted, exchanged orredesignated) for cash pursuant to an effective registration statement (other than on Form S-4 or S-8 or a comparable form), andsubject to the terms of any agreement entered into by Moelis Holdings, SMBC or Nikko pursuant to Section 13.7. Within 60 daysafter Moelis Holdings receives a written notice to register the Registrable Securities, Moelis Holdings will 18file a Registration Statement, on an appropriate form, to register the sale of the Registrable Securities, which RegistrationStatement will (if specified in the SMBC Unit-Holders’ notice) contemplate the ability of the SMBC Unit-Holders to effect anUnderwritten Offering (the “Demand Registration”). The Demand Notice shall specify the intended method of distribution of theRegistrable Securities. Subject to Section 13.2, Moelis Holdings may include in any registration effected pursuant to this Section13.1 any securities for its own account or for the account of holders (other than the SMBC Unit-Holders) of Partnership Interests;provided, that, Moelis Holdings shall pay a portion of all expenses of Moelis Holdings (including those set forth in Section 13.8)in connection with any such registration, in proportion to the aggregate selling price of all securities so included in any suchregistration.  (ii) Moelis Holdings will use its commercially reasonable efforts (i) to cause any Registration Statement to be declaredeffective (unless it becomes effective automatically upon filing) as promptly as practicable after the filing thereof with the SECand (ii) to keep such Registration Statement current and effective for a period of 90 days, or such shorter time necessary for thecompletion of the sale of Registrable Securities registered thereon. Moelis Holdings further agrees to use its commerciallyreasonable efforts to supplement or make amendments to such Registration Statement as may be necessary to keep suchRegistration Statement effective for the period referred to in clause (ii) above, including (A) to respond to the comments of theSEC, if any, (B) as may be required by the registration form utilized by Moelis Holdings for such Registration Statement or by theinstructions to such registration form, (C) as may be required by the Securities Act, or (D) as may reasonably be requested inwriting by the SMBC Unit-Holders or any underwriter and acceptable to Moelis Holdings. Moelis Holdings agrees to furnish tothe SMBC Unit-Holders copies of any such supplement or amendment no later than the time it is first used or filed with the SEC. (b) If the Demand Notice specifies that the Registrable Securities will be sold in an Underwritten Offering, the parties shallmutually agree on the lead underwriter and any additional underwriters. (c) Any registration initiated pursuant to Section 13.1(a) shall not count as a Demand Registration (i) unless and until theRegistration Statement with respect to the Registrable Securities has become effective and remained effective for a period of 90 days or, if a shortertime, until all of the Registrable Securities have been sold, or (ii) if the conditions to closing specified in the underwriting agreement, if any, enteredinto in connection with such registration are not satisfied or waived, other than by reason of a failure on the part of the SMBC Unit-Holders. 13.2 Piggyback Registration. If Moelis Holdings proposes to file a registration statement under the Securities Act (other than non-participating, non-convertible debt or  19equity securities or securities to be issued pursuant to a registration statement on Form S-4 or S-8 or any comparable form) for its own account orfor the account of a holder (other than the SMBC Unit-Holders) of Partnership Interests, including in connection with the IPO and where SMBC/Nikko (including an SMBC Unit-Holder) has the right to sell any or all SMBC Units under this Agreement, then Moelis Holdings shall givewritten notice of such proposed filing to the SMBC Unit-Holders as soon as commercially practicable but in no event less than (i) 20 days beforethe anticipated filing date or (ii) if Moelis Holdings determines to conduct a registration less than 20 days before the anticipated filing date, then onthe date Moelis Holdings determines to proceed with such registration (a “Piggyback Registration”). If Moelis Holdings proposes to file theregistration statement before the termination of the Strategic Alliance, the written notice to the SMBC Unit-Holders shall include the number ofPartnership Interests to be sold by KM and the percentage of the total Partnership Interests held by KM represented by that number. Within 10days after delivery of any such notice by Moelis Holdings, or such shorter period as Moelis Holdings specifies in such notice if Moelis Holdingsdetermines to conduct a registration less than 10 days before the anticipated filing date, the SMBC Unit-Holders may request in writing that MoelisHoldings include any Registrable Securities held by the SMBC Unit-Holders in the proposed registration. The request by the SMBC Unit-Holdersshall specify the number of Registrable Securities proposed to be included in the registration. Moelis Holdings will then, subject to Section 13.3,include such requested Registrable Securities in the proposed registration; provided, however, that if Moelis Holdings proposes to file theregistration statement before the termination of the Strategic Alliance, the percentage of all Registrable Securities that may be included in theproposed registration may not exceed the percentage of KM’s total Partnership Interests to be sold in the proposed registration, as stated in thenotice by Moelis Holdings. The SMBC Unit-Holders may not withdraw any request for a Piggyback Registration involving an UnderwrittenOffering after the preliminary prospectuses for the proposed offering have been printed, or any “road show” has begun, or Moelis Holdings hasmade any public announcement with the consent of the SMBC Unit-Holders that assumes the participation of the SMBC Unit-Holders in theproposed offering, or in any event less than 24 hours before the pricing of such offering. The SMBC Unit-Holders shall have no right to select theunderwriters in an Underwritten Offering in connection with a Piggyback Registration. Notwithstanding anything to the contrary in this Section13.2, Moelis Holdings may, at any time at its sole option, choose not to proceed with the proposed registration that gives rise to the PiggybackRegistration.  13.3 Reduction of Size of Underwritten Offering. Notwithstanding anything to the contrary contained herein, if the lead underwriter orunderwriters in an Underwritten Offering pursuant to Section 13.1 or Section 13.2 advise Moelis Holdings that, in their good faith judgment, thenumber of Partnership Interests (including any Registrable Securities) that Moelis Holdings, the SMBC Unit-Holders and any other persons intendto include in any Registration Statement exceeds the number that can be sold in the offering in light of marketing factors or because the sale of agreater number would adversely affect the price of the Partnership Interests to be sold, then the number of Partnership Interests to be included inthe Registration Statement for the account of Moelis Holdings, the SMBC Unit-Holders and any other persons will be reduced to the 20extent necessary to reduce the total number of securities to be included in any such Registration Statement to the number recommended by the leadunderwriter or underwriters, in accordance with the following priorities: (a) in the case of a Demand Registration pursuant to Section 13.1, priority will be (i) first, all Registrable Securities included in theRegistration Statement, (ii) second, any Partnership Interests proposed to be offered by Moelis Holdings for its own account (iii) third, pro rataamong any other holders of Partnership Interests requested to be registered pursuant to a contractual right, and (iv) fourth, pro rata among anyother holders of Partnership Interests requested to be registered; (b) in the case of a registration statement initiated by Moelis Holdings for its own account that gives rise to a PiggybackRegistration pursuant to Section 13.2, priority will be (i) first, Partnership Interests proposed to be offered by Moelis Holdings for its own account,(ii) second, pro rata among all holders of Partnership Interests requested to be registered pursuant to a contractual right and (iii) third, pro rataamong any other holders of Partnership Interests requested to be registered; and (c) in the case of a registration statement initiated by Moelis Holdings for the account of holders (other than the SMBC Unit-Holders) of Partnership Interests, pursuant to registration rights afforded to such holders by contract, that gives rise to a Piggyback Registrationpursuant to Section 13.2, priority will be (i) first, pro rata among the holders of Partnership Interests for whose account the registration statementwas initiated, (ii) second, Partnership Interests offered by Moelis Holdings for its own account, (iii) third, pro rata among any other holders ofPartnership Interests requested to be registered pursuant to a contractual right and (iv) fourth, pro rata among any other holders of PartnershipInterests requested to be registered.  13.4 Registration Procedures. Subject to the provisions of Section 13.1 or Section 13.2, in connection with the registration of the sale ofRegistrable Securities pursuant to the Demand Registration or a Piggyback Registration hereunder, Moelis Holdings will: (a) furnish to the SMBC Unit-Holders without charge, no later than the time of filing of a Registration Statement, copies of suchRegistration Statement, and thereafter such number of copies of such Registration Statement, each amendment and supplement thereto (in eachcase including all exhibits thereto, including each preliminary prospectus), copies of any and all transmittal letters or other correspondence with theSEC relating to such Registration Statement and such other documents in such quantities as the SMBC Unit-Holders may reasonably request fromtime to time, for as long as Moelis Holdings is required to cause the Registration Statement to remain current, in order to facilitate the disposition ofthe Registrable Securities;  (b) provide the SMBC Unit-Holders and their Representatives with the opportunity to participate in the preparation of theRegistration Statement and the related Prospectus; 21(c) use its commercially reasonable efforts to register or qualify the Partnership Interests being sold under such other securities or“blue sky” laws of such jurisdictions as the SMBC Unit-Holders reasonably request and do any and all other acts and things as may be reasonablynecessary or advisable to enable the SMBC Unit-Holders to consummate the disposition of the Registrable Securities in such jurisdictions;provided, however, that Moelis Holdings shall in no event be required to (w) qualify generally to do business in any jurisdiction where it is notthen so qualified, (x) subject itself to taxation in any jurisdiction where it is not otherwise then so subject, (y) take any action that would subject itto service of process in suits other than those arising out of the offer and sale of the securities covered by the Registration Statement or (z) consentto general service of process in any jurisdiction where it is not then so subject; (d) notify the SMBC Unit-Holders and the lead underwriter or underwriters, if any, at any time when a Prospectus relating toRegistrable Securities is required to be delivered under the Securities Act, of the occurrence of any event as a result of which the RegistrationStatement, the Prospectus included in a Registration Statement or any amendment or supplement thereto relating to Registrable Securities containsan untrue statement of a material fact or omits to state any material fact required to be stated therein or necessary to make the statements therein, inthe light of the circumstances under which they were made, not misleading, and Moelis Holdings will use its commercially reasonable efforts toprepare and file with the SEC a supplement or amendment to such Prospectus and Registration Statement (and comply fully with the applicableprovisions of Rules 424, 430A and 430B under the Securities Act in a timely manner) so that, as thereafter delivered to the purchasers of theRegistrable Securities, such Prospectus and Registration Statement will not contain an untrue statement of a material fact or omit to state anymaterial fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they weremade, not misleading;  (e) advise the lead underwriter or underwriters, if any, and the SMBC Unit-Holders promptly and, if requested by such persons,confirm such advice in writing, of the issuance by the SEC of any stop order suspending the effectiveness of the Registration Statement under theSecurities Act or of the suspension by any state securities commission of the qualification of the Registrable Securities for offering or sale in anyjurisdiction, or the initiation of any proceeding for any of the preceding purposes. If at any time the SEC issues any stop order suspending theeffectiveness of the Registration Statement, or any state securities commission or other regulatory authority issues an order suspending thequalification or exemption from qualification of the Registrable Securities under state securities or “blue sky” laws, Moelis Holdings shall use itscommercially reasonable efforts to obtain the withdrawal or lifting of such order as promptly as practicable; (f) use its commercially reasonable efforts to cause the Registrable Securities to be registered with or approved by such othergovernmental authorities as may be necessary by virtue of the business and operations of Moelis Holdings to enable the SMBC Unit-Holders toconsummate the disposition of the Registrable Securities; provided, however, that Moelis Holdings shall in no event be required to (w) qualify 22generally to do business in any jurisdiction where it is not then so qualified, (x) subject itself to taxation in any jurisdiction where it is not otherwisethen so subject, (y) take any action that would subject it to service of process in suits other than those arising out of the offer and sale of thesecurities covered by the Registration Statement or (z) consent to general service of process in any jurisdiction where it is not then so subject; (g) if requested by the SMBC Unit-Holders or the underwriter or underwriters, if any, promptly include in any RegistrationStatement or Prospectus, pursuant to a supplement or post-effective amendment if necessary, such information as the SMBC Unit-Holders and theunderwriter or underwriters, if any, may reasonably request to have included therein, including information relating to the “Plan of Distribution” ofthe Registrable Securities, information about the number of Registrable Securities being sold to the underwriter or underwriters, the purchase pricebeing paid therefor and any other terms of the offering of the Registrable Securities to be sold in such offering, and make all required filings of suchProspectus supplement or post-effective amendment as soon as practicable after Moelis Holdings is notified of the matters to be included in suchProspectus supplement or post-effective amendment; (h) for the period beginning a reasonable time before the filing of the Registration Statement and for as long as Moelis Holdings isrequired to cause the Registration Statement to remain current under Section 13.1(a)(ii), and except to the extent prohibited by applicable law andsubject to entering into customary confidentiality agreements, after reasonable advance notice, make available for inspection by the SMBC Unit-Holders, any underwriter participating in any disposition of the Registrable Securities, and any Representative for the SMBC Unit-Holders or suchunderwriter, during business hours and at the location designated by Moelis Holdings, any financial and other records and corporate documents ofMoelis Holdings as will be reasonably necessary to enable them to conduct reasonable and customary due diligence with respect to MoelisHoldings and the related Registration Statement and Prospectus, provided, however, that records, documents and information obtained hereunderwill be used by such inspecting person only to conduct such due diligence; and (i) together with any other holder of Partnership Interests proposing to include securities in any Underwritten Offering, enter intoa reasonable and customary written agreement with the underwriter or underwriters, if any, in such form and containing such provisions as arereasonable and customary in the securities business for such an arrangement between underwriters and companies of Moelis Holding’s size andinvestment stature.  13.5 Conditions to Offerings. The obligations of Moelis Holdings to take the actions contemplated by Sections 13.1, 13.2 and 13.4 withrespect to an offering of Registrable Securities will be subject to the following conditions: (a) Moelis Holdings may require each SMBC Unit-Holder to furnish to Moelis Holdings such information regarding such SMBCUnit-Holder, the Registrable Securities or the distribution of such Registrable Securities as Moelis Holdings may from time to time request, in eachcase to the extent reasonably required by the Securities Act 23and the rules and regulations promulgated thereunder, or under state securities or “blue sky” laws; and (b) If an offering of Registrable Securities is an Underwritten Offering, each SMBC Unit-Holder must: (A) agree to sell itsRegistrable Securities on the basis provided in any underwriting agreement approved by Moelis Holdings in accordance with Section 13.4(i), (B)complete and execute, as applicable, all customary questionnaires, powers of attorney, underwriting agreements, lock-up agreements consistentwith Section 13.7 and other documents customarily required under the terms of such underwriting agreement and (iii) agree to make customaryrepresentations and warranties (including as to due organization and good standing, corporate power and authority, due approval, no conflicts andownership and transfer of Registrable Securities, and as to accuracy and completeness of those statements made in the applicable RegistrationStatement, Prospectus or other document in reliance upon and in conformity with written information furnished to Moelis Holdings or theunderwriter or underwriters by such SMBC Unit-Holder) and covenants in such underwriting agreement. 13.6 Suspension Period.  (a) Notwithstanding anything to the contrary contained in this Agreement, Moelis Holdings shall be entitled, by providing priorwritten notice to the SMBC Unit-Holders, to postpone the filing or effectiveness or suspend the use of any Registration Statement pursuant toSection 13.1 for a reasonable period of time not to exceed 60 days in succession or 120 days in any 365-day period (or a longer period of time withthe prior written consent of SMBC, which consent shall not be unreasonably withheld) (a “Suspension Period”) if (A) Moelis Holdings determinesin good faith that effecting the registration (or permitting sales under an effective registration) would reasonably be expected to adversely affect anoffering of securities of Moelis Holdings, (B) Moelis Holdings is in possession of material non-public information and deems it advisable not todisclose such information in a Registration Statement, or (C) due to a pending or contemplated financing, acquisition, disposition, corporatereorganization, merger, public offering of securities or other similar transaction or other material event or circumstance involving Moelis Holdings orits securities. Moelis Holdings will notify the SMBC Unit-Holders promptly upon the termination of the Suspension Period. Upon notice by MoelisHoldings to the SMBC Unit-Holders of any determination to commence a Suspension Period, the SMBC Unit-Holders shall, except as required byapplicable law, including any disclosure obligations under Section 13 of the Exchange Act, keep the fact of any such Suspension Period strictlyconfidential, and during any Suspension Period, promptly halt any offer, sale (including sales pursuant to Rule 144), trading or transfer of anyPartnership Interests for the duration of the Suspension Period until Moelis Holdings has provided notice that the Suspension Period has beenterminated.  (b) If Moelis Holdings suspends the use of a Registration Statement pursuant to Section 13.6(a), the holders of RegistrableSecurities shall receive an extension of the registration period under Section 13.1(a)(ii) and 13.1(c) equal to the number of days of the suspension. 24(c) The SMBC Unit-Holders agrees that, upon receipt of any notice from Moelis Holdings of the occurrence of any event of thekind described in Section 13.4(d) or Section 13.4(e) or a condition described in Section 13.6(a), each SMBC Unit-Holder will forthwith discontinuedisposition of Registrable Securities pursuant to the Registration Statement covering the sale of Registrable Securities until the SMBC Unit-Holdersreceive copies of the supplemented or amended Prospectus contemplated by Section 13.4(d) or Section 13.6(d) or notice from Moelis Holdings ofthe termination of the stop order or Suspension Period. (d) After the expiration of any Suspension Period and without any further request from a holder of Partnership Interests, MoelisHoldings shall use its commercially reasonably efforts to prepare a Registration Statement, or post-effective amendment or supplement to theRegistration Statement or Prospectus or any document incorporated therein by reference, or file any other required document so that, as thereafterdelivered to purchasers of the Registrable Securities included therein, the Prospectus will not include a material misstatement or omission or be noteffective and useable for the sale of Registrable Securities. 13.7 Market Stand-Off Agreement.  (a) In connection with any Underwritten Offering that is the IPO, or any Underwritten Offering in which the SMBC Unit-Holdersare selling Registrable Securities pursuant to Sections 13.1 or 13.2, each SMBC Unit-Holder agrees that, during the period of duration (up to 180days, subject to customary extensions as may be required by the underwriter or underwriters up to a maximum of 214 days) specified by MoelisHoldings and the underwriter or underwriters of Registrable Securities, following the date of the final prospectus or other offering documentdistributed in connection with the Underwritten Offering, it shall not, to the extent requested by Moelis Holdings and such underwriter orunderwriters, directly or indirectly, sell, offer to sell, contract to sell (including any short sale or other hedging transaction), grant any option topurchase or otherwise transfer any Registrable Securities held by it at any time during such period except for such Registrable Securities as shall beincluded in such registration. Notwithstanding the foregoing, the obligations described in this Section 13.7(a) shall not apply (i) to a registrationrelating solely to employee benefit plans on Form S-1 or Form S-8, (ii) to a registration relating solely to an acquisition or similar transaction on FormS-4 or (iii) unless all holders then holding more than 3% of the issued and outstanding Partnership Interests (and/or any securities of MoelisHoldings or any successor entity into which the Partnership Interests are converted, exchanged or redesignated) with a contractual obligationenforceable by Moelis Holdings or its affiliates to do so and all of the then-current executive officers and directors (if applicable) of MoelisHoldings enter into similar agreements.  (b) In order to enforce the foregoing covenant, Moelis Holdings may impose stop-transfer instructions with respect to theRegistrable Securities of each SMBC Unit-Holder until the end of such period. 2513.8 Registration Expenses. All fees and expenses incident to Moelis Holding’s performance of or compliance with the obligations of thisARTICLE XIII, including all fees and expenses incurred in complying with securities or “blue sky” laws, printing expenses, messenger and deliveryexpenses of Moelis Holdings, any registration or filing fees payable under any federal or state securities or “blue sky” laws, the fees and expensesincurred in connection with any listing or quoting of the securities to be registered on any national securities exchange or automated quotationsystem, fees of the Financial Industry Regulatory Authority, fees and disbursements of counsel for Moelis Holdings, its independent registeredcertified public accounting firm and any other public accountants who are required to deliver comfort letters (including the expenses required by orincident to such performance), fees of transfer agents and registrars, costs of insurance, and the fees and expenses of other persons retained byMoelis Holdings, will be borne by Moelis Holdings; provided, however; that the SMBC Unit-Holders shall pay all reasonable out-of-pocketexpenses of Moelis Holdings (including, for the avoidance of doubt, all the fees set forth above in this section) in connection with the DemandRegistration subject to Moelis Holdings’ obligations set forth in Section 13.1(a)(i). The SMBC Unit-Holders will bear and pay any fees andexpenses of SMBC or its affiliates or their Representatives, including their counsel, and any underwriting discounts, fees and commissions and anytransfer taxes applicable to Registrable Securities offered for its account pursuant to any Registration Statement. 13.9 Indemnification; Contribution.  (a) In connection with any registration of Registrable Securities, Moelis Holdings will indemnify, defend and hold harmless eachSMBC Unit-Holder, its affiliates, directors, officers and SMBC Unit-Holders and each person who controls SMBC Unit-Holder within the meaningof either Section 15 of the Securities Act or Section 20 of the Exchange Act (collectively, the “Indemnified Persons”) from and against any and alldirect losses, claims, damages, liabilities, obligations, costs and expenses (including, without limitation, as a result of any notices, actions, suits,proceedings, claims, demands, assessments, judgments, awards, costs, penalties, taxes and reasonable expenses, including reasonable attorneys’and other professionals’ fees and disbursements, but excluding any consequential damages) (collectively “Losses”) caused by (i) any untrue oralleged untrue statement of material fact contained in any part of any Registration Statement or any Prospectus, including any amendment orsupplement thereto, used in connection with the Registrable Securities or any Issuer FWP or (ii) any omission or alleged omission to state therein amaterial fact required to be stated therein or necessary to make the statements therein (in the case of a Prospectus, in the light of the circumstancesunder which they were made) not misleading; provided, however, that Moelis Holdings will not be required to indemnify any Indemnified Personfor any Losses resulting from any such untrue statement or omission if such untrue statement or omission was made in reliance on and inconformity with information with respect to any Indemnified Person furnished to Moelis Holdings in writing by, or on behalf of, any of the SMBCUnit-Holders expressly for use therein.  (b) In connection with any Registration Statement, Prospectus or Issuer FWP, each SMBC Unit-Holder, jointly and severally, willindemnify, defend and  26
 hold harmless Moelis Holdings, its directors, its officers and each person, if any, who controls Moelis Holdings (within the meaning of eitherSection 15 of the Securities Act or Section 20 of the Exchange Act) to the same extent as the foregoing indemnity from Moelis Holdings to eachSMBC Unit-Holder, but only with respect to information furnished to Moelis Holdings in writing by, or on behalf of, any SMBC Unit-Holder or anyIndemnified Persons expressly for use in such Registration Statement, Prospectus or Issuer FWP; and provided, further, however, that in no eventshall the liability for indemnity of any SMBC Unit-Holder under this Section 13.9(b) exceed the dollar amount of the proceeds (net of anyunderwriting discount or commission or other selling expenses) received by such SMBC Unit-Holder from the sale of the Registrable Securitiesgiving rise to such indemnification.  (c) In case any claim, action or proceeding (including any governmental investigation) is instituted involving any person inrespect of which indemnity may be sought pursuant to Section 13.9(a) or 13.9(b), such person (the “Indemnified Party”) will promptly, but in anyevent within 10 Business Days, notify the person against whom such indemnity may be sought (the “Indemnifying Party”) in writing, and theIndemnifying Party shall have the right to participate in, and to the extent the Indemnifying Party so desires, to assume the defense thereof withcounsel reasonably satisfactory to the Indemnified Party; provided, that the failure of any Indemnified Party to give notice within the time limitprovided herein shall not relieve the Indemnifying Party of its obligations under Section 13.9(a) or 13.9(b), except to the extent that the IndemnifyingParty is actually and materially prejudiced by such failure to give notice. In any such claim, action or proceeding where the Indemnifying Party hasassumed the defense thereof, the Indemnified Party shall have the right, but not the obligation, to participate in any such defense and to retain itsown counsel, but the fees and expenses of such counsel will be at the expense of such Indemnified Party unless the Indemnified Party and theIndemnified Party have been advised by counsel that representation of both parties by the same counsel would be inappropriate due to actual orpotential conflicting interests between them. It is understood that the Indemnifying Party will not, in connection with any claim, action orproceeding or related claims, actions or proceedings in the same jurisdiction, be liable for the reasonable fees and expenses of more than oneseparate firm of attorneys (in addition to any local counsel) at any time for all such Indemnified Parties and that all such reasonable fees andexpenses will be reimbursed as they are incurred. In the case of the retention of any such separate firm for the Indemnified Parties, such firm will bedesignated in writing by the Indemnified Parties. No Indemnified Party will, without the prior written consent of the Indemnifying Party, settle,compromise or offer to settle or compromise any pending or threatened proceeding in respect of which any Indemnified Party is seeking indemnityhereunder. The Indemnifying Party will not be liable for any settlement of any claim, action or proceeding effected without its written consent, but ifsuch claim, action or proceeding is settled with such consent or if there has been a final judgment for the plaintiff, the Indemnifying Party agrees toindemnify the Indemnified Party from and against any Loss by reason of such settlement or judgment. No Indemnifying Party will, without the priorwritten consent of the Indemnified Party, settle, compromise or offer to settle or compromise any pending or threatened proceeding in respect ofwhich any Indemnified Party is seeking indemnity hereunder, unless such settlement includes (i) an 27unconditional release of such Indemnified Party from all liability in connection with such proceeding, (ii) no finding or admission of any violation oflaw or any violation of the rights of any person by the Indemnified Party or any of its Affiliates can be made as the result of such action, and (iii)the sole relief (if any) provided is monetary damages that are reimbursed in full by the Indemnifying Party.  (d) If the indemnification provided for in this Section 13.9 from the Indemnifying Party is unavailable to an Indemnified Partyhereunder or is insufficient in respect of any Losses referred to in this Section 13.9, then the Indemnifying Party, in lieu of indemnifying suchIndemnified Party, will contribute to the amount paid or payable by such Indemnified Party as a result of such Losses (i) in such proportion as isappropriate to reflect the relative fault of the Indemnifying Party and Indemnified Party in connection with the actions that resulted in such Losses,as well as any other relevant equitable considerations, or (ii) if the allocation provided by clause (i) is not permitted by applicable law, in suchproportion as is appropriate to reflect not only the relative fault referred to in clause (i) but also the relative benefit of Moelis Holdings, on the onehand, and each SMBC Unit-Holder, on the other, in connection with the statements or omissions that resulted in such Losses, as well as any otherrelevant equitable considerations; provided, however, that in no event shall a SMBC Unit-Holder be required by this Section 13.9(d) to contributean aggregate amount in excess of the dollar amount of proceeds (net of underwriting discounts and commissions and other selling expenses)received by such SMBC Unit-Holder from the sale of Registrable Securities giving rise to such contribution. The relative fault of such IndemnifyingParty and Indemnified Party will be determined by reference to, among other things, whether any action in question, including any untrue or allegeduntrue statement of a material fact or omission or alleged omission to state a material fact, has been taken by, or relates to information supplied by,such Indemnifying Party or Indemnified Party, and the parties’ relative intent, knowledge, access to information and opportunity to correct orprevent such action. The amount paid or payable by a party as a result of the Losses referred to above will be deemed to include, subject to thelimitations set forth in Section 13.9(c), any reasonable out of pocket legal or other out of pocket fees or expenses reasonably incurred by such partyin connection with any investigation or proceeding. (e) The parties agree that it would not be just and equitable if contribution pursuant to Section 13.9(d) were determined by prorata allocation or by any other method of allocation that does not take into account the equitable considerations referred to in Section 13.9(d). Noperson guilty of “fraudulent misrepresentation” (within the meaning of Section 11(f) of the Securities Act) will be entitled to contribution from anyperson who was not guilty of such fraudulent misrepresentation. Notwithstanding the provisions of this Section 13.9(e), a SMBC Unit-Holder shallnot be required to contribute, in the aggregate, any amount in excess of the amount by which the net proceeds received by such SMBC Unit-Holderfrom the sale of the Registrable Securities exceeds the amount of any damages which such SMBC Unit-Holder has otherwise been required to payby reason of such untrue or alleged untrue statement or omission or alleged omission. 28(f) If indemnification is available under this Section 13.9, the Indemnifying Party will indemnify each Indemnified Party to thefullest extent permissible under applicable law provided in Sections 13.9(a) and 13.9(b) without regard to the relative fault of said Indemnifying Partyor Indemnified Party or any other equitable consideration provided for in Section 13.9(d) or 13.9(e). The obligations of Moelis Holdings under thisSection 13.9 shall be in addition to any liability that Moelis Holdings may otherwise have to any Indemnified Person. (g) Notwithstanding anything to the contrary in this Agreement, each of the Indemnified Parties has relied on this Section 13.9, isan express third party beneficiary of this Section 13.9 and is entitled to enforce the obligations of the applicable Indemnified Parties under thisSection 13.9 directly against such Indemnified Parties to the full extent thereof. 13.10 Rule 144. For so long as Moelis Holdings is subject to the requirements of Section 13, 14 or 15(d) of the Securities Act, MoelisHoldings agrees that it will use its reasonable best efforts to (i) make and keep public information available, as those terms are understood anddefined in Rule 144 and (ii) file the reports required to be filed by it under the Securities Act and the Exchange Act. 13.11 Transfer of Registration Rights. The rights to cause Moelis Holdings to register securities granted to the SMBC Unit-Holders underthis ARTICLE XIII may be assigned by the SMBC Unit-Holders with the consent of Moelis Holdings, except that the SMBC Unit-Holders mayassign such rights to their Wholly-Owned Subsidiaries without the consent of Moelis Holdings. 13.12 Termination of Registration Rights. The registration rights contained in Section 13.1 shall automatically terminate when the SMBCUnit-Holders collectively hold Registrable Securities in an amount less than (i) 1% of the issued and outstanding Partnership Interests (and/or anysecurities of Moelis Holdings or any successor entity into which the Partnership Interests are converted, exchanged or redesignated) and (ii) theaverage weekly reported volume of trading in Partnership Interests (and/or any securities of Moelis Holdings or any successor entity into whichthe SMBC Units are converted, exchanged or redesignated) on all national securities exchanges and/or reported through the automated quotationsystem of a registered securities association for the four calendar weeks preceding the date on which such determination is made.  ARTICLE XIV.
REPRESENTATIONS AND WARRANTIES; CONDUCT OF BUSINESS 14.1 Representations and Warranties of Moelis. Moelis Holdings and Moelis General Partner each represent and warrant to SMBC/Nikkothat:   (a) Organization. Moelis General Partner has been duly formed and is validly existing as a limited liability company under theDelaware Limited Liability  29Company Act. Moelis Holdings has been duly formed and is validly existing as a limited partnership under the Delaware Revised Uniform LimitedPartnership Act.  (b) Power, Authority, Etc. Each of Moelis Holdings and Moelis General Partner has all requisite power and authority to enter intothis Agreement and to consummate the transactions contemplated herein. The execution, delivery and performance of this Agreement do notrequire any further consent of any third party or governmental authority. This Agreement has been duly authorized, executed and delivered byMoelis Holdings and Moelis General Partner and, when duly executed and delivered by the other parties hereto, will be the valid and bindingobligation of Moelis Holdings and Moelis General Partner, enforceable in accordance with its terms, except (a) as may be limited by or subject toany bankruptcy, insolvency, reorganization, moratorium or other similar laws affecting creditors’ rights generally and (b) that the remedies ofspecific performance, injunction and other forms of equitable relief may not be available because they are subject to certain tests of equityjurisdiction, equitable defenses and the discretion of the court before which any proceeding therefor may be brought.  (c) Other. Each of the representations and warranties set out in Exhibit A of this Agreement are true and correct on the datehereof.  14.2 Representations and Warranties of SMBC/Nikko. SMBC and Nikko each represent and warrant to Moelis Holdings and MoelisGeneral Partner that:  (a) Organization. SMBC and Nikko have been duly formed and are validly existing as corporations under the laws of Japan. (b) Power, Authority, Etc. SMBC and Nikko have all requisite power and authority to enter into this Agreement and toconsummate the transactions contemplated herein. The execution, delivery and performance of this Agreement by SMBC and Nikko does notrequire any further consent of any third party or governmental authority. This Agreement has been duly authorized, executed and delivered byeach of SMBC and Nikko and, when duly executed and delivered by the other parties hereto, will be the valid and binding obligation of SMBC andNikko, enforceable in accordance with its terms, except (a) as may be limited by or subject to any bankruptcy, insolvency, reorganization,moratorium or other similar laws affecting creditors’ rights generally and (b) that the remedies of specific performance, injunction and other forms ofequitable relief may not be available because they are subject to certain tests of equity jurisdiction, equitable defenses and the discretion of thecourt before which any proceeding therefor may be brought.  14.3 Survival of Covenants, Representations and Warranties. Each of the covenants, representations and warranties of the parties in thisAgreement and the Subscription Agreement shall survive the Closing through and including the date thirty (30) days following the receipt bySMBC/Nikko of the audited financial statements of Moelis Holdings as of and for the year ended December 31, 2012. 30ARTICLE XV. MISCELLANEOUS 15.1 Expenses; No Partnership or Joint Venture. Each party will bear its own legal, marketing, travel and other expenses in connection withthe Strategic Alliance. No party is the partner, joint venture partner or agent of any other party with power to bind any other party contractually.This Agreement and the Strategic Alliance represent an agreement to cooperate and not a partnership or joint venture agreement. No party owesany other party a fiduciary duty by virtue of this Agreement or the operation of the Strategic Alliance. 15.2 Notice. Notice under this Agreement must be in writing and may be delivered by mail, overnight delivery service or email as follows:  If to SMBC: 2-3, Otemachi 1-chomeChiyoda-ku, Tokyo 100-0004Attention: Toshihiro Horiuchi, Senior Vice President, SecuritiesBusiness Planning Dept., Planning Dept., Investment Banking Unit.Email address: horiuchi_toshihiro@ck.smbc.co.jp If to Nikko: Shin-Marunouchi Building 18F,5-1, Marunouchi 1-chome,Chiyoda-ku, Tokyo 100-6518Attention: Masami Hagiwara, Head of Mergers & AcquisitionsAdministrationEmail address: hagiwara_masami@smbcnikko.co.jp If to Moelis Holdings: Moelis & Company Holdings LP399 Park Avenue, 5th FloorNew York, NY 10022Attention: Kate Pilcher Ciafone, Senior Vice PresidentEmail address: kate.ciafone@moelis.com, with a copy to:Attention: Osamu Watanabe, General CounselEmail address: osamu.watanabe@moelis.com 15.3 Entire Agreement; Amendment; Waivers; Counterparts. This Agreement and the Subscription Agreement (as modified by any letteragreement between the parties entered into on the date hereof), incorporates the entire understanding of the parties and supersedes all previousagreements with respect to the subject matter hereof. No 31amendment or modification of this Agreement shall be effective unless it is made in writing and signed by each of the parties. No waiver, expressedor implied, by any party of a breach by another party of this Agreement, or of any terms and provisions of this Agreement, shall constitute a waiverof any subsequent such breaches or of future enforcement of any such terms or provisions. This Agreement may be executed in three or morecounterparts, each of which shall be deemed an original, but all of which shall constitute one and the same agreement.  15.4 No Assignment. This Agreement may not be assigned by any party without the written consent of the other parties, except to asubsidiary or controlled affiliate of such party which succeeds such party’s conduct of Covered Businesses. 15.5 Obligation and Responsibilities of SMBC/Nikko. SMBC and Nikko shall be severally and not jointly responsible for any obligation orresponsibilities incurred or assumed by SMB C/Nikko hereunder. 15.6 Separability. In case one or more of the provisions contained in this Agreement are for any reason held to be invalid, illegal orunenforceable in any respect under any such law or regulation, the invalidity, illegality, or unenforceability will not affect any other provisions ofthis Agreement, which will be construed as if contained in this Agreement, and each illegal, invalid or unenforceable provision will be construed asbroadly as may be possible so that the original intent of the parties is given effect to the greatest extent possible. 15.7 Compliance with Laws. Each of the parties shall execute and perform this Agreement in compliance with all applicable laws orregulations. Notwithstanding the foregoing, a party shall not be obligated to take any action that violates, infringes or conflicts with or prohibitedfrom taking any action required to be in compliance with any applicable laws or regulations. 15.8 Governing Laws; Jurisdiction. This Agreement shall be governed by, and construed in accordance with, the laws of the State of NewYork without regard to principles of conflict of laws. The parties irrevocably and unconditionally submit to the exclusive jurisdiction of any state orFederal court sitting in Manhattan, New York over any suit, action or proceeding arising out of or relating to this Agreement. The parties herebyagree that service of any process, summons, notice or document by U.S. registered mail addressed to such party at the address above shall beeffective service of process for any action, suit or proceeding brought in any such court. The parties irrevocably and unconditionally waive anyobjection to the laying of venue of any such suit, action or proceeding brought in any such court and any claim that any such suit, action orproceeding brought in such a court has been brought in an inconvenient forum. Each party waives any right to trial by jury with respect to anyproceeding arising out of this Agreement. Notwithstanding the foregoing, any matter relating to the SMBC Unit-Holders’ rights or obligations asLimited Partners of Moelis Holdings shall be subject to Sections 10.4 and 10.10 of the Moelis Holdings Agreement and not to this Section 15.8. 3215.9 Effect on Prior Agreement. Commencing as of the Effective Date, the rights and obligations of the parties shall be determined pursuantto this Agreement and the Prior Agreement shall be of no further effect; provided, that, any fees and expenses due to a party outstandingthereunder shall be deemed to be outstanding under this Agreement. 15.10 Good Faith Discussion; Further Assurances. Should there be any dispute or disagreement with respect to any matters not set forth inthis Agreement, the parties will discuss in good faith to resolve such dispute or disagreement. Each party shall use its reasonable efforts tocooperate with the other party if necessary for compliance with laws and regulations applicable to such other party in relation to the SMBC Unit-Holders’ holding of SMBC Units or transactions or matters contemplated under the Subscription Agreement, the Side Letter, this Agreement andthe Moelis Holdings Agreement.  [signature page follows] 33
  IN WITNESS WHEREOF, the parties have caused this Agreement to be executed and delivered on the date first written above. SUMITOMO MITSUI BANKING CORPORATION 
     
 
 
 
 
 
 
 
 
By:
 
  
 
 
 
 
Name: Takeshi Kunibe
 
 
 
 
 
Title: President
 
 
 
 
 
  
  
SMBC NIKKO SECURITIES INC.
 
 
 
 
 
 
                       
 
 
 
 
 
 
 
 
By:
 
  
 
 
 
 
Name: Eiji Watanabe
 
 
 
 
 
Title: President & CEO
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MOELIS & COMPANY HOLDINGS LP
 
 
 
 
 
 
 
 
 
 
 
By: Moelis & Company Holdings GP LLC
 
 
 
 
 
Its: General PartnerBy:
 
  
 
 
 
 
Name: Kenneth D. Moelis
 
 
 
 
 
Title: Chief Executive Officer
 
 
 
 
 
 
 
 
 
 
 
MOELIS & COMPANY HOLDINGS GP LLC
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
By:
 
  
 
 
 
 
Name: Kenneth D. Moelis
 
 
 
 
 
Title: Chief Executive Officer
 
 
 
 
 
 [Signature Page to the Strategic Alliance Agreement] 
  Exhibit A Representations and Warranties of the Moelis Entities In addition to the representations and warranties set forth in the Subscription Agreement, and except as specifically set forth in the DisclosureSchedule delivered to SMBC/Nikko simultaneously with the execution hereof (the “Moelis Disclosure Schedule”), Moelis Holdings and MoelisGeneral Partner represent and warrant to SMBC/Nikko that:  (a) Organization and Authority. Each of the Moelis Entities has all requisite corporate or other entity power and authority to ownor lease all of its properties and assets and to carry on its business as it is now being conducted and is duly licensed or qualified to do business ineach jurisdiction in which the nature of the business conducted by it or the character or location of the properties and assets owned or leased by itmakes such licensing or qualification necessary, other than any failure to be so licensed or qualified that would not reasonably be expected to havea material adverse effect on the Moelis Entities and their controlled affiliates, taken as a whole. (b) Moelis Holdings Agreement. The Moelis Holdings Agreement has been duly authorized, executed and delivered by MoelisGeneral Partner and is a valid and legally binding agreement of Moelis General Partner, enforceable against it in accordance with its terms, except (i)as the enforceability thereof may be limited by bankruptcy, insolvency, reorganization or other similar applicable laws affecting the enforcement ofcreditors’ rights generally and (ii) that the remedies of specific performance, injunction and other forms of equitable relief may not be availablebecause they are subject to certain tests of equity jurisdiction, equitable defenses and the discretion of the court before which any proceedingtherefor may be brought. The Moelis Holdings Agreement attached as Tab 5 of the Subscription Agreement is a true, correct and complete copy ofthe Moelis Holdings Agreement as currently in effect. (c) Affiliates. Each controlled affiliate of Moelis Holdings is duly organized, validly existing and in good standing under the lawsof the jurisdiction of its incorporation or formation and has all requisite corporate or other entity power and authority to own or lease all of itsproperties and assets and to carry on its business as it is now being conducted and is duly licensed or qualified to do business in each jurisdictionin which the nature of the business conducted by it or the character or location of the properties and assets owned or leased by it makes suchlicensing or qualification necessary, other than any failure to be in good standing or to be so licensed or qualified that would not reasonably beexpected to have a material adverse effect on the Moelis Entities and their controlled affiliates, taken as a whole. All the issued and outstandingshares of capital stock or other partnership, equity or ownership interests of such controlled affiliates have been duly authorized and validlyissued, are fully paid and nonassessable with no personal liability attaching to the ownership thereof (except as provided for in the governingdocuments of such controlled affiliate), have been issued in compliance with all applicable securities laws, and were not issued in violation of anypreemptive rights or other right to subscribe for or purchase securities. Except as setforth in the Moelis Disclosure Schedule, Moelis Holdings owns, directly or indirectly, all of the issued and outstanding equity interests of each ofits controlled affiliates, free and clear of all liens or encumbrances.  (d) Capitalization. (1) The Moelis Disclosure Schedule sets forth a true and complete list of the number, class and series of eachissued and outstanding class and series of Partnership Interests as of the date of this Agreement. (2) All of the issued and outstanding PartnershipInterests have been duly authorized and validly issued and are fully paid and nonassessable, and have been issued in compliance with allapplicable securities laws, and were not issued in violation of any preemptive rights or other rights to subscribe for or purchase securities. (3)Except with respect to employees of Moelis Holdings or its controlled affiliates and except as set forth in the Moelis Holdings Agreement, none ofMoelis Holdings or any of its controlled affiliates has or is bound by any outstanding subscriptions, options, warrants, calls, commitments oragreements of any character calling for the purchase or issuance of, or securities or options, warrants or rights convertible or exercisable into orexchangeable for, any Partnership Interests or other equity or synthetic ownership interests of Moelis Holdings or any controlled affiliate, or anysecurities representing or contractual right granting the right (i) to purchase or otherwise receive any equity interest in Moelis Holdings or anycontrolled affiliate (including any rights plan or agreement) or (ii) to receive any periodic or other distribution on net income or net loss or upon theliquidation and winding up of Moelis Holdings or any controlled affiliate. (4) (a) Except as set forth in the Moelis Disclosure Schedule, as of thedate of this Agreement, there are no, written or oral, side letter, contract, memorandum of understanding and any other agreements entered intobetween any of Moelis Entities on one hand and any Limited Partner of Moelis Holdings on the other hand in respect to of the issuance or holdingof any class or type of interest in Moelis Holdings, regardless of whether such side letter, written contract, memorandum of understanding and anyother agreements are entered into by such Limited Partner in its capacity as such, except for any vesting agreements, employment agreements, offerletters or similar agreements entered into between the Moelis Entities and employees of Moelis Holdings or its controlled affiliates; and (b) as of thedate of this Agreement, no preferential voting or economic right granted to any Limited Partner of Moelis Holdings pursuant to any Representation(d) Transaction Agreements (as defined in the Moelis Disclosure Schedule) would reasonably be expected to significantly and adversely affect anyvoting or economic right of the SMBC Unit-Holders under the Moelis Holdings Agreement, the Subscription Agreement, the Side Letter or thisAgreement (as applicable), other than as a result of dilution in accordance with the Moelis Holdings Agreement from the issuance of additionalManagement Units pursuant to such Representation (d) Transaction Agreements. (5) The Moelis Disclosure Schedule sets forth a schedule ofSMBC’s pro forma ownership of Moelis Holdings, as of the date of this Agreement, after giving effect to the transactions contemplated by theSubscription Agreement and the methodology for calculating such pro forma ownership as described in such schedule. (e) Partnership Interests. The issuance of Partnership Interests to SMBC pursuant to the Subscription Agreement has been dulyauthorized by all necessary action on the part of Moelis Holdings. When issued, delivered and sold against receipt of A-2the consideration therefor as provided in the Subscription Agreement, such Partnership Interests will be validly issued, fully paid andnonassessable and without any personal liability attaching to the ownership thereof (except as provided for in the Moelis Holdings Agreement),will not be issued in violation of or subject to preemptive rights of any other unitholder of Moelis Holdings and will not result in the violation ortriggering of any price-based antidilution adjustments under any agreement to which Moelis Holdings is a party. The issuance of PartnershipInterests to SMBC qualifies as an issuance of “Additional Units” to a “Strategic Investor” under Section 3.4.1 of the Moelis Holdings Agreementfor which existing Common Partners will not have the right of first refusal as provided therein.  (f) No Conflicts. Neither the execution and delivery by the Moelis Entities of the Strategic Alliance Agreement or theSubscription Agreement, nor the consummation of the transactions contemplated thereby, nor compliance by the Moelis Entities with any of theprovisions thereof, will violate any applicable law or regulation or violate, conflict with, or result in a breach of any provision of, or constitute adefault (or an event which, with notice or lapse of time or both, would constitute a default) under, or result in the termination of, or result in the lossof any benefit or creation of any right on the part of any third party under, or accelerate the performance required by, or result in a right oftermination or acceleration of, or result in the creation of any lien or encumbrance upon any of the material properties or assets of any of the MoelisEntities or any of their controlled affiliates under any of the terms, conditions or provisions of (i) their respective organizational documents or (ii)any note, bond, mortgage, indenture, deed of trust, license, lease, agreement or other instrument or obligation to which any of the Moelis Entities orany of their controlled affiliates is a party or by which it may be bound, or to which any of the Moelis Entities or any of their controlled affiliates orany of the properties or assets of any of the Moelis Entities or any of their controlled affiliates may be subject, except as would not reasonably beexpected to have a material adverse effect on the Moelis Entities and their controlled affiliates, taken as a whole. (g) Consents. No consents or approvals of or prior filings or registrations with any governmental authority or with any thirdparty are necessary in connection with the execution and delivery by the Moelis Entities of the Strategic Alliance Agreement, the SubscriptionAgreement or the Side Letter, or the consummation of the transactions contemplated thereby. (h) Financial Statements. The Moelis Entities have previously made available to SMBC/Nikko true and correct copies of (i) theconsolidated balance sheets of Moelis Holdings as of December 31 for the fiscal years 2007 through 2010, inclusive, and the related consolidatedstatements of income, changes in total capital and of cash flows for the fiscal years then ended, in each case accompanied by the audit report ofDeloitte and Touche LLP, independent public accountants with respect to Moelis Holdings and (ii) the September 30, 2011 unaudited consolidatedbalance sheet of Moelis Holdings and the related unaudited consolidated statements of income, changes in total capital and of cash flows for thenine-month period then ended (including the related notes, where applicable) (each of the above, the “Financial Statements”). The FinancialStatements have been prepared from, are in accordance with and accurately reflect in all A-3material respects, the books and records of Moelis Holdings and its controlled affiliates, have been prepared in all material respects in accordancewith United States generally accepted accounting principles applied on a consistent basis during the periods involved (except as may be stated inthe notes thereto), are true and complete and fairly present in all material respects the consolidated financial position and the consolidated resultsof operations and cash flows (and changes in financial position, if any) of Moelis Holdings and its controlled affiliates as of the times and for theperiods referred to therein (subject, in the case of unaudited statements, to normally recurring year-end audit adjustments which are not materialeither individually or in the aggregate).  (i) Business Plan. All estimates and pro forma financial information contained in the business plan included in the MoelisDisclosure Schedule, as of the date of the business plan were prepared in good faith by the Moelis Entities. (j) Properties and Leases. Moelis Holdings and its controlled affiliates have good and marketable title to all material propertiesand assets, real and personal, tangible or intangible, owned by them, in each case free from liens or encumbrances that would materially affect thevalue thereof or interfere with the use made or to be made thereof by them in any material respect. Moelis Holdings and its controlled affiliates ownor lease all material properties as are necessary to their operations as now conducted. (k) Taxes. The Moelis Entities and their controlled affiliates have filed, or joined in the filing of, all material tax returns required tobe filed by or with respect to them prior to the date of this Agreement, and to the best knowledge of the Moelis Entities all such tax returns are true,accurate and complete in all material respects and all material amounts of taxes shown to be due in such tax returns have been paid, collected orwithheld, as the case may be. With respect to any completed taxable period for which such tax returns have not yet been filed, or for which taxes arenot yet due or owing, the Moelis Entities and their controlled affiliates have made due and sufficient current accruals for any such taxes on theirrespective balance sheets in accordance with United States generally accepted accounting principles. To the best knowledge of the Moelis Entities,there are no material claims or assessments pending against the Moelis Entities or their controlled affiliates for any alleged deficiency in any tax,and the Moelis Entities and their controlled affiliates have not been notified of any material proposed tax claims or assessments against the MoelisEntities or their controlled affiliates. (l) No Undisclosed Liabilities. As of the date of this Agreement, neither Moelis Holdings nor any of its controlled affiliates hasany liabilities or obligations of any nature (absolute, accrued, contingent or otherwise) except for (i) liabilities or obligations disclosed in theFinancial Statements and current liabilities that have arisen since the date thereof in the ordinary and usual course of business and consistent withpast practice, (ii) liabilities or obligations arising under contracts entered into by Moelis Holdings and/or its controlled affiliates prior to the datehereof, or (iii) liabilities or obligations that would not reasonably be expected to have a material adverse effect on Moelis Holdings and itscontrolled affiliates, taken as a whole.  A-4(m) Employment Agreements. Each managing director of Moelis Holdings or any of its controlled affiliates, as applicable, hasentered into either an offer letter, agreement or term sheet setting forth the terms of such managing director’s employment and vesting ofManagement Units granted to such managing director in connection with his or her employment. The forms of vesting agreements for theManagement Units provided by Moelis Holdings to SMBC/Nikko, taken as a whole, are representative of the vesting agreements entered into byMoelis Holdings or each controlled affiliate, as applicable, with respect to the grant of Management Unit; except for differences that would notreasonably be expected to have a material adverse effect on the Moelis Entities and their controlled affiliates, taken as a whole, or the SMBC Unit-Holders’ Partnership Interests. (n) Litigation. None of the Moelis Entities or any of their controlled affiliates is a party to any, and there are no pending or, to theMoelis Entities’ knowledge, threatened, material legal, administrative, arbitral or other proceedings, claims, actions or governmental or regulatoryinvestigations (i) of any nature against the Moelis Entities or any controlled affiliate except as would not reasonably be expected to have a materialadverse effect on the Moelis Entities and their controlled affiliates, taken as a whole, or (ii) challenging the validity or propriety of the transactionscontemplated by the Subscription Agreement. There is no material injunction, order, judgment, decree or regulatory restriction imposed upon theMoelis Entities, any controlled affiliate or any of their assets, except for regulatory restrictions of general application. (o) Compliance with Laws. Each of the Moelis Entities and each of their controlled affiliates have all permits, licenses, franchises,authorizations, orders and approvals of, and have made all filings, applications and registrations with, all governmental authorities that are requiredin order to permit them to own or lease their properties and assets and to carry on their businesses as they are now being conducted other than anyfailure that would not reasonably be expected to have a material adverse effect on the Moelis Entities and their controlled affiliates, taken as awhole. Except as would not be reasonably expected to have a material adverse effect on the Moelis Entities and their controlled affiliates, taken as awhole, each of the Moelis Entities and their controlled affiliates has complied with, and is not in default or violation of, and none of them is givennotice of any violation or threat of violation of, to the knowledge of the Moelis Entities, under investigation with respect to or, to the knowledge ofthe Moelis Entities, has been threatened to be charged with, any applicable law, statute, ordinance, license, rule, regulation, policy or guideline,order, demand, writ, injunction, decree or judgment of any governmental authority. Except as would not be reasonably expected to have a materialadverse effect on the Moelis Entities and their controlled affiliates, taken as a whole, and except for statutory or regulatory restrictions of generalapplication, no governmental authority has placed any restriction on the business or properties of the Moelis Entities or any of their controlledaffiliates.  (p) Risk Management. The Moelis Entities and their controlled affiliates have in place risk management policies and procedures,of the type and in the form that the Moelis Entities and their controlled affiliates believe, in good faith, are sufficient in scope and operation toprotect against risks of the type and in the form A-5expected to be used by persons of similar size and in similar lines of business as such Moelis Entity or controlled affiliate.  (q) Insurance. The Moelis Entities and their controlled affiliates maintain insurance underwritten by insurers of recognizedfinancial responsibility, of the types and in the amounts that the Moelis Entities and their controlled affiliates believe, in good faith, are adequatefor their respective businesses, all of which insurance is in full force and effect. (r) Permanent Disability. To the knowledge of the Moelis Entities, (i) KM has not (A) suffered and is not currently suffering anyphysical or mental incapacity or disability, total or partial, that would constitute or would reasonably be expected to result in a Key Man Event (assuch term is defined in the Moelis Holdings Agreement) or (B) been absent from work for three or more consecutive months at any time since theinception of the Moelis Entities and (ii) no other circumstance or condition exists that would constitute or would reasonably be expected to result ina Key Man Event. Since the inception of the Moelis Entities, no Key Man Event has occurred. (s) Affiliate Party Transactions. Except as set forth in the Moelis Disclosure Schedule and except for agreements related toemployment, (i) any material transactions between any of the Moelis Entities, on the one hand and the Management Partners of any of the MoelisEntities or any of their affiliates (other than any of the Moelis Entities and any controlled affiliate), on the other hand are on terms and conditions asfavorable to each of the Moelis Entities as would have been obtainable by it in a comparable arm’s-length transaction with an unrelated third party. (t) No Guarantee of Performance. None of the Moelis Entities or any of their controlled affiliates has guaranteed the futureperformance or results of, or is liable in connection with, on behalf of, or for, any obligation of (i) any pooled investment vehicle, open-endinvestment company, closed-end investment company, unit investment trust or business development company or other private or public fund(except, general partner liability to the extent imposed by applicable law) or (ii) any Person to which any of the Moelis Entities or any of theircontrolled affiliates provides investment management or investment advisory services, including any sub-advisory services, pursuant to aninvestment advisory contract. (u) Effect of Agreement. None of this Agreement, the Subscription Agreement or any other agreement entered into in connectiontherewith is subject to the disclosure rights under, or grant other Limited Partners rights pursuant to, Section 10.19 of the Moelis HoldingsAgreement.  A-6Exhibit 10.22 
  
            
1   
       
    Strategic Alliance Agreement   
   
   
    Intricon Corporation 1260 Red Fox Road Arden Hills, Minnesota 55112 United States  
   
   
    and  
   
   
    Dynamic Hearing Pty Ltd 2 Chapel Street, Richmond, VIC 3121 AUSTRALIAAGREEMENT   
This Agreement is entered into and is effective as of the 1st day of October, 2008 (Commencement Date) by and between IntriCon Corporation, a Pennsylvania Corporation having a place of business at 1260 Red Fox Road, Arden Hills, Minnesota 55112 USA (hereinafter IntriCon) and Dynamic Hearing Pty Ltd a Corporation organized under the laws of Victoria, Australia and having a place of business at 2 Chapel Street, Richmond, Victoria 3121, Australia (hereinafter Dynamic Hearing) agree to collaborate with each other as a Strategic Alliance. As such, this Strategic Alliance Agreement (SAA) outlines the principles and the understanding of the parties and defines related terms and conditions.   WHEREAS, Dynamic Hearing has developed technology useful for products in the Hearing Health (HH) Assisted Listening Device (ALD) and Professional Communications (PADA) markets and DSP platforms which are hereinafter defined.   WHEREAS, IntriCon has also developed technology for the HH, ALD and PADA markets and DSP platforms.   
  1.1 The purpose of this alliance is to exploit the parties’ complimentary capabilities for producing DSP Technology products for the HH, ALD, and PADA markets.   
  The following terms in the context of this SAA shall have the following meanings:   
  An Assisted Listening Device (“ALD”) is a    
  
  Hearing Aids are amplification devices primarily designed to compensate for hearing loss, designed for listening only (through a microphone, telecoil, Direct Audio Input or other similar audio pathways and run on a low power hybrid circuit. Hearing Aids may include in-the-ear Hearing Aids (ITE), behind-the-ear Hearing Aids (BTE), or completely-in-the-canal Hearing Aids (CIC).   
  Professional Audio/Communication Devices (“PADA”) are wired or wireless headsets or other devices used for one-way or two-way communications in professional or industrial settings such as law enforcement, sport events, professional performances, search and rescue, and military operations.   
2   
 1.0  
Purpose  
 2.0  
Definitions  
 
    2.1  
Assisted Listening Devices  
 
    1.  
One way communications device   
    2.  
Used for hearing protection or listening in challenging environments, and   
    3.  
Contains Ultra Low Power (ULP) DSP and or ULP Wireless technology  
 
    2.2  
Hearing Aids:  
 
    2.3  
Professional Audio/Communication DevicesDSP means digital signal processing. More specifically, for the purposes of this SAA, DSP Technology shall mean ON Semiconductor hardware and firmware algorithms used for the HH, PADA and ALD markets. Hardware shall include the ON Semiconductor Ezairo DSP, and the Single Chip Hearing Amplifier (SCHA) from ON Semiconductor.   
  IntriCon Technology is that technology:   
  
  
  
  Dynamic Hearing Technology is that technology:   
  
  
  
  K/S HIMPP (hereinafter HIMPP) is a Danish partnership that owns numerous patents relating to Hearing Aids and associated technologies.   
  HIMSA otherwise known as Hearing Instruments Manufacturers’ Software Association is a privately owned company that has developed a standardized hearing care software system.   
3   
 
    2.4  
DSP Technology:  
 
    2.5  
IntriCon Technology:  
 
    (i)  
for which a patent(s) has been granted and all fees relating to the grant including any associated maintenance or annuity fees have been paid. A granted patent does not include pending applications including those pending applications which are associated with a granted patent through a claim of priority;  
 
    (ii)  
or has a patent pending, or  
 
    (iii)  
is Technology under “record of invention”.  
 
    2.6  
Dynamic Hearing Technology:  
 
    (i)  
for which a patent(s) has been granted and all fees relating to the grant including any associated maintenance or annuity fees have been paid. A granted patent does not include pending applications including those pending applications which are associated with a granted patent through a claim of priority; or  
 
    (ii)  
has a patent application pending, or  
 
    (iii)  
is Technology under “record of invention”.  
 
    2.7  
K/S HIMPP:  
 
    2.8  
HIMSA:Base Product means the DSP Technology including the ON Semiconductor Ezairo or SCHA chips, the EEPROM and the firmware loaded onto the EEPROM and the minimum printed circuit board package necessary to connect and house these items. The Base Product does not include additional PCB or flex circuits necessary to connect to other components of an Enhanced Product.   
  Enhanced Product means a value added assembly or completed Hearing Aid or Assistive Listening Device which includes the Base Product as one of the component devices. The Enhanced Product may include other electronic components, flex circuitry, microphones, a receiver, plastic housings, volume controls, trimmer potentiometers, push button switches, programming connectors and other components.   
  Contact Center means a group of people who use Contact Center Products and provide telemarketing, mail ordering, customer care, technical support and similar functions either directly for an enterprise or on an outsourced basis by using automatic call directors for inbound centers and predictive dialers for outbound centers. A Contact Center may also use software-based systems rather than physical equipment.   
  Contact Center Products means any product, including without limitation, headsets (cordless or corded), amplifiers, telephones, soft phones, and software-based systems that are used in Contact Centers. For purposes of clarification, no product shall be deemed a “Contact Center Product” unless it is used in a Contact Center, including, without limitation, Bluetooth Products.   
  
  
  
  
  
   
4   
 
    2.9  
Base Product  
 
    2.10  
Enhanced Product  
 
    2.11  
Contact Center  
 
    2.12  
Contact Center Products  
 
    2.13  
Miscellaneous Definitions:  
 
    (a)  
headings are for convenience only and do not affect interpretation;  
 
    (b)  
the singular includes the plural and conversely;  
 
    (c)  
the meaning of general words introduced by including, or for example, or similar expressions is not limited by specific examples;  
 
    (d)  
a reference to a person, corporation, trust, partnership, unincorporated body or other entity includes any of them;  
 
    (e)  
a reference to a clause or Exhibit is a reference to a clause of, or an Exhibit to, this Agreement;unless the context requires otherwise terms in bold italics have the meaning given below:   Business Day means a day other than a Saturday, Sunday or public holiday in Victoria, Australia;   Confidential Information means information in relation to a party, including its business activities that   
  in connection with this Agreement whether the information is in oral, visual or written form or is recorded or embodied in any other medium and includes all such information disclosed to, or accessed by, the other party before this Agreement commences;   Exclusivity Date means October 1, 2008, the date Intricon makes its first quarterly payment of the Minimum Payment;   Identified Party means a party identified in Exhibit C before January 1, 2009 and all other parties are unidentified parties;   Improvements mean any modification, improvement, enhancement or development to the Licensed Subject Matter excluding always a development, modification, improvement or enhancement that is patentable in its own right or which is proprietary information of IntriCon.   Key Personnel means Elaine Saunders and Anthony Shilton;   
5   
 
    (f)  
a reference to an agreement or document (including a reference to this Agreement) is to the agreement or document as amended, varied, supplemented, novated or replaced, except to the extent prohibited by this Agreement or that other agreement or document;  
 
    (g)  
a reference to a party to this Agreement includes the party’s successors, permitted substitutes and permitted assigns (and, where applicable, the party’s legal personal representatives);  
 
    (h)  
a reference to legislation or to a provision of legislation includes a modification or re-enactment of it, a legislative provision substituted for it and a regulation or statutory instrument issued under it;  
 
    (i)  
if a translation of this Agreement into any other language is produced, the original English version is to be the definitive version of this Agreement;  
 
    (j)  
the term Related Body Corporate has the meaning given in the Corporations Act 2001 (C’th); and  
 
    (a)  
is disclosed to the other party by or on behalf of the first party;   
    (b)  
is acquired by the other party directly or indirectly from the first party; or   
    (c)  
otherwise comes to the knowledge of the other party,Licensed Subject Matter means Dynamic Hearing’s Technology, Software, and Documentation as described in Exhibit A and Exhibit B, in respect of which IntriCon is granted a license under this Agreement;   Product means a Base Product Unit or an Enhanced Product Unit;   For purposes of computing Royalty Payments, a sale shall occur when IntriCon receives payment from a customer for a Base Product Unit., or an Enhanced Product containing a Base Product;   Services means technology transfer and other support provided to IntriCon by Dynamic Hearing;   Base Product Unit means a single Base Product item;   Territory means the world; and   Use means, in relation to:   
  2.14 Additional definitions are provided in Exhibits A and B attached here to which are considered to be part of this Agreement.   
  3.1 Term: The initial term of this Agreement shall be five (5) years from the date of execution and may be extended subject to satisfactory agreement on ongoing commercial terms, to be agreed two (2) months prior to the expiration of this Agreement.   3.2 Dynamic Hearing grants to IntriCon in accordance with this Agreement, for the Term, a license, to Use Dynamic Hearing’s Technology, Software and Documentation developed as of the Commencement Date to manufacture, import, sell and offer for sale throughout the Territory, Products containing Dynamic Hearing’s Technology and Software. This grant specifically excludes products for Contact Centers, and the use of ADRO Technology in electrical stimulation of the auditory system.   3.3 IntriCon accepts that Dynamic Hearing owns all rights in relation to the Licensed Subject Matter except for those rights being specifically granted hereunder, and that Dynamic Hearing is under no obligation to provide the source code of any software.   3.4 Commencing on the Exclusivity Date, and continuing for so long as IntriCon continues to make such payments, the license granted to IntriCon under this Agreement will, subject to the terms and conditions of this Agreement, be exclusive for Hearing Aids. The exclusivity shall not prevent Dynamic Hearing entering into agreements with any Identified Party subject to the terms herein. On or before January 1, 2009, Dynamic Hearing will provide IntriCon with an updated version of Exhibit C which will include a complete list of identified parties. After January 1, 2009, no additions to Exhibit C are allowed unless agreed to by IntriCon in writing.   
6   
 
    (a)  
the Technology, make, hire, sell or otherwise dispose of the product, offer to make, sell, hire or otherwise dispose of it, use or import it; and   
    (b)  
the Software and Documentation to reproduce any copyright works subsisting in such software or documentation.  
 3.0  
License Grant3.5 IntriCon acknowledges that Dynamic Hearing’s rights to license technology and software to companies manufacturing implantable devices is not restricted in any way.   IntriCon acknowledges that Dynamic Hearing’s rights to license any Dynamic Hearing Technology or Software to Identified Parties, and provide support as agreed with Identified Parties, is in no way restricted.   3.6 No further design support will be given to Sound Design Technologies, Ltd (hereinafter Sound Design) which includes the recent purchase of Gennum Corporation’s hearing instrument business after 30 October 2009, if all conditions of IntriCon’s exclusivity are met.   3.7 Intricon acknowledges that Dynamic Hearing is negotiating with several third parties regarding licensing Dynamic Hearing Technology and Software, relating to its Hearing Aid Designer™ and other products and services. The rights granted under such agreements shall be included as exceptions to the exclusivity of IntriCon’s License Grant, if such agreements are executed by Dynamic Hearing and the third party before January 1, 2009. Such third parties and their relevant subsidiaries will be Identified Parties and added to the Exhibit C. Agreements with identified parties are allowed exceptions and no Agreements are allowed with unidentified parties.   3.8 Commencing on October 1, 2008, and continuing for so long as IntriCon continues to make minimum payments as defined in 4.3, Dynamic Hearing agrees that it will not license any Dynamic Hearing Technology for Hearing Aids, subject to Clause 3.5.   3.9 If any Identified Party, (with the exception of Sound Design) purchases DSP product sold or made by IntriCon with Dynamic Hearing’s Hearing Aid Designer™ software and requests assistance to achieve HIMPP compliance for products using such DSP chips, IntriCon will use its best efforts to comply with the request for HIMPP compliance.   3.10 Where IntriCon supplies Products to a third party, IntriCon will, at its cost:   
  
  
7   
 
    (a)  
obtain and maintain all governmental and regulatory approvals necessary for it to exercise, and comply with all laws and regulations applicable to the exercise of, its license rights under this Agreement; and  
 
    (b)  
comply, and ensure that all Products comply, at all times with any technical standards as may reasonably be required by law, and any licensing requirements, standards, or protocols established by the Hearing Instrument Manufacturers’ Software Association (HIMSA) and the Hearing Instrument Manufacturers’ Patent Partnership (HIMPP), it being acknowledged that Dynamic Hearing makes no representation or warranty that the exercise of the rights granted under this Agreement will not infringe any rights held by HIMSA, HIMPP or any other third party.3.11 Where Dynamic Hearing supplies Dynamic Hearing Technology directly to a customer on DSP chips supplied by IntriCon, then, IntriCon will use its best efforts to comply with the request for HIMPP compliance or notify the third party customer of the customers obligations, as per 3.10 (a) and (b).   3.12 Dynamic Hearing may continue indefinitely selling products and services to new customers using the ON Semiconductor DSP hybrid chip. For the absence of doubt, the Exclusivity grant of 3.2 does not restrict Dynamic Hearing from licensing Dynamic Hearing Technology and DSP Software on any ON Semiconductor platform, purchased by a third party or by Dynamic Hearing, from IntriCon. With the exception of the Identified Parties, Dynamic Hearing agrees that it will not sell the Dynamic Hearing DSP Software for Hearing Aids configured to run on any hardware other than that provided by ON Semiconductor, except in circumstances as described in this Agreement. Dynamic Hearing may continue to sell products and services to non-Hearing Aid Customers using the ON Semiconductor DSP hybrid chips including the Bela Signa.   3.13 Dynamic Hearing and IntriCon shall undertake a mutual roadmap review and agree whether or not the current ON Semiconductor chips will meet market requirements. If the Parties agree that the ON Semiconductor chips will not meet market requirements, IntriCon shall have six (6) months to correct the material deficiency. Material deficiency means that ON Semiconductors must have a chip that is within 10% of the best in class performance on each one of these characteristics: physical size, power supply current, computational capability and cost. If IntriCon is unable or unwilling to remedy such deficiency, IntriCon will lose its exclusivity under this license.   3.14 IntriCon agrees that nothing in this Agreement precludes Dynamic Hearing from licensing Dynamic Hearing Technology, including the ADRO™ Algorithm to manufacturers, including Siemens AG, Sonova Holdings AG, GN Resound Group, William Demant Holding A/S, Widex A/S, Starkey Laboratories Inc, and Cochlear Ltd.   3.15 Nothing herein shall preclude Dynamic Hearing from making and selling its own Hearing Aids. Nothing in this agreement prevents Dynamic Hearing from selling Hearing Aids manufactured by third parties in Dynamic Hearing’s own clinics.   3.16 No other exception to IntriCon’s exclusive license being granted herein shall exist unless such exception is specifically identified by a supplemental agreement between IntriCon and Dynamic Hearing.   
  4.1 IntriCon’s payments to Dynamic Hearing will comprise two payment components. A first payment component (minimum payment) will be a technology access fee for access to Dynamic Hearing Technology on a non-exclusive basis. A second payment component hereinafter (Second Component) will be for exclusive rights to Dynamic Hearing Technology as such exclusive rights are defined herein. The second component may comprise a combination of a royalty payment and fees for services.   
8   
 4.0  
Payments4.2 IntriCon will pay to Dynamic Hearing a fixed technology access fee of US$300,000 annually (hereinafter “Access Fee”), the payment of the technology access fee to be paid on a quarterly basis at the beginning of each calendar quarter. Payment of the technology Access Fee will maintain IntriCon’s non-exclusive rights to Dynamic Hearing Technology.   4.3 To maintain exclusive rights to Dynamic Hearing Technology for Hearing Aids IntriCon will make minimum annual payments to Dynamic Hearing as set out in the Minimum Payment Schedule. The Minimum Payment consists of the Access Fee of US$300,000 per annum and the Second Component that increases from year to year.   Minimum Payment Schedule (All amounts are in US Dollars):   
  The Minimum Payments will be paid quarterly in advance in equal installments at the beginning of each royalty quarter, as defined in 4.7. 
The first quarterly Minimum Payment (for the quarter beginning 1st October, 2008) shall be made at the date of signing of this Agreement and the second quarterly minimum payment shall be made at January 1, 2009 with all further quarterly Minimum Payments following the schedule as defined in 4.7.   4.4 Intricon is entitled to credit for any amounts payable to Dynamic Hearing arising from per unit royalties and fees for services up to the value of the corresponding quarterly Second Component. In quarters where the per unit royalties and fees for services are less than the corresponding quarterly Second Component, IntriCon may carry forward the remaining credit to be offset against future quarters per unit royalties and fees for services.   Any amounts due from per unit royalties and fees for services that exceed the value of the corresponding quarterly payment of the Second Component, net of any carried forward credit, will be paid within 30 days of the end of that royalty quarter.   4.5 Once IntriCon has paid the minimum payments in 4.3, no further minimum payments, both Access Fee and Second Component, are required for access to Dynamic Hearing Technology or to maintain exclusivity over the term of this Agreement. IntriCon will continue to have the obligation to pay royalty payments under 4.9 and fees for services under 4.8.   4.6 In the event IntriCon has not yet paid the minimum payments and should IntriCon choose not to continue access to Dynamic Hearing Technology on an exclusive basis as referred to in 4.3, the following amounts will be payable:   
  
9   
       PAYMENT YEAR  
MINIMUM PAYMENT  
ACCESS FEE  
SECOND COMPONENT  
Year 1  
$400,000  
$300,000  
$100,000  Year 2  
$700,000  
$300,000  
$400,000  Year 3  
$1,100,000  
$300,000  
$800,000  Year 4  
$1,600,000  
$300,000  
$1,300,000  Year 5  
$2,100,000  
$300,000  
$1,800,000  
 
    (1)  
the technology Access Fee payable quarterly in advance in equal installments at the beginning of each royalty quarter and;4.7 Payment year 1 of this agreement shall start at the commencement date and the first royalty quarter will be completed at the end of the calendar quarter. Subsequent royalty quarters will correspond with the calendar quarters ending on the last days of March, June, September and December respectively.   4.8 Dynamic Hearing shall provide engineering and other services (hereinafter “Fees For Services”) to IntriCon on a timetable to be agreed upon in writing forming part of this agreement as an exhibit. Dynamic Hearing will invoice IntriCon on a quarterly basis 30 days from the end of the quarter for engineering and services that exceed 260 hours in a single month at the rate of $150 per hour. Payments for such services shall be due and payable within 30 days of the end of that royalty quarter. There will be no charge by Dynamic Hearing to IntriCon for the first 260 hours of engineering and services provided each month, however, any unused hours will not be carried forward as credit to subsequent months or be entitled to be offset against any future monthly amounts payable for engineering and services. IntriCon is entitled to utilize such engineering services for the HH, ALD or PADA markets.   Other service support (e.g. marketing or audiology) may be contracted at the same rates. If Dynamic Hearing staff are required by IntriCon to travel to meetings, all airfares, ground transportation, hotel bills and other out of pocket expenses will be paid by IntriCon.   4.9 Royalty Payments will be made only on the Base Product Unit, or on the Base Product portion of an Enhanced Product for any Base Product included in an Enhanced Product. The initial base rate of royalty shall include the use of the DSP Framework. In no case shall IntriCon pay Royalty Payments on any product or portion of any product other than for revenue received for Base Product Unit or for the Base Product portion of an Enhanced Product, and in the case a Base Product portion of an Enhanced Product such Base Product portion shall not be given a value that is influenced by its inclusion in the Enhanced Product. Royalty Payment for HH, ALD and PADA units that incorporate Dynamic Hearing Technology shall be paid according to the table set forth below:   
  The maximum royalty rate identified in the table herein includes an initial base rate of 3% for each Ezairo DSP platform and 1% for each Single Chip Hearing Aid (SCHA) sold. A 2% royalty rate per Base Product Unit shall be added to the initial base rate for each DSP feature/module that is based on Dynamic Hearing Technology and that is added to a Base Product Unit. However, such additional Royalty Payments when added to the initial base rate shall not exceed in total the stated maximum rates specified in the table herein.   
10   
 
    (2)  
any monthly fees for services and royalties are payable in accordance with clause 4.8 and royalty payments under 4.4 and 4.9.  
        
Cumulative annual HH & ALD Volume that use the Framework  
Ezairo Maximum Royalty Rate  
SCHA Maximum Royalty Rate  
Less Than 20,000 Units  
10%  
8%  
20,000-50,000 units  
9%  
7%  
50,000-100,000 units  
8%  
6%  
100,000-200,000 units  
7%  
5%  
200,000-500,000 units  
6%  
4%  
500,000 to 1,000,000 units  
5%  
3%  
Over 1,000,000  
5%  
1.5%4.10 All amounts payable by IntriCon under this Agreement must be paid free and clear of and without any deduction or withholding for or on account of any present or future withholding tax, including any interest or penalties in relation to such tax (Withholding Taxes). If IntriCon is required to make any deduction or withholding for any Withholding Tax, then IntriCon must pay to Dynamic Hearing such additional amount to ensure that Dynamic Hearing receives such amount that would have been received by it as if no such withholding or deduction had been required.   
  
  
  
  5.1 Within thirty (30) days of the end of each payment quarter IntriCon must provide to Dynamic Hearing a statement of the actual number and value of Base Product Units Sold along with the number and value of DSP features/models sold with those Base Product Units by it or any Related Body Corporate. The statement must also include calculations of the per unit royalty in accordance with clause 4.9. Any royalty due for payment by IntriCon to Dynamic Hearing is payable at the same time the statement is provided.   5.2 A Royalty Payment will be due only once in respect of each Base Product Unit Sold, and the Royalty Payment will be due on the first Sale of the Base Product Unit by IntriCon or a Related Body Corporate.   5.3 Where, in any payment quarter, a Base Product Unit is, in good faith, returned to IntriCon, IntriCon is not required to pay any Royalty Payment on the Sale of that Base Product Unit. If IntriCon has paid a Royalty Payment on that Base Product Unit in a previous payment quarter, IntriCon may reduce the Royalty Payment due for the payment quarter in which the Base Product Unit is returned by the amount of any such Royalty paid.   
  6.1 IntriCon must keep accurate and complete records of orders received, Base Product Units / DSP Features/Modules Sold and returned and all other records reasonably necessary to substantiate all Royalty Payments to be made to Dynamic Hearing under this Agreement.   
11   
 
    1)  
IntriCon must bear all stamp duty that may be levied on this Agreement. IntriCon must bear any other taxes, levies, imposts, charges, rates and duties that may be levied or imposed by a governmental authority on any person (including fines, penalties and interest) in connection with this Agreement (other than income tax payable to the Commonwealth of Australia by Dynamic Hearing).  
 
    2)  
Each party must bear its own costs arising out of the negotiation, preparation and execution of this Agreement.  
 
    3)  
All amounts payable to Dynamic Hearing under this Agreement must be made without set-off, counterclaim or deduction.  
 5.0  
Reports  
 6.0  
Records and Audit6.2 IntriCon must make all such records available for inspection, copying and audit by an independent auditor appointed by Dynamic Hearing (and to which IntriCon has no reasonable objection) during ordinary business hours at any time during the Term and for a period of one year following the expiration or earlier termination of this Agreement, provided that:   
  
  
  
  6.3 If in any audit, the auditor finds an underpayment or an overpayment of fees due under this Agreement, the party who has received the overpayment or has underpaid will within 7 days repay the excess or pay the shortfall (as the case may be) to the other party.   
  7.1 Each party must:   
  
  
  
  
  7.2 This Agreement is confidential and each party must not disclose any part of this Agreement to any person without the prior written consent of the other party.   
12   
 
    (a)  
such inspection, copying or audit must only be made after at least one Business Day’s written notice;  
 
    (b)  
such audit must not unreasonably interfere with the day to day operations of IntriCon; and  
 
    (c)  
such audit must be at Dynamic Hearing’s expense unless the auditor finds an underpayment royalty due under this Agreement in excess of 5% in which case IntriCon must reimburse Dynamic Hearing’s reasonable cost of such audit; and  
 
    (d)  
Audits will be limited to one audit in any calendar year.  
 7.0  
Confidentiality  
 
    (a)  
not disclose any Confidential Information to any person, except in confidence as permitted by this Agreement;  
 
    (b)  
not use any Confidential Information except as reasonably necessary for the purpose of putting this Agreement into effect (Permitted Purpose);  
 
    (c)  
restrict access to Confidential Information to those of its employees and officers for whom such access is not reasonably necessary for the Permitted Purpose;  
 
    (d)  
ensure that its employees and officers comply with this Agreement; and  
 
    (e)  
not reproduce or record, or permit or cause any reproduction or recording of, any Confidential Information except to the extent reasonably necessary for the Permitted Purpose.7.3 This clause 7.0 does not apply where the party receiving the Confidential Information can prove that:   
  
  
  
  
  
  
  
  8.1 Dynamic Hearing will be solely responsible at its cost and at its discretion for applying for, obtaining, maintaining, defending and enforcing all aspects of all rights in respect of the Licensed Subject Matter and IntriCon must:   
  
  8.2 IntriCon must notify Dynamic Hearing immediately upon becoming aware of:   
  
13   
 
    (a)  
the information has become generally available to the public other than because of a breach of this Agreement, or any obligation of confidence owed to the disclosing party;  
 
    (b)  
it has received the information from a third person, legally entitled to possess the information and provide it to that party, if that information is used, disclosed or otherwise dealt with in accordance with the rights or permission lawfully granted to that party by that third person; or  
 
    (c)  
the disclosure of information is necessary to comply with any applicable law or legally binding order of any court, government, semi-government authority or administrative or judicial body or the applicable rules of any stock exchange, provided that before any such disclosure, the receiving party must, at its cost:  
 
    (i)  
immediately notify the other party giving full details of the circumstances of the proposed disclosure and of the relevant information to be disclosed;  
 
    (ii)  
give the other party a reasonable opportunity to protect or preserve the confidentiality of the relevant information;  
 
    (iii)  
co-operate with the other party in any action taken under this paragraph (c); and  
 
    (iv)  
in any event, take all reasonable steps to preserve the confidentiality of the information being disclosed.  
 8.0  
Maintenance, Infringement and Third Party Proceedings  
 
    (a)  
provide all reasonable assistance to Dynamic Hearing in any action which Dynamic Hearing may take in relation to any such matters; and  
 
    (b)  
not take any action in relation to any such matters without the prior written consent of Dynamic Hearing, to be given at Dynamic Hearing’s absolute discretion.  
 
    (a)  
any claim or allegation that the exercise of the rights under this Agreement constitutes an infringement of the rights of any third party; and9.1 Dynamic Hearing hereby represents that, as at the Commencement Date none of the Key Personnel has any actual knowledge that, save for any rights claimed to be owned or held by the HIMPP, any rights of any third person may be infringed by the exercise, in accordance with this Agreement of the rights licensed under clause 3.   9.2 IntriCon accepts that neither Dynamic Hearing nor any person acting on its behalf has made any representation that (a) any patent applications comprised in the Technology will be granted in any part of the Territory or (b) any registered rights arising should any such applications be granted, will be, or any registered rights comprised in the Technology are, valid or enforceable.   9.3 Dynamic Hearing will not be responsible for:   
  
  
  10.1 IntriCon must indemnify Dynamic Hearing and its Related Bodies Corporate and their respective directors, officers, employees and agents from and against any claims, losses, liabilities, costs, expenses (including investigative costs, court costs, legal fees, penalties, fines and interest) and damages of any kind (including those which are prospective or contingent) whatsoever and howsoever, directly or indirectly arising out of or in connection with this Agreement, including liability arising in connection with:   
  
  
  
14   
 
    (b)  
any third party’s infringement or threatened infringement of any rights subsisting in the Licensed Subject Matter.  
 9.0  
Representations and Warranties  
 
    (a)  
the delivery, installation, or support of the Software to end-users of any Product or any other third party; or  
 
    (b)  
the supply, service, installation, and maintenance of any product (including any Product) or any ancillary software required for communication with any other software or device used by IntriCon in relation to the Applications Software Platform or the DSP Platform (including those known as the HiPro interface, the MicroCONNECT interface, the NOAH Hearing Aid fitting database and the NOAH link interface).  
 10.0  
Indemnity and Limitation of Liability  
 
    (a)  
any infringement of third party rights but only to the extent that such third party infringement results from the use of IntriCon Technology;  
 
    (b)  
injury to any person (including death) or loss of or damage to property which may arise from or as a result of manufacture, importation, sale, offer for sale or use of any Product by IntriCon; or  
 
    (c)  
any breach of this Agreement by IntriCon or its Related Bodies Corporate and their respective directors, officers, employees and agents or any unlawful or negligent act or omission of any of them but subject to the provisions of 10.3.10.2 Dynamic Hearing must indemnify IntriCon and its Related Bodies Corporate and their respective directors, officers, employees and agents from and against any claims, losses, liabilities, costs, expenses (including investigative costs, court costs, legal fees, penalties, fines and interest) and damages of any kind (including those which are prospective or contingent) whatsoever and howsoever, directly or indirectly arising out of or in connection with this Agreement, including liability arising in connection with:   
  
  10.3 To the maximum extent permitted by law and notwithstanding anything to the contrary in this Agreement:   
  
  
  
  
  
15   
 
    (a)  
any infringement of third party rights that arise out of the exercise of the rights licensed under this Agreement; or  
 
    (b)  
any breach of this Agreement by Dynamic Hearing or its Related Bodies Corporate and their respective directors, officers, employees and agents or any unlawful or negligent act or omission of any of them but subject to the provisions of 10.3.  
 
    (a)  
all terms and warranties expressed or implied by any legislation, the common law, equity, trade, custom or usage or otherwise in relation to this Agreement are expressly excluded;  
 
    (b)  
Dynamic Hearing is not liable in any way to IntriCon for any indirect, consequential, third party, special or incidental harm, liability, expense, cost, loss or damage, loss of profits, loss of data, exemplary damages or any other indirect commercial or economic loss of any kind whatsoever incurred by IntriCon whether in negligence, tort, equity, contract or otherwise, arising in connection with this Agreement;  
 
    (c)  
IntriCon is not liable in any way to Dynamic Hearing for any indirect, consequential, third party, special or incidental harm, liability, expense, cost, loss or damage, loss of profits, loss of data, exemplary damages or any other indirect commercial or economic loss of any kind whatsoever incurred by Dynamic Hearing whether in negligence, tort, equity, contract or otherwise, arising in connection with this Agreement;  
 
    (d)  
Dynamic Hearing’s aggregate liability to IntriCon for direct loss and damages and all other liability not described herein arising in connection with this Agreement whether in negligence, tort, equity, contract or otherwise, is limited to payment of damages recoverable at law or equity up to a maximum of (and, for the sake of clarity must not exceed) $5m; and  
 
    (e)  
if any legislation implies in this Agreement any term or warranty which cannot be excluded or modified, the liability of Dynamic Hearing for a breach of any such term or warranty is limited, at the option of Dynamic Hearing, to any one or more of the following:11.1 Notwithstanding any provision to the contrary in this Agreement, this Agreement may not be terminated by either party prior to two years from the commencement date other than for the failure to pay the first and second yearly minimum payments as defined in section 4.3.   11.2 Subject to the provisions of 11.1, either party may terminate this Agreement immediately by written notice to the other party if:   
  11.3 Dynamic Hearing may terminate this Agreement immediately by written notice to IntriCon if IntriCon:   
  
  
  
  11.4 IntriCon may terminate this Agreement immediately by written notice to Dynamic Hearing if Dynamic Hearing:    
16   
 
    (i)  
if the breach relates to goods:  
 
    (A)  
the replacement of goods or the supply of equivalent goods; or  
 
    (B)  
the repair of such goods; and  
 
    (ii)  
if the breach relates to services: the supplying of the services again.  
 11.0  
Termination  
 
    (a)  
the other party breaches a material term of this Agreement (unless the breach is capable of remedy, in which case if the other party fails to remedy the breach within 30 days after being required by written notice to do so)  
 
    (a)  
enters into any form of insolvency or administration including the following:  
 
    (i)  
stops or suspends or threatens to stop or suspend payment of all or a class of its debts; or  
 
    (ii)  
becomes insolvent, has an application or order made, proceedings commenced, a resolution passed or proposed in a notice of meeting, an application to a court made or other steps taken against or in respect of it for its winding up, deregistration or dissolution or for it to enter an arrangement, compromise or composition with or assignment for the benefit of its creditors, a class of them or any of them;  
 
    (b)  
sells a significant portion of its assets or undertaking.11.5 (a) Subject to the provisions of 11.1, IntriCon may terminate this Agreement upon three (3) months written notice to Dynamic Hearing, such notice stating that IntriCon will cease making payments, either minimum or second component payments or both, and such termination shall not be considered a breach of this Agreement.   
  
  
  
  
  
  
   
17   
 
    (a)  
enters into any form of insolvency or administration including the following:  
 
    (i)  
stops or suspends or threatens to stop or suspend payment of all or a class of its debts; or  
 
    (ii)  
becomes insolvent, has an application or order made, proceedings commenced, a resolution passed or proposed in a notice of meeting, an application to a court made or other steps taken against or in respect of it for its winding up, deregistration or dissolution or for it to enter an arrangement, compromise or composition with or assignment for the benefit of its creditors, a class of them or any of them;  
 
    (b)  
sells a significant portion of its assets or undertaking.  
 
    (b)  
Subject to the provisions of 11.1, Dynamic Hearing may terminate this Agreement upon three (3) months written notice to IntriCon of such termination.  
 
    11.6  
Termination or expiry of this Agreement will not affect:  
 
    (a)  
any rights or remedies of the parties which may have accrued before the date of termination;  
 
    (b)  
the rights and obligations of the parties which by their nature survive termination, including clauses 6, 7, 8, 9, and 10.  
 
    11.7  
Upon the effective date of expiry or termination of this Agreement for any reason whatsoever:  
 
    (a)  
IntriCon must return all original media and documentation and all copies thereof relating to the Licensed Subject Matter and Confidential Information and all associated documents supplied under this Agreement or otherwise in IntriCon’s possession, custody or control except for such media and documentation necessary to continue selling existing products;  
 
    (b)  
On Dynamic Hearing’s request, IntriCon must procure one of its executive officers to certify (by way of statutory declaration) that it has complied with its obligations under clause 11.7(a).provided that IntriCon may   
  
  
  
  11.8 Upon the Effective Date of expiry or termination of this Agreement for any reason whatsoever:   
  
  11.9 Nothing in this clause 11.0 is intended to prevent end-users of Products continuing to use the Products or to require such end-users to return or destroy any Product.    
18   
 
    (c)  
All rights granted under this Agreement in relation to the Licensed Subject Matter will cease except as otherwise provided herein as to existing products;  
 
    (i)  
retain one copy of the Software until the fifth anniversary of such effective date; and  
 
    (ii)  
Use such Software until the fifth anniversary of such effective date solely as reasonably necessary to repair and maintain any Base Product Units Sold under this Agreement on or before such effective date, for the period (if any, until such anniversary) while such Base Product Unit is covered by a warranty granted by IntriCon and as otherwise provided herein as to existing products.  
 
    (d)  
Notwithstanding anything herein to the contrary, IntriCon shall have a right after termination to continue selling existing products that include the Dynamic Hearing Technology as long as IntriCon pays the appropriate royalties in accordance with the payment clauses in section 4.9 and, for the avoidance of doubt, such other clauses of this Agreement (including 4.3, 4.10, 5, 6 and 10.1 will continue to apply in respect of such sales. Existing products are those products that IntriCon is selling at the date of termination of this Agreement.  
 
    (e)  
IntriCon is not obligated to pay any royalties, Minimum Payments or technology Access Fee after termination of this agreement if IntriCon stops selling Base Product Units, and/or Basic Product Units incorporated into Enhanced Products.  
 
    (a)  
Dynamic Hearing must return all original media and documentation and all copies thereof relating to IntriCon’s Technology and Confidential Information provided to Dynamic Hearing from IntriCon and all associated documents supplied under this Agreement to Dynamic Hearing from IntriCon under Dynamic Hearing’s possession, custody control;  
 
    (b)  
on IntriCon’s request, Dynamic Hearing must procure one of its directors to certify (by way of statutory declaration) that it has complied with its obligations under clause 11.7(a).12.1 Any notice, demand, consent or other communication (Notice) given or made under this Agreement:   
  
  
  
  
  
  
  12.2 This Agreement contains the entire agreement between the parties with respect to its subject matter and supersedes all prior agreements and understandings between the parties in connection with such subject matter.   12.3 No amendment or variation of this Agreement is valid or binding on either party unless made in writing and executed by both parties.   
19   
12.0 General Provisions  
 
    (a)  
must be in writing and signed by a person duly authorized by the sender;  
 
    (b)  
must be delivered to the intended recipient by prepaid post (or, if posted to an address in another country, by registered airmail or private air courier) or by hand or fax to the address or fax number below or the address or fax number last notified by the intended recipient to the sender:  
   (i) to Dynamic Hearing:  
Chief Executive Officer 2 Chapel Street, Richmond, VIC 3121 AUSTRALIA Fax :+613 8420 8599  
   
   (ii) to IntriCon:  
President 1260 Red Fox Road Arden Hills, Minnesota 55112 United States Fax: +651 636 9503  
 
    (c)  
will be taken to be duly given or made:  
 
    (i)  
in the case of delivery in person, when delivered;  
 
    (ii)  
in the case of delivery by post, two Business Days after the date of posting (if posted to an address in the same country) or seven Business Days after the date of posting (if posted to an address in another country); and  
 
    (iii)  
in the case of fax, on receipt by the sender of a transmission control report from the dispatching machine showing the relevant number of pages and the correct destination fax machine number or name of recipient and indicating that the transmission has been made without error, but if the result is that a Notice would be taken to be given on a day that is not a Business Day in the place to which the Notice is sent or is later than 4:00pm (local time) it will be taken to have been duly given or made at the commencement of business on the next Business Day in that place.12.4 Any provision of this Agreement which is unenforceable or partly unenforceable is, where possible, to be severed to the extent necessary to make this Agreement enforceable, unless this would materially change the intended effect of this Agreement.   12.5 No failure to exercise or any delay in exercising any right, power or remedy by a party operates as a waiver. A single or partial exercise of any right, power or remedy does not preclude any other or further exercise of that or any other right, power or remedy. A waiver is not valid or binding on the party granting that waiver unless made in writing.   12.6 IntriCon may not assign or transfer any of its rights or obligations under this Agreement without the prior written consent of Dynamic Hearing. Likewise, Dynamic Hearing may not assign or transfer any of its rights or obligations under this Agreement without the prior written consent of IntriCon.   12.7 This Agreement may be executed in any number of counterparts. All counterparts together will be taken to constitute one instrument.   12.8 This Agreement is governed by the laws of Victoria, Australia and the parties submit to the jurisdiction of the courts of Victoria, Australia. The 1980 United Nations Convention on Contracts for the International Sale of Goods does not apply to this Agreement.    
       
20   
      DYNAMIC HEARING PTY LTD  
    INTRICON CORPORATION  
   
   
   /s/ Elaine Saunders  
    /s/ Mark S. Gorder  
Printed Name:   
Elaine Saunders  
    Printed Name:   
Mark S. Gorder  
Title:   
CEO  
    Title:   
President & CEO  Dated:   
July 20, 2008  
    Dated:   
July 16, 2008EXHIBIT A   
    
21   
             
Technology   DSP FrameWorkTM means DSP software implementing program switching, volume control, reading and writing programs, program beeps, and battery monitoring.  
   
   
    ADRO® Technology means the invention described in patent application PCT/AU99/00076 which is the subject of the following patents and patent applications: AU761865 EP11172020 US 6,731,767 CA 2,361,544 JP 2000-597976  
    and 32 channel ultra-low-delay ADRO® amplification the subject of Patent application US11/283540. 
 
   
   
    Note that Dynamic Hearing does not have rights to ADRO for electrical stimulation of the auditory system and that the rights to ADRO for electrical stimulation are thus explicitly excluded from this Agreement.  
   
   
    Wide Dynamic Range Compression Technology means digital signal processing technology that provides level-dependent amplification of the input signal in multiple frequency bands.  
   
   
    Adaptive Directional Microphone Technology means the technology that is the subject of Australian Patent Application 2004310722 entitled “Adaptive Directional Systems.”  
   
   
    Fixed Directional Microphone Technology means digital signal processing technology that implements a preferential fixed response to sound from a forward direction.22   
    Omni-Directional Microphone Technology means digital signal processing technology that implements a fixed response to sound from all directions.   
  
   
     
    The Adaptive Directional Microphone Technology, Fixed Directional Microphone Technology and Omni-Directional Microphone Technology are collectively known as the Microphone Technology.  
 
   
     
    Single-channel Noise Reduction Technology means digital signal processing technology that reduces the output signal level by an amount related to the internal noise level in multiple frequency bands.  
 
   
     
    Multi-channel Noise Reduction Technology means digital signal processing technology that reduces the output signal level by an amount related to the internal noise level in multiple frequency bands.  
 
   
     
    Active Feedback Cancellation Technology means the technology of the subject of US patent 6876751.    
   
     
    Oscillation Detection Technology means the technology of the subject of United States Patent 7302070.    
   
     
    Oscillation Suppression Technology means digital signal processing technology that reduces the maximum gain temporarily, in an individual frequency band, when a sustained oscillation is detected in that band as more particularly described in European Patent Application 04734786.9 entitled “Oscillation Suppression”.  
 
   
     
    (The Active Feedback Cancellation Technology, Oscillation Detection Technology and Oscillation Suppression Technology are collectively known as the Feedback Technology).  
 
   
     
    Datalogging Technology means software that allows recording of events occurring during use of the device to non-volatile memory.  
 
   
     
    Dynamic Display is a feature that allows parameters of each DSP module to be accessed and displayed in real time without interrupting normal operation of the device.  
 
   
     
    Environmental Noise Reduction means digital signal processing that suppresses environmental noise.EXHIBIT B HEARING AID DESIGNER SOFTWARE   
      
23   
             
Software   The Hearing Aid DesignerTM is software comprising the DSP Software, the Manufacturers’ Toolkit, the 
designCOMTM applications programming interface, and source code sufficient to enable the development and integration of new DSP modules by the Licensee.  
   
   
    (DSP Software means the embedded software that implements the Technology on the DSP Platform.)  
   
   
    Library Software means the designCOM software that runs on the Applications Software Platform to communicate with, and configure, the DSP Software on the DSP Platform, and the ADROpredict software that provides initial estimates of the ADRO fittings for a given audiogram and comfortable level measures.  
   
   
    Manufacturers’ Toolkit means the manufacturing software that allows configuration and calibration of Products.  
   
   
    Unless expressly specified in this Exhibit, Dynamic Hearing will have no obligation to provide updates or revisions to, or new versions of, any software.  
   
   
    (Collectively, the above software is known as the Hearing Aid Designer SoftwareTM).  
   
   
Applications Software Platform  
The Applications Software Platform for Library Software is: Windows 2000, Windows XP, or Windows Vista operating system running on a Personal Computer connected to the Hearing Aid via a HiPro, or NOAHLink interface device.EXHIBIT C Dynamic Hearing’s Identified Customers                               GN RESOUND GROUP and INTERTON ELECTRONIC HÖRGERÄTE GMBH  Existing License Agreement  
   RION CO. LTD.  Existing License Agreement  
   SONIC INNOVATIONS INC.  Existing License Agreement  
   AUDIO CONTROLE INC.  Existing License Agreement  
   EARLENS CORPORATION  Existing License Agreement  
   AUSTRALIA HEARS PTY LTD  Existing License Agreement24   
 
   AMERICA HEARS INC.  Existing License Agreement  
   VITASOUND AUDIO INC.  Existing License Agreement  
   SONOMAX HEARING HEALTH INC.  Existing License Agreement  
   PANASONIC  Commercial negotiations underwayExhibit 10.1  STRATEGIC ALLIANCE AGREEMENT  This Strategic Alliance Agreement (this “Agreement”), effective as of 15 April, 2009 (the “Effective Date”), is by and between Information 
System Associates, Inc., a Florida Corporation whose registered office is 1151 Southwest 30th Street, Suite E, Palm City FL, 34990 (“ISA”) and Rubicon Software Group plc, a company registered under the laws of England and Wales (Registered Company No. 5701810) whose registered office is Rubicon House, Guildford Road, West End, Surrey GU24 9PW (“Rubicon”).  Background  WHEREAS, Rubicon desires to engage ISA as Rubicon’s exclusive agent in the United States for the purposes of reselling Rubicon’s software and services;  WHEREAS, ISA desires to engage Rubicon as its software development partner and to provide various consulting services in Europe; and  WHEREAS, ISA and Rubicon desire to enter into this Agreement for the purpose of granting ISA the right to distribute such products and services and Rubicon to supply such services.  NOW, THEREFORE, the parties hereto, intending to be legally bound, hereby agree as hereinafter set forth.  1. DEFINITIONS.    1.1 Confidential Information shall mean all non-public information of a Party, which is disclosed to the other Party hereunder, including, without limitation, trade secrets, technical information, business information, sales information, marketing information, customer-buying patterns, algorithms, customer and potential customer lists and identities, product sales plans, sublicense agreements, inventions, developments, discoveries, software, know-how, methods, techniques, formulae, data, processes and other trade secrets and proprietary ideas, whether or notprotectable under patent, trademark, copyright or other areas of law, and any other information marked as “proprietary” or “confidential” at the time of disclosure. Notwithstanding the foregoing, “Confidential Information” shall not include any information that (a) was or has become publicly available without restriction through no fault of the receiving Party or its employees or agents; (b) is received without restriction from a third party that, to the best knowledge of the receiving Party, did not have an obligation of confidentiality to the disclosing Party; (c) was rightfully in possession of the receiving Party without restriction prior to its disclosure by the other Party; or (d) was independently developed by employees of the receiving Party that had no knowledge of or access to such information, as evidenced by written records of the receiving Party.   1.2 Contract Services shall mean various software development and implementation services to be provided by Rubicon as described in one or more Statement(s) of Work (“SOW”) that reference this Agreement in a form substantially similar to that set forth in Exhibit A.   1.3 Day Rate shall mean the daily rate at which Rubicon will provide services to ISA or ISA Clients. The Day Rate for each type of service provided will be as per the rate card set out in Exhibit C, such rates to be subject to annual review by the Parties on the anniversary of this Agreement provided that such rates may be reviewed on an ad hoc basis at any time should the Parties become aware of specific information which impacts on the validity or feasibility of the Day Rate.   1.4 Commission Rate shall mean the commission rate which will be used to calculate any amount which Rubicon will pay to ISA after the provision of Rubicon Offerings to ISA Clients as set forth in Exhibit D, such rates to be subject to annual review by the Parties on the anniversary of this Agreement provided that such rates may be reviewed on an ad hoc basis at any time should the Parties become aware of specific information which impacts on the validity or feasibility of the Commission Rate.   1.5 Documentation shall mean the printed and/or electronic materials relating to the Rubicon Offerings, including, but not limited to, user’s manuals and technical manuals as may be provided by Rubicon to ISA.   1.6 Due Diligence Services shall have the meaning set forth in Section 3.3, below.   1.7 End User shall mean a party that obtains a license to use the Rubicon Offerings from ISA or a customer of ISA under the terms and conditions set forth herein.   1.8 Intellectual Property shall mean any and all trade secrets, patents, copyrights, trademarks, service marks, trade names, domain names, trade dress, URLs, brand features, know-how and similar rights of any type under the laws of any applicable governmental authority, including, without limitation, all applications and registrations relating to any of the foregoing..   1.9  ISA Client shall mean: (i) an entity to which Rubicon provides services pursuant to Section 3, below; and (ii) an entity that ISA has consulted with before or during the Term regarding the provision of goods or services.   1.10 Notice shall have the meaning ascribed thereto in Section 11.5.   1.11 Parties shall mean ISA and Rubicon.   1.12 Rubicon Offerings shall mean (i) the software programs described in Exhibit B, (as may be updated from time to time) in object code format, and including all corrections, updates, modifications and enhancements to such software that may be provided to ISA by Rubicon from time to time; and (ii) software development services.   1.13 Term shall have the meaning ascribed thereto in Section 6.1.   1.14 Share Subscription Agreement shall mean the agreement in the agreed form between ISA and Rubicon whereby ISA shall subscribe for shares in Rubicon.   2. ISA RESELLER SERVICES.2.1 Rubicon hereby grants to ISA during the Term (as defined below) and subject to the exclusions described in 2.4 below an exclusive,non-transferable license in the United States to market, sell, use, display, perform, sublicense and distribute the Rubicon Offerings, the Documentation and, subject to Section 2.2, any upgrades thereto, subject to the conditions set forth in this Agreement. As used in this Section 2.1, the terms “market,” “sale,” “sell,” “distribute,” and “sublicense” shall mean the sale of a license having a term of at least one year to an End User pursuant to which the End User may use, perform and display the Rubicon Offerings and the Documentation. This license is granted to ISA for the marketing, sale and distribution of the Rubicon Offerings and the Documentation to End Users for their internal use only.   2.2 Rubicon hereby grants to ISA during the Term and subject to the exclusions described in 2.4 below an exclusive, non-transferable license in the United States to grant licenses to use, display, perform and distribute the Rubicon Offerings and the Documentation to other resellers, including, but not limited to, distributors, Original Equipment Manufacturers, system integrators and Value-Added Resellers, for further sale and distribution to End Users for their use as described above, subject to the conditions set forth in this Agreement.   2.3 The license grants described in Sections 2.1 and 2.2 shall include all upgrades to the Rubicon Offerings and the Documentation. Rubicon shall promptly notify ISA of each such upgrade to the Rubicon Offering and the Documentation which will be available to ISA under this Agreement.   2.4 The exclusive licenses described in Sections 2.1 and 2.2 shall not include customer agreements, sales of Rubicon Offerings and/or Documentation which arise through customer marketing and distribution arrangements which are in place between Rubicon and third parties at the date hereof. Rubicon agrees not to enter into any additional agreement to sell Rubicon Offerings or Documentation or additional distribution arrangements with third parties in the United States from the date hereof without the prior written approval of ISA, which approval shall not be unreasonably withheld.   3. RUBICON SERVICES.    3.1 Subject to the terms and conditions of this Agreement, Rubicon shall provide the Contract Services, as agreed between ISA to Rubicon in the relevant SOW, to ISA’s reasonable satisfaction. The Contract Services shall be performed at the facilities and location reasonably designated by ISA (with appropriate agreements in place to ensure reasonable reimbursement to Rubicon of out-of-pocket expenses). Upon written request of ISA, Rubicon shall provide biweekly written reports describing the progress made in performing the Contract Services since the preceding report, and the progress expected to be made in the next succeeding period.   3.2 ISA may, at any time, request reasonable additions, deletions, or revisions in the Contract Services by delivering a change order to Rubicon. Upon receipt of a change order from ISA, Rubicon shall notify ISA of any price revisions which are associated with the change order and if ISA agree to the revised charges, the parties shall proceed with the Contract Services as revised. All such Contract Services shall be executed under the terms and conditions of this Agreement and the applicable SOW (as revised by the change order). If any change order causes an increase or decrease in the cost of the Services to be performed or scheduled completion date or expenses incurred or to be incurred by Rubicon, an equitable adjustment will be made by mutual agreement.   3.3 From time to time and as agreed between ISA and Rubicon, Rubicon shall provide due diligence services regarding the software and other technology issues of potential merger and acquisition, joint venture or other strategic partner companies (a “Target Company”) that may be identified by ISA (the “Due Diligence Services”). In connection with any such Due Diligence Services, Rubicon agrees that it shall abide by the reasonable terms of any third party confidentiality agreement that may be entered into by ISA with any such Target Company on the same terms as are applicable to ISA. Rubicon’s fees for such due diligence services (the “Due Diligence Fees”) shall be at agreed upon rates which shall not exceed the Day Rate. ISA agrees to reimburse Rubicon upon provision of valid receipts for Rubicon’s reasonable out-of-pocket expenses incurred in the provision of the Due Diligence Services.   4. COMMERCIAL TERMS.   4.1 ISA Fees. In consideration of the services set forth in Section 2, ISA will sell or market the Rubicon Offerings at pre agreed list prices, and shall receive a commission on the gross revenues paid for the Rubicon Offerings less VAT if applicable of the Commission Rate; provided, however, that in the event that Rubicon proposes to charge at other than the Day Rate for the software development the Parties shall use all reasonable endeavours to agree an equitable adjustment to the Commission Rate.   4.2 Rubicon Fees.   4.2.1 In consideration of the Contract Services, Rubicon will receive payment as set forth in an SOW of its undisputed invoices (or its pro rata share) that it has submitted to ISA immediately following receipt of payment by ISA from the ISA Client.   4.2.2 In consideration of the Due Diligence Services, ISA shall pay to Rubicon the Due Diligence Fees within 30 days of receipt from Rubicon of an invoice and any previously requested supporting documentation, including time charges.   4.2.3 In addition to the payments set forth in sections 4.2.1 and 4.2.2, above, ISA will pay Rubicon 30% of ISA’s profits (defined as gross revenues less costs directly incurred in the generation of such revenues) on projects for which Rubicon has provided Contract Services after ISA has recouped any directly attributable start-up costs with respect to such project up to a cumulative maximum of £100,000 of such costs associated with all such projects from the date of this agreement.   4.3 Target Revenues. ISA confirms that its current intention is to try and procure that Rubicon’s total gross revenues less VAT if applicable relating to the provision of services to ISA Clients or to clients referred to Rubicon by ISA will exceed £1million per annum. The Parties acknowledge that any failure by ISA to procure such revenues for Rubicon will not constitute a breach of this Agreement and ISA will have no liability for any such failure or otherwise in connection with this clause 4.3.   4.4 Payment terms. Each party shall account to the other on a monthly basis in respect of all sales and revenue received, and payments shall be made within 30 days of receipt of a properly valid invoice.   4.5 Audits. Each Party shall retain the financial records relating to all payments owed and/or paid under this Agreement for a period of six years from the date such payment obligation arose.   4.6 Purchase of Rubicon Shares. This Agreement is conditional upon ISA and Rubicon entering into the Share Subscription Agreement.5. INTELLECTUAL PROPERTY.   5.1 ISA’s Intellectual Property. As between ISA and Rubicon, all right, title and interest in and to Intellectual Property which is created by or provided by ISA, including, without limitation, as they may be part of or incorporated into any Contract Service or otherwise used by Rubicon, all goodwill associated therewith and the copyright and all other Intellectual Property rights inherent in or appurtenant to the foregoing are and shall be and shall remain the sole property of ISA. Rubicon acknowledges that neither it nor any other persons or entities will by virtue of this Agreement acquire any ownership interest in the Intellectual Property of ISA, or the Intellectual Property rights inherent in or appurtenant to any of the foregoing, or any associated goodwill and that its rights thereunder are strictly limited to those specifically granted in this Agreement.Rubicon shall not contest ownership by ISA of any of the foregoing. No right, license, release or other right is granted by implication, estoppel or otherwise by ISA to Rubicon or any of Rubicon’s affiliates except for the rights and licenses expressly granted under this Agreement. Except for the rights and licenses expressly granted under this Agreement, ISA reserves all rights to the Intellectual Property of ISA, including, without limitation, translation rights, rights of modification and rights to source code.   5.2 Works-for-hire.   5.2.1 As regards Intellectual Property created by Rubicon, Rubicon acknowledges and agrees that those Works, as defined below, shall belong exclusively to ISA subject to payment in accordance with clause 4.2. Works means, collectively, any work product (of any type), software, developments, processes, improvements, and all works of authorship, in whole or in part, whether patentable or not and whether copyrightable or not created as services provided directly to ISA or on behalf of ISA by Rubicon, which (i) are conceived or made by Rubicon, its employees, contractors, consultants or agents during the Term and relate directly to the business in which ISA and Rubicon(during the Term byISA) are, had been or were proposing to be engaged in; or (ii) are conceived or made by Rubicon, its employees, contractors, consultants or agents during or after the Term and are made through the use of any ISA Confidential Information, or which result from any work performed by Rubicon, its employees, contractors, consultants or agents for ISA. It is agreed that the terms under which Rubicon agrees to work with ISA, including the Day Rate, reflect and will reflect any value or potential value of Intellectual Property created by Rubicon on behalf of ISA.   5.2.2 Rubicon shall make full and prompt disclosure to ISA of all Works as they are made (whether or not conceived or made jointly with others). To the extent copyrightable, all Works shall be deemed to be “works for hire” and ISA shall be deemed to be the author thereof under the U.S. Copyright Act. With respect to Works that do not constitute “works for hire,” Rubicon, its employees, contractors, consultants and agents do hereby assign to ISA or its designee all of their respective right, title and interest in and to such Works and all related patents, patent applications, copyrights and copyright applications and does hereby agree that these obligations are binding upon their respective assigns, executors, administrators and other legal representatives. Rubicon, its employees, contractors, consultants and agents do hereby waive all claims to moral rights to the Works. During the Term and continuing thereafter, Rubicon does hereby agree to take all such further reasonable actions on its own behalf and with respect to its employees, contractors, consultants and agents, including without limitation, the execution and delivery of copyright applications, patent applications, declarations, oaths, formal assignments, assignments of priority rights, and powers of attorney, which ISA may deem necessary or desirable in order to protect its rights and interests in and to the Works. If ISA is unable, after reasonable effort, to secure any necessary signature on any such documents, any executive officer of ISA shall be entitled as agent and attorney-in-fact to execute such documents.   5.3 Rubicon’s Intellectual Property. As between ISA and Rubicon, all right, title and interest in and to the Rubicon Offerings and, subject to the provisions of Section 5.2, any other Intellectual Property of Rubicon, including, without limitation, as used by Rubicon or ISA hereunder, all goodwill associated therewith and the copyright and all other Intellectual Property rights inherent in or appurtenant to the foregoing are and shall be the sole property of Rubicon. ISA acknowledges that, except as otherwise set forth herein, neither it nor any other persons or entities will by virtue of this Agreement acquire any ownership interest in such Intellectual Property, or the Intellectual Property rights inherent in or appurtenant to any of the foregoing, or any associated goodwill and that its rights thereunder are strictly limited to those specifically granted in this Agreement. ISA shall not contest ownership by Rubicon of any of the foregoing. No license, release or other right is granted by implication, estoppel or otherwise by Rubicon to ISA or any of ISA’s affiliates except for the rights and licenses expressly granted under this Agreement. Except for the rights and licenses expressly granted herein, Rubicon reserves all rights to the Rubicon Service Offerings, including, without limitation, translation rights, rights of modification and rights to source code.   6. TERM AND TERMINATION; WITHDRAWAL.   6.1 Term. Unless terminated sooner, the term of this Agreement shall begin on the Effective Date and continue for three (3) years thereafter (the “Initial Term”) and shall automatically renew for additional one (1) year terms on the terms and conditions set forth herein (each a “Renewal Term” and collectively, the “Term”) unless either party gives the other Party Notice of its intention to terminate this Agreement ninety (90) days before the end of the Initial Term or Renewal Term, if any.   6.2 Termination.   6.2.1 For Cause. Either Party may serve Notice to the other Party to terminate this Agreement immediately in the event any material breach of a material provision of this Agreement by such other Party remains uncured 30 days in the case of a breach of a payment obligation, or 45 days for all other material breaches, after notice of such breach was received by such other Party.   6.2.2 For Bankruptcy. Either Party may terminate this Agreement immediately upon Notice to the other Party in the event the other Party (a) permanently ceases operations, (b) becomes or is declared insolvent or bankrupt, (c) is the subject of any proceeding related to its liquidation or insolvency (whether voluntary or involuntary) that is not dismissed within 90 calendar days or (d) makes an assignment for the benefit of creditors.   6.2.3 For Contesting Intellectual Property Rights. Either Party may terminate this Agreement upon ten Business Day’s Notice to the other Party in the event the other Party contests or challenges to a material degree any of the other Party’s Intellectual Property rights referred to in Sections 5.1, and 5.3, respectively.   7. NON-COMPETITION.   7.1 During the period beginning on the Effective Date and ending on the later of (i) the end of the Initial Term and (ii) the date falling two years after completion of the most recent services provided by Rubicon under clause 7 (the “Non-Competition Period”) and in the ISA Geographic Area, as defined below, Rubicon agrees not to in any capacity, engage or have a financial interest in any ISA Competing Business, as defined below, or provide managerial, supervisory, administrative, or financial services relating to any ISA Competing Business, including making available any information or funding to any such ISA Competing Business. Further, during the Non-Competition Period, Rubicon shall not solicit anyemployee of ISA or any employee of any ISA Client. If a court determines that the foregoing restrictions are too broad or otherwise unreasonable under applicable law, including with respect to time or space, the court is hereby requested and authorized by the Parties to revise the foregoing restrictions to include the maximum restrictions allowable under applicable law. Rubicon acknowledges, however, that the Parties have negotiated this Section and that the time limitations, the limitation on activities and the geographic limitations are reasonable in light of the circumstances pertaining to ISA and this transaction. “ISA Competing Business” means any person or entity of any type whatsoever engaged in the business ofproviding data centre audit and data centre optimization services. “ISA Geographic Area” means worldwide.   7.2 During the period beginning on the Effective Date and ending on the later of (i) the end of the Initial Term and (ii) the date falling two years after completion of the most recent services provided by Rubicon under clause 7 (the “Non-Competition Period”) and in the Rubicon Geographic Area, as defined below, ISA agrees not to in any capacity, engage or have a financial interest in any Rubicon Competing Business, as defined below, or provide managerial, supervisory, administrative, or financial services relating to any Rubicon Competing Business, including making available any information or funding to any such Rubicon Competing Business. Further, during the Non-Competition Period, ISA shall not solicit any employee of Rubicon or any employee of any Rubicon Client. If a court determines that the foregoing restrictions are too broad or otherwise unreasonable under applicable law, including with respect to time or space, the court is hereby requested and authorized by the Parties to revise the foregoing restrictions to include the maximum restrictions allowable under applicable law. ISA acknowledges, however, that theParties have negotiated this Section and that the time limitations, the limitation on activities and the geographic limitations are reasonable in lightof the circumstances pertaining to Rubicon and this transaction. “Rubicon Competing Business” means any person or entity of any type whatsoever engaged in the business of providing software development services for clients. “Rubicon Geographic Area” means Europe.   7.3 In the event that ISA wishes to carry out any software development work of any nature during the Non-Competition Period, it will notify Rubicon of the same and allow Rubicon the opportunity to pitch for such work.     8. CONFIDENTIALITY.   8.1 Confidentiality Obligations. Except as permitted elsewhere under this Agreement, each Party agrees (a) to take Reasonable Steps (as defined below) to receive and maintain the Confidential Information of the other Party in confidence, (b) to take Reasonable Steps (as defined below) not to disclose such Confidential Information to any third parties other than with the written consent of the disclosing Party and (c) to promptly notify the other Party upon learning of any law, rule, regulation or court order that purports to compel disclosure of any Confidential Information of the other Party and to reasonably cooperate with the other Party in the exercise of the other Party’s right to protect the confidentiality of such Confidential Information, including, but not limited to, seeking to dispute the cause of such disclosure and/or to receiveconfidential treatment for the Confidential Information disclosed as a result of such cause. Neither Party shall use all or any part of the Confidential Information of the other Party for any purpose other than to perform its obligations, or the exercise of such Party’s rights and licenses, under this Agreement. Each Party shall (i) limit access to any Confidential Information of the other Party received by it to its employees, contractors, consultants and agents who have a need-to-know in connection with the performance of such Party’s obligations, or the exercise of such Party’srights, under this Agreement; and (ii) advise such employees, contractors, consultants and agents of the confidential nature thereof and of the obligations set forth in this Agreement and similarly bind them in writing. Each Party shall be responsible for any breaches of the obligations of confidentiality and restricted use set forth herein by any employee, contractor, consultant or agent to whom such Party disclosed any Confidential Information of the other Party. As used herein, “Reasonable Steps” means using at least the same degree of care that the receiving Party uses to protect its own Confidential Information, and, in any event, no less than reasonable care.    8.2 Exclusions. Nothing contained herein shall prevent a Party from disclosing Confidential Information pursuant to any applicable law or by a governmental order, decree, regulation, rule, process or court order; provided, however, that such Party complies with the notice provisions of Section 8.1(c) to the extent permissible under applicable laws, rules, regulations or court orders. Such disclosure shall not of itself alter the status of such information hereunder for all other purposes as Confidential Information.   8.3 Provisions of this Agreement. Each Party agrees that the provisions of this Agreement shall be treated as Confidential Information and that no reference shall be made thereto without the prior written consent of the other Party (which consent shall not be unreasonably withheld) except (a) to its accountants, banks, financing sources, lawyers and other professional advisors, provided that such parties undertake in writing (or are otherwise bound by rules of professional conduct) to keep such information strictly confidential, (b) in connection with theenforcement of this Agreement, (c) in connection with a merger, acquisition or proposed merger or acquisition, or (d) pursuant to joint press releases prepared in good faith or (e) as permitted under Section 8.2. The Parties will consult with each other, in advance, with regard to the terms of all proposed press releases, public announcements and other public statements with respect to the transactions contemplated hereby.   8.4 Termination. Upon termination of this Agreement, all Confidential Information shall be returned to the disclosing Party or destroyed unless otherwise specified or permitted elsewhere under this Agreement or as otherwise mutually agreed upon by the Parties. The confidentiality obligations contained in this Section 8 shall survive termination of this Agreement for a period of three years.   8.5 Injunction. Each Party acknowledges and agrees that the provisions of this Section 8 are reasonable and necessary to protect the other Party’s interests in its Confidential Information, that any breach of the provisions of this Section 8 may result in irreparable harm to such other Party, and in such event the exact amount of damages is now and will be difficult to ascertain and the remedies at law for any such failure would not be reasonable or adequate. Accordingly, in the event of any breach or threatened breach of the provisions of this Section 8 by a Party hereto, the other Party, in addition to any other relief available to it at law, in equity or otherwise, shall be entitled to seek temporary and permanent injunctive relief restraining the breaching Party from engaging in and/or continuing such conduct, without the necessity of proving actual damages or posting a bond or other security. Further, the prevailing Party in any such injunctive action shall be entitled to payment from the other Party of the reasonable attorneys’ fees and costs incurred in such proceeding.   9. REPRESENTATIONS AND WARRANTIES.   9.1 By ISA. ISA hereby represents, covenants and warrants to Rubicon that:   9.1.1 It has the corporate power to enter into this Agreement;   9.1.2 It has the right to perform its obligations this Agreement;   9.1.3 When executed and delivered by it, this Agreement will constitute a legal, valid and binding obligation of it, enforceable against it in accordance with this Agreement’s provisions;9.1.4 ISA shall perform all services required to be performed by ISA under this Agreement in a professional manner and all ISA personnel assigned to provide such services shall be duly qualified to provide such services; and   9.1.5 While at Rubicon’s facilities, all ISA employees, contractors, consultants and agents shall observe and follow Rubicon’s reasonable work rules, policies and standards as the same are communicated to ISA or such persons in writing, including, without limitation, those rules, policies and standards of Rubicon relating to security of and access to its facilities and to its telephone systems, electronic mail systems and computer systems. ISA shall cooperate with Rubicon in promptly removing from the Rubicon premises any of such persons who violates any of the foregoing work rules, policies or standards of Rubicon.   9.2 By Rubicon. Rubicon hereby represents, covenants and warrants to ISA that:   9.2.1 It has the corporate power to enter into this Agreement;   9.2.2 It has the right to perform its obligations this Agreement;   9.2.3 When executed and delivered by it, this Agreement will constitute a legal, valid and binding obligation of it, enforceable against it in accordance with this Agreement’s provisions;   9.2.4 Rubicon shall perform all services required to be performed by Rubicon under this Agreement in a professional manner and all Rubicon personnel assigned to provide such services shall be duly qualified to provide such services; and   9.2.5 While at ISA’s facilities, all Rubicon employees, contractors, consultants and agents shall observe and follow ISA’s reasonable work rules, policies and standards as the same are communicated to Rubicon or such persons in writing, including, without limitation, those rules, policies and standards of ISA relating to security of and access to its facilities and to its telephone systems, electronic mail systems and computer systems. Rubicon shall cooperate with ISA in promptly removing from the ISA premises any of such persons who violates any of the foregoing work rules, policies or standards of ISA.   10. DISCLAIMER OF WARRANTY, LIMITATION OF LIABILITY AND INDEMNIFICATION.   10.1 Disclaimer of Warranties. EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, ISA AND RUBICON HEREBY DISCLAIM ALL WARRANTIES, EXPRESS, IMPLIED OR STATUTORY, WITH RESPECT TO ANY AND ALL ISA AND RUBICON SERVICES RESPECTIVELY, INCLUDING BUT NOT LIMITED TO ANY IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, TITLE AND NON-INFRINGEMENT.    10.2 Limitation of Liability. EXCEPT IN CONNECTION WITH A BREACH BY EITHER PARTY OF SECTION 8, NEITHER PARTY WILL BE LIABLE FOR ANY SPECIAL, INDIRECT, CONSEQUENTIAL, EXEMPLARY, PUNITIVE OR INCIDENTAL DAMAGES ARISING OUT OF OR RELATED TO THIS AGREEMENT, HOWEVER CAUSED AND UNDER ANY THEORY OF LIABILITY (INCLUDING NEGLIGENCE), EVEN IFSUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. ISA SHALL NOT BE LIABLE FOR ANY LOSS OF DATA, OR ANY INTERRUPTION OF OR DELAY IN PROVIDING THE SERVICES. EXCEPT IN CONNECTION WITH A BREACH BY EITHER PARTY OFSECTION 8, EACH PARTY’S LIABILITY FOR DAMAGES HEREUNDER (OTHER THAN IN RESPECT OF ANY CLAIM FOR MONIES DUE) SHALL NOT EXCEED £200,000.   10.3 Indemnification by Rubicon. Rubicon shall indemnify and hold harmless ISA and its officers, directors, employees and agents from and against any and all losses, claims, damages, liabilities, obligations, judgments, awards, costs, expenses (including reasonable attorneys’ fees) and disbursements, including without limitation, the costs, expenses and disbursements, as and when incurred, of preparing or defending any action, suit, proceeding or investigation asserted by a third party (“Losses”), caused by, based upon, arising out of or in connection with a claim 
by a third party that the Rubicon Offerings infringe a 3rd party’s exiting intellectual property rights or due to the gross negligence, recklessness or intentional misconduct on the part of Rubicon or its affiliates or its officers, directors, employees, agents, consultants or users.   10.4 Indemnification by ISA. ISA shall indemnify and hold harmless Rubicon and its officers, directors, employees and agents from and against any and all losses, claims, damages, liabilities, obligations, judgments, awards, costs, expenses (including reasonable attorneys’ fees) and disbursements, including without limitation, the costs, expenses and disbursements, as and when incurred, of preparing or defending any action, suit, proceeding or investigation asserted by a third party (“Losses”), caused by, based upon, arising out of or in connection with ISA’s role in the provision of the Rubicon Offerings or the gross negligence, recklessness or intentional misconduct on the part of ISA or its affiliates or its officers, directors, employees, agents, consultants or users.   10.5 Indemnitee Obligations. Each person seeking to be reimbursed, indemnified, defended and/or held harmless under Sections 10.3 or 10.4 (each, an “Indemnitee”) shall (a) provide the Party obliged to indemnify such Indemnitee with prompt written notice of any claim, suit, demand or other action for which such Indemnitee seeks to be reimbursed, indemnified, defended or held harmless (each, a “Claim”), which notice shall include a reasonable identification of the alleged facts giving rise to such Claim; (b) grant such Party reasonable authority and control over the defense and settlement of any such Claim; and (c) reasonably cooperate with such Party and its agents in defense of any such Claim, at such Party’s cost. Each Indemnitee shall have the right to participate in the defense of any Claim for which such Indemnitee seeks to be reimbursed, indemnified, defended or held harmless, by using attorneys of such Indemnitee’s choice, at such Indemnitee’s expense. Notwithstanding anything to the contrary herein, any settlement of a Claim for which any Indemnitee seeks to be reimbursed, indemnified, defended or held harmless underthis Section 10 shall be subject to the prior written approval of such Indemnitee, such approval not to be unreasonably withheld, conditioned or delayed.   10.6 Essential Part of Bargain. The Parties acknowledge that the disclaimers and limitations set forth in this Section 10 are an essential element of this Agreement between the Parties and that the Parties would not have entered into this Agreement without such disclaimers and limitations.   11. MISCELLANEOUS.   11.1 Governing Law and Jurisdiction. This Agreement shall be governed by and interpreted under the laws of the State of Florida, USA,. The state and federal courts in the jurisdiction in which Palm City, Florida is located shall have non- exclusive jurisdiction for the purposes of adjudicating any controversy or claim between the parties concerning any breach or alleged breach of this Agreement or performance or nonperformance of any obligation under this Agreement, save that the parties agree that any dispute or claim concerning either clause 8 Confidentiality or clause 5 Intellectual Property may be raised in any appropriate jurisdiction where the breach or alleged breach has occurred.11.2 No Assignment. Neither Party shall transfer, assign or cede any rights or delegate any obligations hereunder, in whole or in part, whether voluntarily or by operation of law, without the prior written consent of the other Party, which consent may be withheld at the other Party’s reasonable business discretion; provided, however, that in connection with a merger, sale or transfer of substantially all of the assets or stock of one of the Parties that Party may provide for the assignee to be bound by the terms hereof. This Agreement shall inure to the benefit of, and shall be binding upon, the Parties and their respective successors and permitted assigns.   11.3 Good Faith. The Parties undertake to act in good faith, consistent with their respective rights and obligations set forth in this Agreement.   11.4 Independent Contractors. In connection with this Agreement, each Party is an independent contractor. This Agreement does not, and shall not be construed to, create an employer-employee, agency, joint venture or partnership relationship between the Parties. Neither Party shall have any authority to act for or to bind the other Party in any way, to alter any of the provisions of any of the other Party’s standard forms of invoices, sales agreements, warranties or otherwise, to warrant or to execute agreements on behalf of the other, or to represent that it is in any way responsible for the acts, debts, liabilities or omissions of the other Party.   11.5 Notices. All notices, reports, payments and other communications required or permitted to be given under this Agreement (each, a “Notice”) shall be in writing and shall be given either by personal delivery against a signed receipt, by express delivery using an internationally recognized express courier, or by email (with confirmation of receipt). All Notices shall be properly addressed as follows, or to such otheraddresses as may be specified in a Notice given hereunder:   If to ISA: with a copy to:  Attn: Joseph Coschera Attn: Daniel J. Dugan, Esq. 
1151 SW 30th St., Spector Gadon & Rosen, P.C. 
Palm City, Florida 34990 1635 Market St., 7th Floor 
joe_coschera@isa-inc.net Phila., PA 19103 ddugan@lawsgr.com  If to Rubicon: with a copy to:  Attn: Alistair Hancock Attn: Andrew Kirby Rubicon House Rubicon House Guildford Road Guildford Road West End, Surrey GU24 9PW West End, Surrey, GU24 9PW   A Notice shall be deemed to be effective upon personal delivery or, if sent via overnight delivery, upon receipt thereof. A Notice sent via email is deemed effective on the same day (or if such day is not a Business Day, then on the next succeeding Business Day) if the confirmation that such email was received by the other Party is received before 5:00 p.m. prevailing Eastern time and on the next day (or if such day is not a Business Day, then on the next succeeding Business Day) if the confirmation that such email was received by the other Party is received on or after 5:00 p.m. prevailing Eastern time.  11.6 Amendment or Modification. No subsequent amendment, modification or waiver of any of the provisions of this Agreement shall be effective unless in writing and signed by the Parties.   11.7 Entire Agreement. This Agreement sets out the entire agreement between the Parties with respect to the subject matter of this Agreement and supersedes all prior agreements, proposals, arrangements and communications, whether oral or written, with respect to the subject matter hereof.   11.8 Severability. If any provision of this Agreement is held by a tribunal of competent jurisdiction to be illegal, invalid, or otherwise unenforceable in any relevant jurisdiction, then to the fullest extent permitted by law (a) the same shall not affect the other provisions of this Agreement, (b) such provision shall be deemed modified to the extent necessary in the tribunal’s opinion to render such provision enforceable, and the rights and obligations of the Parties shall be construed and enforced accordingly, preserving to the fullest extent the intent andagreements of the Parties set forth herein and (c) such finding of invalidity, illegality or unenforceability shall not affect the validity, legality orenforceability of such provision in any other relevant jurisdiction.   11.9 No Waiver. Failure to enforce any provision of this Agreement is not a waiver of future enforcement of that or any other provision.No provision of this Agreement will be deemed waived and no breach excused unless such waiver or excuse is in writing and signed by the Party against whom enforcement of such waiver or excuse is sought.   11.10 Survival. Sections 5, 7, 8, 10 and 11; any payment obligations of the Parties hereunder accrued prior to the date of termination; and any other provision herein expressly surviving termination or necessary to interpret the rights and obligations of the Parties in connection with the termination of this Agreement will survive the termination of this Agreement.   11.11 No Third Party Beneficiaries. Except as set forth in Sections 10.3 and 10.4, nothing in this Agreement is intended to confer benefits, rights or remedies unto any person or entity other than the Parties and their permitted successors and assigns. Without limiting the generality of the foregoing, the clients, customers, shareholders or End Users shall not be deemed to be third party beneficiaries of this Agreement or have any other contractual relationship with ISA by reason of this Agreement.   11.12 Captions and Construction. The headings appearing at the beginning of the Sections contained in this Agreement have been inserted for identification and reference purposes only and shall not be used to determine the construction or interpretation of this Agreement.The nomenclature of the defined terms in this Agreement shall only be used for the construction of this Agreement, and are not to be used for any other purpose, including, but not limited to, interpretation for accounting purposes. The parties acknowledge that both ISA and Rubicon participated in the drafting of this Agreement and agree that any rule of law or legal decision that may or would require interpretation of any alleged ambiguities in this Agreement against the party that drafted it has no application and is expressly waived.   11.13 Further Assurances. Each Party shall perform such acts, execute and deliver such instruments and documents, and do all such other things as may be reasonably necessary to accomplish the transactions contemplated in this Agreement.11.14 Language. This Agreement is in the English language only, which language shall be controlling in all respects, and all versions hereof in any other language hereof shall be for accommodation only and shall not be binding upon the Parties. All communications and notices to be made or given pursuant to this Agreement shall be in the English language. All words used in this Agreement will be construed to be of such gender or number as the circumstances require. Unless otherwise expressly provided, the word “including” does not limit the preceding word or terms.   11.15 Force Majeure. Neither Party shall be held to be in breach of this Agreement by reason of a force majeure event, including, but not limited to, act of God, delay in transportation, fire, flood, earthquake, storm, war, act of a public enemy, civil commotion or any law, rule, regulation, order or other action by any public authority or any other matter reasonably beyond a Party’s control (a “Force Majeure Event”). To the extent failure to perform is caused by such a force majeure event, such Party shall be excused from performance hereunder so long as such event continues to prevent such performance, and provided the non-performing Party takes all reasonable steps to resume full performance.   11.16 Compliance with Laws. Each Party shall comply with all prevailing laws, rules and regulations and obtain all necessary approvals, consents and permits required by the applicable agencies of the government of the jurisdictions that apply to its activities or obligations under this Agreement.   11.17 Public Announcements. Any public announcement or similar publicity with respect to this Agreement or the transactions contemplated hereby shall be issued only after consultation with the other party hereto regarding the content of any such announcement or publicity. The parties recognize that, as publicly traded companies, such consultations will be constrained by applicable requirements relating to the disclosure of material information on the part of such party under applicable securities laws.   11.18 Execution in Counterparts, Facsimiles. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original and all of which together shall constitute one and the same instrument. This Agreement shall become binding when any one or more counterparts hereof, individually or taken together, bear the signatures of both Parties hereto. For the purposes hereof, a facsimile copy of this Agreement, including the signature pages hereto, shall be deemed an original.   IN WITNESS WHEREOF, the Parties to this Agreement by their duly authorized representatives have executed this Agreement as of the date first written above.   Information Systems Associates, Inc. Rubicon Software Group plc By: /s/ Joseph P. Coschera By /s/ Alistair C. Hancock: Name: Joseph P. Coschera Name: Alistair C. Hancock Title: President and CEO Title: CEOEXHIBIT 10.02
STRATEGIC ALLIANCE AGREEMENT
THIS AGREEMENT is made on this 1 st day of December, 2015 by and between BOSCH INTERNATIONAL, LLC, a Nevada
Limited Liability Company located at 3753 Howard Hughes Pkwy #200 Las Vegas NV 89169 (hereinafter "CLIENT"), and BOSCH
TECHNOLOGIES, LLC, a Nevada Limited Liability Company located at 6795 Edmonds Street 3rd  Floor, Las Vegas, NV 89118
(hereinafter "BOSCH").
1. PARTIES:
a) BOSCH TECHNOLOGIES, LLC ("BOSCH"); and
b) BOSCH INTERNATIONAL, LLC ("CLIENT")
2. STRATEGIC ALLIANCE: Title of this relationship and agreement between BOSCH and CLIENT are detailed as follows: Both
CLIENT and BOSCH act as two separate and individual companies operating independently of each other. BOSCH and CLIENT
do not have any controlling interest of each other and are independently run and responsible for all of operations, reporting,
taxes, liabilities and relationships. BOSCH reserves the right in keeping product generation and delivery confidential in which is
not available for any type of audit. BOSCH reserves the right to share rights given unless it disrupts and/or interferes with
CLIENTS business and/or productivity.
3. PRODUCT: "Product " BOSCH" has acquired, developed and continues to develop, a business using proprietary "Nano
Printed Lights," and associated other products (the "Products"). BOSCH calls this Nano Printed Lights product "Printed
LightSheets" which is considered the " Product Name".
4. PRODUCT NAME: "PRINTED LIGHT SHEETS" is the name and title CLIENT will use to market for Nano Printed Lights.
5. RIGHTS GRANTED: BOSCH hereby grants CLIENT the "Exclusive Distribution License Rights" sell and distribute the
Products within the "Territory". BOSCH hereby grants CLIENT un-exclusive "Reserved Rights" to sell and distribute the
"Product" within the "Territory".
6. EXCLUSIVE RIGHTS: Bosch hereby grants to Client the exclusive rights to sell and distribute the Product, subject to the
Territory as set forth below, to certain select companies in the Automotive Industry, each of which shall be approved by Bosch in
writing as requested by the Client on a case by case basis.
7. TERRITORY: United States of America and Canada, excluding the US Virgin Islands
8. RESERVED RIGHTS: All business, locations, entities, people, etc... without any limitations. This is in concert and approval with
BOSCH and is limited to any and all of BOSCH's current clients. CLIENT will not exercise nor authorize any other Party to to take
any action which would reasonably be deemed to derogate from, impair or compete with the Exclusive Rights, Reserved rights,
and Rights Granted herein granted.
(i) COST OF PRODUCT: Cost is based upon square inch and reserved confidentially.
(ii) COST OF PRODUCT TO MARKET: The established price for the market place will be negotiated confidentially but
will follow the max and min limitations allowed. Special pricing for large orders and/or custom orders will need written
approval (email) from BOSCH.
(iv) COST AND EXPENSES FOR CLIENT: All Costs, Marketing, sales reports/delivery, sales staff, office locations and
expense as well as miscellaneous delivery costs accrued by CLIENT (including its subsidiaries and affiliates) by
reason of, in connection with the products is the sole responsibility of CLIENT. All manufacturing and delivery will be
the responsibility of BOSCH. CLIENT is responsible for shipping and delivery cost of product to end user.
(v) ASSISTANCE TO CLIENT: In addition to its other obligations under this Agreement, BOSCH shall assist CLIENT
in obtaining (and provide all documentation required to obtain) such licenses and/or permits as may be necessary or
desirable for the sales and/or Distribution and/or Placement of the Product for city, state and/or federal contract
accounts (Exit signs in and on buildings, mandatory safety fixtures, freeway signs, etc...) within the Territory.
19. INDEMNITY: Without limiting any other agreement contained in this Agreement, CLIENT agrees to defend, indemnify and
hold harmless BOSCH and its parents, subsidiary and affiliated entities, successors, assigns and licensees, and their respective
officers, agents, directors, owners, shareholders and employees, harmless from any and all claims, actions or proceedings of any
kind and from any and all damages, liabilities, costs and expenses (including reasonable legal fees) relating to or arising out of
any claim by a third Party.
10. CONFIDENTIALITY: CLIENT acknowledges that irreparable injury and damage will result from the disclosure to any third
party of Proprietary Information associated with the Product and agrees (1) not to disclose any Proprietary Information to any
third party, and (2) not to allow any third party to possess, handle, disassemble, touch, photograph, film or otherwise record
images of the Product while the Product is upon CLIENT'S premises or in CLIENT'S possession, custody or control if the product
is or has not been purchased with a purchase order and payment fulfilled.
11. ENTIRE AGREEMENT: This Strategic Alliance Agreement ("Agreement"), between BOSCH and CLIENT as to the subject
matter hereof, and supersede all previous agreements, warranties or representations, oral or written, which may have been made
between Studio and Licensor as to the subject matter hereof.
By signing in the spaces provided below BOSCH and CLIENT accept and agree to all of the terms and conditions of this
Agreement. 
CLIENT BOSCH
BOSCH INTERNATIONAL, LLC BOSCH TECHNOLOGIES, LLC
3753 Howard Hughes Pkwy. Suite 200 6795 Edmond St 3rd Floor
Las Vegas, NV 89169 Las Vegas NV 89114
/s/ James Schramm /s/ Authorized Agent
signature signature
print name and title print name and title
2Exhibit 7.5
 
STRATEGIC ALLIANCE AGREEMENT
 
This Strategic Alliance Agreement is made and entered into this 14 day of June 2006, by and between UTEK Corporation (“UTEK”), a Delaware
Corporation, 2109 Palm Avenue, Tampa, Florida 33605, and Manakoa Services Corporation (“MKOS”), a Nevada Corporation, 7203 W Deschutes
Avenue, Suite B, Kennewick, Washington 99336.
WITNESSETH:
WHEREAS, MKOS desires to engage UTEK to provide the services as set forth in this Agreement, and
WHEREAS, UTEK is agreeable to provide these services.
NOW THEREFORE, in consideration of the mutual promise made in this Agreement, and for other good and valuable consideration, the
receipt and sufficiency of which is hereby acknowledged, the parties hereto agree as follows:
I. SERVICES 
 
  A. To identify technology acquisition opportunities for MKOS from research universities and government laboratories, while maintaining
MKOS’s confidentiality.
 
  B. In conjunction with the Services, UTEK agrees to:
 
  I. Make itself available at the offices of MKOS or at another mutually agreed upon place, during normal business hours, for
reasonable periods of time, subject to reasonable advance notice and mutually convenient scheduling.
 
  II. Make itself available for telephone conferences with the principal officer(s) of MKOS during normal business hours.
 
  C. MKOS will have 30-days from receipt of information to determine if they wish to go forward with the technology license. UTEK, after 30
days, shall have the right to present the technology to other clients.
 
  D. MKOS acknowledges that the sources of technologies represented by UTEK are 3 rd party research institutions for which UTEK does
not control whether the technology will be shown to other parties by the licensor.
 
  E. At MKOS’s request and upon mutual agreement between MKOS and UTEK, UTEK will negotiate and seek to acquire a license to the
requested technology for subsequent sale to and acquisition by MKOS.
 
  F. On a case-by-case basis, at MKOS’s request and UTEK’s sole discretion, UTEK will propose an equity-financing plan for MKOS’s
consideration, to finance select technology acquisition opportunities for MKOS.
 
  G. MKOS will not seek to acquire any technologies presented to MKOS by UTEK from the technology developer directly or indirectly for
a period of 24 months following the termination of this Strategic Alliance Agreement.
 
- 1 -H. UTEK shall devote such time and efforts, as it deems commercially reasonable, under the circumstances to the affairs of MKOS, as is
commercially reasonable and adequate to render the Services contemplated by this Agreement.
 
  I. UTEK cannot guarantee results on behalf of MKOS, but shall pursue all reasonable avenues available through its network of contacts.
The acceptance and consumption of any transaction is subject to acceptance of the terms and conditions by in its sole discretion.
 
  J. MKOS will cooperate with UTEK and will promptly provide UTEK with all pertinent materials and requested information in order for
UTEK to perform its Services pursuant to this Agreement
II. INDEPENDENT CONTRACTOR 
UTEK shall be, and in all respects be deemed to be, an independent contractor in the performance of its duties hereunder.
 
  A. MKOS shall be solely responsible for making all payments to and on behalf of its employees and UTEK shall in no event
be liable for any debts or other liabilities of MKOS.
 
 
B. UTEK shall not have or be deemed to have, fiduciary obligations or duties to, and shall be able to pursue, conduct and
carry on for its own account (or for the account of others) such activities, ventures, businesses and other pursuits as
UTEK in its sole, absolute and unfettered discretion, may elect.
 
  C. Notwithstanding the above, no activity, venture, business or other pursuit of UTEK, during the term of this Agreement
shall conflict with UTEK’s obligations under this Agreement.
III. EXPENSES 
It is expressly agreed and understood that each party shall be responsible for its own normal and reasonable out-of-pocket expenses.
IV. COMPENSATION
 
 
A. In consideration for providing these Services, MKOS shall pay UTEK $120,000 in the form of unregistered shares of
common stock (923,077 shares) upon the execution of this Strategic Alliance Agreement. 1/12th of the shares (76,923) shall
vest each month during the term of this Agreement. In lieu of payment of shares, MKOS shall have the option of paying
UTEK $10,000 per month for the Services described in this Agreement.
If this Agreement is terminated any unvested shares will be returned to MKOS.
 
 
B. In consideration for the services to be provided herein, MKOS agrees that it will remit the agreed upon stock certificate or
cash payment within five (5) days of both parties executing this Agreement. If no consideration is received in the timeline,
UTEK has the unilateral option to terminate this Agreement.
 
  C. MKOS agrees that UTEK shall be entitled to additional compensation as follows:
Technology Transfer: When a technology is shown to MKOS that MKOS wants to acquire, UTEK will seek to acquire the
license to a technology through one of its subsidiaries. UTEK will then seek to provide a term sheet to MKOS outlining
the consideration to be paid by MKOS for the acquisition of this technology. If MKOS executes the term sheet, agreeing
to the terms set forth, UTEK shall transfer this subsidiary to MKOS in a stock for stock exchange under an “Agreement
and Plan of Acquisition.” The consideration to be paid by MKOS to UTEK will be based upon a markup to the value of
the license and other assets in the subsidiary as determined by UTEK and agreed to by both parties.
 
- 2 -V. TERM AND TERMINATION 
The term of the Agreement will be for 12 months unless terminated sooner. This Agreement may be renewed upon mutual, written agreement of the
parties. Either party may terminate this Agreement at any time with 30 days written notice.
VI. LEGAL COMPLIANCE 
MKOS agrees that it will put in place, if it has not already done so, policies and procedures relating to and addressing, with the commercially
reasonable intent to ensure compliance with, applicable securities laws, rules and regulations, including, but not limited to:
 
 
A. Disclosure requirements regarding the required disclosure of the nature and terms of UTEK’s relationship with, including, but
not limited to press releases, publications on its web site, letters to investors and telephone or other personal communication
with potential or current investors.
 
  B. No press releases or any other forms of communication to third parties, which mention both UTEK and MKOS, shall be released
without the prior written consent and approval of both UTEK and MKOS.
 
 
C. UTEK represents to MKOS that a) it has the experience as may be necessary to perform all the required, b) all Services will be
performed in a professional manner, and c) all individuals it provides to perform the Services will be appropriately qualified and
subject to appropriate agreements concerning the protection of trade secrets and confidential information of which such
persons may have access to over the term of this Agreement.
 
  D. Until termination of the engagement, MKOS will notify UTEK promptly of the occurrence of any event, which might materially
affect the condition (financial or otherwise), or prospects of MKOS.
VII. CONFIDENTIAL DATA 
 
 
A. UTEK shall not divulge to others, any trade secret or confidential information, knowledge, or data concerning or pertaining to
the business and affairs of MKOS, obtained by UTEK as a result of its engagement hereunder, unless authorized, in writing by
MKOS. UTEK represents and warrants that it has established appropriate internal procedures for protecting the trade secrets
and confidential information of, MKOS including, without limitation, restrictions on disclosure of such information to employees
and other persons who may be engaged in such information to employees and other persons who may be engaged in rendering
services to any person, firm or entity which may be a competitor of.
 
 
B. MKOS shall not divulge to others, any trade secret or confidential information, knowledge, or data concerning or pertaining to
the business and affairs of UTEK or confidential information revealed by UTEK obtained as a result of its engagement
hereunder, unless authorized, in writing, by UTEK, and agreed to be bound by any confidentiality agreement entered into by
UTEK with any third party for the purpose of reviewing technology acquisition opportunities.
 
 
C. UTEK shall not be required in the performance of its duties to divulge to MKOS, or any officer, director, agent or employee of
MKOS, any secret or confidential information, knowledge, or data concerning any other person, firm or entity (including, but not
limited to, any such person, firm or entity which may be a competitor or potential competitor of) which UTEK may have or be
able to obtain other than as a result of the relationship established by this Agreement.
 
- 3 -VIII. OTHER MATERIAL TERMS AND CONDITIONS 
 
  A. INDEMNITY.
 
 
1. UTEK shall indemnify, defend and hold harmless MKOS from and against any and all losses incurred by MKOS
which arise out of or result from misrepresentation, breach of warranty or breach or non- fulfillment of any covenant
contained herein or Schedules annexed hereto or in any other documents or instruments furnished by UTEK
pursuant hereto or in connection with this Agreement.
 
 
2. MKOS shall indemnify, defend and hold harmless UTEK from and against any and all losses incurred by UTEK
which arise out of or result from misrepresentation, breach of warranty or breach or non-fulfillment of any covenant
contained herein or Schedules annexed hereto or in any other documents or instruments furnished by MKOS
pursuant hereto or in connection with this Agreement.
 
  B. PROVISIONS. Neither termination nor completion of the assignment shall affect the provisions of this Agreement, and the
Indemnification Provisions that are incorporated herein, which shall remain operative and in full force and effect.
 
 
C. SOLICITATION. MKOS agrees that for a twenty four months (24) following the execution of this Agreement, MKOS shall
not, without UTEK’s prior written consent, directly or indirectly solicit for employment any present employee of UTEK, or
request, induce or advise any employee of UTEK to leave the employ of UTEK. In turn, UTEK agrees that it will not
directly or indirectly solicit any present employee of MKOS.
 
 
D. ADDITIONAL INSTRUMENTS. Each of the parties shall from time to time, at the request of others, execute, acknowledge
and deliver to the other party any and all further instruments that may be reasonably required to give full effect and force
to the provisions of this Agreement.
 
 
E. ENTIRE AGREEMENT. Each of the parties hereby covenants that this Agreement, is intended to and does contain and
embody herein all of the understandings and agreements, both written or oral, of the parties hereby with respect to the
subject matter of this Agreement, and that there exists no oral agreement or understanding expressed or implied liability,
whereby the absolute, final and unconditional character and nature of this Agreement shall be in any way invalidated,
empowered or affected. There are no representations, warranties or covenants other than those set forth herein.
 
 
F. ASSIGNMENTS. The benefits of the Agreement shall inure to the respective successors and assignees of the parties and
assigns and representatives, and the obligations and liabilities assumed in this Agreement by the parties hereto shall be
binding upon their respective successors and assigns; provided that the rights and obligations of UTEK under this
Agreement may not be assigned or delegated without the prior written consent of MKOS and any such purported
assignment shall be null and void. Notwithstanding the foregoing, UTEK may assign this Agreement or any portion of its
Compensation as outlined herein to its subsidiaries in its sole discretion.
 
  G. ORIGINALS. This Agreement may be executed in any number of counterparts, each of which so executed shall be deemed
an original and constitute one and the same agreement.
 
 
H. NOTICES. All notices that are required to be or may be sent pursuant to the provision of this Agreement shall be sent by
certified mail, return receipt requested, or by overnight package delivery service to each of the parties at the addresses
appearing herein, and shall count from the date of mailing or the validated air bill.
 
 
I. MODIFICATION AND WAIVER. A modification or waiver of any of the provisions of this Agreement shall be effective
only if made in writing and executed with the same formality as this Agreement. The failure of any party to insist upon
strict performance of any of the provisions of this Agreement shall not be construed as a waiver of any subsequent
default of the same or similar nature or of any other nature.
 
- 4 -J. INJUNCTIVE RELIEF. Solely by virtue of their respective execution of this Agreement and in consideration for the mutual
covenants of each other, MKOS and UTEK hereby agree, consent and acknowledge that, in the event of a breach of any
material term of this Agreement, the non-breaching party will be without adequate remedy-at-law and shall therefore, be
entitled to immediately redress any material breach of this Agreement by temporary or permanent injunctive or mandatory
relief obtained in an action or proceeding instituted in any court of competent jurisdiction without the necessity of proving
damages and without prejudice to any other remedies which the non-breaching party may have at law or in equity.
 
 
K. ATTORNEY’S FEES. If any arbitration, litigation, action, suit, or other proceeding is instituted to remedy, prevent or obtain
relief from a breach of this Agreement, in relation to a breach of this Agreement or pertaining to a declaration of rights
under this Agreement, the prevailing party will recover all such party’s attorneys’ fees incurred in each and every such
action, suit or other proceeding, including any and all appeals or petitions there from. As used in this Agreement,
attorneys’ fees will be deemed to be the full and actual cost of any legal services actually performed in connection with the
matters involved, including those related to any appeal to the enforcement of any judgment calculated on the basis of the
usual fee charged by attorneys performing such services.
 
  L. INVESTMENT COMPANY STATUS. MKOS represents that it is not an investment company, registered or unregistered.
APPROVED AND AGREED:
 
UTEK Corporation     Manakoa Services Corporation
By:  /s/ Doug Schaedler     By:  /s/ Chris Outwater
  Doug Schaedler       Chris Outwater
  Chief Operating Officer       President
 
- 5 -STRATEGIC ALLIANCE AGREEMENT  
This agreement (“Agreement”), is entered into as of the date on which the Registration Statement is declared effective by the SEC (the “Effective Date”), by and among PHL VARIABLE INSURANCE COMPANY (“PHLVIC”), PHOENIX LIFE INSURANCE COMPANY, (“PLIC” and, together with PHLVIC, “PHL Variable”), PHOENIX EQUITY PLANNING CORPORATION (“PEPCO” and, together with PHLVIC and PLIC, the “PHL Parties”), and INVESTORS CAPITAL CORPORATION (“ICC”). Except as otherwise defined, capitalized terms used herein shall have the meanings given to them in Section 1 Definitions, below.  
RECITALS  
A. PHL Variable will offer to issue the GIE to ICC Customers.  
B. ICC is a broker dealer that is registered under the 1934 Act and with FINRA and an investment adviser that is registered with the SEC under the Advisers Act and doing business as an investment adviser as Investors Capital Advisory Services (“ICAS”).  
C. ICAS has established certain asset allocation Models that are eligible for use with the GIE, and in the future may establish other Models that become eligible for use with the GIE.  
D. ICC and the Phoenix Parties have previously entered into a Selling Agreement, effective as of December 1, 2002 and the addition of GIE to the Selling Agreement effective as of the Effective Date, pursuant to which ICC will solicit sales of the GIE to ICC Customers.  
E. The Parties desire to set forth herein certain of their respective duties and obligations in connection with the GIE, all upon the terms and subject to the conditions more fully set forth below.  
NOW, THEREFORE, in consideration of the foregoing recitals, the mutual covenants and obligations hereinafter set forth, and for other good and valuable considerations, the receipt and sufficiency of which are hereby acknowledged, the Parties hereto, intending to be legally bound, agree as follows:  
SECTION 1 DEFINITIONS  
  
  
  
  
  - 1 -  
  1.01 1933 Act. The Securities Act of 1933, as amended. 
  1.02 1934 Act. The Securities Exchange Act of 1934, as amended. 
  1.03 Advisers Act. The Investment Advisers Act of 1940, as amended. 
  1.04 Affiliate. With respect to a person, any other person controlling, controlled by, or under common control with, such person.- 2 -  
  1.05 Agreement. The term shall have the meaning set forth in the introductory paragraph of this Agreement. 
  1.06 Application. The application, enrollment form, or similar form approved for use by PHL Variable by which an ICC Customer applies for a GIE. 
 
1.07 Books and Records. All books and records maintained or required by applicable Law to be maintained by each of the Parties hereto in connection with the Transaction Documents and the GIE, including to the extent any of the following exist: (i) hard copy and microfiche records; (ii) all paper files; (iii) all electronic images; (iv) all computer data files; and (v) any and all records in other forms. 
  1.08 Business Day. A day when the New York Stock Exchange is open for business. 
  1.09 Certificate. The certificate of insurance issued by PHL Variable to an ICC Customer pursuant to the Master Group Annuity Contract. 
  1.10 Certificate Owner. The person or entity that is the owner of a Certificate. 
  1.11 Change of Control. The term shall have the meaning set forth in Section 16.01.2. 
  1.12 Confidential Information. The term shall have the meaning set forth in Section 11.03.1 
  1.13 Customer Complaint. The term shall have the meaning set forth in Section 11.04. 
  1.14 Determination. The term shall have the meaning set forth in Section 12.02.1.6. 
  1.15 ICC. The term shall have the meaning set forth in the introductory paragraph of this Agreement. 
  1.16 Effective Date. The date set forth in the introductory paragraph of this Agreement. 
  1.17 Fee Increase Notice Date. The term shall have the meaning set forth in Section 8.08.1. 
  1.18 Governmental Entity. Any domestic, federal or State, court, governmental or regulatory authority or agency, including State insurance and State securities regulators. 
 
1.19 GIE. The Master Group Annuity Contracts and each Certificate issued by PHL Variable and registered on Form S-1 under the 1933 Act with the SEC under File No. 333-XXXXXX as in effect on the Effective Date, including any riders, endorsements or amendments to the Master Group Annuity Contracts or the Certificates, and each Application.- 3 -  
  1.20 GIE Fees. The fees due to either PHLVIC or PLIC, as applicable, by a Certificate Owner under a Certificate for coverage under such Certificate. 
  1.21 Investment Company Act. The Investment Company Act of 1940, as amended. 
  1.22 IRC. The Internal Revenue Code of 1986, as amended. 
  1.23 Law. Any law, rule, regulation, order or written interpretation of any governmental body or self regulatory organization, and any writ, judgment, injunction or court decree. 
  1.24 ICAS. A business unit of ICC which is an investment adviser that is registered with the SEC under the Advisers Act 
  1.25 ICC GIE Persons. The term shall have the meaning set forth in Section 8.07.1. 
  1.26 Investors Capital Indemnitees. The term shall have the meaning set forth in Section 12.01. 
  1.27 ICC. The term shall have the meaning set forth in the introductory paragraph of this Agreement. 
  1.28 ICC Licensed Marks. The term shall have the meaning set forth in Section 9.02.2. 
  1.29 Investors Capital Services. The term shall have the meaning set forth in Section 8.02.1. 
  1.30 License. The term shall have the meaning set forth in Section 9.02.2. 
  1.31 Licensee. The term shall have the meaning set forth in Section 9.02.4. 
  1.32 Licensor. The term shall have the meaning set forth in Section 9.02.4. 
  1.33 ICC Account. An account established by an ICC Customer that is invested in accordance with a Model managed by ICAS and eligible for coverage under a GIE. 
  1.34 ICC Customer. A customer or client of ICC who has established an ICC Account. 
  1.35 Master Group Annuity Contracts. The Master Group Annuity Contracts entered into by and between PHLVIC and ICC or an Affiliate, and by and between PLIC and ICC or an Affiliate 
  1.36 Memorandum of Understanding. The confidential Memorandum of Understanding, dated as of the Effective Date, entered into by and among PHLVIC, PLIC and ICC.- 4 -  
  1.37 Models. The confidential and proprietary asset allocation models managed by ICAS more fully described in the Memorandum of Understanding. 
  1.38 Nonpublic Personal Information. The term shall have the meaning set forth in Section 11.03.1 
  1.39 Parties. The term “Parties” refers to PHLVIC, PLIC, PEPCO, and ICC collectively and the term “Party” refers to each of them individually. 
  1.40 PEPCO. The term shall have the meaning set forth in the introductory paragraph of this Agreement. 
  1.41 PHL GIE Persons. This term shall have the meaning set forth in Section 8.07.1 
  1.42 PHL Parties. The term shall have the meaning set forth in the introductory paragraph of this Agreement. 
  1.43 PHL Licensed Marks. This term shall have the meaning set forth in Section 9.02.3. 
  1.44 PHL Services. The term shall have the meaning set forth in Section 7.03.1. 
  1.45 PHL Variable. The term shall have the meaning set forth in the introductory paragraph of this Agreement. 
  1.46 PHLVIC. The term shall have the meaning set forth in the introductory paragraph of this Agreement. 
  1.47 PLIC. The term shall have the meaning set forth in the introductory paragraph of this Agreement. 
  1.48 Prospectus. The prospectus included within a Registration Statement, including supplements thereto filed under Rule 424 under the 1933 Act, prepared by PHL Variable, from and after the date on which each shall have been filed. 
 
1.49 Registration Statement. At any time that this Agreement is in effect, each currently effective registration statement and each currently effective post-effective amendment thereto filed with the SEC under the 1933 Act on Form S-1 or otherwise relating to the GIE including the Prospectus and financial statements included in, and all exhibits to, such registration statement or post-effective amendment prepared by PHL Variable. 
  1.50 SEC. The United States Securities and Exchange Commission. 
 
1.51 Selling Agreement. The Selling Agreement effective as of December 1, 2002 and the addition of GIE to the Selling Agreement effective as of the Effective Date, by and among the Parties, as amended from time to time, pursuant to which ICC will solicit sales of the GIE from ICC Customers.SECTION 2 TERM  
  
SECTION 3 REPRESENTATIONS AND WARRANTIES OF ICC  
ICC hereby represents and warrants to the PHL Parties as follows:  
  
  
  
  
  - 5 -  
  1.52 State. Any state of the United States and the District of Columbia. 
  1.53 Term. The term shall have the meaning set forth in Section 2. 
  1.54 Territory. The Territory shall initially consist of all States, as may be changed from time to time by the written agreement of the Parties. 
  1.55 Trademark Consent. The term shall have the meaning set forth in Section 10.02.1. 
  1.56 Trademark License Terms. The term shall have the meaning set forth in Section 10.02.2. 
  1.57 Transaction Documents. The term shall mean this Agreement, the Memorandum of Understanding, and the GIE. 
  2.01 This Agreement shall commence on the Effective Date and shall continue until it is terminated in accordance with the provisions of Section 15 of this Agreement (“Term”). 
  3.01 Organization. ICC is a corporation duly incorporated and validly existing under the laws of the State of Massachusetts. 
  3.02 Power and Authority. ICC has the requisite power and authority under its articles of incorporation and by-laws to enter into and perform its duties and obligations under the Transaction Documents to which it is a party. 
 
3.03 Corporate Action. All requisite actions have been taken to authorize ICC to enter into and perform its duties and obligations set forth in the Transaction Documents to which it is a party and to execute and deliver the Transaction Documents to which it is a party and, when so executed and delivered, the Transaction Documents to which it is a party shall constitute the valid and binding obligations of ICC enforceable against it in accordance with its terms. 
 
3.04 Non-Contravention. ICC has duly executed and delivered this Agreement and neither such execution and delivery nor the performance by ICC of any of its obligations under the Transaction Documents to which it is a party will (i) violate any provision of its articles of incorporation or by-laws (ii) result in a violation or breach of, or constitute a default or an event of default under, any indenture, mortgage, bond or other contract, license, agreement, permit, instrument or other commitment or obligation to which it is a party or by which it is bound or (iii) materially violate any Law applicable to it or its business.SECTION 4 REPRESENTATIONS AND WARRANTIES OF PHLVIC  
PHLVIC hereby represents and warrants to the ICC as follows:  
  
  - 6 -  
 
3.05 Licenses and Permits. As of the Effective Date, ICC on its behalf and on behalf of ICAS has, and during the term of this Agreement shall use reasonable efforts to maintain, all material licenses, permits, registrations, authorizations, orders, consents, and other approvals by each Government Entity necessary or advisable for the performance of its obligations under the Transaction Documents to which it is a party. 
 
3.06 Compliance with Law. As of the Effective Date, ICC shall use reasonable efforts to conduct and will continue to conduct business operations in connection with performance of its duties and obligations under the Transaction Documents to which it is a party in compliance in all material respects with applicable Law. 
  3.07 Equipment, Facilities and Staff. ICC has the equipment, facilities, systems, staff and other assets necessary to perform its duties and obligations under the Transaction Documents to which it is a party. 
  3.08 Pending Litigation and Actions. ICC is not subject to any current or pending litigation or any pending regulatory actions that would materially impair its ability to carry out its duties and obligations under the Transaction Documents to which it is a party. 
 
3.09 Registration Statement and Prospectus. All information about ICC and ICAS that ICC has provided to PHL Variable for use in the Registration Statement did not, on the effective date of the Registration Statement, contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein not misleading in light of the circumstances under which they were made. ICC shall promptly notify PHLVIC in the event ICC believes the representations and warranties in this Section 3.09 are no longer true in any material respect (it being understood that no representation is made with respect to information about the PHL Parties or the GIE). 
  3.10 Master Group Annuity Contracts. ICC shall cause itself or an Affiliate to enter into the Master Group Annuity Contracts by and between PHLVIC and ICC or an Affiliate, and by and between PLIC and ICC or an Affiliate 
 
3.11 Form ADV, Part II, Sch. H. Schedule H of Part II of ICAS’ Form ADV relating to the Models is in compliance with Rule 204-3(f) under the Advisers Act and the requirements of Schedule H of Part II of Form ADV. ICC shall promptly notify each of the PHL Parties if there are any material changes to the Form ADV, Part II, Schedule H relating to the Models. 
  4.01 Organization. PHLVIC is a corporation duly incorporated and validly existing under the laws of the State of Connecticut.- 7 -  
  4.02 Power and Authority. PHLVIC has the requisite power and authority under its articles of incorporation and by-laws to enter into and perform its duties and obligations under the Transaction Documents to which it is a party. 
 
4.03 Corporate Action. All requisite actions have been taken to authorize PHLVIC to enter into and perform its duties and obligations set forth in the Transaction Documents to which it is a party and to execute and deliver the Transaction Documents to which it is a party and, when so executed and delivered, the Transaction Documents to which it is a party shall constitute the valid and binding obligation of PHLVIC enforceable against it in accordance with its terms. 
 
4.04 Non-Contravention. PHLVIC has duly executed and delivered this Agreement and neither such execution and delivery nor the performance by PHLVIC of any of its obligations under the Transaction Documents to which it is a party will (i) violate any provision of its articles of incorporation or by-laws (ii) result in a violation or breach of, or constitute a default or an event of default under, any indenture, mortgage, bond or other contract, license, agreement, permit, instrument or other commitment or obligation to which it is a party or by which it is bound or (iii) materially violate any Law applicable to it or its business. 
 
4.05 Licenses and Permits. As of the Effective Date, PHLVIC has, and during the term of this Agreement shall use reasonable efforts to maintain all material licenses, permits, registrations, authorizations, orders, consents, and other approvals by each Government Entity necessary or advisable for the performance of its obligations under the Transaction Documents to which it is a party. 
 
4.06 Compliance with Law. As of the Effective Date, PHLVIC shall use reasonable efforts to conduct and will continue to conduct business operations in connection with performance of its duties and obligations under the Transaction Documents to which it is a party in compliance in all material respects with applicable Law. 
  4.07 Equipment, Facilities and Staff. PHLVIC has the equipment, facilities, systems, staff and assets necessary to perform its duties and obligations under the Transaction Documents to which it is a party. 
  4.08 Pending Litigation and Actions. PHLVIC is not subject to any current or pending litigation or regulatory actions that would materially impair its ability to carry out its duties and obligations under the Transaction Documents to which it is a party. 
 
4.09 Registration Statement and Prospectus. The Registration Statement, on the date of which it was declared effective, did not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein not misleading in light of the circumstances under which they were made (it being understood that no representation is made with respect to information about ICAS or ICC provided by ICAS or ICC in writing to PHL Variable). All statements in the Registration Statement, on the date of which it was declared- 8 -  
 
effective, relating to taxation and tax effects are true in all material respects. The Prospectus or other information contained in the Registration Statement, when disseminated or used after the effective date of the Registration Statement, shall not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein not misleading in light of the circumstances under which they were made (it being understood that no representation is made with respect to information about ICAS or ICC provided by ICAS or ICC in writing to PHL Variable). PHLVIC shall immediately notify ICC in the event PHLVIC believes or has reason to believe that the representations and warranties in this paragraph are no longer true or completely accurate.  
 
4.10 Tax Matters. It is more likely than not that: (1) PHLVIC will not be treated as the owner of the assets in an ICC Account for federal income tax purposes; (2) the GIE, including each Certificate, will be treated as an annuity contract for federal income tax purposes; however, if the value of an ICC Account happens to be greater than zero when an Owner’s life expectancy is less than one year (which will only occur at extremely advanced ages), it is possible that the Policy could be treated as no longer constituting an annuity contract for Federal tax purposes from that point on; (3) for all Certificate Holders on the date of GIE issuance and during the entire period during which the GIE and each Certificate is in effect, losses with respect to the ICC Account will be deductible under Section 165(a) of the IRC notwithstanding the existence of the GIE’ conditional guarantee of annual lifetime income payments in the event that the value of the assets in an ICC Account decreases to zero; (4) for all Certificate Owners on the date of GIE issuance and during the entire period during which the GIE and each Certificate is in effect, dividends on stock held in an ICC Account otherwise meeting the requirements of Section 1(h)(11) of the IRC will constitute qualified dividend income notwithstanding the existence of a GIE and its conditional guarantee of annual lifetime income payments in the event the value of the assets in the ICC Account decreases to zero; and (5) for each Certificate Owner on the date of Certificate issuance and during the entire period during which the GIE and each Certificate is in effect, the Certificate and assets in the ICC Account subject thereto will not be treated as a straddle under Section 1092 of the IRC. 
 
4.11 Ownership of GIE; No Claims Relating to GIE. Except as set forth in Section 10.01, PHLVIC and its Affiliates, as applicable, are the exclusive legal and beneficial owner of and have good and marketable title in and to the GIE and all intellectual property rights therein, free and clear of all pledges, claims, liens, charges, encumbrances and security interests of any kind or character, including any claims for infringement of intellectual property rights. For the purposes of this Section, intellectual property includes GIE forms, specimen forms, the features of the GIE, materials filed by any of the PHL Parties with State insurance regulators, and any other forms prepared by any of the PHL Parties or any of their Affiliates in connection with the GIE. There are no claims, actions, suits, investigations or proceedings (arbitration or otherwise) pending against, or to the knowledge of PHLVIC, threatened against or affecting, all or any part of the GIESECTION 5 REPRESENTATIONS AND WARRANTIES OF PLIC  
PLIC hereby represents and warrants to the ICC as follows:  
  
  
  
  
  
  
  
  - 9 -  
 
or to the transactions contemplated by any of the Transaction Documents. To the knowledge of PHLVIC, there are no facts that could reasonably serve as a basis for such claim, action, suit, investigation or proceeding. The use and issuance of the GIE does not and will not infringe, misappropriate, violate or dilute any intellectual property rights of any person.  
  5.01 Organization. PLIC is a corporation duly incorporated and validly existing under the laws of the State of New York. 
  5.02 Power and Authority. PLIC has the requisite power and authority under its articles of incorporation and by-laws to enter into and perform its duties and obligations under the Transaction Documents to which it is a party. 
 
5.03 Corporate Action. All requisite actions have been taken to authorize PLIC to enter into and perform its duties and obligations set forth in the Transaction Documents to which it is a party and to execute and deliver the Transaction Documents to which it is a party and, when so executed and delivered, the Transaction Documents to which it is a party shall constitute the valid and binding obligation of PLIC enforceable against it in accordance with its terms. 
 
5.04 Non-Contravention. PLIC has duly executed and delivered this Agreement and neither such execution and delivery nor the performance by PLIC of any of its obligations under the Transaction Documents to which it is a party will (i) violate any provision of its articles of incorporation or by-laws (ii) result in a violation or breach of, or constitute a default or an event of default under, any indenture, mortgage, bond or other contract, license, agreement, permit, instrument or other commitment or obligation to which it is a party or by which it is bound or (iii) materially violate any Law applicable to it or its business. 
 
5.05 Licenses and Permits. As of the Effective Date, PLIC has, and during the term of this Agreement shall use reasonable efforts to maintain all material licenses, permits, registrations, authorizations, orders, consents, and other approvals by each Government Entity necessary or advisable for the performance of its obligations under the Transaction Documents to which it is a party. 
 
5.06 Compliance with Law. As of the Effective Date, PLIC shall use reasonable efforts to conduct and will continue to conduct business operations in connection with performance of its duties and obligations under the Transaction Documents to which it is a party in compliance in all material respects with applicable Law. 
  5.07 Equipment, Facilities and Staff. PLIC has the equipment, facilities, systems, staff and assets necessary to perform its duties and obligations under the Transaction Documents to which it is a party.- 10 -  
  5.08 Pending Litigation and Actions. PLIC is not subject to any current or pending litigation or regulatory actions that would materially impair its ability to carry out its duties and obligations under the Transaction Documents to which it is a party. 
 
5.09 Registration Statement and Prospectus. The Registration Statement, on the date of which it was declared effective, did not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein not misleading in light of the circumstances under which they were made (it being understood that no representation is made with respect to information about ICAS or ICC provided by ICAS in writing to PHL Variable). All statements in the Registration Statement, on the date of which it was declared effective, relating to taxation and tax effects are true in all material respects. The Prospectus or other information contained in the Registration Statement, when disseminated or used after the effective date of the Registration Statement, shall not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein not misleading in light of the circumstances under which they were made (it being understood that no representation is made with respect to information about ICAS or ICC provided by ICAS or ICC in writing to PHL Variable). PLIC shall immediately notify ICC in the event PLIC believes or has reason to believe that the representations and warranties in this paragraph are no longer true or completely accurate. 
 
5.10 Tax Matters. It is more likely than not that: (1) PLIC will not be treated as the owner of the assets in an ICC Account for federal income tax purposes; (2) the GIE, including each Certificate, will be treated as an annuity contract for federal income tax purposes; (3) for all Certificate Holders on the date of GIE issuance and during the entire period during which the GIE and each Certificate is in effect, losses with respect to the ICC Account will be deductible under Section 165(a) of the IRC notwithstanding the existence of the GIE’ conditional guarantee of annual lifetime income payments in the event that the value of the assets in an ICC Account decreases to zero; (4) for all Certificate Owners on the date of GIE issuance and during the entire period during which the GIE and each Certificate is in effect, dividends on stock held in an ICC Account otherwise meeting the requirements of Section 1(h)(11) of the IRC will constitute qualified dividend income notwithstanding the existence of a GIE and its conditional guarantee of annual lifetime income payments in the event the value of the assets in the ICC Account decreases to zero; and (5) for each Certificate Owners on the date of Certificate issuance and during the entire period during which the GIE and each Certificate is in effect, the Certificate and assets in the ICC Account subject thereto will not be treated as a straddle under Section 1092 of the IRC. 
 
5.11 Ownership of GIE; No Claims Relating to GIE. Except as set forth in Section 11.01, PLIC and its Affiliates, as applicable, are the exclusive legal and beneficial owner of and have good and marketable title in and to the GIE and all intellectual property rights therein, free and clear of all pledges, claims, liens, charges, encumbrances and security interests of any kind or character, including any claims for infringement of intellectual property rights. For the purposes of thisSECTION 6 REPRESENTATIONS AND WARRANTIES OF PEPCO  
PEPCO hereby represents and warrants to the ICC as follows:  
  
  
  
  
  
  
  - 11 -  
 
Section, intellectual property includes GIE forms, specimen forms, the features of the GIE, materials filed by any of the PHL Parties with State insurance regulators, and any other forms prepared by any of the PHL Parties or any of their Affiliates in connection with the GIE. There are no claims, actions, suits, investigations or proceedings (arbitration or otherwise) pending against, or to the knowledge of PLIC, threatened against or affecting, all or any part of the GIE or to the transactions contemplated by any of the Transaction Documents. To the knowledge of PLIC, there are no facts that could reasonably serve as a basis for such claim, action, suit, investigation or proceeding. The use and issuance of the GIE does not and will not infringe, misappropriate, violate or dilute any intellectual property rights of any person.  
  6.01 Organization. PEPCO is a corporation duly incorporated and validly existing under the laws of the State of Delaware. 
  6.02 Power and Authority. PEPCO has the requisite power and authority under its articles of incorporation and by-laws to enter into and perform its duties and obligations under the Transaction Documents to which it is a party. 
 
6.03 Corporate Action. All requisite actions have been taken to authorize PEPCO to enter into and perform its duties and obligations set forth in the Transaction Documents to which it is a party and to execute and deliver the Transaction Documents to which it is a party and, when so executed and delivered, the Transaction Documents to which it is a party shall constitute the valid and binding obligations of PEPCO enforceable against it in accordance with its terms. 
 
6.04 Non-Contravention. PEPCO has duly executed and delivered this Agreement and neither such execution and delivery nor the performance by PEPCO of any of its obligations under the Transaction Documents to which it is a party will (i) violate any provision of its articles of incorporation or by-laws (ii) result in a violation or breach of, or constitute a default or an event of default under, any indenture, mortgage, bond or other contract, license, agreement, permit, instrument or other commitment or obligation to which it is a party or by which it is bound or (iii) materially violate any Law applicable to it or its business. 
 
6.05 Licenses and Permits. As of the Effective Date, PEPCO has, and during the term of this Agreement shall use reasonable efforts to maintain all material licenses, permits, registrations, authorizations, orders, consents, and other approvals by each Government Entity necessary or advisable for the performance of its obligations under the Transaction Documents to which it is a party. 
 
6.06 Compliance with Law. As of the Effective Date, PEPCO shall use reasonable efforts to conduct and will continue to conduct business operations in connection with performance of its duties and obligations under the Transaction Documents to which it is a party in compliance in all material respects with applicable Law.SECTION 7 OBLIGATIONS OF THE PHL PARTIES  
  
  
  - 12 -  
  6.07 Equipment, Facilities and Staff. PEPCO has the equipment, facilities, systems, staff and assets necessary to perform its duties and obligations under the Transaction Documents to which it is a party. 
  6.08 Pending Litigation and Actions. PEPCO is not subject to any current or pending litigation or regulatory actions that would materially impair its ability to carry out its duties and obligations under the Transaction Documents to which it is a party. 
 
6.09 Registration Statement and Prospectus. The Registration Statement, on the date of which it was declared effective, did not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein not misleading in light of the circumstances under which they were made (it being understood that no representation is made with respect to information about ICAS or ICC provided by ICAS or ICC in writing to PHL Variable). All statements in the Registration Statement, on the date of which it was declared effective, relating to taxation and tax effects are true in all material respects. The Prospectus or other information contained in the Registration Statement, when disseminated or used after the effective date of the Registration Statement, shall not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein not misleading in light of the circumstances under which they were made (it being understood that no representation is made with respect to information about ICAS or ICC provided by ICAS or ICC in writing to PHL Variable). PEPCO shall immediately notify ICC in the event PEPCO believes or has reason to believe that the representations and warranties in this paragraph are no longer true or completely accurate. 
  7.01 Adequate Resources. Each of the PHL Parties shall devote commercially reasonable resources to ensure each of them and their Affiliates, as applicable, can perform their respective duties and obligations under the Transaction Documents. 
 
7.02 GIE Filing and Approval. PHL Variable shall take all commercially reasonable efforts to (1) qualify the offer and sale of the GIE in each jurisdiction within the Territory, and (2) obtain any approvals that are or may be required by any Governmental Entity to permit or facilitate the offer and sale of the GIE in each such jurisdiction; provided however that neither PHL Variable nor any other PHL Party shall be required to seek to qualify the offer and sale of the GIE or obtain any approvals to permit or facilitate the offer or sale of the GIE in the State of New York or the State of Maine. Such actions shall include, as applicable, filing the Registration Statement and using commercially reasonable efforts to maintain the effectiveness of the Registration Statement, filing forms of the Master Group Annuity Contracts, Certificates, and Applications with Governmental Entities,- 13 -  
 
including State insurance departments, and filing or submitting such notices, requests, and other documents in furtherance of the foregoing. One or more of the PHL Parties will immediately notify ICC if any Governmental Entity withdraws or modifies a previously issued approval of the GIE.  
  7.03 Administrative Services. 
  7.03.1 PHL Services. During the Term, each of the PHL Parties, as applicable, shall use commercially reasonable efforts to provide those administrative services set forth on Exhibit A (the “PHL Services”). 
 
7.03.2 Standards for Services. In performing the PHL Services, each of the PHL Parties shall at all times (1) act in good faith and with the care, skill, and diligence of a person experienced in providing services similar to the PHL Services; (2) perform such services consistent with applicable Law, and (3) perform such services in a manner the Parties may agree in writing from time to time. 
 
7.03.3 Subcontracting with Affiliates. The PHL Parties may subcontract with one or more of their Affiliates for the performance of some or all of the PHL Services; provided, however, that no subcontract shall relieve any of the PHL Parties from any of their respective duties, obligations or liabilities under this Agreement and each of the PHL Parties shall remain responsible for all such duties, obligations and liabilities, whether or not performed in whole or in part by a subcontractor. 
  7.04 Continuing Duties and Obligations. Nothing contained in the Transaction Documents shall relieve any of the PHL Parties from their respective duties and obligations under any of the other Transaction Documents. 
 
7.05 Registrations and Licenses. Each of the PHL Parties shall maintain, and cause each of the directors, officers, employees, agents and representatives of each of the PHL Parties or any Affiliate thereof to maintain all material registrations, licenses, memberships, approvals, and consents necessary or desirable to carry out their respective obligations under any of the Transaction Documents during the terms of the Transaction Documents, as applicable. PHL Variable shall promptly notify ICC in writing upon the lapse, termination, non-renewal, suspension, revocation, or cancellation (without replacement) of any such registration, license, membership, approval, order or consent. 
  7.05.1 Books and Records. Each of PHLVIC and PLIC shall maintain their respective Books and Records as required by applicable Law. 
 
7.06 Non-Solicitation. During the term hereof and for a period of two years following termination, none of the PHL Parties, any of their Affiliates, or any of their respective officers, directors, employees, agents, or representatives, shall, without the prior written approval of ICC, knowingly and intentionally market anySECTION 8 OBLIGATIONS OF ICC  
  
  
  
  
  
  
  
  
  - 14 -  
 
products or services to an ICC Client or Certificate Owner other than the GIE, if such ICC Client or Certificate Owner is identified from information any of the PHL Parties, any of their Affiliates, or any of their respective officers, directors, employees, agents, or representatives, obtain pursuant to any of the Transaction Documents or any transaction contemplated thereunder. PHLVIC and PLIC may communicate with Certificate Owners as is necessary to administer the Certificates or as required by applicable Law.  
  8.01 Adequate Resources. ICC shall devote commercially reasonable resources to ensure it can perform its duties and obligations under the Transaction Documents. 
  8.02 Administrative Services. 
  8.02.1 Investors Capital Services. During the Term, ICC shall use commercially reasonable efforts to provide those administrative services set forth on Exhibit B (the “Investors Capital Services”). 
 
8.02.2 Standards for Services. In performing the Investors Capital, ICC shall at all times (1) act in good faith and with the care, skill, and diligence of a person experienced in providing services similar to the Investors Capital; (2) perform such services consistent with applicable Law, and (3) perform such services in a manner the Parties may agree in writing from time to time. 
 
8.02.3 Subcontracting with Affiliates. ICC may subcontract with one or more of their Affiliates for the performance of some or all of the Investors Capital; provided, however, that no subcontract shall relieve e ICC from any of its duties, obligations or liabilities under this Agreement and ICC shall remain responsible for all such duties, obligations and liabilities, whether or not performed in whole or in part by a subcontractor. 
  8.03 Continuing Duties and Obligations. Nothing contained in the Transaction Documents shall relieve ICC from its respective duties and obligations under any of the other Transaction Documents. 
 
8.04 Information to be Provided to the PHL Parties. ICC shall provide to the PHL Parties such information reasonably necessary to describe ICAS and ICC in the Registration Statement and Prospectus. Such information shall not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements provided not misleading in light of the circumstances under which they were made (it being understood that no representation is made with respect to information about the PHL Parties or the GIE). 
 
8.05 Registrations and Licenses. ICC shall maintain, and cause each of the directors, officers, employees, agents and representatives of ICC or any Affiliate thereof to maintain all material registrations, licenses, memberships, approvals, and consents- 15 -  
 
necessary or desirable to carry out their respective obligations under this Agreement or the Master Group Annuity Contracts during the terms of such agreements, as applicable. ICC shall promptly notify each of the PHL Parties in writing upon the lapse, termination, non-renewal, suspension, revocation or cancellation (without replacement) of any such registration, license, membership, approval, order or consent.  
  8.06 Books and Records. ICC shall maintain its Books and Records as required by applicable Law. 
  8.07 Proprietary Interests of the PHL Parties. 
  8.07.1 Interference with Contracts. During the term hereof and for a period of two years following termination, ICC, any of their Affiliates, or any of their respective officers, directors, employees, agents, or representatives will: 
 
8.07.1.1 knowingly and intentionally interfere in any way with the contractual relationships existing between or among any of the PHL Parties or their Affiliates (as the case may be), on the one hand, and any officer, director, employee, agent, or other representative of any of the PHL Parties or their Affiliates assigned to assist the Parties or their Affiliates in connection with the negotiation and implementation of the GIEand any Transaction Document, or the sales and marketing of the GIE (“PHL GIE Persons”), on the other; 
 
8.07.1.2 knowingly and intentionally induce, solicit, or encourage PHL GIE Persons to terminate their respective contracts, or otherwise change their relationship, with any of the PHL Parties or their Affiliates; or 
  8.07.1.3 without the prior written consent of the PHL Parties, employ or otherwise contract with any PHL GIE Persons. 
  8.08 ICAS Advisory Fees. 
 
8.08.1 Existing ICC Accounts. During the Term, ICAS may increase the investment advisory fee ICAS charges ICC Customers in connection with any ICC Account that exists on the date ICC provides notice to PHL Variable of the proposed fee increase (such date, the “Fee Increase Notice Date”) only upon receipt of the written consent of PHL Variable, which consent shall not be unreasonably withheld. If PHL Variable does not disapprove the proposed fee increase within 10 days from the Fee Increase Notice Date, then such increase shall be deemed approved. 
  8.08.2 New ICC Accounts. During the Term, ICAS may increase the investment advisory fee ICAS charges ICC Customers in connection withSECTION 9 INTELLECTUAL PROPERTY RIGHTS.  
  
  
  
  
  
  - 16 -  
  any ICC Account established after the Fee Increase Notice Date so long as the fee increase will not take effect for at least 30 days from the Fee Increase Notice Date.  
 
9.01 Ownership of GIE. Notwithstanding anything to the contrary contained in any of the Transaction Documents, none of the PHL Parties or any of their Affiliates shall own (1) any information about ICC or any of their Affiliates, whether contained or referenced in the GIE, Prospectus, Registration Statement, or otherwise, (2) any of the Books or Records of any of ICC or any of their Affiliates, or (3) any data or other information relating to an ICC Account or ICC Client. 
  9.02 Names, Logos, Trademarks, and Service Marks. 
 
9.02.1 Prohibition. No Party shall use any of the names, trade names, trademarks, service marks and logos of another Party without the prior written consent of such Party (the “Trademark Consent”). The provisions of Section 10.02 shall apply in the event a Trademark Consent is given. 
 
9.02.2 ICC Licensed Marks. ICC or one of its Affiliates, as applicable, is the owner of all rights, title and interests in and to the names, trade names, trademarks, service marks and logos specified in and attached to the Trademark Consent of such Party or Affiliate (collectively, the “ICC Licensed Marks”). Except as may be otherwise specified in its Trademark Consent, during the Term and subject to Section 9.02.5, the terms and conditions of the Trademark Consent, and the additional trademark terms and conditions set forth on Exhibit C (“Trademark License Terms”), ICC or its Affiliates, as applicable, shall grant to the PHL Parties and their Affiliates, as applicable, a non-exclusive limited license (a “License”) to use the ICC Licensed Marks solely in connection with the performance of the duties and obligations of each of the PHL Parties and their Affiliates, as applicable, under the Transaction Documents. Each of the PHL Parties, on behalf of itself and any of its Affiliates, acknowledges that this Section 9.02.2, together with the Trademark Consent and Trademark License Terms, constitute a complete grant of the rights within this Section 9.02.2. 
 
9.02.3 PHL Variable Licensed Marks. Each of the PHL Parties or each of their Affiliates, as applicable, is the owner of all rights, title and interests in and to the names, trade names, trademarks, service marks and logos specified in and attached to the Trademark Consent of such Party or Affiliate (collectively, the “PHL Licensed Marks”). Except as may be otherwise specified in its Trademark Consent, during the Term and subject to Section 9.02.5, the terms and conditions of the Trademark Consent and the Trademark License Terms, each of the PHL Parties or its Affiliates, as applicable, shall grant to ICC and their Affiliates, as applicable, a non-exclusive- 17 -  
 
limited license (a “License”) to use the PHL Licensed Marks solely in connection with the performance of the duties and obligations of ICC and its Affiliates, as applicable, under the Transaction Documents. ICC, on behalf of itself and any of its Affiliates, acknowledges that this Section 9.02.3 together with the Trademark Consent and Trademark License Terms constitute a complete grant of the rights within this Section 9.02.3.  
  9.02.4 Definitions. Each Party granting a License is sometimes referred to as a “Licensor” and each recipient of the grant is sometimes referred to as a “Licensee.” 
  9.02.5 Terms and Conditions 
  9.02.5.1 Termination. Subject to the restrictions set forth in this Section, each License shall terminate as follows: 
 
9.02.5.1.1In the event of a complete termination of this Agreement under Sections 15.01 and 15.02 as to all Certificates, the grant of all Licenses shall automatically terminate as of the effective date of termination. In the event of such termination, ICC and its Affiliates shall cease using the PHL Licensed Marks and each of the PHL Parties and their Affiliates shall cease using the Investors Capital Licensed Marks. 
 
9.02.5.1.2In the event of termination under Section 15.02.1 as to new business and during such time as any Certificate remains in force and benefit payments thereunder have not commenced, the grant of all Licenses shall continue only as necessary for the Parties to carry out their respective duties and obligations under the Transaction Documents as applicable. For the purposes of clarity, each Party acknowledges that the Licenses shall not extend to sales and distribution of the GIE after the effective date of termination pursuant to Section 15.02.1, and upon such termination, ICC and its Affiliates shall cease using the PHL Licensed Marks and each PHL Party and their Affiliates shall cease using the Investors Capital Licensed Marks in connection with the sales and distribution of the GIE. 
 
9.02.5.1.3In the event of termination under Section 15.02.1 as to new business and during such time as the only Certificates remaining in force are those with respect to which benefit payments have commenced, the grant of the License to the PHL Parties and their Affiliates shall- 18 -  
 
continue only as necessary to make benefit payments under such Certificates and only until payment of the last benefit due is made under the last Certificate in force. In the event of such termination, (1) the License granted to ICC and its Affiliates shall terminate on the date on which the only remaining Certificates in force are those under which benefit payments have commenced and thereafter ICC and its Affiliates shall cease using all PHL Licensed Marks, and (2) the License granted to the PHL Parties and their Affiliates, restricted as noted in this subsection, shall terminate on the date on which the last benefit payment is made under the last Certificate in force and thereafter the PHL Parties and their Affiliates shall cease using all Investors Capital Licensed Marks.  
 
9.02.5.1.4In the event of suspension under Section 15.02.2, the grant of all Licenses shall continue only as necessary for the Parties to carry out their respective duties and obligations under the Transaction Documents, as applicable. 
 
9.02.5.2 Pre-Use Approval of Trademark-Bearing Materials, Names and Logos. A Licensee shall obtain the prior written consent of the Licensor for the use or public release by such Licensee of any materials bearing the Licensor’s licensed marks. With respect to the use of names or logos, none of the PHL Parties or their Affiliates, as applicable, shall use in advertising or publicity the names of any of ICC or its Affiliates, as applicable, or any symbol, abbreviation, contraction or simulation thereof or relating to ICC or an ICC Account, without the prior written consent of ICC, as applicable. With respect to the use of names or logos, ICC or its Affiliates, as applicable, shall not use in advertising or publicity the names of any of the PHL Parties or their Affiliates, or any symbol, abbreviation, contraction or simulation thereof, without the prior written consent of the PHL Parties, as applicable. 
 
9.02.5.3 Recall. A Licensor may revoke a Trademark Consent or the prior written consent provided pursuant to Section 9.02.5(b) only in the event of a material change in circumstances or in the event of a breach by a Licensee of Section 9.02, the Trademark Consent, and/or the Trademark License Terms. If the Trademark Consent or such other consents are properly revoked, then Licensee shall cease using all licensed marks affected by the revoked consent.SECTION 10 COMPENSATION AND EXPENSES  
  
  
SECTION 11 ADDITIONAL COVENANTS  
  
  
  
  
  
  - 19 -  
  9.02.5.4 Acknowledgment of Ownership. Each Licensee: 
 
9.02.5.4.1acknowledges and stipulates that the Licensor’s licensed marks are valid and enforceable trademarks and/or service marks; and that such Licensee does not own the Licensor’s licensed marks and claims no rights therein other than as a Licensee under this Agreement; and 
 
9.02.5.4.2shall not alter the Licensor’s licensed marks in any respect but shall use them only in the manner in which they are depicted in the Trademark Consent, as may be amended from time to time by Licensor. 
 
10.01Compensation. ICC and its Affiliates shall not be entitled to payment or other compensation of any kind or character from any of the PHL Parties or their Affiliates, and none of the PHL Parties or their Affiliates shall be entitled to payment or other compensation of any kind or character from ICC or its Affiliates, for performing their respective duties and obligations under any of the Transaction Documents. ICC acknowledges that (1) ICC and its Affiliates may benefit from sale of the GIE, and (2) such benefits constitute good and valuable consideration under this Agreement. The Parties acknowledge that the grant of Licenses pursuant to Section 9.02 also constitutes good and valuable consideration. 
 
10.02Expenses. Each Party shall be obligated to pay all costs and expenses it incurs in connection with developing and implementing the GIE and incident to preparing for, entering into and carrying out this each of the Transaction Documents, as applicable, and the transactions contemplated therein. 
  11.01Compliance with Applicable Law. 
  11.01.1Each Party shall perform, and shall cause each of its respective Affiliates, as applicable, to perform, their respective duties and obligations under the Transaction Documents in compliance in all material respects with applicable Law. 
  11.02Confidentiality. 
  11.02.1Definition. 
 
11.02.1.1“Confidential Information” means information obtained from a Party (i) in connection with the development of or performance of any of the Transaction Documents; (ii) concerning customers of the Parties or customers of their Affiliates, including their identities, addresses, and telephone numbers; (iii) as to a Party’s or its Affiliate’s business methods, operations, or affairs, or the- 20 -  
 
processes and systems used in the operation of its or its Affiliate’s business; (iv) concerning the Parties and their Affiliates that is identified as confidential by a Party; or (v) required to be treated as confidential under applicable Law.  
 
11.02.1.2“Confidential Information” does not include (i) information now available in the public domain or that in the future enters the public domain through no fault of the receiving Party; (ii) information disclosed to the receiving Party by a third party without violation by such third party of an independent obligation of confidentiality; (iii) information that is independently developed by or for a Party or its Affiliate in the ordinary course of business outside of any of the Transaction Documents; or (iv) information whose disclosure by the receiving Party is consented to in writing by the disclosing Party. 
  11.02.2Obligation to Keep Confidential. The receiving Party shall: 
 
11.02.2.1hold, and ensure that its Affiliates and the respective officers, directors, employees, agents, and representatives of the receiving Party and its Affiliates hold, the Confidential Information in strict confidence according to standards the receiving Party utilizes for confidential information of a similar nature; 
 
11.02.2.2not copy, reproduce, sell, assign, license, market, transfer, or otherwise dispose of, give, or disclose such Confidential Information to unaffiliated third persons or to the respective officers, directors, employees, agents, and representatives of the receiving Party and its Affiliates who have not agreed in writing to be bound by such obligations except as required by Law; 
 
11.02.2.3not use the Confidential Information for any purposes whatsoever other than the performance of the duties and obligations of the receiving Party or its Affiliates, as applicable, under the Transaction Documents; and 
 
11.02.2.4notify its Affiliates and the respective officers, directors, employees, agents, and representatives of the receiving Party and its Affiliates who may be exposed to such Confidential Information of their obligations to keep such information confidential and not to disclose or use such information except as expressly provided herein. 
  11.02.3Notice of Disclosure. In the event the receiving Party is requested to disclose all or any part of the Confidential Information under the terms of a valid subpoena or order issued by a court of competent jurisdiction or- 21 -  
 
other Governmental Entity, the receiving Party shall promptly notify the disclosing Party promptly of such request and shall provide the disclosing Party with reasonable opportunity to obtain and reasonable assistance in obtaining a protective order or similar remedy, provided that no such notice shall be required if such notice is prohibited by Law or if the Governmental Entity requesting such information has requested that the request not be disclosed.  
  11.02.4Internal Controls, Policies and Procedures. The Parties shall establish and maintain appropriate policies, procedures and internal controls to comply with this Section 11. 
  11.03Nonpublic Personal Information. 
 
11.03.1Confidentiality of Nonpublic Personal Information. The Parties each acknowledge they may come into possession of nonpublic personal information regarding “customers” or “consumers” of the other Party, as those terms are defined in Regulation S-P as enacted by the SEC and in other applicable Laws relating to privacy of nonpublic personal information (collectively, “Nonpublic Personal Information.”). No Party shall (1) share any Nonpublic Personal Information with any person except as permitted by the privacy notices such Party has provided to its consumers and customers in accordance with applicable Laws; (2) share any Nonpublic Personal Information with any unaffiliated third person regardless of whether such sharing is permitted by such Party’s privacy notices; and (3) share any Nonpublic Personal Information with any Affiliate unless such sharing is necessary for performance of that Party’s duties and obligations under this Agreement, the Sales and General Agency Agreement, or the Memorandum of Understanding. 
 
11.03.2Internal Controls, Policies and Procedures. Each Party shall establish and maintain written policies, procedures and internal controls that establish adequate administrative, technical, and physical safeguards for the protection of customer records and information as required by Rule 30 under Regulation S-P or applicable Law. Each Party represents and warrants that its respective policies, procedures and internal controls are reasonably designed to (1) ensure the security and confidentiality of Nonpublic Personal Information, (2) protect against anticipated threats or hazards to the security and integrity of Nonpublic Personal Information, and (3) protect against unauthorized access to or use of Nonpublic Personal Information. 
 
11.04Duty to Notify; Cooperation. Each Party shall promptly notify the others of the following of which any of them has received notice or has otherwise become aware: (1) any violation of Law by the personnel of such Party that would materially impact on the ability of that Party or its Affiliates, as applicable, to perform their respective duties and obligations under any of the TransactionSECTION 12 INDEMNIFICATION  
  
  
  
  
  22  
 
Documents, as applicable, (2) any violation of Law that relates in any way to the GIE; (3) any complaint or allegation by a GIE Certificate Owner relating in any way to the GIE (each, a “Customer Complaint”); and (4) any examination, investigation, allegation, proceeding, or action by a Governmental Entity, including a court, federal or State securities regulators, State insurance regulators, and State attorney general, related to any of the Transaction Documents provided that no such notice shall be required if such notice is prohibited by Law or if the Governmental Entity requesting such information has requested that the request not be disclosed.  
 
11.04.1Customer Complaints. The Parties shall cooperate with each other in resolving each Customer Complaint. Any proposed response by a Party to a Customer Complaint shall be sent to the other Parties not less than five (5) Business Days prior to the response being sent to any person, including the Certificate Owner or any Governmental Entity, provided, however, that if a more prompt response is required, the Parties shall send to the other Parties the proposed response as soon as practicable under the circumstances but in no event shall any Party submit such response to another person without providing the other Party with prior written notice of and a copy of the response. 
  11.04.2Examinations, Investigations and Proceedings. The Parties shall cooperate with each other in connection with any matter described under Section 11.04 as set forth above. 
  12.01Indemnification by the PHL Parties. 
 
12.01.1Indemnification. Each of the PHL Parties shall, jointly and severally, indemnify and hold harmless ICC, its Affiliates, and each of their respective officers, directors, employees, representatives, successors and permitted assigns (collectively, the “Investors Capital Indemnitees”), from and against any and all losses, claims, damages, liabilities, judgments, costs and expenses, including reasonable attorney fees and costs of investigation (collectively, “Loss” or “Losses”), to which any Investor Capital Indemnitee may become subject, relating to or arising from any of the following: 
 
12.01.1.1a material breach by any of the PHL Parties, any of their Affiliates, or any their respective officers, directors, employees, agents, representatives, successors or permitted assigns of any provision of any of the Transaction Documents to which they are a party; 
  12.01.1.2a material violation of applicable Law by any of the PHL Parties, any of their Affiliates, or any their respective officers,- 23 -  
 
directors, employees, agents, representatives, successors or permitted assigns relating to or arising from any of the Transaction Documents to which they are a party; provided, however, that none of the PHL Parties shall owe indemnification for Losses related to a material violation of Law arising out of or based upon reliance by any of the PHL Parties or any of its Affiliates upon information about ICC or any Affiliate thereof provided by ICC in writing to a PHL Party;  
  12.01.1.3the GIE, including its issuance and administration and any benefit payments due under the GIE; 
 
12.01.1.4any and all documents relating to or arising from the GIE that are drafted by, or are reviewed and approved by, any of the PHL Parties or any Affiliate thereof, including the Registration Statement, correspondence with Certificate Owners, and filings with Governmental Entities; or 
  12.01.1.5any claim for infringement of intellectual property rights by an unaffiliated third party in connection with any product that is similar to or resembles all or any part of the GIE. 
 
12.01.2Limitation. Indemnification pursuant to this Section 12.01 shall be in addition to any liability that any of the PHL Parties may otherwise have. Notwithstanding anything to the contrary set forth in this Section, no Investor Capital Indemnitee shall be entitled to indemnification pursuant to this Section to the extent that (a) Losses are attributable to acts, omissions or conduct of any Investor Capital Indemnitee that constitute willful misconduct, gross negligence, bad faith, or recklessness (other than any of the PHL Parties, any of their Affiliates, or any their respective officers, directors, employees, agents, representatives, successors or permitted assigns acting as an agent or representative of any of the Investors Capital Indemnitees), unless such acts, omissions or conduct were committed at the written direction of any of the PHL Parties Authorized Persons, or (b) such Loss is also a Loss for which the PHL Indemnitees are indemnified pursuant to Section 12.02 of this Agreement. Each Investors Capital Party acknowledges that none of the PHL Parties or their Affiliates shall be deemed to have guaranteed the profitability of the GIE or any volume of sales, and no indemnification shall arise based on an assertion of such a guarantee of profitability of the GIE or volume of sales. 
  12.02Indemnification by the ICC. 
  12.02.1Indemnification. ICC shall indemnify and hold harmless each of the PHL Parties, their Affiliates, and each of their respective officers, directors, employees, representatives, successors and permitted assigns- 24 -  
  (collectively, the “PHL Indemnitees”), from and against any and all Losses to which any PHL Indemnitee may become subject, relating to or arising from any of the following:  
 
12.02.1.1a material breach by ICC, any of their Affiliates, or any their respective or any of their officers, directors, employees, agents, representatives, successors or permitted assigns, of any provision of the Transaction Documents to which they are a party; 
 
12.02.1.2a material violation of applicable Law by ICC , any of its Affiliates, or any their respective or any of its officers, directors, employees, agents, representatives, successors or permitted assigns, relating to or arising from the Transaction Documents to which they are a party or ICC; provided, however, that ICC shall not owe indemnification for Losses related to a material violation of Law arising out of or based upon reliance by ICC or any of its Affiliates upon information about any of the PHL Parties or any Affiliate thereof provided by any of the PHL Parties in writing to ICC; 
  12.02.1.3the administration and management of ICC Accounts; 
 
12.02.1.4any claim by any person or entity related in any way to the development of all or any part of ICC, but excluding claims relating in any way to the development of all or any part of the GIE or Registration Statement; 
 
12.02.1.5any claim for infringement of intellectual property rights by an unaffiliated third party in connection with any product that is similar to or resembles all or any part of ICC, but excluding any claim relating in any way to the development of all or any part of the GIE or Registration Statement and any claim described in Sections 12.01.1(e) and (f) of this Agreement; or 
 
12.02.1.6a termination of a Certificate by either PHLVIC or PLIC as a result of a breach of the Memorandum of Understanding by ICAS that is not cured on or before the 5th consecutive Business Day following the date on which either PHLVIC or PLIC delivers notice under the Memorandum of Understanding that PHLVIC or PLIC, as applicable, has determined it cannot hedge changes proposed by ICAS either (i) without incurring material additional risk or additional hedging costs that are material in light of the pricing of the GIE, or (ii) because Phoenix is unable to obtain an appropriate hedge (a determination as to either (i) or (ii), a “Determination”); except a breach shall not be deemed to have occurred if the ICC demonstrates, through binding arbitration pursuant to Section 14.02 of this Agreement, that a Determination was unreasonable, erroneous or not made in good faith.- 25 -  
 
12.02.2Limitation. Indemnification pursuant to this Section 12.02 shall be in addition to any liability that the ICC may otherwise have. Notwithstanding anything to the contrary set forth in this Section, no PHL Indemnitee shall be entitled to indemnification pursuant to this Section to the extent that (a) Losses are attributable to acts, omissions or conduct of any PHL Indemnitee that constitute willful misconduct, gross negligence, bad faith, or recklessness (other than any of ICC, any of their Affiliates, or any their respective officers, directors, employees, agents, representatives, successors or permitted assigns acting as an agent or representative of any of the PHL Indemnitees), unless such acts, omissions or conduct were committed at the written direction of ICC Authorized Persons, or (b) such Loss is also a Loss for which the Investor Capital Indemnitees are indemnified pursuant to Section 12.01 of this Agreement. Each PHL Party acknowledges that neither ICAS nor any of its Affiliates shall be deemed to have guaranteed the profitability of the GIE or any volume of sales, and no indemnification shall arise in connection with profitability of the GIE or volume of sales. 
 
12.03Inter-Party Claims. Any Party seeking indemnification pursuant to this Section 12 (the “Indemnified Party”) shall notify the other Party or Parties from whom such indemnification is sought (the “Indemnifying Party”) of the Indemnified Party’s assertion of such claim for indemnification, specifying the basis of such claim. The Indemnified Party shall thereupon give the Indemnifying Party reasonable access to the documents that evidence or support such claim or the act, omission or occurrence giving rise to such claim. 
  12.04Third Party Claims. 
 
12.04.1Each Indemnified Party shall promptly notify the Indemnifying Party of the assertion by any third party of any claim with respect to which the indemnification set forth in this Article 12 relates (which shall also constitute the notice required by Section 16.03). The Indemnifying Party shall have the right, upon notice to the Indemnified Party within ten business days after the receipt of any such notice, to undertake the defense of or, with the consent of the Indemnified Party, (which consent shall not unreasonably be withheld), to settle or compromise such claim. The failure of the Indemnifying Party to give such notice and to undertake the defense of or to settle or compromise such a claim shall constitute a waiver of the Indemnifying Party’s rights under this Section 12.04.1 and shall preclude the Indemnifying Party from disputing the manner in which the Indemnified Party may conduct the defense of such claim or the reasonableness of any amount paid by the Indemnified Party in satisfaction of such claim.SECTION 13 STATUS OF PARTIES  
  
  
  
  
  - 26 -  
 
12.04.2The election by the Indemnifying Party, pursuant to Section 13.03.1, to undertake the defense of a third-party claim shall not preclude the Party against which such claim has been made also from participating or continuing to participate in such defense, so long as such Party bears its own legal fees and expenses for so doing. 
 
13.01Independent Contractors. Each of the PHL Parties and their Affiliates, on the one hand, and ICC and its Affiliates, on the other, shall be deemed to be an independent contractor as to the others for all purposes. None of the Transaction Documents shall be construed (1) to create the relationship of employer and employee among the Parties hereto or between any Party and any of the officers, directors, employees, or representatives of any other Party, (2) to create a partnership or joint venture among the Parties hereto, or (3) to authorize any Party to act as a general or special agent of any other, except as may be specifically set forth herein. Except as otherwise expressly set for in this Agreement, no Party shall in any manner be prevented or bound to refrain from engaging in any business or businesses of any kind or nature, or owning or dealing in securities of any entity or making any investments of any kind, or performing services for any other person, firm, or entity. 
 
13.02Authority to Act. Except as otherwise expressly set forth in this Agreement or the Sales and General Agency Agreement, none of the PHL Parties or their Affiliates, on the one hand, and ICC or its Affiliates, on the other, shall have or be deemed to have authority to act on behalf of the others. 
 
13.03No Third-Party Beneficiaries. This Agreement, the Selling Agreement, and the Memorandum of Understanding are solely among the Parties hereto, as applicable, and are not intended to create any right or legal relationship, express or implied, among the Parties or any of their respective Affiliates, officers, directors, employees, agents, representatives, successors or permitted assigns, on the one hand, and any third party, including any Certificate Owner or other person covered under a GIE, on the other hand; provided, however, that the Investors Capital Indemnitees and the PHL Indemnitees are expressly intended to be third-party beneficiaries under this Agreement. 
 
13.04ICC Not Underwriter, Insurer or Producer. Notwithstanding anything to the contrary in any Transaction Document, none of the ICC, its Affiliates, or any of their respective directors, officers, employees, agents, or other representatives are or shall be deemed to be (1) underwriters of any security, including the GIE; (2) insurers, guarantors, or underwriters of any obligation of either PHLVIC and PLIC under the GIE, including the obligation of either of PHLVIC or PLIC to pay claims and benefits arising under the GIE, or (3) insurance agents, brokers or producers, except in the case of ICC and certain of its officers, employees, agents, or other representatives, who are licensed as insurance producers as required under applicable State insurance Laws.SECTION 14 DISPUTE RESOLUTION  
  
  
  
  
  
  
  
  - 27 -  
 
13.05PHL Parties not Investment Adviser. Notwithstanding anything to the contrary in any Transaction Document, none of the PHL Parties or any of their respective directors, officers, employees, agents, or other representatives are investment advisers under the Advisers Act or similar State Laws. 
  14.01Disputes Regarding PHL Services or Investors Capital Services. 
 
14.01.1Notice; Authorized Persons. During the Term, if any of the PHL Parties, on the one hand, or ICC, on the other, encounters a problem that it believes constitutes a material breach of the other’s duty to provide either the PHL Services or the Investor Capital Services, as applicable, the non-breaching Parties shall promptly notify the other Parties in writing, and such breaching Party or Parties shall promptly respond. If the problem is not promptly resolved among the Parties, a PHL Parties Authorized Person and an ICC Authorized Person shall, before the end of the first full Business Day following the date on which initial notice is provided by the non-breaching Parties, consult with each other in good faith concerning the existence, cause and remediation of the possible breach. 
 
14.01.1.1If such Authorized Persons mutually determine that the problem constitutes a material breach, the breaching Party or Parties shall promptly take such actions and make any modifications and/or changes as are required to correct the breach, without charge to the non-breaching Parties. 
  14.01.1.2If such Authorized Persons cannot mutually determine whether the problem is the result of a material breach, then the dispute shall be resolved in accordance with Section 15.02 below. 
  14.01.2Indemnification. The non-breaching Party or Parties may seek indemnification for any damages resulting from a breach under this Section pursuant to Section 12 (Indemnification). 
 
14.02Arbitration. All controversies, claims or disputes among the Parties arising out of or relating to this Agreement, either of the Master Group Annuity Contracts, or breach of any of them, including matters relating to formation, shall be settled by binding arbitration by the American Arbitration Association in accordance with its Commercial Arbitration Rules and Title 9 of the U.S. Code. The place of arbitration shall be Hartford, Connecticut. 
 
14.02.1The arbitrators shall be disinterested. The number of arbitrators shall be three, one of whom shall be appointed by the PHL Parties and one of whom shall be appointed by ICC, and the third of whom shall be selected by mutual agreement of the first two arbitrators, or by the administering authority if the first two arbitrators do not arrive at a mutual agreement within thirty (30) days of the selection of the second arbitrator.SECTION 15 DURATION AND TERMINATION  
  
  
  
  
  - 28 -  
 
14.02.2A decision of a majority of the arbitrators shall be final and binding and there shall be no appeal therefrom, unless (i) the decision was procured by corruption, fraud or other undue means; (ii) there was evident partiality by the arbitrator appointed as a neutral or corruption in any of the arbitrators or misconduct prejudicing the rights of any Party; or (iii) the arbitrators exceeded their powers. The arbitrators shall issue a written opinion in support of the arbitration award. 
 
14.02.3The arbitrators shall have no authority to award punitive damages or any other damages not measured by the prevailing Party’s actual damages, and may not, in any event, make any ruling, finding or award that does not conform to the terms and conditions of the applicable agreement. 
 
14.02.4Each Party shall be responsible for the costs and expenses incurred by such Party, including attorneys, although the cost of arbitration, including the fees of the arbitrators, shall be borne equally by the PHL Parties, on the one hand, and the ICC, on the other; provided, however, that the panel of arbitrators may determine to award fees and costs, including attorney fees, to the prevailing Party. 
  14.02.5Any Party may seek injunctive relief from the arbitrators to maintain the status quo until such time as the arbitration award is rendered or the controversy is otherwise resolved. 
  14.02.6Judgment upon the award rendered by the arbitrators may be entered in the courts specified in Section 16.04 below. 
 
15.01Duration. Except as to termination of new business pursuant to Section 16.02 of this Agreement, this Agreement shall remain in effect for so long as any Certificate remains in force with respect to which benefit payments thereunder have not commenced; provided, however, that the Parties shall be obligated to fulfill their obligations under the Transaction Documents to which they are a party with respect to any Certificate that remains in force. 
  15.02Termination and Suspension as to New Business. 
  15.02.1Termination. This Agreement may be terminated by either the PHL Parties, on the one hand, or ICC, on the other, with respect to Certificates that have not been issued as of the effective date of termination in the following manner: 
  15.02.1.1By any of the PHL Parties, on the one hand, or ICC, on the other, providing one hundred and twenty (120) days prior written notice to the other Parties.- 29 -  
 
15.02.1.2By ICC, if any of the PHL Parties or their Affiliates, as applicable, materially breaches any of the Transaction Documents and does not cure such breach within sixty (60) days of being provided written notice of such breach by ICC. 
  15.02.1.3By any of the ICC, immediately, if: 
 
15.02.1.3.1Any of the PHL Parties is placed in receivership or conservatorship or other proceedings pursuant to which it is substantially prevented from continuing to engage in the lines of business relevant to the subject matter hereof. 
 
15.02.1.3.2Any of the PHL Parties becomes a debtor in bankruptcy, whether voluntary or involuntary, is the subject of an insolvency, rehabilitation, or delinquency proceeding, or is determined to be in hazardous financial condition. 
  15.02.1.3.3Any of the PHL Parties becomes the subject of a criminal indictment or information or similar proceedings. 
  15.02.1.3.4Any of the PHL Parties assigns or transfers this Agreement in a manner that does not comply with the provisions of this Agreement. 
 
15.02.1.4By any of the PHL Parties, if any of the ICC or its Affiliate, as applicable, materially breaches any of the Transaction Documents to which they are a party and does not cure such breach within sixty (60) days of being provided written notice of such breach by a PHL Party. 
  15.02.1.5By any of the PHL Parties, immediately, if: 
 
15.02.1.5.1ICC is placed in receivership or conservatorship or other proceedings pursuant to which it is substantially prevented from continuing to engage in the lines of business relevant to the subject matter hereof. 
 
15.02.1.5.2ICC becomes a debtor in bankruptcy, whether voluntary or involuntary, is the subject of an insolvency, rehabilitation, or delinquency proceeding, or is determined to be in hazardous financial condition. 
  15.02.1.5.3ICC becomes the subject of a criminal indictment or information or similar proceedings. 
  15.02.1.5.4ICC assigns or transfers this Agreement in a manner that does not comply with the provisions of this Agreement.SECTION 16 MISCELLANEOUS  
  
  
  
  
  - 30 -  
 
15.02.2Suspension. Any of the PHL Parties, on the one hand, and ICC, on the other, upon 30 days written notice, may suspend issuance of (1) new Certificates entirely or (2) new Certificates guaranteeing ICC Accounts that invest in one or more Models with certain style attributes or investment vehicles, as may be expressly provided in such written notice, provided, however that the PHL Parties may suspend the issuance of new Certificates affected by a change in any of the Models after the 5 consecutive Business Day following the date on which either PHLVIC or PLIC deliver notice under the Memorandum of Understanding concerning its reasonable determination that it cannot hedge proposed changes without incurring material additional risk and/or material additional hedging costs, or because Phoenix is unable to obtain a reasonably appropriate hedge, if ICAS has made the proposed changes and not cured such changes within such five-day period.  
  16.01Assignment or Change of Control. 
 
16.01.1Assignment. This Agreement shall be binding on and shall inure to the benefit of the respective successors and assigns of the Parties except as otherwise provided in this Agreement. No Party shall assign this Agreement or any rights or obligations hereunder or, except as expressly set forth in the Agreement with respect to the PHL Services and Investors Capital Services, delegate any of their respective duties and obligations hereunder, without the prior written consent of the other Parties, which, in view of the unique and specialized nature of each Party’s obligations hereunder, may be declined by any Investors Capital Party on the one hand or any PHL Party, on the other hand, as the case may be, for any reason. Any attempted assignment or delegation in violation of this Section shall be void. A Change of Control, as defined below, shall be considered an assignment under this Section 16.01 and Sections 16.02.1(c) (4) and 16.02.1(e)(4). 
  16.01.2Change of Control. A “Change of Control” means: 
 
(a) the acquisition by any person, entity or group, including a “group” required to file a Schedule 13D or Schedule 14D-1 under the 1934 Act (excluding, for this purpose, a Party, its Affiliates and any employee benefit plan of a Party or its Affiliates that acquires ownership of voting securities of an Affiliate of that Party) of beneficial ownership (within the meaning of Rule 13d-3 under the 1934 Act) of 50% or more of either the (1) then outstanding ordinary shares of a Party, of a person or entity controlling such Party, or of a person or entity controlling such person or entity, up to and including the ultimate controlling person (such Party and persons or entities collectively, the “Control Group”), or (2) the  
thin each case excluding a reorganization, merger, consolidation, sale, transfer, lease or other disposition when the transaction is among Parties that are under common control both before and after such transaction.  
  
  - 31 -  
 
combined voting power of the Control Group’s then outstanding voting securities entitled to vote generally in the election of directors, in each case excluding an acquisition when the transaction is among Parties that are under common control both before and after such transaction;  
 
(b) the election or appointment to the board of directors of any member of the Control Group, or resignation of or removal from such board of directors with the result that the individuals who as of the date hereof constituted the board of directors (the “Incumbent Board”) of each member of the Control Group no longer constitute at least a majority of such board of directors, provided that any person who becomes a director subsequent to the date hereof whose appointment, election, or nomination for election by the shareholders of each member of the Control Group, was approved by a vote of at least a majority of the Incumbent Board (other than an appointment, election or nomination of an individual whose initial assumption of office is in connection with an actual or threatened election contest relating to the election of the directors of a member of the Control Group) shall be, for purposes of this Agreement, considered as though such person were a member of the Incumbent Board; or 
  (c) the approval by the shareholders of any member of the Control Group of: 
 
(1) a reorganization, merger or consolidation by reason of which the persons who were the shareholders of such member of the Control Group immediately prior to such reorganization, merger or consolidation do not, immediately thereafter, own more than 50% of the combined voting power of the reorganized, merged or consolidated company’s then outstanding voting securities entitled to vote generally in the election of directors, or 
 
(2) a liquidation or dissolution of such member of the Control Group or the sale, transfer, lease or other disposition of all or substantially all of the assets of such person (whether such assets are held directly or indirectly), 
 
16.02Rights, Remedies, Etc. are Cumulative. The rights, remedies, and obligations contained in this Agreement are cumulative and are in addition to any and all rights, remedies, and obligations, at law or in equity, which the Parties may be entitled to under State and federal laws.If to the PHL Parties  
Kathleen A. McGah  Vice President  Life and Annuity Counsel  Phoenix Life Insurance Company  One American Row  PO Box 5056  Hartford, CT 06102-5056  
With a simultaneous copy that shall not constitute notice under this section to:  
General Counsel  Phoenix Life Insurance Company  One American Row  PO Box 5056  Hartford, CT 06102-5056  
If to ICC:  General Counsel  Investors Capital Corporation  230 Broadway East  Lynnfield, MA 01940  
  
  - 32 -  
 
16.03Notices. Except as set for in this paragraph, all notices hereunder shall be made in writing and shall be effective upon delivery, which shall be made (1) by hand delivery, (2) by registered or certified United States mail, postage prepaid with return receipt requested, (3) by a nationally-recognized overnight courier service, to the addresses set forth below, or to such other address as any Party may request by giving written notice to the other Parties. A Party may also provide notice by electronic means (such as email or facsimile) or telephone in cases when immediate notice is required so long as the Party giving notice delivers separate written notice to be with 24 hours pursuant to Sections 16.03(1) or 16.03 (3). 
 
16.04Governing Law. This Agreement shall be construed and its provisions interpreted under and in accordance with the internal Laws of the State of Connecticut, without giving effect to principles of conflict or choice of laws of that or any other jurisdiction. Each of the Parties hereto shall submit to the jurisdiction of the courts of the State of Connecticut and the federal courts in Connecticut.- 33 -  
  16.05Amendments. No change may be made to the terms or provisions of this Agreement except by written agreement signed by the Parties. 
 
16.06Severability. If any provision of this Agreement is held invalid, illegal, unenforceable, or in conflict with the Law of any jurisdiction, such provision shall be enforced to the extent permitted under applicable Law, and the validity, legality, and enforceability of the remaining provisions shall not in any way be affected or impaired thereby. 
 
16.07Waiver. The failure by any Party to insist upon strict compliance with any condition of this Agreement shall not be construed as a waiver of such condition. Waiver by one Party to this Agreement of any obligation of another Party to this Agreement does not constitute a waiver of any further or other obligation of such Party. 
 
16.08Interpretation. This Agreement shall be governed by the following rules of interpretation: (a) when a reference is made in this Agreement to an Article, Section, or Exhibit, such reference shall be to an Article of, a Section of, or Exhibit to, this Agreement unless otherwise indicated; (b) the headings contained in this Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement; (c) whenever the words “include,” “includes” or “including” are used in this Agreement, they shall be deemed to be followed by the words “without limitation;” (d) whenever the singular is used herein, the same shall include the plural, and whenever the plural is used herein, the same shall include the singular, where appropriate; and (e) references to currency or amounts due shall mean United States dollars. 
 
16.09Construction. The Parties hereto have participated, directly or indirectly, in the negotiations and preparation of this Agreement. In no event shall this Agreement be construed more or less stringently against any Party by reason of another Party being construed as the principal drafting Party hereto. 
  16.10Survival. The following Sections shall survive termination of this Agreement: Sections7.05, 7.06, 8.06, 8.07, 9 (including Exhibit C), 10, 11.02, 11.03, 12, 13, 14.02, 16. 
 
16.11Entire Agreement. This Agreement, the other Transaction Documents and the Indemnification Agreement between the Parties, effective as of the Effective Date (the “Indemnification Agreement”), constitute the entire agreement between the Parties hereto with respect to the subject matter hereof and thereof, and supersede any and all prior oral or written understandings, agreements or negotiations, between or among the Parties with respect to the subject matter hereof and thereof. No prior writings by or among the Parties with respect to the subject matter hereof and thereof may be used by any Party in connection with the interpretation of any provision of this Agreement, the Indemnification Agreement, or the other Transaction Documents.IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed and delivered by their duly authorized partners and officers, all as of the Effective Date.    
  
  - 34 -  
  16.12Counterparts. This Agreement may be executed in two or more counterparts, each of which taken together shall constitute one and the same instrument. 
PHL VARIABLE INSURANCE COMPANY     PHOENIX EQUITY PLANNING CORPORATION
BY:   /S/ KATHLEEN A. MCGAH     BY:   /S/ KATHLEEN A. MCGAH 
NAME:  KATHLEEN A. MCGAH     NAME:  KATHLEEN A. MCGAH
TITLE:  VICE PRESIDENT     TITLE:  VICE PRESIDENT
PHOENIX LIFE INSURANCE COMPANY     INVESTORS CAPITAL CORPORATION
BY:   /S/ JOHN V. LAGRASSE     BY:   /S/ THEODORE E. CHARLES 
NAME:  JOHN V. LAGRASSE     NAME:  THEODORE E. CHARLES
TITLE:  EXECUTIVE VICE PRESIDENT     TITLE:  DIRECTOREXHIBIT A TO THE STRATEGIC ALLIANCE AGREEMENT  
PHL VARIABLE SERVICES    
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
- 35 -  
A. PHL Variable shall, or shall cause one or more of its Affiliates to, provide all services necessary or desirable to fully administer the GIE, including, but not limited to: 
  1. Notifying ICC of any change to the GIE Fee rate at least ten calendar days prior to the effective date of the fee change via E-mail; 
  2. Calculating the GIE Fee for each Certificate and send the inception and quarterly fee information to ICC; 
  3. Calculating the Retirement Income Base for each Certificate; 
  4. Calculating the Retirement Income Amount for each Certificate; 
  5. Calculating the Required Minimum Distribution for each IRA account, as applicable, but not including tax reporting to the IRS; 
 
6. Providing telephone support to ICC to enable ICC to answer Certificate Owners’ questions about their GIE benefit, including Retirement Income Base; Retirement Income Amount, and the GIE Fee on Business Days during the regular business hours of PHL Variable; 
  7. Drafting and sending the following documents/correspondence to Certificate Owners: 
  a. Welcome Letter and Certificate; 
  b. GIE Retirement Income Base /Retirement Income Amount Adjustment Notice or similar notice, due to a withdrawal, contribution or reaching retirement income date; 
  c. GIE Fee Deduction Notice or similar notice, sent quarterly to confirm the GIE Fee deduction; 
  d. January 1 Letter, with the new Retirement Income Amount for the year;  
  e. GIE Termination Notice or similar notice; and 
  8. Correspondence after the account value reaches zero; 
  9. Sending ICC a report showing any investments in an ICC Account that are not invested in accordance with the ICC models, as necessary; 
  10. Providing ICC with a quarterly data file containing Certificate Owner data, if requested in writing by ICC in order for ICAS to reconcile data maintained by PHL Variable vs. ICAS. ICC shall notify PHL Variable of any discrepancies identified; 
 
11. Notifying ICAS, thirty [30] calendar days in advance of the anniversary date for each Certificate, of fee information relating to the Annual Optional Increase; Correcting Certificate Owner file data upon notification of an incorrect Certificate termination by ICC using current account values; and 
  12. Working with ICC on manual corrections. 
B. All information provided shall be in form and content mutually acceptable to the Parties 
stEXHIBIT B TO THE STRATEGIC ALLIANCE AGREEMENT  
INVESTORS CAPITAL SERVICES    
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
- 36 -  
A. ICCS shall, or shall cause one or more of its Affiliates, to: 
  1. Notify PHL Variable if a Certificate Owner has changed to a non-GIE eligible investment model and has thereby terminated the GIE; 
  2. Notify PHL Variable of the amount of non-cash assets transferred into an ICC Account that are in non-conformance to the model asset allocation in the daily transmission; 
  3. Notify PHL Variable of or errors and corrections relating to a Certificate Owner’s additional contributions and withdrawals; 
  4. For new Certificates, send ICC Account assets and values electronically to PHL Variable on the certificate effective date; 
  5. If ICAS becomes aware of any material pricing errors, notify PHL Variable of such errors; 
  6. On each Business Day, send PHL Variable ICC Account assets, values, and selected transactions electronically; 
  7. ICAS shall provide PHL Variable with a quarterly data file containing Certificate Owner data, if requested in writing by PHL Variable in order for PHL Variable to reconcile data maintained by PHL Variable. PHL Variable shall notify ICAS of any discrepancies identified; 
  8. Work with PHL Variable on manual corrections; and 
  9. Debit the GIE Fee at inception and quarterly, in advance, and remit the fee to PHL Variable. 
  10. Notify PHL Variable if a Certificate Owner has terminated the GIE; 
  11. Notify PHL Variable of the divorce of Certificate Owners promptly after such notification is received by ICC or ICAS; 
  12. Send PHL Variable a copy of Certificate Owners’ divorce decrees promptly after such decrees are received by ICC or ICAS; 
  13. Notify PHL Variable of the death of a Certificate Owner promptly after such notification is received by ICC or ICAS; 
  14. Send PHL Variable a copy of the deceased Certificate Owner’s death certificate promptly after the death certificate is received by ICC or ICAS; 
  15. Verify that each Application is completed; 
  16. Send the completed Application to PHL Variable; and 
  17. Notify PHL Variable if ICC becomes aware of an erroneous termination of a GIE. 
B. All information provided shall be in form and content mutually acceptable to the PartiesEXHIBIT C  
TRADEMARK LICENSE TERMS  
The following terms and conditions apply to each License of Trademarks pursuant to Section 9.02 of the Agreement.  
  
  
  
  
  
  
  - 37 -  
1. LIMITED LICENSE: Nothing in the Agreement or this Exhibit shall be construed to grant Licensee any rights or license to any trademark, trade name, certification mark, service mark, domain name, product name, logo, patent, technical information, or copyright of Licensor other than as specified herein. All rights not specifically granted to Licensee are reserved to Licensor. 
 
a) Use: Licensor reserves the right as owner of the Trademarks to specify all aspects of use of the Trademarks, including but not limited to, the manner, place, type, form, layout, design, channels of trade, channels of distribution, and media of or for such use, on or in connection with, all displays, advertising, labels, literature, Internet sites, sales promotion materials, and all other forms of use of the Trademarks. All use of the licensed Trademarks shall inure to the benefit of Licensor. Licensee shall comply with any specific trademark use rules as may be referenced in any of the Exhibits, or provided to Licensee, which may be amended or revised by Licensor from time to time, upon written notice. 
 
b) Acknowledgment: Licensee hereby acknowledges the validity of Licensor’s Trademarks and Licensor’s exclusive right, title and interest in and to the Trademarks. As requested by Licensor, Licensee shall employ identifying symbols and/or words in connection with its use of the Trademarks. Licensee shall cooperate with Licensor in taking all appropriate measures for the protection of the Trademarks, and shall faithfully observe and execute the requirements, procedures, and directions of Licensor with respect to the use and protection of the Trademarks. Licensee shall not, during the term of this Agreement, or thereafter: 
  (1) do or permit to be done any act or thing which prejudices, infringes or impairs the rights of Licensor with respect to the Trademarks; 
  (2) represent that it has any right, title, or interest in or to the Trademarks, other than the limited license granted hereunder, or in any registration therefore; 
 
(3) use, register or attempt to register any trademarks, trade names, logos, domain names, metatags, meta descriptors, or electronic mail (e-mail) addresses, server names, search-engine markers, that are identical to, or confusingly similar to the Trademarks or any other trademarks, trade names or domain names of Licensor or any of its subsidiaries or affiliated companies;- 38 -  
  (4) do anything or produce any goods in connection with the Trademarks that damages or reflects adversely upon Licensor, its subsidiaries or affiliated companies or any of their trademarks, trade names or domain names; and 
  (5) continue any use or action in relation to or in connection with the Trademarks or this Agreement if objected to by Licensor.  
  c) Goodwill: Licensee recognizes the value of the reputation and goodwill associated with the Trademarks, acknowledges that the Trademarks have acquired secondary meaning, and that all related rights and goodwill belong exclusively to Licensor. 
 
d) Art Work: All art and design or lay-out work that contains, is derived from or used with the Trademarks, shall be solely owned by Licensor. Licensee shall not obtain, attempt to obtain or claim any copyright or trademark rights therein, and upon request, Licensee shall assign same to Licensor. 
 
e) Infringement Action: Licensor shall have the sole right to determine the appropriate action to be taken against any infringement, imitation, or unauthorized use of the Trademarks including having the sole discretion to settle any claims or any controversy arising out of any such claims. Licensee shall provide Licensor with such reasonable assistance as Licensor may require in obtaining any protection of Licensor’s rights to the Trademarks at no expense to Licensor. Licensee shall not have any rights or claim against Licensor for damages or otherwise arising from any determination by Licensor to act or not to act with respect to any alleged infringement, imitation or unauthorized use by others, and any such determination by Licensor shall not affect the validity or enforceability of this Agreement. Any and all damages and settlements recovered arising from any action or proceeding shall belong solely and exclusively to Licensor. 
  f) Assignment to LICENSOR: Upon request, Licensee shall transfer to Licensor any rights which accrue to Licensee arising from its use of the Trademarks or this Agreement. 
2. QUALITY STANDARDS, INSPECTION, AND TESTING: So that the value of the goodwill and reputation associated with the Trademarks will not be diminished, Licensee shall have an obligation to ensure that all materials on which the Trademarks are used shall be of at least the same uniform high quality (i) as may be approved by Licensor hereunder; or (ii) as specified in quality standards provided by Licensor hereunder, as the case may be. To monitor for Licensee’s adherence to such obligations, Licensor shall have the right to inspect such materials from time to time through duly authorized representatives. Materials not meeting the quality or other requirements set forth in this Agreement shall not be in any way promoted in connection with the Trademarks, and all references to the Trademarks on labels, product literature, promotional material, etc., shall be removed at Licensee’s expense.“ ® is a registered Trademark of [Licensor] and is used under license to [Licensee].”    
  
  
  - 39 -  
3. LICENSING NOTICE: Licensee shall include a notice on all labeling, advertising, literature, Internet sites, and sales promotional materials that the Trademarks are licensed from Licensor. The notice shall be as follows or as otherwise specified by Licensor: 
4. NO CONSEQUENTIAL DAMAGES, ETC.: IN NO EVENT SHALL ANY PARTY BE LIABLE FOR ANY SPECIAL, INDIRECT, INCIDENTAL, PUNITIVE, CONSEQUENTIAL, OR ANY SIMILAR DAMAGES WHETHER OR NOT CAUSED BY OR RESULTING FROM THE NEGLIGENCE OF SUCH PARTY EVEN IF SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, IN RELATION TO, ARISING OUT OF OR IN CONNECTION WITH THIS EXHIBIT OR THE TRADEMARKS. 
5. SUPPLEMENTAL PROVISIONS: If any supplemental provisions are made a part of the Agreement or this Exhibit, they are set forth in Annex A to this Exhibit. 
6. SURVIVAL: Notwithstanding termination of the Agreement, Sections 1(a)-1(f) and 4-6 of this Exhibit shall survive termination of the Agreement.Exhibit 10.1
Confidential treatment has been requested for portions of this Exhibit. The copy filed herewith omits the information subject to the confidentialityrequest. Omissions are marked by brackets with asterisks, such as [***]. A complete version of this Exhibit has been filed separately with theSecurities and Exchange Commission.
STRATEGIC ALLIANCE AGREEMENT THIS STRATEGIC ALLIANCE AGREEMENT (“Agreement”), entered into as of October 22, 2010 (the “Effective Date”) by and betweenPPD Development, LP, a Texas limited partnership, with its principal executive offices located at 929 North Front Street, Wilmington, North Carolina28401 (“PPD”) and VirtualScopics, Inc., with an address of 500 Linden Oaks, Second Floor, Rochester, New York 14625 (“VS”). WHEREAS, PPD is a clinical research organization engaged in the business of managing clinical research programs and providing servicesregarding the development of pharmaceuticals, chemicals, biotechnology and other products through clinical testing; WHEREAS, VS is in the business of providing imaging services to the medical, pharmaceutical and related industries; WHEREAS, PPD and VS desire to enter into a mutually beneficial relationship with a mission to deliver a comprehensive set of clinical andmedical imaging services that will enable biopharmaceutical companies to make faster, more confident decisions on the development of theircompounds, creating time and cost efficiencies; and WHEREAS, the parties desire to develop, market, sell, and deliver those joint service offerings pursuant to the terms and conditions set forthherein. NOW, THEREFORE, in consideration of the promises and mutual covenants contained herein and other good and valuable consideration,the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows: 1. Term. The term of this Agreement shall begin on the Effective Date and shall continue for a period of two (2) years (“Initial Term”) unlessterminated earlier in accordance with Section 11 of this Agreement. Upon expiration of the Initial Term, unless written notice to the contrary isprovided by one party to the other party at least 30 days prior to the expiration of the then-current term, this Agreement shall be renewed foradditional, successive periods of one (1) year each (each a “Renewal” and together with the Initial Term, collectively, the “Term”). In connection withany Renewal, the parties shall mutually agree upon and set forth in a written amendment signed by the parties (i) any changes to the Servicesconstituting Preferred Services and (ii) any changes to the [***], VS Preferred Pricing, percentage Discount (defined in Section 4 below) or Bookingsthresholds for all such Preferred Services. Upon any expiration or termination of this Agreement, all active Work Orders issued prior to such expirationor termination shall remain subject to the terms and conditions contained herein so long as such Work Order remains active. 2. Services. PPD or any of its subsidiaries or affiliates may engage VS to perform imaging services (the “Services”) for a specific sponsor’sclinical research study (“Sponsor”) or for a particular project. The Services may be amended, supplemented, or replaced from time to time upon mutualagreement of VS and PPD.
[***] Represents material which has been redacted and filed separately with the Commission pursuant to a request for confidential treatmentpursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended.
13. Services Commitment. “Preferred Services” shall be defined as those imaging services included within the service offerings of VS at thetime of final execution of this Agreement which are specifically provided by VS in the therapeutic areas of hematology and oncology (“DesignatedTherapeutic Areas”) to the extent such imaging services are subject to the commitments of VS set forth in this Section 3 (the “Commitments”). “PPDServices” shall be defined as clinical research organization services regarding the management of clinical trials for the development of pharmaceuticals,chemicals, biotechnology and other products through clinical testing. Preferred Services and PPD Services shall be subject to all of the rights andobligations otherwise set forth in this Agreement. Nothing contained herein shall be construed to limit the provision of non-Preferred Serviceshereunder, however, such non-Preferred Services shall not be subject to the Commitments set forth in this Section 3. a. Joint Commitments (i) The parties acknowledge and agree that it is their intent and commitment to expand the Joint Solution (as definedbelow) to therapeutic areas beyond the Designated Therapeutic Areas. Upon mutual agreement regarding suchexpansion, it is the parties’ further intent to make such additional Joint Solution services subject to substantiallythe same commitments as those set forth herein. (ii) The parties acknowledge and agree that each party has in place, or will develop, processes and proceduresapplicable to their performance hereunder as specified on Exhibit A (“Integration Services”). The IntegrationServices shall be reviewed and assessed by the parties from time to time and may be amended or updated fromtime to time. Exhibit A shall be used as a guide for developing integrated service offerings to meet the needs ofeach party’s clients, as applicable (in each instance, a “Joint Solution” or collectively, the “Joint Solution”). (iii) Where either party determines that an opportunity exists and is appropriate for the offering of the Joint Solution tothat party’s customer or client, it is the parties’ mutual intent and commitment to collaborate, as needed, topropose the Joint Solution to that customer or client. Each party agrees to make a good faith effort to promote aJoint Solution for a Sponsor seeking services that could reasonably be addressed by the Joint Solution. Inconnection with PPD’s response to a request for proposal (an “RFP”) in which a Joint Solution is proposed, PPDshall be responsible for the preparation and submission of such RFP response; provided, however, that PPD shallprovide VS an opportunity to review and provide approval on the Joint Solution framework, including, the scopeof the Preferred Services and the pricing thereof. VS shall provide such review within two (2) business daysfollowing receipt by VS of such RFP response from PPD. Where reasonably appropriate for the proper defense ofan RFP, PPD will use its reasonable efforts to provide VS an opportunity to participate in a call or bid defensemeeting to the extent related to the Joint Solution. In the event PPD is awarded a clinical research study and suchaward includes selection by Sponsor of the Joint Solution, the parties shall mutually agree upon an applicableWork Order in accordance with Section 4 below.
2A. However, nothing contained herein shall be construed to impose upon PPD an obligation to offer theJoint Solution or to use VS for Preferred Services where: (1) Sponsor is not in agreement, (2) VS’s pricingis not competitive, or (3) there have been advances in technology not offered by VS. B. Further, nothing contained herein shall enable either party to utilize the Joint Solution where the clienthas rejected the involvement of either party. For the avoidance of doubt, the Joint Solution shall only beutilized where both parties’ services in furtherance of the Joint Solution have been retained by the client.Nonetheless, a client’s selection or rejection of either party for services outside the Joint Solution shall inno way impact or impede a party from performing such services, regardless of the other party’s selectionor rejection by the client. C. In the event either party discovers, directly or indirectly, technology not currently in use by the otherparty but which could improve the Preferred Services, PPD Services or the Joint Solution, the discoveringparty may elect to share such technology with the other party with the intent of integration by the otherparty. However, to the extent such other party elects not to integrate or otherwise use such technology,the discovering party shall not be prohibited from using that technology without the other party’sinvolvement. (iv) During the Term, VS acknowledges and agrees that, to the extent it is aware of an opportunity for clinical researchservices, it will refer such opportunity to PPD as soon as possible. VS shall not refer that opportunity to any otherthird party provider unless PPD declines to bid on such opportunity or does not offer the service in question.During the Term, PPD acknowledges and agrees that, to the extent it is aware of an opportunity for imagingservices outside of the Joint Solution, it will refer such opportunity to VS as soon as possible. Unless otherwiserequired by a particular Sponsor, PPD shall not refer that opportunity to any other third party provider unless VSdeclines to bid on such opportunity or does not offer the service in question.
3(v) During the Term of this Agreement, except as otherwise permitted by this Section 3(a)(v), VS agrees that it shallnot enter into the same or substantially similar Commitments with any other company or entity which performsclinical research services the same or similar to those provided by PPD or any PPD affiliate (collectively, “PPDCompetitor”), nor shall VS provide preferred pricing to a PPD Competitor which is better than that provided by VShereunder to PPD. Further, during the Term of this Agreement, PPD agrees that it shall not enter into commitmentswhich are the same or substantially similar to the PPD commitments set forth in Section 3 with any other imagingvendor for the performance of Preferred Services. In the event that, during the Term of this Agreement, VS desiresto enter into the same or substantially similar Commitments with a PPD Competitor for imaging services outside ofthe Designated Therapeutic Areas (defined herein or in any amendment hereto), VS shall first notify PPDregarding the same and PPD shall have a right, for a period of 45 days following receipt of such notice (the“Election Period”), to elect to include such imaging services as “Preferred Services” hereunder (the “Right of FirstRefusal”). In the event PPD either (i) fails to respond within the Election Period or (ii) declines to include suchimaging services as “Preferred Services” prior to termination of the Election Period, then in either such event, VSshall be permitted to pursue such relationship without being considered in violation of the Commitments or thisAgreement. Additionally, in the event that PPD enters into a relationship with a VS competitor which provides forcommitments which are the same or substantially similar to the Commitments in a therapeutic area outside theDesignated Therapeutic Areas (defined herein or in any amendment hereto), VS shall have the right, withoutviolating the Commitments or this Agreement (including the Right of First Refusal), to enter into a relationshipwith a PPD Competitor which provides for commitments which are the same or substantially similar to theCommitments outside the Designated Therapeutic Areas (defined herein or in any amendment hereto). (vi) The parties shall form a Steering Committee comprised of high level personnel from each party which shall meetquarterly during the Term of this Agreement to oversee the implementation of this preferred relationship and theobligations set forth herein. The Steering Committee shall be comprised of an equal number of representatives from each party. PPD’s SteeringCommittee representatives shall be comprised of: Director, Finance; Therapeutic Head; Relationship Manager;Executive Director, Business Development; Executive Director, Information Technology; Medical Director, GlobalDrug Development. VS’s Steering Committee representatives shall be comprised of: Chief Financial Officer; ChiefExecutive Officer/President; Director of Operations and Director of Project Management. Each party shall provideprior written notice to the other party of any desired change in Steering Committee representatives. Each party’sSteering Committee representatives shall hold a position of sufficient level within its respective company to beable to obtain timely resolution of disputes submitted to the Steering Committee.
4In the event a Sponsor shall raise concerns or issues with respect to any Preferred Services performed by VS inconjunction with Sponsor’s selection of the Joint Solution, which Preferred Services are agreed upon by the parties in an executedWork Order, VS and PPD shall mutually evaluate such concerns or issues prior to any communication withSponsor and shall mutually agree upon an appropriate response to Sponsor related to such concerns or issues.The resolution of any such matters shall be submitted first to the parties’ respective Project Manager for thestudy, and in the event such persons are unable to agree upon resolution, then to each parties’ RelationshipManager/Senior Director and finally to the Therapeutic Head or equivalent position. The foregoing paragraphshall not be deemed to restrict a PPD project manager from ordinary course discussions with a Sponsor in order tocollect information related to the nature of any such concerns or issues raised by Sponsor. b. VS Commitment. VS agrees to continue to make investments in and improvements to those processes, technologies, techniques,software, hardware and methods which are integral or beneficial to the Services provided by VS, specifically but without limitation, to the PreferredServices. c. PPD Commitment. Where PPD is in a position to make a recommendation to Sponsor with regard to imaging services, and VS isable to provide such imaging services in accordance with Sponsor’s specifications, PPD agrees to recommend VS to Sponsor. PPD also agrees tomaintain, when present, VS’s name and logo on all VS generated deliverables to the Sponsor. 4. Compensation. a. Each time VS is requested to perform Services, PPD shall provide VS with a work order or other similar written document mutuallyagreed upon by VS and PPD which shall set forth the specific services being requested, the compensation therefore and such other terms, conditionsand specifications as VS and PPD may mutually agree (referred to herein as a “Work Order”). The parties acknowledge that no services shall beconducted by VS and no compensation shall be due and payable to VS without a Work Order. In the event PPD receives a change order from aSponsor which includes changes to VS’s Services as set forth in an executed Work Order or may otherwise impact the provision by VS of Services toPPD hereunder, PPD shall promptly notify VS. Thereafter, the parties shall negotiate, in good faith, for an amendment to the applicable Work Order, asappropriate, as a result of such Sponsor change order. b. VS shall be compensated for the Services in accordance with the Work Order. All pricing and rates used to establish the budgetfor Services set forth in each Work Order shall be in accordance with the pricing structures agreed upon by the parties herein and set forth in Exhibit Battached hereto and incorporated herein by reference. PPD acknowledges that VS customarily receives an advance payment in connection with theprovision of imaging services to its clients. PPD agrees that, where appropriate and permitted by the Sponsor, PPD will provide for an advancepayment mutually determined by PPD and VS (and acceptable to Sponsor) in connection with the provision of Preferred Services to such Sponsor.  5c. Exhibit B sets forth the pricing and rates for Preferred Services [***]. The prices and rates set forth in Exhibit B and the Discountand Booking thresholds set forth in Exhibit C shall remain in effect, without adjustment, during the Initial Term of this Agreement and may thereafterbe updated to reflect changes in connection with any Renewal of this Agreement, as specified in Section 1 herein. [*** 2.5 paragraphs omitted] Upon the termination of this Agreement for any reason, VS shall no longer have any obligation to provide PPD with any Discount withrespect to Preferred Services nor shall VS be required to offer VS Preferred Pricing [***]. The parties acknowledge and agree that the VS PreferredPricing [***] shall apply to, and remain in effect for, all active Work Orders issued hereunder, regardless of the expiration or termination of thisAgreement, as well as for any timeline extensions to an active Work Order, provided that in the case of a timeline extension, the parties may mutuallyagree to apply an inflation rate for the extension period. In the event a Work Order shall be amended in any respect (including with respect to thescope of the Preferred Services, the timing for the delivery thereof, or otherwise), the VS Preferred Pricing [***] applicable to any Preferred Servicesincluded in such amendment and the Discount shall be the VS Preferred Pricing [***] and the Discount in effect on the date of the original WorkOrder. The parties further acknowledge and agree that VS Preferred Pricing [***] shall be applicable to any agreed upon expansion of the PreferredServices. With respect to any Services provided to PPD hereunder, PPD shall charge each Sponsor the actual invoiced amounts charged by VS to PPDfor such Services without any mark-up or administrative or other fee, unless VS has agreed otherwise in writing in the applicable Work Order. d. Additionally, PPD shall reimburse VS for all reasonable expenses incurred in the course of performing the Services which are setforth in the Work Order. VS shall maintain a complete accounting of all expenses incurred and shall include such accounting with VS’s invoicesubmitted to PPD. Expenses incurred must be invoiced separately and must include an expense report along with original receipts for such expenses. e. VS shall submit monthly invoices to PPD detailing its activities and fees in accordance with Section 5 of this Agreement.Notwithstanding the foregoing, invoices must be submitted to PPD within thirty (30) days of performing the Service or incurring the expense. PPDshall have no obligation to issue payment to VS for Services performed or expenses incurred which were not invoiced to PPD in accordance with thisAgreement. f. VS acknowledges and agrees that where VS’s Services relate to a specific Sponsor’s clinical research study, all payments under aWork Order are pass through payments from Sponsor and PPD shall not have any payment obligations until such payments are received fromSponsor. PPD shall use all reasonable diligence to obtain timely payment from Sponsor in order to make payment to VS within 45 days following thedate of invoice receipt. In furtherance thereof, PPD shall ensure that Sponsor is invoiced no later than ten (10) days following PPD’s receipt of VS’sinvoice, assuming such invoice was provided to PPD by VS in accordance herewith and provided that Sponsor’s invoice requirements do not precludethe same. PPD shall ensure that VS is aware of any such Sponsor restrictions as soon as possible. Further, PPD shall ensure that payment is made toVS either by wire transfer or PPD check in accordance with PPD’s applicable payment processes no later than ten (10) days following PPD’s receipt ofapplicable funds from Sponsor; provided, however, that in the event such payment occurs more than 45 days following the date of PPD’s receipt ofVS’ invoice, such payment shall be made by wire transfer. Notwithstanding the foregoing, where a Sponsor fails to issue payment to PPD, affectingPPD’s ability to pay VS, the parties shall communicate with the other to jointly pursue communication with the Sponsor to address the non­payment.
[***] Represents material which has been redacted and filed separately with the Commission pursuant to a request for confidential treatmentpursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended.
6g. Where PPD and Sponsor have agreed upon and captured in a fully executed contract any bonus/penalty or other similar,milestone based incentive provisions, and PPD’s ability to meet the terms of such provisions will be impacted by VS’s Services, PPD and VS maymutually agree, case by case, to flow through to the applicable Work Order all or agreed upon portions of such bonuses, penalties or incentives. 5. Invoices and Billing Account Number. PPD shall assign a billing account number (“Purchase Order Number”) to VS for the Services ineach Work Order. All VS invoices must reference the Purchase Order Number, Service fees, any PPD pre-approved expenses incurred by VS, theremittance address, and the total amount of compensation owed to VS. These invoices must be sent to the following address: PPD, 929 North FrontStreet, Wilmington, NC 28401, Attention: Accounts Payable. 6. Independent Contractor. VS shall perform all Services under this Agreement as an independent contractor and not as an employee, partneror agent of PPD. As such, VS shall be solely responsible for the payment of all taxes, payroll deductions and similar items associated withcompensation for its services under this Agreement as may be required by applicable law. VS acknowledges that as an independent contractor it willnot be entitled to insurance or other benefits made available to employees of PPD. 7. Additional Personnel. VS shall have the authority to utilize a third party vendor as may be required to perform the Services(“Subcontractors”); provided, however, that: a. Subcontractors must be approved in advance by PPD, such approval not to be unreasonably withheld, conditioned or delayed. b. VS shall be responsible for all taxes, payroll deductions and similar items which may result from the retention of suchSubcontractors to assist in the performance of VS’s obligations under this Agreement. c. Compensation for the services of said Subcontractor shall be paid to VS by PPD on a pass-through basis and at no profit to VS. d. Any such Subcontractor and its employees or other personnel shall be bound by the terms and conditions of this Agreement withrespect to representations and warranties, privacy, confidential information, intellectual property, indemnification, debarment, record keeping and audit(see Sections 8, 9, 10, 12, 14 and 15), which provisions shall be incorporated into a written agreement between VS and such Subcontractor. e. Notwithstanding the foregoing, VS shall remain responsible for the actions of all of the Subcontractors retained by VS.
78. Representation and Warranties. VS represents and warrants that it shall utilize independent discretion and judgment in discharging itsresponsibilities in a timely, professional and workmanlike manner in accordance with internationally accepted standards, and shall, at all times: (i) useindividuals of suitable training and skill to perform its duties and responsibilities under this Agreement, if applicable; (ii) be in possession of all thenecessary facilities, resources and personnel required to perform its duties and responsibilities under this Agreement; and (iii) comply with allapplicable laws, rules, regulations and guidelines. Further, VS represents and warrants that it has all of the necessary licenses, permits and/or registrations to perform the Services inaccordance with the terms and conditions of this Agreement and that during the Term of this Agreement, all such licenses, permits and/orregistrations are and shall remain current and in good standing. [*** 1 paragraph omitted] 9. Confidential Information. It is understood and agreed that any and all information which may be made available to, learned by or generatedby either party during the Term of this Agreement, including without limitation, information relating to the other party’s businesses, its affiliates or theSponsor, Sponsor’s protocol, and this Agreement (collectively, “Confidential Information”), is to be treated as strictly confidential (the partydisclosing such Confidential Information, the “Disclosing Party” and the party receiving such Confidential Information, the “Receiving Party”, withthe understanding that either term may include, as applicable, an affiliate of either party). Confidential Information shall be used solely in connectionwith performance hereunder or as otherwise may be necessary for a party to fulfill its obligations to a customer or client and shall not to be publishedor disclosed to any third parties other than the Receiving Party’s employees on a strict need­to­know basis and provided that such employee is undera similar written and enforceable obligation to keep such information strictly confidential. Further, nothing contained herein shall prevent PPD fromdisclosing VS Confidential Information to PPD’s customers and clients solely to the extent directly related to the provision of Services to suchcustomer or client. The nondisclosure obligations set forth in this Section 9 shall not apply to any portion of Confidential Information (i) which is, orsubsequently may, become within the knowledge of the general public other than as a result of a breach of this Agreement by the Receiving Party; (ii)which is known to the Receiving Party on a non-confidential basis at the time of receipt thereof from the Disclosing Party; (iii) which maysubsequently be rightfully obtained from a third party not bound by an obligation of confidentiality to the Disclosing Party, or (iv) which is requiredby any law, rule, regulation, order, decision, decree, subpoena or other judicial, administrative or legal process to be disclosed, provided that theDisclosing Party receives prior written notice of such disclosure and that the Receiving Party takes all reasonable and lawful actions to obtainconfidential treatment for such disclosure and, if possible, to minimize the extent of such disclosure. Receiving Party shall take reasonable care of all Confidential Information entrusted to it by or on behalf of the Disclosing Party or Sponsor,and shall return such materials to the Disclosing Party or Sponsor (as the case may be) immediately upon expiration or termination of this Agreement. Both parties agree to handle all information containing personal data in accordance with all applicable privacy laws, rules, and regulations.
[***] Represents material which has been redacted and filed separately with the Commission pursuant to a request for confidential treatmentpursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended.
810. Intellectual Property. Nothing contained herein, nor the delivery of any information to either party hereunder, shall be deemed to grantthe other party a right or license under any patent or patent application or to any know-how, technology, invention or other intellectual property of theother party or of the Sponsor. All inventions, patents, know-how, trademarks, copyrights, information, data, software, methodologies, writings and other property in anyform whatsoever, which are provided to either party and which were owned or controlled by the providing party (“Originator”) shall remain the soleproperty of the Originator. The parties’ ownership rights in any inventions, patents, trademarks, copyrights, software, methodologies, writings and other property in anyform whatsoever that results out of the development of a Joint Solution shall be addressed by the parties by separate written agreement which mayinclude, an applicable Work Order and/or an amendment to this Agreement (“Intellectual Property Amendment”) . Unless otherwise addressed in an Intellectual Property Amendment, VS hereby assigns to PPD (or Sponsor as the case may be) all rights thatVS may have in any invention, technology, know-how or other intellectual property which is developed with use of Confidential Information providedto VS by PPD. Additionally, VS shall assist PPD (or Sponsor), at PPD’s (or Sponsor’s) sole cost and expense, in obtaining or extending protectiontherefor. Unless otherwise addressed in an Intellectual Property Amendment, PPD hereby assigns to VS all rights that PPD may have in any invention,technology, know-how or other intellectual property which is developed with use of Confidential Information provided to PPD by VS. Additionally,PPD shall assist VS, at the sole cost and expense of VS, in obtaining or extending protection therefor. 11. Termination. Either party may terminate this Agreement, without cause, upon ninety (90) days prior written notice to the other party,provided, however, that all outstanding Work Orders shall continue to be governed by the terms and conditions hereof. Either party may terminatethis Agreement, or a relevant Work Order, immediately, upon the occurrence of any of the following for cause events: (a) either party’s material breachof the commitments set forth in Section 3; (b) either party commences a voluntary proceeding under any bankruptcy, insolvency or other similar law oran involuntary case or proceeding is commenced against a party under any bankruptcy, insolvency or other similar law; (c) significant audit findingsare identified by the other party, a Sponsor, or an applicable regulatory authority; or (d) significant operational deficiencies that are not resolved inaccordance with the Steering Committee determinations following escalation. PPD shall further be permitted to terminate this Agreement or a relevantWork Order, immediately, for cause, upon the occurrence of any of the following: (a) VS’s failure to meet the agreed upon timelines, provided that suchfailure is due to circumstances within VS’s reasonable control; (b) VS’s failure to provide pricing which is reasonably competitive; (c) a change ofownership equal to fifty percent (50%) or more in the outstanding voting securities of VS; (d) the acquisition of a number of VS’s outstanding votingsecurities by a PPD Competitor that would require disclosure by such PPD Competitor pursuant to Rule 13d-1 of the Securities Exchange Act of 1934(a “Significant Ownership Position”); (e) a change in any VS Key Leadership Position. In the event Sponsor, with or without cause, terminates, or requests that PPD terminate, VS’s involvement in a project, PPD shall have theright to immediately terminate the Work Order to which such project relates. Additionally, in the event the services requested of PPD by Sponsor arecancelled or put on hold or the services agreement between PPD and Sponsor is terminated, PPD may terminate any relevant Work Order immediatelyupon notice to VS. In the event any Work Order is terminated, PPD shall pay VS for all Services performed in accordance with the Work Order throughthe date of termination plus any agreed upon costs necessary to close-out the Work Order (which costs shall be documented in a Work Orderamendment if not included in the Work Order) and any non-cancelable expenses incurred prior to the termination of such Work Order, provided VSmakes all reasonable attempts to mitigate such non-cancelable expenses.
912. Indemnification. VS shall indemnify, defend and hold harmless PPD, its affiliates, directors, officers and employees thereof for any and alldamages, costs, expenses and other liabilities, including reasonable attorney’s fees and court costs, incurred by any such party as a result of anyclaim, action or proceeding by a third party (a “Third Party Claim”) arising from VS’s negligence, intentional misconduct, or breach of this Agreement. PPD shall indemnify, defend and hold harmless VS, its directors, officers and employees thereof for any and all damages, costs, expenses andother liabilities, including reasonable attorney’s fees and court costs, incurred by any such party as a result of any Third Party Claim arising fromPPD’s negligence, intentional misconduct, or breach of this Agreement. Either indemnified party shall give the indemnifying party prompt notice of any Third Party Claim for which indemnification is soughthereunder. The indemnifying party shall have the right to control the defense and settlement of such Third Party Claim, provided the indemnifyingparty shall act reasonably and in good faith with respect to all matters relating to the settlement or disposition of the claim, and the indemnified partyshall reasonably cooperate in the investigation, defense and settlement of such claim. The indemnified party shall have the right to participate in, butnot control, the defense and settlement of a claim and to employ separate legal counsel of its own choice; provided, however, that such employmentshall be at the indemnified party’s own expense, unless (i) the employment thereof has been specifically authorized by the indemnifying party, or (ii)the indemnifying party has failed to assume the defense and employ counsel (in which case the indemnified party shall control the defense andsettlement of such claim). 13. Limitation of Liability. EXCEPT WITH REGARD TO A PARTY’S BREACH OF SECTION 9, GROSS NEGLIGENCE, WILLFULMISCONDUCT AND INDEMNIFICATION OBLIGATIONS RELATED TO THIRD PARTY CLAIMS PURSUANT TO SECTION 12, EACH PARTY'SENTIRE LIABILITY UNDER THIS AGREEMENT WILL IN NO EVENT EXCEED THREE TIMES (3X) THE TOTAL VALUE OF THE WORK ORDERUNDER WHICH THE CLAIM AROSE. NOTWITHSTANDING ANYTHING TO THE CONTRARY CONTAINED IN THIS AGREEMENT, NEITHERPARTY SHALL BE LIABLE TO THE OTHER PARTY FOR INCIDENTAL, INDIRECT, CONSEQUENTIAL OR SPECIAL DAMAGES OR FOR ANYDAMAGES ARISING OUT OF OR IN CONNECTION WITH ANY LOSS OF PROFIT, INTERRUPTION OF SERVICE OR LOSS OF BUSINESS ORANTICIPATORY PROFITS, EVEN IF A PARTY OR ITS AFFILIATES HAVE BEEN APPRISED OF THE LIKELIHOOD OF SUCH DAMAGESOCCURRING, IN EACH CASE ARISING IN CONNECTION WITH ANY DEFAULT OR BREACH OF OBLIGATIONS UNDER THIS AGREEMENT ORANY ATTACHMENTS HERETO. IN THE EVENT OF A BREACH OR DEFAULT BY VS UNDER THIS AGREEMENT OR ANY WORK ORDER, VS AGREES, AT PPD’SOPTION, TO EITHER REPEAT THE SERVICES AT ISSUE OR REFUND THE PORTION OF THE CONSIDERATION ATTRIBUTABLE THERETO.
10THE WARRANTIES PROVIDED IN SECTION 8 AND ANY WORK ORDER ARE IN LIEU OF ALL OTHER CONDITIONS ORWARRANTIES, EXPRESS OR IMPLIED, WHETHER ARISING BY STATUTE, COURSE OF DEALING OR PERFORMANCE, CUSTOM, USAGE INTHE TRADE OR PROFESSION OR OTHERWISE, INCLUDING BUT NOT LIMITED TO, MERCHANTABILITY, AND FITNESS FOR A PARTICULARPURPOSE, AND ARE IN LIEU OF ALL OTHER OBLIGATIONS RELATING TO THE QUALITY OR ADEQUACY OF THE SERVICES IMPOSED BYLAW, ALL OF WHICH ARE EXPRESSLY DISCLAIMED TO THE EXTENT PERMITTED BY APPLICABLE LAW.
14. Debarment. VS hereby certifies that it has not been debarred, and has not been convicted of a crime which could lead to debarment,under the Generic Drug Enforcement Act of 1992. If VS or any of its employees or agents who perform Services hereunder is debarred or receivesnotice of an action or threat of action of debarment, VS shall immediately notify PPD. 15. Record Keeping and Audit. During the Term of this Agreement, VS shall maintain all materials and all other data obtained or generated byVS in the course of providing the Services hereunder, including all computerized records and files. VS shall cooperate with any internal reviews oraudits by PPD or Sponsor (or its and their representatives) and shall make available for examination and duplication, during normal business hours andat mutually agreeable times, all documentation, data and information relating to this Agreement or any Work Order. Further, VS shall inform PPD within one (1) business day of being notified of an audit by any regulatory authority or by any Sponsor to theextent such audit relates to the Preferred Services, the Joint Solution or a Work Order hereunder. PPD or its representatives shall be permitted to bepresent at and directly communicate with such regulatory authority or Sponsor representatives (as the case may be) concerning any matters related tothe Preferred Services, the Joint Solution or a Work Order hereunder arising in connection with such audit. To the extent permitted by the auditingentity, VS shall ensure that PPD is provided with copies of any written communications, reports and findings resulting from any inspection of VS bythat regulatory authority or Sponsor to the extent related to the Preferred Services, the Joint Solution or a Work Order. To the extent any suchcommunications, reports or findings require action by VS, VS shall include with such copies its remedial plan of action, including timelines forcompletion of the same. To the extent such remedial plan of action impacts the Preferred Services or Joint Solution, and, where applicable, to the extentpermitted by the relevant regulatory authority, VS shall collaborate with PPD prior to developing or implementing any changes to the PreferredServices or Joint Solution as a result of the audit findings. 16. Insurance. VS represents and warrants that it has and will maintain during the Term of this Agreement and, additionally, where applicable,during the term of any active Work Order, and for a period of two (2) years following expiration or termination of either, insurance in the types andlimits generally accepted in the industry. Upon request, VS shall provide PPD with a copy of its certificate of insurance. 17. Governing Law. This Agreement shall be construed in accordance with the laws of the State of Delaware without regard to its conflict oflaws provisions. 18. Assignment. This Agreement shall be binding upon and inure to the benefit of the parties hereto and their successors and assigns.Neither party shall have the right to assign this Agreement or any Work Order or to assign any rights thereunder without the prior written consent ofthe other party. Notwithstanding the foregoing, PPD may assign a Work Order to an affiliate or to Sponsor upon written notice to VS. In the event PPDassigns a Work Order to a Sponsor, VS agrees to release and forever discharge PPD from any and all claims that may arise out of the relevant WorkOrder after the effective date of such assignment. Unless otherwise agreed in writing by VS, PPD shall not be released from any liability or obligationunder this Agreement upon assignment of any Work Order to an affiliate of PPD. VS may subcontract all or a portion of the Services to be providedhereunder in accordance with Section 7 above. Any unauthorized attempt to assign or delegate any portion of this Agreement or any Work Order shallbe void.
1119. Publicity. Except as otherwise specifically set forth herein, neither party shall use the name, insignia, symbol, trademark, trade name, logo,logotype, or any abbreviation or adaptation thereof, of the other party or any affiliate of the other party, in any publication, press release, promotionalmaterial or other form of publicity, nor will either party use the same as verbal endorsement of its services, without the prior written approval of theother party in each instance. Further, VS shall be similarly restricted as it pertains to Sponsor and any Sponsor affiliate. The restrictions imposed bythis Section shall not prohibit the parties from making any disclosure identifying the other party that is required by any applicable law, rule orregulation. Additionally, following final execution of this Agreement, the parties acknowledge and agree that a joint press release statement regardingthe parties’ preferred relationship and its impact on the parties’ ability to provide Services hereunder shall be prepared and mutually agreed upon priorto its release or use by either party. 20. Force Majeure. The parties shall be excused from performing their obligations under this Agreement if its performance is delayed orprevented by any event beyond such party’s reasonable control, including, but not limited to, acts of God, fire, explosion, weather, disease, war,insurrection, civil strife, riots, government action, or power failure, provided that such performance shall be excused only to the extent of and duringsuch disability. 21. Covenant Not to Interfere. Neither party will solicit for employment any employee of the other party during the active term of thisAgreement and further, where applicable, the term of any active Work Order. As used in this section “solicit” means the initiation by a party or itsagent or representative of a contact with any of the other party’s then current employees who are performing services under this Agreement for thepurpose of offering employment to such employees, but shall not include the circumstance where any such employee initiates a contact with the otherparty for the purpose of obtaining employment whether in response to a general advertisement of employment or where such contact is initiated by athird party who was not instructed to contact such employee by the hiring party. 22. Miscellaneous. a. By agreeing to the terms and conditions of this Agreement and performing the Services for PPD, VS is representing that it is not inviolation of any terms and conditions of any agreement with any other individual or entity. b. This Agreement constitutes the entire agreement between the parties and supersedes all prior agreements, whether written or oral.This Agreement shall be construed according to its fair meaning and not strictly for or against any party. c. This Agreement may be modified only by a writing signed by the parties hereto. d. If any provision of this Agreement conflicts with the law under which this Agreement is to be construed or if any such provisionis held invalid by a court, such provision shall be deemed to be restated to reflect as nearly as possible the original intentions of the parties inaccordance with applicable law and the remainder of this Agreement shall remain in full force and effect.
12e. Waiver or forbearance by either party with respect to a breach of any provision of this Agreement or any applicable law shall notbe deemed to constitute a waiver with respect to any subsequent breach of any provision hereof. f. Any notice required or permitted to be given hereunder by either party hereto shall be in writing and shall be deemed given on thedate received if delivered personally, by recognized overnight courier, by facsimile or by electronic delivery, or five (5) days after the date postmarkedif sent by registered or certified U.S. mail, return receipt requested postage prepaid, to the following address: If to PPD: PPD Development, LP929 North Front StreetWilmington, NC 28401Telephone: (910) 251-0081Facsimile: (910) 343-5920Attn.: Chief Executive OfficerWith a Copy to: General Counsel
If to VS: VirtualScopics, Inc.500 Linden Oaks, Second FloorRochester, New York 14625Telephone: (585) 249-6231Facsimile: (585) 218-7350Attn: Molly Henderson
Either party may change its notice address and contact person by giving notice of same in the manner herein provided. g. This Agreement may be executed in one or more counterparts, each of which for all purposes shall be deemed to be an original,and all of which when taken together shall constitute but one and the same instrument. This Agreement and any amendments hereto, to the extentsigned and delivered by means of a facsimile machine or by electronic mail, shall be considered to have the same binding legal effect as if it were theoriginal signed version thereof delivered in person. 23. Survival. The obligations of the parties contained in Sections 4 (provided that any payments due upon termination shall be governed inaccordance with Section 11), 5, 9, 10, 12, 13, 15, 19 and 23 hereof and herein shall survive termination of this Agreement or any Work Order. 24. Conflict. Any and all Services provided during the Term of this Agreement, including all Services provided pursuant to a Work Order,shall be subject to the terms and conditions contained herein. To the extent any terms contained in this Agreement conflict with a Work Order, theterms of this Agreement shall govern and control unless the Work Order specifically states otherwise. To the extent any terms contained in thisAgreement or a Work Order conflict with a Purchase Order, the terms of this Agreement shall govern and control first, followed by the terms of theapplicable Work Order.
13[signatures appear on following page]
14IN WITNESS WHEREOF, the parties have caused their duly authorized representatives to execute this Agreement as of the Effective Date.
VirtualScopics, Inc.By:
Name: Molly J. HendersonTitle: Chief Business and Financial Officer,Sr. Vice PresidentPPD Development, LPBy: PPD GP, LLCIts General PartnerBy:
Name:
Title:
[Signature Page to Strategic Alliance Agreement]Exhibit A
Integration Services
[*** 2 pages omitted]
[***] Represents material which has been redacted and filed separately with the Commission pursuant to a request for confidential treatment pursuantto Rule 24b-2 under the Securities Exchange Act of 1934, as amended.Exhibit B
[***] Pricing
[*** 3 pages omitted]
[***] Represents material which has been redacted and filed separately with the Commission pursuant to a request for confidential treatment pursuantto Rule 24b-2 under the Securities Exchange Act of 1934, as amended.Exhibit C
Discounts and Bookings Thresholds
The percentage Discount applicable to Bookings in any given Measurement Period shall be determined in accordance with the discount structure setforth in the table below:
[*** .5 pages omitted]
[***] Represents material which has been redacted and filed separately with the Commission pursuant to a request for confidential treatment pursuantto Rule 24b-2 under the Securities Exchange Act of 1934, as amended.Exhibit 10.5
                         STRATEGIC ALLIANCE AGREEMENT
                         ----------------------------
THIS  STRATEGIC ALLIANCE AGREEMENT (this "Agreement") is made as of 31 December,
                                          ---------                             
1996, between NORTHERN TELECOM LIMITED, a Canadian corporation ("NTL"), and
                                                                 ---       
ENTRUST TECHNOLOGIES INC., a Maryland corporation ("ETI").
                                                    ---   
WHEREAS, pursuant to an asset transfer agreement between NTL and Entrust
Technologies Limited of even date (the "NTL Transfer Agreement") and an asset
                                        ----------------------               
transfer agreement between Northern Telecom Inc. and ETI of even date, the
Entrust Technology (as defined herein) has been transferred to ETI and ETI's
Canadian subsidiary, Entrust Technologies Limited; and
WHEREAS, NTL desires to license from Entrust on behalf of itself and the Nortel
Subsidiaries (as defined herein) ongoing rights to the Entrust Technology, ETI
desires to license from NTL on behalf of itself and its Subsidiaries some
intellectual property rights associated with the Entrust Technology, and NTL and
ETI desire to cooperate regarding contracting, patent cross-licensing and the
exchange of information, all on the terms and subject to the conditions set
forth herein;
NOW THEREFORE, NTL and ETI, intending to be legally bound agree as follows:
                                   ARTICLE I
                                  DEFINITIONS
                                  -----------
Capitalized terms used in this Agreement are used as defined in this Article I
or elsewhere in this Agreement. As used herein:
"Agreement" has the meaning specified in the preamble hereof.
 ---------                                                   
"Confidential Information" has the meaning specified in Section 8.02.
 ------------------------                                            
"Entrust" shall mean ETI and all Subsidiaries thereof.
 -------                                              
"Entrust Entity" shall mean either ETI or the applicable Entrust Subsidiary, as
 --------------                                                                
the context requires.
"ETI" has the meaning specified in the preamble hereof.
 ---                                                   
"Effective Date" means the close of business on the date specified in the
 --------------                                                          
preamble hereof.
"Enterprise License" has the meaning specified in Section 3.01.
 ------------------                                            
                                       1
 
"Entrust Patents" shall mean all Patents: (i) which are owned or controlled at
 ---------------                                                              
any time during the Patent License Term by Entrust or any Entrust Subsidiary; or
(ii) with respect to which, and to the extent to which, Entrust or any Entrust
Subsidiary shall at any time during the Patent License Term have the right to
grant the licenses and rights which are granted herein by Entrust.  The Entrust
Patents as of the Effective Date are set forth in Exhibit A of the NTL Transfer
Agreement.
"Entrust Products" has the meaning specified in the NTL Transfer Agreement.
 ----------------                                                          
"Entrust Technology" has the meaning specified in the NTL Transfer Agreement.
 ------------------                                                          
"Field of Activity" shall mean , in respect of each Party, the products and
 -----------------                                                         
services forming the business, at the Effective Date, of that Party or any of
its Subsidiaries, including new products and services which normally evolve from
such products and services.
"Grantee" shall mean either Entrust or Nortel, as the case may be, to which
 -------                                                                   
licenses are granted under the Patent License.
"Grantor" shall mean the Party granting licenses under the Patent License, as
 -------                                                                     
well as its Subsidiaries on behalf of which such licenses are granted."Licensed Products" shall mean, in respect of each Party, any products which are
 -----------------                                                              
within its Field of Activity.
"Licensed Services" shall mean, in respect of each Party, any services which are
 -----------------                                                              
within its Field of Activity.
"NTL" has the meaning specified in the preamble hereof.
 ---                                                   
"NTL Technology" has the meaning specified in Section 2.01 hereof.
 --------------                                                   
"Nortel" shall mean NTL and all Nortel Subsidiaries.
 ------                                             
"Nortel Entity" shall mean either NTL or the applicable Nortel Subsidiary, as
 -------------                                                               
the context requires.
"Nortel Patents" shall mean all Patents other than Patents included in NTL
 --------------                                                           
Technology: (i) which are owned or controlled at any time during the Patent
License Term by Nortel or any Nortel Subsidiary; or (ii) with respect to which,
and to the extent to which, Nortel or any Nortel Subsidiary shall at any time
during the Patent License Term have the right to grant the licenses and rights
which are herein granted by Nortel including through cross licenses or
otherwise.
"Nortel Subsidiary" shall mean a Subsidiary of Nortel, excluding ETI and Entrust
 -----------------                                                              
Technologies Limited.
                                       2
 
"Patent" shall mean any patent (other than a design patent or a design
 ------                                                               
registration) and any utility model covering any invention for which a first
application was filed in or for any country prior to the termination of the
Patent License Term, and shall include any such application in or for a country
for which rights under the law of the country are available for compensation for
unauthorized use of the invention covered by such application.
"Party" shall mean either NTL or the ETI, as the context requires except with
 -----                                                                       
respect to Article VIII where "Party" shall refer either to Nortel or Entrust,
as the context requires.
"Patent License" has the meaning specified in Section 6.03.
 --------------                                            
"Patent License Term" shall mean that period of time that ETI is a Subsidiary of
 -------------------                                                            
NTL.
"Reseller Agreement" has the meaning specified in Section 4.01.
 ------------------                                            
"Source Code License" has the meaning specified in Section 5.01.
 -------------------                                            
"Subsidiary" shall mean: (i) a corporation, company or other entity, in which a
 ----------                                                                    
Party now or hereafter, owns or controls, directly or indirectly, fifty percent
(50%) or more of the outstanding shares or securities (representing the right to
vote for the election of directors or other managing authority), provided,
however, that such corporation, company, or other entity shall be deemed to be a
Subsidiary only so long as such ownership or control exists; or (ii) an entity
which does not have outstanding shares or securities, as may be the case in a
partnership, joint venture or unincorporated association, but in which a Party
now or hereafter, owns or controls, directly or indirectly, fifty percent (50%)
or more of the ownership interest representing the right to make the decisions
for such entity, provided, however, that such entity shall be deemed to be a
Subsidiary only so long as such ownership or control exists.
                                   ARTICLE II
                                 NTL TECHNOLOGY
                                 --------------
                                        
Section 2.01 NTL Technology. Entrust shall be entitled to the benefit of the NTL
             --------------                                                     
intellectual property licenses specified in Exhibit A (the "NTL Technology") for
                                                            --------------      
so long as NTL effectively owns or controls more than fifty percent (50%) of the
voting stock or interests in ETI.
Section 2.02. NTL Obligations.  NTL has, to the best of its knowledge, complied
              ----------------                                                 
in all material respects with the provisions of the licenses for NTL Technology.
NTL 
                                       3shall make all reasonable efforts to perform in all material respects the
obligations required to maintain the licenses for the NTL Technology in good
standing for their respective terms.  NTL shall not make any material change to
the licenses for Nortel Technology without the consent of ETI, which shall not
be unreasonably withheld.  NTL shall make commercially reasonable efforts to
acquire for the benefit of Entrust any renewal or extension of NTL a license for
Nortel Technology at Entrust's request provided Entrust agrees to pay all costs
associated with obtaining such benefit for Entrust.  If NTL renews or extends a
license for NTL Technology, NTL may, but shall not be required to obtain rights
thereunder for the renewal period or extension provisions for the benefit of
Entrust.
Section 2.03. ETI Obligations.  Entrust shall comply in all material respects
              ----------------                                               
with the obligations required of it under the licenses for the NTL Technology
for so long as Entrust benefits from those licenses.   ETI shall pay to NTL the
portion of all fees and charges paid by Nortel to obtain continuing rights to
the NTL Technology that are reasonably attributable to Entrust's actual use of
the NTL Technology.
                                  ARTICLE III
                         NORTEL USE OF ENTRUST PRODUCTS
                         ------------------------------
Section 3.01 Right to Use. ETI, on behalf of Entrust, grants to NTL and its
             ------------                                                  
Affiliates (as defined in the Enterprise License) a non-exclusive, fully paid-
up, worldwide, perpetual license to use an unlimited number of copies of the
Entrust Products subject to the terms and conditions of an agreement to be
concluded between NTL and ETI promptly after the Effective Date in substantially
the form of the license set forth in Exhibit B (the "Enterprise License") save
                                                     ------------------       
as amended to comply with the provisions of this Article III.  NTL represents as
of the Effective Date that the terms of the Enterprise License are materially
similar to the terms of an existing agreement with a third-party licensee of the
Entrust Products, except for the terms relating to price and the provisions of
Section 3.02 hereof
Section 3.02 Support.  NTL may contract for support services under the
             -------                                                  
Enterprise License.  Payments to Entrust for the support services identified in
the Enterprise License as of the Effective Date shall be three hundred thousand
U.S. dollars (U.S. $300,000.00) for the calendar year 1997 and shall not
increase by more than inflation as measured by the Canadian CPI for any one-year
renewal period.
Section 3.03 Indemnification.  Notwithstanding any provision of the Enterprise
             -----------------                                                
License:
(a) ETI shall not be required to honour any product warranty or intellectual
    property indemnity set forth in the Enterprise License, to the extent that
    such breach of warranty or indemnity relates to a defect in any of the
    Entrust Products as of the Effective Date or the infringement or
    misappropriation of any third party rights as incorporated into the Entrust
    Products as of the Effective Date.
                                       4
 
(b) ETI's liability to Nortel arising from or relating to the intellectual
    property indemnity set forth in the Enterprise License shall not exceed 50%
    (fifty percent) of the monies paid by Nortel thereunder to a maximum of
    U.S.$1,000,000 (one million U.S. dollars).
                                   ARTICLE IV
                       NORTEL RESALE OF ENTRUST PRODUCTS
                       ---------------------------------
Section 4.01 Reseller Rights. At NTL's option and upon NTL's request, Entrust
             ---------------                                                 
shall promptly enter into a non-exclusive reseller agreement with NTL, on behalf
of Nortel, in substantially the form set forth in Exhibit C (the "Reseller
                                                                  --------
Agreement") save as amended to comply with the provisions of this Article IV.
- ---------                                                                      
NTL represents as of the Effective Date that the terms of the Reseller Agreement
are materially similar to the terms of an agreement recently concluded with a
third-party reseller of the Entrust Products, except for the provisions of
Section 4.02 hereof.  Subject to early termination for material default, such
Reseller Agreement shall expire either in three years or when ETI ceases to be a
Subsidiary of NTL, whichever event occurs later.
Section 4.02 Most Favoured Treatment. During the life of the Reseller Agreement,
             -----------------------                                            
it is the intention of ETI that the terms of the Reseller Agreement shall be no
less favourable to Nortel than the terms in effect with any of Entrust's
resellers of Entrust Products at the time the Reseller Agreement is executed.
Section 4.03 Indemnification.  Notwithstanding any provision of the Reseller
             ----------------                                               
Agreement, ETI shall not be required to honour intellectual property indemnity
set forth in the Reseller Agreement, to the extent that such breach of
representation, warranty, condition or indemnity relates to a defect in any of
the Entrust Products as of the Effective Date or the infringement or
misappropriation of any third party rights incorporated into the EntrustProducts as of the Effective Date.
                                   ARTICLE V
                 NORTEL RIGHTS FOR ENTRUST PRODUCT SOURCE CODE
                 ---------------------------------------------
Section 5.01 Source Code Access. At NTL's option and upon NTL's request, Entrust
             ------------------                                                 
shall promptly enter into a non-exclusive Entrust Products source code license
with NTL, on behalf of Nortel, in substantially the form set forth in Exhibit D
(the "Source Code License").   NTL represents as of the Effective Date that the
      -------------------                                                      
terms of the Source Code License are materially similar to the terms of an
agreement recently concluded with a third-party licensee of the source code for
the Entrust Products, except that NTL is not required to pay any lump sum
royalty and for the provisions of Section 5.02 hereof.
                                       5
 
Section 5.02 Most Favoured Treatment.  For so long as ETI remains a Subsidiary
             -----------------------                                          
of NTL, it is the intention of ETI that the terms of the Source Code License  be
no less favourable to Nortel than the terms then in effect with any of Entrust's
source code licensees that receives substantially similar rights taking into
account the relative size of the licensee and Entrust's potential benefits.
Section 5.03 Indemnification.  Notwithstanding any provision of the Source Code
             -----------------                                                 
License, ETI shall not be required to honour any product warranty or
intellectual property indemnity set forth in the Source Code License, to the
extent that such breach of warranty or indemnity relates to a defect in any of
the Entrust Products as of the Effective Date or the infringement or
misappropriation of any third party rights incorporated into the Entrust
Products as of the Effective Date.
                                   ARTICLE VI
                             PATENT CROSS LICENSING
                             ----------------------
Section 6.01. ETI Benefit from Cross Licenses.  Subject to the terms and
              --------------------------------                          
conditions of this Agreement, NTL, to the extent of its legal right to do so,
hereby grants to Entrust under the Nortel Patents, a non-transferable, non-
assignable, indivisible, non-exclusive, royalty-free, worldwide license for
Licensed Products and Licensed Services.
Section 6.02. Nortel Benefit from Cross Licenses.  Subject to the terms and
              -----------------------------------                          
conditions of this Agreement, Entrust, to the extent of its legal right to do
so, hereby grants to Nortel, under the Entrust Patents, an irrevocable, non-
transferable, non-assignable, indivisible, non-exclusive, royalty-free,
worldwide license for Licensed Products and Licensed Services.
Section 6.03. Extent of Cross Licenses.  The licenses granted pursuant to
              -------------------------                                  
Sections 6.01 and 6.02 (each such license being a "Patent License") include the
                                                   --------------              
following rights:
(a) to make, use, lease, sell or otherwise dispose of, maintain and repair,
    Licensed Products, to license the use of Licensed Products made by or for
    Grantee, to practice any process involved in the manufacture or use of
    Licensed Products, and to provide Licensed Services;
(b) to have made Licensed Products by another manufacturer for the use, lease,
    sale, disposal or transfer by Grantee, but only when both of the following
    conditions are met:
    (i)   the designs, specifications and working drawings for the manufacture 
          of such Licensed Products are furnished by Grantee; and
   (ii)   such designs, specifications and working drawings are in sufficient
          detail that no additional design by the manufacturer is required other
          than adaptation to the production processes and standards normally
          used by the manufacturer which change the characteristics of the
          products only to a negligible extent;
                                       6
 
(c) to make and have made, to use and have used, and to maintain machines,
    tools, materials and other manufacturing instrumentalities, and to use and
    have used methods and processes, insofar as such machines, tools, materials,
    other manufacturing instrumentalities, methods and processes are involved in
    or incidental to the development, manufacture, installation, testing,
    maintenance or repair of Licensed Products, or to the training of personnel
    in the use of such Licensed Products; provided, however, that the rights
    granted in this Section 6.03(c) shall not serve to enlarge the scope of the
    rights granted in Section 6.03(b);
Section 6.04. Limitations to Patent Licenses.  Nothing contained in a Patent
              --------------------------------                              
License shall be construed as:
    (a) requiring the filing of any application for a Patent or utility model,or the prosecution, maintenance or defense of any such application;
    (b) the maintenance or defense of any Patent;
    (c) a warranty or representation by Grantor, or admission by Grantee, as to
the validity or scope of any Patent;
    (d) a warranty or representation that any manufacture, sale, lease, use, or
importation of a Licensed Product, or the provision of any Licensed Service, by
Grantee shall be free from infringement of any intellectual property right of
Grantor other than those Patents under which and to the extent to which licenses
are in force under the Patent License;
    (e) an agreement to bring or prosecute actions or suits against third
parties for infringement;
    (f) an obligation to provide any manufacturing or technical information or
any support or technical assistance;
    (g) conferring any right to use, in advertising, publicity or otherwise, any
name, trade name or trademark, or any contraction, abbreviation or simulation
thereof, except as expressly provided herein;
    (h) conferring by implication, estoppel or otherwise upon Grantee any
license or other right under any Patent or other intellectual property right,
except the licenses and rights expressly granted herein; or
                                       7
 
    (i) an obligation upon grantor to make any determination as to the
applicability of any Patent to any product, Licensed Product or Licensed Service
of Grantee.
Section 6.06 NTL Right to Cross-License.  The licenses granted hereunder do not
             ---------------------------                                       
include for the Grantee the right to grant sublicenses to any third party except
as expressly provide in Section 6.03.  Notwithstanding the foregoing, NTL shall
be entitled to sublicense the Entrust Patents to meet its obligations under its
existing Patent cross license agreements.  For so long as ETI is an NTL
Subsidiary, NTL shall also be entitled, as part of its continuing Patent cross
licensing program, to sublicense Entrust Patents under new Patent cross license
agreements provided that the rights granted in the Entrust Patents pursuant to
any such new Patent cross license agreements do not materially exceed those
rights customarily granted under NTL's existing Patent cross license agreements
(as of the Effective Date) and ETI obtains the benefit of all Nortel Patents
involved.
Section 6.07. Excluded Patents.
              -----------------
(a) Assigned Patents.  It is recognized that Grantor may have entered into or
    -----------------                                                        
    may hereafter enter into a contract with, or a subcontract directly for the
    benefit of, a third party to undertake development work partially or
    completely financed by such third party and that Grantor may be required
    under such contract or subcontract (either unconditionally or by reason of
    any action or inaction thereunder) to assign to such third party its rights
    to grant, or may now or hereafter be restrained by such third party from
    granting, licenses to Grantee under Patents arising out of such work or
    covered by such contract or subcontract.  The resulting inability of Grantor
    to grant the licenses purported to be granted by it under such Patents shall
    not be considered to be a breach of the Patent License.  In such case, upon
    request by the Grantee, Grantor shall make reasonable efforts to secure
    rights and licenses for the Grantee from the third-party equivalent to those
    provided in the Patent License.
(b) Patents Subject to Exclusive Licenses.  ETI acknowledges that NTL may have
    --------------------------------------                                    
    entered into exclusive license arrangements with other corporations or legal
    entities.  The Patent License granted hereunder by NTL does not extend the
    scope of any such exclusive licenses (including any which NTL is negotiating
    as of the Effective Date).
Section 6.08. Jointly Owned Patents.  If the grant by Grantor of licenses and
              ----------------------                                         
rights in accordance with the Patent License in respect of Patents made by its
employees jointly with third parties is subject by contract or by operation of
law to the consent of such third parties or their assignees, upon request of the
Grantee, Grantor shall use reasonable efforts to either secure rights and
licenses for the Grantee from such third-party equivalent to those provided in
                                       8
 
the Patent License, or obtain consent from such third parties to grant rights
and licenses equivalent to those provided in the Patent License; however, the
inability of Grantor to secure such rights or to obtain such consent in spite of
the use of reasonable efforts shall not be considered to be a breach of the
Patent License.  Notwithstanding that such rights or such consent may be subject
to the payment of a royalty or other consideration to any such third party as
provided for in Section 6.09, and notwithstanding other conditions agreed with
the third party, the grant of such licenses and rights shall otherwise be in
accordance with the terms and conditions of the Patent License.
Section 6.09. Royalty Obligations.  Licenses and rights, the grant of which by--------------------                                            
Grantor or the exercise of which by Grantee would make Grantor liable to third
parties for royalties or other payments, shall be granted only upon agreement in
writing of the Grantee to pay an appropriate portion of such royalties or make
such other payments.
Section 6.10. Patent Information.  Each Party shall, upon written request from
              -------------------                                             
the other Party sufficiently identifying any Patent by country, number and date
of issuance, inform such other Party of the extent to which any such Patent is
available for licensing under the Patent License.  If the license or rights
under any such Patent are restricted in scope, or are subject to payments
according to Section 6.09, a statement of the nature of any such restrictions or
payments shall, on request, be provided within a reasonable time.
Section 6.11.  Duration of Cross Licenses.
               ---------------------------
(a) The Patent License shall commence on the Effective Date hereof (except as
    provided in Section 6.12) and shall continue for the Patent License Term
    unless terminated as provided in Article X or Section 6.06.  Notwithstanding
    the expiration of the Patent License Term, the rights and licenses granted
    hereunder shall continue for the entire terms that the Entrust Patents or
    the NTL Patents, as the case may be, are in force or for that part of such
    terms for which the Grantor has the right to grant such rights and licenses.
    Notwithstanding any other provision in this Agreement, the Patent License
    shall terminate immediately upon ETI ceasing to be a Subsidiary of NTL.
(b) Subject to the other sections of this Article VI, any termination of the
    licenses and rights granted to one Party and its Subsidiaries under the
    Patent License shall not affect the licenses and rights granted to the other
    Party and its Subsidiaries.
(c) Notwithstanding the foregoing provisions of this Section 6.11, the Patent
    Licenses shall, for the patents owned or by a party, terminate as provided
    for in Section 6.11(a) or ten years from the Effective Date, whichever is
    later.
                                       9
 
Section 6.12.  Changes to Subsidiaries.
               ------------------------
(a) New Subsidiaries.  Any rights or license granted under this Article VI to a
    -----------------                                                          
    corporation or other legal entity which becomes a Subsidiary of a Party at a
    date later than the Effective Date shall become effective as of the date
    upon which such corporation or other legal entity becomes a Subsidiary of
    such Party.
(b) Former Subsidiary.  When a Subsidiary of either ETI or NTL ceases to be a
    ------------------                                                       
    Subsidiary and holds any Patent under which a Grantee is licensed pursuant
    to the Patent License, such Grantee shall be entitled to exercise such
    rights and licenses for the full term of the Patent (or for that part of the
    term that the Grantor has the right to grant such rights and licenses).
    When a Subsidiary of ETI or NTL ceases to be a Subsidiary of such Party, any
    license granted to such Subsidiary in or pursuant to the Patent License
    shall terminate on the date that such Subsidiary ceases to be a Subsidiary.
Section 6.12.  Restraint on Claims.  Each Grantor undertakes not to assert any
               --------------------                                           
claim for Patent infringement with respect to use and maintenance of Licensed
Products against any end user, customer or distributor of Grantee, or any
subsequent vendee, lessee, or transferee to the extent the Licensed Products
have been acquired from Grantee after the Effective Date and are used for the
purpose for which they predominantly have been made (without modification or
amendment).
Section 6.13. Patent License Limitations.  Neither Party makes any
              --------------------------                          
representations, extends any conditions or warranties of any kind or assumes any
responsibility whatever with respect to the Patent Licenses other than the
licenses, rights and representations expressly granted in this Article VI; in
particular, unless the Parties or their Subsidiaries have expressly agreed
otherwise, neither Grantor warrants that Licensed Products made, used, sold,
disposed of, leased or licensed for use by Grantee, or Licensed Services
provided by Grantee, do not infringe Patents or other intellectual property
rights of third parties.
                                  ARTICLE VII
                          COORDINATION OF CONTRACTING
                          ---------------------------
Section 7.01 Compliance with Nortel Policies.  For so long as ETI remains a
             --------------------------------                              
Subsidiary of NTL, Entrust shall not take any action or enter into any
commitment or agreement which may reasonably be anticipated based on notice from
Nortel to result, with or without notice and with or without lapse of time or
otherwise, in a contravention or event of default by any Nortel Entity of (i)
any provisions of applicable law or regulation, (ii) any provision of NTL's
certificate of incorporation or bylaws, (iii) any credit agreement or other
material instrument binding upon Nortel, or (iv) any judgment, order or decree
of any governmental body, agency or court having jurisdiction over Nortel or any
of its assets.10
 
Section 7.02. Nortel Global Agreements. For so long as ETI remains a Subsidiary
              ------------------------                                         
of NTL, Entrust may purchase goods and services under agreements concluded by
Nortel for the benefit of Subsidiaries of NTL.  Entrust shall comply in all
material respects with the obligations required of it under such agreements for
so long as Entrust benefits from those agreements.
                                  ARTICLE VIII
                             INFORMATION EXCHANGES
                             ---------------------
Section 8.01. Information. Subject to applicable law and privileges, each Party
              -----------                                                      
shall, to the extent legally permitted, provide the other Party with all
information regarding itself and transactions under this Agreement that the
other Party reasonably believes are required: (a) for the other Party to obtain
the benefits provided for herein, and (b) to comply with the provisions of
Section 7.01 and all applicable federal, state, county and local laws,
ordinances, regulations and codes, including, but not limited to, securities
laws and regulations.
Section 8.02. Confidential Information. Entrust and Nortel shall hold in trust
              ------------------------                                        
and maintain confidential all Confidential Information relating to the other
Party. "Confidential Information" shall mean all information disclosed by either
        ------------------------                                                
Party to the other in connection with this Agreement whether orally, visually,
in writing or in any other tangible form, and includes, but is not limited to,
technical, scientific, economic and business data, business plans, and the like,
but shall not include (i) information which becomes generally available other
than by release in violation of the provisions of this Section 8.01, (ii)
information which becomes available on a non-confidential basis to a Party from
a source other than the other Party, provided the Party in question reasonably
believes that such source is not or was not bound to hold such information
confidential, (iii) information acquired or developed independently by a Party
without violating this Section 8.02 or any other confidentiality agreement with
the other Party and (iv) information that any Party reasonably believes it is
required to disclose by law, provided that it first notifies the other Party of
such requirement and allows such Party a reasonable opportunity to seek a
protective order or other appropriate remedy to prevent such disclosure. Without
prejudice to the rights and remedies of either Party, a Party disclosing any
Confidential Information to the other Party in accordance with the provisions of
this Agreement shall be entitled to equitable relief by way of an injunction if
the other Party breaches or threatens to breach any provision of this Section
8.02.
Section 8.03.  Information Exchanges.  The disclosing Party makes no
               ----------------------                               
representations, does not warrant, and shall have no liability whatsoever in
respect of any information disclosed by it pursuant to this Agreement.
                                       11
 
                                   ARTICLE IX
                               OTHER COOPERATION
                               -----------------
Section 9.01.  Cogent.  NTL acknowledges that the agreement between NTL and
              --------                                                     
Nortel Limited dated 17 March 1995 as set forth in Exhibit E (the "Cogent
Agreement") shall be terminated by NTL, without liability to Entrust, except
that Entrust shall, for reasonable consideration from Nortel, make all
commercially reasonable efforts to assist Nortel to perform, in accordance with
the terms of the Cogent Agreement, any agreement made or any bid submitted
pursuant to the Cogent Agreement prior to the Effective Date.
Section 9.02. PDSO.  Entrust acknowledges that NTL will be holding inventory of
              -----                                                            
PDSO as of the Effective Date.  Entrust shall, to the extent it requires further
PDSO equipment endeavor to acquire such equipment from NTL, subject to the
negotiation in good faith of commercially reasonable terms and condition of
supply.
                                   ARTICLE X
                              TERM AND TERMINATION
                              --------------------
Section 10.01. Term. Except as otherwise provided in this Agreement, this
               ----                                                      
Agreement shall terminate on the later of (i) the third anniversary of the
Effective Date or (ii) the date on which ETI ceases to be a Subsidiary of NTL.
Section 10.02. Termination.
               ----------- 
(a)  Termination for Cause.  In the event of any  material breach of this
     ----------------------                                              
    Agreement by either Nortel or Entrust, the non-breaching Party may terminate
    this Agreement by giving sixty (60) days' prior written notice to the other
    Party; provided, however, that this Agreement shall not terminate if the
    other Party has cured the breach prior to the expiration of such 60-day
    period, or if such breach can not be cured within such sixty 60-day period,the other Party has initiated actions to cure such breach within such sixty
    60-day period, and thereafter cures such breach as soon as reasonably
    practical.
(b) Termination for Insolvency.  Either Party may terminate this Agreement in
    --------------------------                                               
    the event the other Party: (i) admits in writing its inability to pay its
    debts generally as they become due; (ii) commits an act of bankruptcy, (iii)
    files a notice of intention to make a proposal under the Bankruptcy and
    Insolvency Act, commences proceedings under the Companies' Creditors
    Arrangement Act, or otherwise seeks a reorganization, adjustment or
    composition under applicable bankruptcy laws or any other similar law or
    statute of any relevant jurisdiction; (iv) enters into an assignment,
    arrangement or composition for the benefit of its creditors; or (v) consents
    to the appointment of a receiver or receiver-manger of itself or of the
    whole or any substantial part of its property.
                                       12
 
Section 10.03. Effect of Termination.
               --------------------- 
When this Agreement expires or terminates, the following provisions shall remain
in effect:
(a)  NTL Technology.  the provisions of Article II shall survive until they
     ---------------                                                       
     expires in accordance with the provisions of Section 2.01 unless this
     Agreement is terminated for cause pursuant to Section 10.02 arising from
     breach of Article II;
(b)  Enterprise License, Reseller Agreement and Source Code License.  the
     ---------------------------------------------------------------     
     Enterprise License, Reseller Agreement and Source Code License shall 
     survive for the term provided therein subject to any right of early
     termination provided therein;
(c)  Patent Licenses.  the provisions of Article VI shall survive until
     ----------------                                                  
     expiration in accordance with the provisions of Article VI, unless this
     Agreement is terminated for cause pursuant to Section 10.02 arising from
     breach of Article VI; and
(d)  Other Provisions.  the provisions of Articles VIII, XI and XII shall 
     -----------------                                                    
     survive any termination.
                                   ARTICLE XI
                              LIMITS OF LIABILITY
                              -------------------
Section 11.01. Enterprise License, Reseller Agreement, Source Code License.  The
               ------------------------------------------------------------     
liability of either Party arising from breach of either the Enterprise License,
the Reseller Agreement or the Source Code License shall be governed exclusively
by the terms of the applicable agreement or license.
Section 11.02. No Other Obligations.  Neither Party makes any representations,
               --------------------                                           
extends any conditions or warranties of any kind or assumes any responsibility
whatever except as expressly provided herein.
Section 11.03. Limitation on Types of Damages.  Except for breach of Article
               -------------------------------                              
VIII and for Article XII, in no event shall either Party be liable to the other
Party for any indirect, incidental and/or consequential damages resulting from a
breach of this agreement, including without limitation lost business, lost
savings, and lost profits even if the breaching Party has been advised of the
possibility of the occurrence of such damages.  In no event shall either Party
be liable for any special or punitive damages arising from breach of this
Agreement.
Section 11.04. Monetary Limit.  For any cause of action arising under this
               ---------------                                            
Agreement, Nortel's liability to Entrust, and Entrust's liability to Nortel
shall not exceed U.S.$5,000,000.  Notwithstanding the foregoing, each of
Nortel's and Entrust's liability to the other Party for breach of Article II
shall not exceed U.S.$10,000,000.
                                       13
 
                                  ARTICLE XII
                                 MISCELLANEOUS
                                 -------------
Section 12.01. Notices. All notices authorized or required to be given pursuant
               -------                                                         
to this Agreement shall be given in writing and either personally delivered to
the Party to whom it is given or delivered by an established delivery service by
which receipts are given or mailed by registered or certified mail, postage
prepaid, or sent by electronic telecopier, addressed to the Party at the
following addresses.  Any Party may change its address for the receipt of
notices at any time by giving notice thereof to the other Party, in which event
this Agreement shall be amended accordingly.(a)  If to NTL:  Northern Telecom Limited
                 8200 Dixie Road, Suite 100
                 Brampton,  Ontario
                 L6T 5P6
                 Attention:  Corporate Secretary
                 Fax No.:  905 863 8425
(b)  If to ETI:  Entrust Technologies Inc.
                 2 Constellation Court
                 Nepean,  Ontario
                 K2G 5J9
                 Attention: President
                 copy:  Secretary
Section 12.02. Entire Agreement. This Agreement embodies the complete Agreement
               ------ ---------                                                
and understanding of Entrust and NTL with respect to the subject matter hereof.
This Agreement supersedes all prior agreements and understandings among the
Parties hereto with respect to the subject matter hereof.
Section 12.03. Modification. No change or modification of this Agreement shall
               -------------                                                  
be of any force unless such change or modification is in writing and has been
signed by the duly authorized representatives of the Parties hereto.
Section 12.04. Waivers. No waiver of any breach of any of the terms of this
               --------                                                    
Agreement shall be effective unless such waiver is in writing and signed by the
Party against which such waiver is claimed. No waiver of any breach shall be
deemed to be a waiver of any other or subsequent breach.
                                       14
 
Section 12.05. Severability. If any provision of this Agreement shall be held to
               ------------                                                     
be invalid, illegal or unenforceable, the validity, legality and enforceability
of the remaining provisions shall not in any way be affected or impaired
thereby.
Section 12.06. Governing Law. This Agreement shall be governed by and be
               --------- ----                                           
construed in accordance with the laws of the Province of Ontario, Canada.
Section 12.07. Waiver of Jury Trial. THE PARTIES HERETO HEREBY IRREVOCABLY WAIVE
               ------ -- ---- -----                                             
ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR
RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY.
Section 12.08. Limitation on Rights of Others. No person other than a Party
               ---------- -- ------ -- -------                             
shall have any legal or equitable right, remedy or claim under or in respect of
this Agreement.
Section 12.09. Assignment, etc.  Each Party's rights under this Agreement are
               ----------------                                              
personal to that Party and that Party shall not assign, sublet or otherwise
transfer any right or interest under this Agreement to anyone, without the prior
written consent of the other Party, which shall not be unreasonably withheld.
Subject to the foregoing, this Agreement and all of the provisions hereof shall
be binding upon and inure to the benefit of, and be enforceable by, the Parties
hereto and their respective heirs, administrators, executors, successors, and
permitted assigns.
IN WITNESS WHEREOF, the Parties have caused this Agreement to be signed by their
authorized representatives.
NORTHERN TELECOM LIMITED                    ENTRUST TECHNOLOGIES INC.
                                  
By:  /s/ Peter W. Currie                    By:  /s/ John A. Ryan
                                  
Name:  Peter W. Currie                      Name:  John A. Ryan
                                  
Title:  Senior Vice President and           Title:  President
        Chief Financial Officer
By:  /s/ David D. Archibald
Name:  David D. Archibald
Title:  Vice President and Deputy
        General Counsel
                                       15Exhibit 10.2
PORTIONS OF THIS EXHIBIT MARKED BY [**] HAVE BEEN OMITTED PURSUANT TO RULE 601(B)(10) OF REGULATION S-K. THE
OMITTED INFORMATION IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF
PUBLICLY DISCLOSED.
EXECUTION VERSION
STRATEGIC ALLIANCE AGREEMENT
STRATEGIC ALLIANCE AGREEMENT, dated as of December 20, 2019 (as amended, supplemented or otherwise modified from time to
time, this “ Agreement”), by and among Farids & Co. LLC, a Delaware limited liability company (“ Farids”), Edible Arrangements, LLC, a
Delaware limited liability company (“EA”), and Rocky Mountain Chocolate Factory, Inc., a Delaware corporation (the “ Company”).
W I T N E S S E T H:
WHEREAS, the Company is an international franchisor, confectionery manufacturer and retail operator;
WHEREAS, Farids is a holding company and, together with TF (as defined below), indirectly controls EA;
WHEREAS, EA is a US-based franchisor that specializes in fresh fruit arrangements and specialty fruit gift items;
WHEREAS, the Company desires to issue and sell, and Farids desires to purchase, 126,839 shares (the “ Purchased Shares ”) of the
Company’s common stock, $0.001 par value per share (the “Common Stock”), on the terms set forth herein;
WHEREAS, substantially concurrently with the execution and delivery of this Agreement, the Company and EA shall execute and
deliver the Warrant (as defined below);
WHEREAS, substantially concurrently with the execution and delivery of this Agreement, the Company and EA shall execute and
deliver the Exclusive Supplier Operating Agreement (as defined below); and
WHEREAS, in connection with the foregoing, the Company, Farids and EA agree and acknowledge that the cooperation between the
Company and EA is an important component to achieve their respective strategic objectives, and they desire to continue and further enhance
the strategic cooperation alliance between them as contemplated under this Agreement.
NOW THEREFORE, in consideration of the foregoing and the mutual representations, warranties, covenants and agreements herein
contained, and intending to be legally bound hereby, the parties hereto agree as follows:
ARTICLE I
DEFINITIONS
Section 1.1 Defined Terms.
(a) “144 Sale ” means (i) a Transfer of Shares (including in any broker assisted cashless exercise) pursuant to Rule 144 under
the Securities Act and (ii) for purposes of Article VII only, any Transfer of Shares pursuant to a Resale Shelf Registration Statement.(b) “Affiliate” of any specified Person means any other Person directly or indirectly controlling or controlled by or under
direct or indirect common control with such specified Person. For purposes of this definition, “control” (including, with correlative meanings,
the terms “controlling,” “controlled by” and “under common control with”), as used with respect to any Person, shall mean the possession,
directly or indirectly, of the power to direct or cause the direction of the management or policies of such Person, whether through the ownership
of voting securities, by agreement or otherwise.
(c) “Amendment” means the Amendment, dated the date hereof, to the Rights Agreement by and between the Company and
Computershare Trust Company, N.A., as Rights Agent, attached as Exhibit E hereto.
(d) “Board of Directors” means the Board of Directors of the Company.
(e) “Bylaws” means the Second Amended and Restated Bylaws of the Company, as in effect as of the date hereof.
(f) “Certificate of Incorporation” means the Company’s Amended and Restated Certificate of Incorporation, as amended, as
in effect as of the date hereof.
(g) “Change in Control” means the occurrence of any of the following:
(i) the sale, lease or transfer, in one or a series of related transactions, of all or substantially all of the assets of the Company
to any Person other than a Permitted Holder; or
(ii) at any time, the Company becomes aware of (by way of a report or any other filing pursuant to Section 13(d) of the
Exchange Act, proxy, vote, written notice or otherwise) the acquisition by any Person or group (within the meaning of Section 13(d)(3)
or Section 14(d)(2) of the Exchange Act, or any successor provision), other than the Permitted Holders, in a single transaction or in a
related series of transactions, by way of merger, consolidation or other business combination or purchase of beneficial ownership
(within the meaning of Rule 13d-3 under the Exchange Act, or any successor provision) of 50% or more of the total voting power of the
Voting Stock of the Company.
(h) “Eligible Registration Statement” means any registration statement (other than (i) a registration statement on Form S-4 or
Form S-8 or any similar or successor form or (ii) with respect to any corporate reorganization or transaction under Rule 145 of the Securities Act
or other business combination or acquisition transaction, any registration statement related to the issuance or resale of securities issued in
such a transaction) filed by the Company under the Securities Act in connection with any primary or secondary offering of Common Stock for
the account of the Company and/or any shareholder of the Company, whether or not through the exercise of any registration rights.
(i) “Exchange Act” means the Securities Exchange Act of 1934, as amended.
2(j) “Exclusive Supplier Operating Agreement ” means the Exclusive Supplier Operating Agreement, dated as of the date
hereof, by and between EA and the Company, attached as Exhibit B hereto.
(k) “Family Member” means, with respect to any natural person, (i) any child, stepchild, grandchild or more remote issue,
parent, stepparent, grandparent, spouse, domestic partner, sibling, child of sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law,
brother-in-law, sister-in-law, cousin and adoptive relationships (each, a “ family member”) or estate of such family member or (ii) any
foundation, trust, family limited partnership, family limited liability company or other entity created and used for estate planning purposes, so
long as any such foundation, trust, family limited partnership, family limited liability company or other entity is controlled by, for the benefit of,
or owned by such natural person or one or more persons described in clause (i) (such entities referred to in this clause (ii), the “ Permitted
Estate Vehicles”).
(l) “Farids Group” means Farids, EA and each and every Farids Transferee. Unless the Company is otherwise notified in
writing by Farids or EA, TF shall at all times serve as the designated representative to act on behalf of the Farids Group for purposes of this
Agreement and shall have the sole power and authority to bind the Farids Group with respect to all provisions of this Agreement; provided,
however, that if TF ceases to serve as the designated representative of the Farids Group, then TF (or his designated legal representative in the
case of his death or permanent disability) shall have the power to designate a new designated representative of the Farids Group, which
designee (and any successor thereafter designated and appointed) shall have the sole power and authority to bind the Farids Group with
respect to all provisions of this Agreement. The Company shall be entitled to rely on all actions taken by TF or such designee on behalf of the
Farids Group.
(m) “Farids Transferee” means each and every direct and indirect transferee of Farids (including transferees of Shares from
any member of the Farids Group so long as such Shares were originally held by the Farids Group) pursuant to Transfer set forth in clause (i) or
(ii) of the definition of Permitted Transfer.
(n) “FINRA” means the Financial Industry Regulatory Authority, Inc.
(o) “GAAP” means U.S. generally accepted accounting principles.
(p) “Holder” means any Person owning of record Common Stock or any security convertible into or exercisable or
exchangeable for, with or without consideration, any Common Stock.
(q) “Indemnification Agreement” means the Indemnification Agreement, dated as of the date hereof, by and between the
Company and TF, attached as Exhibit D hereto.
(r) “Investors” means (i) Farids, (ii) EA and (iii) TF and his Family Members.
(s) “Law” means any domestic or foreign, U.S. Federal, state, municipality or local law, statute, ordinance, code, rule, or
regulation or common law.
3(t) “Lien” means, with respect to any asset, any mortgage, lien, pledge, charge, security interest or encumbrance of any kind
in respect of such asset, including any agreement to give any of the foregoing.
(u) “Lock-Up Securities” means (i) any Common Stock or Preferred Stock of the Company, (ii) any security convertible into or
exercisable or exchangeable for, with or without consideration, any Common Stock or Preferred Stock of the Company (including any option to
purchase such a security), (iii) any security carrying any option, warrant or right to subscribe to or purchase any Common Stock or Preferred
Stock of the Company or other security referred to in clause (ii), or (iv) any such option, warrant or right.
(v) “Nasdaq” means The Nasdaq Stock Market LLC.
(w) “Order” means any decree, order, judgment, writ, award, injunction, rule or consent of or by a Governmental Entity.
(x) “Permitted Holders” means each of (i) the Investors and their respective Affiliates and members of management of the
Company and (ii) any group (within the meaning of Section 13(d)(3) or Section 14(d)(2) of the Exchange Act or any successor provision) of
which any of the foregoing are members; provided that in the case of such group, without giving effect to such group, Persons specified in
clause (i) must collectively beneficially own a majority of the total voting power of the Voting Stock of the Company beneficially owned by such
group.
(y) “Permitted Transfer” means (i) any Transfer to one or more entities that are, directly or indirectly, wholly owned by Farids
or any Family Member of TF, (ii) any Transfer to one or more entities that are members of the Farids Group and (iii) Transfer made following a
Change in Control of Farids or EA or made pursuant to a Change in Control that constitutes a sale of the Company as a whole; provided, with
respect to each of clause (i)-(iii), so long as the transferee (other than a transferee that already is party to this Agreement) agrees to be subject
to the terms of this Agreement (subject to any limitation on the assignment of rights by such Person to the transferee in connection with such
Transfer) by executing and delivering a joinder agreement, substantially in the form of Exhibit A hereto.
(z) “Person” means an individual, partnership, corporation, limited liability company, unincorporated organization, trust, joint
venture, government agency, or other entity.
(aa) “Prospectus” means the prospectus included in the Eligible Registration Statement, including any form of prospectus or
any preliminary prospectus, as amended or supplemented by any prospectus supplement and by all other amendments or supplements to such
prospectus, including all post-effective amendments and all material, if any, incorporated by reference or deemed to be incorporated by
reference into such prospectus.
(bb) “Registrable Securities ” means all Purchased Shares and Warrant Shares and any securities into which Common Stock
may be converted or exchanged pursuant to any merger, consolidation, sale of all or any part of the Company’s assets, corporate conversion or
other extraordinary transaction of the Company held by the Farids Group, other than any Common Stock or securities into which Common Stock
may be converted or exchanged that (i) have been sold by the Farids Group to the public either pursuant to a registration statement or Rule 144
or another exemption from the registration requirements of the Securities Act, (ii) except in connection with a Demand Request by the Farids
Group for a registration pursuant to a Resale Shelf Registration Statement, in the hands of the Farids Group is eligible to be resold pursuant to
Rule 144 without any volume limitation or (iii) shall have ceased to be outstanding; provided, that when determining the amount of Registrable
Securities, only the Purchased Shares, any Vested Warrant Shares and the remaining Warrant Shares eligible for vesting into Vested Warrant
Shares shall be included in such calculation.
4(cc) “Registration Expenses” means all expenses incurred by the Company in complying with Article VI hereof, including,
without limitation, (i) all SEC and other registration and filing fees (including, without limitation, fees and expenses with respect to (A) filings
required to be made with FINRA and (B) securities or “blue sky” laws, including, without limitation, any fees and disbursements of counsel for
the underwriters in connection with any filing and application made to or with (and clearance by) FINRA and any “blue sky” qualifications of
the Registrable Securities pursuant to Section 6.6(d)), (ii) preparation, printing, messenger and delivery expenses, (iii) fees and disbursements of
counsel for the Company, (iv) fees and disbursements of independent certified public accountants and any other persons, including special
experts retained by the Company, (v) expenses related to any special audits incident to or required by any such registration, in each case,
whether or not any Eligible Registration Statement is filed or becomes effective, (vi) all fees and expenses related to the listing of the Registrable
Securities on any securities exchange, (vii) all internal expenses of the Company, including the compensation of officers and employees of the
Company and the fees and expenses in connection with any annual audit and (viii) the fees and expenses of one counsel for the Farids Group in
connection with the review of any registration statement, not to exceed $10,000 for each registration. For the avoidance of doubt, any stamp,
transfer or similar taxes or duties payable by the Farids Group in connection with any registration, sale or distribution of Registrable Securities
shall be borne by the Farids Group and not by the Company.
(dd) “Resale Shelf Registration Statement ” means a “shelf” registration statement on Form S-3 pursuant to Rule 415 under
the Securities Act; provided that any sales of securities thereunder will not (i) require a prospectus supplement, (ii) require any additional
cooperation from the Company (except as set forth in Section 6.4(b)) or (iii) be made pursuant to an underwritten offering.
(ee) “Rights Agreement” means the Rights Agreement dated March 1, 2015 between the Company and Computershare Trust
Company, N.A., as Rights Agent.
(ff) “SEC” or “Commission” means the Securities and Exchange Commission.
(gg) “Securities Act ” means the Securities Act of 1933, as amended.
(hh) “Shares” means, collectively, the Purchased Shares or shares of Common Stock issued or issuable upon exercise of the
Warrants.
(ii) “Significant Block ” means five percent (5%) or more of the Company’s issued and outstanding Common Stock.
5(jj) “Subsidiary” means, any Person of which at least a majority of the securities or ownership interests having by their terms
ordinary voting power to elect a majority of the board of directors or other Persons performing similar functions is directly or indirectly owned
or controlled by the Company or by one or more of its Subsidiaries.
(kk) “TF” means Tariq Farid, an individual.
(ll) “Threshold Block” means one percent (1%) or more of the Company’s issued and outstanding Common Stock.
(mm) “Transaction Documents” means, collectively, this Agreement, the Exclusive Supplier Operating Agreement, the
Warrant, the Indemnification Agreement and the Amendment.
(nn) “Transfer” means any sale, assignment, encumbrance, hypothecation, pledge, conveyance in trust, gift, transfer by
request, devise or descent, entry into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of
ownership (whether to be settled by delivery of the Purchased Shares, in cash or otherwise) or other transfer or disposition of any kind,
including, but not limited to, transfers to receivers, levying creditors, trustees or receivers in bankruptcy proceedings or general assignees for
the benefit of creditors whether voluntary or by operation of law, directly or indirectly, of any Purchased Shares.
(oo) “Vested Warrant Shares” means the shares of Common Stock into which the Warrant shall vest and for which the
Warrant shall become exercisable.
(pp) “Voting Stock” of the Company as of any date means the shares of capital stock of the Company that is at the time
entitled to vote in the election of the Board of Directors of the Company.
(qq) “Warrant” means the common stock purchase warrant, dated the date hereof, issued to the EA, providing for the
purchase at a purchase price per share of $8.76 of up to 960,677 Warrant Shares, attached as Exhibit C hereto.
(rr) “Warrant Shares” means the shares of Common Stock issuable upon exercise of the Warrant.
ARTICLE II
ISSUANCE OF THE PURCHASED SHARES
Section 2.1 Share Purchase . Upon the terms and subject to the conditions set forth in this Agreement, Farids hereby agrees to
purchase, and the Company hereby agrees to issue and sell to Farids, at the Closing (as defined below), the Purchased Shares (the “ Share
Purchase”), in consideration of the payment by Farids to the Company of $999,998.68 (the “ Purchase Price ”) and Farids assistance in
developing the strategic alliance contemplated hereby. The Purchase Price shall be paid by Farids by the Company by wire transfer of
immediately available funds, to one or more bank accounts designated in writing by the Company, on the Closing Date (as defined below).
6Section 2.2 Closing. The closing of the Share Purchase (the “ Closing”) shall take place at the offices of Perkins Coie LLP, 1900
Sixteenth Street Suite 1400, Denver, Colorado 80202, at 11:00 a.m. Mountain Time or before 90 days after the date hereof (such , the “ Closing
Date”).
Section 2.3 Transactions to be Effected At or Prior to the Closing . At or prior to the Closing, the transactions below shall take place
(except (i) to the extent such day is not a business day, (ii) the transactions set forth in clauses (a) through (e) below shall take place on or prior
to the date hereof and (iii) the transactions set forth in clauses (f) through (h) shall take place as promptly as practicable on or after the date
hereof, but in no event later than the Closing Date):
(a) The Board of Directors shall have taken all necessary action related to the nomination of TF for election to the Board of
Directors at the Company’s annual meeting of stockholders to be held on January 9, 2020 (the “ Annual Meeting”), provided that the mailing
and filing of proxy materials reflecting the nomination of TF to the Board of Directors shall be completed no later than two (2) business days
following the date hereof.
(b) The Company and Farids shall execute and deliver this Agreement.
(c) The Company and EA shall execute and deliver the Exclusive Supplier Operating Agreement and, in consideration of EA
entering into the Exclusive Supplier Operating Agreement and the performance of EA’s obligations therein, the Company shall issue the Warrant
to EA. Each of the Exclusive Supplier Operating Agreement and the Warrant is effective as of the date hereof in accordance with the terms of
such document.
(d) The Company and TF shall execute and deliver the Indemnification Agreement.
(e) The Company and Computershare Trust Company, N.A. shall execute and deliver the Amendment.
(f) The Company shall receive the approval of Nasdaq with respect to the supplemental listing of the Purchased Shares and
the reservation for issuance on the Nasdaq Global Market of the Warrant Shares.
(g) The Company shall issue to Farids the Purchased Shares in electronic book-entry form.
(h) The Company shall deliver to Farids the irrevocable letter of instructions addressed to the Company’s transfer agent,
relating to the issuance of the Purchased Shares.
ARTICLE III
REPRESENTATIONS AND WARRANTIES
Section 3.1 Representations and Warranties of the Company .
The Company represents and warrants to each of Farids and EA as of the date hereof and as of the Closing Date that:
7(a) Existence and Power. The Company is a corporation duly organized, validly existing and in good standing under the laws
of the State of Delaware. The Company has all power and authority, corporate and otherwise, and all governmental licenses, franchises, permits,
authorizations, consents and approvals required to own and operate its properties and assets and to carry on the business as presently
conducted and as proposed to be conducted, except as would not, individually or in the aggregate, reasonably be expected to have a material
adverse effect on the business, results of operations or financial condition of the Company and its Subsidiaries, taken as a whole (a “ Company
Material Adverse Effect”).
(b) Capitalization. The authorized capital stock of the Company consists of (i) 46,000,000 shares of Common Stock and (ii)
250,000,000 shares of preferred stock, $0.001 par value per share (the “ Preferred Stock”), of which 50,000 shares are designated as “Series A
Junior Participating Preferred Stock”. As of December 19, 2019, there were 6,004,229 shares of Common Stock issued and outstanding and no
shares of Preferred Stock outstanding. As of December 19, 2019, no shares of Common Stock or Preferred Stock were reserved for issuance,
except for an aggregate of 258,888 shares of Common Stock reserved for issuance upon the exercise of outstanding stock options and the
settlement of restricted stock units issued under the Company’s equity incentive plans and stock incentive plans. All of the issued and
outstanding shares of Common Stock have been duly authorized and validly issued and are fully paid, nonassessable and free of preemptive
rights.
(c) Authority; Approvals . The Company has full corporate power and authority to execute and deliver each of the
Transaction Documents to which it is a party and to consummate the transactions contemplated thereby. The execution and delivery of each of
the Transaction Documents to which it is a party and the consummation by the Company of the transactions contemplated thereby, including,
without limitation, the issuance of the Purchased Shares, the Warrant and the underlying Warrant Shares, have been duly and validly approved
by all necessary corporate action of the Company, and no other corporate and no shareholder proceedings on the part of the Company are
necessary to approve such Transaction Documents or to consummate the transactions contemplated thereby. The Board of Directors has taken
all actions so that the restrictions contained in Section 203 of the Delaware General Corporation Law, as amended (the “ DGCL”), applicable to a
“business combination” (as defined in Section 203 of the DGCL) do not and will not apply to the execution, delivery or performance of any
Transaction Document and the transactions contemplated hereby and thereby. Each of the Transaction Documents to which it is a party has
been duly and validly executed and delivered by the Company and (assuming due execution and delivery by Farids and EA, as applicable)
constitutes a valid and binding obligation of the Company, enforceable against the Company in accordance with its terms, except as
enforcement may be limited by general principles of equity whether applied in a court of law or a court of equity and by bankruptcy, insolvency
and similar laws affecting creditors’ rights and remedies generally (collectively, the “Enforceability Exceptions”).
(d) Non-Contravention . The execution, delivery and performance of the Transaction Documents to which it is a party, and the
consummation by the Company of the transactions contemplated hereby and thereby, does not and will not (i) contravene or conflict with the
Certificate of Incorporation or the Bylaws, (ii) contravene or conflict with or constitute a violation of any provision of any Law or Order binding
upon the Company, (iii) constitute a default under or breach of (with or without the giving of notice or the passage of time or both) or violate or
give rise to any right of termination, cancellation or acceleration of any material contract or other instrument or obligations binding upon the
Company or by which any shares of the Common Stock or the Preferred Stock or any of the Company’s assets is or may be bound or (iv) result
in the creation or imposition of any Lien on any of the shares of Common Stock or Preferred Stock or any of the Company’s assets.
8(e) Consents and Approvals.  Assuming the accuracy of the representations and warranties of each of Farids and EA as set
forth in this Agreement and EA as set forth in the Exclusive Supplier Operating Agreement, as of the Closing Date, no consents or approvals of,
or filings or registrations with, any federal, state or local court, governmental, legislative, judicial, administrative or regulatory authority, agency,
commission, body or other governmental entity or self-regulatory organization (each, a “ Governmental Entity”) or of or with any other third
party by or on behalf of the Company or any of its Subsidiaries are necessary for the execution and delivery by the Company of any
Transaction Document to which it is a party and the consummation by the Company of the transactions contemplated thereby, except for (A)
those already obtained or made, (B) the filing of any Eligible Registration Statement with the Commission pursuant to Article VI, (C) the
supplemental listing application to Nasdaq with respect to the supplemental listing of the Purchased Shares and the reservation for issuance on
the Nasdaq Global Market of the Warrant Shares and (D) any securities or “blue sky” filings of any state. The transactions contemplated by the
Transaction Documents do not require the consent or approval by the holders of a majority of the outstanding shares of Common Stock
pursuant to Nasdaq Listing Rule 5635.
(f) Valid Issuance of Purchased Shares . As of the Purchase Date, the Purchased Shares shall be, and the Warrant Shares,
when issued and delivered to EA in accordance with the terms of the Warrant will be, validly issued, fully paid, non-assessable and free of
preemptive rights and will be delivered free and clear of all Liens. Except for the transactions contemplated in the Transaction Documents, the
issuance and delivery of the Purchased Shares and the Warrant does and will not cause the vesting of any securities of the Company to
accelerate, or trigger or create in any Person the right to acquire, purchase, exercise, exchange or convert any securities of the Company into
Common Stock.
(g) SEC Filings; Financial Statements. All forms, reports, schedules, statements and documents required to be filed with the
SEC by the Company (including all exhibits included therein and financial statements, notes and schedules thereto and documents incorporated
by reference therein, the “ SEC Reports”) during the twelve (12) months prior to the date hereof were prepared in accordance and complied as of
their respective filing dates, in all material respects, with the requirements of the Securities Act and Exchange Act and the rules promulgated
thereunder and did not at the time they were filed (or if amended or superseded by a later filing prior to the date hereof, then on the date of such
later filing) contain any untrue statement of material fact or omit to state a material fact required to be stated therein or necessary in order to
make the statements therein, in the light of the circumstances under which they were made, not misleading. Except as otherwise disclosed in an
SEC Report, each of the audited and unaudited consolidated financial statements (including, in each case, any related notes and schedules
thereto) contained in the SEC Reports (or if amended or superseded by a later filing prior to the date hereof, then on the date of such later filing)
(i) complied in all material respects with applicable accounting requirements and the published regulations of the SEC with respect thereto, (ii)
were prepared in accordance with GAAP (except, in the case of unaudited financial statements, to the extent otherwise permitted by the rules
and regulations of the SEC) applied on a consistent basis throughout the periods involved (except as may be indicated therein or as described
in the notes thereto) and (iii) fairly present in all material respects the financial position of the Company as of the respective dates thereof and
the consolidated results of operations and cash flows for the periods indicated (subject in the case of unaudited financial statements to normal
year-end adjustments and to any other adjustments described therein, including the notes thereto). Other that certain non-recurring expenses,
no material adverse changes have occurred in the financial condition or business of the Company since the date of the most recent financial
statement included in the SEC reports.
9(h) Application to Takeover Protections . The Company and its Board of Directors have taken all necessary action, if any, in
order to render inapplicable any control share acquisition, fair price, business combination, poison pill (including any distribution under a rights
agreement) or other similar anti-takeover provision under the Certificate of Incorporation, the Bylaws or the laws of its jurisdiction of
incorporation that is or could become applicable to the Farids Group or any Person in the Farids Group as a result of Farids, EA and the
Company fulfilling their obligations or exercising their rights under the Transaction Documents, including without limitation as a result of the
Company’s issuance of the Purchased Shares, the Warrants and the underlying Warrant Shares and the ownership of such securities by the
Farids Group or any Person in the Farids Group.
Section 3.2 Representations and Warranties of Farids and EA .
Each of Farids and EA, severally with respect to itself and not jointly, hereby represents and warrants to the Company, as of the date
hereof and as of the Closing Date that:
(a) Existence and Power. Farids is a limited liability company duly organized, validly existing and in good standing under the
laws of the State of Delaware. Farids has all power and authority, limited liability company and otherwise, and all governmental licenses,
franchises, permits, authorizations, consents and approvals required to own and operate its properties and assets and to carry on the business
as presently conducted and as proposed to be conducted, except as would not, individually or in the aggregate, reasonably be expected to
have a material adverse effect on the business, results of operations or financial condition of Farids and its subsidiaries, taken as a whole. EA is
a limited liability company duly organized, validly existing and in good standing under the laws of the State of Delaware. EA has all power and
authority, limited liability company and otherwise, and all governmental licenses, franchises, permits, authorizations, consents and approvals
required to own and operate its properties and assets and to carry on the business as presently conducted and as proposed to be conducted,
except as would not, individually or in the aggregate, reasonably be expected to have a material adverse effect on the business, results of
operations or financial condition of EA and its subsidiaries, taken as a whole.
(b) Authorization; Approvals . Each of Farids and EA has full power and authority to execute and deliver each of the
Transaction Documents to which it is party, as applicable, and to consummate the transactions contemplated thereby and the consummation by
Farids and EA of the transactions contemplated thereby have been duly and validly approved by all necessary limited liability company action
of each of Farids and EA, and no other limited liability company and no member proceedings on the part of either Farids or EA are necessary to
approve such Transaction Documents or to consummate the transactions contemplated thereby. Each of the Transaction Documents that has
been executed and delivered by Farids or EA (assuming due authorization, execution and delivery by the Company), as applicable, constitutes a
valid and binding obligation of Farids or EA, as applicable, enforceable against Farids or EA, as applicable, in accordance with its terms, subject
to Enforceability Exceptions.
10(c) Non-Contravention . The execution, delivery and performance of the Transaction Documents and the consummation by
Farids and EA of the transactions contemplated hereby and thereby, does not and will not (i) contravene or conflict with (A) Farids’ certificate
of formation or operating agreement or (B) EA’s certificate of formation or operating agreement, (ii) contravene or conflict with or constitute a
violation of any provision of any Law or Order binding upon EA or Farids, (iii) constitute a default under or breach of (with or without the
giving of notice or the passage of time or both) or violate or give rise to any right of termination, cancellation or acceleration of any material
contract or other instrument or obligations binding upon Farids or by which any shares of the capital stock of Farids or EA or EA or any of
Farids’ or EA’s assets is or may be bound or (iv) result in the creation or imposition of any Lien on any of the shares of capital stock of Farids or
EA any of Farids’ or EA’s assets.
(d) Consents and Approvals . Assuming the accuracy of the representations and warranties of the Company as set forth in
this Agreement and the Exclusive Supplier Operating Agreement, as of the Closing Date, no consents or approvals of, or filings or registrations
with, any Governmental Entity or of or with any other third party by or on behalf of Farids or EA is necessary for the execution and delivery by
Farids and EA, as applicable, of the Transaction Documents and the consummation by Farids and EA, as applicable, of the transactions
contemplated thereby.
(e) Ownership of the Company; Control of EA . Except for the transactions contemplated in the Transaction Documents, none
of Farids or any of its Affiliates holds or has any rights to acquire, whether directly or indirectly, any Common Stock or any other voting or
equity securities of the Company, or any securities convertible into, exchangeable for or exercisable for Common Stock or any other voting or
equity securities of the Company. EA is controlled by Farids.
(f) Accredited Investor; Experience . Farids is an “accredited investor” (as defined in Rule 501 under the Securities Act) and is
capable of evaluating the merits and risks of its investment in the Company and has the capacity to protect its own interests.
(g) Acquisition for Own Account . Farids is acquiring the Purchased Shares for its own account for investment purposes, and
not with a view to, or for the sale in connection with, any distribution thereof in violation of the Securities Act, and the rules and regulations of
the SEC promulgated thereunder, or that would require the issuance of the Purchased Shares pursuant to this Agreement to be registered under
the Securities Act.
(h) No Reliance. Farids has relied upon the representations and warranties set forth herein and its own investigations and
diligence, including a review of the Company’s annual, quarterly and current reports and other documents filed with or furnished to the SEC,
and not upon any other information provided by or on behalf of the Company in making the decision to purchase the Purchased Shares. Farids
understands and acknowledges that neither the Company nor any of the Company’s representatives, agents or attorneys is making or has made
at any time any warranties or representations of any kind or character, express or implied, with respect to any matter or the Common Stock,
except as expressly set forth herein.
11ARTICLE IV
BOARD NOMINATION RIGHTS
Section 4.1 Springing Nomination Right. Subject to, and only upon the satisfaction of the conditions set forth in, this Section 4.1 and
Section 4.5, (i) the Farids Group shall have the right to designate TF or, in the event of the death or permanent disability of TF, another
individual that is reasonably acceptable to the Company to be a director of the Company (TF or its designee in such capacity, the “ Director
Designee ”), and (ii) the Company shall cause the Director Designee to be nominated as a director of the Company unless and until such
Director Designee is unwilling or unable to serve as a director. The rights and obligations of the Farids Group and the Company (including,
without limitation, the right of the Farids Group to appoint the Director Designee and the obligation of the Company to cause the Director
Designee to be nominated for election to the Board of Directors (other than with respect to the Annual Meeting)) set forth in this Article IV
shall only be effective immediately after, and only upon, the date the Farids Group owns 5.0% or more of the issued and outstanding Common
Stock. Subject to, and only upon the satisfaction of the conditions set forth in, this Section 4.1 and Section 4.5, it is understood and agreed that
in the event that a vacancy is created at any time as a result of (i) the death or permanent disability of any Director Designee or (ii) the
retirement, resignation or removal (with or without cause) of any Director Designee other than TF, then the Farids Group shall have the right to
designate a replacement director (who shall be reasonably acceptable to the Company and shall satisfy the eligibility requirements in Section
4.3) to fill such vacancy.
Section 4.2 Obligations of the Company .
(a) Nomination; Insurance . On or prior to the date of this Agreement or TF’s election to the Board of Directors at the Annual
Meeting, as applicable, the Company shall have (x) nominated TF for election to the Board of Directors at the Annual Meeting, (y) entered into
an Indemnification Agreement with TF as the Director Designee and (z) taken all necessary action for TF to be covered by the Company’s
existing directors’ liability insurance policy.
(b) Nomination. Subject to, and only upon the satisfaction of the conditions set forth in, this Section 4.1 and Section 4.5, the
Company shall cause the Director Designee to be (x) nominated for election to the Board of Directors and included in the Board of Director’s
slate of nominees recommended to the shareholders of the Company for each election of directors, and recommend to the shareholders of the
Company that the Director Designee be elected to the Board of Directors and (y) included in the proxy statement (if any) prepared by
management of the Company in connection with soliciting proxies for every meeting of the shareholders of the Company called with respect to
the election of members of the Board of Directors, and at every adjournment or postponement thereof, and on every action or approval by
written consent of the shareholders of the Company or the Board of Directors with respect to the election of members of the Board of Directors.
When applicable pursuant to Section 4.1 and Section 4.5, the Company shall use its commercially reasonable efforts to cause the election of the
Director Designee and otherwise support the Director Designee for election in a manner no less rigorous and favorable than the manner in
which the Company supports, and has historically supported, its other nominees in the aggregate. Except as otherwise required by applicable
Law, the Company shall not take any action to cause the removal without cause of the Director Designee, unless it is directed to do so by the
Farids Group.
12Section 4.3 Eligibility of Director Designee. Notwithstanding the other provisions of this Article IV, the Company shall not be obligated
to cause to be nominated for election to the Board of Directors (or to be included in the Board of Directors’ slate of nominees to the Company’s
stockholders or any proxy statement prepared by management of the Company in connection with soliciting proxies for meetings of the
stockholders of the Company called with respect to the election of members of the Board of Directors) or recommend to the Company’s
stockholders the election of the Director Designee in the event that (i) the Director Designee fails to satisfy all applicable requirements (other
than those relating to independence) regarding qualifying as a director of the Company under (A) Nasdaq rules (or the rules of the principal
market on which shares of Common Stock are then listed) regarding service as a director and (B) applicable Law; (ii) the Director Designee has
been involved in any of the events enumerated in Item 2(d) or (e) of Schedule 13D under the Exchange Act, (iii) the Director Designee is
currently the target of an investigation by any governmental authority or agency relating to felonious criminal activity or is subject to any order,
decree, or judgment of any court or agency prohibiting service as a director of any public company or providing investment or financial
advisory services or (iv) the Director Designee has declared or otherwise indicated (whether publicly or to the Company or the Board of
Directors) that she or he is unwilling or unable to serve as a director or otherwise takes actions inconsistent with her or his election. If any
event described in clause (i) through (iv) of the preceding sentence occurs, (x) if the Director Designee is TF, then the Farids Group shall forfeit
its rights under this Agreement to designate the Director Designee as a member of the Board of Director and shall not have any right to a
replacement designee and (y) if the Director Designee is an individual other than TF, then the TF Group shall designate a replacement designee
who shall be reasonably acceptable to the Company and shall satisfy the eligibility requirements set forth in this Section 4.3 and such
replacement designee shall thereafter constitute a “Director Designee” under this Agreement. The Company shall promptly notify the Farids
Group in writing of any objection to the Director Designee in advance of the date on which proxy materials are mailed by the Company in
connection with such election of directors.
Section 4.4 Resignation . If Farids’ Nomination Right set forth in this Article IV is currently applicable and is terminated pursuant to
Section 4.5, at the request of the Company, the Director Designee shall offer to resign as a director effective immediately.
Section 4.5 Termination. Subject to Section 4.1, the rights and obligations of the Farids Group and the Company (including, without
limitation, the right of the Farids Group to appoint the Director Designee and the obligation of the Company to cause the Director Designee to
be nominated for election to the Board of Directors) set forth in this Article IV (if applicable, the “ Nomination Right ”) shall terminate
immediately after the date the Farids Group owns less than 5.0% of the issued and outstanding Common Stock of the Company, and the
Director Designee shall no longer be deemed to be a “Director Designee”; provided further, that, even if the Farids Group owns 5.0% or more of
the issued and outstanding Common Stock, such rights and obligations shall terminate on the earliest to occur of: (A) for purposes of
determining the Nomination Right for the third Contract Year (as defined in the Exclusive Supplier Operating Agreement), the EA Revenue (as
defined in the Warrant) for the second Contract Year is less than $[**], (B) for purposes of determining the Nomination Right for the fourth
Contract Year, the EA Revenue for the third Contract Year is less than $[**]; (C) for purposes of determining the Nomination Right for the fifth
Contract Year, the EA Revenue for the fourth Contract Year is less than $[**]; or (D) for purposes of determining the Nomination Right for the
12-month period following the fifth Contract Year, the EA Revenue for the fifth Contract Year is less than $[**].
13ARTICLE V
RESTRICTIONS ON TRANSFER
Section 5.1 Restrictions on Transfer .
(a) Until the second anniversary of the Closing Date, the Farids Group agrees not to make any Transfer of all or any portion of
the Purchased Shares, except that the Farids Group shall be permitted to make Permitted Transfers.
(b) Notwithstanding anything to the contrary in this Agreement, the Farids Group agrees that it will not effect any Transfer of
Purchased Shares unless such Transfer is made pursuant to an effective registration statement under the Securities Act or pursuant to an
exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and, in either case, in compliance with all
applicable state securities laws and all applicable securities laws of any other jurisdiction. The Company agrees, and the Farids Group
understands and consents, that the Company will not take any action to cause or permit the Transfer of any Purchased Shares to be made on its
books (or on any register of securities maintained on its behalf) unless the Transfer is permitted by and has been made in accordance with the
terms of this Agreement and all applicable securities laws. The Farids Group agrees that in connection with any Transfer of Purchased Shares
that is not made pursuant to a registration statement, the Company may, in its sole discretion, request an opinion, certifications and other
information in form and substance reasonably satisfactory to the Company and from counsel reasonably satisfactory to the Company stating
that such transaction is exempt from registration under the Securities Act.
(c) The Purchased Shares shall be stamped or otherwise imprinted with legends substantially similar to the following (in
addition to any legend required under applicable state securities laws) or if held in electronic form, shall be held in an account by the
Company’s stock transfer agent subject to restrictions on Transfer substantially consistent with the following legend, which shall be furnished
in accordance with applicable Law:
THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED (THE “ACT”), AND MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, ASSIGNED, PLEDGED
OR HYPOTHECATED EXCEPT (A) PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT
COVERING ANY SUCH TRANSACTION OR (B) PURSUANT TO AN EXEMPTION FROM REGISTRATION THEREUNDER,
SUBJECT TO THE COMPANY’S RIGHT TO RECEIVE AN OPINION OF COUNSEL, CERTIFICATIONS AND OTHER
INFORMATION IN FORM AND SUBSTANCE REASONABLY SATISFACTORY TO THE COMPANY AND FROM COUNSEL
REASONABLY SATISFACTORY TO THE COMPANY STATING THAT SUCH TRANSACTION IS EXEMPT FROM SUCH
REGISTRATION REQUIREMENTS.
14THE SALE, PLEDGE, HYPOTHECATION OR TRANSFER OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE IS
SUBJECT TO THE TERMS AND CONDITIONS OF A CERTAIN STRATEGIC ALLIANCE AGREEMENT DATED AS OF
DECEMBER 20, 2019, AMONG FARIDS & CO. LLC, EDIBLE ARRANGEMENTS, LLC AND THE COMPANY (AS THE SAME
MAY BE AMENDED AND IN EFFECT FROM TIME TO TIME). NO SALE, PLEDGE, HYPOTHECATION OR TRANSFER OF
THE SECURITIES REPRESENTED BY THIS CERTIFICATE MAY BE MADE EXCEPT IN ACCORDANCE WITH THE
PROVISIONS OF SUCH STRATEGIC ALLIANCE AGREEMENT. COPIES OF SUCH AGREEMENT MAY BE OBTAINED
UPON WRITTEN REQUEST TO THE SECRETARY OF THE COMPANY.
(d) The Farids Group acknowledges and agrees that any Transfer of the limited liability company interests, partnership
interests, shares or other similar equity interests in any member of the Farids Group or a parent entity of such member will be deemed to
constitute a Transfer of Purchased Shares, and any proposed Transfer of all or any portion of any such interests in any member of the Farids
Group or a parent entity of such member shall be subject to compliance with the terms of this Agreement as such terms apply to the Farids
Group.
(e) The Company acknowledges and agrees that the Farids Group may from time to time pledge, and/or grant a security
interest in, some or all of the legended Purchased Shares in connection with applicable securities laws, pursuant to a bona fide margin
agreement in compliance with a bona fide margin loan. Such a pledge would not be subject to approval or consent of the Company and no legal
opinion of legal counsel to the pledgee, secured party or pledgor shall be required in connection with the pledge, but such legal opinion shall
be required in connection with a subsequent transfer or foreclosure following default by the Farids Group transferee of the pledge. No notice
shall be required of such pledge, but the Farids Group’s transferee shall promptly notify the Company of any such subsequent transfer or
foreclosure. The Farids Group acknowledges that the Company shall not be responsible for any pledges relating to, or the grant of any security
interest in, any of the Purchased Shares or for any agreement, understanding or arrangement between the Farids Group and its pledgee or
secured party. At the Farids Group’s expense, the Company will execute and deliver such reasonable documentation as a pledgee or secured
party of Purchased Shares may reasonably request in connection with a pledge or transfer of the Purchased Shares, including the preparation
and filing of any required prospectus supplement under Rule 424(b)(3) of the Securities Act or other applicable provision of the Securities Act
to appropriately amend the list of selling stockholders thereunder.
(f) The legend set forth in Section 5.1(c) above shall be removed and the Company shall issue one or more certificates without
such legend or any other legend to the holder of the Purchased Shares upon which it is stamped or issue to such holder by electronic delivery,
if (i) such Purchased Shares are registered for resale under the Securities Act, (ii) such Purchased Shares are sold or transferred pursuant to
Rule 144, or (iii) such Purchased Shares are eligible for resale under the Securities Act without regard to current public information, manner of
sale or volume limitations. Any fees (with respect to the Company’s transfer agent, Company counsel or otherwise) associated with the removal
of such legend shall be borne by the Company.
15Section 5.2 Remedy for Prohibited Transfer . In the event that any member of the Farids Group Transfers any Purchased Shares in
contravention of Section 5.1, such Transfer shall be null and void, and the Company agrees it will not take any action to effect such a Transfer
nor will it treat any alleged transferee as the holder of such Purchased Shares.
ARTICLE VI
REGISTRATION RIGHTS
Section 6.1 Demand Registration.
(a) If the Company shall receive a written request (a “ Demand Request”) from the Farids Group that the Company file a
registration statement under the Securities Act covering the registration of all or a portion of the Registrable Securities owned by the Farids
Group, then the Company shall, subject to the limitations of this Section 6.1, effect, as expeditiously as reasonably possible, the registration
under the Securities Act of all Registrable Securities in accordance with the intended method of distribution thereof that the Farids Group
requests to be registered, subject to the provisions of Section 6.1(c); provided, however, that any Eligible Resale Registration Statement shall be
filed within 90 days following receipt of such Demand Request and any Resale Shelf Registration Statement shall be filed within 30 days
following receipt of such Demand Request, as applicable. The Farids Group shall have the right to make two (2) Demand Requests on or after
the date that is the second anniversary of the date of this Agreement; provided, that the Farids Group shall not make more than one (1) Demand
Request within any six-month period.
(b) If the Farids Group intends to distribute the Registrable Securities covered by its request by means of an underwritten
public offering, it shall so advise the Company as a part of their request made pursuant to this Section 6.1. The Farids Group shall have the right
to select the investment bank or banks and managers to administer any offering made in connection with a Demand Request, including the lead
managing underwriter; provided that such investment banks or managers shall be reasonably acceptable to the Company; provided, further,
that if the Farids Group declines to exercise such right, the Company shall select the investment bank or banks and managers to administer the
offering, but the Farids Group shall continue to have such right pursuant to this Section 6.1(b) in any subsequent underwritten public offering.
(c) Notwithstanding anything herein to the contrary, the Company shall not be obligated to (i) effect a registration pursuant
to Section 6.1 unless the Registrable Securities requested to be registered by the Farids Group, together with all other shares of Common Stock
requested to be registered by any other holder of piggyback registration rights (each, an “ Other Piggyback Holder ”) pursuant to any
agreement containing similar registration rights as those contained in this Article VI (such other shares, the “ Other Registrable Securities ”),
are reasonably expected to result in aggregate gross cash proceeds in excess of (x) in the case of a Resale Shelf Registration Statement, three (3)
million dollars ($3,000,000) and (y) in the case of any other form of registration statement, one (1) million dollars ($1,000,000) or (ii) prepare, file,
effect or maintain a shelf registration statement on Form S-3 (or any successor to Form S-3) or any similar shelf registration statement (other
than a Resale Shelf Registration Statement) under the Securities Act for the purposes of compliance with any Demand Right pursuant to this
Section 6.1.
16Section 6.2 Piggyback Registrations .
(a) From and after the second anniversary of the date of this Agreement, the Company shall notify the Farids Group (unless
the Farids Group has demanded such registration pursuant to Section 6.1) in writing at least five (5) business days prior to the initial public
filing of any Eligible Registration Statement. Such notice from the Company shall state the intended method of distribution of the Registrable
Securities included in such Eligible Registration Statement. The Company shall afford the Farids Group the opportunity to include Registrable
Securities in such Eligible Registration Statement so long as it agrees to sell its Registrable Securities pursuant to the same method of
distribution. If the Farids Group desires to include Registrable Securities held by it in any such Eligible Registration Statement, it shall, within
four (4) business days after the above-described notice from the Company, so notify the Company in writing. Any such notice from the Farids
Group shall (i) specify the amount of Registrable Securities that the Farids Group would like to include in such Eligible Registration Statement
and (ii) include the agreement of the Farids Group to participate in any related underwritten offering on the same terms as the other participating
Holders. Upon such written notice from the Farids Group, the Company will use its best efforts to effect the registration under the Securities
Act of all Registrable Securities which the Farids Group has requested to be registered. If the Farids Group decides not to or is unable to include
all of its Registrable Securities in any Eligible Registration Statement filed by the Company, the Farids Group shall nevertheless continue to
have the right to include Registrable Securities in any subsequent Eligible Registration Statement as may be filed by the Company, all upon the
terms and conditions set forth herein. Prior to the effectiveness of the applicable Eligible Registration Statement, the Farids Group may withdraw
from such Eligible Registration Statement any of the Registrable Securities at any time upon written notice to the Company.
(b) Underwriting. If the Eligible Registration Statement under which the Company gives notice under this Section 6.2 is for an
underwritten offering, the Company shall so advise the Farids Group. In such event, the right of the Farids Group to be included in an Eligible
Registration Statement pursuant to this Section 6.2 shall be conditioned upon the Farids Group’s participation in such underwriting by
executing and delivering a custody agreement and power of attorney in form and substance reasonably satisfactory to the Company with
respect to such Registrable Securities (the “ Custody Agreement and Power of Attorney”), which Custody Agreement and Power of Attorney
shall permit the Farids Group to, prior to the effectiveness of such Eligible Registration Statement, withdraw any of the Registrable Securities at
any time from such Eligible Registration Statement upon written notice to the Company and the custodian. The Custody Agreement and Power
of Attorney will provide, among other things, that (i) the Farids Group will, to the extent applicable, deliver to and deposit in custody with the
custodian and attorney-in-fact named therein one or more certificates representing such Registrable Securities, accompanied by duly executed
stock powers in blank, and irrevocably appoint said custodian and attorney-in-fact with full power and authority to act under the Custody
Agreement and Power of Attorney on the Farids Group’s behalf with respect to the matters specified therein, including, but not limited to, the
entry into an underwriting agreement (the “ Underwriting Agreement”“) in customary form with the underwriter(s) and such other documents
and agreements reasonably required in connection with such registration or offering and (ii) the Farids Group will perform its obligations under
such Underwriting Agreement and any other agreement entered into in connection with such registration and/or offering. The Farids Group
also agrees to execute such other documents and agreements as the Company may reasonably request to effect the provisions of this Section
6.2 and any transactions contemplated hereby.
17Section 6.3 Priority on Registrations . Notwithstanding any other provision of this Article VI, if the lead managing underwriter or
underwriters advise, in the case of a requested registration pursuant to Section 6.1, the Farids Group or, in all other cases, the Company that
marketing factors (including, but not limited to, an adverse effect on the per share offering price) require a limitation of the number of shares to
be included in an underwritten offering (including Registrable Securities), then the Farids Group or the Company, as the case may be, shall so
advise all holders of Registrable Securities and all Other Piggyback Holders who have requested to participate in such offering, that (i) if the
requested registration is pursuant to Section 6.1, the number of shares that may be included in the underwriting shall be allocated first to the
Farids Group for its own account, and second to the Company (to the extent it is selling shares of Common Stock in such offering) and the
Other Piggyback Holders who have duly requested shares to be included therein on a pro rata basis based on the number of shares proposed
to be sold by the Company and the number of Other Registrable Securities requested to be included by such Other Piggyback Holders, and (ii)
if the requested registration is not pursuant to Section 6.1, the number of shares that may be included in the underwriting shall be allocated first
to the Company for its own account (to the extent such registration was initiated by the Company) or to such Holder of Other Registrable
Securities who demanded such registration pursuant to demand rights similar to those set forth in this Agreement, and second to the Company
(to the extent such registration was not initiated by the Company), the Farids Group and the Other Piggyback Holders who have duly requested
shares to be included therein on a pro rata basis based on the number of shares proposed to be sold by the Company (to the extent such
registration was not initiated by the Company), the number of Registrable Securities requested to be included by the Farids Group and the
number of Other Registrable Securities requested to be included by all such Other Piggyback Holders. For any Other Piggyback Holder which is
a partnership, limited liability company or corporation, the partners, members or shareholders, as applicable, of such Other Piggyback Holder
and the estates and Family Members of any such partners, members and shareholders and any trusts for the benefit of any of the foregoing
Person(s) shall be deemed to be a single “Other Piggyback Holder,” and any pro rata reduction with respect to such “Other Piggyback Holder”
pursuant to this Section 6.3 shall be based upon the aggregate amount of shares carrying registration rights owned by all Persons deemed to
constitute such “Other Piggyback Holder” (as defined in this sentence).
Section 6.4 Termination, Effectiveness, Postponement and Suspension of Registration .
(a) Right to Terminate Registration . If the Farids Group determines for any reason not to proceed with any proposed
registration requested pursuant to Section 6.1, the Farids Group shall promptly notify the Company in writing. Upon receipt of such notice, the
Company shall withdraw or terminate such registration whether or not any Other Piggyback Holder has elected to include any Other Registrable
Securities in such registration. In addition, the Company shall have the right to withdraw or terminate any proposed registration initiated by it
and a Holder of Other Registrable Securities shall have the right to withdraw or terminate any proposed registration initiated by it, whether or
not the Farids Group or any Other Piggyback Holder has elected to include Registrable Securities or Other Registrable Securities, as the case
may be, in such registration. The Company shall promptly give notice of the withdrawal or termination of any registration to the Farids Group,
to the extent the Farids Group has elected to participate in such registration. The Registration Expenses of any such withdrawn or terminated
registration shall be borne by the Company in accordance with Section 6.5.
18(b) Effectiveness of the Registration Statement . The Company shall maintain the effectiveness of the Eligible Registration
Statement until the earlier of (i) the date on which all Registrable Securities included in such Eligible Registration Statement have actually been
sold and (ii) the date that is (x) 180 days (in respect of a Resale Shelf Registration Statement) or (y) 90 days (in respect of any Eligible
Registration Statement other than a Resale Shelf Registration Statement) from the effective date of such Eligible Registration Statement.
(c) Postponement or Suspension of Registration . If the filing, initial effectiveness or continued use of an Eligible Registration
Statement in respect of a registration pursuant to this Agreement at any time would require the Company to make a public disclosure of material
non-public information, (1) which disclosure in the good faith judgment of the Board of Directors (after consultation with external legal counsel)
(x) would be required to be made in any registration statement so that such registration statement would not contain a material misstatement or
omission, (y) would not be required by applicable Law to be made at such time but for the filing, effectiveness or continued use of such Eligible
Registration Statement and (z) would reasonably be expected to have a Company Material Adverse Effect or a material adverse effect on the
Company’s ability to effect a material proposed acquisition, disposition, financing, business opportunity, reorganization, recapitalization or
similar transaction or (2) during a customary “blackout” period of the Company, then the Company may, upon giving prompt written notice of
such determination to the Farids Group, delay the filing or initial effectiveness of, or suspend the use of, such Eligible Registration Statement;
provided, that the Company shall not be permitted to do so pursuant to clause (1) above (x) more than two times during any twelve (12) month
period or (y) for a period exceeding thirty (30) days on any one occasion (unless a longer period is consented to by the Farids Group) (the
“Suspension Period ”). In the event the Company exercises its rights under the preceding sentence, the Farids Group agrees to suspend,
promptly upon its receipt of the notice referred to above, its use of any prospectus relating to such registration in connection with any sale or
offer to sell Registrable Securities. If so requested by the Company, the Farids Group shall use its reasonable best efforts to deliver to the
Company (at the Company’s expense) all copies, other than permanent file copies then in the Farids Group’s possession, of the prospectus
relating to such Registrable Securities at the time of receipt of such notice. The Company agrees that, in the event it exercises its rights under
this Section 6.4(c), it shall (i) promptly notify the Farids Group of the termination or expiration of any Suspension Period, (ii) within thirty (30)
days after delivery of the notice referred to above (unless a longer period is consented to by the Farids Group), resume the process of filing or
request for effectiveness, or update the suspended registration statement, as the case may be, as may be necessary to permit the Farids Group
to offer and sell its Registrable Securities in accordance with applicable Law and (iii) if an Eligible Registration Statement that was already
effective had been suspended as result of the exercise of such rights by the Company, promptly notify the Farids Group after the termination or
expiration of any Suspension Period of the applicable time period during which the Eligible Registration Statement is to remain effective, which
shall be extended by a period of time equal to the duration of the Suspension Period.
19Section 6.5 Expenses of Registration . Except as specifically provided herein, all Registration Expenses incurred in connection with any
registration under Sections 6.1 and 6.2 shall be borne by the Company. All underwriting fees and selling commissions relating to the distribution
of the Registrable Securities and all taxes, if any, on the transfer and sale, respectively, of the Registrable Securities being sold that are incurred
in connection with any registrations hereunder shall be borne by the Farids Group. For the avoidance of doubt, all underwriting fees, selling
commissions and taxes incurred in connection with any registration hereunder relating to securities sold by the Company shall be borne by the
Company.
Section 6.6 Obligations of the Company . If and whenever the Company is required to effect the registration of any Registrable
Securities under the Securities Act as provided in Sections 6.1 and 6.2 (to the extent the Farids Group has requested to include Registrable
Securities in an Eligible Registration Statement pursuant to clause (a) of such Section 6.1 or 6.2, as the case may be), the Company shall effect
such registration to permit the sale of such Registrable Securities in accordance with the intended method or methods of distribution thereof,
and pursuant thereto the Company shall cooperate in the sale of the securities and shall, as expeditiously as reasonably possible:
(a) Prepare and file with the SEC an Eligible Registration Statement on such form as shall be available for the sale of the
Registrable Securities by the Farids Group in accordance with the intended method of distribution thereof and the provisions of this Article VI,
and use its reasonable best efforts to cause each such Eligible Registration Statement to become effective and remain effective as provided
herein; provided, however, that before filing any Eligible Registration Statement or Prospectus or any amendments or supplements thereto (not
including documents that would be incorporated or deemed to be incorporated therein by reference), the Company shall afford the Farids
Group, its counsel and the managing underwriter, if any, an opportunity to review copies of all such documents proposed to be filed. The
Company shall not file any Eligible Registration Statement or Prospectus or any amendments or supplements thereto in respect of which the
Farids Group has a right to review prior to the filing of such document, if the Farids Group, its counsel or the managing underwriter, if any, shall
reasonably object, in writing, on a timely basis.
(b) Prepare and file with the SEC such amendments and post-effective amendments to each Eligible Registration Statement as
may be necessary to keep such Eligible Registration Statement continuously effective for the effectiveness period; and comply with the
provisions of the Securities Act, the Exchange Act and the rules and regulations of the SEC promulgated thereunder applicable to it with
respect to the disposition of all securities covered by such Eligible Registration Statement as so amended or in such Prospectus as so
supplemented.
20(c) Notify the Farids Group, its counsel and the managing underwriter, if any, promptly (but in any event within 10 business
days), and confirm such notice in writing, (i) when a Prospectus or any prospectus supplement or post-effective amendment has been filed, and,
with respect to an Eligible Registration Statement or any post-effective amendment, when the same has become effective (including in such
notice a written statement that the Farids Group may, upon request, obtain, without charge, one conformed copy of such Eligible Registration
Statement or post-effective amendment including financial statements and schedules, all documents incorporated or deemed to be incorporated
by reference and all exhibits), (ii) of the issuance by the SEC of any stop order suspending the effectiveness of a Eligible Registration Statement
or of any order preventing or suspending the use of any preliminary prospectus or the initiation of any proceedings for that purpose, (iii) if at
any time when a prospectus is required by the Securities Act to be delivered in connection with sales of the Eligible Registrable Securities the
representations and warranties of the Company contained in any agreement (including any underwriting agreement) contemplated by Section
6.6(k) below cease to be true and correct in all material respects, (iv) of the receipt by the Company of any notification with respect to the
suspension of the qualification or exemption from qualification of an Eligible Registration Statement or any of the Registrable Securities for offer
or sale in any jurisdiction, or the initiation or threatening of any proceeding for such purpose, (v) of the happening of any event that makes any
statement made in such Eligible Registration Statement or related Prospectus or any document incorporated or deemed to be incorporated
therein by reference untrue in any material respect or that requires the making of any changes in such Eligible Registration Statement,
Prospectus or documents so that, in the case of such Eligible Registration Statement, it will not contain any untrue statement of a material fact
or omit to state any material fact required to be stated therein or necessary to make the statements therein not misleading, and that in the case of
the Prospectus, it will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or
necessary to make the statements therein, in light of the circumstances under which they were made, not misleading, and (vi) of the Company’s
reasonable determination that a post-effective amendment to an Eligible Registration Statement would be appropriate.
(d) Use its reasonable best efforts to prevent the issuance of any order suspending the effectiveness of an Eligible
Registration Statement or of any order preventing or suspending the use of a Prospectus or suspending the qualification (or exemption from
qualification) of any of the Registrable Securities for sale in any jurisdiction, and, if any such order is issued, to obtain the withdrawal of any
such order at the earliest possible moment.
(e) If requested by the managing underwriter, if any, or the Farids Group, (i) promptly incorporate in a post-effective
amendment such information as the managing underwriter, if any, or the Farids Group reasonably requests to be included therein to comply with
applicable Law, (ii) make all required filings of such post-effective amendment as soon as practicable after the Company has received
notification of the matters to be incorporated in such post-effective amendment, and (iii) supplement or make amendments to such Eligible
Registration Statement; provided, however, that the Company shall not be required to take any actions under this Section 6.6(e) that are not, in
the opinion of counsel for the Company, in compliance with applicable Law.
(f) Furnish to the Farids Group and each managing underwriter, if any, without charge, one conformed copy of the Eligible
Registration Statement or Statements and each post-effective amendment thereto, including financial statements and schedules, all documents
incorporated or deemed to be incorporated therein by reference and all exhibits.
21(g) Deliver to the Farids Group, its counsel and the underwriters, if any, without charge, as many copies of the Prospectus or
Prospectuses (including each form of prospectus) and each amendment or supplement thereto as such Persons may reasonably request; and,
the Company hereby consents to the use of such Prospectus and each amendment or supplement thereto by the Farids Group and the
underwriters, if any, in connection with the offering and sale of the Registrable Securities covered by such Prospectus and an amendment or
supplement thereto.
(h) Prior to any public offering of Registrable Securities, to use its reasonable best efforts to register or qualify, and cooperate
with the Farids Group, the underwriters, if any, the sales agent and their respective counsel in connection with the registration or qualification
(or exemption from such registration or qualification) of such Registrable Securities for offer and sale under the securities or “blue sky” laws of
such jurisdictions within the United States as the Farids Group or the managing underwriter, if any, reasonably request in writing; use its
reasonable best efforts to keep each such registration or qualification (or exemption therefrom) effective during the period during which the
related Eligible Registration Statement is required to be kept effective and use its reasonable best efforts to do any and all other acts or things
necessary or advisable to enable the disposition in such jurisdictions of the Registrable Securities covered by the applicable Eligible
Registration Statement; provided, however, that the Company will not be required to (A) qualify generally to do business in any jurisdiction
where it is not then so qualified or (B) take any action that would subject it to general service of process or taxation in any such jurisdiction
where it is not then so subject.
(i) Upon the occurrence of any event contemplated by clause (v) or (vi) of Section 6.6(c) above, as promptly as practicable
prepare a supplement or post-effective amendment to the Eligible Registration Statement or a supplement to the related Prospectus or any
document incorporated or deemed to be incorporated therein by reference, or file any other required document so that, as thereafter delivered to
the purchasers of the Registrable Securities being sold thereunder, such Prospectus will not contain an untrue statement of a material fact or
omit to state a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which
they were made, not misleading.
(j) Enter into an underwriting agreement in form, scope and substance as is customary in underwritten offerings and take all
such other actions as are reasonably requested by the managing underwriter in order to expedite or facilitate the registration or the disposition
of such Registrable Securities, and in such connection, (i) make such customary representations and warranties to the underwriters, with
respect to the business of the Company and its subsidiaries, and the Eligible Registration Statement, Prospectus and documents, if any,
incorporated or deemed to be incorporated by reference therein; (ii) obtain opinions of counsel to the Company and updates thereof (which
counsel and opinions shall be reasonably satisfactory (in form, scope and substance) to the managing underwriter), addressed to the
underwriters covering the matters customarily covered in opinions requested in underwritten offerings and such other matters as may be
reasonably requested by the underwriters; and (iii) obtain “comfort” letters and updates thereof from the independent certified public
accountants of the Company (and, if necessary, any other independent certified public accountants of any subsidiary of the Company or of any
business acquired by the Company for which financial statements and financial data are, or are required to be, included in the Eligible
Registration Statement), addressed to each of the underwriters, such letters to be in customary form and covering matters of the type
customarily covered in “comfort” letters in connection with underwritten offerings. The above shall be done at each closing under such
underwriting agreement, or as and to the extent required thereunder.
22(k) Use its reasonable best efforts to cause all Registrable Securities covered by such Eligible Registration Statement to be
listed on each securities exchange on which the Common Stock is then listed.
(l) Comply with all applicable rules and regulations of the SEC and make generally available to its security-holders earnings
statements satisfying the provisions of Section 11(a) of the Securities Act and Rule 158 thereunder (or any similar rule promulgated under the
Securities Act) no later than 45 days after the end of any 12-month period (or 90 days after the end of any 12-month period if such period is a
fiscal year) (i) commencing at the end of any fiscal quarter in which Registrable Securities are sold to underwriters in a firm commitment or best
efforts underwritten offering and (ii) if not sold to underwriters in such an offering, commencing on the first day of the first fiscal quarter of the
Company after the effectiveness date of an Eligible Registration Statement, which statements shall cover said 12-month periods.
Section 6.7 Delay of Registration; Furnishing Information . It shall be a condition precedent to the obligations of the Company to take
any action pursuant to Section 6.1 or 6.2 that the Farids Group shall furnish to the Company such information regarding itself, the Registrable
Securities held by it and the intended method of distribution of such securities as required by Section 6.12 or as otherwise reasonably
requested by the Company.
Section 6.8 Indemnification. In the event any Registrable Securities are included in an Eligible Registration Statement under Section 6.1
or 6.2:
(a) To the fullest extent permitted by law, the Company will indemnify and hold harmless the Farids Group, the partners,
members, directors and officers of any member of the Farids Group, any underwriter (as defined in the Securities Act), the directors and officers
of such underwriter, and each person, if any, who controls any member of the Farids Group or such underwriter within the meaning of the
Securities Act or the Exchange Act (collectively, the “ Non-Company Indemnified Parties”), against any losses, claims, damages, or liabilities
(joint or several) to which they may become subject under the Securities Act, the Exchange Act or other federal or state law, insofar as such
losses, claims, damages or liabilities (or suits, actions or proceedings in respect thereof) and reasonable documented expenses that arise out of
or are based upon any of the following statements, omissions or violations by the Company: (i) any untrue statement or alleged untrue
statement of a material fact contained in such Eligible Registration Statement or incorporated by reference therein, including any preliminary
prospectus, final prospectus or summary prospectus contained therein or any amendments or supplements thereto or any document
incorporated by reference therein, or any other such disclosure document (including reports and other documents filed under the Exchange Act
and any document incorporated by reference therein) or related document or report, (ii) any omission or alleged omission to state therein a
material fact required to be stated therein (in the case of an Eligible Registration Statement only), or necessary to make the statements therein
not misleading, in the case of a prospectus, in the light of the circumstances when they were made, or (iii) any violation or alleged violation by
the Company or any of its subsidiaries of the Securities Act, the Exchange Act, any state securities law or any rule or regulation promulgated
under the Securities Act, the Exchange Act or any federal, state, foreign or common law, rule or regulation in connection with the offering
covered by such Eligible Registration Statement (collectively, a “ Violation”); and the Company will reimburse each such Non-Company
Indemnified Party for any reasonable legal or other expenses reasonably incurred by them in connection with investigating or defending any
such loss, claim, damage, liability, suit, action or proceeding; provided, however, that the indemnity agreement contained in this Section 6.8(a)
shall not apply to amounts paid in settlement of any such loss, claim, damage, liability, suit, action or proceeding if such settlement is effected
without the consent of the Company, which consent shall not be unreasonably withheld, delayed or conditioned, nor shall the Company be
liable in any such case for any such loss, claim, damage, liability, suit, action or proceeding to the extent that it arises out of or is based upon a
Violation which occurs in reliance upon and in conformity with written information furnished expressly for use in connection with such Eligible
Registration Statement by such Non-Company Indemnified Party.
23(b) To the fullest extent permitted by law, the Farids Group will, jointly and severally, indemnify and hold harmless the
Company, each of its directors, officers, employees, agents, representatives, and each person, if any, who controls the Company within the
meaning of the Securities Act or the Exchange Act, any underwriter (as defined in the Securities Act), the directors and officers of such
underwriter, and each person, if any, who controls such underwriter within the meaning of the Securities Act or the Exchange Act, against any
losses, claims, damages or liabilities (joint or several) to which the Company or any such director, officer, employee, agent, representative,
controlling person or underwriter may become subject under the Securities Act, the Exchange Act or other federal or state law, insofar as such
losses, claims, damages or liabilities (or suits, actions or proceedings in respect thereof) and reasonable documented expenses that arise out of
or are based upon any of the following statements, omissions or violations: (i) any untrue statement or alleged untrue statement of a material
fact contained in such Eligible Registration Statement or incorporated by reference therein, including any preliminary prospectus, final
prospectus or summary prospectus contained therein or any amendments or supplements thereto or any document incorporated by reference
therein, or any other such disclosure document (including reports and other documents filed under the Exchange Act and any document
incorporated by reference therein) or related document or report, (ii) any omission or alleged omission to state therein a material fact required to
be stated therein (in the case of an Eligible Registration Statement only), or necessary to make the statements therein not misleading, in the case
of a prospectus, in the light of the circumstances when they were made, or (iii) any violation or alleged violation by the Company or any of its
subsidiaries of the Securities Act, the Exchange Act, any state securities law or any rule or regulation promulgated under the Securities Act, the
Exchange Act or any federal, state, foreign or common law, rule or regulation in connection with the offering covered by such Eligible
Registration Statement (collectively, a “ Holder Violation”), in each case to the extent (and only to the extent) that such Holder Violation occurs
in reliance upon and in conformity with written information furnished by the Farids Group expressly for use in connection with such Eligible
Registration Statement; and the Farids Group will reimburse any legal or other expenses reasonably incurred by the Company or any such
director, officer, employee, agent, representative, controlling person or underwriter in connection with investigating or defending any such loss,
claim, damage, liability, suit, action or proceeding if it is judicially determined that there was such a Holder Violation; provided, however, that the
indemnity agreement contained in this Section 6.8(b) shall not apply to amounts paid in settlement of any such loss, claim, damage, liability,
suit, action or proceeding if such settlement is effected without the consent of the Farids Group, which consent shall not be unreasonably
withheld, delayed or conditioned; provided, further, that in no event shall any indemnity under this Section 6.8(b) exceed the net proceeds from
the offering received by the Farids Group upon the sale of the Registrable Securities giving rise to such indemnification obligation.
24(c) Promptly after receipt by an indemnified party under paragraph (a) or (b) of this Section 6.8 (an “ Indemnified Party”) of
written notice of the commencement of any claim, damage, suit, action or proceeding (including any governmental or regulatory investigation)
being brought or asserted against it, such Indemnified Party will, if a claim in respect thereof is to be made against any indemnifying party under
paragraph (a) or (b) of this Section 6.8 (an “ Indemnifying Party”), deliver to the Indemnifying Party a written notice of the commencement
thereof; provided, that the failure of the Indemnified Party to deliver written notice to the Indemnifying Party shall not relieve it from any liability
it may have under paragraph (a) or (b) of this Section 6.8 except to the extent such failure has materially prejudiced the Indemnifying Party’s
ability to defend such action (through the forfeiture of substantive rights or defenses). The Indemnifying Party shall have the right to
participate in, and, to the extent the Indemnifying Party so desires, jointly with any other Indemnifying Party who has received a similar notice,
to assume the defense thereof with counsel reasonably satisfactory to the Indemnified Party to represent the Indemnified Party in such
proceeding and shall pay the fees and expenses of such counsel relating to such proceeding, and after notice from the Indemnifying Party to
the Indemnified Party of its election so to assume the defense thereof, the Indemnifying Party shall not, except as specified below, be liable to
such Indemnified Party under paragraph (a) or (b) above, as the case may be, for any legal expenses of other counsel. In any such proceeding,
an Indemnified Party shall have the right to retain its own counsel, with the fees and expenses to be paid by the Indemnified Party; provided the
Indemnifying Party will pay the reasonable fees and expenses of such counsel if (i) the Indemnifying Party and the Indemnified Party shall have
so mutually agreed; (ii) the Indemnifying Party has failed within a reasonable time to retain counsel reasonably satisfactory to the Indemnified
Party; (iii) the Indemnified Party shall have reasonably concluded, based on the advice of counsel, that there may be legal defenses available to
it that are different from or in addition to those available to the Indemnifying Party; or (iv) the named parties in any such proceeding (including
any impleaded parties) include both the Indemnifying Party and the Indemnified Party and representation of both parties by the same counsel
would be inappropriate due to actual or potential differing interest between them. It is understood and agreed that the Indemnifying Party shall
not, in connection with any proceeding or related proceedings in the same jurisdiction, be liable for the fees and expenses of more than one
separate firm (in addition to any local counsel that is required to effectively defend against any such proceeding) for all Indemnified Parties, and
that all such fees and expenses shall be paid or reimbursed promptly. The Indemnifying Party shall not be liable for any settlement of any
proceeding effected without its written consent (which shall not be unreasonably withheld, delayed or conditioned), but if settled with such
consent or if there be a final judgment for the plaintiff, the Indemnifying Party agrees to indemnify each Indemnified Party from and against any
loss or liability by reason of such settlement or judgment. No Indemnifying Party shall, without the written consent of the Indemnified Party
(which shall not be unreasonably withheld, delayed or conditioned), effect any settlement of any pending or threatened proceeding in respect
of which any Indemnified Party is or could have been a party and indemnification could have been sought hereunder by such Indemnified
Party, unless such settlement (x) includes an unconditional release of such Indemnified Party, in form and substance reasonably satisfactory to
such Indemnified Party, from all liability on claims that are the subject matter of such proceeding and (y) does not include any statement as to or
any admission of fault, culpability or a failure to act by or on behalf of any Indemnified Party.
25(d) If the indemnification provided for in this Section 6.8 is held by a court of competent jurisdiction to be unavailable to an
Indemnified Party with respect to any losses, claims, damages or liabilities referred to herein, the Indemnifying Party, in lieu of indemnifying
such Indemnified Party thereunder, shall to the extent permitted by applicable Law contribute to the amount paid or payable by such
Indemnified Party as a result of such loss, claim, damage or liability in such proportion as is appropriate to reflect the relative fault of the
Indemnifying Party on the one hand and of the Indemnified Party on the other in connection with the actions that resulted in such loss, claim,
damage or liability, as well as any other relevant equitable considerations. The relative fault of the Indemnifying Party and of the Indemnified
Party shall be determined by a court of law by reference to, among other things, whether the untrue or alleged untrue statement of a material fact
or the omission to state a material fact relates to information supplied by the Indemnifying Party or by the Indemnified Party and the parties’
relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission; provided, that in no event
shall any contribution by a Holder hereunder exceed the net proceeds from the offering made under such Eligible Registration Statement
received by such Holder.
(e) The parties hereto agree that it would not be just and equitable if contribution pursuant to Section 6.8(d) were determined
by pro rata allocation or by any other method of allocation that does not take account of the equitable considerations referred to in the
immediately preceding paragraph. No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act)
shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation.
(f) The obligations of the Company and the Farids Group under this Section 6.8 shall survive completion of any offering of
Registrable Securities in an Eligible Registration Statement and the termination of this Agreement.
(g) The obligations of the parties under this Section 6.8 will be in addition to any liability, without duplication, which any
party may otherwise have to any other party.
Section 6.9 “Market Stand-Off” Agreement . The Farids Group hereby agrees that the Farids Group shall not Transfer, make any short
sale of, grant any option for the purchase of, or enter into any hedging or similar transaction with the same economic effect as a sale or other
Transfer, any Lock-Up Security held by the Farids Group (other than those included in the registration) for a period specified by the
representative(s) of the underwriters of Registrable Securities or any other securities sold in any offering in respect of which the Farids Group
received notice from the Company in accordance with Section 6.2, such period not to exceed one hundred and eighty (180) days following the
pricing date of any underwritten offering; provided that the Farids Group shall only be required to comply with this Section 6.9 if the Farids
Group beneficially own (within the meaning of Rule 13d-3 under the Exchange Act, or any successor provision) at least 3.0% or more of the
number of shares of Common Stock outstanding at such time. The Company may impose stop transfer instructions with respect to any Lock-Up
Security subject to the foregoing restriction until the end of said one hundred and eighty (180) day or shorter period.
26Section 6.10 Agreement to Furnish Information . The Farids Group agrees to execute and deliver such other agreements as may be
reasonably requested by the Company or the representative(s) of the underwriter(s) that are consistent with the Farids Group’s obligations
under Section 6.9 or that are necessary to give further effect thereto. In addition, if requested by the Company or such representative(s), the
Farids Group shall provide, to the extent the Farids Group has elected to include Registrable Securities in an Eligible Registration Statement,
within one (1) business day of such request, such information relating to itself, the Registrable Securities held by it and the registration and the
intended method of distribution of the Registrable Securities as may be reasonably requested by the Company or such representative(s) in
connection with the completion of any public offering of Common Stock pursuant to such Eligible Registration Statement. The underwriters of
Registrable Securities are intended third party beneficiaries of Sections 6.8 and 6.10 and shall have the right, power and authority to enforce the
provisions hereof as though they were a party hereto.
Section 6.11 Termination. The rights and obligations of the Farids Group set forth in this Article VI (other than those set forth in
Sections 6.8 and 6.9) shall terminate on the date that the Farids Group owns less than 3% of the issued and outstanding Common Stock, but in
no event earlier than the Expiration Date (as defined in the Warrant).
ARTICLE VII
RIGHT OF FIRST REFUSAL; CHANGE IN CONTROL
Section 7.1 Right of First Offer for 144 Sales.
(a) Subject to the restrictions set forth in Section 5.1 of this Agreement and Section 2.3 of the Warrant, in the event any
member of the Farids Group proposes to Transfer (other than a Permitted Transfer) a Threshold Block, in a transaction or series of related
transactions, of Shares in a 144 Sale, the Farids Group shall furnish to the Company a written notice of such proposed Transfer (a “ ROFO Sale
Notice”) at least 48 hours prior to the opening of trading on the Nasdaq Global Market (or such other primary stock exchange upon which the
Common Stock is listed) on the business day that the Farids Group proposes to begin to effect such 144 Sale.
(b) The ROFO Sale Notice shall include:
(i) (A) the number of Shares proposed to be sold (the “ ROFO Shares”), (B) the per share purchase price in cash at
which the Farids Group is prepared to Transfer such ROFO Shares (the “ ROFO Sale Price ”) and (C) the date the Farids Group
proposes to begin to effect such 144 Sale; and
(ii) (ii) an offer to sell to the Company and/or a designee of the Company all or a portion of the ROFO Shares at the
ROFO Sale Price.
(c) If the Company wishes to purchase (and/or cause a designee to purchase) all or a portion of the ROFO Shares at the
ROFO Sale Price, the Company shall deliver a notice (a “ ROFO Purchase Notice”) to the Farids Group no later 8:00 a.m. New York time on the
business day that the Farids Group proposes to effect such 144 Sale specifying the number of ROFO Shares it wishes to purchase (and/or
cause a designee to purchase) from the Farids Group. The closing of the purchase of such ROFO Shares by the Company and/or any such
designee shall take place no later than five (5) business days after delivery of the ROFO Purchase Notice, with payment for such ROFO Shares
being made concurrently with such purchase to the Farids Group’s account designated in the ROFO Sale Notice. If the Company does not
timely deliver a ROFO Purchase Notice it shall be deemed to have waived all of its rights with respect to the offer contained in the ROFO Sale
Notice.
27(d) In the event that the number of ROFO Shares offered to be purchased in the ROFO Purchase Notice is less than the
number of ROFO Shares set forth in the Sale Notice (or the Company does not timely deliver a ROFO Purchase Notice), the Farids Group may
sell the ROFO Shares that are not subject to any such ROFO Purchase Notice during the five (5) day business day period beginning on the date
in the ROFO Sale Notice on which the Farids Group proposed to begin to effect such 144 Sale (the “ ROFO Transfer Period”); provided that no
such ROFO Share may be sold for less than the ROFO Sale Price.
(e) (e) If by the expiration of the ROFO Transfer Period, the Farids Group has not completed the Transfer of any ROFO Shares
at the ROFO Sales Price or a higher price, in order for the Farids Group to Transfer such ROFO Shares (or any other Shares) it shall be necessary
for a new ROFO Sale Notice or ROFR Sale Notice to be delivered, and the terms and provisions of this Article VII to be again complied with. The
Farids Group shall not deliver more than one ROFO Sale Notice or ROFR Sale Notice in any thirty (30) day period.
Section 7.2 Right of First Refusal.
(a) Subject to the restrictions set forth in Section 5.1 of this Agreement and Section 2.3 of the Warrant, in the event any
member of the Farids Group proposes to Transfer (other than a Permitted Transfer) (i) a Threshold Block, in a transaction or series of related
transactions, that, to the Farids Group’s knowledge (after due inquiry in connection with a private, non-open market transaction) is to a Person
whom the Company reasonably determines is a direct or indirect material competitor of the Company or any Affiliate of such Person or (ii) a
Significant Block, in a transaction or series of related transactions, that, to the Farids Group’s knowledge (after due inquiry in connection with a
private, non-open market transaction) is to a Person whom the Company reasonably determines is a direct or indirect material competitor of the
Company or any Affiliate of such Person (in each case, regardless of whether such Transfer will constitute a 144 Sale), the Farids Group shall
furnish to the Company a written notice of such proposed Transfer (a “ ROFR Sale Notice”) at least (5) business days prior to the business day
that the Farids Group proposes to effect such Transfer.
(b) The ROFR Sale Notice shall include:
(i) (A) the identity of the proposed transferee, (B) the purchase agreement and other documentation for the
proposed Transfer (the “ ROFR Sale Documentation”), (C) the number of Shares proposed to be sold (the “ ROFR Shares”), (D) the
per share purchase price in cash at which the Farids Group is prepared to Transfer such ROFR Shares (the “ ROFR Sale Price”) and (E)
the date the Farids Group proposes to effect such Transfer; and
28(ii) an offer to sell to the Company and/or a designee of the Company all of the ROFR Shares at the ROFR Sale Price.
(c) If the Company wishes to purchase (and/or cause a designee to purchase) all of the ROFR Shares at the ROFR Sale Price,
the Company shall deliver a notice (a “ ROFR Purchase Notice”) to the Farids Group within three (3) business day after receipt of the ROFR
Sale Notice. The closing of the purchase of such ROFR Shares by the Company and/or any such designee shall take place no later than the later
of (i) the purchase date set forth in the ROFR Sale Documentation and (ii) five (5) business days after delivery of the ROFR Purchase Notice,
with payment for such ROFR Shares being made concurrently with such purchase to the Farids Group’s account designated in the ROFR Sale
Notice. If the Company does not timely deliver a ROFR Purchase Notice it shall be deemed to have waived all of its rights with respect to the
offer contained in the ROFR Sale Notice.
(d) In the event that Company does not timely delivery a ROFR Purchase Notice, the Farids Group may sell the ROFR Shares
to the proposed transferee identified in the ROFR Sale Notice at the ROFR Sale Price and on the other terms and conditions set forth in the
ROFR Sale Documentation no later than three (3) business days following the date the Farids Group proposed to effect such Transfer in the
ROFR Sale Notice (the “ROFR Transfer Period”).
(e) If by the expiration of the ROFR Transfer Period, the Farids Group has not completed the Transfer of the ROFR Shares, in
order for the Farids Group to Transfer such ROFR Shares (or any other Shares) it shall be necessary for a new ROFO Sale Notice or ROFR Sale
Notice to be delivered, and the terms and provisions of this Article VII to be again complied with. The Farids Group shall not deliver more than
one ROFR Sale Notice or ROFO Sale Notice in any thirty (30) day period.
ARTICLE VIII
MISCELLANEOUS
Section 8.1 Notices. All notices and other communications hereunder shall be in writing and shall be deemed given if delivered
personally, telecopied (upon telephonic confirmation of receipt), on the first business day following the date of dispatch if delivered by a
recognized next day courier service, or on the third business day following the date of mailing if delivered by registered or certified mail, return
receipt requested, postage prepaid. All notices hereunder shall be delivered as set forth below, or pursuant to such other instructions as may be
designated in writing by the party to receive such notice:
(a) if to the Company to:
Rocky Mountain Chocolate Factory, Inc.
265 Turner Drive
Durango, Colorado 81303
Attention: Chief Executive Officer and Chief Financial Officer
29with a copy (which shall not constitute notice) to:
Perkins Coie LLP
1900 Sixteenth Street, Suite 1400
Denver, Colorado 80202
Attention: Sonny Allison and Ned Prusse
(b) If to the Farids Group to:
Farids & Co. LLC
980 Hammond Dr., Suite 1000
Atlanta, GA 30328 USA
Attention: Tariq Farid
(c) If to EA to:
Edible Arrangement, LLC
980 Hammond Dr., Suite 1000
Atlanta, GA 30328 USA
Attention: Tariq Farid
with a copy (which shall not constitute notice) to:
DLA Piper LLP (US)
444 West Lake Street
Suite 900
Chicago, IL 60606
Attention: Neal Aizenstein
Section 8.2 Further Assurances . Each party hereto shall do and perform or cause to be done and performed all further acts and shall
execute and deliver all other agreements, certificates, instruments and documents as any other party hereto reasonably may request in order to
carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby.
Section 8.3 Amendments and Waivers . Any provision of this Agreement may be amended or waived if, but only if, such amendment or
waiver is in writing and is duly executed and delivered by the Company and the Farids Group. No failure or delay by any party in exercising any
right, power or privilege hereunder shall operate as a waiver thereof nor shall any single or partial exercise thereof preclude any other or further
exercise thereof or the exercise of any other right, power or privilege. The rights and remedies herein provided shall be cumulative and not
exclusive of any rights or remedies provided by law. The execution of a joinder agreement to this Agreement by a Family Member of TF shall
not constitute an amendment to this Agreement requiring the consent of any party hereto.
30Section 8.4 Fees and Expenses . Each party hereto shall pay all of its own fees and expenses (including attorneys’ fees) incurred in
connection with this Agreement and the transactions contemplated hereby.
Section 8.5 Successors and Assigns . The provisions of this Agreement shall be binding upon and inure to the benefit of the parties
hereto and their respective successors and assigns, provided , that, unless in connection with Permitted Transfers, neither party may assign,
delegate or otherwise transfer any of its rights or obligations under this Agreement to any person without the express written consent of the
other party hereto and any such assignment or other transfer shall be null and void; provided , further, that no such assignment shall relieve the
assigning party of its obligations hereunder if such assignee does not perform such obligations. Prior to the receipt by the Company of
adequate written notice of the Permitted Transfer of any Purchased Shares in accordance with the provisions of this Agreement and specifying
the full name and address of the transferee, the Company may deem and treat the person listed as the holder of such shares in its records as the
absolute owner and holder of such shares for all purposes, including the payment of dividends.
Section 8.6 Governing Law.
(a) This Agreement shall be governed and construed in accordance with the laws of the State of New York applicable to
contracts made and wholly performed within such state, except for matters directly within the purview of the DGCL, which shall be governed by
the DGCL. Each of the Farids Group and the Company hereby irrevocably and unconditionally consents to submit to the exclusive jurisdiction
and venue of the United States District Court for the Southern District of New York and in the courts hearing appeals therefrom unless no basis
for federal jurisdiction exists, in which event each party hereto irrevocably consents to the exclusive jurisdiction and venue of the Supreme
Court of the State of New York, New York County, and the courts hearing appeals therefrom, for any action, suit or proceeding arising out of or
relating to this Agreement and the transactions contemplated hereby. Each of the Farids Group and the Company hereby irrevocably and
unconditionally waives, and agrees not to assert, by way of motion, as a defense, counterclaim or otherwise, in any such action, suit or
proceeding, any claim that it is not personally subject to the jurisdiction of the aforesaid courts for any reason, other than the failure to serve
process in accordance with this Section 8.6, that it or its property is exempt or immune from jurisdiction of any such court or from any legal
process commenced in such courts (whether through service of notice, attachment prior to judgment, attachment in aid of execution of
judgment, execution of judgment or otherwise), and to the fullest extent permitted by applicable Law, that the action, suit or proceeding in any
such court is brought in an inconvenient forum, that the venue of such action, suit or proceeding is improper, or that this Agreement, or the
subject matter hereof, may not be enforced in or by such courts and further irrevocably waives, to the fullest extent permitted by applicable Law,
the benefit of any defense that would hinder, fetter or delay the levy, execution or collection of any amount to which the party is entitled
pursuant to the final judgment of any court having jurisdiction. Each of the Farids Group and the Company irrevocably and unconditionally
waives, to the fullest extent permitted by applicable Law, any and all rights to trial by jury in connection with any action, suit or proceeding
arising out of or relating to this Agreement or the transactions contemplated hereby.
31(b) Each of the Farids Group and the Company expressly acknowledges that the foregoing waivers are intended to be
irrevocable under the laws of the State of New York, the State of Delaware and of the United States of America; provided, that consent by the
Farids Group and the Company to jurisdiction and service contained in this Section 8.6 is solely for the purpose referred to in this Section 8.6
and shall not be deemed to be a general submission to said courts or in the State of New York other than for such purpose.
Section 8.7 Ownership Limitation. The Farids Group shall not (unless specifically requested in writing by the Company, acting through
a resolution of a majority of the Company’s directors), directly or indirectly, and agrees to cause the Affiliates of the Farid Group to not, directly
or indirectly, in any manner acquire, offer or propose to acquire, or agree to acquire, directly or indirectly, whether by purchase, tender or
exchange offer, through the acquisition of control of another person, by joining a partnership, limited partnership, syndicate or other group
(including any group of persons that would be treated as a single “person” under Section 13(d) of the Exchange Act), through swap or hedging
transactions or otherwise, any securities of the Company, or any rights decoupled from the underlying securities of the Company that would
result in the Farids Group (together with its Affiliates) owning, controlling or otherwise having any beneficial ownership (within the meaning of
Rule 13d-3 under the Exchange Act, or any successor provision) of 19.99% or more of the fully diluted number of shares of Common Stock
outstanding at such time; provided, however, that nothing herein will require Common Stock to be sold to the extent that the Farids Group and
its Affiliates, collectively, exceed the ownership limit under this Section 8.7 as the result of any share repurchase or other Company action that
reduces the number of outstanding shares of Common Stock on or after the date hereof; provided, further, that (a) this Section 8.7 shall not
preclude Farids or EA from privately requesting a waiver of the provisions of Section 8.7, and (b) the provisions of this Section 8.7 shall
terminate and be of no further force and effect if the Company enters into a definitive agreement with respect to, or publicly announces that it
plans to enter into, a transaction involving all or a controlling portion of the Company’s equity securities or all or substantially all of the
Company’s assets (whether by merger, consolidation, business combination, tender or exchange offer, recapitalization, restructuring, sale,
equity issuance or otherwise).
Section 8.8 Non-Disparagement .
(a) Neither the Company nor any of its Affiliates shall in any manner, directly or indirectly, in any capacity or manner, make or
cause to be made, or in any way encourage any other person to make or cause to be made, any public statement or public announcement,
including in any document or report filed with or furnished to the SEC or through the press, media, analysts or other persons, that constitutes
an ad hominem attack on or otherwise disparages, defames or slanders the Farids Group or any of its Affiliates or any of their respective
successors or current or former members, partners, officers, directors or employees (it being understood and agreed that the restrictions in this
Section 8.8(a) shall not apply to any member of the Board of Directors based upon discussions solely among other members of the Board of
Directors and/or management of the Company); provided, that the limitations set forth in this Section 8.8(a) shall not prevent the Company or
any of its Affiliates from (i) responding to any public statement or announcement made by the Farids Group or any of its Affiliates that was
made in breach of Section 8.8(b) below or (ii) if solicited by a Third Party, making objective statements that reflect the Company’s view with
respect to factual matters concerning specific acts or determinations of the Farids Group or any of its Affiliates (or their respective current or
former representatives) occurring after the date hereof. For the avoidance of doubt, a public statement or announcement shall only be deemed
to be made by the Company if such public statement or announcement is made by (X) an executive officer or a member of the Board of Directors
(other than a Director Designee) or (Y) an employee or representative of the Company authorized to make such statement or announcement on
behalf of the Company.
32(b) Neither the Farids Group nor any of its Affiliates shall in any manner, directly or indirectly, in any capacity or manner, make
or cause to be made, or in any way encourage any other person to make or cause to be made, any public statement or public announcement,
including in any document or report filed with or furnished to the SEC or through the press, media, analysts or other persons, that constitutes
an ad hominem attack on or otherwise disparages, defames or slanders the Company or any of its Affiliates or any of their respective
successors or current or former members, partners, officers, directors or employees; provided, that, the limitations set forth in this Section 8.8(b)
shall not prevent the Farids Group or any of its Affiliates from (i) responding to any statement made by the Company or any of its Affiliates or
representatives that was made in breach of Section 8.8(a) above or (ii) if solicited by a Third Party, making objective statements that reflect the
Farids Group’s or any of its Affiliates’ view with respect to factual matters concerning specific acts or determinations of the Company, any of its
Affiliates or any current or former representatives of the Company or any of its Affiliates occurring after the date hereof. For the avoidance of
doubt, a public statement or announcement shall only be deemed to be made by the Farids Group or any of its Affiliates if such public
statement or announcement is made by (X) a Farids manager, director or executive officer or an EA manager, director or executive officer (Y) an
employee or representative of Farids or EA authorized to make such statement or announcement on behalf of Farids or EA, as applicable.
Section 8.9 Non-Solicitation.
(a) Each of EA, Farids and the Company shall not, and shall cause their respective controlled Affiliates to not, either directly
or indirectly solicit, hire, or contract with any of the employees of the other party or its Affiliates during the Term (as defined in the Exclusive
Supplier Operating Agreement) and for one (1) year following the termination or expiration thereof; provided that this Section 8.9(a) shall not
apply with respect to any such employee who employment with the other party and its Affiliates has been terminated for a period in excess of
nine (9) months.
(b) Notwithstanding anything to the contrary in this Agreement, the restrictions regarding solicitation in this Section 8.9 shall
not be deemed to apply to media advertisements of general circulation, open job fairs, the efforts of an employment search firm or other
generalized means of publicizing a job opening, such as on a website or job board which, in each case, are not targeted primarily at the
employees of the other party or its Affiliates; provided that this Section 8.9(b) shall not limit the restrictions or hiring set forth in Section 8.9(a).
Section 8.10 Entire Agreement. This Agreement and the other Transaction Documents constitute the entire agreement between the
parties with respect to the subject matter of this Agreement and supersedes all prior agreements and understandings, both oral and written,
between the parties and/or their Affiliates with respect to the subject matter of this Agreement.
33Section 8.11 Effect of Headings. The Article and Section headings herein are for convenience only and shall not affect the construction
hereof.
Section 8.12 Severability. If one or more provisions of this Agreement are held to be unenforceable under applicable Law, such
provision shall be deemed to be excluded from this Agreement and the balance of this Agreement shall be interpreted as if such provision were
so excluded and shall be enforced in accordance with its terms to the maximum extent permitted by law.
Section 8.13 Counterparts; Third Party Beneficiaries . This Agreement may be signed in any number of counterparts, each of which
shall be an original, with the same effect as if the signatures were upon the same instrument. Facsimile and electronic (.PDF) signatures shall be
sufficient to execute this Agreement. Except for Section 6.8 with respect to the underwriters of Registrable Securities, no provision of this
Agreement shall confer upon any person other than the parties hereto any rights or remedies hereunder.
Section 8.14 Survival. The representations, warranties, agreements and covenants contained herein shall survive the Closing.
Section 8.15 Remedies. The parties agree that irreparable damage would occur in the event that any of the provisions of this
Agreement were not performed in accordance with their specific terms. It is accordingly agreed that the parties shall be entitled to seek specific
performance of the terms hereof, this being in addition to any other remedies to which they are entitled at law or equity. In the event of any
dispute between the parties concerning the terms and provisions of this Agreement, the party prevailing in such dispute shall be entitled to
collect from the other party all costs incurred in such dispute, including reasonable attorneys’ fees.
[Remainder of this page intentionally left blank]
34IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be signed as of the date first written above.
ROCKY MOUNTAIN CHOCOLATE FACTORY, INC.
By: /s/ Bryan J. Merryman
Name: Bryan J. Merryman
Title: Chief Executive Officer and Chief Financial Officer
FARIDS & CO. LLC
By: /s/ Tariq Farid
Name: Tariq Farid
Title: Chief Executive Officer
EDIBLE ARRANGEMENTS, LLC
By: /s/ Tariq Farid
Name: Tariq Farid
Title: Chief Executive Officer
[Signature Page to Strategic Alliance Agreement]EXHIBIT A
FORM OF JOINDER AGREEMENT
This JOINDER AGREEMENT (this “Joinder Agreement”) is executed pursuant to the terms of the Strategic Alliance Agreement, dated as of
December 20, 2019, by and among Farids & Co. LLC, a Delaware limited liability company (“ Farids”), Edible Arrangements, LLC, a Delaware
limited liability company, and Rocky Mountain Chocolate Factory, Inc., a Delaware corporation (the “ Company”), a copy of which is attached
hereto and is incorporated herein by reference (the “ Agreement”), by the undersigned (the “ Farids Transferee”). Capitalized terms used but
not defined herein have the meanings set forth in the Agreement. By execution and delivery of this Joinder Agreement, the Farids Transferee
agrees as follows:
SECTION 1. Acknowledgment . The Farids Transferee acknowledges that it has acquired Purchased Shares from a member of the Farids Group
pursuant to a Permitted Transfer.
SECTION 2. Agreement. The Farids Transferee (a) agrees that the Purchased Shares it owns shall be bound by and subject to the terms of the
Agreement to the same extent as if such Farids Transferee were a member of the Farids Group, (b) hereby adopts the Agreement with the same
force and effect as if it were originally a member of the Farids Group and (c) shall constitute a member of the “Farids Group” under the
Agreement.
SECTION 3. Notice. Any notice required to be provided by the Agreement shall be given to the Farids Transferee at the address of Farids
Group listed in the Agreement.
SECTION 4. Governing Law. This Joinder Agreement and the rights of the parties hereto shall be governed by and construed in accordance
with the laws of the State of New York applicable to contracts made and to be performed therein.
Executed and dated this day of .
Farids Transferee:
[INSERT NAME]
By:
[Title]
Acknowledged and Agreed to by
ROCKY MOUNTAIN CHOCOLATE
FACTORY, INC.
By:
[Title]
A-1EXHIBIT B
EXCLUSIVE SUPPLIER OPERATING AGREEMENT
[Attached]
B-1EXHIBIT C
WARRANT
[Attached]
C-1EXHIBIT D
INDEMNIFICATION AGREEMENT
[Attached]
D-1EXHIBIT E
AMENDMENT
E-1EXHIBIT 10.71
May 04, 2017
Strategic Alliance Agreement
This Strategic Alliance Agreement (this "Agreement") is entered into as of the 26 th  day of May, 2017 (hereinafter referred to as
the effective date of the Agreement), by and between Cool Technologies Inc.., a Nevada corporation (hereinafter referred to as
"COOL TECH"), and VETERAN TECHNOLOGY GROUP, LLC, a Missouri corporation (hereinafter referred to as "VET TECH").
WITNESSETH:
WHEREAS, COOL TECH and VET TECH wish to enter into a strategic alliance to market and perform certain complementary
business consulting services;
NOW, THEREFORE, in consideration of the foregoing and of the mutual premises hereinafter expressed, the parties hereto do
mutually agree as follows:
ARTICLE I. SCOPE OF STRATEGIC ALLIANCE.
A. COOL TECH shall, in a professional manner, take all steps necessary to market and produce its Mobile Generation Program and
its other services (collectively the "COOL TECH Services") for clients referred to COOL TECH by VET TECH. Any engagement to
perform COOL TECH Services shall be on such terms and conditions as COOL TECH may approve at its sole discretion. COOL
TECH will perform, schedule, staff and manage all COOL TECH Services or with COOL TECH/VET TECH approved team.
Notwithstanding the foregoing, VET TECH may, at its election, bill the client directly for COOL TECH Services and under such
circumstances COOL TECH shall bill VET TECH the pre-agreed amount for the engagement as adjusted by any client-approved
change orders. For any Government Sales brought by VET TECH COOL TECH agrees to be held to the same billing and payment
terms as is dictated under the Federal Acquisition Regulation (FAR) guidelines and requirements; otherwise, COOL TECH will bill
the client directly. VET TECH agrees to include reference to COOL TECH in each contract and proposal involving COOL TECH
Services. COOL TECH’s Mobile Generation (“MG”), and other proprietary information and associated products, copyrights,
trademarks, trade names and logos developed by COOL TECH shall remain the property of COOL TECH and reference to COOL
TECH's rights shall be made in all uses of such materials in at least 12 point type.
1B. VET TECH shall, in a professional manner, take all steps necessary to market and perform its business management consulting,
GAIT Software and other AI services (collectively the "VET TECH Services") for clients referred to VET TECH by COOL TECH.
Any engagement to perform VET TECH Services shall be on such terms and conditions as VET TECH may approve in its sole
discretion. VET TECH will perform, schedule, staff and manage all VET TECH Services or a joint VET TECH/COOL TECH team.
VET TECH will perform, schedule, staff and manage all VET TECH Services or with VET TECH/COOL TECH approved team.
Notwithstanding the foregoing, COOL TECH may, at its election, bill the client directly for VET TECH Services and under such
circumstances VET TECH shall bill COOL TECH the pre-agreed amount for the engagement as adjusted by any client-approved
change orders; otherwise, VET TECH will bill the client directly. COOL TECH agrees to include reference to VET TECH in each
contract and proposal involving VET TECH Services. VET TECH’s GAIT Software and other AI services (collectively the "VET
TECH Services"), and other proprietary information and associated products, copyrights, trademarks, trade names and logos
developed by VET TECH shall remain the property of VET TECH and reference to VET TECH's rights shall be made in all uses of
such materials in at least 12 point type.
ARTICLE II. PERIOD OF PERFORMANCE.
This Agreement shall be effective as of the date first set forth above and, shall expire on the later of (i) five (5) years from the date
hereof, or (ii) with respect to any projects identified in any contract for which VET TECH is billing the client directly, upon the
completion of COOL TECH's Services and receipt of payment by COOL TECH from VET TECH for said services. This Agreement
shall be automatically renewed for successive one year periods unless either party gives written notice of termination to the other
party at least thirty (30) days prior to the date of expiration. Notwithstanding the foregoing, this Agreement shall be earlier
terminated (x) by mutual agreement of the parties, or (y) at any time upon sixty (60) days advance written notice to the other party.
Time is of the essence in this Agreement.
2ARTICLE III. MANAGEMENT.
Each party shall designate a partner, officer or other senior person to be responsible for the overall administration of this
Agreement. VET TECH shall have ultimate responsibility for client relationships for those clients that it elects to bill directly for
COOL TECH Services and COOL TECH will respond to VET TECH's direction.
ARTICLE IV. CONFIDENTIAL INFORMATION.
The parties acknowledge and agree that in the course of the performance of the VET TECH Services and the COOL TECH
Services (collectively, the "Services") or additional services pursuant to this Agreement, that each may be given access to, or
come into possession of, confidential information of the other party which information may contain trade secrets, proprietary data
or other confidential material of that party. Therefore the parties have executed a Non-Disclosure Agreement which is attached
hereto as Exhibit A, and incorporated by reference as if fully set forth herein. Materials used in any engagement undertaken
pursuant to this Agreement shall not be altered or changed without the consent of both parties.
ARTICLE V. NO PARTNERSHIP.
Nothing herein contained shall be construed to imply a joint venture, partnership or principal- agent relationship between VET
TECH and COOL TECH, and neither party shall have the right, power or authority to obligate or bind the other in any manner
whatsoever, except as otherwise agreed to in writing. The parties do not contemplate a sharing of profits relating to the VET
TECH Services or the COOL TECH Services so as to create a separate taxable entity under Section 761 of the Internal Revenue
Code of 1986, as amended, nor co-ownership of a business or property so as to create a separate partnership under the law of any
jurisdiction, including, without limitation, MISSOURI or NEVADA. Accordingly, for tax, property and liability purposes VET
TECH will provide the VET TECH Services, and COOL TECH will perform the COOL TECH Services, each on a professional basis
and as an independent contractor of the other. JOINT SERVICES WILL BE DEFINED IN ADDENDUM XX. Revenues and
expenses relating to the Services and any additional services shall be reported separately by the parties for tax purposes. During
the performance of the any of the Services, VET TECH's employees will not be considered employees of COOL TECH, and vice
versa, within the meaning or the applications of any federal, state or local laws or regulations including, but not limited to, laws or
regulations covering unemployment insurance, old age benefits, worker's compensation, industrial accident, labor or taxes of any
kind. VET TECH's personnel who are to perform the VET TECH Services or additional services to be provided by VET TECH
hereunder shall be under the employment, and ultimate control, management and supervision of VET TECH. COOL TECH's
personnel who are to perform the COOL TECH Services or additional services to be provided by COOL TECH hereunder shall be
under the employment, and ultimate control, management and supervision of COOL TECH. It is understood and agreed that
COOL TECH's employees shall not be considered VET TECH's employees within the meaning or application of VET TECH's
employee fringe benefit programs for the purpose of vacations, holidays, pension, group life insurance, accidental death, medical,
hospitalization, and surgical benefits, and vice versa.
3ARTICLE VI. TRADEMARK, TRADE NAME AND COPYRIGHTS.
Except as expressly provided herein, this Agreement does not give either party any ownership rights or interest in the other
party's trade name, trademarks or copyrights.
ARTICLE VII. INDEMNIFICATION.
Each of VET TECH and COOL TECH, at its own expense, shall indemnify, defend and hold the other, its partners, shareholders,
directors, officers, employees, and agents harmless from and against any and all third-party suits, actions, investigations and
proceedings, and related costs and expenses (including reasonable attorney's fees) resulting solely and directly from the
indemnifying party's negligence or willful misconduct. Neither VET TECH nor COOL TECH shall be required hereunder to defend,
indemnify or hold harmless the other and/or its partners, shareholders, directors, officers, directors, employees and agents, or any
of them, from any liability resulting from the negligence or wrongful acts of the party seeking indemnification or of any third-
party. Each of VET TECH and COOL TECH agrees to give the other prompt written notice of any claim or other matter as to which
it believes this indemnification provision is applicable. The indemnifying party shall have the right to defend against any such
claim with counsel of its own choosing and to settle and/or compromise such claim as it deems appropriate. Each party further
agrees to cooperate with the other in the defense of any such claim or other matter.
ARTICLE VIII. NON-SOLICITATION OF PERSONNEL.
COOL TECH and VET TECH agree not to engage in any attempt whatsoever, to hire, or to engage as independent contractors, the
other's employees or independent contractors during the term of this Agreement and for a period of six (6) months following
expiration or termination of this Agreement except as may be mutually agreed in writing.
ARTICLE IX. INTELLECTUAL PROPERTY
Work performed on engagements pursuant to this Agreement by either VET TECH and/or COOL TECH and information,
materials, products and deliverables developed in connection with engagements pursuant to this Agreement shall be the
property of the respective parties performing the work or creating the information. All underlying methodology utilized by COOL
TECH and VET TECH respectively which was created and/or developed by either prior to the date of this Agreement and utilized
in the course of performing engagements pursuant to this Agreement shall not become the property of the other. Each party's
rights, titles and interests are described in the Non-Disclosure Agreement attached hereto as Exhibit A.
4ARTICLE X. GENERAL PROVISIONS.
A. Entire Agreement: This Agreement together with all documents incorporated by reference herein, constitutes the entire and
sole agreement between the parties with respect to the subject matter hereof and supersedes any prior agreements, negotiations,
understandings, or other matters, whether oral or written, with respect to the subject matter hereof. This Agreement cannot be
modified, changed or amended, except for in writing signed by a duly authorized representative of each of the parties.
B. Conflict: In the event of any conflict, ambiguity or inconsistency between this Agreement and any other document which may
be annexed hereto, the terms of this Agreement shall govern.
C. Assignment and Delegation: Neither party shall assign or delegate this Agreement or any rights, duties or obligations
hereunder to any other person and/or entity without prior express written approval of the other party.
D. Notices: Any notice required or permitted to be given under this Agreement shall be in writing, by hand delivery, commercial
overnight courier or registered or certified U.S. Mail, to the address stated below for COOL TECH or to the address stated below
for VET TECH, and shall be deemed duly given upon receipt, or if by registered or certified mail three (3) business days following
deposit in the U.S. Mail. The parties hereto may from time to time designate in writing other addresses expressly for the purpose
of receipt of notice hereunder.
If to VET TECH:
If to COOL TECH:
E. Severability: If any provision of this Agreement is declared invalid or unenforceable, such provision shall be deemed modified
to the extent necessary and possible to render it valid and enforceable. In any event, the unenforceability or invalidity of any
provision shall not affect any other provision of this Agreement, and this Agreement shall continue in full force and effect, and
be construed and enforced, as if such provision had not been included, or had been modified as above provided, as the case may
be.
F. Governing Law: This Agreement shall be governed by and construed in accordance with the laws of the State of Missouri.
Without giving effect to its choice of law principles.
5G. Paragraph Headings: The paragraph headings set forth in this Agreement are for the convenience of the parties, and in no way
define, limit, or describe the scope or intent of this Agreement and are to be given no legal effect.
H. Counterparts: This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all
of which together shall constitute one and the same instrument.
I. Exhibits: The Exhibits attached hereto are made a part of this Agreement as if fully set forth herein.
IN WITNESS WHEREOF, the parties, by their duly authorized representatives, have caused this Agreement to be executed as of
the date first written above.
Veteran Technology Group, LLC Cool Technologies Inc.
By: Name: /s/ Michael Grimes___ /s/ Timothy Hassett___
By: Name: _Michael Grimes ____ ___Timothy Hassett__
6Exhibit 10.1    
KALLO Inc. 
        
  
STRATEGIC ALLIANCE AGREEMENT 
    
MOBILECARESTRATEGIC ALLIANCE AGREEMENT - MOBILE CARE 
  This Agreement is made by and between:  
KALLO Inc.  
With principal offices at 15 Allstate Parkway, Suite 600, Markham, ON L3R 5B4., Canada (“KALLO”)      AND    
Petro data Management Services Limited.,      
With principal offices at Motorways Center, Block-B, 1 Motorways Avenue Alausa, Ikeja, Lagos, Nigeria (“PDMS”)      AND    
Gateway Global Fabrication Ltd.,    
With principal offices at No-2 Olodu Street, Off Oluobasanjo Road, Portharcourt, Rivers state, Nigeria. (“Gateway”) As of the date set forth below.    Whereas, Kallo is the developer, owner and licensor of certain Mobile Care Suite of Products packages designated as the subject matter of this Agreement:    
Whereas, PDMS and Gateway (Agent) desires to become a business associate of Kallo for the region of Nigeria, under the terms and conditions hereof;  Now therefore, all the parties agree as follows:    
   For the purposes of this Agreement, the following definitions will apply: 
“Business Associate” means the Kallo Authorized Agent who could be an individual, organization, or company that desires to represent the Kallo Mobile care suite of products of Kallo Inc., to the end user (customer) market. The Business Associate as it will be defined in this agreement sells the Kallo Mobile care product suite only. Kallo will be fully responsible for the training and implementation of the client  
 
KALLO - MOBILECARE  
1.DEFINITIONS 
Page 2following the sale directly by Kallo Inc., or through it’s wholly owned Canadian subsidiary, Kallo Technologies Inc.,    
“KALLO” means Kallo Inc. and/or its wholly owned subsidiary Kallo Technologies Inc.,    
“Customer” means the end user of the Kallo Mobile care suite of Products that enters into the Kallo Mobile care Suite of Products End User License Agreement (EULA).    
“Schedule A” means the Kallo supplied executable pricing proposal form which must accompany any EULA for the Kallo Mobile care suite of Products in order to be accepted by Kallo.  
“Kallo Mobile care suite of Products” means Kallo products as specified in Schedule A.    
“EULA” means the license agreement (headed “End User License Agreement”) between the Customer (end-user) and Kallo that sets forth the terms and conditions governing the Customer’s use of the Kallo Mobile care suite of Products.    
“Book of Business” means the sales made by the Agent with the flow of income from those sales paid under this Agreement, all of which belongs to the Agent in right, title and interest. The Book of Business is that portion of each sale belonging to the Agent under the commission percentage agreed to at the time of sale and the continuing flow of income produced so long as the customers pay to use the Kallo Mobile care suite of products license.  
"Material Breach" means the violation of the payment terms herein, copyright or trademarks, an attempt to replace or abet others to replace Kallo Mobile care suite of products or services at any existing or potential customer with competing products and any act of malicious conduct by the Agent to disparage Kallo without any justification and malicious conduct against Agent by Kallo.    
"Non Material Breach" means serious neglect of Agent’s customers by the Agent in regards to support and services and any other breach of the terms of this agreement for which the cure of such shall be completed by the Agent within sixty days from written notice of violation.  
"Certified Sales Agent" means a Sales Agent who has completed the initial Sales and Technical Training program and any consecutive  
 
KALLO - MOBILECARE  
Page 3training program provided and mandated by Kallo and who abides by the terms and conditions of the certification program as outlined herein.    
   
 
 
 
 
 
 
KALLO - MOBILECARE  
2.KALLO SALES AGENT PROGRAM TERMS AND CONDITIONS 
a) Appointment: Kallo hereby conditionally appoints Agent as a Sales Agent, and Agent accepts in accordance with the provisions of this Agreement the terms of the Kallo Sales Agent Program. 
b) Responsibilities: Responsibilities of the Agent (PDMS and Gateway) are defined in Schedule C. Failure to comply with this will be considered a material breach of this agreement. This also includes responsibilities for Kallo and the project management entity (BASCIC) appointed jointly by Kallo and the Agent. 
c) Certified Sales Agent: Agent accepts and acknowledges that the Kallo 3 day Sales and 5 day Technical Training Program is required to be completed by the Agent within 90 days of execution of this agreement. Agent is required to pay a Training program fee of $10,000.00 for the Kallo Mobile care suite of Products on or before the date of execution of this agreement for the Authorization of Agent under this agreement by Kallo. Agent shall pay $1000/-per day for any additional days of training requested by Agent and all travel expenses plus per diem for the Kallo representative instructing the program will be due and payable to Kallo on or before execution of this agreement.Certification is mandatory for Agent to become certified to represent the Kallo Mobile care suite of products licensed under this agreement and to benefit from commissions allocated to Agent as outlined in Schedule A of this agreement. Non-compliance of this Section (2), subparagraph (c) on the part of the Agent will automatically void this agreement. 
d)All sales made by the Agent of the Kallo Mobile care suite of products shall create a Book of Business owned by the Agent, which constitutes all funds due to Agent under this agreement flowing from each sale for a period not to exceed 36 months from the date of acceptance by Kallo of the Client EULA or until the EULA terminates under the provision that are outlined therein of the Kallo Mobile care suite of products. 
e)Agent is required bi-monthly to report all prospects, sales activity, activity reported on Kallo provided leads, and any current client 
Page 4accounts relating to the Kallo Mobile care suite of products to the Kallo Sales and Marketing department in an electronic format following the execution of this agreement. Kallo offers and enforces lead and current account protection for Sales Agents. Kallo shall not allow another Agent to solicit the existing Agents book of business unless it is understood by all parties the end user client desires the transfer. Kallo shall use its best reasonable efforts to protect the Agent from aggressive solicitation by another Agent taking any part of the Agent's book of Business. The report MUST include the Business Name, Key Contact name, telephone number, and address.  
 
 
 
 
 
KALLO - MOBILECARE  
f) Exclusivity of territory (Nigeria): Agent’s appointment shall be exclusive for the Kallo Mobile care suite of products and services marked in Schedule A to this Agreement. Such appointment constitutes a grant of specific territory of Nigeria. Exclusivity is granted for the region of Nigeria, The Agent is expected to confirm the first purchase order as per Schedule D with the down payment within thee (3) months of execution of this agreement and in order to retain the exclusivity of the territory the Agent shall achieve the target commitment in Schedule D. 
g)Agent shall be supplied with marketing material at no cost to agent in electronic format only. Print and mail expense are the responsibility of the Agent. Web design services, press release services, trade show design services, marketing content services, and listing services are provided at no cost to Agent as it relates to the Kallo Mobile care suite of products 
h) Marketing and Sales Plan: The Agent shall prior to the signing of this agreement submit and have approved by Kallo a Marketing and Sales Plan for no less than 3 years committing the sale of no less than 15 Mobile Medical Clinics, 5 Mobile Clinics in twelve month period following the signing of this agreement as referred to in Schedule D, with minimum growth per annum thereafter of 20% cumulative. Failure to do this will be considered a material breach of this agreement. 
i)Kallo shall not change the marketing and sales plan during this agreement without first discussing it with Agent and in the event that mutual agreement cannot be reached will provide at least 12 months' notice of any such change. Should agreement not be reached, Agent may maintain its existing "book of business" and cease making sales under this agreement without prejudice so 
Page 5long as Agent meets its support obligations to its clients and financial obligations to Kallo.  
 
 
 
 
 
 
 
KALLO - MOBILECARE  
j) Competence: Agent agrees to comply in full with Section (2). Subparagraph (c) of this agreement and provide and acquire appropriate staffing, training and any other requirements for the marketing, and sales of the Kallo Mobile care suite of products, and to comply with the Kallo training, support, shipping and payment terms. 
k) Conduct: Agent shall undertake no acts injurious to the business or goodwill of Kallo. Agent shall use its best efforts to promote Kallo and its products and service and shall promptly report and follow up all leads provided. Agent may not offer or promote competitive products without the consent of Kallo. 
l) Independent Entities: Notwithstanding the use of the designation "Sales Agent". Agent is an independent contractor and shall at no time have the power 
i.to bind Kallo; 
ii.to alter or change any terms, conditions, warranties or covenants made by Kallo or 
iii.to create in favor of any person any rights, which Kallo has not previously agreed in writing. 
m) Form of Relationship: The relationship under this Agreement shall not create any legal partnership, franchise relationship, agency or other form of legal association between the parties, which would impose a liability of one party upon the other. 
n) Insurance: Agent or its successors shall maintain during the term of this Agreement and while it is still responsible for its Book of Business: 
i.All required workers' compensation or similar insurance; 
ii.Comprehensive general liability insurance. Agent shall promptly supply Kallo with proof of such insurance upon request. Kallo shall maintain comprehensive general liability and errors and omissions insurance for the Kallo Mobile care suite of products. Kallo shall promptly supply Agent with proof of such insurance upon request. 
o) Records: Agent shall supply to Kallo the full business data of each customer as a qualified prospect and at the time of sale and shall, during this Agreement and while it is still responsible for its 
Page 6Book of Business, and for a period of one year after the termination of this Agreement maintain records sufficient for Kallo to verify amounts due under this Agreement relating to the contracts, invoices, accounts, complaints, and other transactions relating to the placement and licensing of the Kallo Mobile care suite of products. Kallo may directly, or through its Agent at any time during normal business hours, upon no less than 10 business days' notice, and for any reason inspect such records and other financial information relevant to Kallo Mobile care suite of products as sold by Agent to its end users, solely for the purpose of verifying amounts due under this Agreement. Any such information will be confidential information of Agent subject to the provisions of Section 4.  
 
 
 
   
Warranties: 
 
 
KALLO - MOBILECARE  
p) Sub-Agents: Agent shall not be permitted to establish sub-Agents without the express written consent of Kallo. 
q) Corrupt Practices: Agent represents that it will not make any payment or transfer anything of value, directly or indirectly, to any government official or employee; to any officer, director, employee, or representative, or Agent of any actual or potential customer; or to any other person or entity if such payments would violate applicable laws. 
r) Prospects: Agent will provide Kallo with a list of active prospects on a regular basis as outlined in Section (2) Subparagraph (e) of this agreement. Kallo will use its best efforts to protect these prospects from being solicited by its other Agents or distributors, and to refrain from solicitation directly by Kallo, while taking into account prospect's wishes, and in as much as allowed by applicable laws. Agent in return agrees to respect active prospect lists of Kallo’s other Agents. For the above purposes, the Agent at least once every six (6) weeks and where details of each such contact are logged with Kallo define an active prospect as a prospect that is contacted. 
3.WARRANTY AND LIMITATIONS 
a)Kallo represents and warrants to Agent that; 
i.it has sufficient right, title and interest in and to the Kallo Mobile care suite of products to enter into this Agreement; and 
ii.all Kallo Mobile care suite of products distributed to Agent is free and clear of all liens. 
Page 7Limitation of Warranties:    
   
   
 
 
 
 
KALLO - MOBILECARE  
b)Kallo Mobile care suite of products’ Warranties Agent's exclusive warranty regarding the Kallo Mobile care suite of products is set forth in the applicable EULA provided with the Kallo Mobile care suite of products. 
c)Except as stated above, Kallo makes no other warranties regarding the Kallo mobile care suite of products and documentation, and any services provided by Kallo including, without limitation, express or implied warranties, and expressly disclaims the warranties of fitness for a particular purpose or merchantability, and any other warranty, express or implied. 
d)In no event shall Kallo be liable for indirect, consequential, or incidental damages (including damages for loss of business profits, business interruption, loss of business information, and the like) arising out of the relationship between Kallo and Agent even if it has been advised of the possibility of such damages. 
e)Kallo's cumulative liability under this agreement, including any cause of action in contract, tort or strict liability, shall be limited to the license fees paid by agent during the 12 months prior to such event. Kallo's limitation of liability is cumulative with all Kallo’s expenditures to address liability being aggregated to determine satisfaction of the limit. Agent releases Kallo from all obligations, liabilities, claims or demands in excess of the limitation. The parties acknowledge that other parts of this agreement rely upon the inclusion of this section and the resulting allocation of risks. 
f) Agent Actions: Kallo shall have no obligation to any party under any warranty given by Agent, its Agents or employees. Agent shall not make any representation or warranty with respect to the Kallo Mobile care suite of products other than those stated by Kallo in its written warranty, documentation and literature. 
g) Agent Indemnification: Agent agrees to indemnify Kallo and to hold it harmless from and against any loss, damage, claims or demands whatsoever arising out of Agent's activities that are outside the scope of the EULA provided by Kallo to the end user regarding use of Kallo Mobile care suite of products. Kallo makes its representations and warrants to the end user and limits 
Page 8of liability therein via the EULA.    
   
 
   Each party agrees not to disclose any confidential information received from the other in any form to any employees who do not have a specific need to use such information or to any outside party (including contractors) without the other party's prior written consent. All employees or contractors who receive such confidential information must be bound by written agreement not to disclose such information to any other party. 
Each party acknowledges that the unauthorized disclosure or use of confidential information of the other party would cause irreparable harm and significant injury to the other party that may be difficult to compensate. Accordingly, each party agrees that the other party will have the right to seek and obtain temporary and permanent injunctive relief in addition to any other rights and remedies it may have. The obligations of confidentiality shall not apply to information which; 
 
 
KALLO - MOBILECARE  
h) Complaints: Agent shall make all reasonable efforts to handle all incidents of customer complaints or demands regarding the Kallo Mobile care suite of products and shall report promptly to Kallo all such incidents. 
i) Kallo indemnification: Kallo agrees to indemnify Agent and to hold it harmless from and against any loss, damage, claims or demands whatsoever arising out of: 
i.Intellectual property infringement arising from the Kallo Suite of Products; 
ii.Breach of implied warranty or negligence. 
iii.Activities that are outside the scope of the EULA provided by Kallo and issued to the customer through Agent regarding the use of the Kallo Mobile care suite of products. Kallo further agrees to indemnify AGENT and to hold it harmless from and against any loss, damage, claims, or demands whatsoever arising out of Kallo's activities that are outside the scope of this Agreement. 
4.CONFIDENTIALITY 
i.is in public domain at the time of disclosure, 
ii.has been released by the other party without restrictions, 
iii.has been lawfully obtained by the disclosing party from a third party under no obligation of confidentiality, or 
iv.is independently developed by employees of the disclosing party without access to the confidential information. 
Page 9Kallo reserves the right to revoke or limit the use of Trademarks at any time upon reasonable notice. Non-Compliance with Trademark and Logo Policies shall be considered a material breach of this Agreement.    
 
If at any time Agent acquires any rights in, or any registration or application for, any of the Trademarks by operation of law or otherwise, it will immediately, upon request by Kallo and at no expense to Kallo, assign such rights, registrations, or applications to Kallo, along with any and all associated goodwill.    
 
 
KALLO - MOBILECARE  
5.TRADEMARKS 
a) Definition: "Trademarks" means any and all current or future company names, product names, marks, logos, designs, trade dress and other designations or brands used by Kallo in connection with its products and services and all marks similar thereto. 
b) License: Kallo grants Agent the right to use the Trademarks solely for the purpose of distributing and marketing the Kallo Mobile care suite of products provided that Agent: 
i.uses the appropriate Trademarks for the corresponding Kallo Mobile care suite of products; 
ii.Identifies all Trademarks are registered trademarks of Kallo; 
iii.take reasonable steps to modify all objectionable uses of the Trademarks. 
c) Ownership: Agent acknowledges that Kallo is the sole owner of the Trademarks and nothing herein shall grant to Agent any right or interest in the Trademarks. Agent shall not register, or attempt to register, any Trademarks or any marks confusingly similar thereto in any jurisdiction. 
d) Limitations: Except as stated above, Agent is granted no right, title, license or interest in the Trademarks. Agent acknowledges Kallo’s rights in the Trademarks and agrees that any and all use of Trademarks by Agent shall inure to the sole benefit of Kallo. Agent agrees that it shall take no action inconsistent with Kallo ownership of the Trademarks and agrees not to challenge Kallo’s rights in or attempt to register any of the Trademarks, or any other name or mark owned or used by Kallo or any mark confusingly similar thereto. 
e) Notification: Agent shall promptly notify Kallo of any use by any third party of Trademarks or any use by such third parties of 
Page 10similar marks which may constitute an infringement or passing off of Trademarks. Kallo reserves the right, in its sole discretion, to institute any proceedings against such third party infringers and Agent shall refrain from doing so itself. Agent agrees to cooperate fully with Kallo in any action taken by Kallo against such third parties, provided that all expenses of such action shall be borne by Kallo and all damages which may be awarded or agreed upon in settlement of such action shall accrue to Kallo. Refer to Schedule B for available means of communication to all parties concerned.    
 
   
   
   
 
 
KALLO - MOBILECARE  
f) Co-Branding: Kallo agrees for co-branding needs with local government and sponsors logo. This is subject to: 
i.The submission to and approval by Kallo of the recommended Logo I Product Name. This is to ensure that the overall look and feel of the Kallo Mobile care product is maintained. 
ii.The supply of the Logo I Product Name in suitable high quality format allowing sufficient time as defined by Kallo to incorporate co-branding logo on the Mobile clinics. 
iii.Kallo agreeing to this will, in no way reduce, undermine, alter or limit their rights as outlined in section 5 and 6 of this agreement. 
6.PROPRIETARY RIGHTS 
a) Ownership: Agent understands and agrees that Agent takes title only to the media on which the Kallo Mobile care suite of products is provided. Title in and ownership of all copies of Kallo products and documentation, Trademarks and all property rights therein, shall remain at all times vested in Kallo. Agent acknowledges that the Kallo Mobile care suite of products is protected by domestic and international copyright and other forms of proprietary rights and agrees not to copy or otherwise reproduce (except as required for distribution to customers), modify, adapt, translate, reverse engineer, decompile, disassemble or create derivative works based on the Kallo Mobile care suite of products or the documentation. 
b) No Rights Granted: No provision in this Agreement shall be interpreted as an assignment or grant to Agent of any right, title or interest in the Kallo Mobile care suite of products, documentation or Trademarks. 
c) Protection: Agent agrees to take any reasonable step necessary to protect the proprietary rights of Kallo and its 
Page 11suppliers or licensors, including, but not limited to, the proper display of copyright, trademark, trade secret and other proprietary notices on any copies of the Kallo Mobile care suite of products. Agent must reproduce and include any such notices, other legends and logos on any backup copies.  
Any printed reference to Kallo products must include the following notice (or such notice as required by Kallo) with: 
© Kallo Inc., [YEAR]. All Rights Reserved.  
 
   
   
 
 
 
KALLO - MOBILECARE  
d) Copyright Notice: Agent agrees not to remove and shall reproduce and include all copyright notices or confidential or proprietary legends in and on all copies of Kallo Mobile care suite of products or documentation. 
e) Breach: Agent understands and agrees that the protection of Kallo rights in and to the Kallo Mobile care suite of products, documentation and Trademarks and the prevention of any unauthorized copying, reproduction, modification, adaptation, translation, reverse engineering, de-compilation, disassembly and creation of derivative works, is of the essence of this Agreement and that any failure on its part, however minor, to discharge its obligations shall constitute a material breach of this Agreement. 
7.TERM AND TERMINATION 
a) Term: This Agreement shall enter into effect on the date it is signed by both parties as shown below. 
b) Termination: This agreement shall terminate: 
i.upon notification of a Material Breach that is not cured within 10 business days thereafter; 
ii.Failure to cure a non-material breach within sixty days of written notice; 
iii.Automatically, unless otherwise agreed between parties, in the event that Agent is the subject of a proceeding in bankruptcy which is not dismissed within 60 days, is placed in receivership, or makes an assignment for the benefit of its creditors; or by 
iv.Termination for "Cause" by giving 3 months written notice by the Agent or Kallo. If given by Kallo, "Cause" shall be defined as non-performance on the part of the Agent by failing to make sufficient efforts to market the Kallo Mobile care suite of products. Should the parties disagree as to what constitutes "sufficient marketing efforts", the issue will be submitted to binding arbitration. This course of action is not intended to be a means for 
Page 12Kallo, its successors or assigns, to take over the successful operation of Agent’s business generated under this agreement without fair and just compensation.  
 
 
   
 
 
KALLO - MOBILECARE  
c) On Termination: Notwithstanding any terms of this agreement to the contrary, upon termination of this Agreement for any reason whatsoever, Kallo, unless otherwise agreed, shall set aside the Agent's Book of Business to be held by Kallo. 
i.The revenue stream defined by the Book of Business at the time Kallo becomes the controlling party will remain constant except in as far as any elected reduction in use by its customers. Any increase in use will not be to the benefit of the Book of Business. 
ii.Kallo shall pay over all funds collected from the Book of Business and due to Agent, less a reasonable administration fee to be assessed and determined by Kallo, to Agent or its designees or assigns immediately upon receipt and act as a conduit for Agent funds, except in as far as Kallo or its assignees are required to support customers in the Book of Business in which case the cost of providing such support, will be reasonably assessed and appropriate deductions made before passing the balance to Agent. In the event Agent does not agree with the costs described in this section, the issue will be submitted to binding arbitration. 
iii.Kallo shall make an accounting of funds collected to Agent or their assigns monthly. Kallo shall permit Agent or its designated Agent(s) to inspect Kallo’s books upon Agent's request at Agent's expense during normal business hours of Kallo. 
iv.Kallo's failure to perform its duties in the event it becomes the controlling party of the Agent's Book of Business is a non-material breach of this agreement. 
v.In any dispute or litigation over the terms of this agreement, the prevailing party shall have reasonable attorney fees in addition to any settlement or damages awarded. 
d) Rights: Upon termination of this Agreement for any reason and unless otherwise agreed, all rights granted to Agent shall immediately cease and Agent shall immediately return to Kallo all Kallo Products and confidential information provided by Kallo except as otherwise provided in this Agreement. 
e) No Compensation: In the event of an agreed termination of this Agreement by both parties, neither party shall be liable to the 
Page 13other for damages, losses, or expenses of any kind or character on account of the termination of this agreement in accordance with its terms, whether such damage, loss, or expense may arise from the loss of prospective customers of Agent, or expenses incurred or investments made in connection with the establishment, development, or maintenance of Agent's business. Termination or expiration shall not affect any claim, demand, or liability of any party created or arising hereunder prior to such time.  
   
   
 
 
 All Kallo Mobile care suite of products distributed by Agent shall be transferred solely in Kallo standard packaging and through the terms of the appropriate Kallo Mobile care suite of products EULA between the customer and Kallo provided by Kallo from time to time. Delivery of copies of the Kallo Mobile care suite of products to Agent is made solely to enable Agent to exercise this right. Agent shall not license or transfer any Kallo product for the purpose of retransfer by or to others.     
 
KALLO - MOBILECARE  
8.FORCE MAJEURE 
a) Definition: "Force Majeure" shall mean any event or condition not reasonably within the control of either party, which prevents in whole or in material part the performance by one of the parties of its obligations hereunder or which renders the performance of such obligations as difficult or costly as to make such performance commercially unreasonable. 
b) Notice: Upon giving notice to the other party, a party affected by an event of Force Majeure shall be released without any liability on its part from the performance of its obligations under this Agreement, except for the obligation to pay any amounts due and owing hereunder, but only to the extent and only for the period that its performance of such obligations is prevented by the event of Force Majeure. The other party may likewise suspend the performance of all or part of its obligations hereunder to the extent that such suspension is commercially reasonable. Refer to Schedule B for available means of communication to all parties concerned 
9.ADDITIONAL PROVISIONS 
a) Rights: Kallo grants to Agent the non-exclusive and non-transferable right to distribute the use of the Kallo Mobile care suite of products to commercial end user customers. Refer to section (2) subparagraph (f) for non-exclusive and exclusive status and qualifying requirements. 
Page 14This Agreement is not assignable by Agent without prior written consent by Kallo. In the event Agent changes its legal structure or undergoes a substantial change in ownership of its stock or other ownership interest, Kallo shall have the option of immediate termination of this Agreement. Kallo may assign this Agreement and its interest in the Kallo Mobile care suite of products to any party without the consent of Agent. This Agreement shall inure to the benefit of any successor of Kallo and shall not be affected by any change in the ownership or control of Kallo. Agent shall re execute this agreement within 60 days of the effective date of the change in ownership or change in legal structure or change of name. "Substantial change" in ownership is defined as a change in at least 51% ownership of the Agent.   
 
KALLO - MOBILECARE  
b) Limitations: Agent shall distribute only Kallo Mobile care suite of products that Agent has obtained from Kallo and not from any other seller of the Kallo Mobile care suite of products. For Tax reasons such distribution is deemed to take place at the Agent’s business location identified above. 
c) Pricing: The pricing given in Schedule A is the transfer price from Kallo to the Agent and the Agent shall, in its discretion establish a reasonable price for each of the Kallo Mobile care suite of products EULA as per Schedule A. For Maintenance Contract pricing and details refer to Schedule A, section (9), subparagraph (B). Kallo reserves the right to revise and republish prices as shown in Schedule A from time to time. 
d) Payment terms: For each Kallo Mobile care suite of products license ordered by Agent from Kallo, Agent shall pay to Kallo the transfer price set forth in Schedule A. 50% of the total amount to be paid with the signed purchase order, 35% upon shipping of the goods to the carrier at Canadian port and 15% upon completion of the installation. Upon delivery of the system the Agent is responsible for getting the signed EULA from the customer before the installation process starts. 
e) Taxes: All taxes from the country of origin and destination including customs duty, withholding taxes, any other levies - international / local and freight and insurance are to the end-user or customers account. The Agent will work with Kallo to add all applicable taxes to the pricing given in Schedule A and should be paid to Kallo along with the purchase order and the 50% of the value of the total system 
10.ASSIGNMENT 
Page 15KALLO - MOBILECARE  
11.MISCELLANEOUS 
a) Complete Agreement: This agreement and the provisions of the current sales agent program guidelines, as amended from time to time, constitute the entire agreement of the parties with respect to the subject matter hereof and supersede all previous agreements by and between Kallo and agent as well as all proposals, oral or written and all prior negotiations, conversations or discussions between the parties related to this agreement. Agent acknowledges that it has not been induced to enter into this agreement by any representations or statements, oral or written, not expressly contained herein. 
b) Amendment: This Agreement shall not be deemed or construed to be modified, amended, rescinded, cancelled or waived, in whole or in part, except by written amendment signed by the parties hereto. Refer to Schedule B for available means of communication to all parties concerned. 
c) Unenforceability: If any provision of this Agreement is held to be invalid, illegal or unenforceable, such provision shall be considered severable from this Agreement and the remaining provisions shall continue in full force and effect. The parties will replace a severed provision by a provision, which is closest to the intent of the parties. 
d) Notices: Notices permitted or required to be given hereunder shall be deemed sufficient if given 
i.by registered or certified mail, postage prepaid, return receipt requested, addressed to the addresses given in schedule B or such other addresses as the respective parties may designate by like notice from time to time, or 
ii.by international courier, telefax to or by email, the details of which are given in Schedule B. 
iii.Any notice shall be deemed effective when received by the receiving party. 
e) Governing Law and Jurisdiction: The laws of the province of Ontario, Canada, govern this AGREEMENT and, in respect of any dispute, which may arise hereunder; Agent consents to the jurisdiction of the federal and provincial courts of Ontario, Canada. 
f) Counterparts: This Agreement shall be executed in two or more counterparts in the English language and each such counterpart shall be deemed an original hereof. 
Page 16KALLO - MOBILECARE  
g) Waiver: No failure by either party to take any action or assert any right hereunder shall be deemed to be a waiver of such right in the event of the continuation or repetition of the circumstances giving rise to such right. 
h) Government: If Agent is acting on behalf of any unit or agency of the United States Government, the following provisions apply: 
i.any products Agent acquires under this Agreement for or on behalf of the United States Government are provided to the United States of America with restricted rights. Use, duplication, or disclosure by the U.S. Government is subject to restrictions as set forth in subparagraph (c)(l)(ii) of the Rights in Technical Data and Computer Kallo Mobile care suite of products clause at DFARS 252.277-7013 and paragraph (d) of the Commercial Computer Kallo Mobile care suite of products-Restricted Rights clause at FAR 52.227-19; 
ii.Kallo grants Agent the right to transfer Kallo Mobile care suite of products to the United States government subject to the following restrictions. With the exception of the Department of Defense, you will not distribute the Kallo Mobile care suite of products to the United States of America except: 
a.on terms at least as restrictive as those set forth in subparagraph (c)(l)(ii) of the Rights in Technical Data and Computer Kallo Mobile care suite of products clause at DFARS 252.227-7013 and paragraph (d) of the Commercial computer Kallo Mobile care suite of products -Restricted Rights clause at FAR 52.227-19, and 
b.in compliance with particular department or agency acquisition regulations that provide Kallo protection at least equivalent to that provided by the above-referenced DFARS and FAR provisions. 
i) Export Restrictions: Agent expressly agrees to neither directly or through third parties export nor transmit any Kallo Mobile care suite of Products to any country to which such export or transmission is restricted or prohibited by applicable regulations or statutes, or any country other than the United States of America or Canada. 
j) Non-Disparagement: During the term hereof and for a period of two years thereafter, each of Agent and Kallo agrees that it will refrain from making any representation, statement, comment or any other form of communication, whether written or oral (hereinafter collectively referred to as a "Communication"), to any third party, including but not limited to the principals, customers, suppliers and competitors of the other party, which Communication reflects any opinion, judgment, observation or 
Page 17representation of fact, which has the effect or tendency to, or could have the effect or tendency to, disparage, denigrate, criticize or otherwise reflect negatively on the other party and/or the other party's products, services, officers, directors, shareholders, employees or investors (a "Disparaging Communication"). Each party agrees that it will use all reasonable commercial efforts to prevent its employees from making any Disparaging Communications regarding the other party and/or the other party's products, services, officers, directors, shareholders, employees or investors; provided, however, that nothing in this Section (11), subparagraph (j) shall restrict or impede the exercise of any rights or remedies of a Party under this Agreement.  
In Witness Whereof, the Parties hereto have executed this Agreement as of the date below. And confirm, we have read, understood and agree to the terms of the strategic alliance agreement - mobile care    
       
 
KALLO - MOBILECARE  
Kallo Inc.    
     
JOHN CECIL    
Signature    
     
John Cecil    
Name    
     
Chairman & CEO    
Title    
     
Markham, ON 24 OCT 2011    
Place Date    
            
Petro data Management Services Limited   Gateway Global Fabrication Ltd.,           
BABAJIDE SOYODE   AJAI KUNNATH 
Signature   Signature      
Babajide Soyode   Ajai Kunnath 
Name   Name      
Chairman & CEO   President & CEO 
Title   Title        
Ikeja, Lagos, Nigeria 24 OCT 2011   River State, Nigeria 24 OCT 2011 
Place Date   Place Date 
Page 18SCHEDULE - A 
Description of Kallo Mobile care suite of products  
 The Kallo Mobile Medical Clinics are one of a kind in the world having all the diagnostic capability for basic to mid tier specialty medical care and these units can be used in the following areas to augment healthcare delivery services. 
  
Places where there is no hospitals or clinics and emergency situations   
The Mobile Medical Clinics can be taken by road to these areas and patients or causalities can be taken into the vehicle and treated immediately with effective and real-time consultation with specialists via satellite. 
  
Hospitals where there is no technology available for diagnosis and treatment   
The Kallo Mobile Medical Clinics can be driven to, and parked in existing hospitals and patients can get the latest in technology for diagnosis and treatment, thus many hospitals in villages and rural areas can be upgraded in their healthcare services with latest equipment for diagnosis and treatment with the specialist care through remote tele-consultation. 
  
The Kallo Mobile Medical Clinics are designed to take comprehensive health care services (preventive, promotive and curative) to rural remote villages and will reach out to the most underprivileged but needy people across the country. 
  
The services provided are outpatient services, Ante-natal/post-natal services, identification of difficult pregnancy and referral for institutional care, Immunization- Mother & children, Minor surgery, BP examination, X-ray, ECG, First Aid, Distribution of Iron Folic tablets, Vit-A Prophylaxis, Treatment of mal-nutrient cases, etc.      
 
KALLO - MOBILECARE  
1.Mobile Acute Care Clinic 
Page 19The Mobile Chemotherapy Clinic serves as an extension to the chemotherapy administration in the regional Oncology departments of the teaching / general hospitals or dedicated Cancer hospitals. 
  
Blood work is performed the day before and a nurse is then able to contact the patient in advance to review test results and schedule treatment sessions and advise pre-treatment preparation of the patient. Chemotherapy drugs and related equipment, all individually packaged for each patient, is received from the Regional Cancer hospital command center.  Chemotherapy chair that includes a chair-side touch-screen interactive system enabling patients to call a nurse, select a book for reading from the exhaustive electronic library. 
  
Integrative medicine services such as Reiki, acupressure, and massage therapy can be delivered chair-side by specially trained nurses on staff. 
Telemedicine system to enable patients to communicate with their physicians, nurses, and healthcare professionals from other disciplines and social work.   
 The mobile dialysis clinic works exactly like a dialysis center. 
The vehicle has the clinical, technical and support staff and is well equipped with the necessary machinery required to perform the standard procedure for dialysis. 
This includes dialysis machine, recliner, power backup, and a water tank with water purified through reverse osmosis (RO) system. 
It has a fully automated and remote controlled dialysis chair, which works like a dialysis bed and there is a monitor defibrillator and an artificial respirator. It also carries accessories and equipment required to tackle emergencies. 
The machine and accompanying accessories can be moved into homes and patients can receive the treatment along the bedside.  
 
KALLO - MOBILECARE  
2.Mobile Chemotherapy Clinic 
3.Mobile Dialysis Clinic 
Page 20Our Mobile care is equipped with a dedicated, affordable and accurate CD4+ T-cell and CD4% enumeration in HIV monitoring and patient follow-up. 
The CyFlow® Counter is a fully equipped portable and ultra compact desktop flow cytometer dedicated for routine CD4 and CD4% counting (as well as total lymphocyte and WBC counting). 
Equipped with Portable and Battery-Operated Fluorescence Microscope for Malaria diagnostics and monitoring. 
The Partec CyScope® is a microscope for fluorescence light detection employing incident UV light and transmitted light detection. Integrated with a CCD camera for taking images of the slide for further investigation by image analysis software.  
 The Mobile Clinic Command Center is installed in Specialist / Teaching hospitals to provide real-time support for the Front line Medical officers and staff in the Mobile Clinics for Clinical care-plan, clinical treatment protocol, clinical diagnostic protocol and procedures to optimize the Mobile clinic function and to establish seamless continuum of care.  Each Command Center, based on the throughput of patients in the Mobile clinics can manage on an average of 4-5 Mobile clinics.  
Note: 
 
  
 
KALLO - MOBILECARE  
4.Mobile HIV & Malaria Clinic 
5.Mobile Clinic Command Center 
a)Medications and medical consumables are not provided in the Mobile Medical Clinics and shall be provided at additional cost. 
b)Auxiliary equipment for the Mobile Clinics: 
i)Stretchers, backboards, collars, drugs, medications and other medical supplies can be provided at additional cost. 
ii)All medical supplies to the government shall be on a contract supply based on demand, negotiated after the principal purchase order is placed for the Mobile Clinic. 
Page 21Paramedic staff in Kallo’s Mobile Medical Clinics are provided a high level of pre-hospital medical training involving key skills not performed by technicians, including cannulation, cardiac monitoring, intubation etc., by Kallo’s Internationally accredited doctors.  
 Specialty training (Focused on providing specialty care in conjunction with Specialists at teaching hospitals or Specialist care hospitals such as Pediatrics, Cardiology, Nephrology etc.,) for Front line Medical officers and staff in the Mobile Clinic and the Command center provided at additional cost based on assessment of resources and training requirements.  
 Basic training for Front line Medical officers and staff is included in the cost. This training is for the duration of 1 week and can hold 10 people.  Student Material for ACLS for one student is US$80/- 
(Includes quick access algorithm cards) 
Text Book for Basic Trauma and life support for one student is US$120/- 
Cost of Training per any additional week of 5 days is US$ 40,000/- (For Doctors and Clinical/Biomedical Engineers travel stay and charges)  
 
 
 
KALLO - MOBILECARE  
6.Training: 
7.Specialty training: 
8.Basic training: 
9.Maintenance: 
A.Mobile Clinic and Command Center maintenance is included in the Five year Standard Mandatory Maintenance as per the Program description given in Schedule E 
Page 22SCHEDULE - B 
Communication  
 
 
KALLO - MOBILECARE  
KALLO Inc., 
 
Attn: Mr. John Cecil 
Address: 15 Allstate Parkway, Suite #600   Markham, Ontario, L3R 5B4   Canada 
Telephone:+1-416-246-9997 
Fax: +1-905-415-0332 
Email: john@kalloinc.com   anna.s@kalloinc.com    
Petro data Management Services Limited., Attn: Mr. Babajide A. Soyode 
Address: Motorways Centre Block 'B', Ground Floor 1   Motorways Avenue, Alausa,   Lagos, Nigeria. 
Telephone:+234-01-2708786 
Fax: + 
Email: info@petrodata.net   Jide.soyode@gmail.com    
Gateway Global Fabrication Ltd., 
Gateway Canada and Gateway International Inc., Attn: Mr. Ajai Kunnath 
Address: GATEWAY GLOBAL FABRICATION LTD.   No-2 Olodu Street,   Off Oluobasanjo Road,   Portharcourt, Rivers state, Nigeria. 
Address: Gateway Canada.   147 Spring Gate Blvd.,   Thorn hill, Ontario, L4J 2B2 
Tel: +1-647-288-2763 
Mobile: +1-647-9385471 
Fax: + 
Email: ajai.kunnath@gvcal.com 
Page 23SCHEDULE - C 
Roles and Responsibilities defined for Kallo’s Mobile Care operations in Nigeria under this Strategic Alliance Agreement 
PETRODATA  OPERATIONS 
 ADMINISTRATIVE 
 
KALLO INC  
 
 
KALLO - MOBILECARE  
1.Customs clearance and delivery of Mobile Clinics. 
2.Training of Client's Operations 
3.Personnel of various cadres, doctors, nurses, paramedics, drivers, and medical technicians / technologists 
4.Maintenance of medical equipment 
5.Maintenance of the automobile and the engine of the Mobile Clinic and diesel generators 
6.Procurement of communication channels such as satellite feed and high-speed internet connectivity for Command Centers 
7.Provision of data acquisition and back-up storage systems 
8.Supply of all local manpower, not provided by clients 
9.Supply of residential accommodation, land transport, and general 
10.Welfare amenities to all foreign personnel 
11.Specialized IT and satellite communication support for Mobile Clinics 
1.Letters of invitation to Kallo personnel for visas 
2.Procurement of all import permits and licenses 
3.Accommodation, welfare, and security arrangements 
4.Arrangements for meetings with various organizations 
5.Local transportation and security 
6.Employment of local operational support staff, as required 
1.Supply of Mobile Clinics and all operating equipment and software 
2.Supply of all training personnel and materials for clinical staff (Doctors, Nurses and Front line Medical officers) and Biomedical Engineers and software Engineers. 
3.Sourcing of backup foreign medical consultants, as required 
4.Tele-health consulting for second opinion from medical specialists from US, Canada and UK 
5.Procurement of all export permits and licenses 
6.Supply of drugs/medications and spare parts during and after the warranty period. 
Page 24GATEWAY  
 
BAS CONSULTANTS INTERNATIONAL CORPORATION (BASCIC) 
 
KALLO - MOBILECARE  
1.Purchasing and transportation of Mobile Clinics, operating equipment, spare parts, medical consumables, drugs/medications to various distribution centers in Nigeria to replenish stocks in the Mobile Clinic, from Kallo Inc. Canada. 
2.Customs clearance and inland transportation 
3.Assistance with local market development and liaison with clients 
(Engr. B. A. Soyode)  
  
SCHEDULE - D 
Mutually accepted Sales Target  
    
1.All Parties in this agreement appoint BASCIC as Project manager without prejudice. 
2.Project development, management and coordination 
3.Liaison with Governments and clients and responsible for payments to Kallo and supply chain management of Medical consumables and medications/drugs from Kallo. 
Mobile Clinics Year Estimated Value Remarks 
2 Q4 2011 $14.575 Million To retain Exclusivity for Nigeria 
3 Q1 - Q2 2012 $21.863 Million To retain Exclusivity for Nigeria 
2 Q3 - Q4 2012 $14.575 Million To retain Exclusivity for Nigeria 
3 Q1 - Q2 2013 $21.863 Million To retain Exclusivity for Nigeria 
2 Q3 - Q4 2013 $14.575 Million To retain Exclusivity for Nigeria 
3 Q1 - Q2 2014 $21.863 Million To retain Exclusivity for Nigeria 
2 Q3 - Q4 2014 $14.575 Million To retain Exclusivity for Nigeria 
3 Q1 - Q2 2015 $21.863 Million To retain Exclusivity for Nigeria 
2 Q3 - Q4 2015 $14.575 Million To retain Exclusivity for Nigeria 
3 Q1 - Q2 2016 $21.863 Million To retain Exclusivity for Nigeria 
2 Q3 - Q4 2016 $14.575 Million To retain Exclusivity for Nigeria 
Page 25SCHEDULE - E 
 
Mandatory Medical Equipment Service Program for Five-year Warranty  All equipment provided in the Mobile Clinic are covered under this program and the service provision is a very unique model, where Senior Biomedical Engineers trained and certified by the manufacturers are to perform the following services located at Kallo Headquarters, coordinate with the manufacturers and the local onsite support Biomedical Technicians and provide the following services:  
 
 This program has a set of planned routine maintenance schedule for each device of medical equipment based on the original equipment manufacturers’ recommendations, applicable codes and standards given in section 7.  
 This program has scheduled and unscheduled calibration of the medical equipment in the Mobile Clinic. Each medical device has a scheduled calibration of certain parts critical to the functional accuracy of the equipment, which is carried out as per the original equipment manufacturers’ guidelines. The unscheduled calibration of the equipment is normally carried out if and when there is a request from the staff or doctors when they observe certain calibration errors.  
  Safety of patients, staff, and environment is paramount to the success of the Mobile Care project. The Joint Commission on the Accreditation of Healthcare Organizations publishes annual lists detailing “National Patient Safety Goals” to be implemented by healthcare organizations. Goals are developed by experts    
 
KALLO - MOBILECARE  
1.Planned and Corrective Maintenance 
2.Calibration of Medical Equipment 
3.Patient, Staff and Environment safety 
4.Breakdown Services and Maintenance 
5.Application and operation support 
6.Risk Management 
7.Codes and Standards adherence for International compliance 
1.Planned and Corrective Maintenance 
2.Calibration of Medical Equipment 
3.Patient, Staff and Environment Safety 
Page 26in patient safety, nurses, physicians, pharmacists, risk managers, and other professionals with patient-safety experience in a variety of settings. Patient safety is among the most important goals of every healthcare provider, and participation in a variety of committees and processes concerned with patient safety provides a way for biomedical managers and clinical engineering departments to gain visibility and positively affect their workplace.   Kallo’s Patient and Operator Safety Program uses a comprehensive software where in the actual work process within the Mobile Care Clinic is monitored by the onsite Biomedical Technicians guided by the Senior Biomedical Engineers at Kallo Headquarters qualified for managing the patient, staff, and environment safety to international standards.   
  The program covers all equipment in the Mobile Clinic. The local onsite Biomedical technicians will be the first response team to attend to any and all breakdown calls from the Mobile Clinic. The Biomedical Technicians will then have Kallo Biomedical Engineer support to resolve the issues as quickly as possible. After the breakdown service is carried out and the equipment is fixed and recalibrated, the Senior Biomedical Engineers would then advise if a maintenance service has to be carried out to due to the nature of breakdown.   
  The program covers all medical equipment in the Mobile Clinic. Kallos’ Certified Clinical Engineers / Biomedical Engineers and Clinical Application support specialists will be available via Video/Teleconference/Telehealth systems in the Mobile clinic for all clinical application support in using technology for diagnostic and therapeutic healthcare services. This is a critical component of the program offered in order to make it successful in using technology at the front end which is normally neglected by all medical equipment manufacturers’ when the equipment is deployed in remote areas with medical staff who are not exposed to technology as the case may be in urban areas, developed cites or countries.   
  This program helps avoid the likelihood of equipment-related risks, minimize liability of mishaps and incidents, and stay compliant with regulatory reporting requirements.   In addition, user error, equipment abuse, no problem/fault found occurrences    
 
KALLO - MOBILECARE  
4.Breakdown Service and Maintenance 
5.Application Support 
6.Risk management 
Page 27must be tracked to assist risk management personnel in determining whether additional clinical staff training must be performed.   Risk management for IT networks incorporating medical devices will be covered by the standard ISO/IEC 80001. Its purpose is: "Recognizing that MEDICAL DEVICES are incorporated into IT-NETWORKS to achieve desirable benefits (for example, INTEROPERABILITY), this international standard defines the roles, responsibilities and activities that are necessary for RISK MANAGEMENT of IT-NETWORKS incorporating MEDICAL DEVICES to address the KEY PROPERTIES". Such as ISO 20000 in the context of medical applications, e.g. configuration, incident, problem, change and release management, and risk analysis, control and evaluation according to ISO 14971. IEC 80001 "applies to RESPONSIBLE ORGANIZATIONS, MEDICAL DEVICE manufacturers and other providers of information technologies for the purpose of comprehensive RISK MANAGEMENT".  
7. Codes and Standards adherence for International compliance:  1. JCAHO Comprehensive Accreditation Manual 
2. AABB 
3. NFPA 99 
a. Gas and Vacuum Systems 
b. Electrical Systems 
4. FDA 
5. SMDA 
6. OSHA        
 
KALLO - MOBILECARE  
Page 28SCHEDULE - F 
Medical Equipment description 
Blood Chemistry Analyzer 
 
KALLO - MOBILECARE  
Advanced i-STAT Cartridge Technology or equivalent system  
Most Comprehensive Bedside Testing Platform:  i-STAT cartridge technology streamlines traditional lab technology, yet contains many of the components found in complex lab testing systems. Each test cartridge contains chemically sensitive biosensors on a silicon chip that are configured to perform specific tests. To perform a test, 2 to 3 drops of blood are applied to a cartridge, which is then inserted into the i-STAT handheld. Prior to running a test, each cartridge initiates a series of preset quality control diagnostics, from monitoring the quality of the sample to validating the reagent.  Each i-STAT single-use cartridge uses advanced biosensor technology that applies microfluidics to process the most comprehensive range of clinical tests in a single platform, allowing clinicians to access the time-sensitive diagnostic information they need, when and where they need it. Available tests include diagnostic indicators related to disease state and clinical practice guidelines.  Test-specific, single-use i-STAT cartridges are available for a range of clinical tests, including cardiac markers, lactate, coagulation, blood gases, chemistries and electrolytes, and hematology.  
Delivers lab-quality test results to the clinician within minutes The portable i-STAT handheld makes patient-side testing easy: 
 Patient-side testing is as easy as entering the operator and patient information into the handheld, inserting one of the several testing cartridges, and then viewing test results: 
 
·requires no special sample preparation or user calibration; maintenance is minimal 
·weighs 18 ounces, making it completely portable 
·features ergonomically designed soft keys for comfort and ease of use 
·The system prompts users step by step through the testing process 
·Operator and patient information can be entered via barcode scanner 
·Operator lockout prevents unauthorized users from performing or viewing test results 
Page 29With over 50,000 handhelds placed in high-acuity settings worldwide-including over 1,800 hospitals-and over 35 million test cartridges produced annually, the i-STAT System is trusted to provide lab-quality results.  
i-STAT Integration Into Point-of-Care Data Management and Electronic Medical Records 
The i-STAT® System can integrate test results with your Lab Information System (LIS) and Electronic Medical Records (EMR). This is achieved through flexible connectivity and interfacing solutions, which serve to ensure your facility gets real-time results in the patient electronic chart.  
i-STAT System integration with Laboratory Information Systems (LIS)/Electronic Medical Records (EMR)   
 The i-STAT System connects to the Point-of-Care Data Management System of your choice and then interfaces to the EMR via your LIS. Integration options include: 
 
Addressing Documentation Challenges with STATNotes™ 
STATNotes is a highly customizable documentation solution for the i-STAT 1 handheld. This unique feature facilitates timely documentation of complex and critical data by prompting the user to enter information into the i-STAT 1 during the testing process. The information is then automatically uploaded to the patient chart with the test results. Customizing your i-STAT System to prompt data entry:  
 
KALLO - MOBILECARE  
·Test results are uploaded automatically when the i-STAT handheld is placed in a downloader 
·The Central Data Station System from Abbott Point of Care 
·Abbott Diabetes Care PrecisionWeb® 
·Medical Automation Systems RALS+™ RALS® Plus 
·Telcor Quick-Linc® 
Page 30STATNotes can help guide users to be compliant with The Joint Commission National Patient Safety Goals and hospital policies. For example, many of our customers use STATNotes to capture comprehensive ventilator setting information, documentation of critical test notification, and “read back” acknowledgment of critical tests and critical values. 
Data Management and Laboratory Regulatory Compliance The i-STAT System gives you control over who can use the device and access test results. It also offers many features designed to help laboratories maintain regulatory compliance, such as: 
 
Abbott Point of Care will work with your team to ensure seamless integration with your data management system.  
Urine Chemistry Analyzer 
CLINITEK Status® Analyzer or equivalent system 
Intended Use 
 
Table of Results The results shown in shaded areas will be marked as positives, if "mark positive results" is selected in Instrument Set Up. The results will be marked by asterisks when displayed, when printed and when the data is transferred to a host computer.  
 
KALLO - MOBILECARE  
·streamlines workflow 
·helps reduce errors 
·allows for increased efficiency 
·facilitates compliance 
·managing operator certification and device lockout 
·reporting on operator performance 
·reporting on both liquid and equivalent quality control 
·reporting on reagent usage 
·laboratory Information System interfacing 
·The Analyzer is for in vitro use in the semi-quantitative detection of albumin, bilirubin, blood (occult), creatinine, glucose, ketone (acetoacetic acid), leukocytes, nitrite, pH, protein, specific gravity and urobilinogen in urine samples, depending on the type of Siemens urinalysis strip used. 
·The semi-quantitative calculation of albumin-to-creatinine and protein-to-creatinine ratios in urine samples, when Clinitek® Microalbumin and Multistix PRO® Reagent Strips for Urinalysis are used. 
·The detection of human Chorionic Gonadotropin (hCG) in urine samples, when Clinitest® hCG cassettes are used. 
Page 31KALLO - MOBILECARE  
Page 32Urinalysis has become an indispensable tool in healthcare.  
 In today's busy physician's office environment, interruptions are frequent and can contribute to timing errors and variability in results when urinalysis strips are read visually. Studies have shown that when urinalysis is performed with an instrument, sensitivity is increased and positives are correctly identified and reported.1 
  
   1. Tighe P. Improving the quality of urine strip testing: The Clinitek 50 urine chemistry analyser. Euro Clin Lab, June 1997,16:20.        
 
KALLO - MOBILECARE  
·Provides important markers to detect early stages of many disease states, such as diabetes, kidney disease and urinary tract infections. 
·Enhances disease monitoring and patient management. 
·Semi-quantitative results have proven to be cost-effective and virtually immediate. 
Page 33KALLO - MOBILECARE  
Page 34Digital Radiography System 
RadPRO D2RS Dynamic Digital Remote RF System or equivalent system 
Digital Radiography & Fluoroscopy Solutions   
 
Features 
   
 
KALLO - MOBILECARE  
•Canon CXDI-50RF Dynamic/Static Digital Radiography System  The RadPRO D2RS Dynamic Digital Remote RF System is compatible with the Canon CXDI-50RF Dynamic/Static Digital Radiography System that includes a Cesium Iodide scintillator. Including both dynamic and static capabilities, high resolution images are produced and may be previewed within 2-4 seconds after exposure in the radiography mode with the optional monitor. The radiography mode produces up to 15 frames per second (fps), and up to 30 fps in the fluoroscopy mode, depending on the image capture mode and size. The detachable cable allows the digital detector to be used in multiple rooms or multiple locations within the same room. 
•Dynamic and Static Imaging  The Canon CXDI Control Software RF, designed specifically for the Canon CXDI-50RF Dynamic/Static Digital Radiography System, features a wide range of fluoroscopic procedures and includes all the standard DICOM functions. Exams include spine, Osteo-articular, Barium swallow and esophagus, stomach and small intestine, Barium enema and large bowel, Endoscopy/ERCP, Urography, Cystography, Hysterosalpingography, Myelography, Arthrography, Venography and more. The software also delivers high-resolution images, generator communication for preset X-ray parameters, provides actual exposure factors and patient dose information in the DICOM header. Studies that require full spine and long leg imaging are fully automated. With the automated stitching capability up to 4 images can be stitched together. 
Page 35Digital Retina Scanner 
CR-2 PLUS or equivalent system 
Digital Non-Mydriatic Retinal Cameras   
 Overview 
 The Canon CR-2 PLUS Digital Non-Mydriatic Retinal Camera provides Color and Fundus Autofluorescence (FAF) imaging within a small compact design. Geographic Atrophy, Macular Degeneration, Glaucoma, Diabetic Retinopathy and other conditions that can affect vision may also be identified and monitored using FAF mode. Using invisible infrared alignment light, the digital non-mydriatic camera may image patients with pupils as small as 3.3 mm (small pupil mode) without dilation drops. This is especially useful when performing retinal screenings or expediting routine retinal imaging exams during office visits.  
 
KALLO - MOBILECARE  
• High Quality Images  High resolution static images can be previewed within 3-5 seconds after exposure on a monitor (optional). Images may be configured automatically with post-processing and are ready to be printed or transmitted through the network using industry standard DICOM protocols. 
• Full Patient Coverage  End-to-end table coverage is available when the motorized tube column angulation is combined with the motorized tube rotation. The motorized table adjusts the height, and the low minimum height simplifies access for patients with mobility issues. When patients arrive at the radiology room on a trolley or in a bed, Smart Access provides clear access to a 47 inch (120 cm) section of the table top to allow for a simplified transfer. The table loading capacity accommodates patients weighing up to 500 lbs (230 kg). 
• Auto-Positioning  Table movements, collimation and spectral filtration settings, exposure and digital acquisition parameters may be administered with the single touch, remote-controlled user-interface reducing the preparation time needed for exams. 
Page 36Features 
  
 
KALLO - MOBILECARE  
•Non-Mydriatic Fundus Autofluorescence (FAF) Photography  Fundus Autofluorescence (FAF) helps monitor macular waste (e.g. lipofuscin) which can accumulate in the Retinal Pigment Epithelial (RPE) layer. The accumulation of macular waste can cause conditions such as Age-Related Macular Degeneration (AMD) which can lead to reduced vision. The FAF mode may be selected by pressing only one button. 
•Digital Filter Processing  Red-Free and Cobalt digital filters are included and provide enhanced screening exams. Red-Free is used for evaluating the Retinal Nerve Fiber Layer (RNFL) and vascular structure of the retina associated with documenting Glaucoma, Diabetic Retinopathy or Hypertension. The Cobalt filter is also used for evaluating the RNFL, as well as Optic Disc and Optic Disc Drusen. Additionally, Green (Vascular view) and Red channel (Choroid view) digital filter views are also included. 
•Compact and Lightweight  The small design of the CR-2 PLUS facilitates portability when needed using an optional hard shell transport case sold separately. Canon instrument tables (sold separately) may comfortably fit both the camera and computer workstation (sold separately). The space saving design also allows for use in limited office space environments. 
•Dedicated EOS Camera Technology  High quality diagnostic images are obtained using a dedicated camera for the CR-2 PLUS which incorporates a large, high-definition CMOS sensor with 18 megapixels. When the camera cover is removed, the LCD may be adjusted to a variety of titled angles to suit the user's point of view. 
•Low Flash Intensity and ISO Sensitivity  The low flash intensity of the CR-2 PLUS minimizes miosis, thus shortening the time required for taking multiple view exams or stereo images. The reduced brightness improves patient comfort and reduces the "ghost" image the patient sees after an exposure. A wide range of low ISO speeds are supported including ISO 200, 400, 800, 1600, 3200 and 6400. 
•Automatic Exposure Function  The CR-2 PLUS measures the volume of infrared light from the retina and automatically adjusts the flash intensity for observation and photography. This feature may be set to ON/OFF and can be adjusted using the operation panel. 
•Control Panel  The simplified design of the control panel can be easily handled by an examiner. The one-handed joystick may be used to position the camera to acquire the desired image. In darkly lit rooms, the operation panel illuminates for easier navigation. The short main body of the CR-2 PLUS provides minimal distance between the patient and the operator allowing easy access to adjust the patient's position or eyelids. 
•Retinal Imaging Control Software  Using the Canon Retinal Imaging Control Software (RICS), images can be captured, viewed, processed, printed and saved to a permanent storage database. The Canon RICS complies with the DICOM®* Standard. Images may be stored as DICOM or JPEG files. For more information, visit Retinal Imaging Control Software. 
Page 37Ultrasound Scanner 
LOGIQ 9 or equivalent system   
 E-Series transducers 
 Incredible transducer technology makes imaging incredibly easy.  E-Series transducers set an entirely new standard in acquiring extraordinary images. The moment you put the transducer on the patient, these highly advanced, ergonomically designed transducers work with the agile architecture to maximize image quality.   
  
Highly advanced transducer technologies for high-quality images: 
 
Acoustic Amplifier Technology built into the new E-Series transducers achieves higher sensitivity by recycling the acoustic energy that used to pass through the transducer crystal. It redirects this previously wasted energy back into the piezoelectric crystal, adding significantly to the transducer sensitivity.   
 
KALLO - MOBILECARE  
·Acoustic Amplifier Technology 
·Single Crystal Technology 
·Matrix Array Technology 
·Volume Hybrid Technology 
Page 38Single Crystal Technology increases bandwidth, offering better signal to noise and improved axial resolution and penetration.  
Matrix Array Technology helps achieve uniform resolution throughout the field of view, eliminating the compromise between penetration and image resolution.  
Volume Hybrid Technology encompasses a new range of Volume transducers bringing an outstanding spatial and temporal resolution.  
LOGIQ E9 knows the next step of a scan and helps you get there like no other ultrasound system can. It’s all part of the technologically advanced Scan Assistant, your customizable scanning protocol.  
Scan Assistant does things that an ultrasound system has never done before, including automatically steering color Doppler and setting up imaging controls and modes for you. Now you can truly concentrate less on keystrokes and more on patient care.  
Digital Smartscope 
 
KALLO - MOBILECARE  
Optomed Smartscope or equivalent system  Optomed Smartscope is a digital camera that provides general, ophthalmoscope, otoscopic and dermatoscopic imaging with one hand -held device.    
              
  
 
Page 39Multi Function Digital Stethoscope 
CMS VESD Digital Stethoscope or equivalent system   
   
CMS-VESD is a multi-functional visual stethoscope. On the basis of stethoscope function, it is added with ECG and SpO2 monitoring function. The multi-functional characteristic of the device makes it is effective on emergency treatment. 
Specification 
Stethoscope 
    
 
KALLO - MOBILECARE  
·Compact and portable, easy to use 
·Suitable for adult, pediatric and neonatal patients. 
·Heart, Lung, Heart and Lung sound models for Stethoscope. 
·Large color LCD display of ECG, SpO2 and Pulse rate 
·Adjustable audible and visual alarms 
·Real-time monitoring.24 hours storage and review of data 
·SD card memory, all data can be transferred to a PC 
·Low power consumption. 
·Power Supply : Lithium Battery DC3.6~DC4.2V 
·Display : 2.4" Color LCD 
·Heart：20～230Hz 
·Lung：100～800Hz 
·H& L：20～800Hz 
·Accuracy:± 2 bpm 
Page 40Heart Rate 
  
Pulse Rate 
  
SpO2 
 
Patient Weighing Scale for Telehealth 
UC321 Digital Weighing scale or equivalent system  
Personal Scales for Telemonitoring 
 
 An accurate and precise scale specifically designed for telemedicine applications. The UC-321 series provides highly accurate and precise measurements for telemedicine applications. These scales are one of the thinnest and lightest scales on the market. Measuring less than 1” thick, it is easy to step on and store.  
 
KALLO - MOBILECARE  
·Measurement range: 30bpm～300bpm; 
·Accuracy: ± 2 bpm 
·Measurement range: 30bpm 250bpm; 
·Accuracy: ± 2 bpm or ± 2% 
·Measurement range: 35%～100%; 
·Accuracy: 70~100% (± 2% ) <70% unspecified. 
·Precise measurements 
·Displays weight in either pounds or kilograms 
·Memory recall with time/date stamp on select models 
·Includes four attachable feet for carpet use 
·Motion Tolerance Mode on select models 
Page 41KALLO - MOBILECARE  
This sleek and stylish unit offers more precise readings and functionality compared to traditional scales. Available with wired or wireless communications.  
Digital Blood Pressure Monitor for Telehealth 
AND Digital Blood Pressure Monitor or equivalent system  
Blood Pressure Monitors for Telemonitoring 
  
 A leading blood pressure monitoring system among telemonitoring service providers. This blood pressure monitor can send real-time blood pressure measurements to the Access Point. These devices can also operate in 
·Professional accuracy via oscillometric method 
·Clinically validated 
·One button operation 
·Memory storage 
·Provides time and date stamp 
·Each monitor has unique serial number 
·Meets ANSI/AAMI SP10 standards 
a batch-mode to send a number of measurements with time and date in a single request command. Available with wired or wireless communications.      Page 42Telepharmacy Solution  Integrates remote or local pharmacist-controlled dispensing system cabinetry and software, pharmacy software and televideo technology into one system individually designed to meet all your needs. It brings real-time medication dispensing and pharmacist counseling to the point of care.   
Improves patient care and satisfaction 
  
 
KALLO - MOBILECARE  
·Provides immediate medication access - no more waiting or unnecessary trips. 
·Enhances prescription fulfillment - resulting in greater patient compliance. 
·System software/multiple barcode verifications virtually eliminate dispensing errors. 
Page 43SCHEDULE - G 
Kallo Mobile care suite of products (Price is subject to change based on the requirement and configuration of various systems in the Mobile Clinic, and is exclusive of taxes, levies custom duties, freight and insurance.)    
 
KALLO - MOBILECARE  
Description Kallo PriceAgent MarkupEnd user priceMobile Acute Care Clinic - Base price $2,650,000 $265,000 $2,915,000
 NOTE: PRICING INCLUDES TELE PHARMACY SYSTEM COSTING $150,000/ - FOR EACH MOBILE CLINIC.      
Standard Mandatory Maintenance Service for 5 years $2,915,000 $1,457,500 $4,372,500    $1,722,500 $7,287,500              Description Kallo PriceAgent MarkupEnd user priceMobile Chemotherapy Clinic - Base price $1,850,000 $185,000 $2,035,000Standard Mandatory Maintenance Service for 5 years $2,035,000 $1,017,500 $3,052,500    $1,202,500 $5,087,500              Description Kallo PriceAgent MarkupEnd user priceMobile Dialysis Clinic - Base price $1,600,000 $160,000 $1,760,000Standard Mandatory Maintenance Service for 5 years $1,760,000 $880,000 $2,640,000    $1,040,000 $4,400,000              Description Kallo PriceAgent MarkupEnd user priceMobile HIV & Malaria Clinic - Base price $1,800,000 $180,000 $1,980,000Standard Mandatory Maintenance Service for 5 years $1,980,000 $990,000 $2,970,000    $1,170,000 $4,950,000              Description Kallo PriceAgent MarkupEnd user priceCommand Center for Mobile Clinics $550,000 $55,000 $605,000Standard Mandatory Maintenance Service for 5 years $605,000 $302,500 $907,500    $357,500 $1,512,500
Page 441.
2.
2.1
2.2
3.
3.1
3.2
4.
4.1
 
EXHIBIT 1.1
Strategic Alliance Agreement
This Agreement is made and entered into this 30th day of June 2017,
Between:
Turnkey Capital Inc., having its office located at 2929 E. Commercial Blvd, Suite PH-D, Ft. Lauderdale, Florida, hereinafter referred
to as "TKCI";
And:
A Seminole Indian Company to be formed by Former Seminole Tribal Chairman James E. Billie and Craig Talesman, having an
office located at 1800 Frank Huff Road, Seminole Reservation, Okeechobee, FL 34974, hereinafter referred to as “SIC".
Overview
The purpose and intent of this strategic alliance is to combine the resources and talents of, TKCI and SIC, in order to take advantage
of every opportunity permitted by tribal sovereignty to create revenue streams in multiple areas in conjunction with operating partners
that have existing marketing and customers in place, thereby limiting the capital requirements and risk. New marketing advantages
based upon competitive pricing, cross marketing and new revenue streams from expansion into other industries will grow the
business beyond anything previously imagined. The structure may also be used for additional compatible acquisitions which will also
fuel growth. TKCI believes that structuring operations with Tribal Sovereignty will deliver the financial advantages of operating in a
tax free environment with limited liability, plus other benefits such as permit and zoning ease, supporting an ideal structure for
investment capital and successful entrepreneurial ventures.
Term
The term of this Agreement is twenty-four (24) months. The Agreement may be renewed, subject to mutual written
approval.
Notwithstanding the completion, expiration or termination of this Agreement, the indemnities warranties and
undertakings contained or referred to in this Agreement shall continue to subsist for as long as may be necessary for the purpose of
giving effect to each one and every one of them.
TKCI Committments
TKCI shall establish a wholly-owned subsidiary (the “Holding Company”) for the sole purpose of conducting and
developing business on behalf of this alliance. The utilization of this subsidiary will provide for separate record keeping, reporting and
tracking of all business related to this agreement.
In addition to capital recruitment functions, TKCI shall perform all of the functions and accept all of the responsibilities
of the position of Chief Financial Officer including but not limited to management of accounts receivable and accounts payable,
interfacing with Holding Company accountants on tax matters, interfacing with Holding Company accountants and lawyers on
regulatory and compliance matters, and all other tasks typically and reasonably associated with the post and position of Chief
Financial Officer.
Committments and Rights of SIC
SIC acknowledges and agrees that the ability of TKCI to render its services is uniquely dependent upon4.2
4.3
4.4
4.5
4.6
4.7
5.
5.1
5.1.1
5.1.2
5.2
5.5.1
5.5.2
5.3
5.4
 
the cooperation and provision of information to TKCI by Chief James E. Billie and Craig Talesman for SIC. In the event that
information is required, it shall be provided in writing.
SIC, represented by Chief James E. Billie and Craig Talesman, will assist in the closing of the transactions by: 1)
participating in meetings with key decision makers, providing process overview, and describing case histories of similarly situated
projects; and 2) providing advice on issues such as i) location; (ii) deal structure; (iii) funding; (iv) timing/phasing; (v) cash
flow/revenue collection issues; and (vi) other major implementation issues.
SIC shall allow TKCI to review and analyze all business opportunities that could be mutually beneficial to TKCI and
SIC within the time frame of this alliance.
SIC, represented by Chief James E. Billie and Craig Talesman, will assist in the finalization of project structuring plans
geared toward maximizing all available revenue streams.
SIC, represented by Chief James E. Billie and Craig Talesman, will provide access to other opportunities.
The decision to join this alliance is at the absolute discretion of Chief James E. Billie and Craig Talesman. TKCI affirms
that it shall not have any claim towards SIC if the management decides not to sign the agreement in the investigation stage, and
before any agreements are signed, for any reasons whatsoever.
SIC may try to locate, or authorize others to locate potential investors who are not Reserved Investors (or Rejected
Investors), and SIC may accept investments from such other investors, without incurring any liability towards TKCI
Fees and Financial Structuring
A wholly-owned subsidiary (the “Holding Company”) shall be established by TKCI to accomplish the following:
To hold the assets and liabilities of the TKCI/SIC alliance and provide for separate management of the alliance
business operations.
Operating capital may be raised and a growing shareholder base may be established to support future
expansion.
Net revenue from business operations created by Holding Company for the alliance will be distributed by Holding
Company equally – 50/50 - to TKCI and SIC:
SIC’s original business concepts and plans, as well as opportunities brought to the table through its
connections, and third-party contracts, are ways that we anticipate business could be generated, and revenues created;
TKCI’s advisory and management services and capital resources will provide the critical structure and
business mechanism to carry concepts through to revenue.
Turnkey Capital Inc. (TKCI) will reserve ten percent (10%) of the shares of TKCI for SIC. These shares will be issued
once an exclusivity agreement is reached.
Once the Holding Company is raising funds and generating revenue, the parties will negotiate a monthly fee.6
7.
8.
8.1
8.2
9.
9.1
9.2
9.3
 
Confidentiality and non-compete
During the term of this Agreement and for one (1) year thereafter, TKCI will keep in confidence, not reveal, not use and not allow or
assist others to use, any information marked “Confidential” received from or through SIC in the context of its activities hereunder,
except as authorized in writing by SIC. However, TKCI may assume that unless SIC specifically advises it to the contrary, in writing,
with respect to an item of information, it may reasonably make such information available to third parties that TKCI is attempting to
introduce to SIC. Such information includes, but is not limited to SIC's business plans and proprietary disclosures. The above
provisions will survive the termination of this Agreement, except they will not apply to information that (i) is in the public domain or
later becomes available to the public through no breach of this Agreement by either party; (ii) is obtained by either party from a third
party who had the legal right to disclose the information to that party; (iii) is already in the possession of the receiving party on the
date this Agreement becomes effective; (iv) is independently developed by either party or (v) is required to be disclosed by law,
government regulation, or court order.
Termination
This Agreement may be terminated early if mutually agreed to by both parties in writing, or for cause, which is defined as conviction
of either party of a criminal offense, actions in bad faith, and knowing or intentional misconduct, failure to perform as determined by
SIC, or a material breach of this Agreement. The expiration or early termination of this Agreement shall not affect any of its
provisions which are expressed to operate or have an effect afterwards or any right of action already accrued to either party in
respect of any breach by the other party.
Warranties and Indemnification
SIC represents and warrants to TKCI that the undersigned are duly authorized to execute and enter into this
Agreement, and that all information relating to SIC furnished by Chief James E. Billie and Craig Talesman, or its other
representatives, to TKCI will be complete, accurate and not misleading.
Each party ("the Defaulting party") shall indemnify the other party ("the Innocent party") and keep the Innocent Party
indemnified and harmless from and against any claims brought against the Innocent Party as a result of any acts or omissions of the
Defaulting Party, whether such acts or omissions relate to the Defaulting Party's tasks under this Agreement or not. The Defaulting
Party's liability under this provision shall extend to legal fees and to court and/or arbitration expenses, as the case may be as well as
any other expenses incurred by the Innocent Party in the course of defending and/or handling and/or settling such claim.
Strategic Alliance
TKCI is performing under this Agreement as a Strategic Alliance member and is not a legal or implied agent or
employee of SIC. This Agreement does not create agency or employment relationship between the parties hereto.
TKCI shall not, by reason of this Agreement or the performance of the services delineated herein, be or be deemed to
be, an employee of SIC, and TKCI shall have no power to enter into any agreement on behalf of, or otherwise bind SIC. Without
limiting the foregoing, TKCI shall not enter into any contract or commitment on behalf of SIC.
SIC acknowledges and agrees that TKCI shall have no liability resulting from TKCI’s failure to obtain any financing for
any of its programs or business concepts. Neither party shall have any claim whatsoever against the other if an investment or a sales
opportunity was lost because of any of the other party's acts or omissions.9.4
9.5
10.
10.1
10.2
10.3
11.
11.1
11.2
11.3
11.4
11.5
 
SIC understands that TKCI is not acting as a broker-dealer or dealer in securities with respect to any transaction
contemplated hereunder, and that any securities which may be sold in respect to any such transaction are being sold directly by or to
SIC, to or by TKCI parties to such transaction. SIC acknowledges and agrees that no liability will be attributed to TKCI in
connection with the issuance of any equity or securities. Any fees due to TKCI are to be paid solely as finder’s fee and as
remuneration for other services provided for under this Agreement.
TKCI will have First Right of Refusal with regard to any sale or disposition of any part or the whole of companies or
projects developed in relationship with this alliance.
Arbitration
This Agreement shall be governed by the laws of the State of Florida.
Any disputes arising under or in connection with the validity, interpretation and performance of this Agreement that
cannot be resolved amicably by the parties shall be settled in arbitration before a single arbitrator. If arbitration fails to render a
mutually agreement resolution the Courts of the State of Florida will be deemed to have jurisdiction.
In addition to all other remedies provided in this Agreement, the prevailing party shall be entitled to all costs and
expenses reasonably incurred as a result of said breach, including arbitration and court costs, and reasonable attorney's fees.
Miscellaneous
This Agreement, together with any added Appendices, constitutes the entire agreement between the parties with
respect to its subject matter and supersedes any prior agreement. This Agreement may be changed only by mutual agreement
between the parties, expressed in writing.
All notices under this Agreement shall be in writing and shall be deemed given if delivered to the party personally, or
five (5) days after sent by registered airmail or by an express courier, as well as delivery by confirmed facsimile transmission or
confirmed electronic mail. The addresses for notices given under this Agreement shall be those provided above.
If any provision of this Agreement is held by an arbitrator to be invalid, void or unenforceable, the remaining
provisions shall nevertheless continue in full force, and the stricken provision shall be replaced by a valid, legal and enforceable
provision having as nearly as possible the same economic and practical effect.
This Agreement shall be binding on all parties’ respective assigns and successors.
Facsimile copies of this Agreement, with signatures, shall be given the same legal effect as an original with original
signatures.
And in witness, the parties sign on the day and date first above written:
For Chief James E. Billie   Craig Talesman   Turnkey Capital Inc.
       
Sign: /s/ Chief James E. Billie   /s/ Craig Talesman   /s/ Neil Swartz
        
Name: Craig Talesman      Neil Swartz
        
Title:       Chief Executive OfficerExhibit 10.18
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS
BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM
TO THE COMPANY IF PUBLICLY DISCLOSED.
STRATEGIC ALLIANCE AGREEMENT
This Strategic Alliance Agreement (this “ Agreement”), effective as of December 10, 2015 (the “Effective Date”), is by and between Allscripts
Healthcare, LLC, a North Carolina limited liability company (“Allscripts”) on behalf of itself and its Affiliates and Phreesia, Inc., a Delaware corporation
(the “Company” or “Phreesia”). Allscripts and the Company are sometimes referred to herein as a “ Party” and collectively as the “ Parties”.
RECITALS
WHEREAS, Allscripts is a leading provider of clinical and revenue cycle software, connectivity and information solutions for physicians, including
its practice management solutions;
WHEREAS, the Company provides Merchant Processing Services, Eligibility and Benefit Services, and Patient Intake Management Offerings
within the healthcare industry;
WHEREAS, the Company has developed, licenses, and makes available (as applicable) certain software and services described herein; and
WHEREAS, Allscripts desires to obtain the right to market, sublicense, and make available such software and services and cause the Company to
provide such software and services, either to Allscripts or to third parties, on the terms and conditions set forth in this Agreement.
AGREEMENT
NOW, THEREFORE, for good and valuable consideration, and in consideration of the mutual covenants and conditions herein contained, the
Parties agree as follows:
1. Definitions. For purposes of this Agreement, the following terms have the meanings ascribed thereto in this Section  1:
“Affiliate” means, with respect to a Person, any other Person that directly or indirectly, through one or more intermediaries, controls, is controlled
by, or is under common control with, such Person. For purposes of this definition, the term “ control” (including the terms “controlled by ” and “under
common control with”) means the direct or indirect power to direct or cause the direction of the management and policies of a Person, whether through
the ownership of voting securities, by contract, or otherwise. Allscripts’ Affiliates may exercise Allscripts’ rights and fulfill its related obligations under
this Agreement, provided that Allscripts shall be responsible for any breach of such obligations by its Affiliates to the same extent as if Allscripts was
the breaching party.
“Allscripts Customer ” means a customer that has contracted for or receiving any of Allscripts’ products or services.
“Allscripts Practice Management ” means the practice management system currently marketed and sold by Allscripts as “Allscripts Practice
Management” (as the same may be renamed, enhanced or expanded from time to time)
“Bank Rules” means the Bank Card Merchant Rules and Regulations provided to Sublicensed Customer in writing, as amended from time to time,
which are incorporated into this Agreement by reference.
1“Change of Control” means any of the following: (a) any merger, reorganization, share exchange, consolidation, or other business combination
involving the Company and its subsidiaries, other than (i) any acquisition or other similar transaction in which the Company acquires the assets or the
securities of another Person and the Company does not issue capital stock of the Company representing more than fifty percent (50%) of the issued and
outstanding shares of any class of capital stock of the Company, or (ii) any merger or similar transaction effected solely to change the domicile of the
Company or any of its subsidiaries; (b) any acquisition by any Person as a result of which such Person (or any group of which such Person is a member)
becomes a beneficial owner of more than fifty percent (50%) of the issued and outstanding shares of any class of capital stock of the Company in any
single transaction or a series of related transactions; (c) any sale, lease, exchange, mortgage, pledge, transfer, or other disposition of all or substantially all
of the assets of the Company and its subsidiaries in any single transaction or a series of related transactions; or (d) any exclusive license of all or
substantially all of the intellectual property of the Company and its subsidiaries, in any single transaction or a series of related transactions. For purposes
of this definition, the term “beneficial owner” has the meaning ascribed to such term in Rules 13d-3 and 13d-5 under the U.S. Securities Exchange Act of
1934, as amended, and the term “group ” means two (2) or more Persons acting as a partnership, limited partnership, syndicate, or other group for the
purpose of acquiring, holding, or disposing of the applicable securities referred to herein.
“Claim” means any claim, action, suit, proceeding, damages, costs, expenses and other liabilities, including reasonable attorneys’ fees and court
costs.
“Clinician” means each healthcare professional contracted under a customer’s license or service agreement and any healthcare professional not
contracted under a customer’s license or service agreement for which such customer subsequently pays a clinician fee. Healthcare professionals are only
Clinicians (1) during the periods in which they are contracted under a license or service agreement or (2) for healthcare professionals not contracted
under a customer’s license or service agreement, solely during the periods for which a Customer pays a clinician fee for such healthcare professional. For
avoidance of doubt, authorized end users of the Subscription Software Services are both Clinicians and their administrative and other front and back
office personnel. For the further avoidance of doubt, there will be no further license fees applicable to the administrative or other front and back office
personnel.
“Company Acquiror” means any Person that acquires the Company in connection with a Change of Control (including, without limitation, a
Competing Provider) and includes each Affiliate of such Person that is not controlled by the Company. For purposes of this definition, the term
“controlled by ” means the Company has the direct or indirect power to direct or cause the direction of the management and policies of such Person,
whether through the ownership of voting securities, by contract, or otherwise.
“Competing Provider” means any electronic health record, revenue cycle management, or health information exchange information technology
vendor whose products or services are directly competitive with a material portion of Allscripts business.
“Confidential Information” means non-public  information of a Disclosing Party, [***].
“Controlled Technology ” means any software, documentation, technology, or other technical data, or any products that include or use any of the
foregoing, of which the export, re-export, or release to certain jurisdictions or countries is prohibited or requires an export license or other governmental
approval under any Law, including the U.S. Export Administration Act and its associated regulations.
“Customer Agreement” means a written agreement between Allscripts (or an Allscripts Reseller or Partnering Organization as permitted herein) and
an Allscripts Customer pursuant to which Allscripts resells any Installed Software or any Subscription Software Services or orders Merchant Processing
Services from Company on behalf of an Allscripts Customer in accordance with this Agreement.
2“Data” means all data, information, and other content (regardless of whether de-identified) of any type and in any format, medium, or form, whether
audio, visual, digital, screen, GUI, or other, that is input, submitted, uploaded to, placed into or collected, stored, processed, generated, or output by any
device, system, or network by or on behalf of Allscripts (or any of its licensors or Affiliates) or any Sublicensed Customer through the Subscription
Software Services, including any and all data, analyses, and other information and materials resulting from any use of the Subscription Software Services
by or on behalf of Allscripts (or any of its licensors or Affiliates) or a Sublicensed Customer under this Agreement.
“Developer Agreement ” means the Allscripts Developer Program Agreement previously entered into between Company and Allscripts with an
effective date of July 1, 2014.
“Documentation ” means all user manuals, operating manuals, technical manuals, and any other instructions, specifications, documents, or
materials, in any form or media, that describe the functionality, installation, testing, operation, use, maintenance, support, technical specifications, or
components, features, or requirements of any of the Installed Software or any of the Subscription Software Services or Merchant Processing Services,
together with all revisions to such documentation delivered by or on behalf of the Company and as updated from time to time by the Company.
“E&B Transaction” means an Electronic Data Interchange (EDI) Health Care Eligibility/Benefit Inquiry (“270 transaction ”) and the retrieval of an
EDI Health Care Eligibility/Benefit Response (“271 transaction ”), with a single E&B Transaction consisting of both the 270 transaction and the 271
transaction. [***].
“Eligibility and Benefit Services” means the Company’s subscription-based software services that submits Electronic Data Interchange (EDI)
Health Care Eligibility/Benefit Inquiries (“270 transactions ”) and the retrieval of the EDI Health Care Eligibility/Benefit Response (“271 transactions ”) to
inquire about the health care eligibility and benefits associated for patients through POS Dashboard or the Eligibility UI and the Eligibility Interface. The
Eligibility and Benefit Services, the Eligibility UI and the Eligibility Interface are further described on Exhibit A attached hereto.
“Error” means [***].
“Harmful Code” means (a) any virus, Trojan horse, worm, backdoor, or other software or hardware devices, the effect of which is to permit
unauthorized access to, or to disable, erase, or otherwise harm, any computer, systems, or software; or (b) any time bomb, drop dead device, or other
software or hardware device designed to disable a computer program automatically with the passage of time or under the positive control of any Person,
or otherwise prevent, restrict, or impede Allscripts’ or any Sublicensed Customer’s use of such software or device.
“HITECH” means the Health Information Technology for Economic and Clinical Health Act of 2009, as amended.
“Implementation Services” means services related to the initial delivery, configuration, and pre-acceptance  usage of the Subscription Software
Services or Merchant Processing Services described in Exhibit C.
3“Installed Software” means the Company’s Integration Client configured to interoperate only with Allscripts products that is installed on a
Sublicensed Customer’s computer systems, and including all enhancements and other Updates thereto and all copies of the foregoing permitted
hereunder.
“Intellectual Property ” means [***].
“Law” means any applicable statute, law, ordinance, regulation, rule, code, order, constitution, treaty, common law, judgment, decree, or other
requirement or rule of any federal, state, local, or foreign government or political subdivision thereof, or any arbitrator, court, or tribunal of competent
jurisdiction.
“Legacy Customers ” means those Company customers listed on Exhibit H.
“Loss” means all losses, damages, liabilities, deficiencies, judgments, settlements, interest, awards, penalties, fines, costs, or expenses of whatever
kind, including reasonable attorneys’ fees, the costs of enforcing any right to indemnification hereunder, and the cost of pursuing any insurance
providers.
“Marks” means, with respect to a Party, such Party’s trade names, trade dress, trademarks, service marks, logos, brand names and other identifiers,
corporate names, meta-tags, and universal resource locators, and any applications, registrations, and renewals thereof.
“Member Bank” shall mean a member of VISA, MasterCard and/or any other networks, as applicable, that provides sponsorship services in
connection with this Agreement. As of the Effective Date, the Member Bank shall be Fifth Third Bank, an Ohio banking corporation.
“Merchant Agreement ” means the Merchant Services Agreement the form of which is attached hereto as Exhibit J to be entered into between
Company and each Sublicensed Customer that purchases any Merchant Processing Services (except in connection with a sale of PIMS directly or
indirectly by Company). Company may update the Merchant Agreement from time-to-time to incorporate such future revisions as required or requested
by the Member Bank provided that Company also makes those revisions to agreements with Company’s other merchant processing services customers;
and further provided that the Merchant Agreement’s terms and conditions shall not be less favorable than those that the Company typically offers to
customers similar to the proposed Sublicensed Customers.
“Merchant Application ” means the merchant application the form of which is attached hereto as Exhibit K, that must be completed by a proposed
Sublicensed Customer that intends to purchase any Merchant Processing Services and which is accepted by Company prior to Sublicensed Customer
product activation. Company may update the Merchant Application from time-to-time to incorporate such future revisions as required or requested by
the Member Bank , provided that Company also makes those revisions to merchant applications with Company’s other merchant processing services
customers; and further provided that the Merchant Application’s terms and conditions shall not be less favorable than those that the Company typically
offers to customers similar to the proposed Sublicensed Customers.
“Merchant Processing Services ” means the Company’s services that authorize and settle payment transactions directly or indirectly through
Member Banks for customers through (1) the POS Dashboard; (2) the default Phreesia Gateway card processing platform for any of Allscripts other
embedded payment products; (3) a Third Party Gateway for transactions received from or posted to an Allscripts service or product for customers who
want to use a separate financial institution for back-end processing; and (4) Phreesia Patient Intake Management Offering. The Merchant Processing
Services are subject to the terms and conditions of the Merchant Agreement, the Operating Regulations and applicable Law. The Merchant Processing
Services are further described on Exhibit A attached hereto. Merchant Processing Services may be provided by Company in conjunction with the
Subscription Software Services but are not, for purposes of this Agreement, deemed Subscription Software Services.
4“Merchant Processing Services Customer ” means an Allscripts Customer excluding Legacy Customers that contracts with the Company for and
receives the Company’s Merchant Processing Services. For the sake of clarity, a Merchant Processing Services Customer (i) may also be a Sublicensed
Customer or (ii) may purchase Merchant Processing Services in connection with its purchase of PIMS from the Company.
“Open Source License ” means an open source license applicable to Open Source Software.
“Open Source Software” means any open source software program, or portion thereof, that is licensed under an Open Source License that requires
as a condition of use, modification, and/or distribution of the software subject to the license, that such software or other software combined and/or
distributed with such software be (i) disclosed or distributed in source code form; (ii) licensed for the purpose of making derivative works; or (iii)
redistributable at no charge (including the GNU General Public License (GPL), GNU Lesser General Public License (LGPL), Mozilla Public License (MPL),
BSD licenses, the Artistic License, the Netscape Public License, the Sun Community Source License (SCSL), the Sun Industry Standards License (SISL),
and the Apache License).
“Operating Regulations ” means the by-laws, operating regulations and/or all other rules (including, without limitation, Bank Rules), guidelines,
policies and procedures of VISA, MasterCard, Discover, and/or Other Networks, and all other applicable rules, regulations and requirements of Member
Bank, banks, and financial institutions which govern or affect any Merchant Processing Services provided under a Merchant Processing Agreement, and
all state and federal laws, rules and regulations which govern or otherwise affect the activities of providers of Merchant Processing Services, including,
but not limited to, those of the National Automated Clearing House Association (“ NACHA”) and the Federal Trade Commission (“FTC”), as any or all of
the foregoing may be amended and in effect from time to time.
“Partnering Organization” means a hospital, health plan, provider group, provider-hospital organization, independent practice association (IPA),
accountable care organization (ACO), health information organization (HIO), Comprehensive Primary Care Initiative group (CPC), billing service provider,
or integrated healthcare delivery system that provides management services and administrative systems.
“Payerpath ” means Allscript’s patient payment and claims solution currently marketed and sold by Allscripts as “Payerpath” (as the same may be
renamed, enhanced or expanded from time to time).
“Person ” means any natural person, corporation, limited liability company, general partnership, limited partnership, trust, proprietorship, joint
venture, business organization, or government, political subdivision, agency, or instrumentality.
“Phreesia Patient Intake Management Offering ” or “PIMS” means Phreesia’s offering with and only with those features and functions as are
generally available to Allscripts Customers on the Effective Date. PIMS features are summarized on Exhibit A, but that summary is qualified in its entirety
by reference to PIMS’ actual features that are generally available to Allscripts Customers on the Effective Date. [***].
“POS Dashboard” means the Company’s web portal Point of Service (POS) Dashboard that may be used to process credit and debit card payment
transactions (as the same may be renamed, enhanced or expanded from time to time). The POS Dashboard is further described on Exhibit A attached
hereto.
5“Purchase Order” means a purchase order or other ordering document signed and issued by Allscripts to order Subscriptions to be resold and
distributed or made available to a Sublicensed Customer, which specifies, at a minimum, (a) the date the applicable Customer Agreement was executed; (b)
the name and address of the Sublicensed Customer; and (c) the Installed Software and Subscription Software Services licenses, Merchant Processing
Services and Services being ordered, and further establishes that the Installed Software and Subscription Software Services (and associated
Documentation) are governed by the Customer Agreement.
“Representatives ” means a Party’s Affiliates, and each of their respective employees, officers, directors, partners, shareholders, agents, attorneys,
and third-party advisors.
“Services” means, collectively, the Implementation Services as described in Exhibit C and the Support Services as described in Section 12.1(b).
“Sublicensed Customer ” means an Allscripts Customer that has purchased a Subscription from Allscripts or its Affiliates or that has entered into a
Merchant Agreement with Company (except in connection with a sale of PIMS directly or indirectly by Company).
“Subscription” or “subscription ” shall mean the right of a Sublicensed Customer to access and use the Subscription Software Services as more
fully set forth in this Agreement.
“Subscription Software Services ” means the Company’s subscription-based software services consisting of the Eligibility and Benefit Services
and/or POS Dashboard (as each may be renamed, enhanced or expanded from time to time), including any Updates thereto. Subscription Software
Services contains functions and features that enable Sublicensed Customers to authorize and settle payment transactions directly or indirectly through
Member Banks, but in order for such functions and features to be operational, Sublicensed Customers must obtain Merchant Processing Services from
Phreesia or similar services from a third party through Phreesia’s Third Party Gateway. Notwithstanding anything to the contrary herein, Subscription
Software Services do not include other Company products or services including, without limitation, the Phreesia Patient Intake Management Offering.
“Territory” means [***].
“Update” means any revision, modification, upgrade, or new feature, functionality, module, or release of the Installed Software, Subscription
Software Services or Merchant Processing Services, and any patch, bug fix, workaround, or Error correction to the Installed Software or Subscription
Software Services (whether created specifically for Allscripts or released by the Company), that Company is required to provide under this Agreement or
that Company generally makes available at no additional charge to the Company’s other eligibility and benefit services and point of service dashboard
customers and licensees. Updates may be customer facing (i.e. updates that are directly displayed to the customer such as new features, etc.) or non-
customer facing (such as bug fixes or workarounds that are not directly displayed to the customer).
2. Appointment as Reseller.
2.1 Appointment . The Company hereby [***]. Allscripts may also disclose Company’s pricing information relating to its Merchant Processing
Services and facilitate procurement of Merchant Processing Services on behalf of Sublicensed Customers, including, without limitation by references to
such pricing information and Merchant Processing Services in Customer Agreements.
62.2 Customer Agreements .
(a) Subscriptions . Allscripts and its Affiliates may sell Subscriptions for terms no less than one year and no greater than four (4) years on a
subscription basis to Persons who subsequently execute a Customer Agreement, provided that Allscripts may enter into Customer Agreements with
terms longer than four  (4) years with large organizations, provided that Phreesia consents in each instance in writing in advance, which consent will not
be unreasonably withheld.
(b) Customer Agreements . Each Customer Agreement will contain terms, in all material respects, no less protective of the Company and its licensors
than the applicable terms and conditions related to Allscripts’ applicable products and services. Each Customer Agreement shall, at a minimum, restrict
Customers from redistributing, reverse engineering, reverse compiling, or disassembling the Installed Software and the Subscription Software Services.
Allscripts will use commercially reasonable efforts to enforce the terms of its Customer Agreement that protect Company’s Intellectual Property at
Allscripts sole cost and expense.
2.3 Merchant Agreements; Pre-approval. All proposed Sublicensed Customers who wish to purchase Merchant Processing Services must complete
a Merchant Application, execute a Merchant Agreement and be Pre-approved  by the Company. “Pre-approved”  shall mean that the Company has
determined based on a proposed Customer’s Merchant Application that the proposed Customer meets OFAC and Member Bank criteria and the
Company’s credit standards (collectively, the “Criteria”). “Rejection” shall mean the Company has not Pre-approved  the proposed Merchant Processing
Services Customer. [***]. Allscripts shall not represent to any prospective Sublicensed Customer that a Merchant Application will be approved.
Company may terminate any Merchant Agreement pursuant to the terms of such Merchant Agreement. All Merchant Processing Services shall be
marketed under Company’s Marks. For avoidance of doubt, Allscripts may market the Subscription Software Services, including without limitation, the
electronic cashiering features and functionality of the Subscription Software Services under the Allscripts name.
2.4 Third Parties. Allscripts will not authorize or allow any value added reseller, distributor, integrator, OEM partner, or other third party to market,
demonstrate, resell, sublicense, or otherwise distribute or make available the Installed Software, Documentation or Subscription Software Services, or
Merchant Processing Services except that Allscripts is permitted to (a)  sign Customer Agreements with Sublicensed Customers who are Partnering
Organizations who, in turn, distribute or make available the Installed Software, Documentation or Subscription Software Services to (or facilitate the
procurement of Merchant Processing Services for) their respective medical staffs, provider participants, or members as permitted under applicable Law, so
long as each such medical staffs, provider participants, and members are bound by the terms and conditions of the applicable Customer Agreement; and
(b) exercise its rights under this Section  2 through Company approved value added resellers appointed by Allscripts from time to time (“Allscripts
Resellers”); provided, however, that each Allscripts Reseller must enter into an agreement with Allscripts that is at least as protective of the Company
and the Installed Software, Documentation, and Subscription Software Services as this Agreement. Allscripts will use commercially reasonable efforts to
enforce the terms of Allscripts Resellers’ agreements that protect Company’s Intellectual Property. For avoidance of doubt, Allscripts may not delegate to
Allscripts Resellers any rights that it does not have under this Agreement.
2.5 Affiliates. To the extent that Allscripts’ Affiliates, Partnering Organizations, and Allscripts Resellers utilize the rights granted hereunder,
Allscripts will require such parties to comply with the restrictions on such rights set forth in this Agreement, and any non-compliance with such
restrictions by such parties shall be deemed a breach of such restrictions by Allscripts, provided that third party Partnering Organizations and Allscripts
Resellers shall not be required to comply with the restrictions set forth in Section  5 [***].
72.6 No Other Rights. Except as specifically set forth in this Agreement, no other rights or entitlements are granted by the Company to Allscripts
with respect to the Installed Software, Documentation, Subscription Software Services, Merchant Processing Services or Services. All rights not
expressly granted hereunder are reserved by the Company and/or its third party licensors.
2.7 Acknowledgments .
(a) The Parties acknowledge and agree that this Agreement is non-exclusive (except as set forth in Section 5) and imposes no limitations upon
either Party’s relationships with other parties or on either Party’s research, development, production, marketing, licensing, reselling, or sales of other
products or services, whether or not similar to any of the Installed Software or the Subscription Software Services or Merchant Processing Services or
any Allscripts products or services, so long as such relationships or activities do not violate any express term of this Agreement or utilize any
Confidential Information of the other Party in violation of this Agreement.
(b) [***]. In no event will anything in this Agreement be construed as an obligation on Allscripts’ part to (i)  incorporate the Installed Software or
Documentation into Allscripts products or services or (ii)  market, promote, distribute or make available the Installed Software or Subscription Software
Services or Merchant Processing Services, [***].
(c) Notwithstanding [***] Allscripts or its Affiliates may, in its sole discretion, develop, market, provide, offer, sell or resell, directly, or indirectly
through its resellers, Other Services (as defined in Section 5) to interface with Allscripts Payerpath or Allscripts Practice Management [***]. In no event
shall Allscripts directly or indirectly utilize any of the Company’s Installed Software, Subscription Software Services or Confidential Information in
connection with any development activities described above in this Section 2.7(c).
2.8 Marketing Materials. The Company agrees to work with Allscripts to develop the initial set of marketing communications materials related to the
Subscription Software Services or Merchant Processing Services (“Company Marketing Materials”). At the time such Company Marketing Materials are
first distributed, each party must consent to their content, [***]. Allscripts must replicate all Company copyright notices on all copies of the Company
Marketing Materials (and all customized versions thereof).
2.9 Forecast . Allscripts will provide Company with a non-binding  [***] sales forecast for Allscripts’ sales of eligibility and payment processing
solutions during [***] within [***] of the Effective Date.
3. Services. Exhibit G sets forth the Amended and Restated Developer Program Agreement (the “Restated Developer Agreement”) in place between
Allscripts and Company, which replaces in its entirety the Developer Agreement. The Restated Developer Agreement is hereby incorporated into this
Agreement as if fully set forth herein and made part hereof.
3.1 Development and Integration .
(a) Within [***] of the Effective Date, Allscripts and the Company will reasonably cooperate to create a mutually satisfactory, sufficiently detailed,
written specification (the “ Integration Specification ”) that describes the desired level of functional integration between Allscripts Payerpath and
Allscripts Practice Management and the Subscription Software Services, along with the technical details and delivery dates (preliminarily defined in
Exhibit B) related to achieving the functional integration as set forth in Exhibit G.
8(b) The Company and Allscripts will each commit appropriate resources needed to complete their respective responsibilities with respect to the
functional integration indicated by the Integration Specification as further described in Exhibits A and B hereto. The Company and Allscripts will each
have the development and integration responsibilities assigned to it and described in the Integration Specification and will each be responsible for their
respective costs associated with such responsibilities and in performing all other tasks assigned to it under the Integration Specifications. The Company
and Allscripts will each use commercially reasonable efforts to complete their respective responsibilities in the Integration Specification within the time
frames set forth in Exhibit B.
(c) Beta Testing. The parties anticipate that there will be up to [***] beta test sites testing the Subscription Software Services. Regardless of when
the testing began or begins, Allscripts will be the primary deployment resource for each of the beta test sites as well as the first [***] implementations of
the Subscription Software Services, as applicable, for Allscripts’ Sublicensed Customers.
3.2 Implementation Services. Allscripts will be responsible for providing Implementation Services for the Installed Software and the Subscription
Software Services (but not implementation for the Phreesia Patient Intake Management Offering, which shall be Phreesia’s responsibility) distributed or
made available hereunder. At Allscripts’ request and direction, on a per-Sublicensed Customer basis, the Company will provide such Implementation
Services directly to such Sublicensed Customer or through Allscripts in exchange for fees set forth in Exhibit  C.
3.3 Provision and Quality of Services . To the extent the Company is required to provide Services under this Agreement, the Company will provide
those Services [***].
3.4 Personnel . [***]. The Parties agree to use their reasonable efforts to promptly resolve any good faith complaints regarding any of the
Company’s personnel, or otherwise concerning the value or efficacy of any Services performed by or on behalf of the Company.
3.5 Books and Records . As applicable under the Omnibus Reconciliation Act of 1980, until the expiration of four  (4) years after the furnishing of
Services pursuant to this Agreement, the Company will, upon receipt of written request, and if then requested to make such information available under
the then-existing Law, make available to the Secretary of the U.S. Department of Health and Human Services, the Comptroller General of the U.S.
Department of Secretary of Health and Human Services, or any of their fully-authorized representatives, the books, documents, and/or records of the
Company that are necessary to verify the nature and extent of costs associated therewith. The record keeping and disclosure provisions of this Section
3.4 will apply to all Services provided by the Company, but will be applicable only if the Company receives remuneration in the amount of $10,000 or more,
with regard to the Services performed in relation to a single Sublicensed Customer.
4. Order and Acceptance.
4.1 Order Process . In order to activate Merchant Processing Services for a Merchant Processing Services Customer, the proposed Merchant
Processing Services Customer must submit (directly or indirectly through Allscripts) a completed Merchant Application and executed Merchant
Agreement to the Company within [***] from the execution by such Merchant Processing Services Customer of a Customer Agreement. Within [***] of
the modification or termination (other than sublicenses that expire at the end of a term previously specified in a Purchase Order) of any Customer
Agreement, Allscripts will provide the Company with written notice of such modification or termination. This Section 4.1 shall not be applicable to
situations where the Allscripts Customer is purchasing Merchant Processing Services in connection with its purchase of PIMS.
94.2 Distribution; Commencement of Subscription Software Services . [***]. Subject to the terms of this Agreement, the terms and conditions relating
to the provision of Merchant Processing Services to Sublicensed Customers, including but not limited to commencement thereof, shall be set forth in the
Merchant Application and Merchant Agreement. [***].
4.3 Configuration and Acceptance .
(a) As part of the Implementation Services, the Company agrees to assist Allscripts in conducting configuration and acceptance testing of the
Subscription Software Services, if and as requested or required by a Sublicensed Customer, in order to ensure that the Subscription Software Services are
fully operable, meet all applicable specifications, and will function in accordance with the Documentation when properly installed and used for its
intended purpose.
(b) In the event of final rejection by Allscripts or a Sublicensed Customer as a result of the Company’s breach of this Agreement, including, without
limitation, a breach of the Company’s representations and warranties in Sections 21.1 and 21.3, if any payments hereunder have already been made by
Allscripts to the Company regarding such Sublicensed Customer, and if Allscripts provides a refund to such Sublicensed Customer based on such
Customer’s rejection of the Subscription Software Services, then the Company will provide Allscripts with a refund of the applicable payment within
[***].
5. [***].
6. FollowMyHealth. When Allscripts refers its FollowMyHealth customers to merchant processing service providers, it may include Phreesia among the
providers referred. [***].
7. Contacts.
7.1 Relationship Contacts . Concurrently with the execution of this Agreement, each Party has designated an individual to serve as that Party’s
initial point of contact to facilitate communications between the Parties on all matters (e.g., marketing, maintenance and support, technical, customer
satisfaction, sales pipeline) that may arise under this Agreement. The initial Allscripts relationship contact is [***] and the initial Company relationship
contact is [***]. Each Party may change its respective relationship contact at any time upon written notice to the other Party.
7.2 Issues . In the event of any issues that may arise pursuant to this Agreement, the Parties’ relationship contacts may confer to resolve such
issues, it being understood that this will not preclude any Party from initiating dispute resolution proceedings pursuant to Section 28.9.
8. Licenses and Intellectual Property.
8.1 License Grant. Subject to the terms and conditions of this Agreement, the Company hereby grants to Allscripts and its Affiliates a non-
exclusive, royalty-free, irrevocable [***] non-transferable (except in accordance with Section 28.4), sublicensable (through multiple levels of
sublicensees), fully paid-up right and license under all of the Company’s Intellectual Property to, throughout the Territory, access, use, reproduce,
perform, display, modify, create derivative works of, transmit, demonstrate, test, operate, port, configure, distribute, and make available the Installed
Software and Subscription Software Services solely for the purposes of:
(a) Allscripts’ and its Affiliates’ internal use of the Installed Software and Subscription Software Services as permitted hereunder, including with
respect to its marketing, selling, development, service, and support activities under this Agreement, and including the training of Allscripts employees,
contractors, and other authorized Representatives on the marketing, selling, planning, supporting, and use of the Installed Software, Subscription
Software Services or any integrated product with any Allscripts products and services;
10(b) the marketing, promoting, distributing, reselling, or provision of the Installed Software or the Subscription Software Services, directly or through
Allscripts Resellers or Partnering Organizations, in accordance with the terms and conditions of this Agreement;
(c) enabling Allscripts products and services to interface or otherwise integrate, interact, or interoperate with the Installed Software and the
Subscription Software Services , including performing any integration or interface development efforts with respect to the Installed Software,
Subscription Software Services or any integrated product with any Allscripts products and services, or internally testing, evaluating, and performing
validation and verification with respect to the Installed Software, Subscription Software Services or any integrated product with any Allscripts products
and services (it being understood that the foregoing activities will not affect the Company’s representations and warranties in Section 21);
(d) reselling Subscriptions (through multiple levels of sublicensees) to (i)  Sublicensed Customers pursuant to Customer Agreements in accordance
with this Agreement and (ii) Allscripts’ Affiliates or to Allscripts Resellers or Partnering Organizations (subject to Sections 2.4 and 2.5) to carry out any of
the purposes set forth in this Agreement;
(e) creating backups and other copies of the Installed Software solely to the extent necessary to perform its obligations hereunder in the ordinary
course of business;
(f) managing, operating, and hosting (i)  any Installed Software, (ii) the Allscripts products that will interface with the Installed Software or
Subscription Software Services on behalf of Sublicensed Customers and (iii)  authorizing its Sublicensed Customers, Allscripts Resellers or Partnering
Organizations to do the same;
(g) generating, printing, copying, downloading, and storing all Data and other displays and output, as may result from any execution or other use
of the Subscription Software Services and authorizing its Sublicensed Customers, Allscripts Resellers or Partnering Organizations to do the same; and
(h) all other purposes reasonably necessary to carry out any of the foregoing.
For the sake of clarity, the Subscription Software Services shall be hosted, managed and operated by Company.
8.2 Documentation and Marketing Materials . Subject to the terms and conditions of this Agreement, the Company hereby grants to Allscripts a
non-exclusive, royalty-free, irrevocable , non-transferable (except in accordance with Section  28.4), sublicensable (through multiple levels of
sublicensees), fully paid-up right and license under all of the Company’s Intellectual Property to access, use, reproduce, perform, display, transmit,
demonstrate, test, operate, port, configure, distribute, and make derivative works of the Documentation, Company Marketing Materials and Allscripts
Marketing Materials, in whole or in part, throughout the Territory, for any purpose consistent with Section 8.1, [***].
8.3 Trademarks.
(a) Company Marks.
11(i) Subject to the terms and conditions of this Agreement, the Company hereby grants to Allscripts and its Affiliates a non-exclusive, royalty-
free, irrevocable [***] non-transferable  (except in accordance with Section 28.4), sublicensable (through multiple levels of sublicensees), fully paid-
up right and license under all of the Company’s Intellectual Property to use the Company’s brands, trademarks, product and service names, logos
and slogans (the “ Company Marks”), throughout the Territory, solely in connection with the marketing, selling, or provision of the Installed
Software and the Subscription Software Services and Merchant Processing Services permitted hereunder or to otherwise fulfill the terms of this
Agreement. [***].
(ii) Except as set forth in Section 11.3, Allscripts’ use of the Company Marks will be in accordance with the Company’s trademark use
guidelines and instructions as set forth in Exhibit I. The Company will give Allscripts written notice of any changes to such specifications or
guidelines, and will give Allscripts a reasonable time to modify its use of the Company Marks to comply therewith.
(iii) Allscripts is not required to display any Company- Marks on its products or marketing collateral, provided that the Subscription Software
Services shall be characterized as “Powered by Phreesia” and shall contain a Phreesia logo. All goodwill in and to the Company Marks will inure
solely to the benefit of Company.
(b) Allscripts Marks .
(i) Subject to the terms and conditions of this Agreement, Allscripts hereby grants to the Company a non-exclusive, royalty-free, irrevocable
[***] non-transferable (except in accordance with Section 28.4), fully paid-up right and license under all of Allscripts’ Intellectual Property to use
the Allscripts Marks, throughout the Territory, solely in connection with providing the Installed Software and Subscription Software Services to
Sublicensed Customers who have signed a Customer Agreement and to otherwise fulfill the terms of this Agreement.
(ii) The Company’s use of the Allscripts Marks will be in accordance with Allscripts’ trademark use guidelines and instructions, if any,
furnished to the Company in writing from time to time. Allscripts will give the Company written notice of any changes to such specifications or
guidelines, and will give the Company a reasonable time to modify its use of the Allscripts Marks to comply therewith.
(iii) The Company is not required to display any Allscripts Marks on any of its products or marketing collateral. All goodwill in and to the
Allscripts Marks will inure solely to the benefit of Allscripts. The Company will not register, seek to register, or contest the validity of any of the
Allscripts Marks in any jurisdiction.
8.4 Restrictions on Use . Except as and to the extent expressly permitted by this Agreement and/or the Integration Specification, Allscripts will not,
and will not permit others to:
(a) reverse engineer, disassemble, decompile, decode, or adapt the Installed Software or Subscription Software Services, or otherwise attempt to
derive or gain access to the source code or algorithms of the Installed Software or Subscription Software Services, in whole or in part, except [***];
(b) rent, lease, assign, or sell the Subscription Software Services or Installed Software to any third party (other than the physical media (if any)
containing any Installed Software distributed by Allscripts);
12(c) use any of the Installed Software or Subscription Software Services to provide time sharing or service bureau services to third parties, other
than Sublicensed Customers;
(d) remove, obscure, or alter from the Installed Software, Subscription Software Services, Documentation or the Marketing Materials any applicable
titles, trademarks, or copyright, patent, or other proprietary or restrictive legends or notices, or any end user warning or advisory, affixed to or contained
therein or thereon;
(e) export or re-export all or any part of the Installed Software or Subscription Software Services in violation of any export control Laws of the
United States or any other relevant jurisdiction;
(f) modify, correct, adapt, translate, enhance, or otherwise prepare or create any derivative works or improvements of the Installed Software or
Subscription Software Services; provided , [***]
(g) (1) provide any materials to Company (including without limitation, the SDK (as defined in the Restated Developer Agreement) or Associated
Allscripts Software (as defined in the Restated Developer Agreement)) that contains any Harmful Code or any Open Source Software or (2)  upload any
materials into the Installed Software or Subscription Software Services that contains any Harmful Code or any Open Source Software.
8.5 Intellectual Property Ownership .
(a) Subject to the express rights and licenses granted by the Company in this Agreement and the provisions of this Section 8.5, the Company and
its licensors reserve and retain their entire right, title, and interest (including Intellectual Property rights) in and to the Installed Software, the Subscription
Software Services, the Merchant Processing Services, the Documentation, the Company Marketing Materials, and the Company Marks, and all
modifications, improvements, enhancements and derivatives of the foregoing (including, subject to Section 8.4(f), any modifications, improvements,
enhancements and derivatives thereto developed or performed by or on behalf of Allscripts). At no time will Allscripts, Allscripts Resellers, Partnering
Organizations, or Sublicensed Customers acquire or retain any title to or ownership to such assets, except as expressly granted under this Agreement.
(b) Subject to the express rights and licenses granted by Allscripts in this Agreement, Allscripts and its licensors reserve and retain their entire
right, title, and interest (including Intellectual Property rights) in and to any modifications, improvements, or derivative works it creates or develops based
on the Documentation or the Company Marketing Materials as authorized under this Agreement ( e.g., any Documentation or Marketing Materials
integrated with Allscripts documentation), as well as to all Allscripts products and services. At no time will the Company acquire or retain any title to or
ownership to such assets, except as expressly granted under this Agreement.
(c) Ownership of all Intellectual Property in Open Source Software will remain with respective owners thereof, subject to Allscripts’ rights under the
applicable Open Source Licenses.
(d) Neither Party will take any action inconsistent with a Party’s nor its licensors’ ownership and interests set forth in this Section 8.5, or assist any
Person in doing the same.
8.6 Data. As between Allscripts, its licensors and Affiliates, and Sublicensed Customers, on the one hand, and the Company and its licensors and
Affiliates, on the other hand, Allscripts, its licensors and Affiliates, and Sublicensed Customers have, reserve, and retain sole and exclusive ownership to
all right, title, and interest in and to all Data, including all Intellectual Property arising therefrom or relating thereto. [***]  have any right or license to, and
shall not, use any Data except solely as and to the extent necessary to [***].
138.7 Open Source Software. The Company has not, and will not, use, modify, or distribute any Open Source Software in a manner that could (a)
require the disclosure, licensing, or distribution of any source code or algorithms underlying any of the Installed Software or any software into which it is
integrated; (b) require the licensing or disclosure of the Installed Software or any software into which it is integrated free of charge; or (c) otherwise
impose any limitation, restriction, waiver of rights, or condition on the right or ability of the Company to use or distribute the Installed Software or any
software into which it is integrated.
8.8 Effect of Company Bankruptcy.
(a) All rights and licenses granted by the Company under this Agreement are and shall be deemed to be rights and licenses to “intellectual
property,” and the subject matter of this Agreement, including all Installed Software, Subscription Software Services Documentation, Company Marketing
Materials, and Company Marks, is and will be deemed to be “embodiment[s]” of “intellectual property,” for purposes of and as such terms are used in and
interpreted under Section 365(n) of the United States Bankruptcy Code (the “ Bankruptcy Code ”). Allscripts will have the right to exercise all rights and
elections under the Bankruptcy Code and all other applicable bankruptcy, insolvency, and similar Laws with respect to this Agreement, and the subject
matter hereof and thereof.
(b) Without limiting the generality of the foregoing, the Company acknowledges and agrees that, if the Company or its estate becomes subject to
any bankruptcy or similar proceeding:
(i) subject to Allscripts’ rights of election, all rights and licenses granted to Allscripts under this Agreement will continue subject to the
respective terms and conditions hereof and thereof, and will not be affected, even by the Company’s rejection of this Agreement; and
(ii) Allscripts will be entitled to a complete duplicate of (or complete access to, as appropriate) [***].
9. [intentionally left blank].
10. Training.
10.1 Training. The Company will provide, [***] periodic training for Allscripts personnel in connection with this Agreement, with the first such
training [***] (such training, the “First Training”). The Company agrees to dedicate sufficient resources in connection with such training. Such training
may be for the benefit of Allscripts personnel either as to Allscripts’ permitted activities under this Agreement or to assist the Sublicensed Customers.
Such training will be provided at such reasonable times and locations (including via remote means) as the Parties may reasonably agree. Such training will
include, but is not limited to, sales and ongoing support training to Allscripts staff. The goal of this training will be to enable Allscripts’ sales personnel
to articulate the benefits of the Services and provide basic functional demonstrations to prospective Sublicensed Customers.
10.2 Support Training. In furtherance of Section 10.1, the Parties agree to cooperate in developing any training programs as may be reasonably
necessary or useful to the provision of Support Services to Sublicensed Customers, which will be provided in a “train the trainer” format. Such programs
will, at a minimum, provide Allscripts personnel with the ability to answer or appropriately refer questions about the Installed Software, Subscription
Software Services or Merchant Processing Services and the Services. Such support training will include up to [***] each year of support training for
Allscripts’ staff adequate to enable Allscripts to provide first line support services to Sublicensed Customers as further defined in the Implementation
and Support Plan.
1411. Marketing.
11.1 Sales and Marketing Support . [***] the Company will provide [***] marketing support for the permitted activities hereunder, which will
include, the following:
(a) assisting Allscripts in developing marketing strategies, plans, and marketing and training materials describing the Installed Software,
Subscription Software Services or Merchant Processing Services or the Services as a complementary solution to any Allscripts product or service;
(b) providing Allscripts with a reasonable quantity of standard Company brochures, presentations, and materials related to the Installed Software,
Subscription Software Services or Merchant Processing Services, the Services and/or the Company in hard copy and electronic form; and
(c) participating in sales meetings with Allscripts sales and/or actual or potential Sublicensed Customer personnel.
11.2 Demonstration Systems . [***], the Company will provide fully-functional demonstration systems or accounts for the Subscription Software
Services, equivalent to those systems made available to the Company’s sales personnel, for use by Allscripts’ sales personnel. Each Party will provide all
commercially reasonable assistance, cooperation, and support requested by the other Party to maintain demonstration systems sufficient to demonstrate
the Installed Software and the Subscription Software Services as integrated with any Allscripts products or services. Each Party will be responsible for its
own costs and expenses in designing, developing, testing, and maintaining such demonstration systems.
11.3 Branding. Branding of the Installed Software and the Subscription Software Services, but not the Merchant Processing Services with respect
to the activities hereunder will be determined [***] Allscripts elects to private label or rebrand the Software Subscription Services, the relabeled or
rebranded [***].
11.4 Request for Proposals . Allscripts may, in its sole discretion, recommend the Subscription Software Services or Merchant Processing Services
and the Services as part of Allscripts’ response to requests for proposals issued by third parties. [***].
11.5 Demonstrations . The Company at its own discretion will provide demonstrations of the Subscription Software Services and Merchant
Processing Services at Allscripts-identified marketing events and activities, including user group meetings or conferences. In addition, either Party may,
from time to time, request that the other Party attend and participate at vendor fairs and industry trade shows, seminars, user group events, and other
similar events. The decision of whether or not to attend such functions will be in the sole discretion of the non-requesting  Party.
12. Support and Maintenance.
12.1 Support Services .
(a) The Company is solely responsible for the development, update, performance, and maintenance of the Subscription Software Service. The
Company covenants to use its best efforts to ensure that the Subscription Software Services are made available to Allscripts and each Sublicensed
Customer and that support for Merchant Processing Services are made available to each Sublicensed Customer in accordance with the warranties, terms,
and conditions of this Agreement and in accordance with any performance standards specified in this Agreement or in the Documentation. [***].
15(b) In furtherance of Section 12.1(a), the Company agrees to provide, at no additional charge to Allscripts or Sublicensed Customers [***] technical
support, assistance, training, and Updates related to the Installed Software or Subscription Software Services or Merchant Processing Services
(collectively, “Support Services ”), in the manner and timeframes set forth on Exhibit D, to Allscripts and its consultants and contractors and, if requested
by Allscripts, directly to Sublicensed Customers. [***]. The parties agree to reasonably cooperate to troubleshoot and resolve technical support issues
that may reasonably involve the products, software, or technology of the other Party or of both Parties. This Section 12.1(b) shall not be applicable to
Merchant Processing Services that an Allscripts Customer receives in connection with its purchase of PIMS.
12.2 Support Levels . Allscripts will provide the first level of support to Sublicensed Customers related to the Installed Software and Subscription
Software Services and their integration with applicable Allscripts products. The first level of support is defined in Exhibit C. [***]. Allscripts, at its sole
expense, will provide the second and all escalating levels of support for all technical issues and upgrades relating to Allscripts products. [***].
12.3 Integration Support . At the Company’s expense and no additional charge to Allscripts, from time to time the Company will provide Allscripts
with reasonable remote integration and implementation assistance, including, without limitation, upon addition of a new or updated Installed Software or
Subscription Software Services under this Agreement.
12.4 Documentation . The Company has delivered or made available to Allscripts complete and accurate Documentation for the Installed Software,
Subscription Software Services and that required to offer the Merchant Processing Services, and will promptly deliver or make available to Allscripts
supplements to such Documentation and manuals, as and when released, to reflect all modifications, releases, supplements, corrections, Updates,
amendments, and other changes to the Installed Software or Subscription Software Services or that required to offer the Merchant Processing Services.
The Company will provide all Documentation in electronic form, in such formats and media as Allscripts may reasonable request. The Company agrees
that all Documentation will include all technical and functional specifications and other such information as may be reasonably necessary for the effective
installation, testing, use, support, and maintenance of the Installed Software and Subscription Software Services other than the Merchant Processing
Services, including the effective configuration, integration, and systems administration of the Installed Software, Subscription Software Services other
than the Merchant Processing Services and the operation and the performance of all its functions.
13. Updates.
13.1 Updates . [***] (either directly or through Allscripts, at Allscripts’ direction) with Updates , either in response to specific requests from
Allscripts to remedy Errors (consistent with the Error correction timing in Exhibit C), or as such Updates are released or generally made available [***].
For the avoidance of doubt, Updates will constitute Installed Software or Subscription Software Services (as applicable) and be subject to the terms and
conditions of this Agreement. With respect to the Merchant Processing, [***].
1613.2 Restrictions on Updates .
(a) With respect to any material customer facing Update that does not relate to Merchant Processing Services, the Company will provide Allscripts
[***] notice before releasing any such Update (except for Error corrections or fixes which may be released earlier). At least [***] before releasing any
such customer facing Update (except for Error corrections or fixes which may be released earlier), the Company will provide Allscripts with (i) technical
documentation of such Update; (ii) commercially reasonable technical assistance and training for such Update; and (iii) a functional, updated
demonstration version of the Subscription Software Services (and for any Update made available via remote access, a testing environment), which will be
sufficient to enable Allscripts to test the applicable Subscription Software Services and Allscripts products and services with respect to such Update.
[***].
(b) The Company agrees to use its best efforts to resolve all support issues (pursuant to Exhibit D) relating to an Update that the Parties classify as
“Critical” or “High” (as on Exhibit D) before releasing such Update.
13.3 Compatibility. With respect to any upgrades, updates, or modifications [***].
13.4 Changes to Merchant Processing Services . The Company may make revisions to the Merchant Processing Services, [***].
14. Other Covenants.
14.1 Insurance .
(a) At the Company’s expense, the Company will maintain policies of insurance with insurance companies having a financial strength rating no
lower than “A” and a size category not lower than “XII” as rated by the A.M. Best Company, and in amounts which are reasonable and prudent in light of
the Company’s business, potential liabilities to Allscripts hereunder, and other relevant factors, including the following: (i) Commercial General Liability
insurance [***] (ii) Errors and Omissions insurance [***] and (iii) Workers’ Compensation insurance with applicable statutory limits.
(b) Allscripts will be named as an additional insured under the foregoing policies, each of which will be primary and non-contributory.  [***] The
Company will give Allscripts [***] notice prior to any alteration, cancellation, or non-renewal of the policies required pursuant to this Agreement;
provided , however, that the Company will not be obligated to provide such notice if, concurrently with such alternation, cancellation, or non-renewal, the
Company obtains similar or better coverage from the same or another qualified insurer, without a lapse in coverage.
14.2 No Subcontractors . Except for the performance of the Merchant Processing Services, the Company will not subcontract any of its obligations
under this Agreement to a third party, including the provision of any Services, without Allscripts’ prior written consent. Allscripts hereby consents to the
use by the Company of offshore developers with respect to the development of the Installed Software and the Subscription Software Services. The
Company will remain responsible to Allscripts for any performance of its obligations hereunder notwithstanding the permitted engagement of any such
third party. Allscripts acknowledges that the provision of the Merchant Processing Services is dependent on the services of the Member Banks.
Company shall use good faith efforts to maintain its ability to provide Merchant Processing Services, including by adhering to the rules and regulations
promulgated by Visa, Master Card and the Member Bank and using good faith efforts to maintain a current contract with the Member Bank or a
reasonably comparable substitute to enable it to fulfill its obligations hereunder. Notwithstanding anything to the contrary [***].
1714.3 Further Assurances . Each Party will, upon the reasonable request of the other Party and at the requesting Party’s sole cost and expense,
promptly execute such documents and perform such acts as may be necessary to give full effect to the terms of this Agreement.
14.4 Non-Solicitation. During the term of this Agreement and for a period of [***] thereafter, neither Party nor its controlled Affiliates will, without
the prior written consent of the other Party, directly or indirectly solicit for employment any then-current employee of the other Party or its controlled
Affiliates; [***].
14.5 Compliance with Laws. Each Party will comply with all applicable Laws and the Operating Regulations, governmental requirements, and
industry standards, including those with respect to privacy, data protection, portability, or accountability, applicable to such Party or its personnel with
respect to the Software, the Services, and the performance of its obligations under this Agreement; provided that Allscripts will have no obligation to
comply with any Operating Regulations unless such Operating Regulations are disclosed to it. Neither Party will, nor permit any third parties to, export,
re-export, or release, directly or indirectly, any Controlled Technology to any country or jurisdiction to which the export, re-export, or release of any
Controlled Technology (a) is prohibited by applicable Law or (b) without first completing all required undertakings (including obtaining any necessary
export license or other governmental approval).
14.6 [***].
15. Force Majeure.
15.1 Force Majeure. Neither Party will be liable or responsible to the other Party, nor be deemed to have defaulted under or breached this
Agreement, for any failure or delay in fulfilling or performing any term of this Agreement, when and to the extent such failure or delay is caused by (a)
acts of God; (b) flood, fire, or explosion; (c) war, terrorism, invasion, riot, or other civil unrest; (d) embargoes or blockades in effect on or after the
Effective Date or (e) any other cause or event beyond its reasonable control (each of the foregoing, a “Force Majeure Event”). The Disaster Recovery
Plan, attached hereto as Exhibit L, sets forth Phreesia’s obligations for disaster recovery preparedness and response, including among other things,
preparing for and responding to Force Majeure Events.
15.2 [***].
16. Regulatory Matters.
16.1 Privacy and Security Matters . Concurrently with the execution of this Agreement, the Parties are executing a HIPAA Business Associate
Agreement (the “BAA”) in the form attached hereto as Exhibit E.
16.2 Technical Standards . The Company will provide Allscripts with Updates so that the Subscription Software Services can be implemented and
configured to comply in all material respects with applicable privacy and security standards (e.g., HITECH, HIPAA, and Omnibus rule) within a
reasonably practicable timeframe (based on the scope of required enhancements and other factors) after their final, formal adoption and publication by
the Secretary of the U.S. Department of Health and Human Services.
16.3 Data. The Company will ensure that all protected health information (PHI), personally identifiable information (PII) or payment card information
(PCI) is (1) encrypted at rest and (2) encrypted while moving in or out of the Company’s data center.
1816.4 Interfaces . In connection with the Subscription Software Services, PIMS and the Services, the Company will use and support Unity API
interfaces that are generally available to Allscripts, and make appropriate adjustments to the Subscription Software Services to support Allscripts’
standard implementation of such interfaces. Upon the Parties’ mutual agreement, and without additional licensing fees, the Company may also use
Allscripts API services ( e.g., Unity), and Allscripts may use the Company’s APIs (as applicable).
16.5 Required Updates . The Company will provide Allscripts with Updates, if and when required, so that the Subscription Software Services
include such functionalities as are necessary to allow Allscripts and Sublicensed Customers to comply with those legal and regulatory requirements that
are binding upon Allscripts or Sublicensed Customers in their respective use of the Installed Software and Subscription Software Services or Merchant
Processing Services and that are binding standards or other requirements regarding the processing of electronic transactions that the Installed Software
and Subscription Software Services or Merchant Processing Services are designed to process, including any and all binding modifications or
replacements to such regulations. [***].
16.6 Regulatory Approvals . The Company will be solely responsible for obtaining and maintaining all licenses, permits, and approvals required by
any governmental authority with respect to the Software or the marketing, use, or distribution thereof. The Company will use reasonable diligence in
connection with the design and development of the Subscription Software Services or Merchant Processing Services to identify any such licenses,
permits, and approvals and any applicable Laws to which the Subscription Software Services or Merchant Processing Services or its use is subject. [***].
16.7 [Intentionally Omitted.]
16.8 Protected Health Information . Except as otherwise expressly provided hereunder, in connection with any transfer of protected health
information (“PHI”) between the Parties pursuant to this Agreement:
(a) each Party will transfer PHI between the Parties only through use of a dedicated connection to which the Parties are the only authorized parties
or such other method of communication, such as encrypted communication, between them;
(b) each Party will not permit any third party to use any such connection to the extent that such use is in its control, unless such third party is
providing services to such Party as permitted under this Agreement;
(c) each Party will take reasonable steps to ensure that the output display of that connection at each facility it has is limited to authorized personnel
or independent contractors of the Party; and
(d) the Company’s use of Sublicensed Customer de-identified and aggregated PHI will be limited to the rights set forth in a Business Associate
Agreement, if any, executed between the Company and the respective Sublicensed Customer. The Company has no rights to de-identify any Sublicensed
Customer PHI under this Agreement.
17. Invoicing, Reporting and Payment Terms.
17.1 Reports and Invoicing .
(a) Invoicing from Company to Allscripts .
19(i) Invoicing for Eligibility and Benefits (E&B) Services. The Company will provide Allscripts with (1) an invoice for the fees set forth on
Exhibit F for all E&B Transactions [***] and (2) a report with reasonably detailed supporting data for all such E&B Transactions by each
Sublicensed Customer, excluding Legacy Customers, [***].
(ii) Invoicing for POS Dashboard . Allscripts shall deliver a report with reasonably detailed supporting data to Company no later than [***]
for current Sublicensed Customers of the POS Dashboard. Company shall deliver an invoice to Allscripts for POS Dashboard fees in accordance
with Exhibit F no later than [***].
(iii) Invoicing for Professional Services and Travel and Expense (T&E) Reimbursement. If services are performed by Company pursuant to a
request by Allscripts for implementation, set up, training or support beyond those services that Company is required to perform under this
Agreement, including, without limitation, as set forth in Sections 10 and 11, Company will deliver an invoice for such fees at the hourly rate
described in Exhibit C and any related reimbursable expenses that Allscripts has pre-approved  no later than [***] together with reasonable
supporting detail.
(iv) Allscripts Internal Use . Notwithstanding anything to the contrary, Allscripts will not be required to make any payments to the Company
in respect of its internal use of the Installed Software or Subscription Software Services, including with respect to its use in connection with its
performing of support obligations hereunder.
(b) Invoicing from Allscripts to Company .
(i) Invoicing for Revenue Share on Merchant Processing Services . Company shall deliver a report with reasonably detailed merchant-level
payment transaction data, [***] to Allscripts [***] for Merchant Processing Services provided to Allscripts Customers, excluding Legacy
Customers. Allscripts will provide the Company with an invoice for merchant processing revenue share in accordance with Exhibit F [***].
(ii) Invoicing for Patient Intake Management Offering . Company shall deliver a report with reasonably detailed data, [***] to Allscripts [***]
for its Patient Intake Management Offering provided to Allscripts Customers, excluding Legacy Customers. Allscripts will provide the Company
with an invoice for merchant Patient Intake Management revenue share in accordance with Exhibit F, [***].
(iii) Legacy Customer’s Fee . Allscripts shall invoice the Company for Legacy Customers (as defined on Exhibit H) quarterly fees in
accordance with Exhibit F [***].
17.2 Reporting for the Purpose of Invoicing Sublicensed Customers . [***].
17.3 Payment Terms.
(a) Each party will submit each invoice in electronic format, via such delivery means and to such address as are specified by Allscripts and the
Company in writing from time to time.
(b) Subject to the terms and conditions of this Section 17.3, each party will pay all properly invoiced fees within [***] after its receipt of a proper
invoice therefor. All payments hereunder will be invoiced in U.S. Dollars. All payments hereunder will be made by wire transfer to the account specified
by each Party; provided that a Party shall provide at least [***] advance notice of any changes to its account. [***].
20(c) Subject to Section 17.3(d), Company will not withhold the Subscription Software Services or Merchant Processing Services or any Services or
fail to perform any obligation hereunder by reason of a good faith withholding of any payment or amount in accordance with this Section 17.3(c) or any
dispute arising therefrom. [***].
(d) [***].
17.4 Audit Rights .
(a) During the term of this Agreement, for the longer of [***], each Party will maintain complete and accurate (in all material respects) books and
records, in accordance with generally accepted accounting practices, regarding its sales and services activities with respect to the subject matter of this
Agreement.
(b) During the term of this Agreement, [***], each Party will have the right to engage, at its own expense, an independent auditor reasonably
acceptable to the other Party to review the other Party’s books and records solely for the purpose of confirming the other Party’s compliance with its
pricing and payment obligations hereunder. Prior to performing any audit, the independent auditor must sign a confidentiality agreement in a form
reasonably acceptable to the audited Party. Any such audit will be limited in scope to the [***] period immediately preceding the commencement date of
such audit. The auditing Party will furnish the audited Party with written notice at least [***] prior to the date that it desires to commence such audit. The
Parties will mutually agree, reasonably and in good faith, on the timeframe for such audit to be conducted. Any such audit will be conducted during the
audited Party’s regular business hours and in a manner that minimizes interference with the audited Party’s normal business activities. All information that
is disclosed in connection with such audit will be deemed to be the Confidential Information of the audited Party, and subject to this Agreement. Any
audit will be conducted in a manner that does not breach or violate any applicable Laws regarding patient confidentiality. The rights set forth in this
Section 17.4(b) may not be exercised by an auditing Party more frequently than one (1) time in any twelve (12)-month period.
(c) If any audit reveals an underpayment or over-charge by a Party, then such Party will promptly remit the full amount of such underpayment or
over-charge to the other Party.
(d) Each Party will bear all costs and expenses it incurs in connection with preparing for, conducting, or complying with any such audit including, in
the case of the auditing Party, the costs and expenses of conducting the audit.
(e) Additionally, Allscripts shall have the right to examine the development and any work-in-progress at any time upon reasonable notice to the
Company. Furthermore, [***], the Company shall provide sufficient access to its books and records as requested by Allscripts for the purpose of
verifying the Company’s compliance with its obligations relating to matters other than payment and pricing. In addition, [***], Allscripts shall provide
sufficient access to its books and records as requested by the Company for the purpose of verifying Allscripts compliance with its fee reporting and
payment obligations hereunder.
(f) Annually, the Company shall have performed, [***], a PCI assessment and a third party privacy and security assessment covering [***]
Company will make available to Allscripts via WebEx or similar web-conferencing  technology a copy of the reports from the PCI assessment and the
privacy and security assessment for Allscripts review [***] of [***]. Additionally [***], upon Allscripts’ reasonable
21request, Company shall cause the firms performing the Security Assessments to make available the personnel responsible for such audits to discuss any
adverse findings with Allscripts. Company shall perform third party external vulnerability scans [***]. All Critical or High vulnerabilities identified during
the scans shall be remediated and validated as closed by the third party scanning vendor. Company shall also perform third party penetration tests
following a major security architectural change. Company shall provide to Allscripts an executive summary of each vulnerability scan and penetration test
[***] of completion of each such scan or test. Vulnerability scans and penetration testing requirements shall commence [***]. The PCI audit, third party
Privacy and Security assessment, vulnerability scan, and penetration test shall collectively be referred to as the “Security Assessments.”
(g) Annually, Allscripts shall have performed, at its costs and expense, a third party privacy and security assessment [***]. Upon request,
Allscripts will coordinate with Company to make available to Company via WebEx or similar web-conferencing  technology a copy of the report from the
privacy and security assessment for Company review, provided that such web-conference  will not be earlier than [***].
Failure to comply with this Section shall be deemed a material breach of this Agreement.
18. Expenses; Taxes.
18.1 Expenses. Unless otherwise expressly set forth in this Agreement, each Party will bear all of its own costs and expenses incurred in connection
with this Agreement or its performance hereunder, including any development costs, sales and marketing costs, and support costs.
18.2 Taxes. All fees set forth herein are inclusive of any taxes, tariffs, duties, assessments, or governmental charges. Each Party will be responsible
for any sales tax, use tax, excise tax, import duty, export duty, or other tax, tariff, duty, assessment, or charges of any kind imposed by any governmental
entity on it as a result of any transaction contemplated by this Agreement.
19. Confidentiality.
19.1 Obligations. From time to time in connection with this Agreement, either Party (as the “Disclosing Party”) may disclose or make available to the
other Party (as the “Receiving Party”) Confidential Information. [***].
19.2 Exceptions. Confidential Information shall not include [***].
19.3 Legally Required Disclosure. Notwithstanding anything in this Section 19 to the contrary, if a Receiving Party or any of its Representatives is
required or receives a request, pursuant to applicable Law or the rules or regulations of a stock exchange or similar self-regulatory authority, to disclose
any of the Disclosing Party’s Confidential Information, then the Receiving Party agrees, to the extent legally permissible and as soon as reasonably
practicable, to provide the Disclosing Party with written notice of the event so that the Disclosing Party may, at the Disclosing Party’s expense, seek a
protective order or other remedy. The Receiving Party or its Representative (as applicable) will use its commercially reasonable efforts to consult and
cooperate with the Disclosing Party with respect to any effort by the Disclosing Party to resist or narrow the scope of such requirement or request, or to
seek such protective order or other remedy. If such protective order or other remedy is not obtained, then the Receiving Party or its Representative (as
applicable): (a) may, without liability, disclose that portion of the Disclosing Party’s Confidential Information that it is required or requested to disclose;
and (b) will use its commercially reasonable efforts to have confidential treatment accorded to the Confidential Information so disclosed. Furthermore,
Section 19 will not apply to the disclosure of Confidential Information if such disclosure is necessary to establish rights or enforce obligations under this
Agreement, but only to the extent that any such disclosure is necessary. Any information disclosed pursuant to this Section 19.3 will retain its
confidential status for all other purposes.
2219.4 Effect of Expiration or Termination. Subject to Section 25.7, upon expiration or termination of this Agreement, at the Disclosing Party’s request,
the Receiving Party will, and will cause its Representatives (and, if applicable, its Affiliates, Allscripts Resellers, and Partnering Organizations) to,
promptly return or destroy all Confidential Information received from the Disclosing Party in tangible form, together with all copies thereof, in such
Person’s possession; provided, however, that the Receiving Party may keep one (1) copy of the Disclosing Party’s Confidential Information (a) to the
extent necessary to exercise its surviving rights and perform its surviving obligations hereunder and (b) in accordance with its corporate security and/or
disaster recovery procedures, to the extent such Confidential Information is in electronic form. The Receiving Party will, upon request, promptly certify in
writing that it has complied with the obligations of this Section 19.4.
19.5 Protected Health Information . For the avoidance of doubt, the protection of PHI or other personally identifiable information received by a Party
or its Representatives hereunder will be governed by the BAA, and will not be deemed to be Confidential Information for purposes of this Agreement.
19.6 No Additional Requirements . Each Party acknowledges that the other Party or its Representatives may, currently or in the future, be
developing internally, or receiving information from other Persons, that is similar to the Confidential Information of the other Party disclosed to it or its
Representatives under this Agreement. Except as otherwise set forth in Section 5, nothing in this Agreement will prohibit any Party or its Representatives
from developing, manufacturing, marketing, selling, servicing, or supporting, or having developed, manufactured, marketed, sold, serviced, or supported
for it, products, concepts, systems, or techniques that are similar to or compete with the products, concepts, systems, or techniques contemplated by or
embodied in the other Party’s Confidential Information; provided, that neither Party nor its Representatives may use the other Party’s Confidential
Information in connection with such activities. Furthermore, neither Party nor its Representatives will have any obligation to limit or restrict the
assignment of its respective employees or consultants as a result of their having had access to the other Party’s Confidential Information.
20. Public Announcements.
20.1 Publicity. Except as may be required by applicable Law or listing standard, neither Party will issue or release any public announcement,
statement, press release, or other publicity relating to this Agreement without the prior written consent of the other Party.
20.2 Use of Marks. Unless expressly permitted by this Agreement, neither Party will use the other Party’s trademarks, service marks, trade names,
logos, domain names, or other indicia of source, origin, association, or sponsorship, without the prior written consent of the other Party.
21. Representations and Warranties.
21.1 Mutual Representations and Warranties . Each Party represents and warrants to the other Party that:
(a) it is duly organized, validly existing, and in good standing as a corporation or other entity as represented herein under the Laws of its
jurisdiction of incorporation, organization, or charter;
23(b) it has, and throughout the term of this Agreement and any Customer Agreement will retain, the full right, power, and authority to enter into this
Agreement, to grant the rights and licenses it grants hereunder, and to perform its obligations under this Agreement;
(c) its execution of this Agreement has been duly authorized by all necessary corporate or organizational action of such Party;
(d) when executed and delivered by it, this Agreement will constitute its legal, valid, and binding obligation, enforceable against it in accordance
with its terms;
(e) there is no outstanding claim, litigation, proceeding, arbitration, or investigation to which it is a party that would reasonably be expected to have
a material adverse effect on its ability to enter into this Agreement or to perform its obligations hereunder; and
(f) its execution, delivery, and performance of its obligations under this Agreement does not and will not violate any judgment, order, decree, or
applicable Law, nor does it or will it violate any agreement to which it is a party.
21.2 Company Representations and Warranties . The Company represents and warrants to Allscripts that:
(a) Company or its licensors, or their permitted successors or assigns are, and throughout the term of this Agreement and any Customer Agreement
will remain, the legal and beneficial owners of the entire right, title, and interest in and to the Installed Software, Subscription Software Services, the
Documentation, and the Company Marketing Materials, including all Intellectual Property relating thereto (or, with respect to any third party software
used to provide the Installed Software, Subscription Software Services it has, and will continue to have throughout the term of this Agreement, sufficient
and valid license rights to grant the licenses and perform its obligations hereunder), including the unconditional and irrevocable right, power, and
authority to grant the licenses and perform its obligations hereunder;
(b) as provided by the Company, no Installed Software or Subscription Software Services (including any Updates) does or will, at any time during
the term of this Agreement or any Customer Agreement, contain any Harmful Code and no Installed Software will contain any Open Source Software;
(c) when used by Allscripts or any Sublicensed Customer, no Installed Software, Subscription Software Services, Documentation or Company
Marketing Materials does or will: (i) infringe, misappropriate, or otherwise violate any Intellectual Property or other proprietary right of any third party
(provided that Company’s sole obligation and Allscripts sole remedy for any breach of the foregoing shall be for Company to indemnify Allscripts
pursuant to Section 22), or (ii) fail to comply with any applicable Law;
(d) there is no settled, pending, or, to the Company’s knowledge, threatened litigation, claim, or proceeding (including in the form of any offer to
provide a license): (i) alleging that any use of the Installed Software, Subscription Software Service, Documentation or Company Marketing Materials
does or would infringe, misappropriate, or otherwise violate any copyright, patent, trade secret, or other Intellectual Property of any third party; (ii)
challenging the Company’s ownership of, or right to use or license, any Installed Software, Subscription Software Services or Merchant Processing
Services, Documentation or Company Marketing Materials, or alleging any adverse right, title, or interest with respect thereto; or (iii) alleging the
invalidity, misuse, unregistrability, unenforceability, or non-infringement of any copyrights, trade secret rights, or patent rights in the Installed Software,
Subscription Software Services or Merchant Processing Services, Documentation, or Company Marketing Materials;
24(e) all Documentation is and will be complete and accurate in all material respects when provided to Allscripts, such that at no time during the term
of this Agreement or any Customer Agreement will the Subscription Software Services or Merchant Processing Services have any material
undocumented feature; and
(f) all Services provided hereunder are and will be in compliance with all applicable Laws.
21.3 Performance Warranty. The Company represents, warrants, and covenants to Allscripts that, during the term of this Agreement and any
Customer Agreement:
(a) when used in accordance with the Documentation, all Subscription Software Services or Merchant Processing Services and the Installed
Software as provided by the Company will meet, in all material respects, all applicable specifications set forth in this Agreement and the Documentation,
and function in all material respects, in conformity with this Agreement and the Documentation;
(b) any media on which the Installed Software or Documentation is delivered will be free of any damage or defect in design, material or
workmanship; and
(c) no Update will have a material adverse effect on the material functionality or operability of the Installed Software or Subscription Software
Services or Merchant Processing Services, as the case may be.
21.4 Breach of Performance Warranty. If the Company breaches any of the warranties set forth in Section 21.3, then the Company will, upon notice
from Allscripts and at the Company’s sole cost and expense, remedy such breach on a timely basis and in accordance with Section 12. [***].
21.5 Disclaimer. EXCEPT FOR THE EXPRESS WARRANTIES SET FORTH IN THIS AGREEMENT, EACH PARTY HEREBY DISCLAIMS ALL
WARRANTIES, WHETHER EXPRESS, IMPLIED, STATUTORY, OR OTHERWISE, WITH RESPECT TO THIS AGREEMENT OR ANY SUBJECT MATTER
HEREOF INCLUDING WITHOUT LIMITATION, THOSE OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE.
22. Indemnification.
22.1 Indemnification by the Company . Subject to the provisions of this Section 22, the Company agrees to defend Allscripts and its
Representatives, and all of such Persons’ successors and assigns (collectively, the “Allscripts Indemnified Persons”), from and against any and all third
party Claims, and indemnify and hold the Allscripts Indemnified Persons harmless from and against any and all Losses incurred or sustained by the
Allscripts Indemnified Persons, or any of them, directly or indirectly, in connection with or to the extent such third party Claim and related Loss is a result
of any of the following:
(a) the Company’s breach of any representation, warranty, covenant, or obligation of the Company under this Agreement or the Restated
Developer Agreement;
(b) any violation of applicable Law by the Company;
(c) any gross negligence or willful misconduct in connection with its performance of any covenant or agreement applicable to the Company
contained in this Agreement (including the performance of the Services), including any personal injury, death, or damage to tangible personal or real
property;
25(d) taxes assessed or claimed against any of the Allscripts Indemnified Persons that are obligations of the Company in connection with this
Agreement or which result from the breach of this Agreement by the Company;
(e) any damage caused to any third party’s IT environment by Company or any Developer App (as defined in the Restated Development
Agreement) or
(f) any Claims that any Developer App, the Installed Software, Subscription Software Services or Merchant Processing Services, Documentation,
Marketing Materials, the Company Marks, or Services, or any use, promotion, marketing, distribution, sale, service, or delivery thereof, infringe,
misappropriate, or violate any Intellectual Property or other rights of a third party, including any damages suffered by Sublicensed Customers as a result
thereof for which Allscripts is liable, including any refunds of fees paid by Sublicensed Customers for use of such infringing materials.
22.2 Infringement Remedy.
(a) In the event of a Claim that the Installed Software, Subscription Software Services or Merchant Processing Services, Documentation, Company
Marketing Materials, or Services, or any use, promotion, marketing, distribution, sale, service, or delivery thereof, infringe, misappropriate, or violate any
Intellectual Property of a third party, or if any use of any of the Installed Software, Subscription Software Services or Merchant Processing Services, the
Documentation, Company Marketing Materials, or the Services (or any respective component thereof) is enjoined, threatened to be enjoined, or is
otherwise the subject of such a Claim, [***].
(b) [***].
(c) [***].
22.3 Indemnification by Allscripts . Subject to the provisions of this Section 22, Allscripts agrees to defend the Company and its Representatives,
and all of such Persons’ successors and assigns (collectively, the “Company Indemnified Persons”), from and against any and all third party Claims, and
indemnify and hold the Company Indemnified Persons harmless from and against any and all Losses incurred or sustained by the Company Indemnified
Persons, or any of them, directly or indirectly, in connection with or to the extent such Claim and related Loss is a result of any of the following:
(a) Allscripts’ breach of any representation, warranty, covenant, or obligation of Allscripts under this Agreement or the Restated Developer
Agreement;
(b) any violation of applicable Law by Allscripts, or by Allscripts’ Affiliates, Allscripts Resellers, and Partnering Organizations solely in connection
with this Agreement;
(c) any gross negligence or willful misconduct in connection with its performance of any covenant or agreement applicable to Allscripts or to
Allscripts’ Affiliates, Allscripts Resellers, and Partnering Organizations contained in this Agreement, including any personal injury, death, or damage to
tangible personal or real property; or
(d) any claim that the SDK (as defined in the Restated Developer Agreement), the Associated Allscripts Software (as defined in the Restated
Developer Agreement) Allscripts Marks or any Allscripts products or services infringe, misappropriate, or violate any Intellectual Property of a third
party; or
26(e) taxes assessed or claimed against any of the Company Indemnified Persons that are obligations of Allscripts, Allscripts’ Affiliates, Allscripts
Resellers, or Partnering Organizations in connection with this Agreement, or which result from the breach of this Agreement by Allscripts, Allscripts’
Affiliates, Allscripts Resellers, or Partnering Organizations.
22.4 Indemnification Procedure.
(a) A Person seeking defense and indemnification under this Section 22.4 (the “Indemnified Person”) will promptly notify the Party from whom
defense and indemnification is being sought (the “ Indemnifying Party”) in writing, describing the circumstances, in reasonable detail, for which it seek
defense and indemnification.
(b) Upon notice of a Claim, the Indemnifying Party will [***] assume the investigation and defense of such Claim, and, in connection therewith, will
employ counsel of national reputation of its own choosing [***]. At the Indemnifying Party’s request and expense, the Indemnified Person will provide
reasonable cooperation in connection with the investigation and defense of such Claim; [***]. The Indemnified Person may also participate in and
observe (but not control) the investigation and defense of such Claim, [***] and with counsel of its choosing.
(c) If the Indemnifying Party fails to defend a Claim hereunder within a reasonable amount of time after receiving notice thereof, the Indemnified
Person will have the right, but not the obligation, and without waiving and of its other rights hereunder, to undertake the defense of and to compromise or
settle such Claim, on behalf of [***] of the Indemnifying Party.
(d) [***].
(e) An Indemnified Person’s failure to perform any obligations under this Section 22.4 will not diminish an Indemnifying Party’s obligations
hereunder, except to the extent that the Indemnifying Party can demonstrate that it has been materially prejudiced as a result of such failure.
(f) [***].
[***].
22.5 Limitations. The Company’s obligations to provide defense and indemnity pursuant to this Section 22 will be reduced to the extent that the
Claim or Loss was caused by (a) the Indemnified Person’s creation of modifications to the Installed Software, Subscription Software Services, Developer
App, Merchant Processing Services, Documentation, Company Marketing Materials, or Services, unless such modifications (i) were authorized in writing
by the Company or were otherwise directed in writing or caused by the Indemnifying Party or (ii) were contemplated and permitted as a feature of any of
the Installed Software or Subscription Software Services or Merchant Processing Services, and in each case solely to the extent such Claim would not
have occurred but for such modifications; (b) the Indemnified Person’s failure to use updates or corrections made available by the Indemnifying Party,
but solely to the extent such Claim would not have occurred if such updates or corrections had been used; or (c) the operation of Allscripts’ products or
services or the combination or use of the Installed Software, Developer App, Subscription Software Services or Merchant Processing Services or
Services in conjunction with Allscripts’ products or services (unless directed in writing or caused by the Company), if such Claim would not have arisen
but for such combination or use, and except to the extent arising from any combination performed by or on behalf of the Company in connection with the
Services.
2723. Limitation of Liability.
23.1 Limitation of Liability.
(a) EXCEPT AS OTHERWISE SET FORTH IN SECTION 23.2, IN NO EVENT WILL ANY PARTY BE LIABLE UNDER THIS AGREEMENT FOR ANY
LOST PROFITS OR FOR ANY CONSEQUENTIAL, INCIDENTAL, INDIRECT, EXEMPLARY, SPECIAL, OR PUNITIVE DAMAGES, REGARDLESS OF
WHETHER SUCH PARTY HAS BEEN NOTIFIED OF THE POTENTIAL FOR SUCH DAMAGES, OR WHETHER SUCH DAMAGES WERE
REASONABLY FORESEEABLE, OR WHETHER ANY CLAIM FOR RECOVERY IS BASED ON THEORIES OF CONTRACT, TORT, OR OTHERWISE.
[***].
(b) EXCEPT AS OTHERWISE SET FORTH IN SECTION 23.2, THE TOTAL CUMULATIVE LIABILITY OF EITHER PARTY FOR ANY AND ALL
CLAIMS AND DAMAGES UNDER THIS AGREEMENT, WHETHER ARISING BY STATUTE, CONTRACT, TORT OR OTHERWISE, WILL NOT EXCEED
THE FEES PAID BY ALLSCRIPTS TO COMPANY HEREUNDER DURING THE [***] PRECEDING THE EVENT GIVING RISE TO THE CLAIM. THE
PROVISIONS OF THIS AGREEMENT ALLOCATE RISKS BETWEEN THE PARTIES. THE PRICING SET FORTH HEREIN REFLECTS THIS
ALLOCATION OF RISK AND THE LIMITATION OF LIABILITY SPECIFIED HEREIN.
23.2 Exceptions. The limitations in Section 23.1(a) will not apply to (a) losses arising out of or relating to a Party’s breach of its obligations in
Section 8 (excluding Section 8.4(g)) or Sections 1.1, 1.2, 1.4, 1.6 or 6.1 of the Restated Developer Agreement, (b) losses arising out of a Party’s breach of
Section 19 or the Business Associate Agreement (c) losses arising from a Party’s gross negligence or more culpable conduct, including any willful
misconduct or intentionally wrongful acts; (d) losses for death, bodily injury, or damage to real or tangible personal property arising out of or relating to a
Party’s negligent or more culpable acts or omissions or (e) a Party’s obligation to pay attorneys’ fees and other costs pursuant to Section 28.9(e). The
limitations in Section 23.1(b) will not apply to (a) losses arising out of or relating to a Party’s breach of its obligations in Section 8 (excluding Section
8.4(g)) or Sections 1.1, 1.2, 1.4, 1.6 or 6.1 of the Restated Developer Agreement, (b) losses arising out of a Party’s breach of Section 19 or the Business
Associate Agreement; (c) a Party’s indemnification obligations under Sections 22.1(b) through 22.1(e) or Sections 22.3(b) through 22.3(e); (d) losses
arising from a Party’s gross negligence or more culpable conduct, including any willful misconduct or intentionally wrongful acts; (e) losses for death,
bodily injury, or damage to real or tangible personal property arising out of or relating to a Party’s negligent or more culpable acts or omissions; or (f) a
Party’s obligation to pay attorneys’ fees and other costs pursuant to Section 28.9(e). In addition, the limitations in Section 23.1(b) will not apply (1) to
Company’s indemnification obligations under Section 22.1(a) or (2) Allscripts indemnification obligations under Section 22.3(a), unless the Company’s or
Allscripts’ indemnification obligation under Section 22.1(a) or 22.3(a), as the case may be, relates to the losses and obligations described in subclauses
(a) through (f) of the preceding sentence. [***].
23.3 Essential Basis . THE DISCLAIMERS, EXCLUSIONS, AND LIMITATIONS OF LIABILITY SET FORTH IN THIS AGREEMENT FORM AN
ESSENTIAL BASIS OF THE BARGAIN BETWEEN THE PARTIES AND, ABSENT ANY OF SUCH DISCLAIMERS, EXCLUSIONS, OR LIMITATIONS OF
LIABILITY, THE PROVISIONS OF THIS AGREEMENT, INCLUDING THE ECONOMIC TERMS, WOULD BE SUBSTANTIALLY DIFFERENT. THE
DISCLAIMERS, EXCLUSIONS, AND LIMITATIONS OF LIABILITY SET FORTH IN THIS AGREEMENT WILL APPLY TO THE MAXIMUM EXTENT
PERMITTED BY APPLICABLE LAW, EVEN IF ANY REMEDY FAILS ITS ESSENTIAL PURPOSE.
2824. Term.
24.1 Term. The initial term of this Agreement commences on the Effective Date and will continue in effect until five (5) year(s) from such date (the
“Initial Term”) unless terminated earlier pursuant to Section 25.
24.2 Renewal. Unless this Agreement is terminated pursuant to Section 25, this Agreement will automatically renew for additional successive [***]
terms (each a “Renewal Term” and together with the Initial Term, the “Term”) unless and until either Party provides written notice of non-renewal to the
other Party at least [***] prior to the end of the then-current Term.
25. Termination.
25.1 Termination for Convenience. [***].
25.2 Termination for Cause. Either Party may terminate this Agreement, immediately upon written notice to the other Party, if the other Party
materially breaches this Agreement and such breach (a) is incapable of cure or (b) being capable of cure, remains uncured [***] after the breaching Party
receives written notice from the non-breaching  Party thereof.
25.3 Termination for Insolvency. Either Party may terminate this Agreement, immediately upon written notice to the other Party, if the other Party (a)
becomes insolvent or admits inability to pay its debts generally as they become due; (b) becomes subject, voluntarily or involuntarily, to any proceeding
under any domestic or foreign bankruptcy or insolvency Law, which is not fully stayed within [***] or is not dismissed or vacated within [***] after
filing; (c) is dissolved or liquidated or takes any action for such purpose; (d) makes a general assignment for the benefit of creditors; or (e) has a receiver,
trustee, custodian, or similar agent appointed by order of any court of competent jurisdiction to take charge of or sell any portion of its property or
business (and such appointment is not discontinued within [***] thereafter).
25.4 Termination for Force Majeure. Subject to Section 15.2, either Party may terminate this Agreement, immediately upon written notice to the other
Party, if a Force Majeure Event affecting the other Party’s performance of its obligations hereunder continues substantially uninterrupted for a period of
[***] or more.
25.5 Termination for Exclusion/Termination of Merchant Processing Services. [***].
25.6 Termination for Change of Control. [***].
25.7 Effect of Expiration or Termination.
(a) The expiration or termination of this Agreement will not have the effect of terminating any Customer Agreement, Merchant Agreement (or the
licenses to the Installed Software or Subscription Software Services distributed thereunder) or agreement directly between [***].
(b) Upon expiration or termination of this Agreement, except in connection with the rights and obligations set forth in this Section 25.7, Allscripts
will immediately (i) cease all use of the Company Marks and all marketing and sales-related efforts with respect to the Installed Software, Subscription
Software Services or Merchant Processing Services and the Services; (ii) discontinue all representations or statements from which it might be inferred
that any relationship exists between the Parties; (iii) cease to solicit or procure orders for the Subscription Software Services or Merchant Processing
Services, Installed Software, Merchant Processing Services or the Services; and (iv) return all copies of the Documentation, and related materials and
copies thereof, to the Company; provided , however, that Allscripts may retain a reasonable number of copies of the Documentation and related materials
in order to fulfill its obligations under this Agreement and the Customer Agreements.
29(c) Upon expiration or termination of this Agreement, the Company will (i) provide reasonable cooperation and assistance to Allscripts, at
Allscripts’ written request and to the extent necessary to fulfill any continuing obligations under this Agreement, in transitioning the terminated Support
Services to an alternative service provider; and [***].
(d) Subject to the foregoing paragraphs of this Section 25.7, upon expiration or termination of this Agreement, [***].
26. Change of Control.
26.1 Competing Providers. This Section 26 will only apply in the event of a Change of Control to a Competing Provider or its Affiliate.
26.2 Removal of Data. [***].
26.3 De-identified Data. As of the consummation of a Competitive Change of Control, [***].
26.4 No Obligation. As of the consummation of a Competitive Change of Control, Allscripts will be under no obligation to provide the Company (or,
for the avoidance of doubt, any Company Acquiror or Competing Provider) with any Data, except Data necessary for Company to fulfill its obligations
under its Merchant Agreements with such customers and to fulfill any of its obligations hereunder for the duration of the applicable Customer
Agreements.
26.5 Support . Notwithstanding anything in this Agreement to the contrary, as of the consummation of a Competitive Change of Control, Allscripts
will have the right, in its sole discretion, to assume the provision of Level 1 Support Services to Sublicensed Customers and to become the first direct
point of contract for each Sublicensed Customer for support and maintenance matters hereunder. A Competitive Change of Control will not release the
Company from any of its obligations under this Agreement, including its obligations to provide Support Services.
27. Survival.
27.1 Survival. The provisions of Sections 1, 2.5-2.7, 8.4-8.6, 8.8, 16.8, 18-25, 27, and 28 and Exhibit E (Business Associate Agreement), Exhibit F (Buy
Rates and Revenue Share) and Exhibit H (List of Legacy Customers) will survive and continue after the expiration or termination of this Agreement
indefinitely. The provisions of the Restated Developer Agreement set forth in its “Survival” provision will survive the expiration or termination of the
Restated Developer Agreement or this Agreement indefinitely. The provisions of Sections 2.1(c)-(d), 2.3, 4.2, 4.3, 8.1-8.3, 8.7, 10, 11.3, and 12-17 (excluding
Sections 14.4 and 17.4, each of which will survive for the duration set forth therein; and Sections 14.6, 16.1 and 16.8), Exhibit C (Services) and Exhibit D
(Service Level Agreement) will survive and continue after the expiration or termination of this Agreement for the full duration of any Customer
Agreement. In addition, the rights and obligations of any Party which, by their nature, extend beyond the expiration or termination of this Agreement will
continue in full force and effect notwithstanding the termination of this Agreement.
3028. Miscellaneous.
28.1 Relationship of the Parties . The relationship between the Parties is that of independent contractors. Nothing contained in this Agreement will
be construed as creating any agency, partnership, joint venture, or other form of joint enterprise, employment, or fiduciary relationship between the
Parties. Neither Party will have authority to contract for or bind the other Party in any manner whatsoever, except as expressly set forth in this Agreement.
28.2 Notices. All notices, requests, consents, claims, demands, waivers, and other communications hereunder will be in writing and addressed to a
Party at the address set forth under such Party’s name on the signature page hereto (or as otherwise specified by a Party in a notice given in accordance
with this Section 28.2). Notices sent in accordance with this Section 28.2 will be deemed effectively given: (a) when received, if delivered by hand (with
written confirmation of receipt); or (b) when received, if sent by a nationally recognized overnight courier (receipt requested).
28.3 Interpretation . For purposes of this Agreement, (a) the words “include,” “includes,” and “including” will be deemed to be followed by the
words “without limitation”; (b) the word “or” is not exclusive; and (c) the words “herein,” “hereof,” “hereby,” “hereto,” and “hereunder” refer to this
Agreement as a whole. Unless the context otherwise requires, references herein: (i) to Sections and Exhibits refer to the sections of, and exhibits attached
to, this Agreement; (ii) to an agreement, instrument, or other document means such agreement, instrument, or other document as amended, supplemented,
and modified from time to time to the extent permitted by the provisions thereof; and (iii) to a statute means such statute as amended from time to time and
includes any successor legislation thereto and any regulations promulgated thereunder. This Agreement will be construed without regard to any
presumption or rule requiring construction or interpretation against the Party drafting an instrument or causing an instrument to be drafted. The Exhibits
referred to herein will be construed with, and as an integral part of, this Agreement to the same extent as if they were set forth verbatim herein. The
headings in this Agreement are for reference only and will not affect the interpretation of this Agreement.
28.4 Assignment . Neither Party may assign or otherwise transfer any of its rights, or delegate or otherwise transfer any of its obligations or
performance, under this Agreement, in each case whether voluntarily or involuntarily, without the other Party’s prior written consent, which will not be
unreasonably withheld, conditioned, or delayed. Any assignment, delegation, or other transfer without such prior written consent will be null and void.
Notwithstanding the foregoing (and subject to Section 25 and 26) either Party may assign this Agreement without the consent of the other Party as part
of a corporate reorganization, consolidation, merger, or sale of all or substantially all of its assets or business to which this Agreement relates. This
Agreement is binding upon and inures to the benefit of the Parties and their respective permitted successors and assigns.
28.5 No Third Party Beneficiaries. This Agreement is for the sole benefit of the Parties, their respective permitted successors and assigns, and the
Persons indemnified in Section 22, and nothing herein, express or implied, is intended to or will confer on any other Person any legal or equitable right,
benefit, or remedy of any nature whatsoever under or by reason of this Agreement.
28.6 Amendment and Modification ; Waiver. This Agreement may only be amended, modified, or supplemented by an agreement in writing signed
by each Party. No waiver by any Party of any of the provisions hereof will be effective unless explicitly set forth in writing and signed by the Party so
waiving. Except as otherwise set forth in this Agreement, no failure to exercise, or delay in exercising, any right, remedy, power, or privilege arising from
this Agreement will operate or be construed as a waiver thereof; nor will any single or partial exercise of any right, remedy, power, or privilege hereunder
preclude any other or further exercise thereof or the exercise of any other right, remedy, power, or privilege.
3128.7 Severability. If any provision of this Agreement or the application thereof to any Party or circumstances is declared void, illegal, or
unenforceable, then the remainder of this Agreement will be valid and enforceable to the extent permitted by applicable Law. In such event, the Parties will
use their reasonable efforts to replace the invalid or unenforceable provision by a provision that, to the extent permitted by applicable Law, achieves the
purposes intended under the invalid or unenforceable provision.
28.8 Governing Law. This Agreement will be governed by and construed in accordance with the Laws of the State of Illinois applicable to
agreements made and to be performed wholly within that State without regard to its conflicts of laws provisions.
28.9 Dispute Resolution .
(a) Except as expressly permitted in Section 28.9(f), neither Party will initiate an arbitration of any dispute hereunder unless (i) such Party has
provided the other Party with written notice of that dispute with reasonable specificity and attempted in good faith to resolve that dispute through
negotiations; (ii) despite such efforts, the dispute remains unresolved [***] after receipt of that notice; and (iii) such initiation is in accordance with this
Section 28.9.
(b) Subject to the foregoing, any dispute arising out of, relating to, or in connection with this Agreement which cannot be settled amicably will be
finally resolved by arbitration in accordance with the International Institute for Conflict Prevention and Resolution (CPR) Rules for Non-Administered
Arbitration by a panel of three arbitrators, of which each Party will designate one arbitrator in accordance with the “screened” appointment procedure
provided in Rule 5.4 thereof. The arbitration will be governed by the Federal Arbitration Act, 9 U.S.C. sec. 1 et seq. Arbitration awards will be final and
binding upon the Parties, and judgment upon the award rendered by the arbitrators may be entered in any court having jurisdiction thereof. The place of
the arbitration will be Chicago, Illinois. All aspects of the arbitration and any award will be confidential (subject to the exceptions set forth in Section
19.3).
(c) The arbitrators will have the authority to grant any equitable and legal remedies that would be available in any judicial proceeding instituted to
resolve a dispute; provided , however, that the arbitrators will have no power or authority to award damages that would be inconsistent with Section 23 of
this Agreement.
(d) In any arbitration under this Section 28.9, the arbitrators will set a limited time period and establish procedures designed to reduce the cost and
time for discovery while allowing each Party to such dispute an opportunity, adequate in the sole judgment of the arbitrators, to discover relevant
information from the other Party about the subject matter of the dispute. The arbitrators will rule upon motions to compel or limit discovery and will have
the authority to impose sanctions for discovery abuses, including attorneys’ fees and costs, to the same extent as a competent court of law or equity,
should the arbitrators determine that discovery was sought without substantial justification or that discovery was refused or objected to without
substantial justification.
(e) Each Party will pay its own costs and expenses (including counsel fees) of any arbitration; provided , however, that the Parties will equally share
the fees and expenses of the arbitrators; provided , further, that in the event any action, suit, arbitration, or other proceeding is instituted or commenced
by either Party against the other Party arising hereunder, the prevailing Party will be entitled to recover its reasonable attorneys’ fees, court costs, and
costs of arbitration from the non-prevailing Party (it being agreed that the arbitrators and/or judge may eliminate or reduce such recovery on the grounds
that it is unreasonable or disproportionate to the harm suffered).
32(f) Notwithstanding anything else in this Section 28.9 to the contrary, either Party may apply to a court of competent jurisdiction for a temporary
restraining order, preliminary injunction, or other interim or conservatory relief, as necessary. For such purpose, each Party irrevocably consents to the
exclusive jurisdiction and venue of any Federal court within Cook County, Illinois, and waives and covenants not to assert or plead any objection which
it might otherwise have to such jurisdiction and venue.
28.10 Waiver of Jury Trial. EACH PARTY HEREBY WAIVES ITS RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED
UPON OR ARISING OUT OF THIS AGREEMENT OR THE SUBJECT MATTER HEREOF. THE SCOPE OF THIS WAIVER IS INTENDED TO BE ALL-
ENCOMPASSING OF ANY AND ALL DISPUTES THAT MAY BE FILED IN ANY COURT AND THAT RELATE TO THE SUBJECT MATTER OF THIS
AGREEMENT, INCLUDING CONTRACT CLAIMS, TORT CLAIMS (INCLUDING NEGLIGENCE), AND ALL OTHER COMMON LAW AND STATUTORY
CLAIMS.
28.11 Equitable Relief. Each Party acknowledges that a breach by a Party of this Agreement may cause the non-breaching  Party immediate and
irreparable harm, for which an award of damages may not be adequate compensation and agrees that notwithstanding Section 28.9(b), in the event of
such breach or threatened breach, the non-breaching  Party will be entitled to seek equitable relief, including in the form of orders for preliminary or
permanent injunction, specific performance, and any other relief that may be available from any court of competent jurisdiction or the arbitration panel,
provided that following the formation of the arbitration panel pursuant to Section 28.9(b), such relief will only be sought from the arbitration panel. The
Parties hereby waive any requirement for the securing or posting of any bond in connection with such relief. Such remedies will not be deemed to be
exclusive but will be in addition to all other remedies available under this Agreement, at law or in equity, subject to any express exclusions or limitations in
this Agreement to the contrary.
28.12 Counterparts . This Agreement may be executed in counterparts, each of which will be deemed an original, but all of which together will
constitute one and the same instrument. Counterparts may be delivered by facsimile, electronic mail (including .pdf or any electronic signature complying
with the U.S. Federal ESIGN Act of 2000) or other transmission method, and any counterpart so delivered will be deemed to have been duly and validly
delivered and be valid and effective for all purposes.
28.13 Entire Agreement. This Agreement, together with all Exhibits, and the BAA, constitutes the sole and entire agreement between the Parties
with respect to the subject matter hereof, and supersedes all prior and contemporaneous understandings and agreements, both written and oral, with
respect to such subject matter, including, without limitation, the Developer Agreement. [***].
[Signature Page Follows]
33IN WITNESS WHEREOF, the parties have executed this Agreement as of the Effective Date.
Allscripts Healthcare, LLC Phreesia, lnc.
By: /s/ Richard Elmore By: /s/ Thomas Altier
Name: Richard Elmore Name: Thomas Altier
Title: SVP Title: CFO
Address for Notices: Address for Notices:
[***] [***]
Attention: SVP, Corporate Development and Strategy Attn: Chief Executive Officer
With a copy (which will not constitute notice) to: With a copy (which will not constitute notice) to:
[***] [***]
Attention: General Counsel Attn: Chief Financial Officer
Signature Page to Strategic Alliance AgreementEXHIBIT A
Description of Eligibility Benefits Services, POS Dashboard, Phreesia Patient Intake Management
Offering and Merchant Processing Services
[***]EXHIBIT B
Product Development Plan
[***]EXHIBIT C
Services
[***]EXHIBIT D
Service Level Agreement
[***]EXHIBIT E
Form of HIPAA Business Associate Agreement
[***]EXHIBIT F
Buy Rates and Revenue Share
[***]EXHIBIT G
Amended and restated Allscripts Developer Program Agreement
[***]EXHIBIT H
List of Legacy Customers
[***]EXHIBIT I
Company’s Trademark Use Guidelines and Instructions
[***]EXHIBIT J
Merchant Agreement
[***]EXHIBIT K
Merchant Application
[***]EXHIBIT L
Disaster Recovery Plan
[***]STRATEGIC ALLIANCE AGREEMENT
This Strategic Alliance Agreement (this “Agreement” ) is made and entered into as of May 17, 2016, (the “Effective Date” ) by and between Giggles
N’ Hugs, Inc., a Nevada corporation (the “Company” ), and Kiddo, Inc., a Florida corporation, Inc., (“Consultant” ).
WHEREAS, Consultant is retained by the Company as an Independent Contractor to introduce investors, celebrity spokespersons, press and
media relationships, raise public awareness of the company and its public securities, and for other services related to Consultant’s expertise; and
WHEREAS, the Company and Consultant have agreed upon, and wish to memorialize their agreement concerning the status and responsibilities of
the parties.
NOW, THEREFORE, the parties agree as follows:
1. Services
(a) General. Consultant shall use all best efforts to provide services including the following:
● Capital
○ Introduction to key investors.
○ Introduction to strategic partners
○ Introduction to celebrity endorsement and involvement, including but not limited to celebrity investors.
● Branding
○ Concept generation for overall brand strategy and market launch.
○ Facilitate and help structure strategic relationships partnerships with key influencers and celebrities and their children in various major
markets, including NY and Los Angeles.
● Marketing
○ Public relations and marketing services, including grass-roots campaign, social media, local and national TV interviews and shows, local
and national newspaper and magazine exposure and interviews, investor relations and shareholder awareness.
○ Expansion of brand awareness through creating and managing social media alliances with mommy bloggers and studios to start using
location/possible tie-ins to national and local events, including Super Saturday LA, Super Saturday Hamptons, etc.
○ Solicit Advertising and partnership opportunities with consultants current and future corporate clients
○ Introduction of company to NY market with pop-up or take over existing play space and brand Company to the NY market.
○ Reach out to mall partners in partnership with the Company. Utilizing the Company’s existing mall relationships and current offers.
● Licensing and Merchandising
○ Review all of Company’s intellectual property for use in future plans, not including legal work
○ Facilitate and help structure strategic partnerships
○ with distribution partners, publishing partners, advertising partners, retail partners, licensing partners, etc.
○ Facilitate and help structure strategic relationship with merchandising and manufacturing partners, such as Hasbro or Mattel, etc.
○ Facilitate and help structure strategic relationship with merchandise partners for children’s clothing line, frozen food line, toys and games,
etc.
○ Create and begin 2017 roll out plan including product placement and further expansion of retail locations.
1● Entertainment
○ Consultant will facilitate and structure strategic relationships with publishing companies for Children’s books, live news shows, TV show,
entertainment shows, movies, and branding, etc.
○ Launch overall concept implementation from Characters development for in-house programming, live shows, TV show, books, product
including apparel and toys, gadgets.
● Food and Beverage
○ Consultant will facilitate and structure strategic relationships with frozen and fresh food manufacturing and delivering companies, such as
the idea of the “brought to home” meals with companies such as Blue Apron for kids meals.
○ Use best efforts to create brand partnerships and other strategic relationships described above. “Best efforts” means that degree of effort
which would be reasonable for a person under similar circumstances.
b) Projected timeline. Consultant will make all best efforts to conduct the following services in the time stated:
Day 1: Concept generation for overall brand strategy ideation. Create plan for concept launch. Review all Giggles IP for use in future
plans.
Begin grass-roots campaign and social media buzz regarding the brand, and its existence as a public company to increase SH
awareness. “Getting the story out”
May: Launch overall concept implementation from Characters development for in-house programming, live shows, TV show, books,
product including apparel and toys, gadgets. “getting ready”
June: Introduction of POSSIBLE key financial partners and brand like partners to align with brand. Aside from raising awareness for the
brand, which should already show appreciable increase in stock price, we will procure individual investors who desire to be part
of Giggle and Hugs in partnership alignments.
July: Reach out to mall partners in partnership with Giggles & Hugs. At this time, the brand has generated more a buzz and we should
be able to make the best deals possible for expansion. The stock price should have shown an increase and there should be more
funds available for growth . This expansion effort will pave the way for the next level of investor. Planning on growth to new
locations within 6-9 months from this point.
Start creating alliances with mommy bloggers and studios to start using location/possible tie in to Super Saturday LA, among
other local events that will help broaden the brand awareness.
Possible tie in to Super Saturday Hamptons, and other events that make sense for the brand. Same as above for purposes of
bringing the brand to influencers and others in the industry.
October: Introduce Giggles & Hugs to NY market with pop-up or take over existing play space and brand Giggles & Hugs to the NY market.
Bring in NY influencers and celebs with their kids. Expand the buzz for the brand.
2November: Merchandise partner such as Hasbro or Mattel
Products in process while trying to partner for a retailer/distributor on both levels
Children’s books - after we have built out Giggles and Hugs characters and figure out what that looks like from live show, TV
show, book, branding etc.
Possible TV show opportunity (not priority)
To accomplish this phase, we will utilize our licensing partner, Brand Centric, and will introduce you to our partners on licensing
to work together on all licensing fronts.
Frozen foods. We will need to revisit your deal that was on the table at that time. It will be appropriate to enter into that deal as
part of the general over-all scheme to grow the brand.
Also, the idea of the “brought to home” meals such as Blue Apron for kids meals. We believe that this area has potential. We
should visor that deal now, and prepare for the roll out of the product in accordance with this area of the proposed timeline.
Merchandise partner for children’s clothing line
December: Create and begin 2017 roll out plan including product placement and further expansion of G&H locations.
January: Implementation of roll out plan.
2. Consideration. In consideration for all duties and obligations contained herein, on or before the Effective date above, Company shall issue
to Consultant a warrant to purchase 4,400,000 shares of the Company’s common stock, which is equal to 10% of the issued and
outstanding shares of common stock of the Company at the time of the grant.
(a) The exercise price for the warrants shall be $0.075 per share, and shall not increase for any reason.
(b) Upon achievement of certain milestones, the Warrants shall immediately vest upon any of the following events which may occur at
any time (“Milestones”):
1) 10% upon the execution of this Agreement; and attached PR contract.
2) 20% upon the Company’s receipt of a net equity investment of $1 million into the Company from any source (“Included
Investors”), except those with a prior relationship with Company or its agents;
3) 20% upon the Company’s receipt of an additional net equity investment of $1 million (an aggregate of $2 million) from Included
Investors;
4) 20% upon the closing price for the Company’s common stock closes above $80 (eighty cents) per share for 10 out of any 20
consecutive trading days;
5) 15% upon the announcement and consummation of a strategic relationship with at least two “A-List Celebrity” upon terms and
conditions mutually agreed upon with the Company and Consultant.
6) 15% upon the launch and initial distribution of a Giggles N’ Hugs branded product line, which may be clothing, furniture, frozen
food, toys or similar merchandising (a “Product Line).
3(c) It is agreed that one event shall not trigger more than one of the above vesting provisions (e.g. a strategic relationship Honest
Company and Jessica Alba shall not vest 30% of the Warrants under items 5 and 6, above). Further, no vesting of Milestones 2-4, will
be triggered as a result of an acquisition of the Company, or a public or registered offering of its securities, unless such result is from
the direct performance of Consultant.
(d) Company will only sell, transfer or issue stock at prices that are in the best interest of the company and its shareholders.
3. Termination. Either party may terminate this agreement after 3 years following the effective date.
(a) In addition, this Agreement will terminate upon the following:
(1) Completion of work or period of work provided in this agreement.
(2) Termination by Company or Consultant for any material breach, which is not cured within 30 days after written notice of
any such material breach from the non-breaching party, pursuant to the terms of the Agreement.
(3) By the Company, at its option, if at least two Milestones (excluding Milestones 1) are not achieved within 12 months
from the Effective Date.
4. Relationship of Parties. Consultant is an independent contractor and is not an agent or employee of, and has no authority to bind, the
Company by contract or otherwise. Consultant will report as self-employment income all compensation received by Consultant pursuant
to this Agreement. Consultant will indemnify the Company and hold it harmless from and against all claims, damages, losses, costs and
expenses, including reasonable fees and expenses of attorneys and other professionals, relating to any obligation imposed by law on the
Company to pay any withholding taxes, social security, unemployment or disability insurance, or similar items in connection with
compensation received by Consultant pursuant to this Agreement. Consultant will not be entitled to receive any vacation or illness
payments or to participate in any plans, arrangements, or distributions by the Company pertaining to any bonus, profit sharing, insurance
or similar benefits for the Company’s employees.
5. Confidential Information. Consultant acknowledges that, in connection with providing the Services, Consultant will acquire confidential
and proprietary information of the Company, including without limitation information relating to the Company’s business, products,
technology and customers, and that all such information is and will be confidential and proprietary information of Company (collectively
“Confidential Information” ). Confidential Information will not include, however, any information that is or becomes part of the public
domain through no fault of Consultant or that Company regularly gives to third parties without restriction on use or disclosure.
Consultant will not disclose or permit disclosure of any Confidential Information of the Company to third parties other than as required to
perform the Services. Consultant agrees to take all reasonable measures to protect the secrecy of and avoid disclosure or use of
Confidential Information of the Company in order to prevent it from falling into the public domain or the possession of persons other than
those persons authorized under this Agreement to have any such information. Consultant further agrees to notify the Company in writing
of any actual or suspected misuse, misappropriation or unauthorized disclosure of the Company’s Confidential Information, which may
come to Consultant’s attention.
46. Non-Solicitation. Consultant will not, during the Term, and for a period of one (1) year thereafter, directly or indirectly: (i) solicit, recruit or
promote the solicitation or recruitment of any employee or consultant of the Company for the purpose of encouraging that employee or
consultant to leave the Company’s employ or sever an agreement for services; or (ii) solicit, participate in or promote the solicitation of
any of the Company’s clients, customers, or prospective customers with whom Consultant had a Material Contact (hereinafter defined)
and/or regarding whom Consultant received Confidential Information, for the purpose of providing products or services (“Competitive
Products/Services”). “Material Contact” means interaction between Consultant and the customer, client or prospective customer within
one year prior to Consultant’s separation of services from the Company that takes place to manage, service or further the business
relationship. This limitation is not intended to limit the Company’s right to prevent misappropriation of its Confidential Information beyond
the non-solicitation period. Consultant and Company agree that if any court of competent jurisdiction shall for any reason conclude that
any portion of this non-solicitation covenant shall be too restrictive, the court shall determine and apply lesser restrictions, it being the
intent of the parties that some such restrictions shall be applicable for the protection of Company and its shareholders.
7. Property of Company.
(i) Definition of Innovations . Consultant agrees to disclose in writing to the Company all inventions, products, designs,
drawings, notes, documents, information, documentation, improvements, works of authorship, processes, techniques, know-how,
algorithms, technical and business plans, specifications, hardware, circuits, computer languages, computer programs, databases, user
interfaces, encoding techniques, and other materials or innovations of any kind that Consultant may make, conceive, develop or reduce to
practice, alone or jointly with others, in connection with performing Services or that result from or that are related to such Services,
whether or not they are eligible for patent, copyright, mask work, trade secret, trademark or other legal protection (collectively,
“Innovations ”).
(ii) Ownership of Innovations . Consultant and the Company agree that, to the fullest extent legally possible, all
Innovations will be works made for hire owned exclusively by the Company. Consultant agrees that, regardless of whether the Innovations
are legally works made for hire, all Innovations will be the sole and exclusive property of the Company. Consultant hereby irrevocably
transfers and assigns to the Company, and agrees to irrevocably transfer and assign to the Company, all right, title and interest in and to
the Innovations, including all worldwide patent rights (including patent applications and disclosures), copyright rights, mask work rights,
trade secret rights, know-how, and any and all other intellectual property or proprietary rights (collectively, “ Intellectual Property
Rights”) therein. At the Company’s request and expense, during and after the term of this Agreement, Consultant will assist and cooperate
with the Company in all respects and will execute documents, and, subject to the reasonable availability of Consultant, give testimony and
take such further acts reasonably requested by the Company to enable the Company to acquire, transfer, maintain, perfect and enforce its
Intellectual Property Rights and other legal protections for the Innovations. Consultant hereby appoints the officers of the Company, as
Consultant’s attorney-in-fact to execute documents on behalf of Consultant for this limited purpose. Consultant’s obligation to assist the
Company shall continue beyond the termination of Consultant’s relationship with the Company, but the Company shall compensate
Consultant at a reasonable rate after the termination of such relationship for time actually spent at the Company’s request providing such
assistance.
58. Moral Rights. Consultant also hereby irrevocably transfers and assigns to the Company, and agrees to irrevocably transfer and assign to
the Company, and waives and agrees never to assert, any and all Moral Rights (as defined below) that Consultant may have in or with
respect to any Innovation, during and after the term of this Agreement. “ Moral Rights ” mean any rights to claim authorship of any
Innovation, to object to or prevent the modification or destruction of any Innovation, to withdraw from circulation or control the
publication or distribution of any Innovation, and any similar right, existing under judicial or statutory law of any country in the world, or
under any treaty, regardless of whether or not such right is called or generally referred to as a “moral right”.
9. No Rights Granted. Nothing in this Agreement will be construed as granting any rights under any patent, copyright or other intellectual
property right of the Company, nor will this Agreement grant Consultant any rights in or to the Company’s Confidential Information,
except the limited right to use the Confidential Information as required in connection with performing the Services.
10. No Conflict. Consultant represents to the Company that Consultant can provide the Services to the Company without conflict with his
obligations to any other party and covenants to the Company that, in performing the Services, he will not violate any obligations to any
third party, including obligations concerning providing services to others and confidentiality of proprietary information.
11. General.
(a) Governing Law. This Agreement will be governed by and construed in accordance with the laws of the State of California excluding that
body of law pertaining to conflict of laws, except with respect to issues governed by the copyright laws of the United States. Any legal action or
proceeding arising under this Agreement will be brought exclusively in the federal or state courts located in Los Angeles County, California, and
the parties hereby irrevocably consent to the personal jurisdiction and venue therein.
(b) Disagreements; Attorneys’ Fees.  The parties agree to attempt to resolve any disputes, controversies or claims (“Dispute”) arising out
of or relating to this Agreement in a meeting between a representative of each party who has decision-making authority with respect to a Dispute.
Should the meeting either not take place or not result in a resolution of the Dispute within thirty (30) days following notice of the Dispute to the
other party, then either party may bring suit or action in accordance with this Agreement. Each party hereto agrees that in the event that the other
party is required to engage an attorney to enforce any of the terms or obligations contained in this Agreement, the non-prevailing party shall pay
all reasonable costs and expenses of that attorney or firm, whether or not a complaint or suit is filed with any court of competent jurisdiction.
6(c) Assignment . The services provided for in this Agreement, are of a personal nature and Consultant may not assign or transfer any of
Consultant’s rights or delegate any of Consultant’s obligations under this Agreement, in whole or in part, without the Company’s express prior
written consent. Any attempted assignment, transfer or delegation, without such consent, will be void. Subject to the foregoing, this Agreement
will be binding upon and will inure to the benefit of the parties permitted successors and assigns.
(d) Complete Understanding; Modification . This Agreement constitutes the complete and exclusive understanding and agreement of the
parties and supersedes all prior understandings and agreements, whether written or oral, with respect to the subject matter hereof. Any waiver,
modification or amendment of any provision of this Agreement will be effective only if in writing and signed by the parties hereto.
(e) Severability. If one or more provisions of this Agreement are held to be illegal or unenforceable, such illegal or unenforceable portion
shall be limited or excluded from this Agreement to the minimum extent required under such jurisdiction so that this Agreement shall otherwise
remain in full force and effect and enforceable.
(f) Notices. All notices must be in writing and delivered to the other party’s principal business address, by personal delivery, overnight
courier service, email or by facsimile. Notices will be deemed given as of the date of receipt, which date shall be evidenced by the signature of an
authorized representative of the receiving party or by written evidence of a successful transmission of an email or facsimile.
(g) No Agency . Nothing in this Agreement shall be deemed or construed by the parties or any other entity to create an agency, partnership
or joint venture between the parties.
(h) Counterparts . This Agreement may be executed in counterparts, each of which will be deemed an original, and all of which together
shall constitute one and the same instrument.
(i) Survival. Sections 5, 6 and 11 shall survive termination of this Agreement.
(j) Remedies and Enforcement. The parties acknowledge and agree that their remedy (ies) at law for a breach or threatened breach of any of
the provisions of this Agreement would be inadequate, and the breach shall be per se deemed as causing irreparable harm to the non-breaching
party. In recognition of this fact in the event of a breach or threatened breach of any of the provisions of this Agreement, the Parties agree that, in
addition to any remedy at law available, including, but not limited to monetary damages, the Parties, without posting any bond, shall be entitled to
obtain equitable relief in the form of specific performance, temporary restraining order, temporary or permanent injunction or any other equitable
remedy which may then be available to the non-breaching Party.
(k) Construction. This Agreement shall be construed within the fair meaning of each of its terms and not against the party drafting the
document.
REMAINDER OF PAGE LEFT INTENTIONALLY BLANK
7IN WITNESS WHEREOF, the parties have entered into this Agreement as of the Effective Date.
GIGGLES N’ HUGS, INC. KIDDO, INC.
By: /s/ Joey Parsi By: /s/ Michelle Steinberg
Name: Joey Parsi Name: Michelle Steinberg
Its: Chief Executive Officer Its: Vice-President
8Exhibit 10.1
Strategic Alliance Agreement
AGREEMENT made as of  , 2013, between Freedom Mortgage Corporation, a New Jersey corporation (“Freedom Mortgage”), and Cherry HillMortgage Investment Corp., a Maryland corporation (“Cherry Hill”).
WITNESSETH:
WHEREAS, Freedom Mortgage is a privately held, national mortgage bank that originates and services mortgage loans secured by liens onone- to four-family properties; and
WHEREAS, Cherry Hill is a newly formed affiliate of Freedom Mortgage that intends to elect and qualify as a Real Estate Investment Trustunder the Internal Revenue Code of 1986, as amended; and
WHEREAS, Cherry Hill will have access to capital, including capital raised through one or more offerings of its securities; and
WHEREAS, Cherry Hill will seek to benefit from having a consistent and predictable source of real estate assets from Freedom Mortgage, andFreedom Mortgage will seek to benefit from the liquidity available to Cherry Hill; and
WHEREAS, the parties desire to set forth the terms of a strategic alliance that is expected to benefit them both;
NOW, THEREFORE, in consideration of the foregoing, and of other good and valuable consideration, the receipt and sufficiency of which ishereby acknowledged, the parties here to agree as follows.
Section 1. Definitions.
(a) The following terms shall have the meanings specified wherever used in this Agreement.
Acknowledgement Agreement: The Acknowledgement Agreement to be entered into by Freedom Mortgage, as Issuer, Cherry Hill, asSecured Party, and the Government National Mortgage Association.
Action: Any civil, criminal, investigative or administrative claim, demand, action, suit, charge, citation, complaint, notice of violation,proceeding (public or private), litigation, prosecution, arbitration or inquiry by or before any Governmental Entity whether at law, in equity orotherwise.
Agreement: This Strategic Alliance Agreement as the same may be amended in accordance with the terms hereof.
 
1Ancillary Agreements: The Acknowledgement Agreement, the Purchase Agreement and the Flow Agreement.
Base Servicing Fee: As to any Mortgage Loan and any Collection Period, an amount equal to the product of the Base Servicing Fee Rate, theUPB of that Mortgage Loan as of the related Measurement Date and 1/12 or, for the first Collection Period, the number of days in such CollectionPeriod divided by 360; provided, however, that payment of the Base Servicing Fee for any delinquent Mortgage Loan shall be suspended unlessand until Freedom Mortgage recovers the amount thereof from payments in respect thereof from the related mortgagor or the amount thereof isotherwise recovered from liquidation of the related property.
Base Servicing Fee Rate: As to any Mortgage Loan, the per annum rate specified to be payable to Freedom Mortgage to cover the actualcosts of servicing. For example, the Base Servicing Fee Rate for the Mortgage Loans in the initial pool will be eight (8) basis points.
Business Day: Any day other than a Saturday or Sunday or a day on which banks in New Jersey and New York are authorized or obligatedby law to close.
Closing: The closing of the initial public offering of the common stock of Cherry Hill.
Closing Date: The date of the Closing.
Collection Period: The period beginning on the Closing Date and ending on the last day of the calendar month in which the Closing Dateoccurs and each calendar month thereafter.
Excess MSR: As to any Mortgage Loan, the portion of the servicing fee for that Mortgage Loan that exceeds the Base Servicing Fee.
Flow Agreement : The Flow and Bulk Purchase Agreement to be entered into between Cherry Hill, as purchaser, and Freedom Mortgage, asseller, substantially in the form of Exhibit B attached hereto.
GAAP: Generally accepted accounting principles in the United States as in effect from time to time as set forth in the statements,pronouncements and opinions of the Accounting Principles Board and the American Institute of Certified Public Accountants.
Ginnie Mae: The Government National Mortgage Association, a corporation within the United States Department of Housing and UrbanDevelopment.
Governmental Entity: Any federal, state or local governmental authority, agency, commission or court or self-regulatory authority orcommission.
Guide: The Ginnie Mae Mortgage Backed Securities Guide.
Law: Any law, statute, ordinance, rule, regulation, code, Permit, Order, or decree of any Governmental Entity.
 
2Lien: Any lien, pledge, security interest, mortgage, deed of trust, claim, encumbrance, easement, servitude, encroachment, covenant, chargeor similar right of any other Person of any kind or nature whatsoever.
Material Adverse Effect: Any effect, event, circumstance, development or change that, individually or in the aggregate, has or is reasonablylikely to have a material adverse effect on the ability of the named Party to consummate the Transactions or perform its material obligationshereunder.
Measurement Date: As to any Collection Period, the first day of such Collection Period.
Mortgage Loan: A loan originated and serviced by Freedom Mortgage and secured by a first lien on a one- to four- family residentialproperty.
MSR: The compensation owing to a servicer of a Mortgage Loan for servicing such loan.
Order: Any applicable order, judgment, ruling, injunction, assessment, award, decree, writ, temporary restraining order, or any other order ofany nature enacted, issued, promulgated, enforced or entered by a Governmental Entity.
Party: Either Freedom Mortgage or Cherry Hill, as the context may require.
Permit: Any license, permit, authorization, approval or consent issued by a Governmental Entity.
Person: Any individual, corporation (including any non-profit corporation), general or limited partnership, limited liability company, limitedliability partnership, joint venture, estate, trust, unincorporated organization, association, organization or other entity or form of business enterpriseor Governmental Entity.
Purchase Agreement: The Excess MSR Acquisition and Recapture Agreement to be entered into by Cherry Hill, as purchaser, and FreedomMortgage, as seller, substantially in the form of Exhibit A attached hereto.
Standby Trigger Event: The existence of any of the following: (i) Freedom Mortgage’s Tangible Net Worth is less than the sum of $40,000,000plus the required net worth determined in accordance with HUD’s regulations; (ii) the percentage of the loans serviced for Ginnie Mae that are morethan 90 days delinquent, determined as provided in the Ginnie Mae guide, exceeds 4.25% as of any date such delinquency percentage is reported toGinnie Mae in accordance with that guide; (iii) the existence of a default, an event of default or an event which with the giving of notice or thepassage of time or both, will become a default or an event of default under any warehouse agreement of Freedom Mortgage; or (iv) FreedomMortgage’s cash and cash equivalents are less than $50,000,000.
 
3Tangible Net Worth: The net worth of Seller determined in accordance with GAAP, minus all intangibles determined in accordance withGAAP (including goodwill, capitalized financing costs and capitalized administration costs but excluding originated and purchased mortgageservicing rights or retained residual securities) and any and all advances to, investments in and receivables held from affiliates; provided, however,that the non­cash effect (gain or loss) of any mark­to­market adjustments made directly to stockholders’ equity for fluctuation of the value offinancial instruments as mandated under the Statement of Financial Accounting Standards No. 133 (or any successor statement) shall be excludedfrom the calculation of Tangible Net Worth.
Transactions: The execution, delivery and performance of this Agreement and the Ancillary Agreements and the performance of the otherobligations set forth herein and therein.
UPB: As to any Mortgage Loan and any date of determination, the unpaid principal balance of such Mortgage Loan as of such date.
(b) When a reference is made in this Agreement to Sections or Exhibits, such reference shall be to a Section of or Exhibit to this Agreementunless otherwise indicated. Whenever the words “herein” or “hereunder” are used in this Agreement, they will be deemed to refer to thisAgreement as a whole and not to any specific Section. References to Sections include subsections which are part of the related Section. Any Lawdefined herein will mean such Law as amended and will include any successor Law. The table of contents, index and headings contained in thisAgreement are for reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement. Whenever the words“include”, “includes” or “including” are used in this Agreement, they shall be deemed to be followed by the words “without limitation”. Anysingular term in this Agreement will be deemed to include the plural, and any plural term the singular. All pronouns and variations of pronouns willbe deemed to refer to the feminine, masculine or neuter, singular or plural, as the identity of the person referred to may require. The phrases “thedate of this Agreement”, “the date hereof’ and terms of similar import, unless the context otherwise requires, shall be deemed to refer to the date setforth in the preamble to this Agreement. Whenever a dollar figure ($) is used in this Agreement, it will mean United States dollars unless otherwisespecified.
Section 2. The Acknowledgement Agreement 
(a) Prior to the purchase and sale of Excess MSRs as contemplated by the Purchase Agreement, Freedom Mortgage and Cherry Hill shallexecute the Acknowledgement Agreement with Ginnie Mae.
(b) Freedom Mortgage agrees that if a Standby Issuer (as defined in the Acknowledgement Agreement) has not yet been appointed, upon theoccurrence of a Standby Trigger Event, it shall designate a Standby Issuer reasonably satisfactory to Cherry Hill and shall use its commerciallyreasonable efforts to cause such Standby Issuer to agree to act as such and to be accepted by Ginnie Mae as the Standby Issuer referred to in theAcknowledgement Agreement. Any costs or expenses incurred in connection with such designation, agreement and/or approval shall be paid byFreedom Mortgage.
(c) Cherry Hill agrees that upon the request of Freedom Mortgage, Cherry Hill shall cooperate with Freedom Mortgage’s efforts to cause theAcknowledgement Agreement to be revised or replaced with an alternative arrangement proposed by Freedom Mortgage that is acceptable toGinnie Mae and that will provide Cherry Hill with benefits, rights and remedies that are, in the reasonable judgment of Cherry Hill, not materially lessfavorable than those provided under the Acknowledgement Agreement.
 
4(d) The Purchase Agreement will provide that Freedom Mortgage will indemnify Cherry Hill against, and hold it harmless from, any loss, costor expense incurred by Cherry Hill as a result of Ginnie Mae’s termination for cause of Freedom Mortgage as an issuer.
Section 3. Ancillary Agreements.
On or prior to the Closing Date, Cherry Hill and Freedom Mortgage shall enter into the Purchase Agreement and the Flow Agreement.
Section 4. Representations and Warranties.
(a) Freedom Mortgage represents and warrants to Cherry Hill that the statements contained in this Section 4(a) are true and correct in allmaterial respects as of the date of this Agreement (or, if made as of a different specified date, as of such date) and will be true and correct in allmaterial respects as of the Closing Date (as though made then and as though the Closing Date were substituted for the date of this Agreementthroughout this Section 4(a)).
(i) Freedom Mortgage is duly organized and validly existing and in good standing under the laws of the jurisdiction of its organization.Freedom Mortgage has all requisite corporate power and authority to own, lease and operate its assets and carry on its business as nowconducted. Freedom Mortgage is duly licensed or qualified to do business in each jurisdiction where its ownership or leasing of assets or theconduct of its business requires such qualification, except where the failure to obtain such license or qualification would not reasonably beexpected to have a Material Adverse Effect.
(ii) Freedom Mortgage has full corporate power and authority to execute and deliver this Agreement and the Ancillary Agreements andto consummate the Transactions. The execution and delivery of this Agreement by Freedom Mortgage and the completion by FreedomMortgage of the Transactions have been duly and validly authorized by all necessary corporate action of Freedom Mortgage. ThisAgreement has been duly and validly executed and delivered by Freedom Mortgage and constitutes the valid and binding obligation ofFreedom Mortgage, enforceable against Freedom Mortgage in accordance with its terms, subject to applicable bankruptcy, insolvency andsimilar Laws affecting creditors’ rights generally, and subject, as to enforceability, to general principles of equity, whether applied in a courtof law or a court of equity.
(iii) The execution and delivery of this Agreement and the consummation of the Transactions and compliance by Freedom Mortgagewith any of the terms or provisions hereof will not: (i) conflict with or result in a breach or violation of or a default under any provision of theorganizational documents of Freedom Mortgage; (ii) violate any Law applicable to Freedom Mortgage or any of its material properties orassets or enable any Person to enjoin the Transactions; or (iii) violate, conflict with, result
 
5in a breach of any provisions of, constitute a default (or an event which, with notice or lapse of time, or both, would constitute a default)under, result in the termination of, accelerate the performance required by, or result in a right of termination or acceleration or the creation ofany Lien upon any of the properties or assets of Freedom Mortgage under any of the terms, conditions or provisions of any material contractto which Freedom Mortgage is a party, or by which it or any of its properties or assets may be bound or affected.
(iv) No consents, waivers or approvals of, or filings or registrations with, any Governmental Entity are necessary, and no consents,waivers or approvals of, or filings or registrations by Freedom Mortgage with, any other third parties are necessary, in connection with theexecution and delivery of this Agreement by Freedom Mortgage, and the completion by Freedom Mortgage of the Transactions.
(v) Freedom Mortgage has all Permits of, and has made all filings, applications and registrations with, all Governmental Entities that arerequired in order for it to consummate the Transactions; all such Permits are in full force and effect and, to the knowledge of FreedomMortgage, no suspension or cancellation of any such Permit is threatened or will result from the consummation of the Transactions.
(vi) Freedom Mortgage is not a party to any, nor are there pending, or to Freedom Mortgage’s knowledge, threatened Actions (i)challenging the validity or propriety of any of the Transactions or (ii) which could materially and adversely affect the ability of FreedomMortgage to perform under this Agreement or any Ancillary Agreement.
(b) Cherry Hill represents and warrants to Freedom Mortgage that the statements contained in this Section 4(b) are true and correct in allmaterial respects as of the date of this Agreement (or, if made as of a different specified date, as of such date) and will be true and correct in allmaterial respects as of the Closing Date (as though made then and as though the Closing Date were substituted for the date of this Agreementthroughout this Section 4(b)) and as of the date of any purchase and sale of Excess MSRs as contemplated hereby.
(i) Cherry Hill is duly organized and validly existing and in good standing under the laws of the jurisdiction of its organization. CherryHill has all requisite corporate power and authority to own, lease and operate its assets and carry on its business as now conducted. CherryHill is duly licensed or qualified to do business in each jurisdiction where its ownership or leasing of assets or the conduct of its businessrequires such qualification, except where the failure to obtain such license or qualification would not reasonably be expected to have aMaterial Adverse Effect.
(ii) Cherry Hill has full corporate power and authority to execute and deliver this Agreement and the Ancillary Agreements and toconsummate the Transactions. The execution and delivery of this Agreement by Cherry Hill and the completion by Cherry Hill of theTransactions have been duly and validly authorized by all necessary corporate action of Cherry Hill. This Agreement has been duly andvalidly executed and delivered by Cherry Hill and constitutes the valid and binding obligation of Cherry Hill, enforceable against Cherry Hillin accordance with its terms, subject to applicable bankruptcy, insolvency and similar Laws affecting creditors’ rights generally, and subject,as to enforceability, to general principles of equity, whether applied in a court of law or a court of equity.
 
6(iii) The execution and delivery of this Agreement and the consummation of the Transactions and compliance by Cherry Hill with any ofthe terms or provisions hereof will not: (i) conflict with or result in a breach or violation of or a default under any provision of theorganizational documents of Cherry Hill; (ii) violate any Law applicable to Cherry Hill or any of its material properties or assets or enable anyPerson to enjoin the Transactions; or (iii) violate, conflict with, result in a breach of any provisions of, constitute a default (or an event which,with notice or lapse of time, or both, would constitute a default) under, result in the termination of, accelerate the performance required by, orresult in a right of termination or acceleration or the creation of any Lien upon any of the properties or assets of Cherry Hill under any of theterms, conditions or provisions of any material contract to which Cherry Hill is a party, or by which it or any of its properties or assets may bebound or affected.
(iv) No consents, waivers or approvals of, or filings or registrations with, any Governmental Entity are necessary, and no consents,waivers or approvals of, or filings or registrations by Cherry Hill with, any other third parties are necessary, in connection with the executionand delivery of this Agreement by Cherry Hill, and the completion by Cherry Hill of the Transactions.
(v) Cherry Hill has all Permits of, and has made all filings, applications and registrations with, all Governmental Entities that are requiredin order for it to consummate the Transactions; all such Permits are in full force and effect and, to the knowledge of Cherry Hill, nosuspension or cancellation of any such Permit is threatened or will result from the consummation of the Transactions.
(vi) Cherry Hill is not a party to any, nor are there pending, or to Cherry Hill’s knowledge, threatened Actions (i) challenging the validityor propriety of any of the Transactions or (ii) which could materially and adversely affect the ability of Cherry Hill to perform under thisAgreement.
Section 5. Term and Termination.
(a) Unless earlier terminated as provided below, this Agreement shall remain in effect until the later to occur of the date that is (x) three (3)years from the date hereof and (y) the date on which an affiliate of Freedom Mortgage is not acting as the external manager of Cherry Hill.
(b) In the event that a party materially breaches any representation or covenant herein, the other party may give written notice of the breachrequiring the same to be remedied within 30 days of receipt of such notice. If the breaching party fails to remedy the material breach in such timeperiod, the non-breaching party may terminate this Agreement by delivery of a written termination notice to the breaching party. Any suchtermination shall not relieve the breaching party from any obligation or liability arising prior to such termination.
 
7Section 6. Miscellaneous.
(a) All notices or other communications hereunder shall be in writing and shall be deemed given if delivered by receipted hand delivery ormailed by prepaid registered or certified mail (return receipt requested) or by recognized overnight courier addressed as follows:
 
If to Freedom Mortgage to:
 
Freedom Mortgage Company907 Pleasant Valley Ave., Suite 3Mount Laurel, New Jersey 08054Attention: Chief Corporate Counsel
If to Cherry Hill to:
 
Cherry Hill Mortgage Investment Corp.301 Harper DriveMoorestown, New Jersey 08057Attention: Chief Financial Officer
or such other address as shall be furnished in writing by any Party. Any such notice or communication shall be deemed to have been given: (i) asof the date delivered by hand; (ii) three (3) Business Days after being delivered to the U.S. mail, postage prepaid; or (iii) one (1) Business Day afterbeing delivered to the overnight courier.
(b) This Agreement shall be binding upon and shall inure to the benefit of the Parties and their respective successors and permitted assigns;provided, however, that neither this Agreement nor any of the rights, interests or obligations hereunder shall be assigned by any Party without theprior written consent of the other Party. Nothing in this Agreement is intended to confer upon any other Person any rights or remedies under or byreason of this Agreement.
(c) This Agreement, including the Exhibits and Schedules hereto and the documents and other writings referred to herein or therein ordelivered pursuant hereto, contains the entire agreement and understanding of the Parties with respect to its subject matter. There are norestrictions, agreements, promises, warranties, covenants or undertakings between the Parties other than those expressly set forth herein or therein.This Agreement supersedes all prior agreements and understandings between the Parties, both written and oral, with respect to its subject matter.
(d) This Agreement may be executed in two or more counterparts, including by facsimile or electronic transmission, each of which shall bedeemed an original but all of such counterparts together shall be deemed to be one and the same agreement.
(e) In the event that any one or more provisions of this Agreement shall for any reason be held invalid, illegal or unenforceable in any respect,by any court of competent jurisdiction, such invalidity, illegality or unenforceability shall not affect any other provisions of this Agreement and theParties shall use their reasonable efforts to substitute a valid, legal and enforceable provision which, insofar as practical, implements the purposesand intents of this Agreement.
 
8(f) The Parties may (i) amend this Agreement, (ii) extend the time for the performance of any of the obligations or other acts of any other Party,(iii) waive any inaccuracies in the representations and warranties contained herein or in any document delivered pursuant hereto, or (iv) waivecompliance with any of the agreements or conditions contained herein. This Agreement may not be amended except by an instrument in writingsigned on behalf of each of the Parties. Any agreement on the part of a Party to any extension or waiver shall be valid only if set forth in aninstrument in writing signed on behalf of such Party, but such waiver or failure to insist on strict compliance with such obligation, covenant,agreement or condition shall not operate as a waiver of, or estoppel with respect to, any subsequent or other failure.
(g) This Agreement shall be governed by the laws of the State of New York, without giving effect to its principles of conflicts of laws, otherthan Section 5-1401 of the New York General Obligations Law.
(h) Each Party irrevocably submits to the jurisdiction, including the personal jurisdiction, of (i) any New York State court sitting in New YorkCounty, and (ii) any Federal court of the United States sitting in New York County in the State of New York, solely for the purposes of any suit,action or other proceeding between any of the Parties arising out of this Agreement or the Transactions. Each Party agrees to commence any suit,action or proceeding relating hereto only in any Federal court of the United States sitting in New York County in the State of New York or, if suchsuit, action or other proceeding may not be brought in such court for reasons of subject matter jurisdiction, in any New York State court sitting inNew York County. Each Party irrevocably and unconditionally waives any objection to the laying of venue of any suit, action or proceedingbetween any of the Parties arising out of this Agreement or the Transactions in (i) any New York State court sitting in New York County, and (ii)any Federal court of the United States sitting in New York County in the State of New York, and hereby further irrevocably and unconditionallywaives and agrees not to plead or claim in any such court that any such suit, action or proceeding brought in any such court has been brought inan inconvenient forum. Each Party irrevocably agrees to request that the applicable court adjudicate any covered claim on an expedited basis andto cooperate with each other to assure that an expedited resolution of any such dispute is achieved. Each Party irrevocably agrees to abide by therules or procedure applied by the Federal courts or New York State courts (as the case may be) (including but not limited to procedures forexpedited pre-trial discovery) and waive any objection to any such procedure on the ground that such procedure would not be permitted in thecourts of some other jurisdiction or would be contrary to the laws of some other jurisdiction. Each Party further irrevocably consents to the serviceof process out of any of the aforementioned courts in any such suit, action or other proceeding by the mailing of copies thereof by registered mailto such Party at its address set forth in this Agreement, such service of process to be effective upon acknowledgment of receipt of such registeredmail; provided, that nothing in this Section 6(h) shall affect the right of any Party to serve legal process in any other manner permitted by Law.
(i) The Parties agree that irreparable damage would occur in the event that the provisions contained in this Agreement were not performed inaccordance with its specific terms or were otherwise breached. It is accordingly agreed that the Parties shall be entitled to an injunction orinjunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions hereof in any court of the United States orany state having jurisdiction, this being in addition to any other remedy to which they are entitled at law or in equity.
 
9(j) FREEDOM MORTGAGE AND CHERRY HILL HEREBY IRREVOCABLY WAIVE, TO THE FULLEST EXTENT PERMITTED BYAPPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THISAGREEMENT, ANY OTHER TRANSACTION DOCUMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY. 
[The remainder of this page left blank intentionally]
 
10IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first above-written.
 FREEDOM MORTGAGE CORPORATION
By:   
 Name: 
 Title:  
CHERRY HILL MORTGAGE INVESTMENT CORP.
By:   
 Name:  Title: